⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21294346 | 0.82 | — | — | |
| SCHEMBL21294349 | 0.82 | — | — | |
| SCHEMBL28730964 | 0.79 | — | — | |
| SCHEMBL21294348 | 0.79 | — | — | |
| SCHEMBL21294351 | 0.79 | — | — | |
| SCHEMBL23546 | 0.71 | — | — | |
| SCHEMBL4665539 | 0.69 | — | — | |
| SCHEMBL4663538 | 0.69 | — | — | |
| SCHEMBL10458007 | 0.67 | — | — | |
| SCHEMBL18783524 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10666 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118136960-B | Electrolyte and battery | 深圳欣界能源科技有限公司 | 2024-07-16 | — | — | CN | claimed |
| CN-118136960-A | Electrolyte and battery | 深圳欣界能源科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| EP-3753941-B1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) | 2024-05-01 | — | — | EP | claimed |
| WO-2023143312-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-08-03 | — | — | WO | claimed |
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | claimed |
| EP-3753941-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Blueray Biopharma Co., Ltd. (CN) | 2020-12-23 | — | — | EP | claimed |
| EP-3130594-B1 | PHOSPHONATES OF ACETYLENIC BETULIN DERIVATIVES WITH ANTICANCER ACTIVITY, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION | SLASKI UNIV MEDYCZNY W KATOWICACH (PL) | 2020-11-11 | — | — | EP | claimed |
| CN-110128998-A | A kind of allyl organic silicon potting adhesive and preparation method thereof | 矽时代材料科技股份有限公司 | 2019-08-16 | — | — | CN | claimed |
| US-20080176858-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-07-24 | — | — | US | claimed |
| EP-1054004-B1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | EP | claimed |
| US-20070244134-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2007-10-18 | — | — | US | claimed |
| US-7217702-B2 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2007-05-15 | — | — | US | claimed |
| EP-1000070-B1 | SILICON-CONTAINING CHAIN EXTENDERS | AORTECH BIOMATERIALS PTY LTD (AU) | 2003-09-10 | — | — | EP | claimed |
| EP-0984997-B1 | SILICON-BASED POLYCARBONATES | AORTECH BIOMATERIALS PTY LTD (AU) | 2002-09-18 | — | — | EP | claimed |
| US-6420452-B1 | POLYURETHANES WITH EXTENDERS | AORTECH BIOMATERIALS PTY LTD (AU) | 2002-07-16 | — | — | US | claimed |
| US-4710491-A | N-glycosylated carboxylic acid derivatives as agents for combating rheumatic diseases | TROPONWERKE GMBH & CO., KG (DE) | 1987-12-01 | — | — | US | claimed |
| EP-0152630-A2 | Organosiloxane polymers and compositions containing same curable upon exposure to gaseous oxygen | UNION CARBIDE CORPORATION (US) | 1985-08-28 | — | — | EP | claimed |
| WO-1985002854-A1 | ORGANOSILOXANE POLYMERS AND COMPOSITIONS CONTAINING SAME CURABLE UPON EXPOSURE TO GASEOUS OXYGEN | UNION CARBIDE CORPORATION (US) | 1985-07-04 | — | — | WO | claimed |
| US-4526954-A | Contains olefinically polyunsaturated radical containing 1,3- or 1,4-pentadienylene group bonded to silicon | UNION CARBIDE CORPORATION (US) | 1985-07-02 | — | — | US | claimed |
| US-12042479-B2 | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | INMED PHARMACEUTICALS INC. | 2024-07-23 | — | — | US | disclosed |
| US-12042523-B2 | Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof | UNIGEN, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-118369335-A | N1-modified pseudouridine and application thereof in mRNA synthesis | 上海吉量医药工程有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118359666-A | Tetravalent cisplatin prodrug, liposome and application thereof | 杭州佰因泰医药科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240239751-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | BRIDGEBIO GENE THERAPY RESEARCH, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238427-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239755-A1 | SUBSTITUTED PYRIDAZINONES, SALTS OR N-OXIDES THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-07-18 | — | — | US | disclosed |
| WO-2024151847-A1 | IDENTIFICATION OF OTUD7B INHIBITOR 7BI AND ITS APPLICATION IN REDUCING GROWTH OF NSCLC AND LEUKEMIA CELLS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024152000-A1 | DISRUPTABLE LINKER COMPOSITIONS, SWITCHABLE BISPECIFIC T CELL NANOENGAGER (SWITCH-BITE) COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151489-A1 | PHARMACEUTICAL PYRIDYL COMPOSITIONS AND METHODS FOR USE | Unicycive Therapeutics Inc. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238311-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | ANTARES PHARMA, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238321-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | SYNTHENA AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240238285-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024150067-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | MOJIA BIOTECH PTE. LTD. (SG) | 2024-07-18 | — | — | WO | disclosed |
| US-20240239775-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | BEIJING BEST PATHWAY MANAGEMENT CONSULTING CENTER (LIMITED PARTNERSHIP) (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239762-A1 | NOVEL HETEROCYCLIC COMPOUNDS | FLORATEK PHARMA S A (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240238438-A1 | CD-90 Targeted Lipid Nanoparticles | FRED HUTCHINSON CANCER CENTER | 2024-07-18 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-118136960-B | Electrolyte and battery | 深圳欣界能源科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118344348-A | Heterocyclic substituted quinazoline and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-113677665-B | Substituted 2-heteroarylaminobenzenes and salts thereof, and their use as herbicides | 拜耳公司 | 2024-07-16 | — | — | CN | disclosed |
| US-12036211-B2 | Nicorandil derivatives | Unicycive Therapeutics Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118339151-A | Compound for inhibiting or degrading BRD9, composition and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-111447939-B | Method for preparing conjugate | 四川科伦博泰生物医药股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-118324782-A | Tricyclic compound for inhibiting HPK1 and medical application thereof | 西藏海思科制药有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118339152-A | Macrocyclic compounds having farnesyl transferase inhibitory activity | 库拉肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118339168-A | Fused ring heterocyclic derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| WO-2024148191-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240226310-A1 | Lipid Nanoparticle Therapeutics that Evade the Immune Response | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-07-11 | — | — | US | disclosed |
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | CURIA GLOBAL, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4395550-A1 | ADDITIVES FOR COLOR DRIFT REDUCTION IN COPPER-BASED ANTIMICROBIAL POLYMERIC FORMULATIONS | Corning Incorporated (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4395828-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| CN-118317956-A | Bis (hetero) aryl thioether oxadiazines as fungicidal compounds | 拜耳公司 | 2024-07-09 | — | — | CN | disclosed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118317955-A | N- (4-aminocyclohexyl) pyrimidine-4-carboxamide as CD38 inhibitor | 塞里文斯股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-112724349-B | Polymer and use thereof | 立邦涂料（中国）有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118302289-A | Method for producing bioactive polymer filaments, and printing method using same | 新加坡科技研究局 | 2024-07-05 | — | — | CN | disclosed |
| CN-116143757-B | Multifunctional compound, composition and application of degradable BTK kinase | 杭州和正医药有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118290446-A | Compound for inhibiting and degrading c-MYC and medical application thereof | 西藏海思科制药有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | THE WISTAR INST (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | disclosed |
| US-20240216523-A1 | Compositions and Methods for Targeting Lipid Nanoparticle Therapeutics to Stem Cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | disclosed |
| WO-2024140653-A1 | SELECTIVE CDK12/13 INHIBITOR AND APPLICATION THEREOF | 南京圣和药业股份有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141052-A1 | ESTROGEN-RECEPTOR MODULATOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-20240218399-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SUZHOU ABOGEN BIOSCIENCES CO LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-4392409-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4146348-B1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4013385-B1 | IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2024-07-03 | — | — | EP | disclosed |
| EP-4394011-A2 | MODIFICATION OF SURFACE PROPERTIES OF MICROFLUIDIC DEVICES | Bio-Rad Laboratories, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118271316-A | Cycloheptenyl-containing derivative, pharmaceutical composition and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271233-A | Nilaparil manufacturing method | 特沙诺有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271284-A | Estrogen receptor modulators and uses thereof | 江苏威凯尔医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118284797-A | Calibration assistance for optical imaging applications | 斯特拉斯堡大学 | 2024-07-02 | — | — | CN | disclosed |
| US-12024595-B2 | Polymer composition | BASF SE (DE) | 2024-07-02 | — | — | US | disclosed |
| US-12024731-B2 | Methods and enzyme catalysts for the synthesis of non-canonical amino acids | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-07-02 | — | — | US | disclosed |
| CN-118271288-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118284602-A | Pyridine derivatives as sodium channel activators and uses thereof | 泽农医药公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118284611-A | Diazabicyclooctane derivatives useful as matrix metalloproteinase inhibitors | VASA治疗有限责任公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118255746-A | Selective CDK12/13 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118255780-A | Compound for inhibiting and degrading c-MYC and medical application thereof | 西藏海思科制药有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024133610-A1 | PROCCESSES FOR THE PREPARATION OF AN NLRP3 INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| WO-2024138052-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024134466-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS, SUBSTITUTED HETEROARYLAMINE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-27 | — | — | WO | disclosed |
| US-20240208982-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. | 2024-06-27 | — | — | US | disclosed |
| WO-2024137780-A1 | PANK MODULATORS AND METHODS OF TREATMENT USING SAME | YALE UNIVERSITY (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209076-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240209214-A1 | METHODS OF ATTACHING AZIDE COMPOUNDS TO SURFACES AND COMPOUNDS AND PRODUCTS THEREOF | VANDERBILT UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| WO-2024131843-A1 | ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 苏州宜联生物医药有限公司 | 2024-06-27 | — | — | WO | disclosed |
| US-20240209011-A1 | HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER | FLORATEK PHARMA S A (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240208975-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208973-A1 | TETRACYCLIC COMPOUNDS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-06-27 | — | — | US | disclosed |
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | disclosed |
| EP-3908568-B1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | ACUITAS THERAPEUTICS INC (CA) | 2024-06-26 | — | — | EP | disclosed |
| EP-4103160-B1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH ZUERICH (CH) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387977-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387610-A1 | TRICYCLIC SULTAMS AND SULFAMIDES AS ANTITUMOR AGENTS | Peloton Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4388127-A1 | METHODS AND COMPOSITIONS FOR IDENTIFYING METHYLATED CYTOSINES | Illumina, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-114502187-B | Peptide amide composition and preparation thereof | 西藏海思科制药有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118251216-A | Method for biofilm disruption | 尼尔利希尔有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-115960109-B | Preparation and application of condensed ring SHP2 phosphatase inhibitor | 药雅科技(上海)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118251389-A | Pyridyl derivatives as sodium channel activators | 泽农医药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-118251393-A | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-12016853-B2 | Methods of treating RBP4 related diseases with triazolopyridines | BELITE BIO, INC (KY) | 2024-06-25 | — | — | US | disclosed |
| US-12021194-B2 | Silicon-based energy storage devices with electrolyte containing a benzoyl peroxide based compound | ENEVATE CORPORATION (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018033-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-114423739-B | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-113395963-B | Non-ATP/catalytic site p38 mitogen-activated protein kinase inhibitors | 马里兰大学巴尔的摩分校 | 2024-06-25 | — | — | CN | disclosed |
| CN-118221656-A | Compounds useful for the treatment of gastrointestinal disorders | 阿德利克斯股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118221642-A | Sulfonamide derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240199596-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240199702-A1 | CELL-PERMEABLE CYCLIC PEPTIDES AND USES THEREOF | UNNATURAL PRODUCTS INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240199650-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240197742-A1 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-20 | — | — | US | disclosed |
| US-20240199542-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024125603-A1 | SHP2 INHIBITOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240199699-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR PEPTIDE ANTAGONIST CONOTOXIN COMPOSITIONS AND RELATED METHODS | GLO PHARMA, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240197738-A1 | COMPOUND 7AI IN TREATING EWING SARCOMA BY INHIBITING OTUD7A | Atomwise Inc. | 2024-06-20 | — | — | US | disclosed |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240197694-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-06-20 | — | — | US | disclosed |
| WO-2024125639-A1 | NOVEL GLUCOCORTICOID, METHOD FOR PREPARING SAME, AND USE THEREOF | 津药生物科技（天津）有限公司 | 2024-06-20 | — | — | WO | disclosed |
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3562893-B1 | MODIFICATION OF SURFACE PROPERTIES OF MICROFLUIDIC DEVICES | BIO RAD LABORATORIES INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4384522-A1 | SELECTIVE KRAS INHIBITORS | Erasca, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4384179-A1 | COVALENT INHIBITORS OF MENIN-MLL INTERACTION FOR DIABETES MELLITUS | Biomea Fusion, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118206558-A | Compound capable of inhibiting and degrading AuroraA, pharmaceutical composition and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-12012392-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| US-12015122-B2 | Silicon-based energy storage devices with carboxylic ether, carboxylic acid based salt, or acrylate electrolyte containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-06-18 | — | — | US | disclosed |
| CN-113318113-B | Use of fibroblast growth factor receptor inhibitors | 药捷安康(南京)科技股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118215472-A | Lipid nanoparticles for oligonucleotide delivery | 纪费亚斯公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-110312730-B | Cytotoxins and conjugates, uses thereof and methods of preparation | 四川科伦博泰生物医药股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118215471-A | Lipid nanoparticles for oligonucleotide delivery | 纪费亚斯公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-112638879-B | Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents | 泽农医药公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118206550-A | SHP2 inhibitor and application thereof | 江苏威凯尔医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118201941-A | CD73 compounds | 吉利德科学公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118201612-A | Compositions and methods for combination therapy for the treatment of lymphomas | 上海睿跃生物科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| US-20240189304-A1 | BET PROTEIN INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240190839-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| US-20240190864-A1 | Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF | YA THERAPEUTICS INC (CN) | 2024-06-13 | — | — | US | disclosed |
| US-20240189445-A1 | Targeted Therapeutic Lipid Nanoparticles and Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| US-20240190917-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO PHARMA, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240191035-A1 | RING OPENING POLYMERIZATION OF CYCLIC SILOXANES | CHT USA INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2024123791-A1 | FORMULATIONS FOR DUAL VEGF/IL-6 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024124143-A2 | HSC TARGETED LNP FOR DELIVERY OF PRO-APOPTOTIC MRNA AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4380566-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-114206463-B | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118159536-A | Substituted 1,2, 4-thiadiazolyl nicotinamide, salts or N-oxides thereof and their use as herbicidal active substances | 拜耳公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118159300-A | Antibody, drug conjugate and application thereof | 苏州信诺维医药科技股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118159542-A | Substituted 2, 3-dihydro [1,3] thiazolo [4,5-b ] pyridines, salts thereof and their use as herbicidal agents | 拜耳公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118146224-A | Nitrogen-containing tricyclic derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024119117-A1 | MODIFIED 5' CAP FOR MRNA AND METHODS OF USE THEREOF | PRIME MEDICINE, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024119099-A1 | GALLIUM-SALOPHEN ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-06 | — | — | US | disclosed |
| US-20240182452-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-06 | — | — | US | disclosed |
| US-20240182498-A1 | DISILYLAMINE PRECURSORS AND RELATED METHODS | ENTEGRIS INC (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024114954-A1 | CHLORIN K ANALOGUES SUITABLE FOR USE IN PHOTODYNAMIC THERAPY (PDT) | RMW CHO GROUP LIMITED (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024115525-A2 | NOVEL COMPOUNDS | RMW CHO GROUP LIMITED (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024115524-A1 | PORPHYRIN AND PHOSPHONIUM-PORPHYRIN BASED COMPOUNDS FOR PHOTODYNAMIC THERAPY AND DIAGNOSTICS | RMW CHO GROUP LIMITED (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024118840-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | OMEROS CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024118571-A2 | RING OPENING POLYMERIZATION OF CYCLIC SILOXANES | CHT USA INC (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2024-06-06 | — | — | US | disclosed |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoirens Serviece (FR) | 2024-06-06 | — | — | US | disclosed |
| US-20240182480-A1 | 5-HT2A AND/OR 5-HT2C RECEPTOR AGONISTS | DIAMOND THERAPEUTICS INC. (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024114953-A1 | PHYLLOCHLORIN ANALOGUES SUITABLE FOR USE IN PHOTODYNAMIC THERAPY (PDT) | RMW CHO GROUP LIMITED (CN) | 2024-06-06 | — | — | WO | disclosed |
| EP-3890737-B1 | USP19 INHIBITORS FOR USE IN A METHOD OF TREATING OBESITY, INSULIN RESISTANCE AND TYPE II DIABETES | ALMAC DISCOVERY LTD (GB) | 2024-06-05 | — | — | EP | disclosed |
| EP-3570838-B1 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY INC (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4376833-A1 | COMPOSITIONS AND METHODS FOR TREATING LIPOMA PAIN | Raziel Therapeutics Ltd. (IL) | 2024-06-05 | — | — | EP | disclosed |
| US-11999733-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| CN-118136960-A | Electrolyte and battery | 深圳欣界能源科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118139860-A | PARP-1 degrading agent and application thereof | 西藏海思科制药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-118126035-A | Cycloalkyl or heterocycle substituted benzo or pyridopyridazine, and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11999821-B2 | Compound, a reaction product of said compound and production methods thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-06-04 | — | — | US | disclosed |
| CN-114829368-B | Method for sequencing by synthesis using a continuous labelling scheme | 豪夫迈·罗氏有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118119275-A | Additives for reducing color shift in copper-based antimicrobial polymer formulations | 康宁公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118108711-A | Glycollic acid oxidase inhibitor and application thereof in medicine | 西藏海思科制药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118119372-A | Malodor-counteracting compositions, compositions and uses thereof | 国际香料和香精公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-113874341-B | Process for preparing derivatives of 1, 1-dialkylethane-1, 2-diols useful as intermediates | 科学与工业研究委员会 | 2024-05-31 | — | — | CN | disclosed |
| WO-2024112796-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112611-A1 | TARGETED PROTEIN MODIFICATION | WEATHERWAX BIOTECHNOLOGIES CORPORATION (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112882-A1 | TARGETED DELIVERY OF GENE EDITING CONSTRUCTS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240175023-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240174690-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| US-20240174618-A1 | SUBSTITUTED (2-HETEROARYLOXYPHENYL)SULFONATES, SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| WO-2024109798-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2024-05-30 | — | — | WO | disclosed |
| US-20240174699-A1 | FUNCTIONALIZED ORGANOTIN PRECURSORS AND RELATED METHODS | ENTEGRIS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240174715-A1 | PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS | INDI MOLECULAR, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240174630-A1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | SHUTTLE PARMACEUTICALS, LLC | 2024-05-30 | — | — | US | disclosed |
| EP-4373823-A1 | SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOF | Arbutus Biopharma Corporation (CA) | 2024-05-29 | — | — | EP | disclosed |
| CN-118084844-A | PI3K alpha inhibitor and application thereof in medicine | 西藏海思科制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118103372-A | Heterocyclic compound capable of inhibiting IL-17A and application thereof | 西藏海思科制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084720-A | Triarylmethane dye and application thereof in biological imaging and tumor photoacoustic imaging | 华东理工大学 | 2024-05-28 | — | — | CN | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| CN-118076357-A | Covalent inhibitors of Mennin-MLL interactions for diabetes | 拜欧米富士恩公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-115197221-B | Dihydropyrazolopyrimidinone macrocyclic derivatives and their use | 轩竹(北京)医药科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-115279368-B | Heteroaryl compounds | 维瓦斯治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118063537-A | Prodrugs of directed lymphatics | 莫纳什大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-118076603-A | CAMKK2 modulators as ligand-directed degradants | 细胞基因公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118076612-A | Sulfur-containing heteroaromatic tricyclic KRAS inhibitors | 医睿世康药业研发公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118076354-A | Methods of treating migraine with MNK inhibitors | 4E治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118063435-A | Piperidine-2, 6-dione derivative and application thereof | 西藏海思科制药有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108090-A1 | METHODS OF TREATING INFLAMMATORY CONDITIONS | ATHIRA PHARMA, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108131-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107565-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| US-20240166641-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-05-23 | — | — | US | disclosed |
| US-20240166661-A1 | Spiropiperidine Derivatives | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| US-20240166658-A1 | PORPHYRIN DERIVATIVES AND USES THEREOF | UNIVERSITY OF TASMANIA (AU) | 2024-05-23 | — | — | US | disclosed |
| WO-2024104956-A1 | SUBSTITUTED CYCLOALKYLSULFANYLPHENYLURACILS AND THEIR SALTS, AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024104954-A1 | SUBSTITUTED CYCLOALKYLOXYPHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024104952-A1 | SUBSTITUTED CYCLOPROPYLOXYPHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| EP-4370109-A1 | SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) DRUGS, CONJUGATES, AND NANOPARTICLES, AND METHODS OF USE THEREOF | University of Maryland, Baltimore (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4370506-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11990585-B2 | Electrolyte formulations for optimal performance in Si-containing lithium ion batteries | ENEVATE CORPORATION (US) | 2024-05-21 | — | — | US | disclosed |
| US-11987597-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11987560-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-118056835-A | Pyridazinones as PARP7 inhibitors | 中山优理生物医药有限公司 | 2024-05-21 | — | — | CN | disclosed |
| CN-118047776-A | Tricyclic compound, preparation method thereof, pharmaceutical composition containing tricyclic compound and application of tricyclic compound | 上海优理惠生医药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-111566104-B | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-115335050-B | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-114514223-B | Process for enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines comprising using novel iridium catalysts | 拜耳公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-118055699-A | Formulation for antimicrobial thermosetting coatings | 康宁公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024102621-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024103012-A1 | POLYCYCLIC COMPOUNDS FOR USE IN NEURODEGENERATIVE CONDITIONS | IMET INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240156791-A1 | METHODS OF TREATING SPINAL CORD INJURY OR DAMAGE | SPINOGENIX INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| US-20240158385-A1 | NOVEL COMPOUNDS | Cerevance, Inc. | 2024-05-16 | — | — | US | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240156999-A1 | MULTIMERIC CHELATOR COMPOUNDS FOR USE IN TARGETED RADIOTHERAPY | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-16 | — | — | US | disclosed |
| WO-2024100276-A2 | SUBSTITUTED 1,3-DIOXOLAN-4-ONES AND 1,3-DIOXAN-4-ONES AS FRAGRANCE INGREDIENTS | BASF SE (DE) | 2024-05-16 | — | — | WO | disclosed |
| US-20240158410-A1 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-05-16 | — | — | US | disclosed |
| EP-4366829-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-118043322-A | PARP inhibitors containing nitrogen heterocyclic derivatives and uses thereof | 西藏海思科制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-111212647-B | Dihydro oxadiazinones | 拜耳股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-118043306-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11980614-B2 | — | — | 2024-05-14 | — | — | US | disclosed |
| US-11981667-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-05-14 | — | — | US | disclosed |
| CN-118043314-A | Benzazepine heteroaromatic ring derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-114728910-B | Pyrazole derivative for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-118043323-A | Bicyclic derivative PARP inhibitors and uses thereof | 西藏海思科制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-115516044-B | Fluorescent dimer compounds useful as probes for detection of endogenous receptors | 斯特拉斯堡大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-118005610-A | PARP-1 degrading agent and application thereof | 西藏海思科制药有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024094875-A1 | CHROMEN-4-ONE COMPOUNDS WITH ANTICANCER PROPERTIES | Floratek Pharma SA (CH) | 2024-05-10 | — | — | WO | disclosed |
| CN-118019737-A | Beta-lactam derivatives for the treatment of diseases | 英矽智能科技知识产权有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-118019740-A | Heteroaryl derivative PARP inhibitors and uses thereof | 海思科医药集团股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024095005-A1 | DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097632-A1 | METHODS OF REDUCING MIRO1 OR PHOSPHORYLATED ALPHA-SYNUCLEIN | ACUREX BIOSCIENCES CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-118019727-A | Methods for preparing NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240150291-A1 | PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240150315-A1 | BETA-2 ADRENORECEPTOR MODULATORS AND METHODS OF USING SAME | THOMAS JEFFERSON UNIVERSITY | 2024-05-09 | — | — | US | disclosed |
| US-20240150653-A1 | ETCHANT COMPOSITIONS AND RELATED METHODS | ENTEGRIS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240150380-A1 | SILANE PRECURSORS AND RELATED METHODS | ENTEGRIS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240150320-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | SYGNATURE DISCOVERY LIMITED (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20240150306-A1 | COMPOUNDS WITH CLEAVABLE DISULFIDE MOIETIES | REINVIGORON THERATECH, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4013756-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| EP-3852766-B1 | COMBINATION THERAPY FOR TREATING BLOOD CANCER | SIGNALCHEM LIFESCIENCES CORP (CA) | 2024-05-08 | — | — | EP | disclosed |
| EP-4362929-A1 | METHODS OF TREATING OR PREVENTING CORONAVIRUS INFECTION WITH CANNABINOID ACIDS | Oregon State University (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-113354811-B | Oxazoline polymer with side chain containing amino and/or hydroxyl, preparation method and application thereof | 华东理工大学 | 2024-05-07 | — | — | CN | disclosed |
| US-11978894-B2 | Silicon anodes with water-soluble maleic anhydride-, and/or maleic acid-containing polymers/copolymers, derivatives, and/or combinations (with or without additives) as binders | ENEVATE CORPORATION (US) | 2024-05-07 | — | — | US | disclosed |
| US-11976219-B2 | Photo-cleavable primer compositions and methods of use | ORMCO CORPORATION (US) | 2024-05-07 | — | — | US | disclosed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117959303-A | PIM kinase inhibitors for the treatment of myeloproliferative neoplasms and cancer-related fibrosis | 住友制药肿瘤公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-114391008-B | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117980306-A | Compound, pharmaceutical composition containing same and application of compound | 中山优理生物医药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240141382-A1 | GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC., | 2024-05-02 | — | — | US | disclosed |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024092185-A1 | ACYL SULFONAMIDE COMPOUNDS AS INHIBITORS OF POLYOMAVIRUS | VIA NOVA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024088379-A1 | TUMOR TREATMENT OR PREVENTION METHOD | 香港科技大学 | 2024-05-02 | — | — | WO | disclosed |
| WO-2024088069-A1 | PREPARATION FOR AROMATIC KRAS MUTANT PROTEIN INHIBITOR AND USE THEREOF | 药雅科技(上海)有限公司 | 2024-05-02 | — | — | WO | disclosed |
| US-20240140940-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-05-02 | — | — | US | disclosed |
| WO-2024088377-A1 | PYRIMIDOPYRROLE ANALOG | 香港科技大学 | 2024-05-02 | — | — | WO | disclosed |
| EP-4359389-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359413-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359385-A2 | PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| EP-3753941-B1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359411-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11970506-B2 | Bioactive molecule conjugate, preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-04-30 | — | — | US | disclosed |
| US-RE49948-E1 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | NOVARTIS AG (CH) | 2024-04-30 | — | — | US | disclosed |
| US-11970552-B2 | Nicotinic acetylcholine receptor peptide antagonist conotoxin compositions and related methods | GLO PHARMA, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-11970731-B2 | Enhancement of nucleic acid polymerization by aromatic compounds | Roche Sequencing Solutions, Inc. (US) | 2024-04-30 | — | — | US | disclosed |
| US-11969472-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-04-30 | — | — | US | disclosed |
| CN-117956990-A | Compositions and methods for treating lipomatous pain | 拉结尔治疗有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117957212-A | IL-17A modulators based on phenylacetamide and uses thereof | 戴斯阿尔法公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-110769689-B | Novel supercooling method for preserving biological samples | 先时迈纳米生物科技股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086614-A2 | TARGETED LNP-MRNA WITH MINIMAL OFF-TARGET EXPRESSION AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086744-A2 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240131150-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | SUZHOU ABOGEN BIOSCIENCES CO LTD (CN) | 2024-04-25 | — | — | US | disclosed |
| US-20240131181-A1 | Therapeutic Targeting of Lipid Nanoparticles | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-04-25 | — | — | US | disclosed |
| WO-2024083172-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2024-04-25 | — | — | WO | disclosed |
| WO-2024083171-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2024-04-25 | — | — | WO | disclosed |
| US-20240132497-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2024-04-25 | — | — | US | disclosed |
| US-20240132484-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-04-25 | — | — | US | disclosed |
| US-20240132461-A1 | FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER | FLORATEK PHARMA S A (CH) | 2024-04-25 | — | — | US | disclosed |
| WO-2024083671-A1 | BROMINE- OR IODINE-PARA-SUBSTITUTED [(1,5-DIPHENYL-1H-1,2,4-TRIAZOL-3-YL)OXY]ACETIC ACID DERIVATIVES AND SALTS THEREOF, PROTECTION AGENTS COMPRISING THEM, FOR USEFUL PLANTS OR CROP PLANTS, METHODS FOR PRODUCING THEM AND USE THEREOF AS SAFENERS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024084028-A1 | PYRIDINE COMPOUNDS FOR COMBATTING DIHYDROOROTATE-DEHYDROGENASE INHIBITOR-RESISTANT PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2024-04-25 | — | — | WO | disclosed |
| US-20240130994-A1 | IONIC LIQUID FORMULATIONS FOR TREATING DIABETES | I2O THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240132493-A1 | IMIDAZOPYRIDINE DERIVATIVES AS STING AGONISTS | FULGENT GENETICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240130969-A1 | LIPID NANOPARTICLES AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240131035-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | ANTARES PHARMA, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024083670-A2 | BROMINE- OR IODINE-PARA-SUBSTITUTED [(1,5-DIPHENYL-1H-1,2,4-TRIAZOL-3-YL)OXY]ACETIC ACID DERIVATIVES AND THEIR SALTS, AGENTS FOR PROTECTING USEFUL PLANTS OR CROP PLANTS COMPRISING THEM, METHODS FOR PRODUCING THEM AND THEIR USE AS SAFENERS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024083024-A1 | PREPARATION AND USE OF RET INHIBITOR | 药雅科技(上海)有限公司 | 2024-04-25 | — | — | WO | disclosed |
| EP-4357020-A2 | ASYMMETRIC PHASE TRANSFER CATALYSIS | Merck Sharp & Dohme LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11964052-B2 | Lipid compounds and lipid nanoparticle compositions | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-04-23 | — | — | US | disclosed |
| CN-114685487-B | Pyrimidine heterocyclic compounds, preparation method and application | 上海凌达生物医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117903016-A | Fluorosulfonyl sulfonimide salt, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024079468-A1 | COMPOUNDS FOR USE AS MEDICAMENTS | CHARIOT INNOVATIONS LTD (GB) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024078906-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024078263-A1 | PREPARATION AND USE OF MACROCYCLIC HETEROCYCLIC COMPOUND AS EGFR INHIBITOR | 药雅科技(上海)有限公司 | 2024-04-18 | — | — | WO | disclosed |
| US-20240122854-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2024-04-18 | — | — | US | disclosed |
| US-20240124413-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2024-04-18 | — | — | US | disclosed |
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240125773-A1 | COMPOSITIONS AND METHODS FOR PREVENTING NON-SPECIFIC INTERACTIONS BETWEEN POLYMER DYES-ANTIBODY CONJUGATES | BECKMAN COULTER, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2024081789-A2 | HISTONE DEMETHYLASE INHIBITORS FOR TREATING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024081653-A2 | METHODS OF LOWERING MIRO2 TO TREAT NEURODEGENERATIVE DISEASES | ACUREX BIOSCIENCES CORPORATION (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024079252-A1 | SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | WO | disclosed |
| US-20240124645-A1 | COMPOSITION FOR REVERSIBLE POLYMERIZATION OF THIOESTER AND METHODS THEREOF | UNIV COLORADO REGENTS (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240124503-A1 | HETEROAROMATIC PHOSPHONIUM SALTS AND THEIR USE TREATING CANCER | FLORATEK PHARMA S A (CH) | 2024-04-18 | — | — | US | disclosed |
| EP-4351651-A1 | LIPID NANOPARTICLES AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-3893645-B1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2024-04-17 | — | — | EP | disclosed |
| EP-4353310-A2 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | Corcept Therapeutics Incorporated (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4353082-A1 | HERBICIDAL COMPOSITIONS | Bayer Aktiengesellschaft (DE) | 2024-04-17 | — | — | EP | disclosed |
| EP-4352062-A2 | 5-HT2A AND/OR 5-HT2C RECEPTOR AGONISTS | Diamond Therapeutics Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| EP-4351620-A1 | CELL-PERMEABLE CYCLIC PEPTIDES AND USES THEREOF | Unnatural Products Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-3737376-B1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASES | SHUTTLE PHARMACEUTICALS INC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117897385-A | Compound for degrading Bcl-2 family proteins and application of compound in medicine | 西藏海思科制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-113262175-B | Skin care compositions and methods of use thereof | 尤尼根公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-11961967-B2 | Silicon-based energy storage devices with phosphorus containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-04-16 | — | — | US | disclosed |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| CN-117881795-A | Methods and compositions for identifying methylated cytosines | 因美纳有限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024077009-A1 | FUNCTIONALIZED MACROMOLECULES AND SYSTEMS, METHODS OF SYNTHESIS, AND USES THEREOF | SEER, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240116877-A1 | KIT KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2024-04-11 | — | — | US | disclosed |
| US-20240117306-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20240116928-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024077057-A1 | PHENYL OXY AMIDE KINASE INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240116899-A1 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | INSILICO MEDICINE IP LIMITED (HK) | 2024-04-11 | — | — | US | disclosed |
| US-20240116949-A1 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | ETERN BIOPHARMA SHANGHAI CO LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| WO-2024074641-A1 | METHOD FOR PREPARING AMIDES FROM ESTERS | BASF SE (DE) | 2024-04-11 | — | — | WO | disclosed |
| EP-3368556-B1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | UNIV TUFTS (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347603-A1 | SULFUR-CONTAINING HETEROAROMATIC TRICYCLIC KRAS INHIBITORS | Erasca, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349833-A1 | PYRIDAZINONE COMPOUND AS PARP7 INHIBITOR | Euregen Biopharma Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349839-A2 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117843567-A | Diazaaryl ring substituted benzene derivatives, compositions and uses thereof | 康迈迪森(北京)医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117838695-A | PIM kinase inhibitors for the treatment of myeloproliferative neoplasms and cancer-related fibrosis | 住友制药肿瘤公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843566-A | Polysubstituted benzene derivative, composition and use thereof | 康迈迪森(北京)医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-112638898-B | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors | 泽农医药公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11951100-B2 | Formulations of RBP4 inhibitors and methods of use | BELITE BIO, LLC (US) | 2024-04-09 | — | — | US | disclosed |
| CN-117858881-A | Phospholipid compounds and methods of making and using the same | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-115043841-B | Preparation and application of heterocyclic compound serving as BTK inhibitor | 药雅科技(上海)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117836289-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use thereof | 上海睿跃生物科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-115181106-B | Quinazoline KRAS G12D Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117826534-A | Method for forming semiconductor device | 台湾积体电路制造股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117820305-A | Heterocyclic substituted quinazoline and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073426-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073410-A1 | TERNARY SOLVENT ELECTROLYTES FOR HIGH VOLTAGE AND HIGH RATE LITHIUM BATTERIES | SEPION TECHNOLOGIES, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024069448-A1 | SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024067744-A1 | HETEROCYCLIC SUBSTITUTED QUINAZOLINE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 苏州泽璟生物制药股份有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024067401-A1 | ULTRA-LONG-ACTING PLATFORM COMPRISING FC-ADVANCED FATTY ACID CHAIN | 中美华世通生物医药科技(武汉)股份有限公司 | 2024-04-04 | — | — | WO | disclosed |
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| US-20240109927-A1 | BIS (ARENE) METAL COMPLEXES AND RELATED METHODS | ENTEGRIS, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | YA THERAPEUTICS INC (CN) | 2024-04-04 | — | — | US | disclosed |
| US-20240109913-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-04-04 | — | — | US | disclosed |
| US-20240109891-A1 | NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2024073610-A2 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073436-A2 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024072908-A1 | COMPOUNDS WITH CLEAVABLE DISULFIDE MOIETIES | REINVIGORON THERATECH, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-3206692-B1 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INC (US) | 2024-04-03 | — | — | EP | disclosed |
| CN-117813288-A | Arylamino derivative estrogen receptor modulator and use thereof | 西藏海思科制药有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11949072-B2 | Silicon-based energy storage devices with electrolyte containing cyanate based compounds | ENEVATE CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | BIOMEA FUSION, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-11945890-B2 | Fluorinated PVC copolymer compositions for increased ultraviolet protection | Mexichem Specialty Resins Inc. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11945812-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-04-02 | — | — | US | disclosed |
| CN-117800976-A | Nitrogen-containing heterocyclic compound, preparation method and application | 上海凌达生物医药有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117794929-A | Selective BCL-XL PROTAC compounds and methods of use | 法国施维雅药厂 | 2024-03-29 | — | — | CN | disclosed |
| CN-112469720-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-114072207-B | Bicyclic compounds | 维瓦斯治疗公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | 858 THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| WO-2024064701-A2 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240101531-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2024-03-28 | — | — | US | disclosed |
| WO-2024064026-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20240101585-A1 | HETEROAROMATIC PHOSPHONIUM SALTS AND THEIR USE TREATING CANCER | FLORATEK PHARMA AG (CH) | 2024-03-28 | — | — | US | disclosed |
| EP-3615510-B1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340701-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | Belite Bio, LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11942599-B2 | Symmetrical or asymmetrical alkylsulfonyl imide or cyclic alkylene sulfonylimide salts as cathode additives, electrolyte additives, or SI anode additives for SI anode-based li-ion cells | ENEVATE CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939474-B2 | Water soluble fluorescent or colored dyes and methods for their use | Sony Group Corporation (JP) | 2024-03-26 | — | — | US | disclosed |
| CN-117751106-A | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2H-pyranylacetic acid compounds as LPA antagonists | 唯久生物技术(苏州)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117736178-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117736207-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-115448923-B | Pyrimidine-fused ring compound, preparation method and application thereof | 上海青煜医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-115362003-B | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20240092756-A1 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | DUNAD THERAPEUTICS LTD. (GB) | 2024-03-21 | — | — | US | disclosed |
| WO-2024056782-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-21 | — | — | WO | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| US-20240092810-A1 | COMPOSITIONS FOR EXTREME ULTRAVIOLET LITHOGRAPHY AND RELATED METHODS | ENTEGRIS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024059085-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES | INVEA THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024059041-A1 | BENZO-FUSED N-HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3641741-B1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3609906-B1 | NOVEL PEPTOID POLYMERS AND METHODS OF USE | X THERMA INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11931347-B2 | Method of screening for agents for differentiating stem cells | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| US-11932634-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-117730082-A | Synthesis of substituted tricyclic amides and analogs thereof | 爱彼特生物制药公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117720517-A | AR inhibitor, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-108137482-B | Prodrugs of directed lymphatics | 莫纳什大学 | 2024-03-15 | — | — | CN | disclosed |
| US-20240084074-A1 | NOVEL PEPTOID POLYMERS AND METHODS OF USE | X-THERMA, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | disclosed |
| US-20240084274-A1 | GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240084043-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. | 2024-03-14 | — | — | US | disclosed |
| WO-2024054387-A1 | BIS (ARENE) METAL COMPLEXES AND RELATED METHODS | ENTEGRIS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| WO-2024054512-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240084193-A1 | METAL OXIDE, METAL BRONZE AND POLYOXOMETALATE AS CHARGE STORAGE MATERIALS IN ELECTROCHROMIC DEVICE | Furcifer Inc. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4335848-A2 | DUAL MAGL AND FAAH INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4090655-B1 | PROCESS FOR PREPARING CYCLIC CARBONATES WITH AN EXOCYCLIC VINYLIDENE GROUP | BASF SE (DE) | 2024-03-13 | — | — | EP | disclosed |
| CN-117693353-A | Cell-permeable cyclic peptides and uses thereof | 安奈彻产品股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-116064598-B | Nucleic acid vaccine for coronavirus | 苏州艾博生物科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11926600-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-03-12 | — | — | US | disclosed |
| US-11926628-B2 | Diacylglyercol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117693511-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117659007-A | Pyrazinone derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-110267944-B | Compounds useful for the treatment of gastrointestinal disorders | 阿德利克斯股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240076306-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240075163-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2024-03-07 | — | — | US | disclosed |
| US-20240079653-A1 | Electrolyte Formulations for Optimal Performance in Si-Containing Lithium Ion Batteries | ENEVATE CORPORATION | 2024-03-07 | — | — | US | disclosed |
| WO-2024049979-A2 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024049919-A1 | COMPOSITIONS FOR EXTREME ULTRAVIOLET LITHOGRAPHY AND RELATED METHODS | ENTEGRIS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4329816-A1 | LIPID NANOPARTICLE THERAPEUTICS THAT EVADE THE IMMUNE RESPONSE | The Trustees of the University of Pennsylvania (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4330249-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | Viva Star Biosciences (Suzhou) Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| EP-4331669-A2 | SELECTIVE P2X3 ANTAGONISTS FOR USE IN TREATING CHRONIC COUGH WITHOUT LOSS OF TASTE RESPONSE | Bellus Health Inc. (CA) | 2024-03-06 | — | — | EP | disclosed |
| EP-4330391-A1 | COMPOSITIONS AND METHODS FOR TARGETING LIPID NANOPARTICLE THERAPEUTICS TO STEM CELLS | The Trustees of the University of Pennsylvania (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4329776-A1 | CD-90 TARGETED LIPID NANOPARTICLES | The Trustees of the University of Pennsylvania (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4330234-A1 | SUBSTITUTED PYRIDAZINONES, SALTS OR N-OXIDES THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2024-03-06 | — | — | EP | disclosed |
| EP-3615537-B1 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | NOVARTIS AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| EP-4330245-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Floratek Pharma SA (CH) | 2024-03-06 | — | — | EP | disclosed |
| EP-3512840-B1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | TSENG YUFENG JANE (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-3691642-B1 | [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-03-06 | — | — | EP | disclosed |
| US-11919869-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11918951-B2 | MOF compositions for selective separation of hydrocarbons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-03-05 | — | — | US | disclosed |
| US-11923545-B2 | Crown ethers as additives for silicon-based Li-ion batteries | ENEVATE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| US-11923506-B2 | Silicon-based energy storage devices with ether containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| US-11919972-B2 | Peptide libraries with non-canonical amino acids | REGENERON PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11919865-B2 | Processes for preparing AG-10, its intermediates, and salts thereof | Eidos Therapeutics, Inc. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117651549-A | Anti-angiogenic agents and related methods | 新加坡科技研究局 | 2024-03-05 | — | — | CN | disclosed |
| CN-117651701-A | Novel substituted bicyclic aza heterocycles as SOS1 inhibitors | 唯久生物技术(苏州)有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117642397-A | Modified proteins and protein binders | 上海睿跃生物科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-112739349-B | Combination therapy for the treatment of hematological cancers | 圣诺康生命科学公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240067625-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067623-A1 | [(1-PHENYL-5-HETEROARYL-1H-PYRAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-29 | — | — | US | disclosed |
| WO-2024041976-A1 | PROCESS FOR DISTILLATIVE RECOVERY OF 1,1,1,3,3,3-HEXAFLUORO-2-PROPANOL (HFIP) FROM MIXTURES WITH 4- SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044327-A1 | DHNT MONOMERS AND POLYMER DYES WITH MODIFIED PHOTOPHYSICAL PROPERTIES | BECKMAN COULTER, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240067626-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024044728-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-3294811-B1 | ULTRA BRIGHT DIMERIC OR POLYMERIC DYES | SONY GROUP CORP (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3705480-B1 | CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI RINGENE BIOPHARMA CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11912784-B2 | Methods of treating an eye disorder | KODIAK SCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911751-B2 | Catalyst compositions for hydroformylation and methods of use thereof | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911392-B2 | Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911393-B2 | Non-catalytic substrate-selective p38alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117597345-A | Heterocyclic derivatives as CaMKK2 inhibitors | 百时美施贵宝公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117597346-A | NEK7 inhibitors | 哈利亚治疗公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2024038356-A1 | SYNTHESIS OF SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS AND SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-22 | — | — | WO | disclosed |
| US-20240059671-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-02-22 | — | — | US | disclosed |
| WO-2024038357-A1 | SYNTHESIS OF SUBSTITUTED TETRACYCLIC CARBOXYLIC ACIDS AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-22 | — | — | WO | disclosed |
| EP-4324825-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Beijing Best Pathway Management Consulting Center (Limited Partnership) (CN) | 2024-02-21 | — | — | EP | disclosed |
| EP-4322962-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-02-21 | — | — | EP | disclosed |
| EP-4323399-A1 | METHODS OF TREATING AN EYE DISORDER | Kodiak Sciences Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-3762365-B1 | METHODS AND COMPOSITIONS OF ISOINDOLINE-1,3-DIONE AND ISOINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES | AMGEN EUROPE GMBH (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-4323359-A2 | TETRACYCLIC COMPOUNDS FOR TREATING BRAIN DISORDERS | The Regents of the University of California (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-117580587-A | Coronavirus nucleic acid vaccine based on sequences derived from SARS-CoV-2 Omikovia strain | 苏州艾博生物科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-114805361-B | Amino substituted aromatic heterocyclic pyrazole compound, preparation method and application | 上海凌达生物医药有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117580477-A | Reducing viral infection | 福克斯生物有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11905291-B2 | — | — | 2024-02-20 | — | — | US | disclosed |
| US-11905444-B2 | Quantum dots and processes for preparation thereof | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-02-20 | — | — | US | disclosed |
| US-11905252-B2 | Compounds | INFLAZOME LIMITED (IE) | 2024-02-20 | — | — | US | disclosed |
| CN-117567478-A | Camptothecins compound and its preparation method and application | 四川科伦博泰生物医药股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20240050512-A1 | REDUCTION OF VIRAL INFECTIONS | PHOXBIO LIMITED (IE) | 2024-02-15 | — | — | US | disclosed |
| WO-2024035339-A1 | AN IMPROVED GALACTOSE OXIDASE ENZYME PANEL FOR OXIDATION OF SECONDARY ALCOHOLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-02-15 | — | — | WO | disclosed |
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| US-20240052092-A1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20240051896-A1 | METHODS OF FORMING LOW SALT NITROGEN-BASED FERTILIZER | Cynagra LLC | 2024-02-15 | — | — | US | disclosed |
| US-20240050573-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2024-02-15 | — | — | US | disclosed |
| US-20240051930-A1 | HETEROAROMATIC SPERMIDINE ANALOGUES AND THEIR ANTICANCER ACTIVITY | FLORATEK PHARMA S.A. (CH) | 2024-02-15 | — | — | US | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4320103-A1 | PYRIMIDINE BASED RAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4320105-A1 | OPIOID RECEPTOR MODULATORS | Epiodyne, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117551073-A | Thienylaniline compounds for the treatment of dermatological disorders | 恩福莱克逊治疗有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117561258-A | Novel substituted tricyclic aza heterocycles as SOS1 inhibitors | 唯久生物技术(苏州)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11897867-B2 | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-13 | — | — | US | disclosed |
| US-11901508-B2 | Silicon-based energy storage devices with functionalized linear sulfonate ester derivative compound containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897865-B2 | ABHD12 inhibitors and methods of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-02-13 | — | — | US | disclosed |
| CN-114656791-B | Polymer-silica hybrid PDOT and methods of use thereof | 华盛顿大学 | 2024-02-09 | — | — | CN | disclosed |
| US-20240047098-A1 | POLYMER-SILICA HYBRID PDOTS AND METHODS OF USE THEREOF | UNIVERSITY OF WASHINGTON (US) | 2024-02-08 | — | — | US | disclosed |
| US-20240042010-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | SUZHOU ABOGEN BIOSCIENCES CO LTD (CN) | 2024-02-08 | — | — | US | disclosed |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-02-08 | — | — | US | disclosed |
| US-20240043455-A1 | WATER SOLUBLE FLUORSCENT OR COLORED DYES COMPRISING CONJUGATING GROUPS | SONY GROUP CORP (JP) | 2024-02-08 | — | — | US | disclosed |
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| US-20240043387-A1 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY INC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20240041827-A1 | COMPOSITIONS FOR THE TREATMENT OF FAT RELATED CONDITIONS AND DISORDERS | RAZIEL THERAPEUTICS LTD. (IL) | 2024-02-08 | — | — | US | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024027703-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2024-02-08 | — | — | WO | disclosed |
| EP-4313100-A2 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO Pharma, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4315330-A1 | HALOGENATED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313968-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313943-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313988-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117510468-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11890275-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. | 2024-02-06 | — | — | US | disclosed |
| US-11894519-B2 | Silicon-based energy storage devices with linear carbonate containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-02-06 | — | — | US | disclosed |
| US-11891404-B2 | Substituted macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-06 | — | — | US | disclosed |
| CN-116478145-B | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117500507-A | Phosphorus derivatives as novel SOS1 inhibitors | 拜耳公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024023641-A1 | METHODS OF TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITOR DOSING FIELD OF THE INVENTION | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026500-A2 | INHIBITORS OF PDE11A4 AND METHODS OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240034845-A1 | POLYMER PARTICLES | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2024-02-01 | — | — | US | disclosed |
| WO-2024024963-A1 | MODIFIED POLYISOCYANATE, COATING AND COATED METAL MATERIAL | 関西ペイント株式会社 | 2024-02-01 | — | — | WO | disclosed |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2024022263-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| CN-117479945-A | Large conductance potassium channel modulators, compositions thereof, methods of making and methods of using the same | 依那拉治疗股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117466868-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117480155-A | Diacylglycerol kinase modulating compounds | 吉利德科学公司 | 2024-01-30 | — | — | CN | disclosed |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-01-30 | — | — | US | disclosed |
| US-11883381-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-30 | — | — | US | disclosed |
| US-11884648-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11884666-B2 | Azabicyclo and diazepine derivatives | ALCON INC. (CH) | 2024-01-30 | — | — | US | disclosed |
| US-11884673-B2 | Modulators of ion channel receptors and uses thereof | BIONOMICS LIMITED (AU) | 2024-01-30 | — | — | US | disclosed |
| US-11883397-B2 | Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11888114-B2 | Silicon-based energy storage devices with fluorinated polymer containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-01-30 | — | — | US | disclosed |
| CN-117460827-A | Nucleic acid vaccine for rabies | 苏州艾博生物科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117460518-A | CD-90 targeted lipid nanoparticles | 宾夕法尼亚大学理事会 | 2024-01-26 | — | — | CN | disclosed |
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240024403-A1 | Compositions and Methods for Managing Weight | UNIGEN, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025868-A1 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240024870-A1 | MODIFICATION OF SURFACE PROPERTIES OF MICROFLUIDIC DEVICES | BIO RAD LABORATORIES INC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2024019770-A1 | METHODS OF MAKING IONIZABLE LIPIDS AND LIPID NANOPARTICLES FOR MRNA DELIVERY | UNIVERSITY OF CINCINNATI (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240025903-A1 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | ATHIRA PHARMA, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240025913-A1 | TERTIARY CARBOXAMIDE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2024018403-A1 | SUBSTITUTED IMIDAZOAMIDE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024018017-A1 | CATIONIC CHROMENONES AND THEIR USE IN ONCOLOGY | Floratek Pharma SA (CH) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020346-A2 | GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4308666-A1 | MULTIFUNCTIONAL LIQUID CRYSTALLINE PHOTOREACTIVE POLYMERS FOR POLARIZATION HOLOGRAPHY | META PLATFORMS TECHNOLOGIES, LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4308982-A1 | RECORDING A LATENT HOLOGRAPHIC GRATING AND AMPLIFICATION OF ITS DYNAMIC RANGE | META PLATFORMS TECHNOLOGIES, LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4308983-A1 | SPATIALLY VARYING DYNAMIC RANGE IN HOLOGRAPHIC GRATINGS | META PLATFORMS TECHNOLOGIES, LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4309002-A1 | RECORDING A LATENT HOLOGRAPHIC GRATING AND AMPLIFICATION OF ITS DYNAMIC RANGE | META PLATFORMS TECHNOLOGIES, LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11878027-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-11878982-B2 | Spiropiperidine derivatives | 89BIO LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| US-11879024-B1 | Soft mold formulations for surface relief grating fabrication with imprinting lithography | META PLATFORMS TECHNOLOGIES, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | 89BIO LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| CN-117440774-A | Biomarkers of age-related macular degeneration | 倍亮生物有限责任公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117430588-A | Pyridazinone heterocyclic compound Myosin II inhibitor and application thereof | 西藏海思科制药有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117425646-A | Phosphono derivative, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117425644-A | Opioid receptor modulators | 埃皮欧黛公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117425496-A | Lipid nanoparticle therapy to evade immune responses | 宾夕法尼亚大学理事会 | 2024-01-19 | — | — | CN | disclosed |
| CN-117417279-A | Phenoxyacetic acid compound, isomer thereof, pharmaceutically acceptable salt or solvate thereof, pharmaceutical composition and medical application | 中国人民解放军军事科学院军事医学研究院 | 2024-01-19 | — | — | CN | disclosed |
| CN-117417281-A | Anti-inflammatory, anti-cancer and anti-angiogenic compounds, pharmaceutical compositions and methods of making and using the same | 麦迪康制药公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2024015950-A1 | METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE | MONSANTO TECHNOLOGY LLC (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024012524-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2024-01-18 | — | — | WO | disclosed |
| WO-2024013015-A1 | HERBICIDAL COMPOSITIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024013193-A1 | ALKOXYLATED ALKANOLS FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS | BASF SE (DE) | 2024-01-18 | — | — | WO | disclosed |
| US-20240018149-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | ANHORN MEDICINES CO., LTD. (TW) | 2024-01-18 | — | — | US | disclosed |
| US-20240016152-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-18 | — | — | US | disclosed |
| US-20240016786-A1 | GLUCOSIDASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PULMONARY INFECTIONS | COVIRIX Medical Pty Ltd (AU) | 2024-01-18 | — | — | US | disclosed |
| WO-2024013016-A1 | HERBICIDAL COMPOSITIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-18 | — | — | WO | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| WO-2024015949-A2 | METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE | MONSANTO TECHNOLOGY LLC (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2024013724-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024012523-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2024-01-18 | — | — | WO | disclosed |
| WO-2024013723-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | disclosed |
| EP-3384549-B1 | SODIUM-ION ELECTROLYTE COMPOSITION | UNIV DEAKIN (AU) | 2024-01-17 | — | — | EP | disclosed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
| EP-4304567-A1 | TARGETED THERAPEUTIC LIPID NANOPARTICLES AND METHODS OF USE | The Trustees of the University of Pennsylvania (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4305030-A1 | HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117398474-A | Bioactive conjugate, preparation method and application thereof | 苏州宜联生物医药有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-113816969-B | Eptification control compound, antibody drug conjugate thereof and application thereof | 联宁（苏州）生物制药有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11872239-B2 | Modified oligomeric compounds comprising tricyclo-DNA nucleosides and uses thereof | SYNTHENA AG (CH) | 2024-01-16 | — | — | US | disclosed |
| CN-117412959-A | Substituted 1-aryl-1 '-heteroaryl compounds, substituted 1,1' -biaryl compounds, and methods of use thereof | 爱彼特生物制药公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11876180-B2 | Silicon-based energy storage devices with metal sulfide containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11876179-B2 | Silicon-based energy storage devices with electrolyte containing dimethoxyethane based compound | ENEVATE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117396478-A | Diacylglycerol kinase modulating compounds | 吉利德科学公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117396604-A | Compositions and methods for targeting lipid nanoparticle therapies to stem cells | 宾夕法尼亚大学理事会 | 2024-01-12 | — | — | CN | disclosed |
| CN-117396480-A | Pyrazolopyrimidinone compounds | 奥弗恩制药公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117396194-A | Targeted therapeutic lipid nanoparticles and methods of use | 宾夕法尼亚大学理事会 | 2024-01-12 | — | — | CN | disclosed |
| CN-114106278-B | Polyurethane/urea materials | 联邦科学和工业研究组织 | 2024-01-12 | — | — | CN | disclosed |
| US-20240011976-A1 | ADDITIVES FOR REDUCING NON-SPECIFIC INTERACTIONS BETWEEN FLUORESCENT POLYMER CONJUGATES AND CELLS IN A BIOLOGICAL SAMPLE | BECKMAN COULTER, INC. | 2024-01-11 | — | — | US | disclosed |
| EP-4301371-A1 | SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA | Bayer Aktiengesellschaft (DE) | 2024-01-10 | — | — | EP | disclosed |
| EP-4301759-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3813784-B1 | PRC1 INHIBITORS AND PRC1 INHIBITORS FOR USE IN METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117377664-A | Small molecule modulators of orphan nuclear receptor TLX | 贝勒医学院 | 2024-01-09 | — | — | CN | disclosed |
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117377671-A | Diacylglycerol kinase modulating compounds | 吉利德科学公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-111454165-B | Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-115919859-B | Pharmaceutical composition of heteroaryl derivative and application of pharmaceutical composition in medicine | 四川海思科制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20240002611-A1 | MULTIFUNCTIONAL RESINS FOR 3D PRINTED MATERIALS AND METHODS OF MAKING SAME | META PLATFORMS TECHNOLOGIES, LLC (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2024006391-A1 | MENIN-MLL INHIBITORS AND COMPOSITIONS FOR PROLIFERATION OF BETA CELLS | BIOMEA FUSION, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024003749-A1 | COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA | PIN THERAPEUTICS, INC. (KR) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024007016-A2 | NOVEL FLUORESCENT DYES AND POLYMERS FROM DIHYDROPHENANTHRENE DERIVATIVES | BECKMAN COULTER, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006929-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3684368-B1 | SELECTIVE P2X3 ANTAGONISTS FOR USE IN TREATING CHRONIC COUGH WITHOUT LOSS OF TASTE RESPONSE | BELLUS HEALTH COUGH INC (CA) | 2024-01-03 | — | — | EP | disclosed |
| EP-4298101-A1 | PORPHYRIN DERIVATIVES AND USES THEREOF | University Of Tasmania (AU) | 2024-01-03 | — | — | EP | disclosed |
| US-11857555-B2 | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol | ANTARES PHARMA, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11859130-B2 | Metal oxide, metal bronze and polyoxometalate as charge storage materials in electrochromic device | Furcifer Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-111050765-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-02 | — | — | US | disclosed |
| CN-112105355-B | ABHD12 inhibitors and methods of making and using the same | 斯克利普斯研究所 | 2024-01-02 | — | — | CN | disclosed |
| CN-115626927-B | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117337289-A | Tetracyclic compounds for the treatment of brain disorders | 加利福尼亚大学董事会 | 2024-01-02 | — | — | CN | disclosed |
| CN-113527299-B | Nitrogen-containing condensed ring compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-114907350-B | Nitrogen-containing condensed ring compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230416269-A1 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | COA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230416245-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-20230416468-A1 | BIOACTIVE POLYETHYLENE COPOLYMER, POLYETHYLENE MACROMOLECULE AND RELATED METHODS THEREOF | MITSUI CHEMICALS, INC. (JP) | 2023-12-28 | — | — | US | disclosed |
| US-20230416229-A1 | [(1,5-DIHETEROARYL-1H-1,2,4-TRIAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-28 | — | — | US | disclosed |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-20230416452-A1 | MULTICOLORED ELECTROCHROMIC POLYMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | LANNRAY ADVANCED MATERIALS CO. LTD (CN) | 2023-12-28 | — | — | US | disclosed |
| US-20230416286-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2023250141-A2 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023250427-A2 | FORMULATIONS FOR MODULATING MYC EXPRESSION | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023250429-A2 | COMBINATION THERAPIES COMPRISING MYC MODULATION | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-117295727-A | Pyridazinones as PARP7 inhibitors | 中山优理生物医药有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117263950-A | Pyridazine compound, pharmaceutical composition and application thereof | 上海优理惠生医药有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-115073469-B | Preparation and application of pyrrolopyrimidine compound as kinase inhibitor | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-114057749-B | Preparation method and application of irreversible alkyne heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-115073468-B | Preparation and application of imidazopyrazines BTK inhibitor | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279644-A | Substituted 3, 6-dihydro-2H-1, 3, 4-oxadiazin-2-ones for the treatment of sarcomas | 拜耳股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117263959-A | Preparation and application of aromatic KRAS mutant protein inhibitor | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117263999-A | Camptothecin prodrugs and pharmaceutical compositions thereof | 天津和美奥康医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-115028633-B | Preparation and application of pyrrolopyrimidine compound | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279913-A | Heterocyclic compounds and their use | 金橘生物科技公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230413432-A1 | SELF-HEALABLE, RECYCLABLE, AND RECONFIGURABLE WEARABLE ELECTRONICS DEVICE | NATIONAL SCIENCE FOUNDATION | 2023-12-21 | — | — | US | disclosed |
| US-20230404984-A1 | FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | Belite Bio (HK) Limited (HK) | 2023-12-21 | — | — | US | disclosed |
| US-20230405015-A1 | SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-21 | — | — | US | disclosed |
| EP-4292655-A2 | HEXADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | Taro Pharmaceuticals Inc. (CA) | 2023-12-20 | — | — | EP | disclosed |
| CN-111757884-B | Substituted macrocyclic indole derivatives | 拜耳股份公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11848419-B2 | Metal amide bases as electrolyte additives for Si anode-based Li-ion batteries | ENEVATE CORPORATION (US) | 2023-12-19 | — | — | US | disclosed |
| US-11845753-B2 | Inhibitors of menin-mll interaction | BIOMEA FUSION, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11848418-B2 | Single lithium-ion conductive polymer electrolytes for Si anode-based lithium-ion batteries | ENEVATE CORPORATION (US) | 2023-12-19 | — | — | US | disclosed |
| CN-117229300-A | Preparation and application of EGFR inhibitor | 药雅科技(上海)有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117229262-A | Preparation and application of polyaromatic ring EGFR inhibitor | 药雅科技(上海)有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117229292-A | Preparation and application of RET inhibitor | 药雅科技(上海)有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117229263-A | Compound for inhibiting or degrading Bcl6 and application of compound in medicine | 四川海思科制药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117229289-A | Preparation and application of EGFR inhibitor with macrocyclic structure | 药雅科技(上海)有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117229261-A | Preparation and application of EGFR inhibitor | 药雅科技(上海)有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117224593-A | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | 尤尼根公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230399565-A1 | POLYMER DYES AND USES THEREOF | BECKMAN COULTER, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230397604-A1 | [(1-PHENYL-5-(HETEROARYL)-1H-1,2,4-TRIAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | BAYER AKTIENGELLSCHAFT (DE) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230399457-A1 | Bioactive Synthetic Copolymer, Bioactive Macromolecule and Related Methods Thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-14 | — | — | US | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-4288418-A1 | SUBSTITUTED (2-HETEROARYLOXYPHENYL)SULFONATES, SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-4288422-A1 | HETEROAROMATIC SPERMIDINE ANALOGUES AND THEIR ANTICANCER ACTIVITY | Floratek Pharma SA (CH) | 2023-12-13 | — | — | EP | disclosed |
| EP-4288433-A1 | NOVEL COMPOUNDS | Cerevance, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4288421-A1 | FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER | Floratek Pharma SA (CH) | 2023-12-13 | — | — | EP | disclosed |
| EP-3612532-B1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | NEUROCRINE BIOSCIENCES INC (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289425-A2 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | Tseng, Yufeng, Jane (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4288423-A1 | COMBINATION OF DUAL ATM AND DNA-PK INHIBITORS AND IMMUNOTHERAPEUTIC AGENTS FOR USE IN CANCER THERAPY | XRad Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4288434-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoires Servier (FR) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289851-A1 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-11840543-B2 | Compounds and uses | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-12-12 | — | — | US | disclosed |
| CN-117222409-A | Methods of treating spinal cord injury or damage | 斯皮诺吉尼克斯公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117222642-A | Analogues for the treatment of disease | 英矽智能科技知识产权有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117222625-A | Substituted pyridazinones, salts or N-oxides thereof and their use as herbicidal agents | 拜耳公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117222641-A | Analogues for the treatment of disease | 英矽智能科技知识产权有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117202895-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023235880-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023235618-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023235321-A1 | CO-MONOMERS FOR POLYMERIZATION OF DECONSTRUCTABLE THERMOSETS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023232048-A1 | CAMPTOTHECIN PRODRUG AND PHARMACEUTICAL COMPOSITION THEREOF | 天津和美奥康医药科技有限公司 | 2023-12-07 | — | — | WO | disclosed |
| WO-2023231988-A1 | PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF | 苏州宜联生物医药有限公司 | 2023-12-07 | — | — | WO | disclosed |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| US-20230389542-A1 | USE OF [(1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AND THEIR SALTS AND COMPOSITIONS CONTAINING THEM, FOR REDUCING PHYTOTOXIC EFFECTS OF AGROCHEMICALS, IN PARTICULAR OF HERBICIDES, IN USEFUL PLANTS AND CROP PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-20230391765-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-12-07 | — | — | US | disclosed |
| US-20230391790-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | TARO PHARMACEUTICALS INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| US-20230391784-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2023-12-07 | — | — | US | disclosed |
| US-20230391815-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2023-12-07 | — | — | US | disclosed |
| WO-2023235753-A2 | ALDH2 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-4284517-A1 | HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER | Floratek Pharma SA (CH) | 2023-12-06 | — | — | EP | disclosed |
| EP-4284515-A1 | HETEROAROMATIC PHOSPHONIUM SALTS AND THEIR USE TREATING CANCER | Floratek Pharma SA (CH) | 2023-12-06 | — | — | EP | disclosed |
| EP-4286381-A2 | TREATMENT OF MERKEL CELLL CARCINOMA | Celgene Quanticel Research, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-4284514-A1 | HETEROAROMATIC PHOSPHONIUM SALTS AND THEIR USE TREATING CANCER | Floratek Pharma SA (CH) | 2023-12-06 | — | — | EP | disclosed |
| EP-3496721-B1 | TREATMENT OF MERKEL CELLL CARCINOMA | CELGENE QUANTICEL RES INC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11837711-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-12-05 | — | — | US | disclosed |
| CN-110143999-B | Cytotoxic and antimitotic compounds and methods of use thereof | 酵活英属哥伦比亚省公司 | 2023-12-05 | — | — | CN | disclosed |
| US-11834551-B2 | Photoactive macromolecules and uses thereof | BECKMAN COULTER, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834440-B2 | Beta-lactam derivatives for the treatment of diseases | INSILICO MEDICINE IP LIMITED (HK) | 2023-12-05 | — | — | US | disclosed |
| US-11834466-B2 | Benzoxaborole compounds and formulations thereof | 5METIS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| CN-117164657-A | Prodrugs of directed lymphatics | 莫纳什大学 | 2023-12-05 | — | — | CN | disclosed |
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11834434-B2 | Substituted 2-heteroaryloxypyridines and salts thereof and their use as herbicidal agents | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-05 | — | — | US | disclosed |
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | THE WISTAR INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| CN-117164661-A | Peptide compound, preparation method thereof, pharmaceutical composition containing peptide compound and application of pharmaceutical composition | 上海优理惠生医药有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-117143177-A | Preparation method of drug connector conjugate and intermediate thereof | 苏州宜联生物医药有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-114524810-B | Pyrimidine heterocyclic compounds, preparation method and application | 上海凌达生物医药有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117143079-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-113563323-B | Benzothiazolyl biaryl compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117143178-A | Preparation method of drug connector conjugate and intermediate thereof | 苏州宜联生物医药有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230381329-A1 | Zwitterion Polymer-Drug Conjugates | UNIV UTAH RES FOUND (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023230472-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230383038-A1 | CO-MONOMERS FOR POLYMERIZATION OF DECONSTRUCTABLE THERMOSETS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2023-11-30 | — | — | US | disclosed |
| US-20230382983-A1 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382874-A1 | [(5-PHENYL-1-HETEROARYL-1H-TRIAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227867-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Cerevance, Inc. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-11-30 | — | — | US | disclosed |
| EP-3735404-B1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | SEAL ROCK THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-4281069-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | NFlection Therapeutics, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11827661-B2 | Water soluble fluorescent or colored dyes comprising conjugating groups | Sony Group Corporation (JP) | 2023-11-28 | — | — | US | disclosed |
| CN-117136056-A | Process for preparing pyrrolopyridine-anilines | 恩福莱克逊治疗有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-115028634-B | Acetylenic pyrazino heterocycle FGFR inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117136076-A | MCL-1 inhibitor antibody drug conjugates and methods of use | 诺华股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-111902399-B | Enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts | 拜耳公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117120415-A | Modified indole alkaloids for therapeutic use | 指南针探路者有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-114853723-B | Preparation and application of indole compound BTK inhibitor | 药雅科技(上海)有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023225005-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023223097-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023221975-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING PROTEIN DEGRADATION AGENT BIOACTIVE COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 苏州宜联生物医药有限公司 | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224998-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373832-A1 | MICROBIAL REMEDIATION OF HALOGENATED COMPOUNDS VIA CHAIN ELONGATION AND DEHALOGENATION | NATIONAL SCIENCE FOUNDATION | 2023-11-23 | — | — | US | disclosed |
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230372537-A1 | LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2023-11-23 | — | — | US | disclosed |
| WO-2023225001-A1 | NAPHTHYRIDINE BASED ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-3586835-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ARYL ETHERS | PELOTON THERAPEUTICS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3988631-B1 | POLYMER-SILICA HYBRID PDOTS | UNIV WASHINGTON (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11820728-B2 | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2023-11-21 | — | — | US | disclosed |
| US-11823809-B2 | Polymer-silica hybrid pdots and methods of use thereof | UNIVERSITY OF WASHINGTON (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| CN-111132974-B | Sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-117088931-A | Prodrugs of directed lymphatics | 莫纳什大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-112218873-B | Metallocene synthesis process | 埃克森美孚化学专利公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-117069785-A | Lipid compounds and lipid nanoparticle compositions | 中生复诺健生物科技(上海)有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117083274-A | Fused ring heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069682-A | Phenoxyacetic acid compound, pharmaceutical composition and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-11-17 | — | — | CN | disclosed |
| CN-117083291-A | Coronavirus nucleic acid vaccine based on sequences derived from SARS-CoV-2Delta strain | 苏州艾博生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | RMW CHO GROUP LIMITED (HK) | 2023-11-16 | — | — | US | disclosed |
| WO-2023220741-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| WO-2023216956-A1 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4276126-A1 | POLYURETHANE/UREA MATERIALS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2023-11-15 | — | — | EP | disclosed |
| CN-117050058-A | Fused heterocyclic compound, composition thereof and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-113061132-B | Condensed ring lactam compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-112262142-B | Benzenesulfonamide compounds and their use as therapeutic agents | 泽农医药公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11817578-B2 | Silicon-based energy storage devices with silyl amine compounds or derivatives of silyl amine containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814795-B2 | Coating for recyclable paper | JL DARLING LLC (US) | 2023-11-14 | — | — | US | disclosed |
| CN-110582480-B | Therapeutic compounds and methods | 塔斯马尼亚大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-117043862-A | Halogenated monomers and polymers for volume Bragg gratings | 元平台技术有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117043343-A | Nucleic acid vaccine for mutant coronaviruses | 苏州艾博生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117043140-A | Substituted pyrrolidin-2-ones, salts thereof and their use as herbicidal active substances | 拜耳公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117043143-A | Substituted 2- (heteroaryloxyphenyl) sulfonates, salts thereof and their use as herbicides | 拜耳公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117042780-A | In vivo targeting of T cells for mRNA therapeutic agents | 宾夕法尼亚大学理事会 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023215377-A1 | METHODS OF TREATING NEUROINFLAMMATORY CONDITIONS | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215709-A1 | EFFICIENT METHOD OF SYNTHESIZING LINEAR OLIGOMERS AND APPLICATION TO FRONTAL RING-OPENING METATHESIS POLYMERIZATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230357239-A1 | PYRIDO[2,3-D]PYRIMIDIN-4-AMINES AS SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357490-A1 | EFFICIENT METHOD OF SYNTHESIZING LINEAR OLIGOMERS AND APPLICATION TO FRONTAL RING-OPENING METATHESIS POLYMERIZATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023215710-A1 | EVERGREEN UPCYCLING PROCESS FOR THERMOSETS AND THERMOPLASTICS WITH DECONSTRUCTABLE AND UPGRADABLE MONOMERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357459-A1 | MECHANICALLY STIMULATED MECHANOPHORES, POLYMERS THEREOF, METHODS OF PREPARATION THEREOF, AND SYSTEMS THEREOF FOR CONTROLLED EMISSION OF SMALL MOLECULES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2023-11-09 | — | — | US | disclosed |
| US-20230355584-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIPID-RELATED DISORDERS | RAZIEL THERAPEUTICS LTD. (IL) | 2023-11-09 | — | — | US | disclosed |
| WO-2023215376-A1 | METHODS OF TREATING NEUROPATHIES | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | disclosed |
| CN-117003658-A | Lipid Nanoparticle Compositions | 苏州艾博生物科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| CN-117015711-A | Compositions and methods for preventing non-specific interactions between polymer dye-antibody conjugates | 贝克曼库尔特有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-117015534-A | Combination of dual ATM and DNA-PK inhibitors for cancer therapy and immunotherapeutic agents | 艾科思莱德制药公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-117015745-A | Recording a latent holographic grating and magnifying its dynamic range | 元平台技术有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-111655666-B | Anti-inflammatory, anti-cancer and anti-angiogenic compounds, pharmaceutical compositions and methods of making and using the same | 麦迪康制药公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116997827-A | Spatially varying dynamic range in holographic gratings | 元平台技术有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-110312533-B | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | 拜耳公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116987509-A | Liquid crystal compound, composition and application thereof | 北京燕化集联光电技术有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116997797-A | Additives for reducing non-specific interactions between fluorescent polymer conjugates and cells in biological samples | 贝克曼库尔特有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20230348852-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212612-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN SHAWN (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230348674-A1 | HYDROGELS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2023-11-02 | — | — | US | disclosed |
| US-20230348689-A1 | EVERGREEN UPCYCLING PROCESS FOR THERMOSETS AND THERMOPLASTICS WITH DECONSTRUCTABLE AND UPGRADABLE MONOMERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2023-11-02 | — | — | US | disclosed |
| WO-2023212548-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230348362-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348419-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| US-20230348392-A1 | PYRIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230346927-A1 | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-02 | — | — | US | disclosed |
| WO-2023209368-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230348475-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 | TRANSLATIONAL GENOMICS RES INST (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2023212549-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4267561-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | Baylor College of Medicine (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-112707893-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-111801314-B | ASK1 inhibitor compounds and uses thereof | 西尔洛克治疗公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969921-A | Compound for inhibiting or degrading HPK1 kinase and application thereof in medicine | 四川海思科制药有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116981665-A | Novel compounds | 思瑞万斯公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116981968-A | Recording latent holographic grating and amplification of dynamic range thereof | 元平台技术有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116948657-A | Liquid crystal compound, composition and application thereof | 北京燕化集联光电技术有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-114805359-B | Preparation method and application of acetylenic heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116947877-A | Benzimidazole derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023204822-A1 | PHENYL PHOSPHINE OXIDE COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023202582-A1 | GPCR REGULATOR AND USE THEREOF | 北京昌平实验室 | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023205719-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-26 | — | — | US | disclosed |
| US-20230338565-A1 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023205116-A1 | PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-4265616-A1 | SPIROCYCLIC COMPOUND AS KRAS-G12C INHIBITOR | Shanghai Euregen Biopharma Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-4263504-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS Pathfinder Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| EP-3659591-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-3041830-B1 | POLYMER-FLAVONOID CONJUGATES AND HYDROGELS FOR BIOMEDICAL APPLICATIONS | AGENCY SCIENCE TECH & RES (SG) | 2023-10-25 | — | — | EP | disclosed |
| EP-4263542-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | Biomea Fusion, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116940679-A | Oligomeric compounds for dystrophin rescue in DMD patients by skipping of exon-51 | SQY治疗公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116925070-A | Substituted aza-fused ring compounds and medical uses thereof | 扬子江药业集团有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-115368381-B | Preparation and application of heterocyclic inhibitor | 药雅科技(上海)有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116940685-A | Coronavirus multivalent nucleic acid vaccine based on sequences derived from SARS-CoV-2Beta and Delta strains | 苏州艾博生物科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116903695-A | Cyclic peptide compound, preparation method thereof, pharmaceutical composition containing cyclic peptide compound and application of cyclic peptide compound | 上海优理惠生医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116903563-A | GPCR modulators and uses thereof | 北京昌平实验室 | 2023-10-20 | — | — | CN | disclosed |
| CN-116917440-A | Multifunctional liquid crystal photoreactive polymers for polarization holography | 元平台技术有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116903609-A | Compound, pharmaceutical composition containing same and application of compound | 上海优理惠生医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116903610-A | Heterocyclic condensed pyridines, pharmaceutical compositions and uses thereof | 上海优理惠生医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-114591334-B | Dihydropyrazolopyrimidinone derivatives | 山东轩竹医药科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116903696-A | Peptide compound, preparation method thereof, pharmaceutical composition containing peptide compound and application of pharmaceutical composition | 上海优理惠生医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116903611-A | Phthalazinone compound, preparation method thereof, pharmaceutical composition containing phthalazinone compound and application of pharmaceutical composition | 上海优理惠生医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116917289-A | T-type calcium channel antagonists and uses thereof | 小利兰·斯坦福大学董事会 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023200766-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO, INC (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230331655-A1 | HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-19 | — | — | US | disclosed |
| WO-2023198114-A1 | ALK2 KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2023-10-19 | — | — | WO | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| EP-4259105-A1 | IN VIVO TARGETING OF CD4+ -T CELLS FOR MRNA THERAPEUTICS | The Trustees of the University of Pennsylvania (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116888127-A | Tri-fused ring HPK1 inhibitor and application thereof | 轩竹生物科技股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230323031-A1 | POLYMER COMPRISING A PLURALITY OF ACTIVE AMINE GROUPS, RELATED POLYMERS AND RELATED METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-10-12 | — | — | US | disclosed |
| US-20230322672-A1 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | VIEWPOINT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257591-A2 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11780862-B2 | Inhibitors of MEK kinase | KINNATE BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780850-B2 | Purification of rapamycin derivatives using temperature induced phase separation | BIOSENSORS INTERNATIONAL GROUP, LTD. (BM) | 2023-10-10 | — | — | US | disclosed |
| US-11780819-B2 | Aromatic substituted alkane-core monomers and polymers thereof for volume Bragg gratings | META PLATFORMS TECHNOLOGIES, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-116850163-A | Methods for treating diabetic retinopathy and other ophthalmic diseases | 奥克塞拉有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116854709-A | Reversible inhibitors of Bruton's tyrosine kinase and application thereof | 药雅科技(上海)有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116867372-A | [ (5-phenyl-1-heteroaryl-1H-pyrazol-3-yl) oxy ] acetic acid derivatives as safeners for protecting useful plants and crop plants | 拜耳公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230310398-A1 | NICORANDIL DERIVATIVES | Unicycive Therapeutics Inc. | 2023-10-05 | — | — | US | disclosed |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312564-A1 | AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230313245-A1 | Engineered Enzymes and Method for the Synthesis of Diverse Tyrosine Analogs | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312557-A1 | P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| US-20230312713-A1 | In vivo targeting of T cells for mRNA therapeutics | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-10-05 | — | — | US | disclosed |
| WO-2023190111-A1 | RAFT POLYMERIZATION REACTION SOLUTION AND RAFT POLYMERIZATION REACTION SOLUTION PRODUCTION METHOD | テクノＵＭＧ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023187670-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | VASA THERAPEUTICS SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023186842-A1 | SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192602-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-4251627-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW Cho Group Limited (CN) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251209-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| EP-3774836-B1 | HEXADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | TARO PHARMACEUTICALS INC (CA) | 2023-10-04 | — | — | EP | disclosed |
| EP-4250991-A1 | REDUCTION OF VIRAL INFECTIONS | Phoxbio Limited (IE) | 2023-10-04 | — | — | EP | disclosed |
| CN-111557942-B | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | 科赛普特治疗学股份有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11773096-B2 | Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same | YALE UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| CN-116836184-A | Preparation and application of Wee1 kinase inhibitor | 药雅科技(上海)有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11773108-B2 | Indene derivatives useful in treating pain and inflammation | TARO PHARMACEUTICALS INC. (CA) | 2023-10-03 | — | — | US | disclosed |
| US-11773214-B2 | Multicolored electrochromic polymer compositions and methods of making and using the same | Furcifer Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773114-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | SAINT JOSEPH'S UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| US-11771696-B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | ACERTA PHARMA B.V. (NL) | 2023-10-03 | — | — | US | disclosed |
| CN-116829197-A | Polychelator compounds for targeted radiation therapy | 拜耳股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-109414596-B | ASH1L inhibitors and methods of treatment therewith | 密歇根大学董事会 | 2023-09-29 | — | — | CN | disclosed |
| CN-116813647-A | Nitrogen-containing condensed ring STING regulator compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116829561-A | Camptothecins compound and its preparation method and application | 四川科伦博泰生物医药股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116829578-A | Polynucleotides encoding interleukin-12 (IL-12) and compositions and methods related thereto | 苏州艾博生物科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116829570-A | WEE1 degrading compounds | 北京星奇原生物科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230303739-A1 | FLUORINATED PVC COPOLYMER COMPOSITIONS FOR INCREASED ULTRAVIOLET PROTECTION | Mexichem Specialty Resins Inc. | 2023-09-28 | — | — | US | disclosed |
| US-20230301948-A1 | REDUCTION OF VIRAL INFECTIONS | PHOXBIO LIMITED (IE) | 2023-09-28 | — | — | US | disclosed |
| WO-2023183807-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | ANTARES PHARMA, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230302016-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | ANTARES PHARMA, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303549-A1 | SUBSTITUTED HETEROARYLOXYPYRIDINES, THE SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-09-28 | — | — | US | disclosed |
| WO-2023183755-A1 | TRICYCLIC PYRIMIDONES | ERASCA, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183616-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4249519-A1 | FLUORINATED PVC COPOLYMER COMPOSITIONS FOR INCREASED ULTRAVIOLET PROTECTION | Mexichem Specialty Resins Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4247794-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2023-09-27 | — | — | EP | disclosed |
| EP-4247787-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 Ontario, Inc. (CA) | 2023-09-27 | — | — | EP | disclosed |
| EP-3546454-B1 | BENZOHETEROCYCLYL ALKYLAMINE COMPOUND AND USE THEREOF | UNIV EAST CHINA SCIENCE & TECH (CN) | 2023-09-27 | — | — | EP | disclosed |
| CN-116804020-A | Nitrogen-containing heterocyclic organic compound and application thereof in OLED device | 北京燕化集联光电技术有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-11767295-B2 | Isoindole derivative | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| CN-112011002-B | Method of controlled radical polymerization and apparatus for controlled radical polymerization | 立邦工业涂料(上海)有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-114853739-B | Acetylenic pyrazine FGFR inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116785342-A | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | 尤尼根公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-113185740-B | Method for improving antibacterial activity and biocompatibility of substrate surface | 华东理工大学 | 2023-09-22 | — | — | CN | disclosed |
| CN-116789677-A | Organic electroluminescent compound and application thereof | 北京燕化集联光电技术有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023175536-A1 | LIPID MONOMERS FOR THERAPEUTIC DELIVERY OF RNA | JANSSEN BIOTECH, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295138-A1 | HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230292741-A1 | NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES | X-THERMA, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023178144-A2 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023175615-A1 | ARTS MIMETIC COMPONDS AND COMBINATIONS THEREOF FOR TREATING HIGH-RISK NEUROBLASTOMA | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295630-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4244625-A1 | ADDITIVES FOR REDUCING NON-SPECIFIC INTERACTIONS BETWEEN FLUORESCENT POLYMER CONJUGATES AND CELLS IN A BIOLOGICAL SAMPLE | Beckman Coulter, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-3159344-B1 | AMINO PYRANOID RING DERIVATIVE AND COMPOSITION AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| EP-4244203-A1 | SUBSTITUTED PROPANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4244204-A1 | SUBSTITUTED MONO- AND POLY-PHENYL-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116783188-A | Dihydro-isoquinolone derivative and application thereof | 上海奕拓医药科技有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759780-B2 | Modification of surface properties of microfluidic devices | BIO-RAD LABORATORIES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-116751156-A | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using the same | 梅比斯发现公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116761635-A | BCL-XL inhibitor antibody drug conjugates and methods of use thereof | 诺华股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116751200-A | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-111138412-B | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-114075196-B | Aromatic ring lactam compound, preparation method and application thereof | 上海凌达生物医药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116761510-A | Use of [ (1, 5-diphenyl-1H-pyrazol-3-yl) oxy ] acetic acid derivatives and salts thereof and compositions containing them for reducing the phytotoxic effect of agrochemicals, in particular herbicides, on useful plants and crops | 拜耳公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-114751903-B | Nitrogen-containing fused heterocycle SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20230286902-A1 | LIPID NANOPARTICLE COMPOSITION | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-09-14 | — | — | US | disclosed |
| WO-2023278691-A9 | METHODS OF TREATING OR PREVENTING CORONAVIRUS INFECTION WITH CANNABINOID ACIDS | OREGON STATE UNIVERSITY (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2023168484-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170160-A1 | POLYMERIC IMIDAZOLIUM COMPOUNDS FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS | BASF SE (DE) | 2023-09-14 | — | — | WO | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286934-A1 | Use of Multi-Kinase Inhibitors to Treat RNA Virus Infections | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2023169438-A1 | NITROGEN-CONTAINING HETEROCYCLIC CELL CYCLE INHIBITOR COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海凌达生物医药有限公司 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170142-A1 | PRINTABLE SUBSTRATES WITH BARRIER PROPERTIES | KNOWFORT HOLDING B.V. (NL) | 2023-09-14 | — | — | WO | disclosed |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| EP-4240723-A1 | USE OF [(1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AND THEIR SALTS AND COMPOSITIONS CONTAINING THEM, FOR REDUCING PHYTOTOXIC EFFECTS OF AGROCHEMICALS, IN PARTICULAR OF HERBICIDES, IN USEFUL PLANTS AND CROP PLANTS | Bayer Aktiengesellschaft (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242255-A1 | PRINTABLE SUBSTRATES WITH BARRIER PROPERTIES | Knowfort Holding B.V. (NL) | 2023-09-13 | — | — | EP | disclosed |
| EP-4240727-A1 | [(5-PHENYL-5-HETEROARYL-1H-PYRAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | Bayer Aktiengesellschaft (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3774735-B1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-4240355-A1 | INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4 | Cassava Sciences, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4240725-A1 | [(1-PHENYL-5-HETEROARYL-1H-PYRAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | Bayer Aktiengesellschaft (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-4240726-A1 | [(1-PHENYL-5-(HETEROARYL)-1H-1,2,4-TRIAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | Bayer Aktiengesellschaft (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-4241541-A1 | SELF-HEALABLE, RECYCLABLE, AND RECONFIGURABLE WEARABLE ELECTRONICS DEVICE | The Regents of the University of Colorado, a body corporate (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3661517-B1 | DIHYDROOXADIAZINONES | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242204-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-4240728-A1 | [(5-PHENYL-1-HETEROARYL-1H-TRIAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | Bayer Aktiengesellschaft (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-4240731-A1 | [(1,5-DIHETEROARYL-1H-1,2,4-TRIAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | Bayer Aktiengesellschaft (DE) | 2023-09-13 | — | — | EP | disclosed |
| CN-116745285-A | [ (1-phenyl-5- (heteroaryl) -1H-1,2, 4-triazol-3-yl) oxy ] acetic acid derivatives as safeners for protecting useful plants and crop plants | 拜耳公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-116730920-A | AG-10 preparation method, intermediate and salt thereof | 文涵治疗有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116730921-A | AG-10 preparation method, intermediate and salt thereof | 文涵治疗有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116745268-A | Benzenesulfonamide derivatives and uses thereof | 2692372安大略公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11752149-B2 | Muscarinic acetylcholine M1 receptor antagonists | Pipeline Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-116745264-A | Methods and compositions for KRAS modification | 2692372安大略公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11753395-B2 | Inhibitors of MET kinase | KINNATE BIOPHARMA INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-111542324-B | Cytotoxic agent and conjugate thereof, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116724043-A | Photodynamic therapy and diagnosis | RMW曹氏集团有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116715668-A | Nitrogen-containing heterocyclic cell cycle inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230276788-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | X-THERMA, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230277652-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | SUZHOU ABOGEN BIOSCIENCES CO LTD (CN) | 2023-09-07 | — | — | US | disclosed |
| WO-2023168203-A1 | INHIBITORS OF MEK KINASE | KINNATE BIOPHARMA INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168254-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166507-A1 | APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS) AND ARTS MIMETIC SMALL MOLECULE COMPOUNDS FOR UPREGULATING P53 LEVEL | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2023-09-07 | — | — | WO | disclosed |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230278994-A1 | HETEROCYCLYL PYRIMIDINES AND TRIAZINES AS NOVEL FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230279033-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279026-A1 | NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| WO-2023165958-A1 | SUBSTITUTED 1,2,4-THIADIAZOLYL ISONICOTINAMIDES, SALTS OR N-OXIDES THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166488-A1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | REVAGENIX, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4238972-A1 | SUBSTITUTED 1,2,4-THIADIAZOLYL PICOLINAMIDES, SALTS OR N-OXIDES THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer AG (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-4238973-A1 | SUBSTITUTED 1,2,4-THIADIAZOLYL ISONICOTINAMIDES, SALTS OR N-OXIDES THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer AG (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-3436445-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4236944-A1 | BICYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF DISEASES | Athira Pharma, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| EP-4237423-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-3475387-B1 | PHOTOCHROMIC WATER HARVESTING PLATFORM | WARNER BABCOCK INST FOR GREEN CHEMISTRY LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116693411-A | Novel carbonyl lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116709916-A | [ (1-phenyl-5-heteroaryl-1H-pyrazol-3-yl) oxy ] acetic acid derivatives as safeners for protecting useful plants and crop plants | 拜耳公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116710457-A | Spirocyclic compounds as KRAS-G12C inhibitors | 上海优理惠生医药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11749839-B2 | Silicon-based energy storage devices with electrolyte containing sulfonate or carboxylate salt based compounds | ENEVATE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-116693542-A | Tetrahydroquinoline compound containing spiro structure and preparation method thereof | 云南农业大学 | 2023-09-05 | — | — | CN | disclosed |
| US-11746123-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11745147-B2 | Curable poly(RTIL)-based mixed-matrix membranes and methods using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-09-05 | — | — | US | disclosed |
| CN-116685316-A | Compositions and methods for treating lipid-related disorders | 拉结尔治疗有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116675674-A | Novel substituted benzimidazole derivatives as inhibitors of D-amino acid oxidase (DAAO) | 宇凤·简·曾 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023163971-A1 | METHODS OF TREATING COVID-RELATED DISORDERS | ATHIRA PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230270700-A1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023161940-A1 | APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS) MIMETIC COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164057-A1 | DI-CYCLOPROPYL BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230275230-A1 | AQUEOUS BASED POLYMERS FOR SILICON ANODES | ENEVATE CORPORATION | 2023-08-31 | — | — | US | disclosed |
| WO-2023161172-A1 | SUBSTITUTED N-BENZOIC ACID URACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | WO | disclosed |
| EP-3699184-B1 | TRIPTOLIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | CINKATE PHARMACEUTICAL INTERMEDIATES CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3151919-B1 | CARBON MONOXIDE-RELEASING MOLECULES FOR THERAPEUTIC APPLICATIONS AND METHODS OF MAKING AND USING THEREOF | UNIV GEORGIA STATE RES FOUND (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233871-A2 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Eli Lilly and Company (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-106715456-B | Prodrugs of directed lymphatics | 莫纳什大学 | 2023-08-29 | — | — | CN | disclosed |
| US-11742519-B2 | Silicon-based energy storage devices with electrolyte additive compounds | ENEVATE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738087-B2 | Lymph directing prodrugs | MONASH UNIVERSITY (AU) | 2023-08-29 | — | — | US | disclosed |
| CN-116669727-A | Triazole-pyridinyl substituted azacyclohexylacetic acid compounds as LPA receptor antagonists | 唯久生物有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116670267-A | Tetravalent mRNA vaccine for influenza virus | 苏州艾博生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116670928-A | Self-healing, recyclable and reconfigurable wearable electronic device | 科罗拉多大学评议会公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11739077-B2 | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-29 | — | — | US | disclosed |
| US-11739223-B2 | Surface primer compositions and methods of use | ENVISTA (US) | 2023-08-29 | — | — | US | disclosed |
| CN-111448226-B | Polymerization process | 埃克森美孚化学专利公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116640140-A | Polycyclic-carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116640157-A | METTL3 inhibitor and composition thereof and application of METTL3 inhibitor and composition thereof in medicine | 海思科医药集团股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-111526877-B | Compounds and compositions for IRE1 inhibition | 奥普提卡拉公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116648472-A | Bioactive synthetic copolymers, bioactive macromolecules and related methods | 新加坡科技研究局 | 2023-08-25 | — | — | CN | disclosed |
| CN-116648471-A | Bioactive polyethylene copolymers, polyethylene macromolecules and related methods | 新加坡科技研究局 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023158824-A1 | NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN- 1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023155808-A1 | CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 苏州宜联生物医药有限公司 | 2023-08-24 | — | — | WO | disclosed |
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-20230263790-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2023-08-24 | — | — | US | disclosed |
| EP-4228601-A1 | IN VIVO TARGETING OF FIBROSIS BY ANTI-CD5-TARGETED FAP-CAR T MRNA-LNP | The Trustees of the University of Pennsylvania (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3370518-B1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | X THERMA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230620-A1 | SUBSTITUTED N-AMINO-N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-08-23 | — | — | EP | disclosed |
| EP-4228602-A1 | IN VIVO TARGETING OF T CELLS FOR MRNA THERAPEUTICS | The Trustees of the University of Pennsylvania (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4229045-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230621-A1 | SUBSTITUTED N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer AG (DE) | 2023-08-23 | — | — | EP | disclosed |
| CN-115043832-B | FGFR inhibitor acetylenic heterocyclic compound and preparation method and application thereof | 药雅科技(上海)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-113816990-B | Modified amino acids and their use in ADCs | 联宁（苏州）生物制药有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-114957242-B | Preparation and application of pyrido heterocyclic compounds as kinase inhibitors | 药雅科技(上海)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-115141176-B | Acetylenic indole FGFR inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-113939544-B | non-core-shell polymer particles | 悉尼大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-114957241-B | Preparation and Application of Heterocyclic Compounds as Kinase Inhibitors | 药雅科技(上海)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11731954-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RES INC (US) | 2023-08-22 | — | — | US | disclosed |
| CN-116635023-A | Ionic liquid preparation for treating diabetes | I2O治疗公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-114853752-B | Preparation and application of BTK inhibitor pyrido heterocyclic compound | 药雅科技(上海)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-116615468-A | Polymer particles | 昆士兰科技大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-116615428-A | Tricyclic pyridones and pyrimidinones | 医睿世康药业研发公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116615472-A | Polymer conjugated lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | Blaze Bioscience, Inc. | 2023-08-17 | — | — | US | disclosed |
| WO-2023154822-A2 | METHODS OF PURIFYING A PRODUCT | KODIAK SCIENCES INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230255945-A1 | FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS | NFLECTION THERAPEUTICS, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230257374-A1 | NOVEL KRAS G12C PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | INNOVENT BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225915-A1 | OLIGOMERIC COMPOUND FOR DYSTROPHIN RESCUE IN DMD PATIENTS THROUGHOUT SKIPPING OF EXON-51 | SQY Therapeutics (FR) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225811-A1 | POLYMER PARTICLES | Queensland University Of Technology (AU) | 2023-08-16 | — | — | EP | disclosed |
| EP-3959202-B1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AG (DE) | 2023-08-16 | — | — | EP | disclosed |
| CN-111410659-B | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-111909083-B | Inhibitors of histone demethylase | 赛尔基因昆蒂赛尔研究公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116601152-A | Pyrrolopyridine-anilines for the treatment of cognitive dysfunction | 恩福莱克逊治疗有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-11723944-B2 | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making | INDI MOLECULAR, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| CN-116570594-A | Selective p38α -specific MAPK inhibitors | 马里兰大学巴尔的摩分校 | 2023-08-11 | — | — | CN | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116574104-A | Biaryl benzylamine compound, preparation method and application | 如东凌达生物医药科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116574105-A | Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023150663-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RETUNE PHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150681-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230248736-A1 | SELECTIVE P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250536-A1 | MODIFICATION OF METALLIC SURFACES WITH PHOSPHONIC ACIDS | BIOLOGICAL DYNAMICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230248752-A1 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | EMPIRICO INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250133-A1 | METHODS OF PURIFYING A PRODUCT | KODIAK SCIENCES GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | disclosed |
| EP-3966202-B1 | THIANTHRENE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | FACEBOOK TECH LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| CN-116568669-A | Substituted mono-and poly-benzene nuclear monomers and polymers thereof for volume Bragg gratings | 元平台技术有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116554461-A | Use of polymers to promote endothelialization of interventional/implant materials | 华东理工大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-116549598-A | Polypeptide polymer or polypeptide mimic and application thereof in treating tumors | 华东理工大学 | 2023-08-08 | — | — | CN | disclosed |
| US-11718580-B2 | Fluorene derivatized monomers and polymers for volume Bragg gratings | META PLATFORMS TECHNOLOGIES, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| CN-116568136-A | [ (5-phenyl-1-heteroaryl-1H-triazol-3-yl) oxy ] acetic acid derivatives as safeners for protecting useful plants and crop plants | 拜耳公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116568301-A | Bicyclic compounds for treating diseases and uses thereof | 雅斯娜制药公司 | 2023-08-08 | — | — | CN | disclosed |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-08-08 | — | — | US | disclosed |
| CN-116554147-A | Pyrazole derivative, composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116554166-A | Pyridazinopyridone compound, pharmaceutical composition and application thereof | 上海优理惠生医药有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-11721809-B2 | Silicate and organosilicon containing additives for silicon-based Li ion batteries | ENEVATE CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| CN-116546991-A | mRNA therapeutic agent versus CD4 + In vivo targeting of T cells | 宾夕法尼亚大学理事会 | 2023-08-04 | — | — | CN | disclosed |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230241034-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2023147372-A1 | INHIBITORS OF CDK4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023143147-A1 | PYRIDAZOPYRIDONE COMPOUNDS, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海优理惠生医药有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230242538-A1 | PanK Modulators and Methods Using Same | UNIV YALE (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2023143263-A1 | ANTIBODY AGAINST HER3, CONJUGATE AND USE THEREOF | 苏州宜联生物医药有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147312-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023143210-A1 | PHTHALAZINONE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING PHTHALAZINONE COMPOUNDS AND USES THEREOF | 上海优理惠生医药有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230242551-A1 | ISOTOPE-SUBSTITUTED SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2023146831-A1 | NOVEL EXCITATORY AMINO ACID GLUTAMATE TRANSPORT MODULATORS AND METHODS USING THE SAME | DREXEL UNIVERSITY (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023143312-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146513-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3898612-B1 | SUBSTITUTED PYRIDINYLOXYBENZENES, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | BAYER AG (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-4216952-A1 | TREATMENT OF COGNITIVE DYSFUNCTION WITH PYRROLOPYRIDINE-ANILINE COMPOUNDS | NFlection Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219493-A1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2023-08-02 | — | — | EP | disclosed |
| US-11712481-B2 | Lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2023-08-01 | — | — | US | disclosed |
| CN-112262145-B | 2-aminopyrimidine derivative and preparation method and application thereof | 上海奕拓医药科技有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-114853740-B | Preparation method and application of acetylenic pyrimidine compound as FGFR inhibitor | 药雅科技(上海)有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| CN-107216312-B | Compound with mutant IDH inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116528674-A | [ (1, 5-bis (heteroaryl) -1H-1,2, 4-triazol-3-yl) oxy ] acetic acid derivatives as safeners for protecting useful plants and crop plants | 拜耳公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116529248-A | Benzene ring derivative, composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116496318-A | Heterocyclic derivative, composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116507333-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116507618-A | Spiro compound, pharmaceutical composition containing spiro compound and application of spiro compound | 上海优理惠生医药有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023141364-A1 | SILYL-LIPID N-ACYL L-HOMOSERINE LACTONES AS QUORUM SENSING MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230233706-A1 | In vivo targeting of CD4+-T cells for mRNA therapeutics | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-07-27 | — | — | US | disclosed |
| US-20230234945-A1 | AZABICYCLYL-SUBSTITUTED HETEROCYCLES AS FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-27 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4213835-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIPID-RELATED DISORDERS | Raziel Therapeutics Ltd. (IL) | 2023-07-26 | — | — | EP | disclosed |
| EP-4213827-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | Antares Pharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-4065564-B1 | [ (1,5-DIPHENYL-1H-1,2,4-TRIAZOL-3-YL) OXY ] ACETIC ACID DERIVATIVES AND SALTS THEREOF, USEFUL OR CULTIVATING AGENTS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SAFENERS | BAYER AG (DE) | 2023-07-26 | — | — | EP | disclosed |
| EP-4214204-A1 | PYRIDO[2,3-D]PYRIMIDIN-4-AMINES AS SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-07-26 | — | — | EP | disclosed |
| CN-116478145-A | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116473965-A | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116490501-A | Tyrosine kinase 2 (TYK 2) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11710854-B2 | Functional epoxides in catalyst-based electrolyte compositions for Li-ion batteries | ENEVATE CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| CN-116462679-A | Pyrazolopyrimidine derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116472275-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-110381940-B | AG-10 preparation method, intermediate and salt thereof | 文涵治疗有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-110092750-B | Pentafluoro sulfanyl substituted amide compound, preparation method and application thereof in medicine | 北京诺诚健华医药科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230227458-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| US-20230227476-A1 | GALLIUM-SALOPHEN ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-20 | — | — | US | disclosed |
| WO-2023134374-A1 | PYRIMIDO-HETEROCYCLIC COMPOUND, PREPARATION METHOD, AND USE | 如东凌达生物医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| EP-4212510-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics Inc. (CA) | 2023-07-19 | — | — | EP | disclosed |
| CN-116444497-A | Pyridazinone compound, preparation and application thereof | 如东凌达生物医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| CN-116457356-A | A3 adenosine receptor agonists for use in medicine | 生物干预公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701377-B2 | Methods for treating cancers by prodrugs of clofarabine | BoYen Therapeutics, Inc. (TW) | 2023-07-18 | — | — | US | disclosed |
| CN-116457336-A | Substituted propane nuclear monomer for volume Bragg grating and polymer thereof | 元平台技术有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11702421-B2 | Substituted pyridines as irreversible inhibitors of menin-MLL interaction | BIOMEA FUSION, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| CN-116425796-A | Pyrimidine heterocyclic compounds, preparation method and application | 如东凌达生物医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116438183-A | Thienopyrimidine compound, pharmaceutical composition containing thienopyrimidine compound and application of thienopyrimidine compound | 上海优理惠生医药有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023131254-A1 | PSEUDOURIDINE MODIFIED AT N1 POSITION AND USE THEREOF IN MRNA SYNTHESIS | 上海吉量医药工程有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219929-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023133507-A1 | ESTRADIOL PRODRUGS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230218621-A1 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219994-A1 | MODIFIED NUCLEOSIDE AND SYNTHESIS METHOD THEREFOR | Stemirna Therapeutics Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| EP-4208160-A1 | IONIC LIQUID FORMULATIONS FOR TREATING DIABETES | I2O Therapeutics, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-111511781-B | Catalyst system and polymerization process using the same | 埃克森美孚化学专利公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-116419754-A | Glucosidase inhibitors for the treatment and prevention of pulmonary infections | 科威里克斯医疗有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-11697713-B2 | Chromophoric polymer dots with narrow-band emission | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023129502-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129667-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230211000-A1 | TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4206199-A1 | AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Ringene BioPharma Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| EP-3966195-B1 | FLUORENE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | FACEBOOK TECH LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-4203954-A1 | GLUCOSIDASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PULMONARY INFECTIONS | Covirix Medical Pty Ltd (AU) | 2023-07-05 | — | — | EP | disclosed |
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| EP-4204414-A1 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | Viewpoint Therapeutics, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3474835-B1 | NON-CATALYTIC SUBSTRATE-SELECTIVE P38 -SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF | UNIV MARYLAND (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116375742-A | Azaaromatic ring derivative, composition and pharmaceutical application thereof | 海思科医药集团股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11690911-B2 | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| CN-110114071-B | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| CN-110392571-B | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using the same | 梅比斯发现公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11690921-B2 | Delivery of target specific nucleases | SANGAMO THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-116354957-A | CDK9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116367835-A | Aqueous pharmaceutical formulations of hydrocortisone sodium phosphate and monothioglycerol | 安塔雷斯药品公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230201295-A1 | Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination Thereof | UNIGEN, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203077-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | NATIONAL SCIENCE FOUNDATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023115167-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116707-A1 | PREPARATION FOR THIOPHENE DERIVATIVE | 赣州和美药业有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230203538-A1 | In vivo targeting of Fibrosis by anti-CD5-targeted FAP-CAR T mRNA-LNP | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-06-29 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230203089-A1 | HEXADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | TARO PHARMACEUTICALS INC. (CA) | 2023-06-29 | — | — | US | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| WO-2023115165-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116763-A1 | PYRIDAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海优理惠生医药有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116804-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122600-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230201211-A1 | NON-CATALYTIC SUBSTRATE-SELECTIVE p38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-06-29 | — | — | US | disclosed |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4200282-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-06-28 | — | — | EP | disclosed |
| CN-110799492-B | Novel carbonyl lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11685748-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11685801-B2 | Derivatizable monomers and polymers, and methods for making and using same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-06-27 | — | — | US | disclosed |
| CN-116332960-A | Pyridazine compound, pharmaceutical composition and application thereof | 上海优理惠生医药有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116332954-A | Preparation of thiophene derivatives | 赣州和美药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116332830-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116348638-A | Modification of metal surfaces by phosphonic acids | 生物动力学公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116348451-A | ENPP1 modulators and uses thereof | 维艾尔生物科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116323623-A | Pyrido [2,3-d ] pyrimidin-4-amines as SOS1 inhibitors | 拜耳公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116323627-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116323570-A | Compounds and methods for treating diseases | 上海睿跃生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| WO-2023114943-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| US-20230192700-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192666-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-06-22 | — | — | US | disclosed |
| WO-2023114710-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-06-22 | — | — | WO | disclosed |
| US-20230192760-A1 | SYSTEMS AND METHODS FOR TYROSINASE-MEDIATED SITE-SPECIFIC PROTEIN CONJUGATION | GENENTECH, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192617-A1 | AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2023-06-22 | — | — | US | disclosed |
| WO-2023114428-A1 | HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109959-A1 | CDK9 INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023115060-A1 | PSYCHOPLASTOGENS FOR TREATING HEARING-RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230190852-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | UNIGEN, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023114809-A1 | INHIBITORS OF MET KINASE | KINNATE BIOPHARMA INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230192667-A1 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| WO-2023114733-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114456-A1 | USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | ATHIRA PHARMA, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114472-A1 | HETEROCYCLIC COMPOUNDS AS 5HT2A BIASED AGONISTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3735409-B1 | ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS | STRATOS GENOMICS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-3271370-B1 | NICOTINIC ACID RIBOSIDE OR NICOTINAMIDE RIBOSIDE COMPOSITIONS, REDUCED DERIVATIVES THEREOF, AND THE USE THEREOF | CHROMADEX INC (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4196219-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | Biointervene, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-3615502-B1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIV TASMANIA (AU) | 2023-06-21 | — | — | EP | disclosed |
| EP-4196220-A1 | TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS | Viva Star Biosciences Limited (HK) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| CN-110950842-B | Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-116262753-A | Novel PIM kinase inhibitors | 杭州邦顺制药有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20230180756-A1 | TRIAZINE AND PYRIMIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183210-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-15 | — | — | US | disclosed |
| US-20230180758-A1 | SUBSTITUTED PYRROLINE-2-ONES AND THEIR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-15 | — | — | US | disclosed |
| WO-2023107863-A1 | HETEROCYCLIC COMPOUNDS AS KIT KINASE INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023102600-A1 | SYNTHESIS OF AMPHIPHILIC BLOCK COPOLYMERS AND POLYMERIC NANOFIBERS PRODUCED THEREFROM | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2023-06-15 | — | — | WO | disclosed |
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023107870-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230183189-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| EP-4192431-A1 | FORMULATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS | Venthera, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192462-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING SAME | Optikira LLC (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116253717-A | Pyridazine derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-116261561-A | Certain chemical compositions and methods of use thereof | 奧基生物技术有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11674964-B2 | Encoded chromophoric polymer particles and methods of use thereof | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2023-06-13 | — | — | US | disclosed |
| CN-110678177-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11672788-B2 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2023-06-13 | — | — | US | disclosed |
| US-20230174526-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | SHANGHAI RINGENE THERAPEUTICS CO. LTD (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-06-08 | — | — | US | disclosed |
| US-20230174535-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023099612-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102378-A1 | MACROCYCLIC COMPOUNDS HAVING FARNESYLTRANSFERASE INHIBITORY ACTIVITY | KURA ONCOLOGY, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023099623-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023099620-A1 | KRAS DEGRADING COMPOUNDS COMPRISING ANNULATED 2-AMINO-3-CYANO THIOPHENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| US-20230174506-A1 | (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME | PURDUE RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| US-20230178803-A1 | Silicon-Based Energy Storage Devices With Electrolyte Containing Sulfonate or Carboxylate Salt Based Compounds | ENEVATE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20230173081-A1 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174480-A1 | FLUOROGENIC DIMER COMPOUND, USEFUL AS A PROBE FOR DETECTION OF ENDOGENOUS RECEPTORS | UNIVERSITE DE STRASBOURG (FR) | 2023-06-08 | — | — | US | disclosed |
| WO-2023099624-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023099445-A1 | BIS(HETERO)ARYL THIOETHER OXADIAZINES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-08 | — | — | WO | disclosed |
| US-20230174477-A1 | METHODS FOR SYNTHESIS OF THE TRICYCLIC PROSTAGLANDIN D2 METABOLITE METHYL ESTER | PURDUE RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| EP-3445359-B1 | USE OF NICOTINIC ACID RIBOSIDE OR NICOTINAMIDE RIBOSITE DERIVATIVES, AND REDUCED DERIVATIVES THEREOF, AS NAD+INCREASING PRECURSORS | CHROMADEX INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3717525-B1 | CATALYST SYSTEMS AND POLYMERIZATION PROCESSES FOR USING THE SAME | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-111511465-B | Method for producing organic silicon dioxide material and use thereof | 埃克森美孚科技工程公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116217581-A | Methods and compositions for inhibiting interactions of multiple endocrine oncostatin proteins with MLL proteins | 库拉肿瘤学公司 | 2023-06-06 | — | — | CN | disclosed |
| US-11667669-B2 | Epoxy-(meth)acrylate monomers and polymers and methods of making and using the same | ROWAN UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666588-B2 | Prodrugs of ALOX-15 inhibitors and methods of using the same | EMPIRICO INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-116199685-A | HER2 degradation agent and application thereof | 四川海思科制药有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230165252-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| WO-2023094679-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096845-A1 | ANTIMICROBIAL POLYMER COMPOSITIONS, ANTIMICROBIAL POLYMER ARTICLES, AND METHODS OF MAKING THE SAME | CORNING INCORPORATED (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023092195-A1 | ANALOGUES OF MDMA FOR MODULATING SERT, DAT, AND / OR NET ACTIVITY | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023039240-A9 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094680-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2023-06-01 | — | — | WO | disclosed |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2023096935-A1 | FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS | NFLECTION THERAPEUTICS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094677-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2023-06-01 | — | — | WO | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2023094594-A1 | SUBSTITUTED DIHYDROPYRANOPYRIDINES, SALTS OR N-OXIDES THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097020-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230167088-A1 | 1-PYRAZINYLPYRAZOLYL-3-OXYALKYL ACIDS AND THEIR DERIVATIVES, AND THEIR USE FOR CONTROL OF UNDESIRED PLANT GROWTH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| WO-2023097221-A1 | TABLET FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | BELITE BIO, INC (US) | 2023-06-01 | — | — | WO | disclosed |
| CN-116194448-A | Compounds and formulations for the treatment of ophthalmic diseases | 视点医疗股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| CN-116178360-A | PRMT5 inhibitors and uses thereof | 四川海思科制药有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11661429-B2 | Topical phosphoinositide 3-kinase inhibitors | VENTHERA, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11660301-B2 | Combination of ATR kinase inhibitors with PARP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-05-30 | — | — | US | disclosed |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-116194112-A | Pyridine-1, 5-diones exhibiting MNK inhibition and methods of use thereof | 4E治疗公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-114573566-B | Selective ROCK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116194463-A | Cyclic peptide compounds and methods of use | 李丰桥 | 2023-05-30 | — | — | CN | disclosed |
| CN-111527090-B | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | 拜耳公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230159544-A1 | AZEPINO-INDOLES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023091707-A1 | BICYCLIC INHIBITORS OF JAK AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230158469-A1 | DEVICES AND METHODS FOR SYNTHESIS | Twist Bioscience Corporation | 2023-05-25 | — | — | US | disclosed |
| WO-2023091606-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023092133-A1 | STEREOSELECTIVE COVALENT LIGANDS FOR ONCOGENIC AND IMMUNOLOGICAL PROTEINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091490-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230159569-A1 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | THE WISTAR INST (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4183853-A1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | Beckman Coulter, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| CN-116157388-A | Carbocyclic amide derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116143766-A | CDK2 degrading agent and application thereof | 四川海思科制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116143744-A | Aromatic ester compound and application thereof | 陈艳莉 | 2023-05-23 | — | — | CN | disclosed |
| CN-114206827-B | Lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-110139644-B | Compositions and methods for treating insulin resistance | 坦普尔大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-109640970-B | Selective p38α -specific MAPK inhibitors | 马里兰大学巴尔的摩分校 | 2023-05-23 | — | — | CN | disclosed |
| CN-116157397-A | Heterocyclylpyridines as novel fungicides | 拜耳公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116143805-A | Nitrogen-containing heterocyclic biaryl compounds, preparation method and application | 上海凌达生物医药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116143777-A | Heterocyclic compound capable of inhibiting IL-17A and application thereof | 四川海思科制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116143806-A | Nitrogen-containing heterocyclic compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| WO-2023086520-A2 | ENGINEERED ENZYMES AND METHOD FOR THE SYNTHESIS OF DIVERSE TYROSINE ANALOGS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086417-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023084206-A1 | N-(4-AMINOCYCLOHEXYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | CEREVANCE LTD (GB) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086341-A1 | INHIBITORS OF KRAS | BIOMEA FUSION, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086638-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086830-A1 | INTRASPINAL DELIVERY OF THERAPEUTIC AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-111587256-B | Catalyst system and polymerization process using the same | 埃克森美孚化学专利公司 | 2023-05-19 | — | — | CN | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230151025-A1 | SUBSTITUTED THIAZOLOPYRIDINES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AG (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| EP-4179133-A1 | MODIFICATION OF METALLIC SURFACES WITH PHOSPHONIC ACIDS | Biological Dynamics, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| EP-4178574-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | Purdue Research Foundation (US) | 2023-05-17 | — | — | EP | disclosed |
| EP-4178571-A1 | GAS41 INHIBITORS AND METHODS OF USE THEREOF | The Regents Of The University Of Michigan (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-109996790-B | Piperazine carbamates and methods of making and using the same | H.隆德贝克有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11652239-B2 | Silicon-based energy storage devices with electrolyte containing dihydrofuranone based compound | ENEVATE CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648324-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2023-05-16 | — | — | US | disclosed |
| US-11649237-B2 | Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition | OPTIKIRA LLC (US) | 2023-05-16 | — | — | US | disclosed |
| CN-111542315-B | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-116113406-A | GAS41 inhibitors and methods of use thereof | 密歇根大学董事会 | 2023-05-12 | — | — | CN | disclosed |
| US-20230142139-A1 | CATALYST COMPOSITIONS FOR HYDROFORMYLATION AND METHODS OF USE THEREOF | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2023-05-11 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144095-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-05-11 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| WO-2023081185-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
| WO-2023078915-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | WO | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023078946-A1 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | ZIPHIUS VACCINES NV (BE) | 2023-05-11 | — | — | WO | disclosed |
| US-20230146903-A1 | CXCR5 Antagonists and Methods of Treating Diseases or Disorders Using Same | YALE UNIVERSITY | 2023-05-11 | — | — | US | disclosed |
| WO-2023078954-A1 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | ZIPHIUS VACCINES NV (BE) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081312-A1 | SMALL MOLECULE INDUCERS OF AUTOPHAGY | Vir Biotechnology, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230148152-A1 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-05-11 | — | — | US | disclosed |
| WO-2023078426-A1 | COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 上海优理惠生医药有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078950-A1 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | ZIPHIUS VACCINES NV (BE) | 2023-05-11 | — | — | WO | disclosed |
| EP-3851469-B1 | POLYURETHANE/UREA MATERIALS | COMMW SCIENT IND RES ORG (AU) | 2023-05-10 | — | — | EP | disclosed |
| EP-4175503-A1 | REDUCTION OF VIRAL INFECTIONS | Phoxbio Limited (IE) | 2023-05-10 | — | — | EP | disclosed |
| CN-112390904-B | Polyethylene containing polar functional groups and preparation method thereof | 中国科学院上海有机化学研究所 | 2023-05-09 | — | — | CN | disclosed |
| CN-116096707-A | Inhibitors of fibroblast growth factor receptor kinase | 金耐特生物制药公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11646449-B2 | Cyclodextrin-based compounds and their derivatives for silicon-based li-ion batteries | ENEVATE CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116059390-A | Prodrugs of cytotoxic actives with enzymatically cleavable groups | 拜耳制药股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-112778336-B | Nitrogen-containing condensed ring STING regulator compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116063639-A | Multiblock copolymers and uses thereof | 广州立邦涂料有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116075513-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116064598-A | Nucleic acid vaccine for coronavirus | 苏州艾博生物科技有限公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023077146-A1 | CANNABIGEROL FOR TREATMENT OF SEIZURES AND EPILEPSY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230134760-A1 | CAR AND NRF2 DUAL ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED AND DOXORUBICIN-BASED TREATMENTS OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| WO-2023077125-A2 | AZEPINO-INDOLES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023077127-A2 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076687-A1 | DEVICES AND METHODS FOR SYNTHESIS | Twist Bioscience Corporation (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023073423-A1 | ERGOLINE-DERIVED AGONISTS OF THE 5-HT2A RECEPTOR | DIAMOND THERAPEUTICS INC. (CA) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023077030-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4172272-A1 | HYDROGELS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2023-05-03 | — | — | EP | disclosed |
| EP-4171565-A2 | PYRIDINE-1,5-DIONES EXHIBITNG MNK INHIBITION AND THEIR METHOD OF USE | 4E Therapeutics, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3590932-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3511319-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-4172153-A1 | SUBSTITUTED HETEROARYLOXYPYRIDINES, THE SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| CN-116057056-A | Azabicyclo-substituted heterocyclic compounds as fungicides | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-110678456-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-111032034-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-116057045-A | Fibroblast growth factor receptor kinase inhibitors | 金耐特生物制药公司 | 2023-05-02 | — | — | CN | disclosed |
| US-11639329-B2 | Lipids for use in lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2023-05-02 | — | — | US | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | ARAXES PHARMA LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639332-B2 | Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases | Amgen (Europe) GmbH (CH) | 2023-05-02 | — | — | US | disclosed |
| CN-113929729-B | Veratramine compound, preparation method and application thereof | 上海医药工业研究院有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-116033904-A | Histone deacetylase inhibitor for tumor microenvironment immunomodulation | 华上生技医药股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230131260-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2023-04-27 | — | — | US | disclosed |
| WO-2023070053-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230128972-A1 | Anat Inhibitors and Methods of Use Thereof | Atomwise Inc. | 2023-04-27 | — | — | US | disclosed |
| US-20230127931-A1 | SINGLE LITHIUM-ION CONDUCTIVE POLYMER ELECTROLYTES FOR SI ANODE-BASED LITHIUM-ION BATTERIES | ENEVATE CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20230126893-A1 | [(1,4,5-TRISUBSTITUTED-1H-PYRAZOL-3-YL)SULFANYL]ACETIC ACID DERIVATIVES, SALTS THEREOF, AND USE THEREOF AS ACTIVE HERBICIDAL INGREDIENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-27 | — | — | US | disclosed |
| WO-2023070114-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069548-A1 | MALODOR-COUNTERACTING COMPOUNDS, COMPOSITIONS, AND USES THEREOF | INTERNATIONAL FLAVORS AND FRAGRANCES INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4167740-A1 | ACTIVE COMPOUND COMBINATIONS | Bayer Aktiengesellschaft (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-4168402-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | Corcept Therapeutics Incorporated (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11634528-B2 | Latent imaging for volume Bragg gratings | META PLATFORMS TECHNOLOGIES, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| CN-110573511-B | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11633490-B2 | — | — | 2023-04-25 | — | — | US | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| CN-115996923-A | Nitrile derivative as dipeptidyl peptidase 1 inhibitor and application thereof | 四川海思科制药有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115996638-A | Substituted N-phenyluracils and salts thereof and their use as herbicidal agents | 拜耳股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115996919-A | Substituted heteroaryloxy pyridines, salts thereof and their use as herbicides | 拜耳公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20230117791-A1 | SUBSTITUTED 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-20 | — | — | US | disclosed |
| US-20230121768-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230120115-A1 | COVALENT INHIBITORS OF MENIN-MLL INTERACTION FOR DIABETES MELLITUS | BIOMEA FUSION, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230121031-A1 | MASKED FLUOROGENIC COMPOUNDS AND METHODS OF USING THE SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-20 | — | — | US | disclosed |
| US-20230121952-A1 | COMPOUNDS | INFLAZOME LIMITED (IE) | 2023-04-20 | — | — | US | disclosed |
| US-20230123534-A1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | ACUITAS THERAPEUTICS INC (CA) | 2023-04-20 | — | — | US | disclosed |
| US-20230119934-A1 | NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME | UNIV COLORADO REGENTS (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2023064152-A1 | TRICYCLIC SULFAMIDES AND SULTAMS | MERCK SHARP & DOHME LLC (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064058-A1 | TRICYCLIC SULTAMS AND SULFAMIDES AS ANTITUMOR AGENTS | PELOTON THERAPEUTICS INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023062492-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | VASA THERAPEUTICS SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ (PL) | 2023-04-20 | — | — | WO | disclosed |
| EP-4165038-A1 | AZABICYCLYL-SUBSTITUTED HETEROCYCLES AS FUNGICIDES | Bayer Aktiengesellschaft (DE) | 2023-04-19 | — | — | EP | disclosed |
| EP-4166549-A1 | ISOTOPE-SUBSTITUTED SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-11629230-B1 | Ternary orthogonal photopolymers | META PLATFORMS TECHNOLOGIES, LLC (US) | 2023-04-18 | — | — | US | disclosed |
| US-11629137-B2 | Methods of manufacturing of niraparib | TESARO, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| CN-115960098-A | Preparation method and application of nitrogen-containing fused ring compounds | 上海凌达生物医药有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115960109-A | Preparation and application of fused-ring SHP2 phosphatase inhibitor | 药雅科技(上海)有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-114096550-B | Modified nucleosides and methods of synthesis thereof | 斯微(上海)生物科技股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20230112489-A1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE | TRANSFUSION HEALTH LLC | 2023-04-13 | — | — | US | disclosed |
| US-20230116632-A1 | ANALOGS FOR THE TREATMENT OF DISEASE | Insilico Medicine Hong Kong Limited (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230116253-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230115836-A1 | ANALOGS FOR THE TREATMENT OF DISEASE | Insilico Medicine Hong Kong Limited (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230114728-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-13 | — | — | US | disclosed |
| US-20230111793-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230115890-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LINEAR CARBONATE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2023-04-13 | — | — | US | disclosed |
| US-20230112086-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | ORMCO CORPORATION | 2023-04-13 | — | — | US | disclosed |
| US-20230112244-A1 | SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-4162950-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161916-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161379-A1 | GALLIUM-SALOPHEN ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | University of Maryland, Baltimore (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161905-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | Arbutus Biopharma Corporation (CA) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161656-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161933-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161914-A1 | HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES | Bayer Aktiengesellschaft (DE) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161657-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161906-A1 | HETEROCYCLYL PYRIMIDINES AND TRIAZINES AS NOVEL FUNGICIDES | Bayer Aktiengesellschaft (DE) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161922-A1 | USE OF MULTI-KINASE INHIBITORS TO TREAT RNA VIRUS INFECTIONS | Icahn School of Medicine at Mount Sinai (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11622960-B2 | Microtubule polymerization inhibitor prodrugs and methods of using the same | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-04-11 | — | — | US | disclosed |
| US-11623922-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-04-11 | — | — | US | disclosed |
| CN-115955916-A | Active compound combinations | 拜耳公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-111303152-B | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | 吉利德科学公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115943143-A | 1-pyrazinylpyrazolyl-3-oxyalkyl acids and derivatives thereof and their use for controlling undesired vegetation | 拜耳公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111848573-B | Benzothiophene amide compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230108157-A1 | FORMULATIONS OF (S)-3-(1-(9H-PURIN-6-YLAMINO)ETHYL)-8-CHLORO-2-PHENYLISOQUINOLIN-1(2H)-ONE | INTELLIKINE LLC | 2023-04-06 | — | — | US | disclosed |
| US-20230107642-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230103958-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING A BENZOYL PEROXIDE BASED COMPOUND | ENEVATE CORPORATION | 2023-04-06 | — | — | US | disclosed |
| WO-2023056460-A1 | WATER-SOLUBLE TETRAHYDROPYRENE BASED FLUORESCENT POLYMERS | BECKMAN COULTER, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230106583-A1 | HETEROARYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2023055702-A1 | MAIN PROTEASE (M PRO) INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023056264-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023052363-A1 | NOVEL TETRAHYDROQUINOLINES AND PROTEOLYSIS TARGETING CHIMERA (PROTACS) COMPRISING THEM AS DEGRADERS OF SMARCA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-04-06 | — | — | WO | disclosed |
| US-20230106032-A1 | IMIDAZOTRIAZINES ACTING ON CANCER VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-06 | — | — | US | disclosed |
| US-20230108463-A1 | PHOSPHORUS-CONTAINING COMPOUNDS AS ADDITIVES FOR SILICON-BASED LI ION BATTERIES | ENEVATE CORPORATION | 2023-04-06 | — | — | US | disclosed |
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | US | disclosed |
| EP-3755694-B1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157836-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157837-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157835-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157851-A1 | SUBSTITUTED PYRROLINE-2-ONES AND THEIR USE AS HERBICIDES | Bayer Aktiengesellschaft (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-4156936-A1 | ACTIVE COMPOUND COMBINATIONS | Bayer Aktiengesellschaft (DE) | 2023-04-05 | — | — | EP | disclosed |
| CN-115916342-A | Compounds, compositions and methods for treating fibrotic diseases and cancer | 普渡研究基金会 | 2023-04-04 | — | — | CN | disclosed |
| CN-115915941-A | Pyridine (thio) amides as fungicidal compounds | 拜耳公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2023-04-04 | — | — | US | disclosed |
| CN-109311789-B | Process for preparing 2, 3-unsaturated alcohols | 巴斯夫欧洲公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115916747-A | Fused heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20230099165-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | ANTARES PHARMA, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230101934-A1 | CYCLODEXTRIN-BASED COMPOUNDS AND THEIR DERIVATIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| US-20230096870-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230094796-A1 | PROCESS FOR PREPARING CYCLIC CARBONATES WITH AN EXOCYCLIC VINYLIDENE GROUP | BASF SE (DE) | 2023-03-30 | — | — | US | disclosed |
| US-20230096965-A1 | SILICATE AND ORGANOSILICON CONTAINING ADDITIVES FOR SILICON-BASED LI ION BATTERIES | ENEVATE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ARIAD PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2023049919-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023046729-A1 | CALIBRATION AID FOR OPTICAL IMAGING APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2023-03-30 | — | — | WO | disclosed |
| US-20230103027-A1 | SURFACE PRIMER COMPOSITIONS AND METHODS OF USE | ENVISTA (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230097090-A1 | IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2023-03-30 | — | — | US | disclosed |
| US-20230095171-A1 | ORGANIC ACID ADDITIVES FOR SILICON-BASED LI ION BATTERIES | ENEVATE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| US-20230099618-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CYCLIC CARBONATE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| US-20230096187-A1 | Compounds, Compositions, and Methods for Coloring Edible Materials | THE PENN STATE RESEARCH FOUNDATION | 2023-03-30 | — | — | US | disclosed |
| US-20230094087-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH PHOSPHAZENE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| EP-4155293-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | The Regents of The University of Michigan (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-4155694-A1 | CALIBRATION AID FOR OPTICAL IMAGING APPLICATIONS | Université de Strasbourg (FR) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153566-A1 | AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer CropScience Aktiengesellschaft (DE) | 2023-03-29 | — | — | EP | disclosed |
| CN-111655693-B | Inhibition of transient receptor potential A1 ion channels | 伊莱利利公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11613542-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-03-28 | — | — | US | disclosed |
| CN-110090308-B | Method for preparing conjugate | 四川科伦博泰生物医药股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-110770236-B | VMAT2 inhibitor compounds and compositions thereof | 纽罗克里生物科学有限公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-115843272-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20230091510-A1 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230089484-A1 | COMPOSITIONS FOR THE TREATMENT OF ANGIOLIPOMA | RAZIEL THERAPEUTICS LTD. (IL) | 2023-03-23 | — | — | US | disclosed |
| US-20230087744-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230089921-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230093099-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-03-23 | — | — | US | disclosed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230091115-A1 | CROSSLINKABLE POLYSILOXANE | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2023-03-23 | — | — | US | disclosed |
| EP-4151235-A1 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2023-03-22 | — | — | EP | disclosed |
| EP-4150009-A1 | FLUOROGENIC DIMER COMPOUND, USEFUL AS A PROBE FOR DETECTION OF ENDOGENOUS RECEPTORS | Université de Strasbourg (FR) | 2023-03-22 | — | — | EP | disclosed |
| EP-4149927-A1 | ENPP1 MODULATORS AND USES THEREOF | VIR Biotechnology, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4149941-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | Algen Biotechnologies, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| EP-4149929-A1 | TRIAZINE AND PYRIMIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2023-03-22 | — | — | EP | disclosed |
| CN-111448223-B | Polyethylene compositions and articles made therefrom | 埃克森美孚化学专利公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11608414-B2 | Peptoid polymers and methods of use | X-THERMA, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-110878048-B | Anilines as psychotropic disorders | 中国科学院上海药物研究所 | 2023-03-17 | — | — | CN | disclosed |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2023036706-A1 | SUBSTITUTED THIAZOLOPYRIDINES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-16 | — | — | WO | disclosed |
| US-20230078839-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KHORA SPV 1, LLC | 2023-03-16 | — | — | US | disclosed |
| US-20230083973-A1 | SUBSTITUTED CYCLOPROPYL-2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-03-16 | — | — | US | disclosed |
| US-20230080270-A1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH ZURICH (CH) | 2023-03-16 | — | — | US | disclosed |
| WO-2023039240-A1 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20230081390-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-03-16 | — | — | US | disclosed |
| EP-4146168-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | Kodiak Sciences Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146665-A1 | SYSTEMS AND METHODS FOR TYROSINASE-MEDIATED SITE-SPECIFIC PROTEIN CONJUGATION | GENENTECH, INC. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146628-A1 | PYRIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146348-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| CN-115803320-A | Heterocyclyl pyrimidines and triazines as novel fungicides | 拜耳公司 | 2023-03-14 | — | — | CN | disclosed |
| US-11603381-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | YALE UNIVERSITY (US) | 2023-03-14 | — | — | US | disclosed |
| US-11605813-B2 | Silicon-based energy storage devices with functional terthiophene compound or thiophene oligomer compound containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-03-14 | — | — | US | disclosed |
| CN-115803317-A | Azabicyclo (thio) amides as fungicidal compounds | 拜耳作物科学股份公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-112390832-B | Metal complex, intermediate, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2023-03-14 | — | — | CN | disclosed |
| CN-110234635-B | Novel substituted benzimidazole derivatives as D-amino oxidase (DAAO) inhibitors | 宇凤·简·曾 | 2023-03-10 | — | — | CN | disclosed |
| WO-2023033723-A2 | A MEMBRANE AND A METHOD OF MAKING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034262-A1 | FORMULATIONS FOR ANTIMICROBIAL THERMOSET COATINGS | CORNING INCORPORATED (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034393-A1 | ADDITIVES FOR COLOR DRIFT REDUCTION IN COPPER-BASED ANTIMICROBIAL POLYMERIC FORMULATIONS | CORNING INCORPORATED (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023031801-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |
| US-20230073334-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2023-03-09 | — | — | US | disclosed |
| US-20230073777-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-03-09 | — | — | US | disclosed |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-03-09 | — | — | US | disclosed |
| US-20230074545-A1 | TREATMENT OF CANCER WITH CDK12/13 INHIBITORS | KINNATE BIOPHARMA INC. | 2023-03-09 | — | — | US | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4144732-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | Shanghai Ringene BioPharma Co., Ltd. (CN) | 2023-03-08 | — | — | EP | disclosed |
| EP-4142879-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | Novartis AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| EP-3867263-B1 | PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND/OR SMARCA4 | BOEHRINGER INGELHEIM INT (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-4143181-A1 | 1-PYRAZINYLPYRAZOLYL-3-OXYALKYL ACIDS AND THEIR DERIVATIVES, AND THEIR USE FOR CONTROL OF UNDESIRED PLANT GROWTH | Bayer Aktiengesellschaft (DE) | 2023-03-08 | — | — | EP | disclosed |
| CN-115746227-A | Fluorine-containing block copolymer and use thereof | 广州立邦涂料有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115747223-A | Nucleic acid compositions of anti-coronavirus antibodies | 中国人民解放军军事科学院军事医学研究院 | 2023-03-07 | — | — | CN | disclosed |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-03-07 | — | — | US | disclosed |
| CN-115724920-A | Nucleic acid vaccine for coronavirus and influenza virus | 中国人民解放军军事科学院军事医学研究院 | 2023-03-03 | — | — | CN | disclosed |
| WO-2023027966-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230066946-A1 | 1,5-DIPHENYLPYRAZOLYL-3-OXYALKYL ACIDS AND 1-PHENYL-5-THIENYLPYRAZOLYL-3-OXYALKYL ACIDS AND THE USE THEREOF FOR CONTROL OF UNWANTED PLANT GROWTH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230064576-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230061438-A1 | METHODS OF SEQUENCING BY SYNTHESIS USING A CONSECUTIVE LABELING SCHEME | Roche Sequencing Solutions, Inc. | 2023-03-02 | — | — | US | disclosed |
| US-20230064809-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-4138812-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | Temple University - Of The Commonwealth System of Higher Education (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4138823-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BerGenBio ASA (NO) | 2023-03-01 | — | — | EP | disclosed |
| CN-109311813-B | Palladium-catalyzed meta-C-H functionalized universal ligands | 斯克利普斯研究院 | 2023-02-28 | — | — | CN | disclosed |
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11590135-B2 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | CORCEPT THERAPEUTICS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591333-B2 | Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | CINAKATE PHARM TECH (SHANGHAI) CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591322-B2 | Certain chemical compositions and methods of use thereof | ALGEN BIOTECHNOLOGIES, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11590235-B2 | Factor VIII zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11594733-B1 | Aqueous-based solid polymer suspensions in a polymer solution as a binder for Si dominant anodes | ENEVATE CORPORATION (US) | 2023-02-28 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| CN-115715202-A | Antibody drug conjugate, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20230054449-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| US-20230053437-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-02-23 | — | — | US | disclosed |
| WO-2023023500-A1 | METHODS AND COMPOSITIONS FOR IDENTIFYING METHYLATED CYTOSINES | ILLUMINA, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023527-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
| US-20230060004-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3529254-B1 | PRODRUGS OF CLOFARABINE | WU LAURENCE I (TW) | 2023-02-22 | — | — | EP | disclosed |
| EP-3652111-B1 | ELECTROCHROMIC POLYMER THIN FILMS HAVING REDUCED SELF-BLEACHING BEHAVIOR AND ENHANCED CYCLING STABILITY | FURCIFER INC (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115707710-A | Sample derivatization reagent and application thereof in detecting optical isomer | 中国科学院上海有机化学研究所 | 2023-02-21 | — | — | CN | disclosed |
| US-11584790-B2 | Complement factor D antagonist antibodies and conjugates thereof | KODIAK SCIENCES INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584733-B2 | Selective histone deacetylase inhibitors for the treatment of human disease | SHUTTLE PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| CN-115707708-A | Wee1 kinase inhibitors | 轩竹生物科技股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-113616656-B | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2023018825-A1 | COVALENT INHIBITORS OF MENIN-MLL INTERACTION FOR DIABETES MELLITUS | BIOMEA FUSION, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018699-A1 | SELECTIVE KRAS INHIBITORS | ERASCA, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023019163-A1 | METHODS AND COMPOSITIONS FOR EDMAN-LIKE REACTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230046340-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-02-16 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| EP-4132947-A2 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4132652-A1 | AXL INHIBITORS FOR ANTIVIRAL THERAPY | BerGenBio ASA (NO) | 2023-02-15 | — | — | EP | disclosed |
| EP-4132938-A1 | SUBSTITUTED THIAZOLOPYRIDINES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-02-15 | — | — | EP | disclosed |
| EP-3728254-B1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-02-15 | — | — | EP | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115702161-A | Peptide compositions and methods for inhibiting nicotinic acetylcholine receptor activity | 格罗制药公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-110526912-B | Heteroaryl compounds for kinase inhibition | 武田药品工业株式会社 | 2023-02-14 | — | — | CN | disclosed |
| CN-115702157-A | Substituted pyrrolin-2-ones and their use as herbicides | 拜耳公司 | 2023-02-14 | — | — | CN | disclosed |
| US-20230039244-A1 | 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME | UNIV PENNSYLVANIA (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20230044488-A1 | AMINE COMPOUND, REACTIVE COALESCING AGENT, COATING COMPOSITION, COATING LAYER AND RELATED METHODS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-02-09 | — | — | US | disclosed |
| WO-2023014943-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20230037660-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | Blaze Bioscience, Inc. | 2023-02-09 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-4126824-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | Theravance Biopharma R&D IP, LLC (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4125908-A1 | COMBINATION THERAPY COMPRISING AN AXL INHIBITOR | BerGenBio ASA (NO) | 2023-02-08 | — | — | EP | disclosed |
| US-11572353-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-111344316-B | Polyethylene compositions and articles made therefrom | 埃克森美孚化学专利公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115697986-A | Isotopically substituted spiroaromatic ring compounds and their use | 上海奕拓医药科技有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115697059-A | Active compound combinations | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115698021-A | Substituted thiazolopyridines, salts thereof and their use as herbicidal active substances | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115697989-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-20230031776-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| WO-2023009629-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023007247-A1 | COMPOSITIONS AND METHODS FOR TREATING LIPOMA PAIN | RAZIEL THERAPEUTICS LTD. (IL) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022086937-A9 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-02-02 | — | — | WO | disclosed |
| CN-115667504-A | Methods and compositions for ocular cell therapy | 诺华股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11566002-B2 | Substituted tetrahydrocyclopenta[C]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-01-31 | — | — | US | disclosed |
| US-11564388-B2 | Supercooling methods for preservation of biological samples | X-THERMA, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-115667238-A | Five-membered ring derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-110294742-B | Fused ring ASK1 inhibitor and application thereof | 山东轩竹医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11569530-B2 | Silicon-based energy storage devices with functional thiophene compounds or derivatives of thiophene containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2023002323-A1 | SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-01-26 | — | — | WO | disclosed |
| US-20230027219-A1 | Skin Care Compositions and Methods of Use Thereof | UNIGEN, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AG (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230029191-A1 | PRELITHIATION OF FREE-STANDING SILICON DOMINANT ANODE BATTERIES | ENEVATE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-20230022235-A1 | DUAL ANDROGEN RECEPTOR/AKR1C3 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3630744-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-01-25 | — | — | EP | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-4122935-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | disclosed |
| US-11559580-B1 | Tissue-homing peptide conjugates and methods of use thereof | Blaze Bioscience, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115626927-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20230019280-A1 | SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-01-19 | — | — | US | disclosed |
| WO-2023287984-A1 | SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) DRUGS, CONJUGATES, AND NANOPARTICLES, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230018615-A1 | STEROIDS AND METHODS OF MANUFACTURE | TRUSTEES OF DARTMOUTH COLLEGE | 2023-01-19 | — | — | US | disclosed |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-19 | — | — | US | disclosed |
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | YODA THERAPEUTICS INC. (TW) | 2023-01-19 | — | — | US | disclosed |
| US-20230019342-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-01-19 | — | — | US | disclosed |
| US-11554153-B2 | Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof | UNIGEN, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-11555010-B2 | Diamide antimicrobial agents | BROWN UNIVERSITY (US) | 2023-01-17 | — | — | US | disclosed |
| CN-115605462-A | Triazine and pyrimidine (thio) amides as fungicidal compounds | 拜耳公司（DE） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-4114837-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | Bayer Aktiengesellschaft (DE) | 2023-01-11 | — | — | EP | disclosed |
| EP-4114528-A1 | IMIDAZOTRIAZINES ACTING ON CANCER VIA INHIBITION OF CDK12 | Bayer Aktiengesellschaft (DE) | 2023-01-11 | — | — | EP | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11552334-B1 | Nitrogen-containing compounds as additives for silicon-based Li-ion batteries | ENEVATE CORPORATION (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548901-B2 | Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-111349128-B | Flavonol derivative and preparation method and application thereof | 上海医药工业研究院 | 2023-01-06 | — | — | CN | disclosed |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230006252-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONALIZED LINEAR SULFONATE ESTER DERIVATIVE COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-20230002366-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | TARO PHARMACEUTICALS INC. (CA) | 2023-01-05 | — | — | US | disclosed |
| WO-2023278691-A1 | METHODS OF TREATING OR PREVENTING CORONAVIRUS INFECTION WITH CANNABINOID ACIDS | OREGON STATE UNIVERSITY (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023274257-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | 诸葛国琴 | 2023-01-05 | — | — | WO | disclosed |
| EP-4112602-A1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | Bayer Aktiengesellschaft (DE) | 2023-01-04 | — | — | EP | disclosed |
| US-11543584-B2 | Inorganic matrix nanoimprint lithographs and methods of making thereof with reduced carbon | META PLATFORMS TECHNOLOGIES, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542291-B2 | Compounds, compositions, and methods for coloring edible materials | THE PENN STATE RESEARCH FOUNDATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542248-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542225-B2 | Lipids for use in lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2023-01-03 | — | — | US | disclosed |
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-01-03 | — | — | US | disclosed |
| CN-115557898-A | Imidazole compound, intermediate and application thereof | 诸葛国琴 | 2023-01-03 | — | — | CN | disclosed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-109843379-B | Substituted ureas and methods of making and using the same | 梅比斯发现公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115551875-A | Systems and methods for tyrosinase-mediated site-specific protein conjugation | 基因泰克公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022271658-A1 | TRICYCLIC KRAS INHIBITORS | ERASCA, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271659-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271677-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271650-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022268935-A2 | NOVEL PROCESS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022268520-A1 | USE OF SUBSTITUTED PYRROLIDINONES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE OF PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-29 | — | — | WO | disclosed |
| US-20220409707-A1 | DEVICES AND METHODS FOR MODULATING ADMA IN BLOOD | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-12-29 | — | — | US | disclosed |
| US-20220411448-A1 | CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS | Floratek Pharma SA (CH) | 2022-12-29 | — | — | US | disclosed |
| EP-4106877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-4108240-A2 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | Yoda Pharmaceuticals Inc. (KY) | 2022-12-28 | — | — | EP | disclosed |
| EP-4107153-A1 | COMPOUNDS | Inflazome Limited (IE) | 2022-12-28 | — | — | EP | disclosed |
| EP-3889237-B1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11535616-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | BERGENBIO ASA (NO) | 2022-12-27 | — | — | US | disclosed |
| US-11539077-B2 | Electrolyte additives containing one, two, or more triple-bonded moieties for silicon anode-based li-ion batteries | ENEVATE CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-11535713-B2 | Network polymers and methods of making and using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-12-27 | — | — | US | disclosed |
| CN-115516044-A | Fluorescent dimeric compounds useful as probes for the detection of endogenous receptors | 斯特拉斯堡大学 | 2022-12-23 | — | — | CN | disclosed |
| CN-115504962-A | Benzimidazole derivatives for the treatment and/or prevention of diseases and disorders mediated by NLRP3 | 思捷优达股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220401335-A1 | SILK HAIR CARE COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220402889-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Floratek Pharma SA (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2022265974-A1 | AMINOHETEROCYCLE-SUBSTITUTED TRICYCLIC KRAS INHIBITORS | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266491-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022265913-A1 | COPOLYMERS AND ELECTROCHEMICAL SYSTEMS AND METHODS FOR THE REMEDIATION OF ORGANIC POLLUTANTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266206-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266167-A1 | AMIDE AND UREA-CONTAINING TRICYCLIC KRAS INHIBITORS | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266069-A1 | TRICYCLIC KRAS G12D INHIBITORS | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-4103564-A1 | P2X3 MODULATORS | Bellus Health Cough Inc. (CA) | 2022-12-21 | — | — | EP | disclosed |
| EP-4103160-A1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH Zurich (CH) | 2022-12-21 | — | — | EP | disclosed |
| CN-115490709-A | KRASG12D inhibitor and application thereof in medicine | 四川海思科制药有限公司 | 2022-12-20 | — | — | CN | disclosed |
| US-11530199-B2 | Analogs for the treatment of disease | INSILICO MEDICINE IP LIMITED (HK) | 2022-12-20 | — | — | US | disclosed |
| US-11530197-B2 | Analogs for the treatment of disease | INSILICO MEDICINE IP LIMITED (HK) | 2022-12-20 | — | — | US | disclosed |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
| CN-115477640-A | Pyridazinones as PARP7 inhibitors | 由理生物医药（上海）有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220396556-A1 | Lipid and Lipid Nanoparticle Formulation for Drug Delivery | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2022-12-15 | — | — | US | disclosed |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-15 | — | — | US | disclosed |
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | UNIV MARYLAND (US) | 2022-12-15 | — | — | US | disclosed |
| WO-2022261220-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261210-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| EP-3746432-B1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-12-14 | — | — | EP | disclosed |
| US-11524932-B2 | Lipids for use in lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2022-12-13 | — | — | US | disclosed |
| US-11525123-B2 | Diverse carbene transferase enzyme catalysts derived from a P450 enzyme | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524943-B1 | Benzocarbonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| CN-107474024-B | Glutaminase inhibitor and composition and application thereof | 北京赛林泰医药技术有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-115448923-A | Pyrimido-cyclic compounds, process for their preparation and their use | 青煜医药研发(上海)有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115461049-A | (S) -2-amino-6- ((3-aminopropyl) amino) hexanoic Acid (APL) for the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | 坦普尔大学 | 2022-12-09 | — | — | CN | disclosed |
| US-20220393174-A1 | CROWN ETHERS AS ADDITIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION | 2022-12-08 | — | — | US | disclosed |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-12-08 | — | — | US | disclosed |
| US-20220388990-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220388971-A1 | [(1,5-DIPHENYL-1H-1,2,4-TRIAZOL-3-YL)OXY]ACETIC ACID DERIVATIVES AND SALTS THEREOF, CROP PROTECTION COMPOSITIONS COMPRISING THEM, METHODS FOR PRODUCING THEM AND USE THEREOF AS SAFENERS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-08 | — | — | US | disclosed |
| US-20220387608-A1 | ADRENOMEDULLIN-ANALOGUES FOR LONG-TERM STABILIZATION AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-08 | — | — | US | disclosed |
| WO-2022256459-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220387400-A1 | FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | Belite Bio (HK) Limited (HK) | 2022-12-08 | — | — | US | disclosed |
| WO-2022253101-A1 | PYRIDAZINONE COMPOUND AS PARP7 INHIBITOR | 上海优理惠生医药有限公司 | 2022-12-08 | — | — | WO | disclosed |
| EP-3368507-B1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2022-12-07 | — | — | EP | disclosed |
| EP-4096653-A1 | COMPOSITIONS FOR THE TREATMENT OF ANGIOLIPOMA | Raziel Therapeutics Ltd. (IL) | 2022-12-07 | — | — | EP | disclosed |
| EP-4096661-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2022-12-07 | — | — | EP | disclosed |
| EP-4096415-A1 | WATER RESISTANT MATERIALS FOR FOOD-SAFE USES | JL Darling LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4097087-A1 | [(1,4,5-TRISUBSTITUTED-1H-PYRAZOL-3-YL)SULFANYL]ACETIC ACID DERIVATIVES, SALTS THEREOF, AND USE THEREOF AS HERBICIDAL INGREDIENTS | Bayer Aktiengesellschaft (DE) | 2022-12-07 | — | — | EP | disclosed |
| CN-115443269-A | Substituted pyrimidines and methods of use | 施万生物制药研发IP有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115433190-A | Preparation method and application of irreversible heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-11518739-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| US-11522223-B2 | Silicon-based energy storage devices with phosphazene containing electrolyte additives | ENEVATE CORPORATION (US) | 2022-12-06 | — | — | US | disclosed |
| US-11518840-B2 | Dynamic covalent thermoset nanocomposites and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2022-12-06 | — | — | US | disclosed |
| US-11518768-B2 | Artificial metalloenzymes containing noble metal-porphyrins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-06 | — | — | US | disclosed |
| CN-111471059-B | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220380371-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| EP-3080100-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115413279-A | P2X3 modulators | 贝卢斯医疗咳嗽病公司 | 2022-11-29 | — | — | CN | disclosed |
| US-11512066-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-29 | — | — | US | disclosed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-110945001-B | FMS-like tyrosine kinase inhibitors | 硕英生医股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-4090655-A1 | PROCESS FOR PREPARING CYCLIC CARBONATES WITH AN EXOCYCLIC VINYLIDENE GROUP | BASF SE (DE) | 2022-11-23 | — | — | EP | disclosed |
| CN-115379831-A | Nanoparticles encapsulating small molecules | 苏黎世联邦理工学院 | 2022-11-22 | — | — | CN | disclosed |
| CN-115368381-A | Preparation and application of heterocyclic inhibitor | 药雅科技(上海)有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-113710661-B | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| CN-113861195-B | Multi-condensed-ring EGFR inhibitor as well as preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115362152-A | Compound (I) | 英夫拉索姆有限公司 | 2022-11-18 | — | — | CN | disclosed |
| WO-2022200540-A9 | HETERO BENZYL AMINES AND THEIR USE TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Floratek Pharma SA (CH) | 2022-11-17 | — | — | WO | disclosed |
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-11-15 | — | — | US | disclosed |
| CN-109790160-B | Pyrido five-membered aromatic ring compound, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115340552-A | Heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115340561-A | Preparation and application of SHP2 phosphatase fused ring inhibitor | 药雅科技(上海)有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115340559-A | Preparation and application of SHP2 phosphatase heterocyclic inhibitor | 药雅科技(上海)有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115335081-A | Targeted plasma protein degradation | 诺华股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115335047-A | Composition for treating vascular lipoma | 拉结尔治疗有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115335050-A | Compounds and compositions for treating skin conditions | 卡玛瑞制药有限公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2022234339-A2 | 5-HT2A AND/OR 5-HT2C RECEPTOR AGONISTS | DIAMOND THERAPEUTICS INC. (CA) | 2022-11-10 | — | — | WO | disclosed |
| CN-115304623-A | Pyrimido-cyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-111196816-B | Seven-membered ring compound and application thereof in preventing and treating diabetes and metabolic syndrome | 中国科学院上海药物研究所 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022232552-A1 | LIPID NANOPARTICLE THERAPEUTICS THAT EVADE THE IMMUNE RESPONSE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232514-A1 | COMPOSITIONS AND METHODS FOR TARGETING LIPID NANOPARTICLE THERAPEUTICS TO STEM CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-11-03 | — | — | WO | disclosed |
| CN-115279368-A | Heteroaryl compounds | 维瓦斯治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115260214-A | Condensed ring KRASG12DPreparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115279417-A | Bioactive substance conjugate and preparation method and application thereof | 苏州宜联生物医药有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115252762-A | Growth factor binding application of macromolecular compound | 华东理工大学 | 2022-11-01 | — | — | CN | disclosed |
| CN-111278872-B | Polyethylene compositions and articles made therefrom | 埃克森美孚化学专利公司 | 2022-10-28 | — | — | CN | disclosed |
| US-11478451-B1 | Macrocyclic chlorine substituted indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-25 | — | — | US | disclosed |
| CN-110317212-B | Synthesis of polycyclic carbamoylpyridone compounds | 吉利德科学公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-115215823-A | FXR (FXR) regulator and preparation method, pharmaceutical composition and application thereof | 青岛睿吉医疗技术有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-115215868-A | Preparation method and application of heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022218440-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 青岛睿吉医疗技术有限公司 | 2022-10-20 | — | — | WO | disclosed |
| WO-2022221395-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220332721-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2022-10-20 | — | — | US | disclosed |
| CN-111465626-B | Polyethylene compositions and films made therefrom | 埃克森美孚化学专利公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115210225-A | Substituted aminoquinolones as immuno-activated DGKALPHA inhibitors | 拜耳公司 | 2022-10-18 | — | — | CN | disclosed |
| US-11472799-B2 | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-10-18 | — | — | US | disclosed |
| CN-115197221-A | Dihydropyrazolopyrimidinone macrocyclic derivatives and application thereof | 轩竹生物科技股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-11472766-B2 | Lipid nanoparticle composition | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2022-10-18 | — | — | US | disclosed |
| CN-110551105-B | Substituted triazoles useful as AXL inhibitors | 里格尔制药公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115181106-A | Quinazoline KRAS G12D Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-10-14 | — | — | CN | disclosed |
| WO-2022216386-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220323378-A1 | Pharmaceutical Compositions and Methods for Treating Mental Health Disorders and Promoting Neural Plasticity | JOSEPH SHAWN (US) | 2022-10-13 | — | — | US | disclosed |
| CN-115175735-A | Antiviral compounds | 吉利德科学公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-115175899-A | Treatment of cancer using CDK12/13 inhibitors | 金耐特生物制药公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220315706-A1 | PHOTOPOLYMERIZABLE THERMOPLASTICS AND METHODS OF MAKING AND USING SAME | UNIV COLORADO REGENTS (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220315895-A1 | METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS | IMMUNEBRIDGE LLC | 2022-10-06 | — | — | US | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-4065552-A1 | ANTHRAQUINONE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | Facebook Technologies, LLC (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| EP-4065551-A1 | AROMATIC SUBSTITUTED METHANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | Facebook Technologies, LLC (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-4065570-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | disclosed |
| CN-110156770-B | Aminopyridine derivatives as inhibitors of TAM family kinases | 圣诺康生命科学公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-115141176-A | Alkyne-indole FGFR inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-109568323-B | Antibacterial composition and use thereof | 吉林四环制药有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-115135152-A | 1, 5-diphenylpyrazolyl-3-oxyalkyl acids and 1-phenyl-5-thienylpyrazolyl-3-oxyalkyl acids and their use for controlling undesired vegetation | 拜耳公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022200208-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204301-A1 | ELECTROCHEMICAL POLYNUCLEOTIDE SYNTHESIS | Twist Bioscience Corporation (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204481-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-115112898-A | IL-17F-specific capture agents, compositions, and methods of use and manufacture | 加州理工学院 | 2022-09-27 | — | — | CN | disclosed |
| CN-115108988-A | Synthesis and use of polyfunctional diaziridines binders for elastomer bonding | 元平台技术有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-11453790-B2 | Photo-cleavable primer compositions and methods of use | ENVISTA (US) | 2022-09-27 | — | — | US | disclosed |
| CN-115103907-A | Compositions and methods for enhancing immune activity | 金橘生物科技公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115103709-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220298420-A1 | MULTIFUNCTIONAL LIQUID CRYSTALLINE PHOTOREACTIVE POLYMERS FOR POLARIZATION HOLOGRAPHY | META PLATFORMS TECHNOLOGIES, LLC | 2022-09-22 | — | — | US | disclosed |
| US-20220298102-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20220299938-A1 | SPATIALLY VARYING DYNAMIC RANGE IN HOLOGRAPHIC GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2022-09-22 | — | — | US | disclosed |
| CN-115073468-A | Preparation and application of imidazopyrazine BTK inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115068574-A | Compositions and methods for joint health | 尤妮金公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073469-A | Preparation and application of pyrrolopyrimidine compound as kinase inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115087486-A | Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073451-A | KRAS G12D Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073450-A | KRAS G12C Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-11447504-B2 | Macrocyclic chlorine substituted indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-20 | — | — | US | disclosed |
| CN-115066241-A | Compositions for treating solid tumors | 拉结尔治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-115066457-A | Crosslinkable polysiloxanes | 联邦科学和工业研究组织 | 2022-09-16 | — | — | CN | disclosed |
| US-20220294016-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ETHER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2022-09-15 | — | — | US | disclosed |
| WO-2022192598-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220289708-A1 | SUBSTITUTED N-PHENYL URACILS, SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-15 | — | — | US | disclosed |
| CN-115043841-A | Preparation and application of heterocyclic compound as BTK inhibitor | 药雅科技(上海)有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11440923-B2 | Substituted macrocyclic indole derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-13 | — | — | US | disclosed |
| CN-115052604-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-115052862-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-115043832-A | FGFR inhibitor alkyne-substituted heterocyclic compound and preparation method and application thereof | 药雅科技(上海)有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022184748-A1 | SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-09 | — | — | WO | disclosed |
| CN-111658653-B | Use of phosphodiesterase inhibitors | 药捷安康(南京)科技股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115028634-A | Alkynylpyrazine heterocyclic FGFR inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115028633-A | Preparation and application of pyrrolopyrimidine compounds | 药雅科技(上海)有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11433065-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2022-09-06 | — | — | US | disclosed |
| CN-115023418-A | Bis-aminoquinoline and nanoformulation for cancer treatment | 加利福尼亚大学董事会 | 2022-09-06 | — | — | CN | disclosed |
| CN-115023427-A | Pyrazolotriazines | 拜耳公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-115003656-A | [ (1,4, 5-trisubstituted-1H-pyrazol-3-yl) sulfanyl ] acetic acid derivatives and salts thereof, and their use as active herbicidal agents | 拜耳公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-109311822-B | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-115003665-A | Substituted aminoquinolones as immunoactive DGK alpha inhibitors | 拜耳公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220274954-A1 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-01 | — | — | US | disclosed |
| CN-114957242-A | Preparation and application of pyrido-heterocyclic compound as kinase inhibitor | 药雅科技(上海)有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114957241-A | Preparation and application of heterocyclic compound as kinase inhibitor | 药雅科技(上海)有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114957150-A | Cyclic anhydride monomer and preparation method and application thereof | 华东理工大学 | 2022-08-30 | — | — | CN | disclosed |
| US-11431029-B2 | Silicon-based energy storage devices with functionalized linear sulfonate ester derivative compound containing electrolyte additives | ENEVATE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| CN-114949267-A | Drug conjugates and uses thereof | 米度（南京）生物技术有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-108473483-B | Compounds for medical use | 奥斯维尔医疗私人有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114981255-A | Method for preparing cyclic carbonate with exocyclic vinylidene | 巴斯夫欧洲公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114981270-A | MLL1 inhibitors and anticancer agents | 诺华公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11431027-B1 | Single lithium-ion conductive polymer electrolytes for Si anode-based lithium-ion batteries | ENEVATE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| CN-109790112-B | Cyanopyrrolidine derivatives having activity as USP30 inhibitors | 特殊治疗有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220267303-A1 | Compounds and Methods for Treating or Preventing Bacterial Infections | BAYLOR COLLEGE OF MEDICINE | 2022-08-25 | — | — | US | disclosed |
| EP-4045505-A1 | 2-METHYL-AZA-QUINAZOLINES | Bayer Aktiengesellschaft (DE) | 2022-08-24 | — | — | EP | disclosed |
| US-11420962-B2 | Indene derivatives useful in treating pain and inflammation | TARO PHARMACEUTICALS INC. (CA) | 2022-08-23 | — | — | US | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |
| CN-109790146-B | Pharmaceutical compounds | 阿尔麦克探索有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-109563045-B | Pd (II) -catalysed enantioselective beta-methylene C (sp) 3 ) -H bond activation | 斯克里普斯研究学院 | 2022-08-23 | — | — | CN | disclosed |
| CN-114929705-A | MLL1 inhibitor and anticancer agent | 诺华公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114917361-A | Antibody Drug Conjugates (ADC) and antibody prodrug conjugates (APDC) with enzyme cleavable groups | 拜耳医药股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022170971-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2022-08-18 | — | — | WO | disclosed |
| CN-114907350-A | Nitrogen-containing condensed ring compounds, preparation method and application | 上海凌达生物医药有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-114901253-A | Improved lipid nanoparticles for delivery of nucleic acids | 爱康泰生治疗公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022167696-A1 | FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER | Floratek Pharma SA (CH) | 2022-08-11 | — | — | WO | disclosed |
| US-11407737-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-08-09 | — | — | US | disclosed |
| CN-114853723-A | Preparation and application of indole compound BTK inhibitor | 药雅科技(上海)有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114853739-A | Alkynyl pyrazine FGFR inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114853752-A | Preparation and application of BTK inhibitor pyridine heterocyclic compound | 药雅科技(上海)有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114853740-A | Preparation method and application of alkyne pyrimidine compound as FGFR inhibitor | 药雅科技(上海)有限公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022162025-A1 | HETEROAROMATIC PHOSPHONIUM SALTS AND THEIR USE TREATING CANCER | FLORATEK PHARMA AG (CH) | 2022-08-04 | — | — | WO | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| EP-4034528-A1 | PROCESS COMPRISING THE USE OF NEW IRIDIUM CATALYSTS FOR ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES | Bayer Aktiengesellschaft (DE) | 2022-08-03 | — | — | EP | disclosed |
| CN-107108527-B | Ataxia telangiectasia and Rad 3-Associated (ATR) protein kinase inhibitors | 阿特林制药有限责任公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114845711-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114845721-A | Otic formulations for drug-induced ototoxicity | 奥德纳米有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-112384508-B | Tricyclic ASK1 inhibitor and application thereof | 山东轩竹医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114805359-A | Preparation method and application of alkynyl heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114805361-A | Amino-substituted aromatic heterocyclic pyrazole compounds, preparation method and application | 上海凌达生物医药有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114828836-A | Lipid and lipid nanoparticle formulations for drug delivery | 宾夕法尼亚大学理事会 | 2022-07-29 | — | — | CN | disclosed |
| CN-114829368-A | Method for sequencing by synthesis using a sequential labelling scheme | 豪夫迈·罗氏有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114828837-A | Lipid nanoparticles for CAR mRNA delivery and formulations thereof | 宾夕法尼亚大学理事会 | 2022-07-29 | — | — | CN | disclosed |
| US-20220233525-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-07-28 | — | — | US | disclosed |
| EP-3207128-B1 | BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-11398641-B2 | Silicon-based energy storage devices with silicon containing electrolyte additives | ENEVATE CORPORATION (US) | 2022-07-26 | — | — | US | disclosed |
| CN-113004788-B | Surface finishing composition | 3M中国有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114786731-A | Methods of treating ocular disorders | 科达制药股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220226461-A1 | Nucleoside-modified RNA for Inducing an Adaptive Immune Response | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2022-07-21 | — | — | US | disclosed |
| US-20220229065-A1 | SENSORS AND METHODS FOR RAPID MICROBIAL DETECTION | BAMBU VAULT LLC (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. | 2022-07-21 | — | — | US | disclosed |
| EP-4029510-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | Kodiak Sciences Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3615513-B1 | METHODS OF MANUFACTURING OF NIRAPARIB | TESARO INC (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-108341774-B | Substituted quinolinone inhibitors | 首药控股(北京)股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-07-19 | — | — | US | disclosed |
| US-11390618-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11389444-B2 | Methods of treating metabolic diseases with fused bicyclic pyrazoles | BELITE BIO, INC (KY) | 2022-07-19 | — | — | US | disclosed |
| US-11389445-B2 | Pentafluorosulfanyl-substituted amide derivatives, preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-07-19 | — | — | US | disclosed |
| CN-114751903-A | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220218816-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-4025565-A1 | NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-07-13 | — | — | EP | disclosed |
| EP-4025564-A1 | NITRIFICATION INHIBITORS | The University of Melbourne (AU) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026832-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Almac Discovery Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3612546-B1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | SYNTHENA AG (CH) | 2022-07-13 | — | — | EP | disclosed |
| CN-109535155-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-111087612-B | Phosphorus-containing flame-retardant nylon and preparation method and application thereof | 今创景新材料科技（上海）有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-11384049-B2 | — | — | 2022-07-12 | — | — | US | disclosed |
| US-11384085-B2 | Modulators of ion channel receptors and uses thereof | BIONOMICS LIMITED (AU) | 2022-07-12 | — | — | US | disclosed |
| US-11385221-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-111087796-B | Phosphorus-containing copolymerized nylon and preparation method and application thereof | 今创景新材料科技（上海）有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114728910-A | Pyrazole derivatives for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728915-A | [ (1, 5-diphenyl-1H-1, 2, 4-triazol-3-yl) oxy ] acetic acid derivatives and salts thereof, crop protection compositions comprising the same, method for the production thereof and use thereof as safeners | 拜耳公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-109415623-B | Photosensitive macromolecules and uses thereof | 拜克门寇尔特公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728888-A | Aromatic substituted ethane-core monomers and polymers thereof for volume bragg gratings | 脸谱科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728889-A | Aromatic substituted alkane-nuclear monomers and polymers thereof for volume bragg gratings | 脸谱科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-110723748-B | Metal oxides, metal bronzes and polyoxometallates as charge storage materials in electrochromic devices | 菲尔齐费尔公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728941-A | Substituted 1, 5-naphthyridines or quinolines as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728076-A | MCL-1 inhibitor antibody-drug conjugates and methods of use | 诺华股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728077-A | MCL-1 inhibitor antibody-drug conjugates and methods of use | 诺华股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728992-A | Method for producing phosphate compound | 斯泰拉化工公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728993-A | Thiophosphate and phosphine sulfide derivative monomer and polymer for volume Bragg grating | 脸谱科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728893-A | Aromatic substituted methane-core monomers and polymers thereof for volume bragg gratings | 脸谱科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728894-A | Anthraquinone derivative monomer and polymer for volume Bragg grating | 脸谱科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114729044-A | Muscarinic acetylcholine M1Receptor antagonists | 帕珀莱恩医疗公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-108026142-B | Ligands for orphan nuclear receptor Nur77 and uses thereof | 艾凯奇（厦门）生物科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114727975-A | Antiandrogen receptor/AKR 1C3 inhibitors | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | disclosed |
| US-20220213260-A1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220211664-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2022-07-07 | — | — | US | disclosed |
| WO-2022147189-A1 | VARENICLINE PRODRUGS | ANTARES PHARMA, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022147180-A1 | HIGH REFRACTIVE INDEX OVERCOAT FORMULATION AND METHOD OF USE WITH INKJET PRINTING | META PLATFORMS TECHNOLOGIES, LLC (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-3608325-B1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-4023639-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3527573-B9 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3710449-B1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | BROAD INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3280262-B1 | SYNERGISTIC BENZOXABOROLE-CONTAINING ANTI-FUNGICIDAL COMPOSITION | PENN STATE RES FOUND (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114703144-A | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-11377441-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377431-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-05 | — | — | US | disclosed |
| CN-114685487-A | Pyrimidine heterocyclic compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685502-A | Spirocyclic compounds as KRAS-G12C inhibitors | 由理生物医药（上海）有限公司 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022133544-A1 | CBD CANNABINOIDS AND CBD CANNABINOID ANALOGUES | Botanix Pharmaceuticals Limited (AU) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140643-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204790-A1 | HIGH REFRACTIVE INDEX OVERCOAT FORMULATION AND METHOD OF USE WITH INKJET PRINTING | META PLATFORMS TECHNOLOGIES, LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220209227-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED CYCLIC COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORP (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220205165-A1 | CHEMICALLY LINKED SILK FIBROIN COATINGS AND METHODS OF MAKING AND USING THEREOF | EVOLVED BY NATURE, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220204486-A1 | THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| EP-4019516-A1 | ASYMMETRIC PHASE TRANSFER CATALYSIS | Merck Sharp & Dohme Corp. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-4017843-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2022-06-29 | — | — | EP | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| EP-3517535-B1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | Tseng, Yufeng Jane (US) | 2022-06-28 | — | — | US | disclosed |
| US-11371994-B2 | Phosphorylated Akt-specific capture agents, compositions, and methods of using and making | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-11370776-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2022-06-28 | — | — | US | disclosed |
| CN-109476680-B | Organic magnesium phosphide, process for producing the same, complex thereof, process for producing the same, and process for producing organic phosphorus compound using the same | 北兴化学工业株式会社 | 2022-06-28 | — | — | CN | disclosed |
| CN-111763217-B | Thieno-nitrogen heterocyclic compounds, preparation method and application | 上海凌达生物医药有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-114656791-A | Polymer-silica hybrid PDOT and methods of use thereof | 华盛顿大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-108290927-B | IL-17F-specific capture agents, compositions, and methods of use and manufacture | 加州理工学院 | 2022-06-24 | — | — | CN | disclosed |
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-06-23 | — | — | US | disclosed |
| WO-2022133314-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | NEW ATLAS BIOTECHNOLOGIES, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133280-A1 | COMPOSITION FOR REVERSIBLE POLYMERIZATION OF THIOESTER AND METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| WO-2022133064-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| EP-4013755-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013762-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013756-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013761-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013500-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-3652235-B1 | ELECTROCHROMIC POLYMER AND SYNTHESIS AND USES THEREOF | FURCIFER INC (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-109071446-B | Organic reaction in aqueous solution in the presence of hydroxyalkyl (alkyl) cellulose or alkylcellulose | 艾伯维德国有限责任两合公司 | 2022-06-21 | — | — | CN | disclosed |
| US-11365220-B2 | Methods of making anti-GP41 antibody-specific capture agents | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-21 | — | — | US | disclosed |
| US-11365219-B2 | Cyclic peptides as protein targeting agents | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-21 | — | — | US | disclosed |
| CN-110229157-B | Pyrimido five-membered heteroaromatic compound, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-110437230-B | Tertiary amine compound, diphosphine ligand, intermediate and preparation method thereof | 中国科学院上海有机化学研究所 | 2022-06-21 | — | — | CN | disclosed |
| CN-109843873-B | Alkyne heterocyclic compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220185808-A1 | ACYLAMINOPYRROLO-PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2022-06-16 | — | — | US | disclosed |
| US-20220185846-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | PROTAGONIST THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220183998-A1 | USE OF 8,9- DIHYDROCANNABIDIOL COMPOUNDS | UNIV CALIFORNIA (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3837301-B1 | POLYMER COMPOSITION | BASF SE (DE) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011876-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-114621222-A | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-11357856-B2 | Lipids for delivery of active agents | Acuitas Therapeutics, Inc. (CA) | 2022-06-14 | — | — | US | disclosed |
| US-11357770-B2 | Method of treating immunoglobulin light chain amyloidosis | Alterity Therapeutics Limited (AU) | 2022-06-14 | — | — | US | disclosed |
| US-11358959-B2 | Benzothiophene and benzothiazole compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358958-B2 | — | — | 2022-06-14 | — | — | US | disclosed |
| CN-110177822-B | Synthesis of polycarbonate siloxane diol | 奥特克国际公开有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-11357781-B2 | Non-catalytic substrate-selective, p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-06-14 | — | — | US | disclosed |
| CN-114616227-A | Nitrification inhibitors | 墨尔本大学 | 2022-06-10 | — | — | CN | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| US-20220177659-A1 | NON-CORE SHELL POLYMER PARTICLES | THE UNIVERSITY OF SYDNEY (AU) | 2022-06-09 | — | — | US | disclosed |
| WO-2022120207-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-4007578-A1 | SUBSTITUTED CYCLOPROPYL-2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11352554-B2 | Photochromic water harvesting platform | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| US-11352512-B2 | Surface primer compositions and methods of use | ENVISTA (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352367-B2 | Indene derivatives useful in treating pain and inflammation | TARO PHARMACEUTICALS INC. (CA) | 2022-06-07 | — | — | US | disclosed |
| CN-109790148-B | Cyano-substituted heterocycles having USP30 inhibitor activity | 特殊治疗有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114591334-A | Dihydropyrazolopyrimidinone derivatives | 山东轩竹医药科技有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114599408-A | Devices and methods for modulating ADMA in blood | 印地安纳大学理事会 | 2022-06-07 | — | — | CN | disclosed |
| CN-114569552-A | Anti-malarial compositions and uses thereof | 斯克利普斯研究院 | 2022-06-03 | — | — | CN | disclosed |
| CN-114573566-A | Selective ROCK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-110156786-B | Pyrimido-cyclic compounds, process for their preparation and their use | 青煜医药研发(上海)有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114585622-A | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents | 诺华股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022112430-A1 | REDUCTION OF VIRAL INFECTIONS | PHOXBIO LIMITED (IE) | 2022-06-02 | — | — | WO | disclosed |
| US-20220169618-A1 | SUBSTITUTED 2-HETEROARYLAMINOBENZENES AND THE SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-02 | — | — | US | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112537-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2022-06-02 | — | — | WO | disclosed |
| US-20220169627-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, LLC | 2022-06-02 | — | — | US | disclosed |
| US-20220170053-A1 | HIGH GRAVITY, FED-BATCH IONIC LIQUID BASED PROCESS FOR DECONSTRUCTING BIOMASS | UNITED STATES DEPARTMENT OF ENERGY | 2022-06-02 | — | — | US | disclosed |
| EP-4003981-A1 | SUBSTITUTED N-PHENYL URACILS, SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2022-06-01 | — | — | EP | disclosed |
| EP-4006030-A2 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | Kura Oncology, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4003345-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4003975-A1 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2022-06-01 | — | — | EP | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
| CN-112204025-B | Compounds for the treatment of pain, compositions comprising the same and methods of using the same | 瑟赛治疗公司 | 2022-05-31 | — | — | CN | disclosed |
| US-11349153-B2 | Silicon-based energy storage devices with ether containing electrolyte additives | ENEVATE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114560893-A | Planar chiral metallocene compound, and synthesis method and application thereof | 中国科学院上海有机化学研究所 | 2022-05-31 | — | — | CN | disclosed |
| US-11345720-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2022-05-31 | — | — | US | disclosed |
| US-11344559-B2 | PI3KGAMMA inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | KINNATE BIOPHARMA INC. (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114555609-A | Macrocyclic sulfonamide derivatives useful as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022106902-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106897-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
| US-20220160696-A1 | USES OF PHOSPHODIESTERASE INHIBITORS | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-05-26 | — | — | US | disclosed |
| US-20220162193-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | PELOTON THERAPEUTICS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220160724-A1 | SELECTIVE P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
| EP-3999061-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BETA-CATENIN / TCF4 INTERACTION | Agency for Science, Technology and Research (SG) | 2022-05-25 | — | — | EP | disclosed |
| EP-3999498-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-4000610-A1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | Acucela Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11342588-B2 | Silicon-based energy storage devices with electrolyte containing dihydrofuranone based compound | ENEVATE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| CN-114524810-A | Pyrimidine heterocyclic compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-114516883-A | Thienopyrimidine compound, and pharmaceutical composition and application thereof | 苏州优理生物医药科技有限公司 | 2022-05-20 | — | — | CN | disclosed |
| CN-114516873-A | Spiro compound, pharmaceutical composition containing same and application thereof | 苏州优理生物医药科技有限公司 | 2022-05-20 | — | — | CN | disclosed |
| US-20220153895-A1 | SUBSTITUTED PROPANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2022-05-19 | — | — | US | disclosed |
| US-20220153686-A1 | LIPID NANOPARTICLE COMPOSITION | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2022-05-19 | — | — | US | disclosed |
| WO-2022104113-A1 | SUBSTITUTED MONO- AND POLY-PHENYL-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104137-A1 | SUBSTITUTED PROPANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104070-A2 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104147-A1 | ADDITIVES FOR REDUCING NON-SPECIFIC INTERACTIONS BETWEEN FLUORESCENT POLYMER CONJUGATES AND CELLS IN A BIOLOGICAL SAMPLE | BECKMAN COULTER, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20220153731-A1 | Compounds for Pain Treatment, Compositions Comprising Same, and Methods of Using Same | ACADIA PHARM INC (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
| US-20220153693-A1 | SUBSTITUTED MONO- AND POLY-PHENYL-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2022-05-19 | — | — | US | disclosed |
| US-20220153706-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3996714-A1 | FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | Belite Bio, LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114514322-A | Method for producing oligoenergetic and monoenergetic precursors | 投资健康有限责任公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114507190-A | Deuterated 1, 4-benzodiazepine-2, 5-diketone compound and application thereof | 宁波康柏睿格医药科技有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-11332453-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2022-05-17 | — | — | US | disclosed |
| US-11332476-B2 | Fms-like tyrosine kinase inhibitors | 3SM BIOTRON INC. (TW) | 2022-05-17 | — | — | US | disclosed |
| CN-114514223-A | Process comprising enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines using a novel iridium catalyst | 拜耳公司 | 2022-05-17 | — | — | CN | disclosed |
| US-11332485-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-114478568-A | Thienopyrimidine compound, pharmaceutical composition containing thienopyrimidine compound and application of thienopyrimidine compound | 苏州优理生物医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114478409-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-109721620-B | HPK1 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114478585-A | Nitrogen-containing fused heterocyclic compound and preparation method and application thereof | 上海青煜医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-111885914-B | Compositions and methods for producing expanded hematopoietic stem cells using fluorene derivatives | 投资健康有限责任公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114502533-A | Benzenesulfonamide derivatives and use thereof | 2692372安大略公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022096446-A1 | [(1-PHENYL-5-(HETEROARYL)-1H-1,2,4-TRIAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | WO | disclosed |
| US-20220144819-A1 | NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220144815-A1 | 1,3,4-OXADIAZOLES AND THEIR DERIVATIVES AS NEW ANTIFUNGAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144845-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | UNIV DREXEL (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220142995-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-05-12 | — | — | US | disclosed |
| US-20220145171-A1 | QUANTUM DOTS AND PROCESSES FOR PREPARATION THEREOF | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-05-12 | — | — | US | disclosed |
| WO-2022098892-A1 | SELF-HEALABLE, RECYCLABLE, AND RECONFIGURABLE WEARABLE ELECTRONICS DEVICE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098700-A1 | INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4 | CASSAVA SCIENCES, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022096448-A1 | [(5-PHENYL-5-HETEROARYL-1H-PYRAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022096442-A1 | [(5-PHENYL-1-HETEROARYL-1H-TRIAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022096445-A1 | [(1-PHENYL-5-HETEROARYL-1H-PYRAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022096449-A1 | [(1,5-DIHETEROARYL-1H-1,2,4-TRIAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | WO | disclosed |
| EP-3661917-B1 | 6-((3-TRIFLUOROMETHYL)PHENYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AG (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994262-A1 | ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS | Stratos Genomics Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3995611-A1 | HIGH THROUGHPUT METHOD FOR CONSTRUCTING AND SCREENING COMPOUND LIBRARY AND REACTION DEVICE | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2022-05-11 | — | — | EP | disclosed |
| EP-3102207-B1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY SCIENCE TECH & RES (SG) | 2022-05-11 | — | — | EP | disclosed |
| EP-3179992-B1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA BV (NL) | 2022-05-11 | — | — | EP | disclosed |
| US-11325902-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-05-10 | — | — | US | disclosed |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-10 | — | — | US | disclosed |
| US-11325111-B2 | Catalysts and methods of making the same | EXXONMOBIL RESEARCH & ENGINEERING COMPANY (US) | 2022-05-10 | — | — | US | disclosed |
| CN-109384790-B | Fibroblast growth factor receptor inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-108101826-B | Indole-substituted alkylamine compound and application thereof | 华东理工大学 | 2022-05-10 | — | — | CN | disclosed |
| CN-114437039-A | CD73 inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022094400-A1 | BICYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF DISEASES | ATHIRA PHARMA, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220135612-A1 | MODIFIED NUCLEOSIDE AND SYNTHETIC METHODS THEREOF | Stemirna Therapeutics Co., Ltd. (CN) | 2022-05-05 | — | — | US | disclosed |
| US-20220140392-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-20220133734-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20220135563-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-05 | — | — | US | disclosed |
| WO-2022090481-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| EP-3433246-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-04 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-03 | — | — | US | disclosed |
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319344-B2 | Non-membrane disruptive P53 activating stapled peptides | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-05-03 | — | — | US | disclosed |
| US-11319290-B2 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114423463-A | Heterobifunctional compounds as HPK1 degradants | 西奈山伊坎医学院 | 2022-04-29 | — | — | CN | disclosed |
| CN-114423739-A | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220125771-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-04-28 | — | — | US | disclosed |
| US-20220131148-A1 | BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-04-28 | — | — | US | disclosed |
| US-20220126270-A1 | CAPTURE OF FLUORINATED CARBON COMPOUNDS | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-04-28 | — | — | US | disclosed |
| US-20220131195-A1 | ELECTROLYTE ADDITIVES CONTAINING ONE, TWO, OR MORE TRIPLE-BONDED MOIETIES FOR SILICON ANODE-BASED LI-ION BATTERIES | ENEVATE CORPORATION | 2022-04-28 | — | — | US | disclosed |
| US-20220131194-A1 | METAL AMIDE BASES AS ELECTROLYTE ADDITIVES FOR SI ANODE-BASED LI-ION BATTERIES | ENEVATE CORPORATION | 2022-04-28 | — | — | US | disclosed |
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
| US-20220131193-A1 | SYMMETRICAL OR ASYMMETRICAL ALKYLSULFONYL IMIDE OR CYCLIC ALKYLENE SULFONYLIMIDE SALTS AS CATHODE ADDITIVES, ELECTROLYTE ADDITIVES, OR SI ANODE ADDITIVES FOR SI ANODE-BASED LI-ION CELLS | ENEVATE CORPORATION | 2022-04-28 | — | — | US | disclosed |
| WO-2022087008-A1 | TERTIARY CARBOXAMIDE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022087456-A1 | NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022086937-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3986408-A1 | ANTICANCER COMBINATION THERAPY | Boehringer Ingelheim International GmbH (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986874-A1 | BENZYLPHENYL HYDROXYISOXAZOLINES AND ANALOGUES AS NEW ANTIFUNGAL AGENTS | Bayer Aktiengesellschaft (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986875-A1 | PHENOXYPHENYL HYDROXYISOXAZOLINES AND ANALOGUES AS NEW ANTIFUNGAL AGENTS | Bayer Aktiengesellschaft (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986564-A1 | NEW MACROCYCLIC COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3988120-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3988631-A1 | POLYMER-SILICA HYBRID PDOTS | University of Washington (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986918-A1 | ADRENOMEDULLIN-ANALOGUES FOR LONG-TERM STABILIZATION AND THEIR USE | Bayer Aktiengesellschaft (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-11311512-B2 | Lymph directing prodrugs | MONASH UNIVERSITY (AU) | 2022-04-26 | — | — | US | disclosed |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-04-26 | — | — | US | disclosed |
| US-11312718-B2 | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one | INFINITY PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| CN-109803963-B | Cyano-substituted heterocycles having USP30 inhibitor activity | 特殊治疗有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114395065-A | Spray-dried olefin polymerization catalyst composition and polymerization process using the same | 埃克森美孚化学专利公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114401956-A | Substituted N-phenyluracils, their salts and their use as herbicides | 拜耳公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114401971-A | Macrocyclic sulfonylurea derivatives as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-109689652-B | Fused heterocyclic derivative, preparation method and medical application thereof | 北京诺诚健华医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-109313954-B | Polymer-silica hybrid PDOT and methods of use thereof | 华盛顿大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-114401955-A | Inhibitors of cyclin dependent kinases | 金耐特生物制药公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114394983-A | Synthesis of polycyclic carbamoylpyridone compounds | 吉利德科学公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-108473502-B | 4, 6-dihydropyrrolo [3,4-C ] pyrazole-5 (1H) -carbonitrile derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114390920-A | Chemically linked silk fibroin coatings and methods of making and using the same | 自然进化公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114391008-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2022081702-A1 | IN VIVO TARGETING OF CD4+-T CELLS FOR MRNA THERAPEUTICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081842-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081699-A1 | IN VIVO TARGETING OF T CELLS FOR MRNA THERAPEUTICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081694-A1 | IN VIVO TARGETING OF FIBROSIS BY ANTI-CD5-TARGETED FAP-CAR T MRNA-LNP | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081469-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220119567-A1 | NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME | NATIONAL SCIENCE FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220119580-A1 | POLYURETHANE/UREA MATERIALS | FOLDAX, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220118123-A1 | COMBINATION OF AR ANTAGONISTS AND TARGETED THORIUM CONJUGATES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-21 | — | — | US | disclosed |
| EP-3490982-B1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LTD (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-109476629-B | Urea and thiourea substituted bicyclic derivatives as pesticides | 先正达参股股份有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-111356706-B | Polymerization process | 埃克森美孚化学专利公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114364382-A | Formulations and methods of use of RBP4 inhibitors | 倍亮生物有限责任公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114364363-A | Silk hair care composition | 自然进化公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114364666-A | Substituted N-phenyl-N-semicarbazides pyrimidines and salts thereof and their use as herbicides | 拜耳公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-04-14 | — | — | US | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| WO-2022073920-A1 | OLIGOMERIC COMPOUND FOR DYSTROPHIN RESCUE IN DMD PATIENTS THROUGHOUT SKIPPING OF EXON-51 | SQY THERAPEUTICS (FR) | 2022-04-14 | — | — | WO | disclosed |
| US-20220110862-A1 | TREATMENT OF COGNITIVE DYSFUNCTION WITH PYRROLOPYRIDINE-ANILINE COMPOUNDS | NFLECTION THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3980015-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | University of Maryland, Baltimore (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-110204544-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11299513-B2 | Cyclative release of peptidic compounds | CIRCLE PHARMA, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-114302876-A | NLRP3 inhibitor | 英夫拉索姆有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114288294-A | Compounds and methods for treating or preventing hematologic cancers | 布罗德研究所股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-109311001-B | Organosilica polymer catalyst and method for producing same | 埃克森美孚研究工程公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-04-07 | — | — | US | disclosed |
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| EP-3319938-B1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEREOF | UNIV MARYLAND (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-105682658-B | Cancer therapy using PI3 kinase subtype modulators | 无限药品公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114286677-A | Heterocyclic compounds as modulators of beta-catenin/TCF 4 interaction | 新加坡科技研究局 | 2022-04-05 | — | — | CN | disclosed |
| CN-108864149-B | Purification of rapamycin derivatives | 生物传感器国际集团有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-110563773-B | Planar chiral ferrocene compound, intermediate thereof, preparation method and application | 中国科学院上海有机化学研究所 | 2022-04-01 | — | — | CN | disclosed |
| CN-110248947-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-110267963-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-108602823-B | Spiro-condensed pyrrolidine derivatives as Deubiquitinase (DUB) inhibitors | 特殊治疗有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114269746-A | Spiro aromatic ring compound, preparation and application thereof | 上海奕拓医药科技有限责任公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-110267962-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220102713-A1 | AQUEOUS BASED POLYMERS FOR SILICON DOMINANT ANODES | ENEVATE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| US-20220096513-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERS | THE BROAD INSTITUTE, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| CN-107849013-B | Cyanopyrrolidines as DUB inhibitors for the treatment of cancer | 特殊治疗有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-109790169-B | Cyanopyrrolidine derivatives having activity as USP30 inhibitors | 特殊治疗有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114258301-A | Dual ATM and DNA-PK inhibitors for use in antitumor therapy | 艾科思莱德制药公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-108026141-B | Ligands for orphan nuclear receptor Nur77 and uses thereof | 艾凯奇（厦门）生物科技有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11286263-B2 | Macrocyclic fluorine substituted indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| EP-3969442-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
| CN-111867646-B | Fluorescent polymer coated films for medical devices | 斯特拉斯堡大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-111704610-B | Pyrrolylamido pyridone compounds, preparation method and application | 上海凌达生物医药有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114206870-A | Tricyclic AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114206463-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114206827-A | Lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114195804-A | Piperidine condensed ring compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-111057048-B | Aminopyrazine/pyridine compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220081392-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2022-03-17 | — | — | US | disclosed |
| WO-2022052924-A1 | PREPARATION METHOD FOR CLASS OF NITROGEN-CONTAINING FUSED RING COMPOUNDS AND USE THEREOF | 上海凌达生物医药有限公司 | 2022-03-17 | — | — | WO | disclosed |
| US-20220081409-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-17 | — | — | US | disclosed |
| US-20220081407-A1 | METHODS OF PREPARING SUBSTITUTED INDANES | PELOTON THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| EP-3966202-A1 | THIANTHRENE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | Facebook Technologies, LLC. (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3153023-B1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| EP-3613743-B1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | INTELLIKINE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-15 | — | — | US | disclosed |
| US-11274093-B2 | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2022-03-15 | — | — | US | disclosed |
| CN-112868659-B | Composition applicable to user equipment and application thereof | 3M中国有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-108350034-B | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-114174326-A | Long-term stable adrenomedullin analogues and uses thereof | 拜耳公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220072155-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2022-03-10 | — | — | US | disclosed |
| EP-3962484-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3565549-B1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | SHUTTLE PHARMACEUTICALS INC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3700907-B1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AG (DE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3963082-A1 | METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS | Transfusion Health LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | Celltaxsis, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| CN-109496213-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-114144520-A | Enhanced nucleic acid polymerization by aromatic compounds | 斯特拉托斯基因公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-114144178-A | Nicorandil derivatives | 尤尼赛夫医疗公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2022046642-A1 | COMPOUNDS AND COMPOSITIONS FOR DISRUPTING PROGRAMMED RIBOSOMAL FRAMESHIFTING | YALE UNIVERSITY (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022047315-A1 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | VIEWPOINT THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-114106341-A | Comb copolymer and preparation method and application thereof | 广州立邦涂料有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-109020887-B | Amide compounds as agents for the prophylaxis and treatment of psychotic disorders | 绍兴从零医药科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11261184-B2 | [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-03-01 | — | — | US | disclosed |
| CN-114126615-A | Opioid receptor antagonist prodrugs | 尼萨姆实验室公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114127051-A | Inhibitors of fibroblast growth factor receptor kinase | 金耐特生物制药公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114106278-A | Polyurethane/urea materials | 联邦科学和工业研究组织 | 2022-03-01 | — | — | CN | disclosed |
| CN-114106088-A | Bromomethylpyrazine-based drug conjugates and ADCs | 联宁（苏州）生物制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114085198-A | Lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114096550-A | Modified nucleosides and methods of synthesis thereof | 斯微(上海)生物科技股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2022040241-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | BIOINTERVENE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3955878-A1 | CHEMICALLY LINKED SILK FIBROIN COATINGS AND METHODS OF MAKING AND USING THEREOF | Evolved by Nature, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3955886-A1 | SILK HAIR CARE COMPOSITIONS | Evolved by Nature, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3956033-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
| CN-114075196-A | Aromatic ring-lactam compound, preparation method and application thereof | 上海凌达生物医药有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-11254637-B2 | Conversion of lignin to ionic liquids | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| CN-110256427-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-114057749-A | Preparation method and application of irreversible alkyne heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114053431-A | Liposome composition of compound with STING agonistic activity, and preparation method and application thereof | 四川科伦药物研究院有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114072207-A | Bicyclic compounds | 维瓦斯治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114072144-A | External phosphoinositide 3-kinase inhibitors | 维瑟拉有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114072148-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2022034568-A1 | TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS | VIVA STAR BIOSCIENCES LIMITED (CN) | 2022-02-17 | — | — | WO | disclosed |
| US-20220048950-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR PEPTIDE ANTAGONIST CONOTOXIN COMPOSITIONS AND RELATED METHODS | GLO PHARMA, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220052380-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CYCLIC ORGANOSILICON CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2022-02-17 | — | — | US | disclosed |
| US-20220047612-A1 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | EMPIRICO INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3953376-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | Protagonist Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3953331-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | Peloton Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-112457326-B | Aromatic heterocyclic lactam compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-114040760-A | Irreversible inhibitors of the MENIN-MLL interaction | 拜欧米富士恩公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-114031658-A | Lymphatic prodrugs | 莫纳什大学 | 2022-02-11 | — | — | CN | disclosed |
| US-20220040193-A1 | FORMULATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS | BRIDGEBIO GENE THERAPY RESEARCH, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20220040285-A1 | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response | UNIV PENNSYLVANIA (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3947476-A1 | NON-CORE-SHELL POLYMER PARTICLES | The University of Sydney (AU) | 2022-02-09 | — | — | EP | disclosed |
| EP-3086815-B1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS INC (CA) | 2022-02-09 | — | — | EP | disclosed |
| EP-3728237-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| EP-3164380-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3728235-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| EP-3193881-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3947350-A1 | SUBSTITUTED 2-HETEROARYLAMINOBENZENES AND THE SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2022-02-09 | — | — | EP | disclosed |
| CN-108347916-B | Composition and method for reducing ice crystal formation | 先时迈纳米生物科技股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11242364-B1 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | ChromaDex Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242337-B2 | Compounds useful for treating gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220031676-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-02-03 | — | — | US | disclosed |
| US-20220031685-A1 | COMBINATION THERAPY FOR TREATING BLOOD CANCER | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2022-02-03 | — | — | US | disclosed |
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-02-03 | — | — | US | disclosed |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20220024936-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220026803-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| US-20220024947-A1 | Purification of Rapamycin Derivatives Using Temperature Induced Phase Separation | BIOSENSORS INTERNATIONAL GROUP, LTD. (BM) | 2022-01-27 | — | — | US | disclosed |
| US-20220025111-A1 | NARROW ABSORPTION POLYMER NANOPARTICLES AND RELATED METHODS | UNIVERSITY OF WASHINGTON (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| EP-3941922-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-111153901-B | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-01-25 | — | — | CN | disclosed |
| CN-113956252-A | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-01-21 | — | — | CN | disclosed |
| US-20220017522-A1 | METHOD FOR PREPARING PYRROLOPYRIMIDINE COMPOUND AND APPLICATION THEREOF | CINKATE PHARMACEUTICAL INTERMEDIATES CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20220016115-A1 | USP19 INHIBITORS FOR USE IN THERAPY | ALMAC DISCOVERY LIMITED (GB) | 2022-01-20 | — | — | US | disclosed |
| US-20220019015-A1 | INORGANIC MATRIX NANOIMPRINT LITHOGRAPHS AND METHODS OF MAKING THEREOF | META PLATFORMS TECHNOLOGIES, LLC | 2022-01-20 | — | — | US | disclosed |
| US-20220017477-A1 | BENZOTHIAZOLE AND RELATED COMPOUNDS | SPINOGENIX, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220016106-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS | THE BROAD INSTITUTE, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20220017509-A1 | GAS41 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| EP-3937938-A1 | NICORANDIL DERIVATIVES | Unicycive Therapeutics Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3940456-A1 | NANOIMPRINT LITHOGRAPHY GRATING AND OPTICAL COMPONENT COMPRISING SUCH GRATING | Facebook Technologies, LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939964-A1 | COMBINATIONS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939588-A1 | USES OF PHOSPHODIESTERASE INHIBITORS | Transthera Sciences (Nanjing), Inc. (CN) | 2022-01-19 | — | — | EP | disclosed |
| EP-3454945-B1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3541822-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2022-01-19 | — | — | EP | disclosed |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | disclosed |
| CN-113929729-A | Veratramine compound, preparation method and application thereof | 上海医药工业研究院 | 2022-01-14 | — | — | CN | disclosed |
| CN-106255513-B | Sulfonamide-containing linking systems for drug conjugates | 酵活有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113933921-A | Inorganic substrate nanoimprint lithography body and method for manufacturing same | 脸谱科技有限责任公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113939544-A | Non-core-shell polymer particles | 悉尼大学 | 2022-01-14 | — | — | CN | disclosed |
| CN-111704611-B | Aryl spiro SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-112300194-B | Condensed ring pyridone compounds, preparation method and application | 上海凌达生物医药有限公司 | 2022-01-14 | — | — | CN | disclosed |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| US-20220009887-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2022011313-A1 | MODIFICATION OF METALLIC SURFACES WITH PHOSPHONIC ACIDS | BIOLOGICAL DYNAMICS, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022010676-A1 | SILICON ANODES WITH WATER-SOLUBLE MALEIC ANHYDRIDE-. AND/OR MALEIC ACID-CONTAINING POLYMERS/COPOLYMERS, DERIVATIVES, AND/OR COMBINATIONS (WITH OR WITHOUT ADDITIVES) AS BINDERS | ENEVATE CORPORATION (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022010537-A1 | GAS41 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20220013768-A1 | SILICON ANODES WITH WATER-SOLUBLE MALEIC ANHYDRIDE-, AND/OR MALEIC ACID-CONTAINING POLYMERS/COPOLYMERS, DERIVATIVES, AND/OR COMBINATIONS (WITH OR WITHOUT ADDITIVES) AS BINDERS | ENEVATE CORPORATION | 2022-01-13 | — | — | US | disclosed |
| WO-2022011043-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-3377487-B1 | COMPOUNDS FOR MEDICINAL APPLICATIONS | AusVir Therapeutics Pty Ltd (AU) | 2022-01-12 | — | — | EP | disclosed |
| EP-3445752-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3549963-B1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3935037-A1 | USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-113923988-A | Substituted arylmethyl and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-01-11 | — | — | CN | disclosed |
| US-11221336-B2 | Encoded chromophoric polymer particles and methods of use thereof | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-01-11 | — | — | US | disclosed |
| WO-2022006331-A2 | PYRIDINE-1,5-DIONES EXHIBITNG MNK INHIBITION AND THEIR METHOD OF USE | 4E THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20220002264-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| WO-2022002838-A1 | SUBSTITUTED HETEROARYLOXYPYRIDINES, THE SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022003200-A1 | REDUCTION OF VIRAL INFECTIONS | pHOxgen Limited (IE) | 2022-01-06 | — | — | WO | disclosed |
| EP-3930718-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR IRE1 INHIBITION | Optikira LLC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3930722-A1 | TREATMENT WITH P2X3 MODULATORS | Bellus Health Cough Inc. (CA) | 2022-01-05 | — | — | EP | disclosed |
| EP-3930759-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2022-01-05 | — | — | EP | disclosed |
| EP-3930712-A1 | IMIDAZOLOPYRAZINE COMPOUNDS FOR IRE1 INHIBITION | Optikira LLC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3930708-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3931189-A1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-109575016-B | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11213031-B2 | Tetrazolylpropyl derivatives and their use as fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-04 | — | — | US | disclosed |
| US-11213523-B2 | Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-04 | — | — | US | disclosed |
| US-11214542-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214557-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2022-01-04 | — | — | US | disclosed |
| CN-113874381-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113874341-A | Process for preparing derivatives of 1, 1-dialkylethane-1, 2-diols as useful intermediates | 科学与工业研究委员会 | 2021-12-31 | — | — | CN | disclosed |
| CN-113874507-A | Nucleic acid vaccine for coronavirus | 苏州艾博生物科技有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113874344-A | Use of 8, 9-dihydrocannabidiol compounds | 加利福尼亚大学董事会 | 2021-12-31 | — | — | CN | disclosed |
| CN-107922364-B | Lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20210401814-A1 | MACROCYCLIC TYROSINE KINASE INHIBITOR AND USES THEREOF | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-20210402015-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210401835-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA B.V. (NL) | 2021-12-30 | — | — | US | disclosed |
| US-20210403802-A1 | METAL OXIDE, METAL BRONZE AND POLYOXOMETALATE AS CHARGE STORAGE MATERIALS IN ELECTROCHROMIC DEVICE | Furcifer Inc. (US) | 2021-12-30 | — | — | US | disclosed |
| WO-2021258147-A1 | HYDROGELS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021260443-A1 | COMBINATIONS OF 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262587-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262786-A1 | PANK MODULATORS AND METHODS USING SAME | YALE UNIVERSITY (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3929204-A1 | MODIFIED NUCLEOSIDE AND SYNTHETIC METHOD THEREFOR | Stemirna Therapeutics Co., Ltd. (CN) | 2021-12-29 | — | — | EP | disclosed |
| EP-3164509-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3927339-A1 | COMBINATION OF AR ANTAGONISTS AND TARGETED THORIUM CONJUGATES | Bayer Aktiengesellschaft (DE) | 2021-12-29 | — | — | EP | disclosed |
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-12-28 | — | — | US | disclosed |
| US-11208432-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208527-B2 | Photoactive macromolecules and uses thereof | BECKMAN COULTER, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-113853219-A | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| CN-113840600-A | N-substituted indoles and other heterocyclic compounds for treating brain diseases | 加利福尼亚大学董事会 | 2021-12-24 | — | — | CN | disclosed |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210395275-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE SEPARATION OF HYDROCARBON ISOMERS | UNITED STATES DEPARTMENT OF ENERGY | 2021-12-23 | — | — | US | disclosed |
| WO-2021255091-A1 | 1,3,4-OXADIAZOLES AND THEIR DERIVATIVES AS FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021255070-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021255089-A1 | 1,3,4-OXADIAZOLE PYRIMIDINES AND 1,3,4-OXADIAZOLE PYRIDINES AS FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021255169-A1 | 1,3,4-OXADIAZOLE PYRIMIDINES AS FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-23 | — | — | WO | disclosed |
| US-20210395188-A1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | Acuitas Therapeutics, Inc. (CA) | 2021-12-23 | — | — | US | disclosed |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-12-23 | — | — | US | disclosed |
| WO-2021255170-A1 | 1,3,4-OXADIAZOLE PYRIMIDINES AS FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021257669-A1 | SYNTHESIS OF SUBSTITUTED ARYLMETHYLUREAS, ANALOGUES, AND CRYSTALLINE FORMS THEREOF AND METHODS OF USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-12-23 | — | — | WO | disclosed |
| US-20210395295-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| EP-3074385-B1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-12-22 | — | — | EP | disclosed |
| CN-113825756-A | Substituted polycyclic carboxylic acids, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-113816969-A | Irinotecan compound, antibody drug conjugate thereof and application thereof | 联宁（苏州）生物制药有限公司 | 2021-12-21 | — | — | CN | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| CN-108026046-B | Substituted quinazoline compounds and their use as inhibitors of G12C mutant KRAS, HRAS and/or NRAS proteins | 亚瑞克西斯制药公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-113816990-A | Modified amino acids and their use in ADCs | 联宁（苏州）生物制药有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-113813399-A | Camptothecin compound, antibody drug conjugate thereof and application thereof | 联宁（苏州）生物制药有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-113801297-A | Photosensitive macromolecules and uses thereof | 拜克门寇尔特公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-113801296-A | Photosensitive macromolecules and uses thereof | 拜克门寇尔特公司 | 2021-12-17 | — | — | CN | disclosed |
| US-20210386751-A1 | TREATMENT WITH P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| US-20210389298-A1 | Alzheimer's Disease Assay in a Living Patient | PAIN THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210388138-A1 | DERIVATIZABLE MONOMERS AND POLYMERS, AND METHODS FOR MAKING AND USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2021-12-16 | — | — | US | disclosed |
| WO-2021252494-A1 | USE OF MULTI-KINASE INHIBITORS TO TREAT RNA VIRUS INFECTIONS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252709-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING SIGMA RECEPTOR RELATED DISEASES AND/OR DISORDERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021250461-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021249995-A1 | AZABICYCLYL-SUBSTITUTED HETEROCYCLES AS FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-16 | — | — | WO | disclosed |
| US-20210386734-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2021-12-16 | — | — | US | disclosed |
| WO-2021252488-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021250466-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-12-16 | — | — | WO | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3921080-A1 | CAPTURE OF FLUORINATED CARBON COMPOUNDS | The University of Queensland (AU) | 2021-12-15 | — | — | EP | disclosed |
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| CN-113795254-A | Pyrazolopyridine compounds for IRE1 inhibition | 奥普提卡拉公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-113784962-A | Azacyclo-indoles and other heterocycles useful in the treatment of cerebral disorders | 加利福尼亚大学董事会 | 2021-12-10 | — | — | CN | disclosed |
| CN-113784946-A | Fluorene derived monomers and polymers for volume bragg gratings | 脸谱科技有限责任公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-108276410-B | Anaplastic lymphoma kinase inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-20210379032-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2021-12-09 | — | — | US | disclosed |
| US-20210379052-A1 | QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-20210380579-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND /OR SMARCA4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| US-20210380574-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2021-12-09 | — | — | US | disclosed |
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | ARAXES PHARMA LLC (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210379084-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210379064-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | MIDCAP FINANCIAL TRUST | 2021-12-09 | — | — | US | disclosed |
| EP-3917915-A1 | 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Aktiengesellschaft (DE) | 2021-12-08 | — | — | EP | disclosed |
| EP-3469601-B1 | POLYMER-SILICA HYBRID PDOTS | UNIV WASHINGTON (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3918028-A1 | QUANTUM DOTS AND PROCESSES FOR PREPARATION THEREOF | The University of Queensland (AU) | 2021-12-08 | — | — | EP | disclosed |
| CN-113754683-A | Isotopically substituted spiroaromatic ring compounds and their use | 上海奕拓医药科技有限责任公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-112094269-B | Saturated six-membered ring heterocyclic compound, preparation method and application | 上海凌达生物医药有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-RE48842-E1 | Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| CN-110892001-B | Electrochromic polymers and their synthesis and use | 菲尔齐费尔公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-113748108-A | Thianthrene-derived monomers and polymers for volume bragg gratings | 脸谱科技有限责任公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-113748148-A | Latent image for volume Bragg grating | 脸谱科技有限责任公司 | 2021-12-03 | — | — | CN | disclosed |
| US-20210371855-A1 | METHODS OF INHIBITING PROLIFERATIVE CELLS | IDEAYA BIOSCIENCES, INC. | 2021-12-02 | — | — | US | disclosed |
| WO-2021242505-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021239673-A1 | SUBSTITUTED PYRROLINE-2-ONES AND THEIR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021239766-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-02 | — | — | WO | disclosed |
| US-20210369807-A1 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | REGENERON PHARMACEUTICALS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210369724-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-02 | — | — | US | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3519412-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3915971-A1 | PHENYL-S(O)N-PHENYLAMIDINES AND THE USE THEREOF AS FUNGICIDES | Bayer Aktiengesellschaft (DE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3914589-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2021-12-01 | — | — | EP | disclosed |
| EP-3915992-A1 | PDE9 INHIBITOR AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2021-12-01 | — | — | EP | disclosed |
| CN-113728029-A | Thermally reversible and reconfigurable cross-linked polymers for volume bragg gratings | 脸谱科技有限责任公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-105979959-B | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113727716-A | Treatment with P2X3 modulators | 贝卢斯医疗咳嗽病公司 | 2021-11-30 | — | — | CN | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186563-B2 | Pd(II)-catalyzed enantioselective β-methylene C(sp3)—H bond activation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-30 | — | — | US | disclosed |
| CN-113710661-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-113698414-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | disclosed |
| US-20210363168-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2021-11-25 | — | — | US | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| WO-2021233861-A1 | AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-11-25 | — | — | WO | disclosed |
| EP-3911653-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-11-24 | — | — | EP | disclosed |
| EP-3911632-A1 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | EMPIRICO INC. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3661925-B1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2021-11-24 | — | — | EP | disclosed |
| EP-3763712-B1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2021-11-24 | — | — | EP | disclosed |
| CN-113683622-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-107660199-B | Piperazine carbamates and methods of making and using the same | H.隆德贝克有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-113677665-A | Substituted 2-heteroarylaminobenzenes and their salts and their use as herbicides | 拜耳公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2021228734-A1 | TRIAZINE AND PYRIMIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021228939-A1 | FLUOROGENIC DIMER COMPOUND, USEFUL AS A PROBE FOR DETECTION OF ENDOGENOUS RECEPTORS | UNIVERSITE DE STRASBOURG (FR) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021231726-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021231892-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210353630-A1 | 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-11-18 | — | — | US | disclosed |
| US-20210353555-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-11-18 | — | — | US | disclosed |
| US-20210355073-A1 | COPPER NANOPARTICLE BASED CHEMOSELECTIVE REDUCTION | BROWN UNIVERSITY | 2021-11-18 | — | — | US | disclosed |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2021-11-18 | — | — | US | disclosed |
| EP-3908568-A1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | Acuitas Therapeutics, Inc. (CA) | 2021-11-17 | — | — | EP | disclosed |
| CN-107531759-B | Non-membrane disruptive p 53-activated stapled peptides | 新加坡科技研究局 | 2021-11-16 | — | — | CN | disclosed |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-11174275-B2 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | DREXEL UNIVERSITY (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174263-B2 | Inhibitors of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| CN-113651831-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113660931-A | Arylaniline and heteroarylaniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113645964-A | Arylaniline and heteroarylaniline compounds for use in fetal marker therapy | 恩福莱克逊治疗有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-113646002-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degradation compounds and methods of use | 上海睿跃生物科技有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-113636947-A | Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-108434197-B | Compositions and methods for weight management | 尤妮金公司 | 2021-11-12 | — | — | CN | disclosed |
| US-20210346391-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-11-11 | — | — | US | disclosed |
| US-20210346382-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2021-11-11 | — | — | US | disclosed |
| WO-2021226547-A2 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226404-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | KODIAK SCIENCES INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226247-A1 | SYSTEMS AND METHODS FOR TYROSINASE-MEDIATED SITE-SPECIFIC PROTEIN CONJUGATION | GENENTECH, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021224220-A1 | PYRIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-11-11 | — | — | WO | disclosed |
| US-20210347806-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2021-11-11 | — | — | US | disclosed |
| US-20210347804-A1 | COMPOUNDS, COMPOSITIONS AND METHOD FOR COLORING EDIBLE MATERIALS | THE PENN STATE RESEARCH FOUNDATION | 2021-11-11 | — | — | US | disclosed |
| US-20210347737-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-11-11 | — | — | US | disclosed |
| US-20210347950-A1 | POLYMER COMPOSITION | BASF SE (DE) | 2021-11-11 | — | — | US | disclosed |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-11-11 | — | — | US | disclosed |
| EP-3906026-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | Biomea Fusion, LLC (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3137169-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3906029-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Biomea Fusion, LLC (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113620958-A | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-108699057-B | 5-substituted 2- (morpholin-4-yl) -1, 7-naphthyridines | 拜耳医药股份公司 | 2021-11-09 | — | — | CN | disclosed |
| US-11168115-B2 | Cyclic peptides as protein targeting agents | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-11-09 | — | — | US | disclosed |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| CN-113616656-A | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-110809560-B | Electrochromic polymer films with reduced self-bleaching behavior and enhanced cycling stability | 菲尔齐费尔公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113631569-A | Process for the synthesis of beta-homoamino acids | 领导医疗有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-110857300-B | Condensed ring triazole compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-108558889-B | Bromodomain inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-108290992-B | Polyurethane/urea materials | 联邦科学和工业研究组织 | 2021-11-05 | — | — | CN | disclosed |
| CN-113603703-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021220132-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
| US-20210344047-A1 | Silicon-Based Energy Storage Devices With Fluorinated Polymer Containing Electrolyte Additives | ENEVATE CORPORATION | 2021-11-04 | — | — | US | disclosed |
| US-20210340534-A1 | Mixed Tricyclo-DNA, 2'-Modified RNA Oligonucleotide Compositions and Uses Thereof | SYNTHENA AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20210340547-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2021-11-04 | — | — | US | disclosed |
| US-20210339186-A1 | MOF COMPOSITIONS FOR SELECTIVE SEPARATION OF HYDROCARBONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2021-11-04 | — | — | US | disclosed |
| US-20210340313-A1 | MULTICOLORED ELECTROCHROMIC POLYMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Furcifer Inc. (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2021-11-04 | — | — | US | disclosed |
| US-20210343445-A1 | POLYMER-SILICA HYBRID PDOTS AND METHODS OF USE THEREOF | UNIVERSITY OF WASHINGTON (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3487850-B1 | UREA AND THIOUREA SUBSTITUTED BICYCLES DERIVATIVES AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| US-11161834-B2 | Methods of manufacturing of niraparib | TESARO, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11165099-B2 | Silicon-based energy storage devices with cyclic organosilicon containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| US-11161849-B2 | Inhibiting the transient receptor potential al ion channel | ELI LILLY AND COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| CN-109912599-B | Chemical entities, compositions, and methods | 英特利凯恩有限责任公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-113563323-A | Benzothiazolyl biaryl compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20210332027-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-20210332020-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-10-28 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
| WO-2021217006-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214492-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BERGENBIO ASA (NO) | 2021-10-28 | — | — | WO | disclosed |
| EP-2448569-B1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA INC (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898620-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898978-A2 | NANOCAPSULES FOR THE DELIVERY OF CELL MODULATING AGENTS | CSL Behring LLC (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3010550-B1 | CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS | CALIFORNIA INST OF TECHN (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898612-A1 | SUBSTITUTED PYRIDINYLOXYBENZENES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897154-A1 | 1,3,4-OXADIAZOLES AND THEIR DERIVATIVES AS NEW ANTIFUNGAL AGENTS | Bayer Aktiengesellschaft (DE) | 2021-10-27 | — | — | EP | disclosed |
| CN-108713023-B | Glucocorticoid receptor inhibitors | 欧瑞克制药公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-107624115-B | Botulinum neurotoxin specific capture agents, compositions, methods of use, and methods of manufacture | 加州理工学院 | 2021-10-26 | — | — | CN | disclosed |
| US-11154554-B2 | Therapeutic combinations of a MEK inhibitor and a BTK inhibitor | Acera Pharma B.V. (NL) | 2021-10-26 | — | — | US | disclosed |
| US-11155610-B2 | Dual PDGF/VEGF antagonists | KODIAK SCIENCES INC. (US) | 2021-10-26 | — | — | US | disclosed |
| CN-109715632-B | Macrocyclic indole derivatives | 拜尔公开股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-111295389-B | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113544270-A | Nanocapsules for delivery of cell modulators | 美国杰特贝林生物制品有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-105102000-B | Cancer therapy using PI3 kinase subtype modulators | 无限药品公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-109293652-B | Substituted thiazole derivative and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113527299-A | Nitrogen-containing condensed ring compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021209490-A1 | CYCLAMINEPHENYLAMINOQUINOLINES AS FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021209486-A1 | SPECIFICALLY SUBSTITUTED PYRROLINE-2-ONES AND THEIR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-21 | — | — | WO | disclosed |
| US-20210324006-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210322331-A1 | NANOCAPSULES FOR THE DELIVERY OF CELL MODULATING AGENTS | CSL BEHRING LLC (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210322432-A1 | SELECTIVE P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-10-21 | — | — | US | disclosed |
| US-20210322408-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | ACERTA PHARMA BV (NL) | 2021-10-21 | — | — | US | disclosed |
| US-20210324063-A1 | ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3268362-B1 | SUBSTITUTED PYRIDINES AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3356359-B1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3087091-B1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC (CA) | 2021-10-20 | — | — | EP | disclosed |
| EP-2367800-B9 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | IPHARMA H K LTD (HK) | 2021-10-20 | — | — | EP | disclosed |
| EP-3893892-A1 | ORGANIC COMPOUNDS | Rutgers, the State University of New Jersey (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3893645-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-10-20 | — | — | EP | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-11148125-B2 | Catalysts for olefin isomerization | BRANDEIS UNIVERSITY (US) | 2021-10-19 | — | — | US | disclosed |
| US-11147885-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-10-19 | — | — | US | disclosed |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | ARDELYX, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| CN-108699035-B | Novel compounds | 特殊治疗有限公司 | 2021-10-15 | — | — | CN | disclosed |
| CN-107709293-B | Ligand activated meta C-H activation using transient mediators | 斯克里普斯研究学院 | 2021-10-15 | — | — | CN | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| US-20210317097-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2021-10-14 | — | — | US | disclosed |
| EP-3890745-A1 | SYNTHETIC DERIVATIVES OF CHOLIC ACID 7-SULFATE AND USES THEREOF | President and Fellows of Harvard College (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3890733-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | University of Maryland, Baltimore (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3890742-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | University of Maryland, Baltimore (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-113498340-A | Thienylaniline compounds for the treatment of skin diseases | 恩福莱克逊治疗有限公司 | 2021-10-12 | — | — | CN | disclosed |
| US-11142682-B2 | Metal oxide, metal bronze and polyoxometalate as charge storage materials in electrochromic device | Furcifer Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142526-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-10-12 | — | — | US | disclosed |
| CN-108137639-B | Nicotinamide mononucleotide derivative and application thereof | 麦德龙国际生物科技有限责任公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-113490663-A | Pyridazine (thio) amides as fungicidal compounds | 拜耳公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-113476499-A | Compositions and methods for weight management | 尤妮金公司 | 2021-10-08 | — | — | CN | disclosed |
| WO-2021202540-A1 | HSP70 INHIBITORS AND METHODS OF USING SAME | THE WISTAR INSTITUTE (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021195716-A1 | ANTIBIOTIC CONJUGATES | MONASH UNIVERSITY (AU) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202553-A1 | CXCR5 ANTAGONISTS AND METHODS OF TREATING DISEASES OR DISORDERS USING SAME | YALE UNIVERSITY (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021203131-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3886844-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887362-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3303317-B1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | KURA ONCOLOGY INC (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3179991-B1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR AND A BCL-2 INHIBITOR | ACERTA PHARMA BV (NL) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889237-A1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | Beckman Coulter, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887373-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11136678-B2 | Electrochemical oxidation of aliphatic and aromatic compounds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136308-B2 | Substituted quinazoline and quinazolinone compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2021-10-05 | — | — | US | disclosed |
| CN-108349936-B | Compounds as muscarinic receptor 4 antagonists | 纽罗克里生物科学有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-107964016-B | Thiophene derivatives | 天津合美医药科技有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-108530424-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-113474328-A | Lipids for lipid nanoparticle delivery of active agents | 爱康泰生治疗公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-108059635-B | Thiophene derivatives | 天津合美医药科技有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-113473986-A | Nalidinone aniline compounds for the treatment of skin disorders | 恩福莱克逊治疗有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-113473860-A | 1, 3, 4-oxadiazoles and derivatives thereof as novel antifungal agents | 拜耳公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-113473978-A | Cyanoarene-aniline compounds for the treatment of skin diseases | 恩福莱克逊治疗有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-112300173-B | Nitrogen-containing polycyclic compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210300904-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-09-30 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| WO-2021191197-A1 | COMBINATION THERAPY COMPRISING AN AXL INHIBITOR | BERGENBIO ASA (NO) | 2021-09-30 | — | — | WO | disclosed |
| EP-3884935-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3883646-A1 | NLRP3 INHIBITORS | Inflazome Limited (IE) | 2021-09-29 | — | — | EP | disclosed |
| CN-113454079-A | Heterocyclylpyridazines as fungicidal compounds | 拜耳公司 | 2021-09-28 | — | — | CN | disclosed |
| US-11130748-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| US-11129827-B2 | Dual MAGL and FAAH inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-28 | — | — | US | disclosed |
| US-11130827-B2 | Polyethylene compositions and articles made therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11130740-B2 | Substituted 2,3-dihydro-1H-indene analogs and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-09-28 | — | — | US | disclosed |
| US-11130782-B2 | Nicotinic acetylcholine receptor peptide antagonist conotoxin compositions and related methods | GLO PHARMA, INC. | 2021-09-28 | — | — | US | disclosed |
| US-20210291156-A1 | CATALYST COMPOSITIONS FOR HYDROFORMYLATION AND METHODS OF USE THEREOF | NATIONAL SCIENCE FOUNDATION | 2021-09-23 | — | — | US | disclosed |
| US-20210292718-A1 | DIVERSE CARBENE TRANSFERASE ENZYME CATALYSTS DERIVED FROM A P450 ENZYME | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292326-A1 | Small-Molecule PI5P4K alpha/beta Inhibitors and Methods of Treatment Using Same | UNIV YALE (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292482-A1 | NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME | THE REGENTS OF THE UNIV OF COLORADO A BODY CORPORTATE (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | ERASCA, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-3395818-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2021-09-22 | — | — | EP | disclosed |
| US-11124537-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124601-B2 | Electrochromic polymer and synthesis and uses thereof | Furcifer Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-09-21 | — | — | US | disclosed |
| US-11123393-B2 | Compositions and methods for joint health | UNIGEN, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123352-B2 | Testosterone ester triglyceride formulations | ANTARES PHARMA, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| CN-112142735-B | Condensed cyanopyridine compound, preparation method and application | 上海凌达生物医药有限公司 | 2021-09-17 | — | — | CN | disclosed |
| WO-2021183970-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20210284972-A1 | HOST CELLS AND METHODS USEFUL FOR PRODUCING UNNATURAL TERPENOIDS USING A NOVEL ARTIFICIAL METALLOENZYME | UNITED STATES DEPARTMENT OF ENERGY | 2021-09-16 | — | — | US | disclosed |
| US-20210283170-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS | SAREPTA THERAPEUTICS INC (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210284651-A1 | Spiropiperidine Derivatives | CEPHALON LLC | 2021-09-16 | — | — | US | disclosed |
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| EP-3877811-A1 | CURABLE FORMULATION WITH HIGH REFRACTIVE INDEX AND ITS APPLICATION IN SURFACE RELIEF GRATING USING NANOIMPRINTING LITHOGRAPHY | Facebook Technologies, LLC. (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3877430-A1 | POLYETHYLENE COMPOSITIONS AND ARTICLES MADE THEREFROM | ExxonMobil Chemical Patents Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3878853-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | Shanghai Ringene BioPharma Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| EP-3877356-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3878850-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-09-15 | — | — | EP | disclosed |
| EP-3878854-A1 | MACROCYCLIC TYROSINE KINASE INHIBITOR AND USES THEREOF | Shandong Xuanzhu Pharma Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-113395965-A | USP19 inhibitors for treatment | 阿尔麦克探索有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-113395963-A | non-ATP/catalytic site p38 mitogen-activated protein kinase inhibitors | 马里兰大学巴尔的摩分校 | 2021-09-14 | — | — | CN | disclosed |
| US-11118179-B2 | Mixed tricyclo-DNA, 2′-modified RNA oligonucleotide compositions and uses thereof | SYNTHENA AG (CH) | 2021-09-14 | — | — | US | disclosed |
| US-11116778-B2 | Prodrugs of ALOX-15 inhibitors and methods of using the same | EMPIRICO INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11118204-B2 | Switchable ionic liquids for biomass pretreatment and enzymatic hydrolysis | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117878-B2 | Benzothiazole and related compounds | SPINOGENIX, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11118197-B2 | High gravity, fed-batch ionic liquid based process for deconstructing biomass | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2021176045-A1 | IMIDAZOTRIAZINES ACTING ON CANCER VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021176049-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178684-A1 | CAR AND NRF2 DUAL ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED AND DOXORUBICIN-BASED TREATMENTS OF CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-09-10 | — | — | WO | disclosed |
| CN-113383272-A | Curable formulations with high refractive index and their use in surface relief gratings using nanoimprint lithography | 脸谱科技有限责任公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-111592541-B | Macrocyclic kinase inhibitors and uses thereof | 山东轩竹医药科技有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-113382736-A | Compounds, compositions and methods for treating androgen mediated diseases | 加利福尼亚大学董事会 | 2021-09-10 | — | — | CN | disclosed |
| CN-110229151-B | Indolizine compound, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-108619141-B | Antibacterial composition and application thereof | 山东轩竹医药科技有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-20210277022-A1 | MACROCYCLIC CHLORINE SUBSTITUTED INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210276974-A1 | SUBSTITUTED 2-HETEROARYLOXYPYRIDINES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-09-09 | — | — | US | disclosed |
| EP-3874556-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH PHOSPHAZENE CONTAINING ELECTROLYTE ADDITIVES | Enevate Corporation (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3873479-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF ANDROGEN-MEDIATED DISEASE | The Regents of the University of California (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113365696-A | Pharmaceutical compounds and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-113354811-A | Oxazoline polymer with side chain containing amino and/or hydroxyl, preparation method and application thereof | 华东理工大学 | 2021-09-07 | — | — | CN | disclosed |
| US-11110103-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-11114660-B1 | Silicon anodes with water-soluble maleic anhydride-, and/or maleic acid-containing polymers/copolymers, derivatives, and/or combinations (with or without additives) as binders | ENEVATE CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111352-B2 | Methods of producing organosilica materials and uses thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111325-B2 | Polymerization processes | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-09-07 | — | — | US | disclosed |
| CN-108601769-B | Pyrazole compounds and methods of making and using the same | H.隆德贝克有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-113348165-A | 1,2, 4-triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases | 拜耳股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-113347971-A | Methods of treating diseases with MAGL inhibitors | H.隆德贝克有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-113348181-A | DC-SIGN antibody conjugates comprising a STING agonist | 诺华股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-108368028-B | Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-113330005-A | Methods of treating diseases with MAGL inhibitors | H.隆德贝克有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-113318113-A | Use of fibroblast growth factor receptor inhibitors | 南京药捷安康生物科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-113302187-A | Substituted pyridyloxybenzenes and their salts and their use as herbicides | 拜耳公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-110372550-B | Aryl ethers and their use | 佩洛通治疗公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-113302175-A | Bicyclic compounds | 维瓦斯治疗公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-107281490-B | Compositions and methods for weight management | 尤妮金公司 | 2021-08-20 | — | — | CN | disclosed |
| US-20210253598-A1 | ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | disclosed |
| US-20210253628-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF ANDROGEN-MEDIATED DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2021161105-A1 | P2X3 MODULATORS | BELLUS HEALTH COUGH INC. (CA) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021160873-A1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH ZURICH (CH) | 2021-08-19 | — | — | WO | disclosed |
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-19 | — | — | US | disclosed |
| US-20210253595-A1 | 2-Aminopyrimidine Derivative and Preparation Method and Use Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | PELOTON THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3863640-A1 | TREATMENT OF PRURITUS WITH P2X3 ANTAGONISTS | Bellus Health Cough Inc. (CA) | 2021-08-18 | — | — | EP | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| CN-113262175-A | Skin care compositions and methods of use thereof | 尤尼根公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-110950876-B | Furanolactam compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-11090302-B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | ACERTA PHARMA B.V. (NL) | 2021-08-17 | — | — | US | disclosed |
| US-11090309-B2 | Anti-thrombotic agents and methods of use thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| US-11091473-B2 | Compounds for pain treatment, compositions comprising same, and methods of using same | ACADIA PHARMACEUTICALS INC. (US) | 2021-08-17 | — | — | US | disclosed |
| CN-110964012-B | Fused heterocyclic biaryl benzyl alcohol compound, preparation method and application | 上海凌达生物医药有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-20210249689-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING CYANATE BASED COMPOUNDS | ENEVATE CORPORATION | 2021-08-12 | — | — | US | disclosed |
| US-20210244755-A1 | METHODS FOR TREATING CANCERS BY PRODRUGS OF CLOFARABINE | BoYen Therapeutics, Inc. (TW) | 2021-08-12 | — | — | US | disclosed |
| US-20210246155-A1 | Metallocene Synthesis Process | EXXONMOBIL CHEMICAL PATENTS INC. | 2021-08-12 | — | — | US | disclosed |
| US-20210246266-A1 | HIGH DYNAMIC RANGE TWO-STAGE PHOTOPOLYMERS | NATIONAL SCIENCE FOUNDATION | 2021-08-12 | — | — | US | disclosed |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
| US-20210246614-A1 | WATER RESISTANT MATERIALS FOR FOOD-SAFE USES | JL DARLING LLC (US) | 2021-08-12 | — | — | US | disclosed |
| WO-2021158366-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING CYANATE BASED COMPOUNDS | ENEVATE CORPORATION (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158481-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-11084825-B2 | Substituted pyridines as irreversible inhibitors of menin-MLL interaction | BIOMEA FUSION, LLC (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084793-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084932-B2 | Phenylethynylnaphthalene dyes and methods for their use | Sony Group Corporation (JP) | 2021-08-10 | — | — | US | disclosed |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-11087900-B2 | Polymer-silica hybrid Pdots and methods of use thereof | UNIVERSITY OF WASHINGTON (US) | 2021-08-10 | — | — | US | disclosed |
| CN-113226321-A | Pyrazolyl compounds and methods of use thereof | 阿利安制药有限责任公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113227092-A | Compounds and methods of use thereof for treating cancer | 亚瑞克西斯制药公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238196-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2021-08-05 | — | — | US | disclosed |
| US-20210238221-A1 | TRIPTOLIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | CINKATE PHARMACEUTICAL INTERMEDIATES CO., LTD. (CN) | 2021-08-05 | — | — | US | disclosed |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| WO-2021151976-A1 | [(1,4,5-TRISUBSTITUTED-1H-PYRAZOL-3-YL)SULFANYL]ACETIC ACID DERIVATIVES, SALTS THEREOF, AND USE THEREOF AS HERBICIDAL INGREDIENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021152390-A1 | COMPOSITIONS FOR THE TREATMENT OF ANGIOLIPOMA | RAZIEL THERAPEUTICS LTD. (IL) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155253-A1 | ANAT INHIBITORS AND METHODS OF USE THEREOF | Atomwise Inc. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021152481-A1 | HYBRID POLYETHER ETHER KETONE POLYMERS | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021154966-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155062-A1 | WATER RESISTANT MATERIALS FOR FOOD-SAFE USES | JL DARLING LLC (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-2972258-B1 | PURIFICATION OF RAPAMYCIN DERIVATIVES | BIOSENSORS INT GROUP LTD (BM) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858813-A1 | QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| CN-113207291-A | 2- (2-acryloyl-2, 6-diazaspiro [3.4] oct-6-yl) -6- (1H-indazol-4-yl) benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis | 亚瑞克西斯制药公司 | 2021-08-03 | — | — | CN | disclosed |
| US-11077107-B2 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2021-08-03 | — | — | US | disclosed |
| US-11078171-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078162-B2 | Processes for preparing AG-10, its intermediates, and salts thereof | Eidos Therapeutics, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-113194977-A | Nicotinamide acetylcholine receptor peptide antagonist conotoxin compositions and related methods | 格罗制药公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113185740-A | Method for improving antibacterial activity and biocompatibility of substrate surface | 华东理工大学 | 2021-07-30 | — | — | CN | disclosed |
| CN-108778270-B | Antibacterial composition and application thereof | 吉林四环制药有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113195492-A | Novel compound with three-fused ring structure, preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | disclosed |
| US-20210228563-A1 | METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-29 | — | — | US | disclosed |
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| US-20210228565-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210230165-A1 | MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| EP-3853590-A1 | NARROW ABSORPTION POLYMER NANOPARTICLES AND RELATED METHODS | University of Washington (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3852911-A2 | SYSTEMS AND METHODS FOR MANUFACTURING LIPID NANOPARTICLES AND LIPOSOMES | Acuitas Therapeutics, Inc. (CA) | 2021-07-28 | — | — | EP | disclosed |
| EP-3052485-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3852766-A1 | COMBINATION THERAPY FOR TREATING BLOOD CANCER | SignalChem Lifesciences Corporation (CA) | 2021-07-28 | — | — | EP | disclosed |
| EP-3853210-A1 | ANTIBACTERIAL COMPOUNDS | Forge Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11075408-B2 | Silicon-based energy storage devices with fluorinated polymer containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| US-11072793-B2 | DsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071771-B2 | Butyrylcholinesterase zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| CN-113166155-A | Macrocyclic tyrosine kinase inhibitors and uses thereof | 山东轩竹医药科技有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113164490-A | Treatment of pruritis with P2X3 antagonists | 贝卢斯医疗咳嗽病公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166077-A | Antibacterial compounds | 福至治疗公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113149941-A | Ether compound and pharmaceutical application thereof in preventing and treating diabetes and metabolic syndrome | 中国科学院上海药物研究所 | 2021-07-23 | — | — | CN | disclosed |
| CN-113164381-A | Pharmaceutical compositions and methods relating to otic therapeutic agents | 频率医疗公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113164763-A | NLRP3 inhibitor | 英夫拉索姆有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021144162-A1 | PROCESS FOR PREPARING CYCLIC CARBONATES WITH AN EXOCYCLIC VINYLIDENE GROUP | BASF SE (DE) | 2021-07-22 | — | — | WO | disclosed |
| US-20210221835-A1 | CARBON-MONOXIDE-RELEASING MOLECULES AND THERAPEUTIC APPLICATIONS THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20210221781-A1 | FATTY ACID ANALOGUES AND METHODS OF USE | LIN BIOSCIENCE INC. (TW) | 2021-07-22 | — | — | US | disclosed |
| US-20210226251-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING CROWN ETHER BASED COMPOUNDS | ENEVATE CORPORATION | 2021-07-22 | — | — | US | disclosed |
| US-20210221796-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210222257-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-22 | — | — | US | disclosed |
| US-20210221790-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-22 | — | — | US | disclosed |
| US-20210221813-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (AE) | 2021-07-22 | — | — | US | disclosed |
| EP-3851444-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | Oric Pharmaceuticals, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3851469-A1 | POLYURETHANE/UREA MATERIALS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2021-07-21 | — | — | EP | disclosed |
| EP-3849990-A2 | MOF COMPOSITIONS FOR SELECTIVE SEPARATION OF HYDROCARBONS | Rutgers, The State University of New Jersey (US) | 2021-07-21 | — | — | EP | disclosed |
| US-11066513-B2 | Multicolored electrochromic polymer compositions and methods of making and using the same | Furcifer Inc. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066465-B2 | Antibodies and conjugates thereof | KODIAK SCIENCES INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| US-20210218059-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-07-15 | — | — | US | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| EP-3846806-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-11059819-B2 | Fused hetero-hetero bicyclic compounds and methods of use thereof | JANSSEN BIOTECH, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059805-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-07-13 | — | — | US | disclosed |
| US-11059822-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| WO-2021138215-A1 | TREATMENT OF CANCER WITH CDK12/13 INHIBITORS | KINNATE BIOPHARMA INC. (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20210206735-A1 | MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210205762-A1 | CURABLE POLY(RTIL)-BASED MIXED-MATRIX MEMBRANES AND METHODS USING SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210205291-A1 | NITROGENOUS HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| EP-3844158-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | Xenon Pharmaceuticals Inc. (CA) | 2021-07-07 | — | — | EP | disclosed |
| EP-3844150-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2021-07-07 | — | — | EP | disclosed |
| CN-106794362-B | Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using the same | 乔治亚州立大学研究基金会股份有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-11053237-B2 | Process for the manufacture of 6-alkynyl-pyridine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-07-06 | — | — | US | disclosed |
| US-11053213-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053221-B2 | Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity | ARRIEN PHARMACEUTICALS LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053342-B2 | Polyurethane/urea materials | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2021-07-06 | — | — | US | disclosed |
| CN-108368089-B | Deubiquitinase inhibitor | 特殊治疗有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| CN-113061132-A | Condensed ring lactam compound, preparation method and application | 上海凌达生物医药有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20210198708-A1 | CONVERSION OF SUGARS TO IONIC LIQUIDS | UNITED STATES DEPARTMENT OF ENERGY | 2021-07-01 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2021-07-01 | — | — | US | disclosed |
| EP-3842427-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-11046711-B2 | Purification of rapamycin derivatives using temperature induced phase separation | BIOSENSORS INTERNATIONAL GROUP, LTD. (BM) | 2021-06-29 | — | — | US | disclosed |
| US-11046707-B2 | Spiropiperidine derivatives | 89BIO LTD (IL) | 2021-06-29 | — | — | US | disclosed |
| US-11046679-B2 | Indoleamine 2,3-dioxygenase inhibitor and application | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| US-20210186953-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210186943-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021127404-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127356-A1 | Substituted Bicyclic and Tricyclic Ureas and Amides, Analogues Thereof, and Methods Using Same | ARBUTUS BIOPHARMA, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021122728-A1 | 1,5-DIPHENYLPYRAZOLYL-3-OXYALKYL ACIDS AND 1-PHENYL-5-THIENYLPYRAZOLYL-3-OXYALKYL ACIDS AND THE USE THEREOF FOR CONTROL OF UNDESIRED PLANT GROWTH | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126341-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | Blaze Bioscience, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021123074-A1 | METHODS OF SEQUENCING BY SYNTHESIS USING A CONSECUTIVE LABELING SCHEME | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| US-20210194056-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING SULFONATE OR CARBOXYLATE SALT BASED COMPOUNDS | ENEVATE CORPORATION | 2021-06-24 | — | — | US | disclosed |
| EP-3837242-A1 | NOVEL SULFONEUREA COMPOUNDS | Inflazome Limited (IE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3256484-B1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | AGENCY SCIENCE TECH & RES (SG) | 2021-06-23 | — | — | EP | disclosed |
| EP-3836917-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | Inflazome Limited (IE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3837243-A1 | NOVEL SULFONEUREA COMPOUNDS | Inflazome Limited (IE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3837301-A1 | POLYMER COMPOSITION | BASF SE (DE) | 2021-06-23 | — | — | EP | disclosed |
| US-11040038-B2 | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040970-B2 | VMAT2 inhibitor compounds and compositions thereof | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| US-11040112-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2021-06-22 | — | — | US | disclosed |
| CN-113004788-A | Surface finishing composition | 3M中国有限公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-112996518-A | WD40 repeat domain protein 5(WDR5) degradation/disruption compounds and methods of use | 西奈山伊坎医学院 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021119554-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021113922-A1 | IMPROVED METHOD FOR PREPARING N-(BENZENESULFONYL)-L-PROLYL- L-O-(1-PYRROLIDINYLCARBONYL)TYROSINE | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2021-06-17 | — | — | WO | disclosed |
| US-20210179524-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179616-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2021-06-17 | — | — | US | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20210179557-A1 | SUBSTITUTED TETRAHYDROCYCLOPENTA[C]PYRROLES, SUBSTITUTED DIHYDROPYRROLIZINES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-06-17 | — | — | US | disclosed |
| US-20210184258-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING DIHYDROFURANONE BASED COMPOUND | ENEVATE CORPORATION | 2021-06-17 | — | — | US | disclosed |
| EP-3833353-A1 | SMALL-MOLECULE PI5P4K ALPHA/BETA INHIBITORS AND METHODS OF TREATMENT USING SAME | Yale University (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3833348-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3430012-B1 | 4,6-DIHYDROPYRROLO[3,4-C]PYRAZOLE-5(1H)-CARBONITRILE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| CN-107973741-B | Synthesis method of 1H-pyrrole-2, 5-diketone derivative | 重庆文理学院 | 2021-06-15 | — | — | CN | disclosed |
| CN-112969472-A | Methods and compositions for ocular cell therapy | 诺华股份有限公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-112970141-A | Silicon-based energy storage device with electrolyte additive containing phosphazene | 新强能电池公司 | 2021-06-15 | — | — | CN | disclosed |
| US-11034719-B2 | 7-dehydrocholesterol derivatives and methods using same | UNIVERSITY OF ROCHESTER (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034686-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2021-06-15 | — | — | US | disclosed |
| US-11034667-B2 | Selective histone deacetylase inhibitors for the treatment of human disease | SHUTTLE PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034685-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2021-06-15 | — | — | US | disclosed |
| CN-112939982-A | Alkyne heterocyclic BTK inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210172957-A1 | METHODS AND SYSTEMS FOR ANALYSIS USING POLYMER DOTS | UNIVERSITY OF WASHINGTON (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171435-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ACUCELA INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021113686-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113690-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113698-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| EP-3351248-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3829580-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3829570-A1 | SUBSTITUTED TETRAHYDROCYCLOPENTA[C]PYRROLES, SUBSTITUTED DIHYDROPYRROLIZINES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-06-09 | — | — | EP | disclosed |
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-11028066-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| CN-111171049-B | Tyrosine kinase inhibitors and uses thereof | 山东轩竹医药科技有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2021108023-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108282-A1 | AROMATIC SUBSTITUTED METHANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108204-A1 | AROMATIC SUBSTITUTED ETHANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108232-A1 | ANTHRAQUINONE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108191-A1 | AROMATIC SUBSTITUTED ALKANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105115-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105101-A1 | [(1,5-DIPHENYL-1H-1,2,4-TRIAZOL-3-YL)OXY]ACETIC ACID DERIVATIVES AND SALTS THEREOF, CROP PROTECTION COMPOSITIONS COMPRISING THEM, METHODS FOR PRODUCING THEM AND USE THEREOF AS SAFENERS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105117-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105116-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108597-A1 | THIOPHOSPHATE AND PHOSPHINE SULFIDE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210161889-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210167361-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-06-03 | — | — | US | disclosed |
| US-20210161837-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163412-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-06-03 | — | — | US | disclosed |
| US-20210162406-A1 | MODIFICATION OF SURFACE PROPERTIES OF MICROFLUIDIC DEVICES | BIO RAD LABORATORIES (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210167423-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING A BENZOYL PEROXIDE BASED COMPOUND | ENEVATE CORPORATION | 2021-06-03 | — | — | US | disclosed |
| EP-3826684-A1 | METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| CN-112888675-A | Novel sulfonylurea compound | 英夫拉索姆有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-111690031-B | Glucocorticoid receptor inhibitors | 欧瑞克制药公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112888681-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112868659-A | Composition applicable to user equipment and application thereof | 3M中国有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-11020417-B2 | Methods and compounds for treatment of lymphocyte-related diseases and conditions | SAREPTA THERAPEUTICS, INC (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021470-B2 | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof | ARAXES PHARMA LLC (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021510-B2 | Prodrugs of clofarabine | BoYen Therapeutics, Inc. (TW) | 2021-06-01 | — | — | US | disclosed |
| US-11021471-B2 | Antibacterial compounds | FORGE THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11020380-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11020731-B2 | Catalysts for selective coupling of olefins, and methods of making and using same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-06-01 | — | — | US | disclosed |
| CN-112851587-A | Alkyne heterocyclic compound for treating cancer and preparation method and application thereof | 药雅科技(上海)有限公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2021099842-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC. (CA) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021102204-A1 | HETEROARYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021101903-A1 | DUAL ANDROGEN RECEPTOR/AKR1C3 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021102468-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210155615-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2021-05-27 | — | — | US | disclosed |
| US-20210155639-A1 | THIOPHOSPHATE AND PHOSPHINE SULFIDE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2021-05-27 | — | — | US | disclosed |
| US-20210155581-A1 | AROMATIC SUBSTITUTED ETHANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2021-05-27 | — | — | US | disclosed |
| US-20210155599-A1 | AROMATIC SUBSTITUTED ALKANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2021-05-27 | — | — | US | disclosed |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210155964-A1 | AMMONIUM BASED IONIC LIQUIDS USEFUL FOR LIGNOCELLULOSIC PROCESSING | UNITED STATES DEPARTMENT OF ENERGY | 2021-05-27 | — | — | US | disclosed |
| US-20210155590-A1 | ISOINDOLE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20210155584-A1 | AROMATIC SUBSTITUTED METHANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2021-05-27 | — | — | US | disclosed |
| US-20210155601-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-27 | — | — | US | disclosed |
| US-20210155585-A1 | ANTHRAQUINONE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2021-05-27 | — | — | US | disclosed |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| EP-3823465-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR COLORING EDIBLE MATERIALS | Ziegler, Gregory Ray (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-108290861-B | 1-cyano-pyrrolidine derivatives as USP30 inhibitors | 特殊治疗有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-11014960-B2 | Amino acid and peptide conjugates and uses thereof | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-05-25 | — | — | US | disclosed |
| US-11015002-B2 | Polymerization processes | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-25 | — | — | US | disclosed |
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-11013741-B1 | AXL kinase inhibitors and use of the same | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210147371-A1 | OXADIAZOLINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210147349-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-20 | — | — | US | disclosed |
| WO-2021097075-A1 | SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3519397-B1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3380536-B1 | A POLYMERIC COMPOSITION | AGENCY SCIENCE TECH & RES (SG) | 2021-05-19 | — | — | EP | disclosed |
| US-11008596-B2 | Cytochrome P450 BM3 enzyme variants for preparation of cyclopropanes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007245-B2 | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making | INDI MOLECULAR, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007274-B2 | Compounds for medicinal applications | AusVir Therapeutics Pty Ltd (AU) | 2021-05-18 | — | — | US | disclosed |
| US-11007186-B2 | Methods of treating RBP4 related diseases with triazolopyridines | BELITE BIO, INC (KY) | 2021-05-18 | — | — | US | disclosed |
| US-11008297-B2 | Bio-based, multi-aromatic compounds, and methods of making and using same | ROWAN UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| CN-106967257-B | Method of forming polythiophene polysulfonate complexes | 新加坡科技研究局 | 2021-05-18 | — | — | CN | disclosed |
| CN-112805292-A | Modified nucleoside and synthetic method thereof | 斯微(上海) 生物科技有限公司 | 2021-05-14 | — | — | CN | disclosed |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210139460-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-13 | — | — | US | disclosed |
| EP-3271352-B1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2021-05-12 | — | — | EP | disclosed |
| EP-3817745-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112789040-A | Transglutaminase 2(TG2) inhibitors | 思达利医药公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-107693797-B | Peptide oligonucleotide conjugates | 萨勒普塔医疗公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-112778336-A | Nitrogen-containing fused ring STING regulator compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-112789264-A | Novel sulfonylurea compound | 英夫拉索姆有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-11001601-B2 | Compounds, compositions and methods for coloring edible materials | THE PENN STATE RESEARCH FOUNDATION (US) | 2021-05-11 | — | — | US | disclosed |
| US-11001568-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| CN-110878052-B | FXR agonist-containing compound and preparation method and application thereof | 山东大学 | 2021-05-07 | — | — | CN | disclosed |
| WO-2021087408-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTONOMY, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130354-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210135288-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH WITH METAL SULFIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-05-06 | — | — | US | disclosed |
| US-20210128488-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2021-05-06 | — | — | US | disclosed |
| US-20210130366-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| WO-2021083383-A1 | NITROGEN-CONTAINING FUSED CYCLIC COMPOUND AS STING REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海凌达生物医药有限公司 | 2021-05-06 | — | — | WO | disclosed |
| US-20210128572-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | Beta Therapeutics Pty Ltd (AU) | 2021-05-06 | — | — | US | disclosed |
| US-20210128723-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-05-06 | — | — | US | disclosed |
| EP-3813819-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3813784-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | The Regents Of The University Of Michigan (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3071591-B1 | ANTIMICROBIAL PEPTIDOMIMETICS | AGENCY SCIENCE TECH & RES (SG) | 2021-05-05 | — | — | EP | disclosed |
| CN-107847765-B | 1, 4-substituted piperidine derivatives | 89生物有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112724349-A | Novel polymers and uses thereof | 立邦涂料（中国）有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-112740018-A | Narrow absorbing polymeric nanoparticles and related methods | 华盛顿大学 | 2021-04-30 | — | — | CN | disclosed |
| CN-107936024-B | Anaplastic lymphoma kinase inhibitor and preparation method and application thereof | 北京赛林泰医药技术有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-112739349-A | Combination therapy for the treatment of leukemia | 圣诺康生命科学公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20210122703-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2021-04-29 | — | — | US | disclosed |
| US-20210122739-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-04-29 | — | — | US | disclosed |
| US-20210122773-A1 | HETEROATOMIC-BASED HOLE-TRANSPORT MATERIALS | SIGMA-ALDRICH CO. LLC | 2021-04-29 | — | — | US | disclosed |
| WO-2021081375-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081380-A1 | PEROVSKITE NANOCRYSTAL COMPOSITIONS | QUANTUM ADVANCED SOLUTIONS LTD (GB) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021078811-A1 | NOVEL HETEROCYCLIC COMPOUNDS | FLORATEK PHARMA AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| US-20210122702-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2021-04-29 | — | — | US | disclosed |
| US-20210122730-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ORIC PHARMACEUTICALS, INC. | 2021-04-29 | — | — | US | disclosed |
| US-20210122716-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-04-29 | — | — | US | disclosed |
| EP-3810589-A1 | SUBSTITUTED 2-HETEROARYLOXYPYRIDINES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810588-A1 | SUBSTITUTED 4-HETEROARYLOXYPYRIDINES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810146-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | Otonomy, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3811974-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3169325-B1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810145-A1 | WD40 REPEAT DOMAIN PROTEIN 5 (WDR5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810109-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | Peloton Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-109721600-B | Nitrogen-containing fused ring compounds and preparation method and application thereof | 上海凌达生物医药有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-112714646-A | Protein tyrosine kinase 6(PTK6) degradation/disruption compounds and methods of use | 西奈山伊坎医学院 | 2021-04-27 | — | — | CN | disclosed |
| CN-112707893-A | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2021-04-27 | — | — | CN | disclosed |
| WO-2021076572-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021077066-A1 | LIPID AND LIPID NANOPARTICLE FORMULATION FOR DRUG DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021077067-A1 | LIPID NANOPARTICLES AND FORMULATIONS THEREOF FOR CAR MRNA DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021074227-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-22 | — | — | WO | disclosed |
| US-20210113562-A1 | PIM KINASE INHIBITORS FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND FIBROSIS ASSOCIATED WITH CANCER | SUMITOMO PHARMA AMERICA, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20210114953-A1 | SYNTHESIS OF E,E-FARNESOL, FARNESYL ACETATE AND SQUALENE FROM FARNESENE VIA FARNESYL CHLORIDE | EUAGORE, LLC | 2021-04-22 | — | — | US | disclosed |
| EP-3806850-A2 | METHODS OF INHIBITING PROLIFERATIVE CELLS | Ideaya Biosciences, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3806856-A1 | VMAT2 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3807281-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2021-04-21 | — | — | EP | disclosed |
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | disclosed |
| EP-3464289-B1 | ULTRA-POTENT VINCA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBULIN DIMER-DIMER INTERFACE | SCRIPPS RESEARCH INST (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3233866-B1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma AG (DE) | 2021-04-21 | — | — | EP | disclosed |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-10981893-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| CN-112661696-A | Green synthesis method of multi-aryl substituted methanol | 华东理工大学 | 2021-04-16 | — | — | CN | disclosed |
| CN-112672995-A | Novel sulfonamide urea compounds | 英夫拉索姆有限公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20210107999-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. | 2021-04-15 | — | — | US | disclosed |
| WO-2021071843-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072265-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210107896-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3804723-A1 | COMBINATION THERAPY | BerGenBio ASA (NO) | 2021-04-14 | — | — | EP | disclosed |
| EP-3802551-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3802524-A1 | COMPOUNDS FOR PAIN TREATMENT, COMPOSITIONS COMPRISING SAME, AND METHODS OF USING SAME | Cersci Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3802471-A1 | SYNTHESIS OF E,E-FARNESOL, FARNESYL ACETATE AND SQUALENE FROM FARNESENE VIA FARNESYL CHLORIDE | Amyris, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3443049-B1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER INC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3598218-B1 | METAL OXIDE, METAL BRONZE AND POLYOXOMETALATE AS CHARGE STORAGE MATERIALS IN ELECTROCHROMIC DEVICE | FURCIFER INC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3207031-B1 | ATAXIA TELENGIECTASIA AND RAD3-RELATED (ATR) PROTEIN KINASE INHIBITORS | Atrin Pharmaceuticals LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3523291-B1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-04-14 | — | — | EP | disclosed |
| US-10975071-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975096-B2 | Synthesis of polycyclic-carbamoylpyridone compounds | GILEAD SCIENCES, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975123-B2 | Mutant Akt-specific capture agents, compositions, and methods of using and making | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-04-13 | — | — | US | disclosed |
| US-10978739-B2 | Silicon-based energy storage devices with carboxylic ether, carboxylic acid based salt, or acrylate electrolyte containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| CN-112654632-A | Hexahydro-1H-cyclopenta [ alpha ] phenanthrene derivatives useful for the treatment of pain and inflammation | 塔罗制药公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-112638381-A | Muscarinic acetylcholine M1 receptor antagonists | 帕珀莱恩医疗公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112638387-A | VMAT2 inhibitor compounds, compositions, and methods related thereto | 纽罗克里生物科学有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112638898-A | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors | 泽农医药公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112638879-A | Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents | 泽农医药公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112638373-A | Cyclin-dependent kinase inhibitors | 金耐特生物制药公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112638376-A | Substituted tetrahydrocyclopenta [ c ] pyrroles, substituted dihydropyrrolizines, analogs thereof and methods of use thereof | 爱彼特生物制药公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112638927-A | Gemcitabine prodrugs | 治愈生物医药公司 | 2021-04-09 | — | — | CN | disclosed |
| US-20210100238-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | X-THERMA, INC. (US) | 2021-04-08 | — | — | US | disclosed |
| US-20210101868-A1 | Substituted 3-Dialkylaminomethyl-Piperidin-4-yl-Benzamides and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2021-04-08 | — | — | US | disclosed |
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| US-20210101912-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-04-08 | — | — | US | disclosed |
| US-20210101936-A1 | CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2021-04-08 | — | — | US | disclosed |
| EP-3800186-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | Mission Therapeutics Limited (GB) | 2021-04-07 | — | — | EP | disclosed |
| CN-109942665-B | Triptolide derivative and preparation method and application thereof | 欣凯医药化工中间体（上海）有限公司 | 2021-04-06 | — | — | CN | disclosed |
| US-10968215-B2 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| WO-2021058458-A1 | PROCESS COMPRISING THE USE OF NEW IRIDIUM CATALYSTS FOR ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021058457-A1 | IMPROVED ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST AND AN ADDITIVE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-01 | — | — | WO | disclosed |
| US-20210098827-A1 | Silicon-Based Energy Storage Devices With Electrolyte Containing Dimethoxyethane Based Compound | ENEVATE CORPORATION | 2021-04-01 | — | — | US | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
| CN-112584833-A | Heterocyclic spiro compounds and methods of use thereof for treating cancer | 亚瑞克西斯制药公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10960005-B2 | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10959984-B2 | Methods for treating cancer with RORγ inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2021053205-A1 | CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS | FLORATEK PHARMA AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-25 | — | — | US | disclosed |
| US-20210085682-A1 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210087151-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2021-03-25 | — | — | US | disclosed |
| WO-2021055705-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055560-A1 | FLUORINATED ELECTROLYTE ADDITIVES | E3TRIGEN, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021053617-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| EP-3793550-A2 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-03-24 | — | — | EP | disclosed |
| EP-3793551-A1 | OXADIAZOLE COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3793547-A1 | MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2021-03-24 | — | — | EP | disclosed |
| EP-3793552-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | The Scripps Research Institute (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-112543753-A | Indene derivatives useful for treating pain and inflammation | 塔罗制药公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-107922345-B | Arylsulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use | 圣诺康生命科学公司 | 2021-03-23 | — | — | CN | disclosed |
| US-10957898-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954328-B2 | Polymerization processes | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954391-B2 | Water soluble fluorescent or colored dyes and methods for their use | SONY CORPORATION (JP) | 2021-03-23 | — | — | US | disclosed |
| US-10955419-B2 | Methods and systems for analysis using polymer dots | UNIVERSITY OF WASHINGTON (US) | 2021-03-23 | — | — | US | disclosed |
| US-10957938-B2 | Sodium-ion electrolyte composition | DEAKIN UNIVERSITY (AU) | 2021-03-23 | — | — | US | disclosed |
| CN-112533581-A | PRC1 inhibitors and methods of treatment therewith | 密歇根大学董事会 | 2021-03-19 | — | — | CN | disclosed |
| CN-112533913-A | Novel compounds | 英夫拉索姆有限公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-112533602-A | AXL kinase inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-112533905-A | Indene derivatives useful for treating pain and inflammation | 塔罗制药公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20210078963-A1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | SHUTTLE PHARMACEUTICALS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-18 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| WO-2021048626-A1 | COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS | RAZIEL THERAPEUTICS LTD. (IL) | 2021-03-18 | — | — | WO | disclosed |
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS ACQUISITION CORPORATION | 2021-03-18 | — | — | US | disclosed |
| EP-3359542-B1 | SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-17 | — | — | EP | disclosed |
| EP-3791875-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| CN-112512597-A | Methods for treating diseases associated with aberrant ACVR1 expression and ACVR1 inhibitors useful therefor | 大日本住友制药肿瘤公司 | 2021-03-16 | — | — | CN | disclosed |
| US-10947176-B2 | Antimalarial compositions and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-16 | — | — | US | disclosed |
| CN-109526219-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2021-03-12 | — | — | CN | disclosed |
| WO-2021045686-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BETA-CATENIN / TCF4 INTERACTION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021043966-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021042169-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2021-03-11 | — | — | WO | disclosed |
| US-20210069201-A1 | SELECTIVE P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-03-11 | — | — | US | disclosed |
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210070773-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2021-03-11 | — | — | US | disclosed |
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3787629-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3788041-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-03-10 | — | — | EP | disclosed |
| CN-112469725-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112457326-A | Aromatic heterocyclic lactam compound, preparation method and application | 上海凌达生物医药有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112469720-A | Dual ATM and DNA-PK inhibitors for use in antitumor therapy | 艾科思莱德制药公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112469712-A | Substituted 2-heteroaryloxypyridines and their salts and their use as herbicides | 拜耳公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10940146-B2 | NHE3-binding compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10941162-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| CN-112441980-A | Pyrazole derivatives for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2021-03-05 | — | — | CN | disclosed |
| WO-2021037219-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | 上海奕拓医药科技有限责任公司 | 2021-03-04 | — | — | WO | disclosed |
| US-20210062251-A1 | ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS | Roche Sequencing Solutions, Inc. | 2021-03-04 | — | — | US | disclosed |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210061834-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | NATIONAL SCIENCE FOUNDATION | 2021-03-04 | — | — | US | disclosed |
| EP-3596064-B1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-03 | — | — | EP | disclosed |
| EP-3784229-A2 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3786166-A1 | 2-AMINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-10934253-B2 | Therapeutic compounds and methods | UNIVERSITY OF TASMANIA (AU) | 2021-03-02 | — | — | US | disclosed |
| US-10934322-B2 | B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | ChromaDex Inc. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934568-B2 | Conversion of sugars to ionic liquids | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934531-B2 | Method for enantioselective carbene C—H insertion using an iron-containing protein catalyst | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934376-B2 | Polyethylene compositions and films made therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-03-02 | — | — | US | disclosed |
| CN-107406548-B | Compositions and methods for treating hyperkalemia | 阿德利克斯公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-112430250-A | Lymphatic prodrugs | 莫纳什大学 | 2021-03-02 | — | — | CN | disclosed |
| CN-108884068-B | 1-cyano-pyrrolidine derivatives as DUB inhibitors | 特殊治疗有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210053969-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-20210053953-A1 | A COMPOUND, A REACTION PRODUCT OF SAID COMPOUND AND PRODUCTION METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-25 | — | — | US | disclosed |
| US-20210053988-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210052585-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-02-25 | — | — | US | disclosed |
| WO-2021035096-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032883-A1 | COMBINATION THERAPY OF A PATIENT SUBGROUP | BERGENBIO ASA (NO) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032591-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032588-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2021-02-25 | — | — | US | disclosed |
| US-20210052532-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210054003-A1 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | DREXEL UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
| EP-3783001-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781565-A1 | 2-METHYL-AZA-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781194-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | Avelas Biosciences, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782983-A1 | ISOINDOLE DERIVATIVE | Tianjin Hemay Pharmaceutical Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-3277677-B1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3434674-B1 | ((4-(2-OXOIMIDAZOLIDINE-1-YL)PYRIMIDIN-2-YL)AMINE DERIVATIVES AS MUTANT IDH INHIBITORS FOR TREATING CANCER | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-02-24 | — | — | EP | disclosed |
| CN-112390832-A | Metal complex, intermediate, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2021-02-23 | — | — | CN | disclosed |
| CN-112390904-A | Polyethylene containing polar functional group and preparation method thereof | 中国科学院上海有机化学研究所 | 2021-02-23 | — | — | CN | disclosed |
| CN-112390838-A | Modified nucleoside and synthetic method thereof | 斯微(上海)生物科技有限公司 | 2021-02-23 | — | — | CN | disclosed |
| US-10927202-B2 | Polyethylene compositions and articles made therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927203-B2 | Polyethylene compositions and articles made therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927205-B2 | Polymerization processes and polymers made therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927111-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927355-B2 | Method for producing an organosilicon product | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-02-23 | — | — | US | disclosed |
| CN-112384507-A | Substituted 4-heteroaryloxypyridines and their salts and their use as herbicides | 拜耳公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-106604997-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-108473632-B | Polymeric compositions | 新加坡科技研究局 | 2021-02-19 | — | — | CN | disclosed |
| CN-107531738-B | Niacinetoside or nicotinamide riboside compositions, reduced derivatives thereof and uses thereof | 可劳迈戴斯有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-107922405-B | Compound with ERK kinase inhibitory activity, preparation method and application thereof | 中国科学院上海药物研究所 | 2021-02-19 | — | — | CN | disclosed |
| CN-112384508-A | Tricyclic ASK1 inhibitor and application thereof | 山东轩竹医药科技有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20210047302-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-18 | — | — | US | disclosed |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-02-18 | — | — | US | disclosed |
| US-20210046069-A1 | PENTAFLUOROSULFANYL-SUBSTITUTED AMIDE DERIVATIVES, PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| WO-2021028419-A1 | SUBSTITUTED 3-(2-HETEROARYLOXYPHENYL)ISOXAZOLINES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028421-A1 | SUBSTITUTED (2-HETEROARYLOXYPHENYL)ISOXAZOLINES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028854-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021027614-A1 | MODIFIED NUCLEOSIDE AND SYNTHESIS METHOD THEREFOR | 斯微(上海)生物科技有限公司 | 2021-02-18 | — | — | WO | disclosed |
| EP-3774836-A1 | HEXADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2021-02-17 | — | — | EP | disclosed |
| EP-3774748-A1 | OXADIAZOLINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-02-17 | — | — | EP | disclosed |
| EP-3773560-A1 | PIM KINASE INHIBITORS FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND FIBROSIS ASSOCIATED WITH CANCER | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3774709-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2-ALPHA | Peloton Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3394049-B1 | CYANOPYRROLIDINE DERVIVATIVES AS INHBITORS FOR DUBS | MISSION THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3331894-B1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METRO INT BIOTECH LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3558979-B1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-02-17 | — | — | EP | disclosed |
| EP-3774746-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2021-02-17 | — | — | EP | disclosed |
| EP-3492106-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3773591-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10918643-B2 | No-donors for the treatment of cerebrovascular vasospasms after brain hemorrhage | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2021-02-16 | — | — | US | disclosed |
| US-10919913-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-16 | — | — | US | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | 89BIO LTD (IL) | 2021-02-16 | — | — | US | disclosed |
| US-10919914-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10921674-B2 | Electrochromic polymer thin films having reduced self-bleaching behavior and enhanced cycling stability | Furcifer Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919038-B2 | Modification of surface properties of microfluidic devices | BIO-RAD LABORATORIES, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| CN-109908356-B | Cyanoacrylate material loaded with antitumor drug | 中国人民解放军军事医学科学院毒物药物研究所 | 2021-02-12 | — | — | CN | disclosed |
| US-20210040065-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-11 | — | — | US | disclosed |
| US-20210038628-A1 | NANOPARTICLE COMPOSITIONS | JANUARY THERAPEUTICS, INC. (US) | 2021-02-11 | — | — | US | disclosed |
| WO-2021026257-A1 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | EMPIRICO INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021025976-A1 | SUBSTITUTED CYCLOPROPYL-2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| CN-106661229-B | Organosilicon ligands for quantum dots | 纳米系统公司 | 2021-02-09 | — | — | CN | disclosed |
| CN-108117534-B | Benzo-oxygenated aliphatic cyclomethylamines | 华东理工大学 | 2021-02-05 | — | — | CN | disclosed |
| CN-107531613-B | Benzo-aliphatic ring-substituted alkylamine compound and application thereof | 华东理工大学 | 2021-02-05 | — | — | CN | disclosed |
| US-20210030772-A1 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | EMPIRICO INC. | 2021-02-04 | — | — | US | disclosed |
| US-20210030005-A1 | BENZOXABOROLE COMPOSITIONS HAVING A GROWTH ENHANCING EFFECT | 5METIS, INC. | 2021-02-04 | — | — | US | disclosed |
| US-20210032264-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2021-02-04 | — | — | US | disclosed |
| WO-2021022078-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021018287-A1 | SPIROAROMATIC COMPOUND, PREPARATION AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2021-02-04 | — | — | WO | disclosed |
| CN-112300196-A | Piperidine condensed ring compound, preparation method and application | 上海凌达生物医药有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-112300194-A | Condensed ring pyridone compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-112300173-A | Nitrogen-containing polycyclic compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-10907184-B2 | Ammonium based ionic liquids useful for lignocellulosic processing | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2021-02-02 | — | — | US | disclosed |
| US-10905702-B2 | Inhibition of galectin 3 binding to the airway epithelial surface to treat or prevent septic shock resulting from influenza and subsequent pneumococcal pneumonia infection | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-02-02 | — | — | US | disclosed |
| CN-112300160-A | Spiro aromatic ring compound, preparation and application thereof | 上海奕拓医药科技有限责任公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-112300159-A | Dual ATM and DNA-PK inhibitors for use in antitumor therapy | 艾科思莱德制药公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-107484415-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-107709470-B | Super bright dimeric or polymeric dyes | 索尼公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-112280553-A | Encoded chromophoric polymer particles | 华盛顿大学商业中心 | 2021-01-29 | — | — | CN | disclosed |
| CN-112292184-A | Nanoparticle compositions | 詹纽瑞治疗公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20210023095-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20210024501-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC | 2021-01-28 | — | — | US | disclosed |
| US-20210024571-A1 | HEXADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2021-01-28 | — | — | US | disclosed |
| US-20210024457-A1 | DIAMIDE ANTIMICROBIAL AGENTS | BROWN UNIVERSITY | 2021-01-28 | — | — | US | disclosed |
| WO-2021013800-A1 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021013799-A1 | SUBSTITUTED N-PHENYL URACILS, SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021013978-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2021-01-28 | — | — | WO | disclosed |
| EP-3521399-B1 | ENCODED CHROMOPHORIC POLYMER PARTICLES | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10899860-B2 | Polymerization processes and polymers made therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-10899739-B2 | Macrophage migration inhibitory factor inhibitors, and methods of making and using same | YALE UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10898487-B2 | Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| CN-112262116-A | Synthesis of E, E-farnesol, farnesyl acetate and squalene from farnesene via farnesyl chloride | 阿迈瑞斯公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-112262142-A | Benzenesulfonamide compounds and their use as therapeutic agents | 泽农医药公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-112262145-A | 2-aminopyrimidine derivatives, preparation method and application thereof | 上海奕拓医药科技有限责任公司 | 2021-01-22 | — | — | CN | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017219-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20210017174-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-21 | — | — | US | disclosed |
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | PELOTON THERAPEUTICS INC. (US) | 2021-01-21 | — | — | US | disclosed |
| WO-2021011796-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021009568-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2021-01-21 | — | — | WO | disclosed |
| US-20210017220-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-01-21 | — | — | US | disclosed |
| EP-3349747-B1 | NO-DONORS FOR THE TREATMENT OF CEREBROVASCULAR VASOSPASMS AFTER BRAIN HEMORRHAGE | UNIV MUENSTER WESTFAELISCHE WILHELMS (DE) | 2021-01-20 | — | — | EP | disclosed |
| EP-3458441-B1 | PROCESS FOR THE MANUFACTURE OF 6-ALKYNYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2021-01-20 | — | — | EP | disclosed |
| EP-3765158-A1 | NANOPARTICLE COMPOSITIONS | January Therapeutics, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-105873564-B | Skin care compositions and methods of use thereof | 尤尼根公司 | 2021-01-19 | — | — | CN | disclosed |
| US-10894788-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894802-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | YALE UNIVERSITY (US) | 2021-01-19 | — | — | US | disclosed |
| CN-112236139-A | PIM kinase inhibitors for the treatment of myeloproliferative tumors and cancer-associated fibrosis | 大日本住友制药肿瘤公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2021007236-A1 | NON-NATIVE O-GLCNAC MODIFICATION OF PEPTIDE HORMONES YIELDS POTENT GPCR AGONISTS WITH IMPROVED SERUM STABILITY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2021005586-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2021-01-14 | — | — | WO | disclosed |
| WO-2021007172-A1 | FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | BELITE BIO, LLC (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20210008076-A1 | NANOPARTICLE COMPOSITIONS | JANUARY THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210013536-A1 | MEMBRANES FOR AQUEOUS REDOX FLOW BATTERIES | FIRST-CITIZENS BANK & TRUST COMPANY | 2021-01-14 | — | — | US | disclosed |
| US-20210009521-A1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-14 | — | — | US | disclosed |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210007999-A1 | NANOPARTICLE COMPOSITIONS | JANUARY THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210008043-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | NATIONAL INSTITUTES OF HEALTH | 2021-01-14 | — | — | US | disclosed |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| EP-3763367-A1 | PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3761984-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University - Of The Commonwealth System of Higher Education (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3762381-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3763712-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2021-01-13 | — | — | EP | disclosed |
| EP-3761985-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University - Of The Commonwealth System of Higher Education (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3762365-A1 | METHODS AND COMPOSITIONS OF ISOINDOLINE-1,3-DIONE AND ISOINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES | Amgen (Europe) GmbH (CH) | 2021-01-13 | — | — | EP | disclosed |
| EP-3762379-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2021-01-13 | — | — | EP | disclosed |
| CN-112218860-A | Substituted phenylthiouracils, their salts and their use as herbicides | 先正达农作物保护股份公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-112218533-A | Nanoparticle compositions | 詹纽瑞治疗公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-112218873-A | Metallocene synthesis method | 埃克森美孚化学专利公司 | 2021-01-12 | — | — | CN | disclosed |
| US-10888853-B2 | Cinchonium betaine catalysts and methods of using same | BRANDEIS UNIVERSITY (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889591-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| US-10889586-B2 | Multi-kinase inhibitor compound, and crystal form and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| US-10888562-B1 | — | — | 2021-01-12 | — | — | US | disclosed |
| CN-112204025-A | Compounds for the treatment of pain, compositions comprising the same and methods of using the same | 瑟赛治疗公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-107098908-B | Preparation method and application of pyrrolopyrimidine compound | 欣凯医药科技(上海)有限公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-112203679-A | IL-6 antibodies and fusion constructs and conjugates thereof | 科达制药股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| US-20210002324-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20210002469-A1 | TOUGH, HEALABLE COMPOSITES DISPLAYING STRESS RELAXATION AT THE RESIN-FILLER INTERFACE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-07 | — | — | US | disclosed |
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20210000837-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20210003916-A1 | POSITIVE RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-01-07 | — | — | US | disclosed |
| EP-3759090-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3760639-A1 | ZWITTERIONIC POLYMER CONJUGATES | Kodiak Sciences Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3758801-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3759073-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3758737-A1 | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | Kodiak Sciences Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3759089-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3758490-A1 | NANOPARTICLE COMPOSITIONS | January Therapeutics, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3759227-A1 | IMPROVED METHOD FOR THE SYNTHESIS OF TRYPTOPHAN ANALOGS IN AQUEOUS SOLVENTS AT REDUCED TEMPERATURES | California Institute of Technology (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3759102-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3759103-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3758495-A1 | NANOPARTICLE COMPOSITIONS | January Therapeutics, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3759077-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3759078-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3759084-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | disclosed |
| EP-3377110-B1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | ABBVIE DEUTSCHLAND (DE) | 2021-01-06 | — | — | EP | disclosed |
| CN-108290893-B | Dihydroperidinone derivatives, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-107793395-B | Fibroblast growth factor receptor inhibitors and uses thereof | 南京药捷安康生物科技有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-10881660-B2 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | CORCEPT THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10882866-B1 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-05 | — | — | US | disclosed |
| US-10882847-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2021-01-05 | — | — | US | disclosed |
| CN-112176418-A | High-flux compound library construction and screening method and reaction device | 中国科学院上海有机化学研究所 | 2021-01-05 | — | — | CN | disclosed |
| CN-107454903-B | Water-soluble fluorescent or colored dyes containing conjugated groups | 索尼公司 | 2021-01-01 | — | — | CN | disclosed |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-12-31 | — | — | US | disclosed |
| US-20200407375-A1 | PROTECTIVE GROUPS AND METHODS FOR PROTECTING BENZOXABOROLES OR OXABOROLES | UNIVERSITY OF THE SCIENCES (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200405730-A1 | PI3KGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-12-31 | — | — | US | disclosed |
| WO-2020263703-A1 | ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS | STRATOS GENOMICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020260252-A1 | NEW MACROCYCLIC COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264120-A1 | PI3KGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264128-A1 | METHODS AND COMPOSITIONS RELATED TO PRINTED CELLULAR NICHES FOR PRESERVING AND CONTROLLING SYNTHETIC MICROBIAL CONSORTIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-3755317-A1 | PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3755694-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2020-12-30 | — | — | EP | disclosed |
| EP-3455226-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3368582-B1 | POLYURETHANE/UREA MATERIALS | COMMW SCIENT IND RES ORG (AU) | 2020-12-30 | — | — | EP | disclosed |
| CN-112154146-A | Serine threonine kinase (AKT) degradation/disruption compounds and methods of use | 西奈山伊坎医学院 | 2020-12-29 | — | — | CN | disclosed |
| CN-112154147-A | Substituted phenylthiouracils, their salts and their use as herbicides | 先正达农作物保护股份公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-112142735-A | Condensed cyanopyridine compound, preparation method and application | 上海凌达生物医药有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-10875842-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-12-29 | — | — | US | disclosed |
| CN-112135818-A | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2020-12-25 | — | — | CN | disclosed |
| CN-112125901-A | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200399270-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-12-24 | — | — | US | disclosed |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200397798-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | AKARNA THERAPEUTICS, LTD. (GB) | 2020-12-24 | — | — | US | disclosed |
| US-20200399243-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
| US-20200399242-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
| WO-2020254197-A1 | ADRENOMEDULLIN-ANALOGUES FOR LONG-TERM STABILIZATION AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254451-A1 | ANTICANCER COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257733-A1 | HISTONE DEMETHYLASE INHIBITORS FOR TREATING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257734-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING BACTERIAL INFECTIONS | BAYLOR COLLEGE OF MEDICINE (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254489-A1 | BENZYLPHENYL HYDROXYISOXAZOLINES AND ANALOGUES AS NEW ANTIFUNGAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254490-A1 | PHENOXYPHENYL HYDROXYISOXAZOLINES AND ANALOGUES AS NEW ANTIFUNGAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-12-24 | — | — | WO | disclosed |
| EP-3753941-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Blueray Biopharma Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-10870634-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| CN-112105364-A | Compositions and methods for treating insulin resistance | 坦普尔大学 | 2020-12-18 | — | — | CN | disclosed |
| CN-107001945-B | Aromatic hydrogenation catalyst and use thereof | 埃克森美孚研究工程公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-112105355-A | ABHD12 inhibitors and methods of making and using the same | 斯克利普斯研究所 | 2020-12-18 | — | — | CN | disclosed |
| CN-112094269-A | Saturated six-membered ring heterocyclic compound, preparation method and application | 上海凌达生物医药有限公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AG (DE) | 2020-12-17 | — | — | US | disclosed |
| US-20200392075-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | UNIV TEMPLE (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200390792-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | SYNTHENA AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20200392136-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2020-12-17 | — | — | US | disclosed |
| US-20200392082-A1 | METHODS AND COMPOSITIONS OF ISOINDOLINE-1,3-DIONE AND ISOINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES | PRO-ONICS PHARMACEUTCIALS LLC | 2020-12-17 | — | — | US | disclosed |
| EP-3508482-B1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) | 2020-12-16 | — | — | EP | disclosed |
| CN-112088006-A | Compositions and methods for treating insulin resistance | 坦普尔大学 | 2020-12-15 | — | — | CN | disclosed |
| CN-112088001-A | MAGL inhibitors | 隆德贝克拉荷亚研究中心有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-109721599-B | Amino-substituted nitrogen-containing fused ring compound and preparation method and application thereof | 上海凌达生物医药有限公司 | 2020-12-15 | — | — | CN | disclosed |
| US-10865384-B2 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-15 | — | — | US | disclosed |
| US-10865310-B2 | Ultra bright dimeric or polymeric dyes | SONY CORPORATION OF AMERICA (US) | 2020-12-15 | — | — | US | disclosed |
| US-10864202-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200388880-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE ADDITIVE COMPOUNDS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388881-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONAL THIOPHENE COMPOUNDS OR DERIVATIVES OF THIOPHENE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388876-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH SILICON CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388885-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LIPO2F2 SALT-CONTAINING ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200383985-A1 | Inhibitors of Protease Activated Receptor-2 | MONASH UNIVERSITY (AU) | 2020-12-10 | — | — | US | disclosed |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-12-10 | — | — | US | disclosed |
| US-20200385364-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2020-12-10 | — | — | US | disclosed |
| US-20200385409-A1 | BENZOXABOROLE COMPOUNDS AND FORMULATIONS THEREOF | Boragen, Inc. | 2020-12-10 | — | — | US | disclosed |
| US-20200388836-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONAL TERTHIOPHENE COMPOUND OR THIOPHENE OLIGOMER COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388837-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH SILYL AMINE COMPOUNDS OR DERIVATIVES OF SILYL AMINE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388882-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388879-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONALIZED LINEAR SULFONATE ESTER DERIVATIVE COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200385388-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | INFINITY PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| WO-2020245097-A1 | SUBSTITUTED PYRIDINYLOXYPYRIDINES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247540-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247546-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247860-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247928-A1 | PHOTOPOLYMERIZABLE THERMOPLASTICS AND METHODS OF MAKING AND USING SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3747868-A1 | SUBSTITUTED PHENOXYPYRIDINES, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer AG (DE) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747867-A1 | SUBSTITUTED PYRIDINYLOXYANILINES, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer AG (DE) | 2020-12-09 | — | — | EP | disclosed |
| EP-3746445-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3746430-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | Padforward LLC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747865-A1 | PENTAFLUOROSULFANYL-SUBSTITUTED AMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL APPLICATION THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
| EP-3344243-B1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS | BROAD INST INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747472-A1 | THERAPEUTIC COMBINATIONS OF A CD19 INHIBITOR AND A BTK INHIBITOR | Acerta Pharma B.V. (NL) | 2020-12-09 | — | — | EP | disclosed |
| CN-111592525-B | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2020-12-08 | — | — | CN | disclosed |
| US-10858343-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858316-B2 | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858338-B2 | Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-08 | — | — | US | disclosed |
| CN-112040947-A | NSD family inhibitors and methods of treatment therewith | 密歇根大学董事会 | 2020-12-04 | — | — | CN | disclosed |
| US-20200377553-A1 | ANTIBODY SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-12-03 | — | — | US | disclosed |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| WO-2020243008-A1 | SENSORS AND METHODS FOR RAPID MICROBIAL DETECTION | BAMBU VAULT LLC (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020023910-A9 | METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-3743126-A1 | FLUORESCENT POLYMERIC COATING FILM FOR MEDICAL DEVICES | Université de Strasbourg (FR) | 2020-12-02 | — | — | EP | disclosed |
| EP-3310773-B1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-12-02 | — | — | EP | disclosed |
| EP-3160952-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3283462-B1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| CN-107108522-B | Benzimidazol-2-amines as mIDH1 inhibitors | 德国癌症研究中心 | 2020-12-01 | — | — | CN | disclosed |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2020-12-01 | — | — | US | disclosed |
| US-10849898-B2 | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| CN-107501297-B | Phenothiazine-pyridine compounds and uses thereof | 香港中文大学 | 2020-12-01 | — | — | CN | disclosed |
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | disclosed |
| CN-112011002-A | Method for controlled radical polymerization and apparatus for controlled radical polymerization | 立邦工业涂料(上海)有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-112004537-A | Selective histone deacetylase inhibitors for the treatment of human diseases | 穿梭药业公司 | 2020-11-27 | — | — | CN | disclosed |
| CN-112004790-A | Novel indoleamine 2, 3-dioxygenase inhibitor and preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2020-11-27 | — | — | CN | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| WO-2020236524-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236556-A1 | METHODS OF PREPARING MACROCYCLIC INDOLES | THE BROAD INSTITUTE, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236841-A2 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236817-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| US-20200369633-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-26 | — | — | US | disclosed |
| US-20200369639-A1 | TRICYCLO-DNA NUCLEOSIDE PRECURSORS AND PROCESSES FOR PREPARING THE SAME | SYNTHENA AG (CH) | 2020-11-26 | — | — | US | disclosed |
| US-20200373620-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ETHER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORP (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200369695-A1 | ORGANOPHOSPHATE DERIVATIVES | JANUARY THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| EP-3740472-A1 | TRICYCLO-DNA NUCLEOSIDE PRECURSORS AND PROCESSES FOR PREPARING THE SAME | Synthena AG (CH) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741742-A1 | METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES | Acucela Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10844054-B2 | Compounds for pain treatment, compositions comprising same, and methods of using same | CERSCI THERAPEUTICS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| CN-111983219-A | Polymer dot compositions and related methods | 华盛顿大学商业中心 | 2020-11-24 | — | — | CN | disclosed |
| US-10844079-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-11-19 | — | — | US | disclosed |
| US-20200361894-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2020-11-19 | — | — | US | disclosed |
| US-20200361927-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-19 | — | — | US | disclosed |
| EP-3519385-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3737376-A1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | Shuttle Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10836761-B2 | Cinchonine-derived catalysts and methods of using same | BRANDEIS UNIVERSITY (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836789-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836728-B2 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| WO-2020227264-A1 | FLUORENE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227296-A1 | THERMALLY REVERSIBLE AND REORGANIZABLE CROSSLINKING POLYMERS FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227020-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227305-A1 | LATENT IMAGING FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227325-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227276-A1 | THIANTHRENE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200354594-A1 | THERMALLY REVERSIBLE AND REORGANIZABLE CROSSLINKING POLYMERS FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2020-11-12 | — | — | US | disclosed |
| US-20200354341-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2020-11-12 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| US-20200352966-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2020-11-12 | — | — | US | disclosed |
| US-20200355997-A1 | THIANTHRENE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2020-11-12 | — | — | US | disclosed |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-12 | — | — | US | disclosed |
| US-20200354311-A1 | FLUORENE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2020-11-12 | — | — | US | disclosed |
| US-20200354496-A1 | LATENT IMAGING FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2020-11-12 | — | — | US | disclosed |
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-12 | — | — | US | disclosed |
| EP-3736279-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | Yale University (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3735409-A1 | ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS | Stratos Genomics Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3735404-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10829464-B2 | Benzoheterocyclic alkylamine compounds and use thereof | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2020-11-10 | — | — | US | disclosed |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829440-B2 | Antibacterial compounds and methods of making and using same | BROWN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829792-B2 | Biocatalytic synthesis of strained carbocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| CN-111909083-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-111902399-A | Enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts | 拜耳公司 | 2020-11-06 | — | — | CN | disclosed |
| CN-107108554-B | 1-cyclohexyl-2-phenylaminobenzimidazole as MIDH1 inhibitor for treating tumors | 德国癌症研究中心 | 2020-11-06 | — | — | CN | disclosed |
| CN-106660987-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20200347248-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | ENVISTA (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200347009-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2020-11-05 | — | — | US | disclosed |
| US-20200347247-A1 | SURFACE PRIMER COMPOSITIONS AND METHODS OF USE | ENVISTA (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200347075-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20200347061-A1 | CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20200347243-A1 | FLUORESCENT POLYMERIC COATING FILM FOR MEDICAL DEVICES | UNIVERSITE DE STRASBOURG (FR) | 2020-11-05 | — | — | US | disclosed |
| WO-2020223530-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020223517-A1 | METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS | TRANSFUSION HEALTH, LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-10822312-B2 | Substituted quinazoline compounds and methods of use | ARAXES PHARMA LLC (US) | 2020-11-03 | — | — | US | disclosed |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-03 | — | — | US | disclosed |
| US-10822434-B2 | Catalyst systems and polymerization processes for using the same | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2020-11-03 | — | — | US | disclosed |
| CN-107814798-B | 3-substituted acrylic acid compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-106458996-B | Fused pyrimidines as inhibitors of the p97 complex | 克里弗生物科学公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-105820103-B | N-benzoyloxy-substituted benzopyrroline-2-ketone derivative and application thereof | 北京韩美药品有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-111885914-A | Compositions and methods for producing expanded hematopoietic stem cells using fluorene derivatives | 投资健康有限责任公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-111848573-A | Benzothiophene amide compounds, and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-111867646-A | Fluorescent polymer coated films for medical devices | 斯特拉斯堡大学 | 2020-10-30 | — | — | CN | disclosed |
| US-20200339541-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20200340024-A1 | METHODS AND ENZYME CATALYSTS FOR THE SYNTHESIS OF NON-CANONICAL AMINO ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-10-29 | — | — | US | disclosed |
| WO-2020216701-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| EP-3727386-A1 | INHIBITORS OF PROTEASE ACTIVATED RECEPTOR-2 | Takeda Pharmaceutical Company Limited (JP) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728254-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3727677-A1 | METHODS OF PRODUCING ORGANOSILICA MATERIALS AND USES THEREOF | ExxonMobil Research and Engineering Company (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728235-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | Syngenta Crop Protection AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728237-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | Syngenta Crop Protection AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728214-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111825595-A | Sodium channel blockers | 山东轩竹医药科技有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-107074787-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-10-27 | — | — | US | disclosed |
| US-10815234-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| CN-111808135-A | Functionally modified oligonucleotides and subunits thereof | 萨勒普塔医疗公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-107531709-B | Beta-lactamase inhibitor and use thereof | 吉林四环制药有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-20200331874-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-10-22 | — | — | US | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| US-20200331886-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| WO-2020214854-A1 | SILK HAIR CARE COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020214734-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020214860-A1 | CHEMICALLY LINKED SILK FIBROIN COATINGS AND METHODS OF MAKING AND USING THEREOF | EVOLVED BY NATURE, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-3193851-B1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3725798-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-10-21 | — | — | EP | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| CN-111801314-A | ASK1 inhibitor compounds and uses thereof | 西尔洛克治疗公司 | 2020-10-20 | — | — | CN | disclosed |
| CN-111801321-A | tricyclic-DNA nucleoside precursors and methods for their preparation | 新特纳股份公司 | 2020-10-20 | — | — | CN | disclosed |
| US-10807956-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10808053-B2 | Polyethylene compositions and articles made therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807948-B2 | Aromatic compounds and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10811727-B2 | Silicon-based energy storage devices with ether containing electrolyte additives | ENEVATE CORPORATION (US) | 2020-10-20 | — | — | US | disclosed |
| US-10808005-B2 | Ligand for orphan nuclear receptor Nur77 and uses thereof | IXMEDICINE (XIAMEN) BIOLOGICAL TECHNOLOGY COMPANY LIMITED (CN) | 2020-10-20 | — | — | US | disclosed |
| US-20200325168-A9 | WITHANOLIDES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARNA THERAPEUTICS INC. (CA) | 2020-10-15 | — | — | US | disclosed |
| WO-2020210139-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | PELOTON THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3720430-A1 | BENZOCARBONYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3720436-A1 | TUBULIN INHIBITORS | Lin Bioscience, Pty Ltd. (AU) | 2020-10-14 | — | — | EP | disclosed |
| EP-3720439-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | The Regents Of The University Of Michigan (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3464224-B1 | PROCESS FOR PREPARING 2,3-UNSATURATED ALCOHOLS | BASF SE (DE) | 2020-10-14 | — | — | EP | disclosed |
| EP-3464296-B1 | ISOTHIAZOLOPYRIDONES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2020-10-14 | — | — | EP | disclosed |
| EP-3179990-B1 | FATTY ACID SYNTHASE INHIBITOR FOR USE IN THE TREATMENT OF DRUG RESISTANT CANCER | SAGIMET BIOSCIENCES INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-2928471-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-111771001-A | Enhanced nucleic acid polymerization by aromatic compounds | 斯特拉托斯基因公司 | 2020-10-13 | — | — | CN | disclosed |
| CN-111763217-A | Thieno-nitrogen heterocyclic compound, preparation method and application | 上海凌达生物医药有限公司 | 2020-10-13 | — | — | CN | disclosed |
| CN-107667090-B | Pesticidally active oxime and hydrazone derivatives | 先正达参股股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | NATIONAL INSTITUTES OF HEALTH | 2020-10-08 | — | — | US | disclosed |
| US-20200317695-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| US-20200315174-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2020-10-08 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200317690-A1 | NOVEL ISOTHIAZOLOPYRIDONES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-10-08 | — | — | US | disclosed |
| WO-2020198789-A1 | NON-CORE-SHELL POLYMER PARTICLES | THE UNIVERSITY OF SYDNEY (AU) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020200154-A1 | A CLASS OF THIOPHENE FUSED N-HETEROCYCLIES, PREPARATION METHOD AND USE | 上海凌达生物医药有限公司 | 2020-10-08 | — | — | WO | disclosed |
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-08 | — | — | US | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3716981-A1 | COMPOUNDS FOR TREATING NEAR VISION DISORDERS | Viewpoint Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3716766-A1 | BENZOXABOROLE COMPOUNDS AND FORMULATIONS THEREOF | Boragen, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3718573-A1 | CHROMOPHORIC POLYMER DOTS WITH NARROW-BAND EMISSION | University of Washington Through Its Center for Commercialization (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-108290872-B | Cyanopyrrolidine derivatives as DUBs inhibitors | 特殊治疗有限公司 | 2020-10-02 | — | — | CN | disclosed |
| US-20200308181-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2020-10-01 | — | — | US | disclosed |
| WO-2020198682-A1 | METHODS FOR SYNTHESIZING β-HOMOAMINO ACIDS | PROTAGONIST THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198058-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020193474-A1 | SUBSTITUTED 2-HETEROARYLAMINOBENZENES AND THE SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-01 | — | — | WO | disclosed |
| US-20200312481-A1 | POLYMER-SILICA HYBRID PDOTS AND METHODS OF USE THEREOF | UNIVERSITY OF WASHINGTON | 2020-10-01 | — | — | US | disclosed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | disclosed |
| US-20200306370-A1 | AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS | AUCKLAND UNISERVICES LTD (NZ) | 2020-10-01 | — | — | US | disclosed |
| CN-111727185-A | Substituted N-heterocyclyl-and N-heteroaryltetrahydropyrimidines and their salts and their use as herbicidal active substances | 拜耳公司 | 2020-09-29 | — | — | CN | disclosed |
| CN-111727042-A | Tubulin inhibitors | 仁新医药私人有限公司 | 2020-09-29 | — | — | CN | disclosed |
| US-10787483-B2 | Antimicrobial peptidomimetics | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-09-29 | — | — | US | disclosed |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10787668-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2020-09-29 | — | — | US | disclosed |
| CN-111704611-A | Aryl spiro SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-111704610-A | Pyrrolylamido pyridone compounds, preparation method and application | 上海凌达生物医药有限公司 | 2020-09-25 | — | — | CN | disclosed |
| US-20200299285-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-20200299287-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-09-24 | — | — | US | disclosed |
| US-20200297727-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299288-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-09-24 | — | — | US | disclosed |
| WO-2020190890-A1 | NICORANDIL DERIVATIVES | Unicycive Therapeutics Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020187123-A1 | PYRROLE AMIDOPYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海凌达生物医药有限公司 | 2020-09-24 | — | — | WO | disclosed |
| EP-3464267-B1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3712151-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710502-A1 | POLYMERIZATION PROCESSES | ExxonMobil Chemical Patents Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710447-A1 | ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710456-A1 | MACROCYCLIC INDOLE DERIVATIVES | The Broad Institute, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710448-A1 | MACROCYCLIC CHLORINE SUBSTITUTED INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710449-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | The Broad Institute, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710450-A1 | MACROCYCLIC CHLORINE SUBSTITUTED INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710451-A1 | SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710432-A1 | TETRAZOLYLPROPYL DERIVATIVES AND THEIR USE AS FUNGICIDES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
| US-10781200-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| CN-111698991-A | Inhibitors of protease activated receptor-2 | 武田药品工业株式会社 | 2020-09-22 | — | — | CN | disclosed |
| CN-111690031-A | Glucocorticoid receptor inhibitors | 欧瑞克制药公司 | 2020-09-22 | — | — | CN | disclosed |
| CN-107438606-B | [9, 10-dimethoxy-3- (2-methylpropyl) -1H,2H,3H,4H,6H,7H,11 BH-pyrido- [2,1-A ] isoquinolin-2-yl ] methanol and compounds, compositions, and methods related thereto | 纽罗克里生物科学有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-20200291060-A1 | NOVEL 7-DEHYDROCHOLESTEROL DERIVATIVES AND METHODS USING SAME | WOMEN & INFANTS HOSPITAL OF RHODE ISLAND | 2020-09-17 | — | — | US | disclosed |
| US-20200291023-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-09-17 | — | — | US | disclosed |
| WO-2020182076-A1 | USES OF PHOSPHODIESTERASE INHIBITORS | 南京药捷安康生物科技有限公司 | 2020-09-17 | — | — | WO | disclosed |
| WO-2020182929-A1 | SUBSTITUTED UREAS AND DERIVATIVES AS NEW ANTIFUNGAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020185661-A1 | USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200291020-A1 | NEW [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM RCV GMBH & CO. KG (AT) | 2020-09-17 | — | — | US | disclosed |
| US-20200291058-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200289528-A1 | Testosterone Ester Triglyceride Formulations | ANTARES PHARMA, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200291164-A1 | DYNAMIC COVALENT THERMOSET NANOCOMPOSITES AND USES THEREOF | NATIONAL SCIENCE FOUNDATION | 2020-09-17 | — | — | US | disclosed |
| US-20200289458-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | INMED PHARMACEUTICALS INC (CA) | 2020-09-17 | — | — | US | disclosed |
| EP-3555063-B1 | 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3707137-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3706736-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | The Regents of the University of Michigan (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3707134-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3706737-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | The Regents of the University of Michigan (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3708565-A1 | PYRIMIDINYLOXYPHENYLAMIDINES AND THE USE THEREOF AS FUNGICIDES | Bayer AG (DE) | 2020-09-16 | — | — | EP | disclosed |
| CN-111658653-A | Use of phosphodiesterase inhibitors | 南京药捷安康生物科技有限公司 | 2020-09-15 | — | — | CN | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-15 | — | — | US | disclosed |
| CN-111655666-A | Anti-inflammatory, anti-cancer and anti-angiogenic compounds, pharmaceutical compositions and methods of making and using the same | 麦迪康制药公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-111655035-A | Benzoxaborole compounds and formulations thereof | 博瑞金股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-111655257-A | ASH1L inhibitors and methods of treatment therewith | 密歇根大学董事会 | 2020-09-11 | — | — | CN | disclosed |
| CN-111655693-A | Inhibition of transient receptor potential A1 ion channels | 伊莱利利公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-111643512-A | Niacinetoside or nicotinamide riboside compositions, reduced derivatives thereof and uses thereof | 可劳迈戴斯有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200283372-A1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | Acuitas Therapeutics, Inc. (CA) | 2020-09-10 | — | — | US | disclosed |
| EP-3270951-B1 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INST OF TECHN (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3003309-B1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3704117-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES FOR TREATING OCULAR DISORDERS | ALCON INC. (CH) | 2020-09-09 | — | — | EP | disclosed |
| EP-3705480-A1 | CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | Rudong Ringene Pharmaceuticals, Co. Ltd (CN) | 2020-09-09 | — | — | EP | disclosed |
| US-10770197-B2 | Polymer-silica hybrid Pdots and methods of use thereof | UNIVERSITY OF WASHINGTON (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766903-B2 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | ALMAC DISCOVERY LIMITED (GB) | 2020-09-08 | — | — | US | disclosed |
| US-10766865-B2 | PKM2 modulators and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766902-B2 | Wee-1 inhibiting pyrazolopyrimidinone compounds | ALMAC DISCOVERY LIMITED (GB) | 2020-09-08 | — | — | US | disclosed |
| CN-106660982-B | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-09-08 | — | — | CN | disclosed |
| CN-107722036-B | Thiophene derivatives | 天津合美医药科技有限公司 | 2020-09-04 | — | — | CN | disclosed |
| US-20200277251-A1 | NOVEL ANTIBACTERIAL COMPOUNDS AND METHODS OF MAKING AND USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
| US-20200276211-A1 | COMPOUNDS FOR TREATING NEAR VISION DISORDERS | VIEWPOINT THERAPEUTICS INC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-09-03 | — | — | US | disclosed |
| US-20200275660-A1 | TETRAZOLYLPROPYL DERIVATIVES AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-09-03 | — | — | US | disclosed |
| US-10759806-B2 | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | Cassava Science, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| CN-111592541-A | Macrocyclic kinase inhibitors and uses thereof | 山东轩竹医药科技有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-111592525-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-111592534-A | Novel compounds | 特殊治疗有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-111601601-A | Selective P2X3 modulators | 贝卢斯医疗咳嗽病公司 | 2020-08-28 | — | — | CN | disclosed |
| US-20200271427-A1 | LEUCO DYE SHOOTING TARGETS | JL DARLING LLC | 2020-08-27 | — | — | US | disclosed |
| US-20200270272-A1 | PURIFICATION OF RAPAMYCIN DERIVATIVES USING TEMPERATURE INDUCED PHASE SEPARATION | JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC. D/B/A JOHNSON MATTHEY PHARMA SERVICES | 2020-08-27 | — | — | US | disclosed |
| US-20200270227-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-08-27 | — | — | US | disclosed |
| US-20200268741-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| EP-3699184-A1 | TRIPTOLIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | Cinkate Pharmaceutical Intermediates Co., Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| EP-3054956-B1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS INC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3097092-B1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2020-08-26 | — | — | EP | disclosed |
| CN-107438613-B | Compounds and methods for preventing or treating sensory hair cell death | 华盛顿大学 | 2020-08-25 | — | — | CN | disclosed |
| US-10752628-B2 | Compounds and methods for treating synovial sarcomas | THE BROAD INSTITUTE, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752625-B2 | Method of making tetrahydronaphthyridinyl nonanoic acid compounds | SCIFLUOR LIFE SCIENCES, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10751344-B2 | Carbon monoxide-releasing molecules for therapeutic applications and methods for the preparation and use thereof | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752927-B2 | Method for the synthesis of tryptophan analogs in aqueous solvents at reduced temperatures | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-10752594-B2 | JAK1 and ALK2 inhibitors and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| CN-111587256-A | Catalyst system and polymerization process using the same | 埃克森美孚化学专利公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-111557942-A | Treatment of fatty liver disease using glucocorticoid and mineralocorticoid receptor antagonists | 科赛普特治疗学股份有限公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-111566104-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20200262838-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| US-20200261590-A1 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20200262834-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200262905-A1 | DUAL PDGF/VEGF ANTAGONISTS | KODIAK SCIENCES INC. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3377060-B1 | PYRAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3197870-B1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-107106562-B | Treatment of fatty liver disease using glucocorticoid and mineralocorticoid receptor antagonists | 科赛普特治疗学股份有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111548313-A | Guanidine compounds as medicine for preventing and treating chronic pain | 绍兴从零医药科技有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-10744139-B2 | Inhibitors of fibroblast growth factor receptor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-08-18 | — | — | US | disclosed |
| US-10745673-B2 | Heme protein catalysts for carbon-boron bond formation in vitro and in vivo | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745392-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-08-18 | — | — | US | disclosed |
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-18 | — | — | US | disclosed |
| US-10745385-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2020-08-18 | — | — | US | disclosed |
| CN-108084125-B | Benzoheterocyclylalkylamines and their use | 华东理工大学 | 2020-08-18 | — | — | CN | disclosed |
| CN-111542318-A | ASH1L degradants and methods of treatment therewith | 密歇根大学董事会 | 2020-08-14 | — | — | CN | disclosed |
| CN-111542324-A | Cytotoxic agents and conjugates thereof, methods of making and uses thereof | 四川科伦博泰生物医药股份有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-111542315-A | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2020-08-14 | — | — | CN | disclosed |
| US-20200255413-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200255434-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200255427-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2020-08-13 | — | — | US | disclosed |
| US-20200255371-A1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE | IMMUNEBRIDGE LLC | 2020-08-13 | — | — | US | disclosed |
| US-20200253954-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-08-13 | — | — | US | disclosed |
| WO-2020160626-A1 | CAPTURE OF FLUORINATED CARBON COMPOUNDS | THE UNIVERSITY OF QUEENSLAND (AU) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163334-A1 | CURABLE FORMULATION WITH HIGH REFRACTIVE INDEX AND ITS APPLICATION IN SURFACE RELIEF GRATING USING NANOIMPRINTING LITHOGRAPHY | FACEBOOK TECHNOLOGIES, LLC (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-3691642-A1 | NEW [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3692020-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3691623-A1 | BENZOSULFONYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3527573-B1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | ARAXES PHARMA LLC (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738297-B2 | 3D printable hydrogel materials | UNIVERSITY OF WASHINGTON (US) | 2020-08-11 | — | — | US | disclosed |
| CN-106188175-B | Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds | 轩竹(北京)医药科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-104411831-B | Boronic acid conjugates of oligonucleotide analogs | 萨勒普塔医疗公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111526877-A | Compounds and compositions for IRE1 inhibition | 奥普提卡拉公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111518100-A | Cyclopropenoarylbenzofuran substituted nitrogen heteroaryl compound and application thereof | 上海青煜医药科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111527090-A | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | 拜耳公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-107207735-B | Organosilica material | 埃克森美孚研究工程公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-111511781-A | Catalyst system and polymerization process using the same | 埃克森美孚化学专利公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-111511465-A | Method for producing organosilica materials and uses thereof | 埃克森美孚研究工程公司 | 2020-08-07 | — | — | CN | disclosed |
| WO-2020154775-A1 | QUANTUM DOTS AND PROCESSES FOR PREPARATION THEREOF | THE UNIVERSITY OF QUEENSLAND (AU) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157199-A1 | ANNULATED DIHYDROPYRIDAZINONE COMPOUNDS AS ANTI-CANCER COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157236-A1 | PYRIDYL SUBSTITUTED DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157201-A1 | OXADIAZINONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157194-A1 | 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157189-A1 | 1,2,4-TRIAZIN-6(1H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| US-20200247816-A1 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | NAVIRE PHARMA, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20200246474-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2020-08-06 | — | — | US | disclosed |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200247756-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | Ferro Therapeutics, Inc. | 2020-08-06 | — | — | US | disclosed |
| US-20200249568-A1 | CURABLE FORMULATION WITH HIGH REFRACTIVE INDEX AND ITS APPLICATION IN SURFACE RELIEF GRATING USING NANOIMPRINTING LITHOGRAPHY | META PLATFORMS TECHNOLOGIES, LLC | 2020-08-06 | — | — | US | disclosed |
| US-20200247783-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | US | disclosed |
| US-20200247803-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| EP-3689876-A1 | PDE9 INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| EP-3687972-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | Medicon Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3041513-B1 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10730867-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730825-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of The Commonwealth Systems Of Higher Education (US) | 2020-08-04 | — | — | US | disclosed |
| US-10729680-B2 | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-04 | — | — | US | disclosed |
| US-10730994-B2 | Synthesis of polycarbonate siloxane diols | AORTECH INTERNATIONAL PLC (GB) | 2020-08-04 | — | — | US | disclosed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | disclosed |
| CN-111491634-A | Organic phosphate derivatives | 詹纽瑞治疗公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-106488910-B | Inhibitors of KRAS G12C | 亚瑞克西斯制药公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-111471059-A | PDE9 inhibitors and uses thereof | 南京药捷安康生物科技有限公司 | 2020-07-31 | — | — | CN | disclosed |
| WO-2020154683-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20200239632-A1 | NOVEL PEPTOID POLYMERS AND METHODS OF USE | X-THERMA, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| EP-2970341-B1 | POLYHEDRAL OLIGOMERIC SILSESQUIOXANE NANOCRYSTAL STABILIZATION LIGANDS | NANOSYS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | disclosed |
| EP-3328384-B1 | FIBROTIC TREATMENT | UNIV MONASH (AU) | 2020-07-29 | — | — | EP | disclosed |
| EP-3684368-A2 | SELECTIVE P2X3 MODULATORS | Bellus Health Cough Inc. (CA) | 2020-07-29 | — | — | EP | disclosed |
| EP-3684353-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | Inmed Pharmaceuticals Inc. (CA) | 2020-07-29 | — | — | EP | disclosed |
| US-10723759-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723725-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-07-28 | — | — | US | disclosed |
| US-10723738-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723844-B2 | Polyurethane/urea compositions | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2020-07-28 | — | — | US | disclosed |
| CN-111454165-A | Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2020-07-28 | — | — | CN | disclosed |
| CN-111465626-A | Polyethylene compositions and films made therefrom | 埃克森美孚化学专利公司 | 2020-07-28 | — | — | CN | disclosed |
| CN-111448299-A | Odorants and compositions comprising odorants | 丝趣科尔卡有限公司 | 2020-07-24 | — | — | CN | disclosed |
| CN-111448226-A | Polymerization process | 埃克森美孚化学专利公司 | 2020-07-24 | — | — | CN | disclosed |
| CN-111447939-A | Method for preparing conjugate | 四川科伦博泰生物医药股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| CN-111448223-A | Polyethylene compositions and articles made therefrom | 埃克森美孚化学专利公司 | 2020-07-24 | — | — | CN | disclosed |
| WO-2020150366-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150265-A1 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | EMPIRICO INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200231549-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200230148-A1 | SELECTIVE P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| US-20200235415-A1 | MEMBRANE ELECTRODE ASSEMBLY WITH FLUORO ALKYL COMPOUND ADDITIVE | BALLARD POWER SYSTEMS (CA) | 2020-07-23 | — | — | US | disclosed |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| EP-3417851-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3209646-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-10717929-B2 | Ionic liquid flame retardants | IONIC FLAME RETARDANT INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717798-B2 | Polymeric composition | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-07-21 | — | — | US | disclosed |
| US-10717742-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-07-21 | — | — | US | disclosed |
| US-10716959-B2 | Polymer-flavonoid conjugates and hydrogels for biomedical applications | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-07-21 | — | — | US | disclosed |
| CN-111433336-A | Odorants and compositions comprising odorants | 丝趣科尔卡有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-20200222304-A1 | Skin Care Compositions and Methods of Use Thereof | UNIGEN, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2020-07-16 | — | — | US | disclosed |
| WO-2020146805-A1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | Acuitas Therapeutics, Inc. (CA) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020143626-A1 | PDE9 INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2020-07-16 | — | — | WO | disclosed |
| US-20200223866-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200223853-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, LLC | 2020-07-16 | — | — | US | disclosed |
| EP-2536485-B1 | A SUBSTRATE FOR IMMOBILIZING FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME | TEMASEK POLYTECHNIC (SG) | 2020-07-15 | — | — | EP | disclosed |
| EP-3680240-A1 | ASYMMETRIC PHASE TRANSFER CATALYSIS | MERCK SHARP & DOHME CORP. (US) | 2020-07-15 | — | — | EP | disclosed |
| CN-111407750-A | Methods for treating brain cancer | 有联生技股份有限公司 | 2020-07-14 | — | — | CN | disclosed |
| US-10710981-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| CN-111410659-A | PDE9 inhibitors and uses thereof | 南京药捷安康生物科技有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-111407751-A | Methods for treating inflammatory disorders | 有联生技股份有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-111407749-A | Methods for treating neurodegenerative disorders | 有联生技股份有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-106604746-B | Fatty acid synthetase inhibitors for the treatment of drug resistant cancers | 3-V生物科学股份有限公司 | 2020-07-10 | — | — | CN | disclosed |
| CN-107872956-B | Synergistic antifungal composition containing benzoxaborole | 宾夕法尼亚州研究基金会 | 2020-07-10 | — | — | CN | disclosed |
| US-20200214999-A1 | Method for Treating an Inflammatory Disorder | ALLIANZ PHARMASCIENCE LTD. | 2020-07-09 | — | — | US | disclosed |
| US-20200214998-A1 | Method for Treating a Brain Cancer | ALLIANZ PHARMASCIENCE LTD. (TW) | 2020-07-09 | — | — | US | disclosed |
| US-20200215062-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200215064-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | BERGENBIO ASA (NO) | 2020-07-09 | — | — | US | disclosed |
| WO-2020142557-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, LLC (US) | 2020-07-09 | — | — | WO | disclosed |
| WO-2020142559-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, LLC (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20200216389-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-07-09 | — | — | US | disclosed |
| US-20200216401-A1 | NOVEL SYRINGOLIN ANALOGUES AND METHODS OF MAKING AND USING SAME | UNIV BROWN (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200215035-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-07-09 | — | — | US | disclosed |
| US-20200214997-A1 | Method for Treating a Neurodegenerative Disorder | Annji Pharmaceutical Co., Ltd. (TW) | 2020-07-09 | — | — | US | disclosed |
| US-20200216420-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| EP-3677257-A1 | METHOD FOR TREATING AN INFLAMMATORY DISORDER WITH A SUBSTITUTED PHENYL-PROPENAL MOIETY | Allianz Pharmascience Ltd (TW) | 2020-07-08 | — | — | EP | disclosed |
| EP-3677256-A1 | METHOD FOR TREATING A NEURODEGENERATIVE DISORDER WITH A SUBSTITUTED PHENYL-PROPENAL MOITEY | Allianz Pharmascience Ltd (TW) | 2020-07-08 | — | — | EP | disclosed |
| EP-3675847-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Lundbeck La Jolla Research Center, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3677255-A1 | METHOD FOR TREATING A BRAIN CANCER WITH A SUBSTITUTED PHENYL-PROPENAL MOIETY | Allianz Pharmascience Ltd (TW) | 2020-07-08 | — | — | EP | disclosed |
| EP-3675868-A1 | TESTOSTERONE ESTER TRIGLYCERIDE FORMULATIONS | Antares Pharma, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3675848-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Lundbeck La Jolla Research Center, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3675858-A2 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | Optikira LLC (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3074390-B1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2020-07-08 | — | — | EP | disclosed |
| US-10702608-B2 | Factor VIII zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2020-07-07 | — | — | US | disclosed |
| CN-106795191-B | Novel precatalyst scaffolds for crosslinking reactions and methods of making and using same | 耶鲁大学 | 2020-07-03 | — | — | CN | disclosed |
| WO-2020139748-A1 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASES THAT TARGET RIPK2 | CEDARS-SINAI MEDICAL CENTER (US) | 2020-07-02 | — | — | WO | disclosed |
| US-20200207780-A1 | NOVEL COMPOUNDS AND USES | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2020-07-02 | — | — | US | disclosed |
| US-20200206292-A1 | Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination Thereof | UNIGEN, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207803-A1 | CYCLATIVE RELEASE OF PEPTIDIC COMPOUNDS | CIRCLE PHARMA, INC. | 2020-07-02 | — | — | US | disclosed |
| WO-2020139807-A2 | NANOCAPSULES FOR THE DELIVERY OF CELL MODULATING AGENTS | CSL BEHRING L.L.C. (US) | 2020-07-02 | — | — | WO | disclosed |
| EP-3408258-B1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE DEUTSCHLAND (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-10696698-B2 | Surface primer compositions and methods of use | ORMCO CORPORATION | 2020-06-30 | — | — | US | disclosed |
| US-10694739-B2 | Compositions and methods for reducing ice crystal formation | X-THERMA, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696635-B2 | Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-30 | — | — | US | disclosed |
| CN-111356705-A | Polymerization process | 埃克森美孚化学专利公司 | 2020-06-30 | — | — | CN | disclosed |
| CN-111356706-A | Polymerization process | 埃克森美孚化学专利公司 | 2020-06-30 | — | — | CN | disclosed |
| CN-111349128-A | Flavonol derivative and preparation method and application thereof | 上海医药工业研究院 | 2020-06-30 | — | — | CN | disclosed |
| CN-111344316-A | Polyethylene compositions and articles made therefrom | 埃克森美孚化学专利公司 | 2020-06-26 | — | — | CN | disclosed |
| WO-2020127780-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127974-A1 | 1,3,4-OXADIAZOLES AND THEIR DERIVATIVES AS NEW ANTIFUNGAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132072-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CYCLIC ORGANOSILICON CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132057-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200203711-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-20200203764-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CYCLIC ORGANOSILICON CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-20200197390-A1 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | BELITE BIO, INC (KY) | 2020-06-25 | — | — | US | disclosed |
| US-20200199171-A1 | NOVEL STEROIDS AND METHODS OF MANUFACTURE | TRUSTEES OF DARTMOUTH COLLEGE | 2020-06-25 | — | — | US | disclosed |
| US-20200199087-A1 | BIO-BASED, MULTI-AROMATIC COMPOUNDS, AND METHODS OF MAKING AND USING SAME | ROWAN UNIVERSITY | 2020-06-25 | — | — | US | disclosed |
| US-20200199126-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-25 | — | — | US | disclosed |
| WO-2020126746-A1 | SUBSTITUTED PYRIDINYLOXYBENZENES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| EP-3668833-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668843-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668840-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668601-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668842-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668599-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668862-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668861-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3670505-A1 | SUBSTITUTED PYRIDINYLOXYBENZENES, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer AG (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-10689407-B2 | Photo-cleavable primer compositions and methods of use | ENVISTA (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689399-B2 | Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10687531-B2 | Urea and thiourea substituted bicycles derivatives as pesticides | SYNGENTA PARTICIPATIONS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-10689381-B2 | Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689411-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2020-06-23 | — | — | US | disclosed |
| US-10689356-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| CN-111315733-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-06-19 | — | — | CN | disclosed |
| CN-106659914-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2020-06-19 | — | — | CN | disclosed |
| CN-111303152-A | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | 吉利德科学公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2020123674-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-06-18 | — | — | WO | disclosed |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188536-A1 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2020-06-18 | — | — | US | disclosed |
| WO-2020123847-A1 | ORGANIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-18 | — | — | US | disclosed |
| US-20200188336-A1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA INC. | 2020-06-18 | — | — | US | disclosed |
| EP-3209660-B1 | 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2020-06-17 | — | — | EP | disclosed |
| EP-2825536-B1 | BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS | MERCK SHARP & DOHME (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3230325-B1 | METHODS OF SEPARATING AROMATIC COMPOUNDS FROM LUBE BASE STOCKES | EXXONMOBIL RES & ENG CO (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-2989089-B1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF - III | MERCK SHARP & DOHME (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| US-10683324-B2 | 7-dehydrocholesterol derivatives and methods using same | UNIVERSITY OF ROCHESTER (US) | 2020-06-16 | — | — | US | disclosed |
| CN-111282598-A | Novel precatalyst scaffolds for crosslinking reactions and methods of making and using same | 耶鲁大学 | 2020-06-16 | — | — | CN | disclosed |
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| CN-111295389-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| CN-111278872-A | Polyethylene compositions and articles made therefrom | 埃克森美孚化学专利公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2020118194-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117945-A1 | SYNTHETIC DERIVATIVES OF CHOLIC ACID 7-SULFATE AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117938-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117755-A1 | COMPOSITIONS AND METHODS FOR TREATING BIOFILMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20200181131-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200181317-A1 | Bisphenol A-Free Crosslinked Polymer Composition | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181117-A1 | SUBSTITUTED 3-HETEROARYLOXY-1H-PYRAZOLES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-06-11 | — | — | US | disclosed |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20200181123-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2020-06-11 | — | — | US | disclosed |
| EP-3661917-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | Bayer Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661925-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661505-A1 | BENZOTHIAZOLE AND RELATED COMPOUNDS | Spinogenix, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661560-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661513-A1 | ORGANOPHOSPHATE DERIVATIVES | January Therapeutics, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661517-A1 | DIHYDROOXADIAZINONES | Bayer Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | disclosed |
| US-10675286-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10675355-B2 | VAR2CSA-drug conjugates | VAR2 PHARMACEUTICALS APS (DK) | 2020-06-09 | — | — | US | disclosed |
| CN-111247147-A | Azabicyclo and diazepatriene derivatives useful for treating ocular disorders | 爱尔康公司 | 2020-06-05 | — | — | CN | disclosed |
| US-20200172506-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200170241-A1 | NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES | X-THERMA, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2020113071-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020112905-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20200172516-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200171179-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200172491-A1 | SUBSTITUTED 5-(HET-)ARYLPYRAZOLAMIDES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-06-04 | — | — | US | disclosed |
| WO-2020109391-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-04 | — | — | WO | disclosed |
| EP-3659591-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | Kodiak Sciences Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3658567-A1 | CYCLATIVE RELEASE OF PEPTIDIC COMPOUNDS | Circle Pharma, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-02 | — | — | US | disclosed |
| US-10668064-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| CN-106795096-B | Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2020-05-29 | — | — | CN | disclosed |
| CN-111212647-A | Dihydroxadiazinones | 拜耳股份有限公司 | 2020-05-29 | — | — | CN | disclosed |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200165224-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2020-05-28 | — | — | US | disclosed |
| US-20200165213-A1 | SUBSTITUTED 2,3-DIHYDRO-1H-INDENE ANALOGS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-05-28 | — | — | US | disclosed |
| EP-3204395-B1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3160956-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3655393-A1 | SUBSTITUTED 5-(HET-)ARYLPYRAZOLAMIDES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES | Bayer CropScience Aktiengesellschaft (DE) | 2020-05-27 | — | — | EP | disclosed |
| EP-3655402-A1 | SUBSTITUTED 3-HETEROARYLOXY-1H-PYRAZOLES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES | Bayer CropScience Aktiengesellschaft (DE) | 2020-05-27 | — | — | EP | disclosed |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-05-26 | — | — | US | disclosed |
| US-10661262-B2 | Aromatic hydrogenation catalysts and uses thereof | EXXONMOBIL RESEARCH & ENGINEERING COMPANY (US) | 2020-05-26 | — | — | US | disclosed |
| CN-111196816-A | Seven-membered ring compound and application thereof in preventing and treating diabetes and metabolic syndrome | 中国科学院上海药物研究所 | 2020-05-26 | — | — | CN | disclosed |
| WO-2020102707-A1 | COPPER NANOPARTICLE BASED CHEMOSELECTIVE REDUCTION | BROWN UNIVERSITY (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200158724-A1 | POLYMER DOT COMPOSITIONS AND RELATED METHODS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2020-05-21 | — | — | US | disclosed |
| US-20200155609-A1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING PTEN INHIBITORS | TRANSFUSION HEALTH LLC | 2020-05-21 | — | — | US | disclosed |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| US-20200157068-A1 | BENZOTHIAZOLE AND RELATED COMPOUNDS | SPINOGENIX, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200157077-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-21 | — | — | US | disclosed |
| EP-3652235-A1 | ELECTROCHROMIC POLYMER AND SYNTHESIS AND USES THEREOF | Furcifer Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3652111-A1 | ELECTROCHROMIC POLYMER THIN FILMS HAVING REDUCED SELF-BLEACHING BEHAVIOR AND ENHANCED CYCLING STABILITY | Furcifer Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-2797635-B1 | CHROMOPHORIC POLYMER DOTS WITH NARROW-BAND EMISSION | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10655012-B2 | Process for the preparation of polyurethane solutions based on silicon-polycarbonate diols | AORTECH INTERNATIONAL PLC (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10654830-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| CN-111171049-A | Tyrosine kinase inhibitors and uses thereof | 山东轩竹医药科技有限公司 | 2020-05-19 | — | — | CN | disclosed |
| US-10654810-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654852-B2 | Antibiotics and methods of using same | THE BROAD INSTITUTE, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| CN-111163773-A | Benzothiazoles and related compounds | 斯皮诺吉尼克斯公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-111153901-A | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | 如东凌达生物医药科技有限公司 | 2020-05-15 | — | — | CN | disclosed |
| US-20200148653-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-05-14 | — | — | US | disclosed |
| US-20200147119-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-05-14 | — | — | US | disclosed |
| US-20200147593-A1 | Cinchonium betaine catalysts and methods of using same | BRANDEIS UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200148610-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3649112-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2020-05-13 | — | — | EP | disclosed |
| CN-111138412-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2020-05-12 | — | — | CN | disclosed |
| US-10647798-B2 | Spray-dried olefin polymerization catalyst compositions and polymerization processes for using the same | EXXONMOBIL CHEMICAL PATENTS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647703-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-10646488-B2 | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-10646495-B2 | Testosterone ester triglyceride formulations | ANTARES PHARMA, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| CN-111132964-A | Glucocorticoid receptor modulators | 欧瑞克制药公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111132673-A | Non-fused tricyclic compounds | 维瓦斯治疗公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111132973-A | Substituted 3-heteroaryloxy-1H-pyrazoles and their salts and their use as herbicidal active substances | 拜耳作物科学股份公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111132974-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-20200144672-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH PHOSPHORUS CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-05-07 | — | — | US | disclosed |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-20200140487-A1 | PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS | REGENERON PHARMACEUTICALS, INC. | 2020-05-07 | — | — | US | disclosed |
| US-20200138828-A1 | Anti-thrombotic Agents and Methods of Use Thereof | UNIV TEMPLE (US) | 2020-05-07 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640498-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-05 | — | — | US | disclosed |
| CN-107033157-B | Bisbenzylisoquinoline derivative and application thereof in preparing medicament for treating or preventing tumor | 贵州省中国科学院天然产物化学重点实验室 | 2020-05-05 | — | — | CN | disclosed |
| CN-111107903-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-111087612-A | Phosphorus-containing flame-retardant nylon and preparation method and application thereof | 今创景新材料科技（上海）有限公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-111093773-A | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-111087796-A | Phosphorus-containing copolymerized nylon and preparation method and application thereof | 今创景新材料科技（上海）有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-20200131194-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | Sagabio Co., Ltd. (TW) | 2020-04-30 | — | — | US | disclosed |
| US-20200131474-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200131170-A1 | Compounds for Pain Treatment, Compositions Comprising Same, and Methods of Using Same | CERSCI THERAPEUTICS, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200131154-A1 | PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | ARRIEN PHARMACEUTICALS LLC | 2020-04-30 | — | — | US | disclosed |
| US-20200136185-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH PHOSPHAZENE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-20200131119-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIVERSITY OF TASMANIA (AU) | 2020-04-30 | — | — | US | disclosed |
| US-20200131304-A1 | MULTICOLORED ELECTROCHROMIC POLYMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Furcifer Inc. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20200131173-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | NEUROCRINE BIOSCIENCES, INC. | 2020-04-30 | — | — | US | disclosed |
| EP-3641760-A1 | NOVEL ANTIBACTERIAL COMPOUNDS AND METHODS OF MAKING AND USING SAME | Brown University (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3641741-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | University of Maryland, Baltimore (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3383859-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-04-29 | — | — | EP | disclosed |
| US-10632209-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-28 | — | — | US | disclosed |
| CN-111057048-A | Aminopyrazine/pyridine compound, preparation method and application | 如东凌达生物医药科技有限公司 | 2020-04-24 | — | — | CN | disclosed |
| WO-2020081583-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR PEPTIDE ANTAGONIST CONOTOXIN COMPOSITIONS AND RELATED METHODS | Glo Pharma, LLC (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020078933-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND/OR SMARCA4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020078788-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081938-A1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | Acuitas Therapeutics, Inc. (CA) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| US-20200121678-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-23 | — | — | US | disclosed |
| US-20200123313-A1 | ELECTROCHROMIC POLYMER AND SYNTHESIS AND USES THEREOF | Furcifer Inc. (US) | 2020-04-23 | — | — | US | disclosed |
| US-20200121809-A1 | LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2020-04-23 | — | — | US | disclosed |
| EP-3640241-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-2844636-B1 | METHODS FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY | ACUCELA INC (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3638239-A1 | METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES | Belite Bio, Inc (KY) | 2020-04-22 | — | — | EP | disclosed |
| EP-3638238-A1 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | Belite Bio, Inc (KY) | 2020-04-22 | — | — | EP | disclosed |
| CN-111050765-A | Spiro compounds and methods of making and using the same | 隆德贝克拉荷亚研究中心有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10626104-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626103-B2 | Inhibitor of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| CN-111032034-A | Spiro compounds and methods of making and using the same | 隆德贝克拉荷亚研究中心有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
| US-20200113905-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115384-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2020-04-16 | — | — | US | disclosed |
| US-20200115414-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR PEPTIDE ANTAGONIST CONOTOXIN COMPOSITIONS AND RELATED METHODS | GLO PHARMA, INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115363-A1 | QUINAZOLINE DERIVATIVES AS MODULATORS OF MUTANT KRAS, HRAS OR NRAS | ARAXES PHARMA LLC | 2020-04-16 | — | — | US | disclosed |
| EP-3033335-B1 | PYRIDINONES | BOEHRINGER INGELHEIM INT (DE) | 2020-04-15 | — | — | EP | disclosed |
| EP-3634404-A1 | PYRAZOLE MAGL INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636639-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-111000898-A | Compositions and methods for joint health | 尤妮金公司 | 2020-04-14 | — | — | CN | disclosed |
| US-10617680-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| WO-2020070050-A1 | FUNGICIDAL 5-SUBSTITUTED IMIDAZOL-1-YL CARBINOL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-09 | — | — | WO | disclosed |
| US-20200108052-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200108070-A2 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-04-09 | — | — | US | disclosed |
| WO-2020072602-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200109287-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES AND METHODS FOR THEIR USE | Sony Group Corporation (JP) | 2020-04-09 | — | — | US | disclosed |
| US-20200109120-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-04-09 | — | — | US | disclosed |
| EP-3630746-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3630956-A1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING PTEN INHIBITORS | Transfusion Health, LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3630744-A1 | PYRAZOLE MAGL INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3252038-B1 | N-BENZOATE GROUP SUBSTITUTED BENZOPYRROLINE-2-ONE DERIVATIVE AND USE THEREOF | BEIJING HANMI PHARMACEUTICAL CO LTD (CN) | 2020-04-08 | — | — | EP | disclosed |
| EP-3630782-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3630783-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3630747-A1 | QUINAZOLINE DERIVATIVES AS MODULATORS OF MUTANT KRAS, HRAS OR NRAS | Araxes Pharma LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3630745-A2 | COVALENT INHIBITORS OF KRAS | Araxes Pharma LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10610857-B2 | Cinchonium betaine catalysts and methods of using same | BRANDEIS UNIVERSITY (US) | 2020-04-07 | — | — | US | disclosed |
| US-10611775-B2 | Thiophene derivatives | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2020-04-07 | — | — | US | disclosed |
| US-10611723-B2 | Ligand-enabled meta-C-H activation using a transient mediator | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-04-07 | — | — | US | disclosed |
| US-10611763-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10612056-B2 | Beta-substituted non-canonical amino acids | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-04-07 | — | — | US | disclosed |
| CN-110964012-A | Fused heterocyclic biaryl benzyl alcohol compound, preparation method and application | 如东凌达生物医药科技有限公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-110950876-A | Furanolactam compounds, preparation method and application | 如东凌达生物医药科技有限公司 | 2020-04-03 | — | — | CN | disclosed |
| CN-110950842-A | Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2020-04-03 | — | — | CN | disclosed |
| CN-110959008-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2020-04-03 | — | — | CN | disclosed |
| WO-2020061617-A1 | OPTICAL DATA STORAGE MATERIAL AND METHOD | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020063727-A1 | TRICYCLIC RING ASK1 INHIBITORS AND USE THEREOF | 山东轩竹医药科技有限公司 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020063976-A1 | FUSED HETEROCYCLIC BIARYL BENZYL ALCOHOL COMPOUND, PREPARATION METHOD, AND USE | 如东凌达生物医药科技有限公司 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020063618-A1 | QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY | 深圳微芯生物科技股份有限公司 | 2020-04-02 | — | — | WO | disclosed |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| WO-2020064260-A1 | SUBSTITUTED 5-(SULFANYL)-3,4-DIHYDRO-2H-PYRROL-4-CARBOXAMIDES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-02 | — | — | WO | disclosed |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| EP-3057617-B1 | NANOPARTICLE-CONTAINING HYDROGELS | AGENCY SCIENCE TECH & RES (SG) | 2020-04-01 | — | — | EP | disclosed |
| US-10603270-B2 | Skin care compositions and methods of use thereof | UNIGEN, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| CN-107674086-B | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | 吉利德科学公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-105742702-B | Rechargeable lithium battery | 三星SDI株式会社 | 2020-03-31 | — | — | CN | disclosed |
| CN-110945697-A | Membrane electrode assembly with fluorocarbon additives | 百拉得动力系统公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-110945005-A | Modified oligomeric compounds comprising tricyclic DNA nucleosides and uses thereof | 新特纳股份公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-110945001-A | FMS-like tyrosine kinase inhibitors | 三日月生技股份有限公司 | 2020-03-31 | — | — | CN | disclosed |
| US-20200093936-A1 | Therapeutic Targeting of Lipid Nanoparticles | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-03-26 | — | — | US | disclosed |
| US-20200095272-A1 | PRODRUGS OF CLOFARABINE | BoYen Therapeutics, Inc. (TW) | 2020-03-26 | — | — | US | disclosed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| WO-2020061216-A1 | COMBINATION THERAPY FOR TREATING BLOOD CANCER | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-03-26 | — | — | WO | disclosed |
| US-20200095236-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. | 2020-03-26 | — | — | US | disclosed |
| WO-2020061375-A1 | ANTIBACTERIAL COMPOUNDS | FORGE THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020060937-A1 | NARROW ABSORPTION POLYMER NANOPARTICLES AND RELATED METHODS | UNIVERSITY OF WASHINGTON (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020060873-A2 | MOF COMPOSITIONS FOR SELECTIVE SEPARATION OF HYDROCARBONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061426-A2 | SYSTEMS AND METHODS FOR MANUFACTURING LIPID NANOPARTICLES AND LIPOSOMES | Acuitas Therapeutics, Inc. (CA) | 2020-03-26 | — | — | WO | disclosed |
| US-20200095241-A1 | SUBSTITUTED 1,2,4-THIADIAZOLYLPYRROLONES AND 1,2,4-THIADIAZOLYLHYDANTOINS AND SALTS THEREOF AND USE THEREOF AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-03-26 | — | — | US | disclosed |
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3625200-A1 | BIO-BASED, MULTI-AROMATIC COMPOUNDS, AND METHODS OF MAKING AND USING SAME | Rowan University (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-110903275-A | Process for producing iobitridol, intermediate therefor, and process for producing the same | 苏州科伦药物研究有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-10597425-B2 | Anti-GP41 antibody-specific capture agents, compositions, and methods of using and making | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597368-B2 | Syringolin analogues and methods of making and using same | BROWN UNIVERSITY (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597406-B2 | Purification of rapamycin derivatives using temperature induced phase separation | BIOSENSORS INTERNATIONAL GROUP, LTD. (BM) | 2020-03-24 | — | — | US | disclosed |
| CN-110914256-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-110913858-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2020-03-24 | — | — | CN | disclosed |
| US-10597366-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597376-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597379-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597365-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| CN-107082782-B | Substituted xanthines and methods of use thereof | 海德拉生物科学有限责任公司 | 2020-03-20 | — | — | CN | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| US-20200085823-A1 | METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-03-19 | — | — | US | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
| EP-3621461-A1 | METHODS AND ENZYME CATALYSTS FOR THE SYNTHESIS OF NON-CANONICAL AMINO ACIDS | California Institute of Technology (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3197883-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| EP-3621961-A2 | ANTIBACTERIAL COMPOUNDS | Forge Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3621962-A2 | ANTIBACTERIAL COMPOUNDS | Forge Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10590075-B2 | Cyanopyrrolidine derivatives as inhibitors for DUBs | MISSION THERAPEUTICS LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| CN-107001339-B | Novel compounds | 特殊治疗有限公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-110892001-A | Electrochromic polymers and their synthesis and use | 菲尔齐费尔公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-110891941-A | Substituted 5- (hetero) arylpyrazolamides and their salts and their use as herbicidally active substances | 拜耳作物科学股份公司 | 2020-03-17 | — | — | CN | disclosed |
| US-10588907-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| CN-110878052-A | FXR agonist-containing compound and preparation method and application thereof | 山东大学 | 2020-03-13 | — | — | CN | disclosed |
| CN-110878048-A | Anilines as psychotropic disorders | 中国科学院上海药物研究所 | 2020-03-13 | — | — | CN | disclosed |
| US-20200081398-A1 | PHOTOSENSITIVE POLYMERS FOR VOLUME HOLOGRAPHY | META PLATFORMS TECHNOLOGIES, LLC | 2020-03-12 | — | — | US | disclosed |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2020-03-12 | — | — | US | disclosed |
| US-20200079765-A1 | SUBSTITUTED HETEROARYL PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-03-12 | — | — | US | disclosed |
| EP-3620053-A1 | FUNGICIDAL ACTIVE COMPOUND COMBINATIONS | Bayer Aktiengesellschaft (DE) | 2020-03-11 | — | — | EP | disclosed |
| EP-3618818-A1 | NON-FUSED TRICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-105828838-B | Hydrogel containing nanoparticles | 新加坡科技研究局 | 2020-03-10 | — | — | CN | disclosed |
| US-10583161-B2 | Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof | UNIGEN, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-10583137-B2 | Triazole DAGLα inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-03-10 | — | — | US | disclosed |
| CN-110869358-A | Covalent inhibitors of KRAS | 亚瑞克西斯制药公司 | 2020-03-06 | — | — | CN | disclosed |
| CN-110869357-A | Compounds and methods of use thereof for treating cancer | 亚瑞克西斯制药公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20200071436-A1 | Polymerization Processes and Polymers Made Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200069668-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| US-20200071437-A1 | Polymerization Processes and Polymers Made Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
| US-20200069796-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| US-20200071288-A1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | SHUTTLE PHARMACEUTICALS, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
| WO-2020047487-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS AND STATINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047323-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047312-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| EP-3013789-B1 | AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS | AUCKLAND UNISERVICES LTD (NZ) | 2020-03-04 | — | — | EP | disclosed |
| EP-2753613-B1 | DERIVATIVES OF XANTHONE COMPOUNDS | AGENCY SCIENCE TECH & RES (SG) | 2020-03-04 | — | — | EP | disclosed |
| EP-3617204-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615513-A1 | METHODS OF MANUFACTURING OF NIRAPARIB | Tesaro Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615502-A1 | THERAPEUTIC COMPOUNDS AND METHODS | University Of Tasmania (AU) | 2020-03-04 | — | — | EP | disclosed |
| EP-3617221-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME, AND PREPARATION METHOD THEREFOR | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615080-A1 | ANTIBODY CONJUGATES COMPRISING STING AGONIST | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615510-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615537-A2 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-10576144-B2 | Amino acid and peptide conjugates and conjugation process | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-03-03 | — | — | US | disclosed |
| US-10576453-B2 | Membrane fabrication methods using organosilica materials and uses thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577308-B2 | Sodium channel modulators | The Florey Institute (AU) | 2020-03-03 | — | — | US | disclosed |
| US-10576064-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-03 | — | — | US | disclosed |
| CN-110857300-A | Condensed ring triazole compounds, preparation method and application | 如东凌达生物医药科技有限公司 | 2020-03-03 | — | — | CN | disclosed |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2020-02-27 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2020038458-A1 | CLASS OF FUSED RING TRIAZOLE COMPOUND, PREPARATION METHOD, AND USE | 如东凌达生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041051-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041050-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | DREXEL UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
| EP-3612546-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | Synthena AG (CH) | 2020-02-26 | — | — | EP | disclosed |
| EP-3612522-A1 | THERAPEUTIC COMPOUNDS | Celgene Quanticel Research, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3612532-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | Neurocrine Biosciences, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3613743-A1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | Intellikine, LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10570106-B2 | MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110831933-A | Quinazoline derivatives as modulators of mutated KRAS, HRAS or NRAS | 亚瑞克西斯制药公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20200055892-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20200054764-A1 | MEDICAL USE OF ANTI-C MET ANTIBODY-CYTOTOXIC DRUG CONJUGATE | Suzhou Suncadia Biopharmaceuticals Co., Ltd. (CN) | 2020-02-20 | — | — | US | disclosed |
| US-20200055837-A1 | METHODS OF MANUFACTURING OF NIRAPARIB | TESARO, INC. | 2020-02-20 | — | — | US | disclosed |
| WO-2020035465-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035464-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035300-A1 | POLYMER COMPOSITION | BASF SE (DE) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035466-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
| EP-3610010-A2 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | Kodiak Sciences Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3609872-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Oric Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3254678-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3303285-B1 | PESTICIDALLY ACTIVE OXIME AND HYDRAZONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-02-19 | — | — | EP | disclosed |
| EP-3417852-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3150203-B1 | COMPOUNDS WITH (1E,6E)-1,7-BIS-(3,4- DIMETHOXYPHENYL)-4,4-DISSTITUTED-HEPA-1,6-DIENE-3,5-DI-ONE STRUCTURAL SCAFFOLD,THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | ALLIANZ PHARMASCIENCE LTD (TW) | 2020-02-19 | — | — | EP | disclosed |
| US-10562915-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562859-B2 | Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-02-18 | — | — | US | disclosed |
| US-10562882-B2 | Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-18 | — | — | US | disclosed |
| CN-110809560-A | Electrochromic polymer films with reduced self-bleaching behavior and enhanced cycling stability | 菲尔齐费尔公司 | 2020-02-18 | — | — | CN | disclosed |
| CN-110799492-A | Novel carbonyl lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2020-02-14 | — | — | CN | disclosed |
| CN-110799218-A | Antibody conjugates comprising STING agonists | 诺华股份有限公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20200046838-A1 | LIPIDS FOR DELIVERY OF ACTIVE AGENTS | Acuitas Therapeutics, Inc. (CA) | 2020-02-13 | — | — | US | disclosed |
| US-20200048243-A1 | CINCHONINE-DERIVED CATALYSTS AND METHODS OF USING SAME | BRANDEIS UNIVERSITY (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048228-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200048301-A1 | EPOXY-(METH)ACRYLATE MONOMERS AND POLYMERS AND METHODS OF MAKING AND USING THE SAME | ROWAN UNIVERSITY | 2020-02-13 | — | — | US | disclosed |
| US-20200047169-A1 | CATALYSTS FOR OLEFIN ISOMERIZATION | BRANDEIS UNIVERSITY (US) | 2020-02-13 | — | — | US | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033823-A1 | SMALL-MOLECULE PI5P4K ALPHA/BETA INHIBITORS AND METHODS OF TREATMENT USING SAME | YALE UNIVERSITY (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-3606743-A1 | COATING FOR RECYCLABLE PAPER | JL Darling LLC (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3608325-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3094687-B1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES | SONY CORP (JP) | 2020-02-12 | — | — | EP | disclosed |
| CN-107207524-B | Bisbenzylisoquinoline derivatives, preparation method thereof and application thereof in treatment and prevention of liver diseases | 贵州省中国科学院天然产物化学重点实验室 | 2020-02-07 | — | — | CN | disclosed |
| CN-107072985-B | Therapeutic inhibiting compounds | 莱福斯希医药公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-110770236-A | VMAT2 inhibitor compounds and compositions thereof | 纽罗克里生物科学有限公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-110769689-A | Novel supercooling method for preserving biological samples | 先时迈纳米生物科技股份有限公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2020028706-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20200038475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200039963-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
| US-20200039941-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH | 2020-02-06 | — | — | US | disclosed |
| EP-3601267-A1 | 2-METHYL-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| EP-3601307-A1 | CROSS-COUPLING REACTION CATALYSTS, AND METHODS OF MAKING AND USING SAME | Yale University (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3600273-A1 | CD73 INHIBITORS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3604271-A1 | PEPTIDES FOR AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS | Auckland Uniservices Limited (NZ) | 2020-02-05 | — | — | EP | disclosed |
| EP-3601216-A1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2020-02-05 | — | — | EP | disclosed |
| EP-3600451-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | Minerva Biotechnologies Corporation (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3236940-B1 | COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX INC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10548896-B2 | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550122-B2 | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550221-B2 | Electrochromic polymer and synthesis and uses thereof | Furcifer Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-02-04 | — | — | US | disclosed |
| US-10548913-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| CN-110753684-A | Method for producing nilapali | 特沙诺有限公司 | 2020-02-04 | — | — | CN | disclosed |
| CN-110734436-A | Pyrimidine or pyrazine ring compounds and application thereof | 上海青煜医药科技有限公司 | 2020-01-31 | — | — | CN | disclosed |
| WO-2019014370-A9 | ELECTROCHROMIC POLYMER AND SYNTHESIS AND USES THEREOF | Furcifer Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200030309-A1 | COMPOUNDS FOR INCREASING NEURAL PLASTICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-01-30 | — | — | US | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031840-A1 | SPIROPIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| WO-2020023710-A1 | SUBSTITUTED TETRAHYDROCYCLOPENTA[C]PYRROLES, SUBSTITUTED DIHYDROPYRROLIZINES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020020813-A1 | FUNGICIDAL ACTIVE COMPOUND COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020020816-A1 | NOVEL TRIAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | WO | disclosed |
| US-20200032055-A1 | PROCESS FOR THE PREPARATION OF POLYURETHANE SOLUTIONS BASED ON SILICONPOLYCARBONATE DIOLS | AORTECH INTERNATIONAL PLC (GB) | 2020-01-30 | — | — | US | disclosed |
| WO-2020023910-A1 | METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME | TOLERO PHARMACEUTICALS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| US-10544239-B2 | Organosilica materials and uses thereof | EXXONMOBILE RESEARCH AND ENGINEERING COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544154-B2 | Opioid receptor antagonist prodrugs | NIRSUM LABORATORIES, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10543198-B2 | Inhibitor of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10543213-B2 | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| US-10543207-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544257-B2 | Multicolored electrochromic polymer compositions and methods of making and using the same | Furcifer Inc. (US) | 2020-01-28 | — | — | US | disclosed |
| CN-110730786-A | Novel peptoid polymers and methods of use | 先时迈纳米生物科技股份有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-110723748-A | Metal oxides, metal bronzes and polyoxometallates as charge storage materials in electrochromic devices | 菲尔齐费尔公司 | 2020-01-24 | — | — | CN | disclosed |
| WO-2020018474-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR COLORING EDIBLE MATERIALS | ZIEGLER GREGORY RAY (US) | 2020-01-23 | — | — | WO | disclosed |
| CN-110709084-A | Dual MAGL and FAAH inhibitors | 阿比德治疗公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-106687457-B | Heteroaryl compounds for kinase inhibition | 阿里亚德医药股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-110678177-A | Pyrazole MAGL inhibitors | 隆德贝克拉荷亚研究中心有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-105452269-B | Compositions and methods for joint health | 尤妮金公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-110678456-A | Pyrazole MAGL inhibitors | 隆德贝克拉荷亚研究中心有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-105828820-B | Bromodomain inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-01-07 | — | — | CN | disclosed |
| CN-105916506-B | Quinazoline derivatives as inhibitors of TAM family kinases | 圣诺康生命科学公司 | 2020-01-07 | — | — | CN | disclosed |
| CN-110662753-A | Cross-coupling reaction catalysts and methods of making and using the same | 耶鲁大学 | 2020-01-07 | — | — | CN | disclosed |
| CN-110655520-A | Pyrimido-cyclic compounds, process for their preparation and their use | 上海青煜医药科技有限公司 | 2020-01-07 | — | — | CN | disclosed |
| CN-110662542-A | Efficient and scalable synthesis of nicotinyl nucleosides and reduced nicotinyl nucleosides, modified derivatives thereof, phosphorylated analogs thereof, adenosine dinucleotide conjugates thereof, and novel crystalline forms thereof | 英国贝尔法斯特女王大学 | 2020-01-07 | — | — | CN | disclosed |
| WO-2020002091-A1 | SUBSTITUTED THIAZOLYLPYRROLONES, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020002089-A1 | SUBSTITUTED 2-HETEROARYLOXYPYRIDINES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020002085-A1 | SUBSTITUTED 4-HETEROARYLOXYPYRIDINES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020002090-A1 | SUBSTITUTED THIAZOLYLPYRROLONES, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020002087-A1 | SUBSTITUTED 3-HETEROARYLOXYPYRIDINES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020002083-A1 | SUBSTITUTED HETEROCYCLIC PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| CN-110582480-A | Therapeutic compounds and methods | 塔斯马尼亚大学 | 2019-12-17 | — | — | CN | disclosed |
| CN-110563773-A | Planar chiral ferrocene compound, intermediate thereof, preparation method and application | 中国科学院上海有机化学研究所 | 2019-12-13 | — | — | CN | disclosed |
| CN-110573511-A | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2019-12-13 | — | — | CN | disclosed |
| CN-110563722-A | pyridine or pyridazine ring compound and application thereof | 上海青煜医药科技有限公司 | 2019-12-13 | — | — | CN | disclosed |
| CN-110551105-A | substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2019-12-10 | — | — | CN | disclosed |
| WO-2019227173-A1 | STABLE PROTEIN LIGANDS AS ANTI-INFECTIVE AGENTS | MONASH UNIVERSITY (AU) | 2019-12-05 | — | — | WO | disclosed |
| US-20190367499-A1 | Compounds for Pain Treatment, Compositions Comprising Same, and Methods of Using Same | ACADIA PHARMACEUTICALS INC. | 2019-12-05 | — | — | US | disclosed |
| CN-110498769-A | IDO inhibitor and application | NANJING TRANSTHERA BIOSCIENCES CO LTD | 2019-11-26 | — | — | CN | disclosed |
| US-RE47741-E1 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| WO-2019218027-A1 | CORE-SHELL PARTICLES | MONASH UNIVERSITY (AU) | 2019-11-21 | — | — | WO | disclosed |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2019-11-21 | — | — | US | disclosed |
| US-20190352273-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2019-11-21 | — | — | US | disclosed |
| US-20190350910-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-11-21 | — | — | US | disclosed |
| US-20190350937-A1 | CARBON MONOXIDE-RELEASING MOLECULES FOR THERAPEUTIC APPLICATIONS AND METHODS FOR THE PREPARATION AND USE THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20190351066-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-11-21 | — | — | US | disclosed |
| EP-3043784-B9 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3322702-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2019-11-20 | — | — | EP | disclosed |
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | disclosed |
| US-20190345158-A1 | FUSED HETERO-HETERO BICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190343825-A1 | Method of Treating Immunoglobulin Light Chain Amyloidosis | Alterity Therapeutics Limited (AU) | 2019-11-14 | — | — | US | disclosed |
| US-20190345143-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2019-11-14 | — | — | US | disclosed |
| EP-3565811-A1 | INHIBITORS OF NHE-MEDIATED ANTIPORT | Ardelyx, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3565808-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3565549-A1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | Shuttle Pharmaceuticals, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10471027-B2 | Pharmacology of visual cycle modulators | ACUCELA, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472387-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472328-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| CN-110430877-A | Compositions and methods for treating androgen-independent cancer | UNIV CALIFORNIA | 2019-11-08 | — | — | CN | disclosed |
| US-20190336500-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
| US-20190337901-A1 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY, INC. | 2019-11-07 | — | — | US | disclosed |
| EP-3562893-A1 | MODIFICATION OF SURFACE PROPERTIES OF MICROFLUIDIC DEVICES | Bio-Rad Laboratories, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-2701505-B1 | FORMULATION COMPONENT | SYNGENTA LTD (GB) | 2019-11-06 | — | — | EP | disclosed |
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10465147-B2 | Copolymers | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-11-05 | — | — | US | disclosed |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20190330202-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190330261-A1 | LIGAND FOR ORPHAN NUCLEAR RECEPTOR NUR77 AND USES THEREOF | XIAMEN UNIVERSITY (CN) | 2019-10-31 | — | — | US | disclosed |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2019-10-31 | — | — | US | disclosed |
| US-20190330192-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-31 | — | — | US | disclosed |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-10-31 | — | — | US | disclosed |
| EP-3559058-A1 | SPRAY-DRIED OLEFIN POLYMERIZATION CATALYST COMPOSITIONS AND POLYMERIZATION PROCESSES FOR USING THE SAME | ExxonMobil Chemical Patents Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558976-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | Bayer CropScience Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3402795-B1 | 5-SUBSTITUTED 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558975-A1 | SUBSTITUTED HETEROARYL PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | Bayer CropScience Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558979-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558986-A1 | SUBSTITUTED 1,2,4-THIADIAZOLYL PYRROLONES AND 1,2,4-THIADIAZOLYL HYDANTOINES AND SALTS THEREOF AND USE THEREOF AS HERBICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3559120-A1 | AQUEOUS POLYMER COMPOSITION | Commonwealth Scientific and Industrial Research Organisation (AU) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558386-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| CN-110386921-A | Fibroblast growth factor acceptor inhibitor compound | 南京药捷安康生物科技有限公司 | 2019-10-29 | — | — | CN | disclosed |
| CN-110392571-A | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using the same | 梅比斯发现公司 | 2019-10-29 | — | — | CN | disclosed |
| US-10456395-B2 | Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190322684-A1 | THIOPHENE DERIVATIVES | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2019-10-24 | — | — | US | disclosed |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| WO-2019204364-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS BIOSCIENCES, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201255-A1 | ISOINDOLE DERIVATIVE | 天津合美医药科技有限公司 | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201848-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-24 | — | — | WO | disclosed |
| EP-2972349-B1 | POLYMER DOT COMPOSITIONS AND RELATED METHODS | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3555063-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2019-10-23 | — | — | EP | disclosed |
| EP-3554505-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| CN-110357888-A | Heterocycle phosphodiesterase inhibitors and application thereof | 南京药捷安康生物科技有限公司 | 2019-10-22 | — | — | CN | disclosed |
| US-20190314524-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2019-10-17 | — | — | US | disclosed |
| US-20190315710-A1 | Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-17 | — | — | US | disclosed |
| US-20190315798-A1 | WITHANOLIDES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | IMSTAR THERAPEUTICS INC (CA) | 2019-10-17 | — | — | US | disclosed |
| US-20190315703-A1 | BENZOHETEROCYCLIC ALKYLAMINE COMPOUNDS AND USE THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190314369-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | ACERTA PHARMA BV (NL) | 2019-10-17 | — | — | US | disclosed |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019200254-A1 | PIM KINASE INHIBITORS FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND FIBROSIS ASSOCIATED WITH CANCER | TOLERO PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019197371-A1 | OXADIAZOLINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | WO | disclosed |
| EP-3551628-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3551608-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3551611-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3551626-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-10-16 | — | — | EP | disclosed |
| EP-3551169-A1 | DELIVERY OF TARGET SPECIFIC NUCLEASES | Sangamo Therapeutics, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3552630-A1 | NHE3-BINDING COMPOUNDS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-2970543-B1 | ALKYL-ACID LIGANDS FOR NANOCRYSTALS | NANOSYS INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10444243-B2 | Encoded chromophoric polymer particles and methods of use thereof | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-15 | — | — | US | disclosed |
| CN-110325542-A | The pro-drug of clofarabine | 劳伦斯·I·吴 | 2019-10-11 | — | — | CN | disclosed |
| WO-2019192031-A1 | TRIPTOLIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 欣凯医药化工中间体（上海）有限公司 | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195751-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195753-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | TOLERO PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195692-A1 | HEXADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195135-A1 | SUBSTITUTED CHROMENONES, IRE1 INHIBITORS, AND METHODS OF USING SAME | THE WISTAR INSTITUTE (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308967-A1 | PROCESS FOR THE MANUFACTURE OF 6-ALKYNYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-10 | — | — | US | disclosed |
| US-20190307743-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308989-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308988-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-2739678-B1 | GLASS FILLED COPOLYMER PRODUCTS FOR THIN WALL AND HIGH SURFACE GLOSS ARTICLES | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2019-10-09 | — | — | EP | disclosed |
| EP-3169721-B1 | SILICONE LIGANDS FOR QUANTUM DOTS | NANOSYS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3549963-A2 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | Kodiak Sciences Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3549581-A2 | COMPOUNDS WITH (1E, 6E)-1,7-BIS-(3,4-DIMETHOXYPHENYL)-4,4-DISSTITUTED-HEPA-1,6-DIENE-3,5-DIONE STRUCTURAL SCAFFOLD, THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | Allianz Pharmascience Ltd (TW) | 2019-10-09 | — | — | EP | disclosed |
| US-10435563-B2 | Water soluble fluorescent or colored dyes and methods for their use | SONY CORPORATION (JP) | 2019-10-08 | — | — | US | disclosed |
| US-10435375-B2 | CXCR4 chemokine receptor modulators | NORTHWESTERN UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435514-B2 | Organosilica materials, methods of making, and uses thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| CN-110312730-A | Cytotoxin and conjugate, its Use and preparation method | 四川科伦博泰生物医药股份有限公司 | 2019-10-08 | — | — | CN | disclosed |
| WO-2019191624-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019191227-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2-ALPHA | PELOTON THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| EP-3546454-A1 | BENZOHETEROCYCLYL ALKYLAMINE COMPOUND AND USE THEREOF | East China University of Science and Technology (CN) | 2019-10-02 | — | — | EP | disclosed |
| EP-3545974-A1 | MEDICAL USE OF ANTI-C MET ANTIBODY-CYTOTOXIC DRUG CONJUGATE | Suzhou Suncadia Biopharmaceuticals Co., Ltd. (CN) | 2019-10-02 | — | — | EP | disclosed |
| EP-3055290-B1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| CN-110294742-A | And ring class ASK1 inhibitor and its application | 山东轩竹医药科技有限公司 | 2019-10-01 | — | — | CN | disclosed |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428064-B2 | Fused-tricyclic inhibitors of KRAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-10-01 | — | — | US | disclosed |
| CN-110291073-A | Heparanase inhibitors and application thereof | 贝塔医疗私人有限公司 | 2019-09-27 | — | — | CN | disclosed |
| WO-2019179928-A1 | SUBSTITUTED SUCCINIMIDE-3-CARBOXAMIDES, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-26 | — | — | WO | disclosed |
| US-20190290637-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20190292155-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS INC (BB) | 2019-09-26 | — | — | US | disclosed |
| US-20190290644-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA B.V. (NL) | 2019-09-26 | — | — | US | disclosed |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| WO-2019183140-A1 | TOUGH, HEALABLE COMPOSITES DISPLAYING STRESS RELAXATION AT THE RESIN-FILLER INTERFACE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-3541820-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3541822-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3541821-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3543207-A1 | WESTERN BLOT ANALYSIS USING POLYMER DOTS | University Of Washington Through Its Center For Commercialization (US) | 2019-09-25 | — | — | EP | disclosed |
| CN-105793249-B | Piperidine derivatives for the treatment or prevention of psychiatric and neurological disorders | 武田药品工业株式会社 | 2019-09-24 | — | — | CN | disclosed |
| US-20190282568-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2019-09-19 | — | — | US | disclosed |
| US-20190282661-A1 | METHODS OF TREATING BREAST CANCER | Blaze Bioscience, Inc. | 2019-09-19 | — | — | US | disclosed |
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-09-19 | — | — | US | disclosed |
| US-20190284343-A1 | POLYURETHANE/UREA COMPOSITIONS | FOLDAX, INC. | 2019-09-19 | — | — | US | disclosed |
| WO-2019178528-A1 | NANOPARTICLE COMPOSITIONS | JANUARY THERAPEUTICS, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019177937-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-3538099-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | The Queen's University of Belfast (GB) | 2019-09-18 | — | — | EP | disclosed |
| EP-3074482-B1 | ENCODED CHROMOPHORIC POLYMER PARTICLES | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-09-18 | — | — | EP | disclosed |
| US-10414750-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10413536-B2 | 6-alkyny-pyridine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-09-17 | — | — | US | disclosed |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414757-B2 | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-09-17 | — | — | US | disclosed |
| CN-110229157-A | Pyrimido 5-membered aromatic heterocycle class compound, preparation method and the usage | 上海海和药物研究开发有限公司 | 2019-09-13 | — | — | CN | disclosed |
| US-20190275028-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190274968-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE | NIH - DEITR | 2019-09-12 | — | — | US | disclosed |
| US-20190276805-A1 | METHOD FOR ENANTIOSELECTIVE CARBENE C-H INSERTION USING AN IRON-CONTAINING PROTEIN CATALYST | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2019170543-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019170063-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | 上海海和药物研究开发有限公司 | 2019-09-12 | — | — | WO | disclosed |
| WO-2019170750-A1 | METHODS AND COMPOSITIONS OF ISOINDOLINE-1,3-DIONE AND ISOINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES | CELGENE INTERNATIONAL II SARL (CH) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173633-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173640-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019143560-A9 | METHODS FOR PROMOTING MITOCHONDRIAL BIOGENESIS IN NEURAL CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173516-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173814-A1 | PROTECTIVE GROUPS AND METHODS FOR PROTECTING BENZOXABOROLES OR OXABOROLES | UNIVERSITY OF THE SCIENCES (US) | 2019-09-12 | — | — | WO | disclosed |
| EP-3534903-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-20190270708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-20190271016-A1 | METHOD FOR THE SYNTHESIS OF TRYPTOPHAN ANALOGS IN AQUEOUS SOLVENTS AT REDUCED TEMPERATURES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190269718-A1 | METHODS FOR ADVERSELY AFFECTING BIOFILMS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2019-09-05 | — | — | US | disclosed |
| US-20190271686-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20190270806-A1 | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2019-09-05 | — | — | US | disclosed |
| EP-3532103-A1 | LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2019-09-04 | — | — | EP | disclosed |
| EP-3532097-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE | The Trustees Of The University Of Pennsylvania (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3253766-B1 | COMPOUNDS AND METHODS FOR PREVENTING OR TREATING SENSORY HAIR CELL DEATH | UNIV WASHINGTON (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10399994-B2 | Compounds and methods for preventing or treating sensory hair cell death | UNIVERSITY OF WASHINGTON (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399953-B2 | Preparation of furan fatty acids from 5-(chloromethyl)furfural | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399986-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10398721-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399982-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190263748-A1 | CONVERSION OF LIGNIN TO IONIC LIQUIDS | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC | 2019-08-29 | — | — | US | disclosed |
| US-20190263953-A1 | Polyethylene Compositions and Articles Made Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-20190263783-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263738-A1 | PROCESS FOR PREPARING 2,3-UNSATURATED ALCOHOLS | BASF SE (DE) | 2019-08-29 | — | — | US | disclosed |
| US-20190263818-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | disclosed |
| WO-2019162228-A1 | 1-(5-SUBSTITUTED IMIDAZOL-1-YL)BUT-3-EN DERIVATIVES AND THEIR USE AS FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019162323-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165189-A1 | PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-08-29 | — | — | WO | disclosed |
| EP-3529254-A1 | PRODRUGS OF CLOFARABINE | Wu, Laurence I. (TW) | 2019-08-28 | — | — | EP | disclosed |
| CN-110177822-A | The synthesis of polycarbonate siloxane glycol | 奥特克国际公开有限公司 | 2019-08-27 | — | — | CN | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| CN-110156770-A | Aminopyrazole derivatives as TAM race kinase inhibitor | 圣诺康生命科学公司 | 2019-08-23 | — | — | CN | disclosed |
| US-20190256527-A1 | Purification of Rapamycin Derivatives Using Temperature Induced Phase Separation | JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC. D/B/A JOHNSON MATTHEY PHARMA SERVICES | 2019-08-22 | — | — | US | disclosed |
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | GENETECH, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190255155-A1 | BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS, LLC | 2019-08-22 | — | — | US | disclosed |
| US-20190256552-A1 | Amino Acid and Peptide Conjugates and Uses Thereof | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-08-22 | — | — | US | disclosed |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| EP-3105209-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3527573-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10385057-B2 | Pyrazole compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385062-B2 | Thiophene derivatives | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2019-08-20 | — | — | US | disclosed |
| US-10385047-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10383831-B2 | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use | Temple University—Of the Commonwealth System of Higher Education (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385007-B2 | Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385024-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| CN-110128998-A | A kind of allyl organic silicon potting adhesive and preparation method thereof | 矽时代材料科技股份有限公司 | 2019-08-16 | — | — | CN | disclosed |
| US-20190248815-A1 | ORGANIC MAGNESIUM PHOSPHIDE AND MANUFACTURING METHOD THEREOF, ORGANIC MAGNESIUM PHOSPHIDE COMPLEX AND MANUFACTURING METHOD THEREOF, AND MANUFACTURING METHOD OF ORGANIC PHOSPHORUS COMPOUND USING SAID PHOSPHIDE | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190248795-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| WO-2019154120-A1 | CYTOTOXIC AGENT AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-08-15 | — | — | WO | disclosed |
| WO-2019157013-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE SEPARATION OF HYDROCARBON ISOMERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-08-15 | — | — | WO | disclosed |
| US-20190249179-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2019-08-15 | — | — | US | disclosed |
| EP-3523315-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | Oric Pharmaceuticals, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3523289-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3524602-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| US-10376481-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-10376535-B2 | Therapy for malignant disease | UNIVERSITY OF ROCHESTER (US) | 2019-08-13 | — | — | US | disclosed |
| WO-2019152883-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADFORWARD LLC (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152641-A1 | BENZOXABOROLE COMPOSITIONS HAVING A GROWTH ENHANCING EFFECT | Boragen, Inc. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152465-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019149116-A1 | METHOD FOR PREPARING CONJUGATE | 四川科伦博泰生物医药股份有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-20190240223-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | CELGENE CORPORATION (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190240212-A1 | METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-08-08 | — | — | US | disclosed |
| US-20190241890-A1 | METHODS AND COMPOSITIONS FOR MANIPULATING TRANSLATION OF PROTEIN ISOFORMS FROM ALTERNATIVE INITIATION START SITES | SAREPTA THERAPEUTICS INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190240219-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190240203-A1 | NOVEL ANTIBIOTICS AND METHODS OF USING SAME | THE BROAD INSTITUTE, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190240217-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190240222-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | CELGENE CORPORATION (US) | 2019-08-08 | — | — | US | disclosed |
| EP-3519412-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | Mission Therapeutics Limited (GB) | 2019-08-07 | — | — | EP | disclosed |
| EP-3521399-A1 | ENCODED CHROMOPHORIC POLYMER PARTICLES | University of Washington through its Center for Commercialization (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3519816-A1 | COMPOUNDS FOR INCREASING NEURAL PLASTICITY | The Regents of the University of California (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3519402-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3519397-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | Mission Therapeutics Limited (GB) | 2019-08-07 | — | — | EP | disclosed |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| CN-110090308-A | The method for preparing conjugate | 四川科伦博泰生物医药股份有限公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-110092750-A | Amides compound that Pentafluorosulfanyl replaces, preparation method and its in application pharmaceutically | 北京诺诚健华医药科技有限公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-110088096-A | Piperidine derivatives as inhibitors of ubiquitin-specific protease 7 | 阿尔麦克探索有限公司 | 2019-08-02 | — | — | CN | disclosed |
| WO-2019145532-A1 | FLUORESCENT POLYMERIC COATING FILM FOR MEDICAL DEVICES | UNIVERSITE DE STRASBOURG (FR) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019147865-A1 | A METHOD FOR ENANTIOSELECTIVE CARBENE C-H INSERTION USING AN IRON-CONTAINING PROTEIN CATALYST | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20190231775-A1 | Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine Kinase | ACERTA PHARMA BV (NL) | 2019-08-01 | — | — | US | disclosed |
| EP-3517146-A1 | FLUORESCENT POLYMERIC COATING FILM FOR MEDICAL DEVICES | Université de Strasbourg (FR) | 2019-07-31 | — | — | EP | disclosed |
| EP-3517535-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-31 | — | — | EP | disclosed |
| EP-3516061-A1 | MIXED TRICYCLO-DNA, 2'-MODIFIED RNA OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF | Synthena AG (CH) | 2019-07-31 | — | — | EP | disclosed |
| EP-3515897-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3194387-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2831042-B1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | INTERVET INT BV (NL) | 2019-07-31 | — | — | EP | disclosed |
| US-10363290-B2 | Butyrylcholinesterase zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS (US) | 2019-07-30 | — | — | US | disclosed |
| US-10363249-B2 | Fatty acid synthase inhibitor for use in the treatment of drug resistant cancer | 3-V BIOSCIENCES, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| WO-2019143560-A1 | METHODS FOR PROMOTING MITOCHONDRIAL BIOGENESIS IN NEURAL CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019142053-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019142135-A1 | TRICYCLO-DNA NUCLEOSIDE PRECURSORS AND PROCESSES FOR PREPARING THE SAME | SYNTHENA AG (CH) | 2019-07-25 | — | — | WO | disclosed |
| US-20190223438-A1 | UREA AND THIOUREA SUBSTITUTED BICYCLES DERIVATIVES AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-07-25 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
| EP-2864420-B1 | SILICONE LIGANDS FOR STABILIZING QUANTUM DOT FILMS | NANOSYS INC (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3512840-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | Tseng, Yufeng, Jane (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10358447-B2 | Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| US-20190218554-A1 | Mixed Tricyclo-DNA, 2'-Modified RNA Oligonucleotide Compositions and Uses Thereof | SYNTHENA AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190218246-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| EP-3511319-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10351580-B2 | Acene-based transmitter molecules for photon upconversion | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351639-B2 | Organosilica materials for use as adsorbents for oxygenate removal | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-07-16 | — | — | US | disclosed |
| US-10350205-B2 | Dual MAGL and FAAH inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351590-B2 | Withanolides useful for the treatment of neurodegenerative diseases | IMSTAR THERAPEUTICS INC. (CA) | 2019-07-16 | — | — | US | disclosed |
| US-10351550-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190211010-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HAIHE BIOPHARMA CO. LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190209591-A1 | Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2019-07-11 | — | — | US | disclosed |
| US-20190212326-A1 | Method for the Selection of Patients and Kit | ALLIANZ PHARMASCIENCE LTD. (TW) | 2019-07-11 | — | — | US | disclosed |
| US-20190209564-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190211367-A1 | VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190210997-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| WO-2019136025-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
| WO-2019135975-A1 | ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS | STRATOS GENOMICS INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| EP-3508855-A1 | METHOD FOR THE SELECTION OF PATIENTS AND KIT | Allianz Pharmascience Ltd (TW) | 2019-07-10 | — | — | EP | disclosed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3508482-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2019-07-10 | — | — | EP | disclosed |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Missions Therapeutics Limited (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20190207113-A1 | POLYTHIOPHENE DERIVATIVE, COMPOSITE AND MANUFACTURE METHOD THEREOF | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| US-20190202766-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2019-07-04 | — | — | US | disclosed |
| US-20190202835-A1 | ISOTOPOLOGUES OF ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS AND USES THEREOF AS PI3K KINASE INHIBITORS | TWELVE THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| EP-3505517-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
| EP-3504251-A1 | NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME | The Regents of the University of Colorado, a Body Corporate (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2887964-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2822938-B1 | RODENTICIDAL NORBORMIDE ANALOGUES | LANDCARE RES NEW ZEALAND LIMITED (NZ) | 2019-07-03 | — | — | EP | disclosed |
| EP-3229953-B1 | COATING METHOD USING ORGANOSILICA MATERIAL, COATED SUBSTRATE, AND GAS SEPARATION PROCESS EMPLOYING SAID SUBSTRATE | EXXONMOBIL RES & ENG CO (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2558538-B1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10336709-B2 | Lp-PLA2 inhibitors | ABIDE THERAPEUTICS, INC (US) | 2019-07-02 | — | — | US | disclosed |
| CN-109956927-A | Benzimidazoles derivative, preparation method and its in application pharmaceutically | 北京诺诚健华医药科技有限公司 | 2019-07-02 | — | — | CN | disclosed |
| US-10335402-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-10336691-B2 | Pesticidally active oxime and hydrazone derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2019-07-02 | — | — | US | disclosed |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336727-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190194195-A1 | METHOD OF MAKING TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID COMPOUNDS | FELIQS CORPORATION (JP) | 2019-06-27 | — | — | US | disclosed |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190194414-A1 | METHODS OF PRODUCING ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RES & ENG CO (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190192454-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2019-06-27 | — | — | US | disclosed |
| US-20190194162-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-06-27 | — | — | US | disclosed |
| US-20190192521-A1 | Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors | WISTAR INST (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
| EP-3180342-B1 | PYRROLO[3,2-D]PYRIMIDINE-2,4(3H,5H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES INC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-10329299-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10328074-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-10328080-B2 | Therapeutic combination of PI3K inhibitor and a BTK inhibitor | Acerta Pharma, B.V. (NL) | 2019-06-25 | — | — | US | disclosed |
| US-10328077-B2 | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas | CELGENE CORPORATION (US) | 2019-06-25 | — | — | US | disclosed |
| CN-109908356-A | Load the alpha-cyanoacrylate ester material of anti-tumor drug | 中国人民解放军军事医学科学院毒物药物研究所 | 2019-06-21 | — | — | CN | disclosed |
| CN-109913203-A | Chromophoric polymers point with narrow emission | 华盛顿大学商业中心 | 2019-06-21 | — | — | CN | disclosed |
| WO-2019115338-A1 | PROCESS FOR THE PREPARATION OF (5-CYANO-IMIDAZOL-1-YL)ETHANONE DERIVATIVES AND INTERMEDIATES USEFUL THEREFOR | BAYER AKTIENGESELLSCHAFT (DE) | 2019-06-20 | — | — | WO | disclosed |
| US-20190186026-A1 | ELECTROCHEMICAL OXIDATION OF ALIPHATIC AND AROMATIC COMPOUNDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2019-06-20 | — | — | US | disclosed |
| US-20190190069-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LINEAR CARBONATE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-20 | — | — | US | disclosed |
| US-20190190070-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-20 | — | — | US | disclosed |
| US-20190183865-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-20 | — | — | US | disclosed |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2019-06-20 | — | — | US | disclosed |
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| EP-3496721-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | Celgene Corporation (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3497092-A1 | SUBSTITUTED PYRAZOLINYL DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND/OR PLANT GROWTH REGULATORS | Bayer CropScience Aktiengesellschaft (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-10323038-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | SHANTON PHARMA CO., LTD (CN) | 2019-06-18 | — | — | US | disclosed |
| US-10322108-B2 | N-benzoate group substituted benzopyrroline-2-one derivative and use thereof | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2019-06-18 | — | — | US | disclosed |
| US-10322995-B2 | Substituted cyano cycloalkyl penta-2,4-dienes, cyano cycloalkyl pent-2-en-4-ynes, cyano heterocyclyl penta-2,4-dienes and cyano heterocyclyl pent-2-en-4-ynes as active substances against abiotic plant stress | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-06-18 | — | — | US | disclosed |
| WO-2019113236-A1 | BENZOCARBONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113532-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED CYCLIC COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190181441-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED CYCLIC COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-13 | — | — | US | disclosed |
| WO-2019113518-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LINEAR CARBONATE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113530-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ETHER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113469-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113528-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113242-A1 | TUBULIN INHIBITORS | Lin BioScience, LLC (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190181502-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ETHER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-13 | — | — | US | disclosed |
| US-20190181501-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CYCLIC CARBONATE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-13 | — | — | US | disclosed |
| US-20190181500-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED POLYMER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-13 | — | — | US | disclosed |
| US-20190167816-A1 | METHODS FOR PREVENTING OR TREATING FIBROTIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190166840-A1 | SUBSTITUTED PYRAZOLINYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-06-06 | — | — | US | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
| US-20190169185-A1 | SUBSTITUTED 2-N-HYDROXY-1,3-DIOXO-1,2,3,4-TETRAHYDRONAPHTHYRIDINES, AND METHODS OF MAKING AND USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169611-A1 | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-06-06 | — | — | US | disclosed |
| US-20190169209-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-06 | — | — | US | disclosed |
| EP-3492106-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3009436-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-2968440-B1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS INC (CA) | 2019-06-05 | — | — | EP | disclosed |
| US-10308637-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-06-04 | — | — | US | disclosed |
| US-10308635-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20190159457-A1 | Combinatorial Compositions of Benzoxaboroles and Biologic Agents | 5METIS, INC. | 2019-05-30 | — | — | US | disclosed |
| US-20190161437-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2019-05-30 | — | — | US | disclosed |
| US-20190161567-A1 | Polyethylene Compositions and Films Made Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-05-30 | — | — | US | disclosed |
| US-20190161523-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | Blaze Bioscience, Inc. | 2019-05-30 | — | — | US | disclosed |
| US-20190161471-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2019-05-30 | — | — | US | disclosed |
| US-20190161559-A1 | Catalyst Systems and Polymerization Processes for Using the Same | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-05-30 | — | — | US | disclosed |
| EP-2240452-B1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES AS PI3 KINASE MODULATORS, THEIR COMPOSITIONS AND USES | INTELLIKINE LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-3487850-A1 | UREA AND THIOUREA SUBSTITUTED BICYCLES DERIVATIVES AS PESTICIDES | Syngenta Participations AG (CH) | 2019-05-29 | — | — | EP | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10301284-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-05-28 | — | — | US | disclosed |
| US-10300069-B2 | Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190151318-A1 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190152972-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2019-05-23 | — | — | US | disclosed |
| US-20190151289-A1 | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) Histone Demethylase | UNIV YALE (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190152993-A1 | Reversibly Switchable Surfactants and Methods of Use | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190153306-A1 | Photochromic Water Harvesting Platform | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190152965-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2019-05-23 | — | — | US | disclosed |
| US-20190151324-A1 | NON-CATALYTIC SUBSTRATE-SELECTIVE P38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2019-05-23 | — | — | US | disclosed |
| EP-3484887-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | Almac Discovery Limited (GB) | 2019-05-22 | — | — | EP | disclosed |
| EP-3183254-B1 | NEW SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| CN-109790112-A | Cyanopyrrolidine derivatives having activity as USP30 inhibitors | 特殊治疗有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109790169-A | With the Cyanopyrolidine derivatives as USP30 inhibitor activity | 特殊治疗有限公司 | 2019-05-21 | — | — | CN | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-10294312-B2 | Olefin polymerization catalyst system comprising mesoporous organosilica support | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-05-21 | — | — | US | disclosed |
| CN-109790146-A | Medical compounds | 阿尔麦克探索有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109776517-A | Heterocyclic indole amine 2,3-dioxygenase inhibitor | 南京药捷安康生物科技有限公司 | 2019-05-21 | — | — | CN | disclosed |
| US-20190144442-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| US-20190144578-A1 | Polymerization Processes | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190142788-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2019-05-16 | — | — | US | disclosed |
| US-20190144601-A1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190144579-A1 | Polymerization Processes | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190144575-A1 | Polyethylene Compositions and Articles Made Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190144576-A1 | Polyethylene Compositions and Articles Made Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190144580-A1 | Polymerization Processes | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190142812-A1 | 5-SUBSTITUTED 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-16 | — | — | US | disclosed |
| US-20190142853-A1 | Inhibition of Galectin 3 Binding to the Airway Epithelial Surface to Treat or Prevent Septic Shock Resulting From Influenza and Subsequent Pneumococcal Pneumonia Infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-16 | — | — | US | disclosed |
| US-20190144451-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS LLC | 2019-05-16 | — | — | US | disclosed |
| US-20190142799-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| US-20190144424-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | YALE UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-20190142961-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| EP-3481391-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2019-05-15 | — | — | EP | disclosed |
| EP-2456842-B1 | IONIC LIQUID FLAME RETARDANTS | INOVIA MAT LLC (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3043784-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10287286-B2 | Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190136281-A1 | CONVERSION OF SUGARS TO IONIC LIQUIDS | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190134028-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3480204-A1 | ORGANIC MAGNESIUM PHOSPHIDE AND METHOD FOR PRODUCING SAME, ORGANIC MAGNESIUM PHOSPHIDE COMPLEX AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING ORGANIC PHOSPHORUS-CONTAINING COMPOUND USING SAID PHOSPHIDE | Hokko Chemical Industry Co., Ltd. (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-3480207-A1 | ORPHAN NUCLEAR RECEPTOR NUR77 LIGAND AND APPLICATION THEREOF | Xiamen University (CN) | 2019-05-08 | — | — | EP | disclosed |
| EP-3478288-A1 | METHOD OF TREATING IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS | Prana Biotechnology Ltd (AU) | 2019-05-08 | — | — | EP | disclosed |
| EP-2970205-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2969007-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2970122-B1 | SHIP1 MODULATORS | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2019-05-08 | — | — | EP | disclosed |
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | PELOTON THERAPEUTICS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280172-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280190-B2 | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions | CHROMADEX, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| CN-109721620-A | HPK1 inhibitors and uses thereof | 南京药捷安康生物科技有限公司 | 2019-05-07 | — | — | CN | disclosed |
| CN-109715598-A | Process for preparing carotenoid monoesters | 巴斯夫欧洲公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109715605-A | Process for preparing carotenoid monoesters | 巴斯夫欧洲公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109715638-A | The method for preparing the structural unit phosphonium salt ester as carotenoid | 巴斯夫欧洲公司 | 2019-05-03 | — | — | CN | disclosed |
| US-20190127336-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | ARAXES PHARMA, LLC | 2019-05-02 | — | — | US | disclosed |
| US-20190126260-A1 | Catalysts for Selective Coupling of Olefins, and Methods of Making and Using Same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2019-05-02 | — | — | US | disclosed |
| US-20190127366-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-05-02 | — | — | US | disclosed |
| EP-3475387-A1 | PHOTOCHROMIC WATER HARVESTING PLATFORM | The Warner-Babcock Institute For Green Chemistry LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3474835-A1 | NON-CATALYTIC SUBSTRATE-SELECTIVE P38 -SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF | University of Maryland, Baltimore (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3474975-A1 | REVERSIBLY SWITCHABLE SURFACTANTS AND METHODS OF USE | The Warner-Babcock Institute For Green Chemistry LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3475324-A1 | BISPHENOL A-FREE CROSSLINKED POLYMER COMPOSITIONS | The Warner-Babcock Institute For Green Chemistry LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-2427195-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10272083-B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | ACERTA PHARMA B.V. (NL) | 2019-04-30 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10272079-B2 | NHE3-binding compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273242-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2019-04-30 | — | — | US | disclosed |
| US-10273222-B2 | Histone demethylase inhibitors | CELGENE QUANTSCEL RESEARCH, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10272081-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-04-30 | — | — | US | disclosed |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-04-30 | — | — | US | disclosed |
| CN-109689610-A | The method for preparing 12 '-apocarotenal esters of the structural unit as carotenoid | 巴斯夫欧洲公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-109689045-A | Purposes of the topical formulations of cannboid in treatment epidermolysis bollosa and Related connective tissue illness | 因美制药公司 | 2019-04-26 | — | — | CN | disclosed |
| US-20190119413-A1 | Catalyst Systems and Polymerization Processes for Using the Same | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119417-A1 | Polyethylene Compositions and Articles Made Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119221-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119214-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119277-A1 | VINBLASTINE 20' AMIDES: SYNTHETIC ANALOGS THAT MAINTAIN OR IMPROVE POTENCY AND SIMULTANEOUSLY OVERCOME Pgp-DERIVED EFFLUX AND RESISTANCE | THE SCRIPPS RESEARCH INSTITUTE | 2019-04-25 | — | — | US | disclosed |
| US-20190119212-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | THE SCRIPPS RESEARCH INSTITUTE | 2019-04-25 | — | — | US | disclosed |
| US-20190117532-A1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | PROCTER & GAMBLE (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3471711-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | The Scripps Research Institute (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10266622-B2 | Olefin polymerization catalyst system comprising mesoporous organosilica support | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266515-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-23 | — | — | US | disclosed |
| US-10266497-B2 | Pyrazole MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266657-B2 | Polyurethane/urea compositions | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2019-04-23 | — | — | US | disclosed |
| CN-109661229-A | Compound and composition for treating cancer | 加利福尼亚大学董事会 | 2019-04-19 | — | — | CN | disclosed |
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-18 | — | — | US | disclosed |
| US-20190112312-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-18 | — | — | US | disclosed |
| WO-2019075367-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | TOLERO PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190110476-A1 | NOVEL ISOTHIAZOLAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-04-18 | — | — | US | disclosed |
| EP-3469601-A1 | POLYMER-SILICA HYBRID PDOTS AND METHODS OF USE THEREOF | University of Washington (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468915-A1 | ORGANOSILICA MATERIALS, METHODS OF MAKING, AND USES THEREOF | Exxonmobil Research And Engineering Company (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468712-A1 | ORGANOSILICA POLYMER CATALYSTS AND METHODS OF MAKING THE SAME | Exxonmobil Research And Engineering Company (US) | 2019-04-17 | — | — | EP | disclosed |
| CN-109640984-A | The purposes of nicotinic acid nucleoside or nicotinamide riboside derivative and its derivative of reduction as the precursor for increasing NAD+ | 可劳迈戴斯有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-10259803-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-16 | — | — | US | disclosed |
| CN-106164047-B | 1,2- substituted cyclopentane as orexin receptor antagonists | 武田药品工业株式会社 | 2019-04-16 | — | — | CN | disclosed |
| US-20190105647-A1 | CATALYSTS AND METHODS OF MAKING THE SAME | EXXONMOBIL RES & ENG CO (US) | 2019-04-11 | — | — | US | disclosed |
| WO-2019068613-A1 | NEW [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019068772-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-04-11 | — | — | WO | disclosed |
| US-20190105643-A1 | CINCHONIUM BETAINE CATALYSTS AND METHODS OF USING SAME | BRANDEIS UNIVERSITY (US) | 2019-04-11 | — | — | US | disclosed |
| US-20190105299-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2019-04-11 | — | — | US | disclosed |
| US-20190106542-A1 | CHROMOPHORIC POLYMER DOTS WITH NARROW-BAND EMISSION | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2019-04-11 | — | — | US | disclosed |
| EP-3230410-B1 | AROMATICS HYDROGENATION CATALYST, ITS PREPARATION AND USE THEREOF | EXXONMOBIL RES & ENG CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464267-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2019-04-10 | — | — | EP | disclosed |
| EP-3463373-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | Akarna Therapeutics, Ltd. (GB) | 2019-04-10 | — | — | EP | disclosed |
| US-10253025-B2 | Method of making tetrahydronaphthyridinyl nonanoic acid compounds | SCIFLUOR LIFE SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10253010-B2 | C-glycoside derivative | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2019-04-09 | — | — | US | disclosed |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10253062-B2 | Amino acid and peptide conjugates and uses thereof | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-04-09 | — | — | US | disclosed |
| CN-109575016-A | PDE9 inhibitors and uses thereof | 南京药捷安康生物科技有限公司 | 2019-04-05 | — | — | CN | disclosed |
| WO-2019067974-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICALS COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICAL PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190099747-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | UNIV CALIFORNIA (US) | 2019-04-04 | — | — | US | disclosed |
| US-10245259-B2 | Methods of treating RBP4 related diseases with triazolopyridines | BELITE BIO, INC (KY) | 2019-04-02 | — | — | US | disclosed |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246443-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-04-02 | — | — | US | disclosed |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-10246464-B2 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246467-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-02 | — | — | US | disclosed |
| US-20190092767-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2019-03-28 | — | — | US | disclosed |
| US-20190092787-A1 | SUBSTITUTED 2,3,4,5,7,9,13,13A-OCTAHYDRO-1,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[1,3]DIAZEPINES AND METHODS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
| US-20190092771-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-28 | — | — | US | disclosed |
| WO-2019056123-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | INMED PHARMACEUTICALS INC. (CA) | 2019-03-28 | — | — | WO | disclosed |
| EP-3458441-A1 | PROCESS FOR THE MANUFACTURE OF 6-ALKYNYL-PYRIDINE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458449-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458459-A1 | MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2019-03-27 | — | — | EP | disclosed |
| US-10239967-B2 | Olefin polymerization catalyst system comprising mesoporous organosilica support | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-03-26 | — | — | US | disclosed |
| US-10238659-B2 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | CORCEPT THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| CN-106164064-B | Substituted cyclopentane, tetrahydrofuran and pyrrolidines as orexin receptor antagonists | 武田药品工业株式会社 | 2019-03-22 | — | — | CN | disclosed |
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-21 | — | — | US | disclosed |
| US-20190086757-A1 | ELECTROCHROMIC POLYMER THIN FILMS HAVING REDUCED SELF-BLEACHING BEHAVIOR AND ENHANCED CYCLING STABILITY | LANNRAY ADVANCED MATERIALS CO. LTD (CN) | 2019-03-21 | — | — | US | disclosed |
| EP-3454945-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | The Regents Of The University Of Michigan (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3455226-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-2983667-B1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-2900239-B1 | DIHYDRO-6-AZAPHENALENE DERIVATIVES FOR THE TREATMENT OF CNS, OCULAR DISEASES AND RELATED DISORDERS | WARNER BABCOCK INST FOR GREEN CHEMISTRY LLC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10231957-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233176-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2019-03-19 | — | — | US | disclosed |
| CN-109475661-A | Preparation method based on silicon-polycarbonate glycol polyurethane solutions | 奥特克国际公开有限公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20190077785-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-03-14 | — | — | US | disclosed |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| EP-3453710-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-3452036-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | Inmed Pharmaceuticals Inc. (CA) | 2019-03-13 | — | — | EP | disclosed |
| EP-3238722-B1 | SOLID FORMS OF ISOQUINOLINONES | INFINITY PHARMACEUTICALS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2019046330-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046318-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046711-A2 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046582-A1 | TESTOSTERONE ESTER TRIGLYCERIDE FORMULATIONS | ANTARES PHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20190069537-A1 | Compositions and Methods for Reducing Ice Crystal Formation | X-THERMA, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190070212-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2019-03-05 | — | — | US | disclosed |
| US-10222368-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | HYDRA BIOSCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| CN-109414437-A | The method for treating light chain immunoglobulin amyloidosis | 普拉纳生物技术有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-109415623-A | Photosensitive macromolecules and uses thereof | 拜克门寇尔特公司 | 2019-03-01 | — | — | CN | disclosed |
| WO-2019040467-A1 | SELECTIVE α-CYANOACRYLAMIDE AND α-CYANOACRYLATE INHIBTORS OF THE MCL-1 ONCOPROTEIN AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040511-A1 | DUAL INHIBITORS OF THE BCL-2 AND HDM2 FAMILIES THROUGH CO-MIMICRY OF THE BH3 AND P53-ALPHA-HELICES | UNIVERSITY OF MARYLAND BATIMORE (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| CN-109384790-A | Fibroblast growth factor acceptor inhibitor and application thereof | 南京药捷安康生物科技有限公司 | 2019-02-26 | — | — | CN | disclosed |
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2019-02-21 | — | — | US | disclosed |
| US-20190055211-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2019-02-21 | — | — | US | disclosed |
| US-20190055221-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-21 | — | — | US | disclosed |
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-02-21 | — | — | US | disclosed |
| US-20190055232-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| WO-2019035061-A1 | NOVEL STEROIDS AND METHODS OF MANUFACTURE | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036008-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036030-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034693-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034688-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034686-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034690-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034696-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034692-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034697-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| EP-3143015-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3071204-B1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2019-02-20 | — | — | EP | disclosed |
| EP-3180318-B1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | HYDRA BIOSCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3443049-A2 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | Beckman Coulter Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3442996-A2 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | Blaze Bioscience, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3442555-A1 | METHODS OF TREATING BREAST CANCER | Blaze Bioscience, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10208039-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10207999-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10207249-B2 | Organosilica materials and uses thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208016-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-19 | — | — | US | disclosed |
| US-10208042-B1 | Multi-kinase inhibitor compound, and crystal form and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2019-02-19 | — | — | US | disclosed |
| US-10208322-B2 | In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10207996-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| CN-108218868-B | Multi-kinase inhibitor compound, its crystal form and purposes | 南京药捷安康生物科技有限公司 | 2019-02-19 | — | — | CN | disclosed |
| US-20190046526-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20190048421-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-14 | — | — | US | disclosed |
| EP-3441392-A1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Intellikine, LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3440056-A2 | PD(II)-CATALYZED ENANTIOSELECTIVE BETA-METHYLENE C(SP3)-H BOND ACTIVATION | The Scripps Research Institute (US) | 2019-02-13 | — | — | EP | disclosed |
| US-10202402-B2 | Purification of rapamycin derivatives using temperature induced phase separation | BIOSENSORS INTERNATIONAL GROUP, LTD. (BM) | 2019-02-12 | — | — | US | disclosed |
| US-10202381-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10201614-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2019-02-12 | — | — | US | disclosed |
| US-10202356-B2 | JAK2 and ALK2 inhibitors and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202334-B2 | Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202620-B2 | Synthesis of olefinic alcohols via enzymatic terminal hydroxylation | PROVIVI, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202360-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202362-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202602-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| CN-103958508-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2019-02-12 | — | — | CN | disclosed |
| US-20190040064-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2019-02-07 | — | — | US | disclosed |
| WO-2019027905-A1 | ORGANOPHOSPHATE DERIVATIVES | JANUARY THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019028164-A1 | BENZOTHIAZOLE AND RELATED COMPOUNDS | SPINOGENIX, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019025440-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019025562-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019025554-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
| US-20190037848-A1 | Novel isothiazolamides, processes for their preparation and their use as herbicides and/or plant growth regulators | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | US | disclosed |
| EP-3436445-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2019-02-06 | — | — | EP | disclosed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-10196405-B2 | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors | Atrin Pharmaceuticals LLC (US) | 2019-02-05 | — | — | US | disclosed |
| CN-109313954-A | Polymer-silica hybrid PDOT and methods of use thereof | 华盛顿大学 | 2019-02-05 | — | — | CN | disclosed |
| CN-109303918-A | It can be used for the cyanoacrylate and combinations thereof of cutaneous penetration | 中国人民解放军军事科学院军事医学研究院 | 2019-02-05 | — | — | CN | disclosed |
| US-10195600-B2 | Catalysts and methods of making the same | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-02-05 | — | — | US | disclosed |
| CN-109293652-A | A kind of substituted thiazole and application thereof | 四川科伦博泰生物医药股份有限公司 | 2019-02-01 | — | — | CN | disclosed |
| WO-2019023634-A1 | CYCLATIVE RELEASE OF PEPTIDIC COMPOUNDS | CIRCLE PHARMA, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| EP-3434674-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| EP-3433246-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| EP-3432934-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
| EP-3105210-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-10189862-B2 | Phenothiazine-pyridine compounds and uses thereof | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2019-01-29 | — | — | US | disclosed |
| US-10189812-B2 | Bi-benzyl isoquinoline derivative, preparation method and use thereof in hepatopathy treatment and prevention | THE KEY LABORATORY OF CHEMISTRY FOR NATURAL PRODUC (CN) | 2019-01-29 | — | — | US | disclosed |
| US-10188615-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189016-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-29 | — | — | US | disclosed |
| US-20190023704-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190022092-A1 | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist | ACERTA PHARMA BV (NL) | 2019-01-24 | — | — | US | disclosed |
| US-20190022247-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20190023709-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20190023690-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2019-01-24 | — | — | US | disclosed |
| EP-3229952-B1 | ORGANOSILICA MATERIALS | EXXONMOBIL RES & ENG CO (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-3429994-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| EP-3429354-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | Chromadex Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-3430008-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-3430012-A1 | 4,6 DIHYDROPYRROLO [3,4-C]PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-10183272-B2 | Adsorbent for heteroatom species removal and uses thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183036-B2 | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors | ChromaDex Inc. (US) | 2019-01-22 | — | — | US | disclosed |
| CN-104487097-B | Chromophoric polymer dots with narrow-band emission | 华盛顿大学商业中心 | 2019-01-18 | — | — | CN | disclosed |
| WO-2019014370-A1 | ELECTROCHROMIC POLYMER AND SYNTHESIS AND USES THEREOF | Furcifer Inc. (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016852-A1 | ELECTROCHROMIC POLYMER AND SYNTHESIS AND USES THEREOF | LANNRAY ADVANCED MATERIALS CO. LTD (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190015377-A1 | Compositions for Use in Treating Pulmonary Arterial Hypertension | PELOTON THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3426671-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS | Spring Bank Pharmaceuticals, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2882428-B1 | A METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS INC (US) | 2019-01-16 | — | — | EP | disclosed |
| US-10179839-B2 | Sulfur terminated organosilica materials and uses thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-01-15 | — | — | US | disclosed |
| CN-109207137-A | Polyacrylamide particle oil displacement agent and preparation method thereof | 中国石油化工股份有限公司胜利油田分公司勘探开发研究院 | 2019-01-15 | — | — | CN | disclosed |
| US-10179769-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| WO-2019008029-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| US-20190010133-A1 | Novel Syringolin Analogues and Methods of Making and Using Same | BROWN UNIVERSITY | 2019-01-10 | — | — | US | disclosed |
| US-20190008869-A1 | Therapeutic Combinations of an Antifolate and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2019-01-10 | — | — | US | disclosed |
| US-20190010129-A1 | Amide derivatives as lysophosphatidic acid receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2019-01-10 | — | — | US | disclosed |
| US-20190008859-A1 | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2019-01-10 | — | — | US | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| EP-3074414-B1 | WITHANOLIDES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | IMSTAR THERAPEUTICS INC (CA) | 2019-01-09 | — | — | EP | disclosed |
| EP-3423454-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-09 | — | — | EP | disclosed |
| US-10174041-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174026-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172350-B2 | Substituted 5-hydroxy-2-phenyl-3-heteroaryl pentanenitrile derivatives, method for the production thereof and use thereof as herbicides and/or plant growth regulators | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-01-08 | — | — | US | disclosed |
| US-10173996-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172837-B2 | Insulin sensitisers and methods of treatment | NAIA Metabolic, Inc. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174046-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-01-08 | — | — | US | disclosed |
| US-10174003-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| WO-2019006445-A1 | ANTI-THROMBOTIC AGENTS AND METHODS OF USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002429-A1 | Derivatives of Xanthone Compounds | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2019-01-03 | — | — | US | disclosed |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-01-03 | — | — | US | disclosed |
| EP-3421473-A1 | METHOD FOR PREPARING PYRROLOPYRIMIDINE COMPOUND AND APPLICATION THEREOF | Cinkate Pharm Tech (Shanghai) Co., Ltd. (CN) | 2019-01-02 | — | — | EP | disclosed |
| US-10167283-B2 | β-lactamase inhibitors and uses thereof | SUANZHU PHARMA CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| US-10166237-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-01 | — | — | US | disclosed |
| US-10166298-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2019-01-01 | — | — | US | disclosed |
| US-10167267-B2 | Conversion and purification of biomass | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-01-01 | — | — | US | disclosed |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-01 | — | — | US | disclosed |
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| WO-2018236879-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-12-27 | — | — | WO | disclosed |
| WO-2018236856-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20180369244-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2018-12-27 | — | — | US | disclosed |
| US-20180371430-A1 | Heme Protein Catalysts for Carbon-Silicon Bond Formation In Vitro and In Vivo | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180370911-A1 | PHOTOCATALYST-FREE, LIGHT-INDUCED CARBON-SULFUR CROSS-COUPLING METHODS | U.S. DEPARTMENT OF ENERGY | 2018-12-27 | — | — | US | disclosed |
| WO-2018237268-A1 | NOVEL ANTIBACTERIAL COMPOUNDS AND METHODS OF MAKING AND USING SAME | BROWN UNIVERSITY (US) | 2018-12-27 | — | — | WO | disclosed |
| EP-3417852-A1 | ARYL ETHERS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| EP-3417851-A1 | ARYL ETHERS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| EP-3416960-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2018-12-26 | — | — | EP | disclosed |
| EP-3164401-B1 | NEW SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-12-26 | — | — | EP | disclosed |
| US-10160745-B2 | Piperidine and azepine derivatives as prokineticin receptor modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-12-25 | — | — | US | disclosed |
| US-10160756-B2 | Antiviral compounds and methods using same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180364253-A1 | IL-17F AND IL-17A-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | REGENERON PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2018-12-20 | — | — | US | disclosed |
| WO-2018232160-A1 | METHODS OF TREATING METABOLIC DISEASES WITH PHENOXYETHYLAMIDES | BELITE BIO, INC (KY) | 2018-12-20 | — | — | WO | disclosed |
| WO-2018232158-A1 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRROLES | BELITE BIO, INC. (KY) | 2018-12-20 | — | — | WO | disclosed |
| WO-2018229543-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-12-20 | — | — | WO | disclosed |
| WO-2018232150-A1 | METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES | BELITE BIO, INC (KY) | 2018-12-20 | — | — | WO | disclosed |
| WO-2018232154-A1 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | BELITE BIO, INC (KY) | 2018-12-20 | — | — | WO | disclosed |
| US-20180362460-A1 | CYANOPYRROLIDINE DERIVATIVES AS INHIBITORS FOR DUBS | MISSION THERAPEUTICS LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180360818-A1 | METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2018-12-20 | — | — | US | disclosed |
| US-10155826-B2 | Olefin polymerization catalyst system comprising mesoporous organosilica support | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2018-12-18 | — | — | US | disclosed |
| US-10155726-B2 | Substituted pyridines and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-12-18 | — | — | US | disclosed |
| CN-109020887-A | Amides compound as prevention and treatment mental disorder | 绍兴从零医药科技有限公司 | 2018-12-18 | — | — | CN | disclosed |
| US-20180358654-A1 | SODIUM-ION ELECTROLYTE COMPOSITION | MONASH UNIVERSITY (AU) | 2018-12-13 | — | — | US | disclosed |
| US-20180355392-A1 | AMMONIUM BASED IONIC LIQUIDS USEFUL FOR LIGNOCELLULOSIC PROCESSING | UNITED STATES DEPARTMENT OF ENERGY | 2018-12-13 | — | — | US | disclosed |
| US-20180354989-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-12-13 | — | — | US | disclosed |
| EP-3157916-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10150754-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-10150841-B2 | Chromophoric polymer dots with narrow-band emission | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180346938-A1 | HIGH GRAVITY, FED-BATCH IONIC LIQUID BASED PROCESS FOR DECONSTRUCTING BIOMASS | UNITED STATES DEPARTMENT OF ENERGY | 2018-12-06 | — | — | US | disclosed |
| US-20180346407-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ACUCELA INC. | 2018-12-06 | — | — | US | disclosed |
| US-20180344738-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS AG (CH) | 2018-12-06 | — | — | US | disclosed |
| US-20180346626-A1 | A POLYMERIC COMPOSITION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-12-06 | — | — | US | disclosed |
| US-20180346654-A1 | POLYURETHANE/UREA MATERIALS | FOLDAX, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20180344729-A1 | TRIAZOLE DAGLAlpha INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2018-12-06 | — | — | US | disclosed |
| US-20180344763-A1 | METHODS FOR ADVERSELY AFFECTING BIOFILMS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2018-12-06 | — | — | US | disclosed |
| EP-2340271-B1 | POLYMER-BIOACTIVE AGENT CONJUGATES | POLYACTIVA PTY LTD (AU) | 2018-12-05 | — | — | EP | disclosed |
| EP-2838902-B1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2018-12-05 | — | — | EP | disclosed |
| EP-3180339-B1 | 6-ALKYNYL-PYRIDINE DERIVATIVES AS SMAC MIMETICS | BOEHRINGER INGELHEIM INT (DE) | 2018-12-05 | — | — | EP | disclosed |
| EP-3408258-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | Abbvie Deutschland GmbH & Co. KG (DE) | 2018-12-05 | — | — | EP | disclosed |
| EP-3407974-A1 | AMLEXANOX ANALOGS | The Regents Of The University Of Michigan (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-3408272-A1 | SURFACE PRIMER COMPOSITIONS AND METHODS OF USE | Acatechol, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-3408253-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | Acatechol, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-3409669-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| US-10144739-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-04 | — | — | US | disclosed |
| US-10144711-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-10144724-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2018-12-04 | — | — | US | disclosed |
| US-10143638-B2 | Method of treating skin with ingenol mebutate | LEO LABORATORIES LIMITED (IE) | 2018-12-04 | — | — | US | disclosed |
| WO-2018215818-A1 | NOVEL COMPOUNDS AND USES | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018218071-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018218069-A1 | QUINAZOLINE DERIVATIVES AS MODULATORS OF MUTANT KRAS, HRAS OR NRAS | ARAXES PHARMA LLC (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018218070-A2 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018217809-A1 | PYRAZOLE MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018218154-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018217567-A1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING PTEN INHIBITORS | TRANSFUSION HEALTH, LLC (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018217805-A1 | PYRAZOLE MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018218190-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-3406606-A1 | NITROGENOUS HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2018-11-28 | — | — | EP | disclosed |
| EP-3129380-B1 | SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE DERIVATIVES AND THEIR USE AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-11-28 | — | — | EP | disclosed |
| US-10138251-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| US-10138226-B2 | Benzimidazol-2-amines as MIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-27 | — | — | US | disclosed |
| US-10137110-B2 | 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-27 | — | — | US | disclosed |
| CN-108884068-A | 1- cyano-pyrolidin derivative as DUB inhibitor | 特殊治疗有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-107501279-B | Furanoquinoline dione compound and medical application thereof | 东莞市真兴贝特医药技术有限公司 | 2018-11-23 | — | — | CN | disclosed |
| WO-2018213236-A1 | BIO-BASED, MULTI-AROMATIC COMPOUNDS, AND METHODS OF MAKING AND USING SAME | ROWAN UNIVERSITY (US) | 2018-11-22 | — | — | WO | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| US-20180334496-A1 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2018-11-22 | — | — | US | disclosed |
| EP-3402795-A1 | 5-SUBSTITUTED 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2018-11-21 | — | — | EP | disclosed |
| EP-3402503-A1 | THERAPEUTIC COMBINATIONS OF AN ANTIFOLATE AND A BTK INHIBITOR | Acerta Pharma B.V. (NL) | 2018-11-21 | — | — | EP | disclosed |
| US-10130633-B2 | Compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-20 | — | — | US | disclosed |
| US-10131664-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180327519-A1 | AMPHIPHILIC RAFT AGENT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 2018-11-15 | — | — | US | disclosed |
| US-20180327414-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2018-11-15 | — | — | US | disclosed |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180327793-A1 | METHODS AND ENZYME CATALYSTS FOR THE SYNTHESIS OF NON-CANONICAL AMINO ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-11-15 | — | — | US | disclosed |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180325900-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | QUANTIEL PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180327416-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-11-15 | — | — | US | disclosed |
| US-20180325833-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-11-15 | — | — | US | disclosed |
| US-20180327407-A1 | COMPOUNDS AND METHODS FOR TREATING SYNOVIAL SARCOMAS | HOWARD HUGHES MEDICAL INSTITUTE | 2018-11-15 | — | — | US | disclosed |
| WO-2018208985-A2 | ANTIBACTERIAL COMPOUNDS | FORGE THERAPEUTICS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20180327410-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-11-15 | — | — | US | disclosed |
| WO-2018208987-A2 | ANTIBACTERIAL COMPOUNDS | FORGE THERAPEUTICS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| WO-2018206547-A1 | COMBINATION OF BUB1 AND ATR INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-15 | — | — | WO | disclosed |
| EP-3401314-A1 | COVALENT INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-2363419-B1 | Polymer product formed using raft agent | UNIV SYDNEY (AU) | 2018-11-14 | — | — | EP | disclosed |
| US-10124007-B2 | Combination of PI3K-inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-13 | — | — | US | disclosed |
| CN-108779138-A | Design and synthesis of nucleotides based on novel disulfide linkers for use as reversible terminators for DNA sequencing by synthesis | 哥伦比亚大学董事会 | 2018-11-09 | — | — | CN | disclosed |
| CN-108778270-A | A kind of bactericidal composition and application thereof | 山东轩竹医药科技有限公司 | 2018-11-09 | — | — | CN | disclosed |
| WO-2018204691-A1 | METHODS AND ENZYME CATALYSTS FOR THE SYNTHESIS OF NON-CANONICAL AMINO ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-11-08 | — | — | WO | disclosed |
| WO-2018204532-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20180318438-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| WO-2018204370-A1 | CX3CR1 SMALL MOLECULE ANTAGONISTS, AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20180319775-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-11-08 | — | — | US | disclosed |
| US-20180318437-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| US-20180318304-A1 | Methods of Using BTK Inhibitors to Treat Dermatoses | ACERTA PHARMA BV (NL) | 2018-11-08 | — | — | US | disclosed |
| US-20180318790-A1 | AROMATIC HYDROGENATION CATALYSTS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2018-11-08 | — | — | US | disclosed |
| US-20180319769-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| EP-3399038-A2 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | Sarepta Therapeutics, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3030252-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3397613-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics Inc. (CA) | 2018-11-07 | — | — | EP | disclosed |
| EP-3397276-A1 | ANTIBODIES AND CONJUGATES THEREOF | Kodiak Sciences Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3397617-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| CN-108727361-A | Indole amine 2,3-dioxygenase inhibitor and application | 南京药捷安康生物科技有限公司 | 2018-11-02 | — | — | CN | disclosed |
| US-20180311210-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS | 2018-11-01 | — | — | US | disclosed |
| WO-2018200571-A1 | SUBSTITUTED 2,3-DIHYDRO-1H-INDENE ANALOGS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018200812-A1 | ANTIBODY CONJUGATES COMPRISING STING AGONIST | NOVARTIS AG (CH) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018200943-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018200517-A1 | METHODS OF MANUFACTURING OF NIRAPARIB | TESARO, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018198077-A2 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | NOVARTIS AG (CH) | 2018-11-01 | — | — | WO | disclosed |
| EP-3394079-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | Oric Pharmaceuticals, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-3394049-A1 | CYANOPYRROLIDINE DERIVATIVES AS INHIBITORS FOR DUBS | Mission Therapeutics Limited (GB) | 2018-10-31 | — | — | EP | disclosed |
| EP-2836487-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-3395818-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-31 | — | — | EP | disclosed |
| EP-2467141-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-3394078-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | Oric Pharmaceuticals, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| US-10111883-B1 | Selective P2X3 modulators | BELLUS HEALTH COUGH INC. (CA) | 2018-10-30 | — | — | US | disclosed |
| US-10111874-B2 | Combination therapies for treatment of cancer | ARAXES PHARMA LLC (US) | 2018-10-30 | — | — | US | disclosed |
| US-10112940-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC | 2018-10-25 | — | — | US | disclosed |
| US-20180305721-A1 | Biocatalytic Synthesis of Strained Carbocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-10-25 | — | — | US | disclosed |
| US-20180305305-A1 | 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2018-10-25 | — | — | US | disclosed |
| US-20180305368-A1 | ARTIFICIAL METALLOENZYMES CONTAINING NOBLE METAL-PORPHYRINS | U.S. DEPARTMENT OF ENERGY | 2018-10-25 | — | — | US | disclosed |
| WO-2018191789-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIVERSITY OF TASMANIA (AU) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018193428-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | SYNTHENA AG (CH) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018195121-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018195155-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180305336-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-25 | — | — | US | disclosed |
| US-20180303925-A1 | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response | Acuitas Therapeutics, Inc. (CA) | 2018-10-25 | — | — | US | disclosed |
| EP-3390391-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| EP-2920175-B1 | TRIAZOLOPYRIDAZINE DERIVATIVES AS BROMODOMAIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-10-24 | — | — | EP | disclosed |
| EP-2828395-B1 | BORONIC ACID CONJUGATES OF OLIGONUCLEOTIDE ANALOGUES | SAREPTA THERAPEUTICS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| CN-106488919-B | 3-substituted 2-aminoindole derivatives | 武田药品工业株式会社 | 2018-10-23 | — | — | CN | disclosed |
| US-10106534-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| CN-108699035-A | Noval chemical compound | 特殊治疗有限公司 | 2018-10-23 | — | — | CN | disclosed |
| WO-2018191657-A1 | LIPIDS FOR DELIVERY OF ACTIVE AGENTS | Acuitas Therapeutics, Inc. (CA) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018191270-A1 | CATALYSTS FOR OLEFIN ISOMERIZATION | BRANDEIS UNIVERSITY (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018191719-A1 | LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | Acuitas Therapeutics, Inc. (CA) | 2018-10-18 | — | — | WO | disclosed |
| US-20180297984-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2018-10-18 | — | — | US | disclosed |
| US-20180297999-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2018-10-18 | — | — | US | disclosed |
| US-20180298383-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-10-18 | — | — | US | disclosed |
| WO-2018191548-A2 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018191283-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ORIC PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| EP-3386504-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2018-10-17 | — | — | EP | disclosed |
| US-10100311-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2018-10-16 | — | — | US | disclosed |
| US-10100046-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-10098878-B2 | HIF-2α inhibitors for treating iron overload disorders | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-10-16 | — | — | US | disclosed |
| US-10100018-B2 | Amide derivatives as lysophosphatidic acid receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| US-10100056-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2018-10-16 | — | — | US | disclosed |
| US-10100305-B2 | Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites | SAREPTA THERAPEUTICS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180290967-A1 | Novel Antibacterial Compounds and Methods of Making and Using Same | BRYANT UNIVERSITY | 2018-10-11 | — | — | US | disclosed |
| US-20180291030-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-10-11 | — | — | US | disclosed |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-11 | — | — | US | disclosed |
| EP-3383859-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30. | Mission Therapeutics Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| EP-3180345-B1 | THIENO- AND FURO[2,3-D]PYRIMIDINE-2,4[1H,3H]-DIONE DERIVATIVES AS TRPC5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | HYDRA BIOSCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-3384549-A1 | SODIUM-ION ELECTROLYTE COMPOSITION | Deakin University (AU) | 2018-10-10 | — | — | EP | disclosed |
| EP-3180337-B1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-3180340-B1 | PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-10093906-B2 | Cytochrome C protein variants for catalyzing carbon-silicon bond formation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-10-09 | — | — | US | disclosed |
| US-10093635-B2 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018183936-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERS | THE BROAD INSTITUTE, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018183635-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018183795-A1 | METHOD OF MAKING TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID COMPOUNDS | SCIFLUOR LIFE SCIENCES, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018183654-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018183328-A1 | CROSS-COUPLING REACTION CATALYSTS, AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20180280367-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | MONASH UNIVERSITY (AU) | 2018-10-04 | — | — | US | disclosed |
| US-20180282947-A1 | COATING FOR RECYCLABLE PAPER | JL DARLING, LLC | 2018-10-04 | — | — | US | disclosed |
| US-20180282327-A1 | METHOD OF MAKING TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID COMPOUNDS | FELIQS CORPORATION (JP) | 2018-10-04 | — | — | US | disclosed |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
| US-20180282288-A1 | LP-PLA2 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-10-04 | — | — | US | disclosed |
| US-20180282818-A1 | Therapeutic Cancer Treatments Based on TP53 Gene Mutations | WISTAR INST (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180282307-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-10-04 | — | — | US | disclosed |
| US-20180282308-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-10-04 | — | — | US | disclosed |
| EP-3380536-A1 | A POLYMERIC COMPOSITION | Agency For Science, Technology And Research (SG) | 2018-10-03 | — | — | EP | disclosed |
| US-10087320-B2 | Conductive polymer-matrix compositions and uses thereof | POLYDROP, LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-10085452-B2 | Synergistic benzoxaborole-containing anti-fungicidal composition | THE PENN STATE RESEARCH FOUNDATION (US) | 2018-10-02 | — | — | US | disclosed |
| CN-108601832-A | The medical usage of anti-C-met antibodies-cytotoxic drug conjugate | 苏州盛迪亚生物医药有限公司 | 2018-09-28 | — | — | CN | disclosed |
| WO-2018172250-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018172852-A1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175628-A1 | BIOCATALYTIC SYNTHESIS OF STRAINED CARBOCYCLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-09-27 | — | — | WO | disclosed |
| US-20180273541-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-09-27 | — | — | US | disclosed |
| US-20180271893-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. | 2018-09-27 | — | — | US | disclosed |
| US-20180273580-A1 | NOVEL 7-DEHYDROCHOLESTEROL DERIVATIVES AND METHODS USING SAME | UNIVERSITY OF ROCHESTER | 2018-09-27 | — | — | US | disclosed |
| US-20180273515-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-09-27 | — | — | US | disclosed |
| US-20180273535-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | HCR COLLATERAL MANAGEMENT, LLC | 2018-09-27 | — | — | US | disclosed |
| US-20180271843-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180273505-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180273547-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180273533-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2018-09-27 | — | — | US | disclosed |
| US-20180273523-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-09-27 | — | — | US | disclosed |
| US-20180273917-A1 | HEME PROTEIN CATALYSTS FOR CARBON-BORON BOND FORMATION IN VITRO AND IN VIVO | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-09-27 | — | — | US | disclosed |
| EP-3377499-A1 | COMPOUNDS AND METHODS FOR TREATING SYNOVIAL SARCOMAS | Kadoch, Cigall (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-3377060-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-3377487-A1 | COMPOUNDS FOR MEDICINAL APPLICATIONS | Australian Biomedical Co. Pty Ltd (AU) | 2018-09-26 | — | — | EP | disclosed |
| EP-3377481-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-2686296-B1 | SUBSTITUTED 4-CYAN-3-(2,6-DIFLUOROPHENYL)-4-PHENYLBUTANOATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2018-09-26 | — | — | EP | disclosed |
| US-20180263964-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2018-09-20 | — | — | US | disclosed |
| US-20180264128-A1 | COMPOUNDS FOR MEDICINAL APPLICATIONS | Australian Biomedical Co. Pty Ltd. (AU) | 2018-09-20 | — | — | US | disclosed |
| US-20180265491-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-09-20 | — | — | US | disclosed |
| WO-2018169880-A1 | DUAL MAGL AND FAAH INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180263970-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS | THE BROAD INSTITUTE, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| WO-2018167019-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-09-20 | — | — | WO | disclosed |
| EP-3375781-A1 | BENZO RING DERIVATIVE WITH B2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2018-09-19 | — | — | EP | disclosed |
| CN-105263855-B | The system and method analyzed using polymer point | 华盛顿大学商业中心 | 2018-09-18 | — | — | CN | disclosed |
| US-10076536-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-10077271-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| WO-2018165325-A1 | HEME PROTEIN CATALYSTS FOR CARBON-BORON BOND FORMATION IN VITRO AND IN VIVO | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-09-13 | — | — | WO | disclosed |
| US-20180258111-A1 | Acene-based transmitter molecules for photon upconversion | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-09-13 | — | — | US | disclosed |
| US-20180256591-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-20180258103-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180258127-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180256566-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2018-09-13 | — | — | US | disclosed |
| EP-3150609-B1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | INTELLIKINE LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-3370523-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR COLORING EDIBLE MATERIALS | The Penn State Research Foundation (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-3371164-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-3370518-A2 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | X-Therma, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| US-10071101-B2 | Use of cinnabarinic acid as a modulator of immune response in autoimmune disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-11 | — | — | US | disclosed |
| US-10071984-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| CN-108513537-A | Method for screening agent for differentiating stem cells | 米纳瓦生物技术公司 | 2018-09-07 | — | — | CN | disclosed |
| US-20180250298-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| US-20180251445-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-09-06 | — | — | US | disclosed |
| US-20180250313-A1 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | VIEWPOINT THERAPEUTICS, INC. | 2018-09-06 | — | — | US | disclosed |
| US-20180251458-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180250400-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| EP-3367999-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | The Procter and Gamble Company (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3368507-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2018-09-05 | — | — | EP | disclosed |
| EP-3368582-A1 | POLYURETHANE/UREA MATERIALS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2018-09-05 | — | — | EP | disclosed |
| EP-3368556-A2 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | Tufts University (US) | 2018-09-05 | — | — | EP | disclosed |
| US-10065926-B2 | Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-09-04 | — | — | US | disclosed |
| CN-108473632-A | Polymeric compositions | 新加坡科技研究局 | 2018-08-31 | — | — | CN | disclosed |
| CN-108473483-A | Compound for medical applications | 澳大利亚生物医学公司 | 2018-08-31 | — | — | CN | disclosed |
| US-20180244839-A1 | MULTICOLORED ELECTROCHROMIC POLYMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | LANNRAY ADVANCED MATERIALS CO. LTD (CN) | 2018-08-30 | — | — | US | disclosed |
| US-20180243314-A1 | NO-DONORS FOR THE TREATMENT OF CEREBROVASCULAR VASOSPASMS AFTER BRAIN HEMORRHAGE | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2018-08-30 | — | — | US | disclosed |
| US-20180243303-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2018-08-30 | — | — | US | disclosed |
| US-20180244762-A1 | DUAL PDGF/VEGF ANTAGONISTS | KODIAK SCIENCES INC. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180243425-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2018-08-30 | — | — | US | disclosed |
| US-20180245011-A1 | A BASE OIL ADDITIVE | AGENCY FOR SCIENCE, TECHOLOGY AND RESEARCH (SG) | 2018-08-30 | — | — | US | disclosed |
| US-20180246102-A1 | METHOD FOR SCREENING INHIBITORS OF RAS | ARAXES PHARMA LLC | 2018-08-30 | — | — | US | disclosed |
| US-20180243239-A1 | 2,4,6-TRIALKOXYSTRYL ARYL SULFONES, SULFONAMIDES AND CARBOXAMIDES, AND METHODS OF PREPARATION AND USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2018-08-30 | — | — | US | disclosed |
| US-20180244674-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| WO-2018153972-A1 | COMBINATION OF ATR KINASE INHIBITORS AND ANTIANDROGENS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153973-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153971-A1 | COMBINATION OF ATR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153969-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH RADIUM-223 SALT | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| EP-3364977-A2 | METHOD FOR SCREENING INHIBITORS OF RAS | Araxes Pharma LLC (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-2768830-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-10059687-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-10059796-B2 | Conjugated polymers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2018-08-28 | — | — | US | disclosed |
| US-10059713-B2 | 3-substituted 2-amino-indole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-28 | — | — | US | disclosed |
| CN-105745196-B | The conversion and purifying of biomass | 新加坡科技研究局 | 2018-08-28 | — | — | CN | disclosed |
| US-20180237626-A1 | CONDUCTIVE POLYMER-MATRIX COMPOSITIONS AND USES THEREOF | POLYDROP, LLC | 2018-08-23 | — | — | US | disclosed |
| US-20180237641-A1 | PHENYLETHYNYLNAPHTHALENE DYES AND METHODS FOR THEIR USE | SONY CORPORATION (JP) | 2018-08-23 | — | — | US | disclosed |
| US-20180237396-A1 | Processes For Preparing AG-10, Its Intermediates, and Salts Thereof | CALCILYTIX THERAPEUTICS INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2018-08-23 | — | — | US | disclosed |
| WO-2018151837-A1 | CONDUCTIVE POLYMER-MATRIX COMPOSITIONS AND USES THEREOF | POLYDROP, LLC (US) | 2018-08-23 | — | — | WO | disclosed |
| US-20180240565-A1 | CONDUCTIVE POLYMER-MATRIX COMPOSITIONS AND USES THEREOF | POLYDROP LLC (US) | 2018-08-23 | — | — | US | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-3363800-A1 | HETEROCYCLIC INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2953940-B1 | PIPERIDIN-1-YL AND AZEPIN-1-YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| US-10053490-B2 | Antimicrobial peptidomimetics | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-08-21 | — | — | US | disclosed |
| US-20180221406-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | FORESIGHT BIOTHERAPEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180223287-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2018-08-09 | — | — | US | disclosed |
| EP-3356354-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356339-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356347-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356353-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356387-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | Monash University (AU) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356349-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356359-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356351-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040779-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| CN-108368089-A | Novel Compounds | 特殊治疗有限公司 | 2018-08-03 | — | — | CN | disclosed |
| US-20180215769-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2018140599-A1 | BENZOTHIOPHENE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140600-A1 | FUSED HETERO-HETERO BICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140598-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140514-A1 | 1-(6-(3-HYDROXYNAPHTHALEN-1-YL)QUINAZOLIN-2-YL)AZETIDIN-1-YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140512-A1 | FUSED BICYCLIC BENZOHETEROAROMATIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140513-A1 | 1-(3-(6-(3-HYDROXYNAPHTHALEN-1-YL)BENZOFURAN-2-YL)AZETIDIN-1YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C MODULATORS FOR TREATING CANCER | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| EP-2367799-B1 | 2-AMINO-5-TRIFLUOROMETHYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS PTK2 KINASE INHIBITORS | IPHARMA H K LTD (HK) | 2018-08-01 | — | — | EP | disclosed |
| EP-3352566-A2 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | Minerva Biotechnologies Corporation (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2970303-B3 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-10035809-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10036754-B2 | Water soluble fluorescent or colored dyes and methods for their use | SONY CORPORATION (JP) | 2018-07-31 | — | — | US | disclosed |
| CN-108350034-A | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2018-07-31 | — | — | CN | disclosed |
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-26 | — | — | US | disclosed |
| US-20180206495-A1 | SUBSTITUTED ARYL AND HETEROARYL CARBOXYLIC ACID HYDRAZIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180208554-A1 | Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof | UNIVERSITY OF MARYLAND, BALTIMORE | 2018-07-26 | — | — | US | disclosed |
| US-20180206491-A1 | SUBSTITUTED CYCLIC ARYL AND HETEROARYL CARBOXYLIC ACID HYDRAZIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180206498-A1 | SUBSTITUTED HETEROARYL CARBOXYLIC ACID HYDRAZIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207154-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-07-26 | — | — | US | disclosed |
| WO-2018136650-A1 | COMPOSITIONS AND METHODS FOR TREATING ANDROGEN-INDEPENDENT CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018136546-A1 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018134335-A1 | SUBSTITUTED IMIDAZOPYRIDINPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018136014-A1 | A FORMULATION, A METHOD OF FORMING THE SAME AND ITS USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018134148-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018134786-A1 | COMPOSITIONS AND METHODS FOR THE ASSESSMENT OF DRUG TARGET OCCUPANCY FOR BRUTON'S TYROSINE KINASE | ACERTA PHARMA B.V. (NL) | 2018-07-26 | — | — | WO | disclosed |
| EP-3349747-A1 | NO-DONORS FOR THE TREATMENT OF CEREBROVASCULAR VASOSPASMS AFTER BRAIN HEMORRHAGE | Ehlert, Angelika (DE) | 2018-07-25 | — | — | EP | disclosed |
| EP-3156387-B1 | METHOD OF PREPARING INDENE DERIVATIVES | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-07-25 | — | — | EP | disclosed |
| EP-3351248-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-10029207-B2 | Composite gas separation membrane | THE UNIVERSITY OF MELBOURNE (AU) | 2018-07-24 | — | — | US | disclosed |
| US-10030017-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030012-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-20180199575-A1 | SUBSTITUTED OXOTETRAHYDROQUINOLINYLPHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-07-19 | — | — | US | disclosed |
| US-20180201584-A1 | ARYL SULFONAMIDE COMPOUNDS AS CARBONIC ANHYDRASE INHIBITORS AND THEIR THERAPEUTIC USE | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2018-07-19 | — | — | US | disclosed |
| EP-1463765-B1 | AQUEOUS DISPERSIONS OF POLYMER PARTICLES | UNIV SYDNEY (AU) | 2018-07-18 | — | — | EP | disclosed |
| EP-3347368-A1 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | Viewpoint Therapeutics, Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3347340-A1 | LYMPH DIRECTING PRODRUGS | Monash University (AU) | 2018-07-18 | — | — | EP | disclosed |
| EP-3004239-B1 | SCRATCH RESISTANT POLYMERS | TENASITECH PTY LTD (AU) | 2018-07-18 | — | — | EP | disclosed |
| US-10022701-B2 | Coating methods using organosilica materials and uses thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023543-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10021877-B2 | Substituted 5-hydroxy-2,3-diphenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10022700-B2 | Organosilica materials and uses thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023557-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-07-17 | — | — | US | disclosed |
| CN-108290861-A | 1- cyano-pyrolidin derivatives as USP30 inhibitor | 特殊治疗有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-108290893-A | Dihydroperidinone derivatives, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-108290872-A | Cyanopyrolidine derivatives as DUBs inhibitor | 特殊治疗有限公司 | 2018-07-17 | — | — | CN | disclosed |
| WO-2018129552-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018129556-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018129533-A1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | SHUTTLE PHARMACEUTICALS, LLC (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180193337-A1 | Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine Kinase | ACERTA PHARMA BV (NL) | 2018-07-12 | — | — | US | disclosed |
| WO-2018129557-A1 | INHIBITORS OF NHE-MEDIATED ANTIPORT | ARDELYX, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180194748-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-07-12 | — | — | US | disclosed |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194724-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| EP-3169662-B1 | SUBSTITUTED VINYL- AND ALKINYL-CYANOCYCLOALKANOLS AND VINYL- AND ALKINYL-CYANOHETEROCYCLOALKANOLS AS AGENTS TO COMBAT ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2964645-B1 | PROCESS FOR IXABEPILONE, AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN LTD (TW) | 2018-07-11 | — | — | EP | disclosed |
| EP-2872899-B1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS INC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-10016401-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | PAIN THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017763-B2 | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2018125901-A1 | MODIFICATION OF SURFACE PROPERTIES OF MICROFLUIDIC DEVICES | BIO-RAD LABORATORIES, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
| US-20180185516-A1 | DELIVERY OF TARGET SPECIFIC NUCLEASES | Acuitas Therapeutics, Inc. (CA) | 2018-07-05 | — | — | US | disclosed |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
| EP-3341421-A1 | AMPHIPHILIC RAFT AGENT | Commonwealth Scientific and Industrial Research Organisation (AU) | 2018-07-04 | — | — | EP | disclosed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | disclosed |
| US-10010538-B2 | Use of anthelmintic agents against Dirofilaria immitis | INTERVET INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011583-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| CN-108218868-A | Multi-kinase inhibitor compound, its crystal form and purposes | 南京药捷安康生物科技有限公司 | 2018-06-29 | — | — | CN | disclosed |
| CN-104955454-B | Chemokine receptor anagonists | 凯莫森特里克斯股份有限公司 | 2018-06-29 | — | — | CN | disclosed |
| US-20180179310-A1 | Spray-Dried Olefin Polymerization Catalyst Compositions and Polymerization Processes for Using the Same | EXXONMOBIL CHEMICAL PATENTS INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179324-A1 | SYNTHESIS OF POLYCARBONATE SILOXANE DIOLS | AORTECH INTERNATIONAL PLC (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2018-06-28 | — | — | US | disclosed |
| US-20180179204-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180178213-A1 | MODIFICATION OF SURFACE PROPERTIES OF MICROFLUIDIC DEVICES | BIO-RAD LABORATORIES, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180177754-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | PELOTON THERAPEUTICS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | disclosed |
| WO-2018118259-A1 | SPRAY-DRIED OLEFIN POLYMERIZATION CATALYST COMPOSITIONS AND POLYMERIZATION PROCESSES FOR USING THE SAME | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018117974-A1 | A CURABLE COATING COMPOSITION AND METHOD OF PREPARING A COATING FILM | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018114662-A1 | SUBSTITUTED 1,2,4-THIADIAZOLYL PYRROLONES AND 1,2,4-THIADIAZOLYL HYDANTOINES AND SALTS THEREOF AND USE THEREOF AS HERBICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018115380-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018114798-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018112555-A1 | AQUEOUS POLYMER COMPOSITION | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2018-06-28 | — | — | WO | disclosed |
| EP-2993165-B1 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USE THEREOF | ALLIANZ PHARMASCIENCE LTD (TW) | 2018-06-27 | — | — | EP | disclosed |
| EP-2693878-B1 | SUBSTITUTED (3R,4R)-4-CYAN-3,4-DIPHENYLBUTANOATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER IP GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| US-20180170891-A1 | 4H-Pyran Compounds as Insulin-Regulated Aminopeptidase (IRAP) Inhibitors | MONASH UNIVERSITY (AU) | 2018-06-21 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2018-06-21 | — | — | US | disclosed |
| WO-2018108704-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018107226-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2018-06-21 | — | — | WO | disclosed |
| US-10000520-B2 | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | ChromaDex Inc. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9999217-B2 | Compositions for stabilizing DNA, RNA, and proteins in blood and other biological samples during shipping and storage at ambient temperatures | BIOMATRICA, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20180162804-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162854-A1 | Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180163052-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES AND METHODS FOR THEIR USE | Sony Group Corporation (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162877-A1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-14 | — | — | US | disclosed |
| US-20180161359-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20180162836-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162802-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| WO-2018107167-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018107153-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018107026-A1 | DELIVERY OF TARGET SPECIFIC NUCLEASES | SANGAMO THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018107158-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106284-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | WO | disclosed |
| EP-3332645-A1 | USE OF SUBSTITUTED PYRIMIDINE DIONES OR THEIR SALTS AS AGENTS TO COMBAT ABIOTIC PLANT STRESS | Bayer Cropscience AG (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-3203841-B1 | SUBSTITUTED 5-HYDROXY-2-PHENYL-3-HETEROARYLPENTANONITRILE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2001911-B1 | POLYMER PRODUCT AND INTERFACIAL POLYMERISATION PROCESS USING RAFT AGENT | UNIV SYDNEY (AU) | 2018-06-13 | — | — | EP | disclosed |
| EP-3331894-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | Metro International Biotech, LLC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994561-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993484-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994534-B2 | Pain-relieving compositions and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-06-12 | — | — | US | disclosed |
| US-9994518-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| CN-108137482-A | Lymphatic prodrugs | 莫纳什大学 | 2018-06-08 | — | — | CN | disclosed |
| US-20180155279-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155359-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | TARO PHARMACEUTICALS INC. (CA) | 2018-06-07 | — | — | US | disclosed |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NORTHWESTERN UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-20180153888-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | BERGENBIO ASA (NO) | 2018-06-07 | — | — | US | disclosed |
| US-20180153887-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-06-07 | — | — | US | disclosed |
| EP-3328384-A1 | FIBROTIC TREATMENT | Monash University (AU) | 2018-06-06 | — | — | EP | disclosed |
| US-9988357-B2 | Methods for preparation of quinazoline derivatives | ARAXES PHARMA LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988382-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9986733-B2 | Compositions and methods for reducing ice crystal formation | X-THERMA, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| CN-105308041-B | Preparation method for ixabepilone and intermediate thereof | 台湾神隆股份有限公司 | 2018-06-01 | — | — | CN | disclosed |
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2018-05-31 | — | — | US | disclosed |
| US-20180148745-A1 | HEMOPROTEIN CATALYSTS FOR IMPROVED ENANTIOSELECTIVE ENZYMATIC SYNTHESIS OF TICAGRELOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148413-A1 | SUBSTITUTED PYRIDINES AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
| EP-3325467-A1 | SUBSTITUTED HETEROARYL CARBOXYLIC ACID HYDRAZIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325466-A1 | SUBSTITUTED CYCLIC ARYL AND HETEROARYL CARBOXYLIC ACID HYDRAZIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325446-A1 | SUBSTITUTED ARYL AND HETEROARYL CARBOXYLIC ACID HYDRAZIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325447-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND THEIR USE AS INHIBITORS OF G12C MUTANT KRAS, HRAS AND/OR NRAS PROTEINS | Araxes Pharma LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9981989-B2 | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors | Atrin Pharmaceuticals LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981972-B2 | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9982010-B2 | 7-dehydrocholesterol derivatives and methods using same | WOMEN & INFANTS HOSPITAL OF RHODE ISLAND (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180140595-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141898-A1 | PESTICIDALLY ACTIVE OXIME AND HYDRAZONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-05-24 | — | — | US | disclosed |
| US-20180141912-A1 | VERSATILE RAFT AGENT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2018-05-24 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-05-24 | — | — | US | disclosed |
| WO-2018094275-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093946-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093924-A1 | CARBON MONOXIDE-RELEASING MOLECULES AND THERAPEUTIC APPLICATIONS THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180142066-A1 | SULFUR TERMINATED ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2018-05-24 | — | — | US | disclosed |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| EP-3322702-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | Mission Therapeutics Limited (GB) | 2018-05-23 | — | — | EP | disclosed |
| EP-3322296-A1 | SUBSTITUTED OXO-TETRAHYDROQUINOLINYL-PHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2018-05-23 | — | — | EP | disclosed |
| US-9975989-B2 | Multicolored electrochromic polymer compositions and methods of making and using the same | Furcifer Inc. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975915-B1 | Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-05-22 | — | — | US | disclosed |
| US-20180134742-A1 | CRYSTALLINE FORMS OF NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, AND PHOSPHORYLATED ANALOGS THEREOF, AND METHODS OF PREPARATION THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| WO-2018089830-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-05-17 | — | — | WO | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134743-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| EP-2410987-B1 | METHODS OF TREATMENT USING COMBINATION THERAPY | AMBIT BIOSCIENCES CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3319938-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEREOF | University of Maryland, Baltimore (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9969844-B2 | Silicone ligands for quantum dots | NANOSYS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969736-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968684-B2 | Polymer-NSAID conjugate | POLYACTIVA PTY LTD (AU) | 2018-05-15 | — | — | US | disclosed |
| US-9969689-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| CN-108026142-A | Ligands for orphan nuclear receptor Nur77 and uses thereof | 厦门大学 | 2018-05-11 | — | — | CN | disclosed |
| CN-108026141-A | Ligand of orphan nuclear receptor Nur77 and application thereof | 厦门大学 | 2018-05-11 | — | — | CN | disclosed |
| US-20180127424-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-05-10 | — | — | US | disclosed |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180125844-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | CELGENE CORPORATION (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127464-A1 | NOVEL EPHA4 INHIBITORS TARGETING ITS LIGAND BINDING DOMAIN | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2018-05-10 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
| EP-3317255-A1 | ARYL SULFONAMIDE COMPOUNDS AS CARBONIC ANHYDRASE INHIBITORS AND THEIR THERAPEUTIC USE | SignalChem Lifesciences Corporation (CA) | 2018-05-09 | — | — | EP | disclosed |
| EP-3317241-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2018-05-09 | — | — | EP | disclosed |
| EP-3317259-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2018-05-09 | — | — | EP | disclosed |
| EP-3316890-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | Neurad Ltd. (IL) | 2018-05-09 | — | — | EP | disclosed |
| EP-3316884-A1 | THERAPEUTIC INHIBITORY COMPOUDS | Lifesci Pharmaceuticals, Inc. (BB) | 2018-05-09 | — | — | EP | disclosed |
| EP-2968282-B1 | HISTONE DEMENTHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9963492-B2 | High molecular weight, post-translationally modified protein brushes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| CN-105189484-B | Cxcr7 antagonists | 凯莫森特里克斯股份有限公司 | 2018-05-04 | — | — | CN | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| WO-2018081638-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018081672-A1 | BIARYL LIGANDS FOR TRANSITION METAL-CATALYZED REACTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| WO-2018081480-A1 | LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2018-05-03 | — | — | WO | disclosed |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2018-05-03 | — | — | US | disclosed |
| US-20180117075-A1 | THERAPY FOR MALIGNANT DISEASE | WOMEN & INFANTS HOSPITAL OF RHODE ISLAND | 2018-05-03 | — | — | US | disclosed |
| US-20180117574-A1 | BIARYL LIGANDS FOR TRANSITION METAL-CATALYZED REACTIONS | UNIV CALIFORNIA (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | GRA VENTURE FUND, LLC | 2018-05-03 | — | — | US | disclosed |
| EP-3313522-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3140304-B1 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3313525-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2095131-B1 | TAGGED PETROLEUM PRODUCTS AND METHODS OF DETECTING THE SAME | AUTHENTIX INC (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-3313521-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| US-9957235-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-01 | — | — | US | disclosed |
| US-9956222-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-9956541-B2 | Methods of separating aromatic compounds from lube base stocks | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956551-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957248-B2 | Substituted 5-hydroxy-2-heteroaryl-3-phenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators | BAYER CROPSCIENCE AKTIENGESELLSHAFT (DE) | 2018-05-01 | — | — | US | disclosed |
| US-9957224-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2018075871-A1 | NOVEL ANTIBIOTICS AND METHODS OF USING SAME | THE BROAD INSTITUTE, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180111910-A1 | PAIN-RELIEVING COMPOSITIONS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-04-26 | — | — | US | disclosed |
| EP-3310440-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-25 | — | — | EP | disclosed |
| EP-3177619-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2018-04-25 | — | — | EP | disclosed |
| EP-3310773-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3310776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9951027-B2 | Benzimidazol-2-amines as MIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949971-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2018-04-24 | — | — | US | disclosed |
| US-9951086-B2 | Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9951078-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180105521-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105531-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2018-04-19 | — | — | US | disclosed |
| EP-3307716-A1 | VERSATILE RAFT AGENT | Commonwealth Scientific and Industrial Research Organisation (AU) | 2018-04-18 | — | — | EP | disclosed |
| EP-2595987-B1 | NEW AMINOPYRAZOLOQUINAZOLINES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-18 | — | — | EP | disclosed |
| EP-2863921-B1 | POLYMER-NSAID CONJUGATE | POLYACTIVA PTY LTD (AU) | 2018-04-18 | — | — | EP | disclosed |
| US-9944628-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944636-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| CN-107922344-A | general RAFT agent | 联邦科学与工业研究组织 | 2018-04-17 | — | — | CN | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| WO-2018068017-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-04-12 | — | — | WO | disclosed |
| WO-2018068021-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20180100861-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES AND METHODS FOR THEIR USE | SONY CORPORATION (JP) | 2018-04-12 | — | — | US | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099019-A1 | Compositions and Methods for Managing Weight | UNIGEN, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| EP-2882439-B1 | APOPTOSIS-INDUCING AGENTS | ABBVIE INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3302481-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | BerGenBio ASA (NO) | 2018-04-11 | — | — | EP | disclosed |
| EP-3303285-A1 | PESTICIDALLY ACTIVE OXIME AND HYDRAZONE DERIVATIVES | Syngenta Participations AG (CH) | 2018-04-11 | — | — | EP | disclosed |
| EP-3003036-B1 | SUBSTITUTED 5-HYDROXY-2,3-DIPHENYLPENTANONITRILE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2018-04-11 | — | — | EP | disclosed |
| EP-3303317-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | Kura Oncology, Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3302589-A1 | PROCESS FOR THE PREPARATION OF POLYURETHANE SOLUTIONS BASED ON SILICON-POLYCARBONATE DIOLS | Aortech International PLC (GB) | 2018-04-11 | — | — | EP | disclosed |
| EP-3303267-A2 | HEMOPROTEIN CATALYSTS FOR IMPROVED ENANTIOSELECTIVE ENZYMATIC SYNTHESIS OF TICAGRELOR | California Institute of Technology (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3302489-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS | Sarepta Therapeutics, Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3302057-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | Kura Oncology, Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9938261-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937171-B2 | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase | ACERTA PHARMA B.V. (NL) | 2018-04-10 | — | — | US | disclosed |
| US-9937167-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| WO-2018060742-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018060691-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-05 | — | — | US | disclosed |
| WO-2018064510-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018064465-A1 | COMPOUNDS FOR INCREASING NEURAL PLASTICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-05 | — | — | WO | disclosed |
| EP-2918587-B1 | Filamin A binding compounds and their use as anti-inflammatory and analgesic agents | PAIN THERAPEUTICS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2788487-B1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2919790-B1 | GEMCITABINE PRODRUGS AND USES THEREOF | BOYEN THERAPEUTICS INC (TW) | 2018-04-04 | — | — | EP | disclosed |
| US-9931340-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-03 | — | — | US | disclosed |
| CN-104797257-B | Polymer NSAID conjugates | 波利艾克蒂瓦有限公司 | 2018-04-03 | — | — | CN | disclosed |
| CN-107872956-A | Synergistic antifungal composition containing benzoxaborole | 宾夕法尼亚州研究基金会 | 2018-04-03 | — | — | CN | disclosed |
| US-20180085348-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086753-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-03-29 | — | — | US | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| WO-2018055577-A1 | MIXED TRICYCLO-DNA, 2'-MODIFIED RNA OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF | SYNTHENA AG (CH) | 2018-03-29 | — | — | WO | disclosed |
| US-20180087005-A1 | Fragrance Compositions Comprising Ionic Liquids | THE PROCTER & GAMBLE COMPANY | 2018-03-29 | — | — | US | disclosed |
| EP-3297758-A1 | NANO-TO-NANO FE/PPM PD CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2160192-B1 | ANTIMICROBIAL MATERIALS AND COATINGS | COVIDIEN LP (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3297990-A1 | SODIUM CHANNEL MODULATORS | The Florey Institute Of Neuroscience And Mental Health (AU) | 2018-03-28 | — | — | EP | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-9926245-B2 | Fuels and chemicals from lower alkanes | Pioneer Energy (US) | 2018-03-27 | — | — | US | disclosed |
| CN-107847765-A | The piperidine derivative of 1,4 substitutions | 赛福伦公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107846883-A | The solvent-free phosphorylation of selectivity | 可劳迈戴斯有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107849013-A | It is used for the cyanopyrrole alkanes for the treatment of cancer as DUB inhibitor | 特殊治疗有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107840842-A | Alkynes is for heterocyclic compound, its preparation method and its in application pharmaceutically | 北京天诚医药科技有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-105473548-B | Amide derivatives as lpa receptor antagonist | 武田药品工业株式会社 | 2018-03-23 | — | — | CN | disclosed |
| WO-2018050794-A1 | PROCESS FOR PREPARING OF CAROTENOID MONO-ESTERS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050792-A1 | PROCESS FOR PREPARING ESTERS OF 12'-APOCAROTENALS AS BUILDING BLOCKS FOR CAROTENOIDS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050795-A1 | PROCESS FOR PREPARING OF CAROTENOID MONO-ESTERS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018052967-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050793-A1 | PROCESS FOR PREPARING PHOSPHONIUM SALT ESTERS AS BUILDING BLOCKS FOR CAROTENOIDES | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053161-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | NATIONAL TAIWAN UNIVERSITY (TW) | 2018-03-22 | — | — | WO | disclosed |
| US-20180079909-A1 | ULTRA BRIGHT DIMERIC OR POLYMERIC DYES | SONY CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3294811-A1 | ULTRA BRIGHT DIMERIC OR POLYMERIC DYES | Sony Corporation (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-2701506-B1 | FORMULATION COMPONENT | SYNGENTA LTD (GB) | 2018-03-21 | — | — | EP | disclosed |
| EP-3294721-A1 | 4H-PYRAN COMPOUNDS AS INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS | Monash University (AU) | 2018-03-21 | — | — | EP | disclosed |
| EP-2788488-B1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-3294712-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9920085-B2 | Boronic acid conjugates of oligonucleotide analogues | SAREPTA THERAPEUTICS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9919288-B2 | ZIF-containing adsorbent materials and uses thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9919006-B2 | Compositions and methods for treating hyperkalemia | ARDELYX, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9919003-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2018-03-20 | — | — | US | disclosed |
| CN-107814798-A | 3 substitutional crylic acid class compounds and its production and use | 四川科伦博泰生物医药股份有限公司 | 2018-03-20 | — | — | CN | disclosed |
| US-20180072772-A1 | MUTANT AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2018-03-15 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072714-A1 | Novel Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072656-A1 | Sodium Channel Modulators | THE UNIVERSITY OF MELBOURNE (AU) | 2018-03-15 | — | — | US | disclosed |
| EP-2934136-B1 | SUBSTITUTED 4-CYAN-3-(PYRIDYL)-4-PHENYLBUTANOATES, METHOD FOR THE PRODUCTION THEREOF AND USES AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2018-03-14 | — | — | EP | disclosed |
| US-9917328-B2 | Halogenated organosilicon electrolytes, methods of using them, and electrochemical devices containing them | SILATRONIX, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9913875-B2 | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-03-13 | — | — | US | disclosed |
| CN-107793395-A | Fibroblast growth factor acceptor inhibitor and application thereof | 南京药捷安康生物科技有限公司 | 2018-03-13 | — | — | CN | disclosed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180064779-A1 | Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination Thereof | UNIGEN, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180064751-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065998-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES COMPRISING CONJUGATING GROUPS | Sony Group Corporation (JP) | 2018-03-08 | — | — | US | disclosed |
| EP-3290407-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3288932-A1 | NOVEL EPHA4 INHIBITORS TARGETING ITS LIGAND BINDING DOMAIN | Sanford-Burnham Medical Research Institute (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3288589-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | Foresight Biotherapeutics, Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2855449-B1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2074115-B1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2970764-B1 | METHOD FOR SOLVENTLESS QUANTUM DOT EXCHANGE | NANOSYS INC (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3289083-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE | The Trustees Of The University Of Pennsylvania (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9908865-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908845-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| CN-105324372-B | 1-sulfonylpiperidine derivatives as prokineticin receptor modulators | 武田药品工业株式会社 | 2018-03-06 | — | — | CN | disclosed |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| WO-2018039331-A1 | NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20180055899-A1 | Compositions and Methods for Managing or Improving Bone Disorders, Cartilage Disorders, or Both | UNIGEN, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| EP-3041840-B1 | RILYAZINE DERIVATIVES AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE WARNER-BABCOCK INST FOR GREEN CHEMISTRY LLC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2367800-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INT (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902738-B2 | Compounds and methods for preventing, treating and/or protecting against sensory hair cell death | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902719-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902727-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| CN-104902898-B | Diazole lactams | 凯莫森特里克斯股份有限公司 | 2018-02-23 | — | — | CN | disclosed |
| US-20180051036-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2018-02-22 | — | — | US | disclosed |
| WO-2018034801-A1 | METHODS OF TREATING ARID1A-MUTATED CANCERS WITH HDAC6 INHIBITORS AND EZH2 INHIBITORS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-02-22 | — | — | WO | disclosed |
| EP-2847163-B1 | IRON CHELATORS AS HIV-1 INHIBITORS | UNIV HOWARD (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2925760-B1 | C20'-SUBSTITITED UREA DERIVATIVES OF VINCA ALKALOIDS | SCRIPPS RESEARCH INST (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283462-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283076-A1 | METHODS OF TREATING HEPATITIS B VIRUS | Gilead Sciences, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283077-A2 | BROMODOMAIN INHIBITOR | Celgene Quanticel Research, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895334-B2 | Treatment of virally induced lesions | LEO LABORATORIES LIMITED (IE) | 2018-02-20 | — | — | US | disclosed |
| US-9896418-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| CN-107708757-A | Method for negatively affecting biomembrane | 联邦科学和工业研究组织 | 2018-02-16 | — | — | CN | disclosed |
| CN-107708701-A | Novel respiratory control modulating compounds and methods of making and using the same | 纽拉德有限公司 | 2018-02-16 | — | — | CN | disclosed |
| US-20180044346-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-20180044306-A1 | 1,3,4-THIADIAZOL-2-YL-BENZAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044334-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180042931-A1 | N-PHENYL-(MORPHOLIN-4-YL OR PIPERAZINYL)ACETAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| WO-2018031658-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | CELGENE CORPORATION (US) | 2018-02-15 | — | — | WO | disclosed |
| US-20180044296-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-3280708-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-02-14 | — | — | EP | disclosed |
| EP-2875018-B1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2018-02-14 | — | — | EP | disclosed |
| EP-3281942-A1 | B-LACTAMASE INHIBITOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3280262-A1 | SYNERGISTIC BENZOXABOROLE-CONTAINING ANTI-FUNGICIDAL COMPOSITION | The Penn State Research Foundation (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9890189-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2018-02-13 | — | — | US | disclosed |
| US-20180037583-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS LLC (US) | 2018-02-08 | — | — | US | disclosed |
| WO-2018026441-A1 | METHODS FOR PREVENTING OR TREATING FIBROTIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-3277677-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2018-02-07 | — | — | EP | disclosed |
| US-9884843-B2 | Cyclic sulfone and sulfoximine analogs and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20180030090-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | US | disclosed |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028507-A1 | 3-CARBAMOYLPHENYL-4-CARBOXAMIDE AND ISOPHTALAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-01 | — | — | US | disclosed |
| WO-2018022624-A1 | INHIBITION OF GALECTIN 3 BINDING TO THE AIRWAY EPITHELIAL SURFACE TO TREAT OR PREVENT SEPTIC SHOCK RESULTING FROM INFLUENZA AND SUBSEQUENT PNEUMOCOCCAL PNEUMONIA INFECTION | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20180028508-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-02-01 | — | — | US | disclosed |
| EP-3273974-A1 | THERAPY FOR MALIGNANT DISEASE | Women and Infants Hospital of Rhode Island Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9877958-B2 | Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879025-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879200-B2 | Lubricating compositions and methods for the use thereof | INGEVITY SOUTH CAROLINA, LLC (US) | 2018-01-30 | — | — | US | disclosed |
| WO-2018015328-A1 | UREA AND THIOUREA SUBSTITUTED BICYCLES DERIVATIVES AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018015818-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-01-25 | — | — | WO | disclosed |
| US-20180022756-A1 | COMPOUNDS AND METHODS FOR PREVENTING OR TREATING SENSORY HAIR CELL DEATH | FRED HUTCHINSON CANCER CENTER | 2018-01-25 | — | — | US | disclosed |
| US-20180020662-A1 | Substituted 1-cycloalkyl-2-oxotetrahydroquinolin-6-ylsulfonamides or salts thereof and use thereof to increase stress tolerance in plants | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180022757-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES, INC. | 2018-01-25 | — | — | US | disclosed |
| EP-3270951-A1 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | California Institute of Technology (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-3271352-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9873697-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2018-01-23 | — | — | US | disclosed |
| CN-107614062-A | Methods of treating cancer with ROR gamma inhibitors | 加利福尼亚大学董事会 | 2018-01-19 | — | — | CN | disclosed |
| WO-2018011569-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-01-18 | — | — | WO | disclosed |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-01-18 | — | — | US | disclosed |
| WO-2018011628-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-01-18 | — | — | WO | disclosed |
| US-20180015082-A1 | 6-Alkynyl-pyridine Derivatives | BOEHRINGER INGELHEIM INT (DE) | 2018-01-18 | — | — | US | disclosed |
| EP-3052096-B1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3267792-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | Peloton Therapeutics, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3268362-A1 | SUBSTITUTED PYRIDINES AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3268087-A1 | METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS | The Regents of the University of California (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9868722-B2 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9867848-B2 | Compositions and methods for treating hyperkalemia | ARDELYX, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| WO-2018009891-A1 | CONDUCTIVE CONFORMAL COATINGS | POLYDROP, LLC (US) | 2018-01-11 | — | — | WO | disclosed |
| US-20180009739-A1 | Ligand-Enabled meta-C-H Activation Using a Transient Mediator | THE SCRIPPS RESEARCH INSTITUTE | 2018-01-11 | — | — | US | disclosed |
| US-20180009780-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3265453-A1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | Boehringer Ingelheim International GmbH (DE) | 2018-01-10 | — | — | EP | disclosed |
| EP-3266776-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-2858993-B1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2018-01-10 | — | — | EP | disclosed |
| EP-3265143-A1 | METHODS FOR ADVERSELY AFFECTING BIOFILMS | Commonwealth Scientific & Industrial Research Organisation ( C.S.I.R.O. ) (AU) | 2018-01-10 | — | — | EP | disclosed |
| US-9862701-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-9862946-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| WO-2018005430-A1 | BISPHENOL A-FREE CROSSLINKED POLYMER COMPOSITIONS | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2018-01-04 | — | — | WO | disclosed |
| WO-2018000047-A1 | METHOD OF TREATING IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2018-01-04 | — | — | WO | disclosed |
| US-20180002373-A1 | Amino Acid and Peptide Conjugates and Uses Thereof | AUCKLAND UNISERVICES LIMITED (NZ) | 2018-01-04 | — | — | US | disclosed |
| US-20180002335-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20180002348-A1 | PHENOTHIAZINE-PYRIDINE COMPOUNDS AND USES THEREOF | THE CHINESE UNIVERSITY OF HONG KONG, OFFICE OF RESEARCH AND KNOWLEDGE TRANSFER SERVICES (CN) | 2018-01-04 | — | — | US | disclosed |
| EP-3262055-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES COMPRISING CONJUGATING GROUPS | Sony Corporation (JP) | 2018-01-03 | — | — | EP | disclosed |
| EP-3262022-A1 | PHENYLETHYNYLNAPHTHALENE DYES AND METHODS FOR THEIR USE | Sony Corporation (JP) | 2018-01-03 | — | — | EP | disclosed |
| EP-3057957-B1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-03 | — | — | EP | disclosed |
| EP-3030553-B1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-03 | — | — | EP | disclosed |
| EP-2738156-B1 | 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS | KBP BIOSCIENCES USA INC (US) | 2018-01-03 | — | — | EP | disclosed |
| EP-3010900-B1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9856249-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856260-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2018-01-02 | — | — | US | disclosed |
| US-9855289-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| CN-107531759-A | Non-film destructiveness p53 activation bookbinding peptides | 新加坡科技研究局 | 2018-01-02 | — | — | CN | disclosed |
| CN-107531738-A | Niacinetoside or nicotinamide riboside compositions, reduced derivatives thereof and uses thereof | 可劳迈戴斯有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107531698-A | With the active fused bicyclic heteroaryl group derivative as PHD inhibitor | 武田药品工业株式会社 | 2018-01-02 | — | — | CN | disclosed |
| CN-107531709-A | Beta lactamase restrainer and application thereof | 山东轩竹医药科技有限公司 | 2018-01-02 | — | — | CN | disclosed |
| US-20170369474-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-28 | — | — | US | disclosed |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| WO-2017223413-A1 | REVERSIBLY SWITCHABLE SURFACTANTS AND METHODS OF USE | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017223284-A1 | NON-CATALYTIC SUBSTRATE-SELECTIVE P38α-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017222996-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170368028-A1 | N-BENZOATE GROUP SUBSTITUTED BENZOPYRROLINE-2-ONE DERIVATIVE AND USE THEREOF | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-28 | — | — | US | disclosed |
| US-20170368004-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. | 2017-12-28 | — | — | US | disclosed |
| WO-2017223397-A1 | PHOTOCHROMIC WATER HARVESTING PLATFORM | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2017-12-28 | — | — | WO | disclosed |
| EP-3259268-A1 | 1,3,4-THIADIAZOL-2-YL-BENZAMIDE DERIVATIVES AS INHIBITORSOF THE WNT SIGNALLING PATHWAY | Bayer Pharma Aktiengesellschaft (DE) | 2017-12-27 | — | — | EP | disclosed |
| EP-3259251-A1 | N-PHENYL-(MORPHOLIN-4-YL OR PIPERAZINYL)ACETAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE WNT SIGNALLING PATHWAYS | Bayer Pharma Aktiengesellschaft (DE) | 2017-12-27 | — | — | EP | disclosed |
| EP-3259263-A1 | 3-CARBAMOYLPHENYL-4-CARBOXAMIDE AND ISOPHTALAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Bayer Pharma Aktiengesellschaft (DE) | 2017-12-27 | — | — | EP | disclosed |
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| CN-107501297-A | Phenothiazine-pyridine compounds and uses thereof | 香港中文大学 | 2017-12-22 | — | — | CN | disclosed |
| CN-107501279-A | Furanoquinoline dione compound and medical application thereof | 东莞市真兴贝特医药技术有限公司 | 2017-12-22 | — | — | CN | disclosed |
| US-20170362263-A1 | PHOSPHORUS LIGANDS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360726-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360791-A1 | PHARMACEUTICAL COMPOSITIONS FOR INCREASING THE BIOAVAILABILITY OF POORLY SOLUBLE DRUGS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2017-12-21 | — | — | US | disclosed |
| US-20170362250-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS (CANADA) INC (CA) | 2017-12-21 | — | — | US | disclosed |
| WO-2017218516-A1 | COMPOSITIONS COMPRISING CONJUGATED POLYMERS AND USES THEREOF | POLYDROP, LLC (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-2776475-B1 | CLEAN POLYCARBONATE MATERIAL FOR USE IN HARD DISK DRIVE AND SEMICONDUCTOR APPLICATIONS | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2017-12-20 | — | — | EP | disclosed |
| EP-2560967-B1 | Heterocyclic carboxylic acid amides as PDK1 inihibitors | BOEHRINGER INGELHEIM INT (DE) | 2017-12-20 | — | — | EP | disclosed |
| EP-2776393-B1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256484-A1 | NON-MEMBRANE DISRUPTIVE p53 ACTIVATING STAPLED PEPTIDES | Agency For Science, Technology And Research (SG) | 2017-12-20 | — | — | EP | disclosed |
| US-9844547-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9844576-B2 | Compositions and methods for managing weight | UNIGEN, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845489-B2 | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures | BIOMATRICA, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| CN-107484415-A | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2017-12-15 | — | — | CN | disclosed |
| US-20170355823-A1 | METHODS OF PRODUCING ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2017-12-14 | — | — | US | disclosed |
| US-20170355822-A1 | ORGANOSILICA MATERIALS, METHODS OF MAKING, AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2017-12-14 | — | — | US | disclosed |
| US-20170354961-A1 | CATALYSTS AND METHODS OF MAKING THE SAME | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2017-12-14 | — | — | US | disclosed |
| WO-2017214332-A1 | CONVERSION OF SUGARS TO IONIC LIQUIDS | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214334-A1 | CONVERSION OF LIGNIN TO IONIC LIQUIDS | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214269-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-9840680-B2 | Fragrance compositions comprising ionic liquids | THE PROCTER & GAMBLE COMPANY (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840505-B2 | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840553-B2 | Dual PDGF/VEGF antagonists | KODIAK SCIENCES INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840517-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-12 | — | — | US | disclosed |
| CN-105452233-B | Piperidine and azepane derivatives as prokineticin receptor modulators | 武田药品工业株式会社 | 2017-12-08 | — | — | CN | disclosed |
| US-20170349586-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349556-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | QUANTIEL PHARMACEUTICALS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170349555-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| EP-3251675-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Co., Ltd. (CN) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252058-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252038-A1 | N-BENZOATE GROUP SUBSTITUTED BENZOPYRROLINE-2-ONE DERIVATIVE AND USE THEREOF | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-06 | — | — | EP | disclosed |
| EP-2106260-B1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | VERVA PHARMACEUTICALS LTD (AU) | 2017-12-06 | — | — | EP | disclosed |
| EP-3066104-B1 | TRIAZOLOPYRAZINE DERIVATIVES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252053-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9833468-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-RE46621-E1 | Processes for preparing isoquinolinones and solid forms of isoquinolinones | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| CN-107428824-A | PDGF/VEGF dual antagonists | 科达制药 | 2017-12-01 | — | — | CN | disclosed |
| WO-2017205766-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | PHARMACYCLICS LLC (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205762-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | PHARMACYCLICS LLC (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205769-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | PHARMACYCLICS LLC (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170341069-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | UNIV CALIFORNIA (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340621-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-30 | — | — | US | disclosed |
| WO-2017205684-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | AKARNA THERAPEUTICS, LTD. (GB) | 2017-11-30 | — | — | WO | disclosed |
| US-20170340623-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. | 2017-11-30 | — | — | US | disclosed |
| WO-2017202719-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-30 | — | — | WO | disclosed |
| EP-3051946-B1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2017-11-29 | — | — | EP | disclosed |
| US-9828377-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828379-B2 | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof | ABIDE THERAPEUTICS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828363-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828351-B2 | Enzyme interacting agents | MONASH UNIVERSITY (AU) | 2017-11-28 | — | — | US | disclosed |
| US-9828343-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2017198341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017198734-A1 | PROCESS FOR THE MANUFACTURE OF 6-ALKYNYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-23 | — | — | WO | disclosed |
| US-20170333942-A1 | POLYMERISATION PROCESS AND POLYMER PRODUCT | THE UNIVERSITY OF SYDNEY (AU) | 2017-11-23 | — | — | US | disclosed |
| WO-2017201468-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
| US-20170334899-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20170334928-A1 | Purification of Rapamycin Derivatives Using Temperature Induced Phase Separation | JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC. D/B/A JOHNSON MATTHEY PHARMA SERVICES | 2017-11-23 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-9822131-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822106-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822119-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2017197192-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170326103-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2017-11-16 | — | — | US | disclosed |
| WO-2017197210-A1 | IDENTIFICATION OF SMALL MOLECULE INHIBITORS OF JUMONJI AT-RICH INTERACTIVE DOMAIN 1A (JARID1A) HISTONE DEMETHYLASE | YALE UNIVERSITY (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Pte. Ltd. (SG) | 2017-11-16 | — | — | US | disclosed |
| US-20170327693-A1 | IN VACUO COATING COMPOSITIONS | CAMVAC LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-16 | — | — | US | disclosed |
| WO-2017196261-A1 | JAK AND HDAC DUAL-INHIBITOR COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327813-A1 | 3D Printable Hydrogel Materials | UNIVERSITY OF WASHINGTON | 2017-11-16 | — | — | US | disclosed |
| WO-2017197240-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327604-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEM COMPRISING MESOPOROUS ORGANOSILICA SUPPORT | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2017-11-16 | — | — | US | disclosed |
| EP-2748149-B9 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2934145-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2384318-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9815828-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815746-B2 | Stereodynamic chemosensors | GEORGETOWN UNIVERSITY (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170321002-A1 | MULTICOLORED ELECTROCHROMIC POLYMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | LANNRAY ADVANCED MATERIALS CO. LTD (CN) | 2017-11-09 | — | — | US | disclosed |
| US-20170321101-A1 | Refrigeration System With Dual Refrigerants and Liquid Working Fluids | JEFF YANJIE (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2017190249-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2017-11-09 | — | — | WO | disclosed |
| US-20170320971-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEM COMPRISING MESOPOROUS ORGANOSILICA SUPPORT | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2017-11-09 | — | — | US | disclosed |
| US-20170320977-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEM COMPRISING MESOPOROUS ORGANOSILICA SUPPORT | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2017-11-09 | — | — | US | disclosed |
| US-20170320861-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20170319549-A1 | 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-09 | — | — | US | disclosed |
| EP-2970316-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3241834-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-11-08 | — | — | EP | disclosed |
| US-9810690-B2 | Method for screening inhibitors of Ras | ARAXES PHARMA LLC (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170313702-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313669-A1 | LACTONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | THE SCRIPPS RESEARCH INSTITUTE | 2017-11-02 | — | — | US | disclosed |
| EP-3236752-A2 | NOVEL ISOTHIAZOLAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-3238722-A1 | SOLID FORMS OF ISOQUINOLINONES | Infinity Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3237374-A1 | AMINO ACID AND PEPTIDE CONJUGATES AND USES THEREOF | Brimble, Margaret, Anne (NZ) | 2017-11-01 | — | — | EP | disclosed |
| EP-3236940-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-9801871-B2 | 6-alkynyl-pyridine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| WO-2017184589-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170304300-A1 | HIF-2alpha INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2017184462-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170306068-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEM COMPRISING MESOPOROUS ORGANOSILICA SUPPORT | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2017-10-26 | — | — | US | disclosed |
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| WO-2017184491-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170304338-A1 | USE OF NICOTINIC ACID RIBOSIDE OR NICOTINAMIDE RIBOSIDE DERIVATIVES, AND REDUCED DERIVATIVES THEREOF, AS NAD+ INCREASING PRECURSORS | ChromaDex Inc. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170303542-A1 | SYNERGISTIC BENZOXABOROLE-CONTAINING ANTI-FUNGICIDAL COMPOSITION | THE PENN STATE RESEARCH FOUNDATION | 2017-10-26 | — | — | US | disclosed |
| US-20170305948-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3234094-A1 | IONIC LIQUID SYSTEMS | The Procter and Gamble Company (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3233866-A1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796697-B2 | Tricyclic inhibitors of HIF-2-alpha and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| CN-105247010-B | Solvent-free quantum dot exchange method | 纳米系统公司 | 2017-10-24 | — | — | CN | disclosed |
| WO-2017180789-A2 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | Blaze Bioscience, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170295777-A1 | Compositions and Methods for Reducing Ice Crystal Formation | X-THERMA, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298044-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296531-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2017-10-19 | — | — | US | disclosed |
| WO-2017181012-A1 | CINCHONIUM BETAINE CATALYSTS AND METHODS OF USING SAME | BRANDEIS UNIVERSITY (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170298026-A1 | ALL PURPOSE RAFT AGENT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-10-19 | — | — | US | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
| WO-2017181149-A1 | METHODS OF TREATING BREAST CANCER | Blaze Bioscience, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017180998-A2 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170298025-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3230325-A1 | METHODS OF SEPARATING AROMATIC COMPOUNDS FROM LUBE BASE STOCKES | ExxonMobil Research and Engineering Company (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3229807-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | President and Fellows of Harvard College (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3230296-A1 | PHOSPHORUS LIGANDS AND METHODS OF USE | The Regents of The University of California (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3229593-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | Synereca Pharmaceuticals, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2729449-B1 | 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-18 | — | — | EP | disclosed |
| EP-3230409-A1 | ORGANOSILICA MATERIALS AND USES THEREOF | ExxonMobil Research and Engineering Company (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3229952-A1 | ORGANOSILICA MATERIALS | ExxonMobil Research and Engineering Company (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3229944-A1 | MEMBRANE FABRICATION METHODS USING ORGANOSILICA MATERIALS AND USES THEREOF | ExxonMobil Research and Engineering Company (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3230410-A1 | AROMATIC HYDROGENATION CATALYSTS AND USES THEREOF | Exxonmobil Research And Engineering Company (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2079736-B1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3229953-A1 | COATING METHODS USING ORGANOSILICA MATERIALS AND USES THEREOF | ExxonMobil Research and Engineering Company (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9790201-B2 | Piperidine and azepine derivatives as prokineticin receptor modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790173-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I | MERCK SHARP & DOHME CORP. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790220-B2 | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790218-B2 | Small molecule activators of calcium-activated chloride channels and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170290330-A1 | SUBSTITUTED 5-HYDROXY-2-PHENYL-3-HETEROARYL PENTANENITRILE DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND/OR PLANT GROWH REGULATORS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-10-12 | — | — | US | disclosed |
| US-20170290850-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METRO INTERNATIONAL BIOTECH, LLC | 2017-10-12 | — | — | US | disclosed |
| EP-2752415-B1 | Fluorinated ligands for targeting peripheral benzodiazepine receptors | AUSTRALIAN NUCLEAR SCIENCE & TECH ORGANISATION (AU) | 2017-10-11 | — | — | EP | disclosed |
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| WO-2017172979-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| EP-2951175-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | Bayer Pharma AG (DE) | 2017-10-04 | — | — | EP | disclosed |
| US-9776974-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777006-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777004-B2 | Amino-substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-10-03 | — | — | US | disclosed |
| US-9775844-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| CN-107216312-A | A kind of compound with saltant type IDH inhibitory activity, preparation method and the usage | 上海海和药物研究开发有限公司 | 2017-09-29 | — | — | CN | disclosed |
| WO-2017163078-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162510-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162663-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| US-20170273964-A1 | FATTY ACID SYNTHASE INHIBITOR FOR USE IN THE TREATMENT OF DRUG RESISTANT CANCER | SAGIMET BIOSCIENCES INC. | 2017-09-28 | — | — | US | disclosed |
| WO-2017165304-A2 | Pd(II)-CATALYZED ENANTIOSELECTIVE BETA-METHYLENE C(sp3)-H BOND ACTIVATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20170275266-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3222620-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-09-27 | — | — | EP | disclosed |
| EP-2598661-B1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | BIOMATRICA INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771333-B2 | Quinazoline derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORP. (CA) | 2017-09-26 | — | — | US | disclosed |
| US-9771329-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| CN-107208076-A | Butyrylcholine esterase amphoteric ion polymer conjugate | 科达制药 | 2017-09-26 | — | — | CN | disclosed |
| CN-107207735-A | Organic silica material | 埃克森美孚研究工程公司 | 2017-09-26 | — | — | CN | disclosed |
| WO-2017161165-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017157418-A1 | COMBINATION OF MKNK1-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | WO | disclosed |
| US-20170266191-A1 | Therapeutic Combination of PI3K Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-09-21 | — | — | US | disclosed |
| WO-2017160861-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017158388-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
| US-20170267709-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OFNICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2017158381-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TRATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161116-A1 | ISOTOPOLOGUES OF ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS AND USES THEREOF AS PI3K KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161012-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20170267679-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2970303-B9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3218363-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2017-09-20 | — | — | EP | disclosed |
| US-9765220-B2 | Water soluble fluorescent or colored dyes and methods for their use | SONY CORPORATION (JP) | 2017-09-19 | — | — | US | disclosed |
| US-9765085-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20170260204-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170260161-A1 | BI-BENZYL ISOQUINOLINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF IN HEPATOPATHY TREATMENT AND PREVENTION | VERSITECH LIMITED (CN) | 2017-09-14 | — | — | US | disclosed |
| WO-2017156391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| EP-2920176-B1 | AMINOIMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-3003381-B1 | PHARMACEUTICAL COMPOSITIONS | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2785688-B1 | A PROCESS FOR THE MANUFACTURE OF CHIRAL CATALYSTS AND THEIR SALTS | SCINOPHARM TAIWAN LTD (TW) | 2017-09-13 | — | — | EP | disclosed |
| US-9758517-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758511-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2017-09-12 | — | — | US | disclosed |
| CN-104684850-B | Melamine-aldehyde polymers | 新加坡科技研究局 | 2017-09-08 | — | — | CN | disclosed |
| US-20170253562-A1 | Nampt Inhibitors | ABBVIE INC (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253596-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | TARO PHARMACEUTICALS INC. (CA) | 2017-09-07 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2804864-B1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-9751888-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247725-A1 | IN VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247394-A1 | SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170247729-A1 | SWITCHABLE IONIC LIQUIDS FOR BIOMASS PRETREATMENT AND ENZYMATIC HYDROLYSIS | UNITED STATES DEPARTMENT OF ENERGY | 2017-08-31 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | WELLSPRING BIOSCIENCES LLC | 2017-08-31 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247389-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | TARO PHARMACEUTICALS INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| EP-3210469-A1 | USE OF SUBSTITUTED THIO-1,2,4-TRIAZOLES FOR INCREASING STRESS TOLERANCE IN PLANTS | Bayer Cropscience AG (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2638044-B1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER IP GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-3209660-A1 | 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-3210966-A1 | ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Acucela, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-3209646-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-08-30 | — | — | EP | disclosed |
| US-9745304-B2 | Amidoimidazopyridazines as MKNK-1 kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-29 | — | — | US | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| CN-107108489-A | general RAFT agent | 联邦科学与工业研究组织 | 2017-08-29 | — | — | CN | disclosed |
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240529-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| WO-2017141036-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2017-08-24 | — | — | WO | disclosed |
| US-20170238544-A1 | MOLECULES THAT INDUCE DISEASE RESISTANCE IN PLANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-08-24 | — | — | US | disclosed |
| US-20170239351-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-24 | — | — | US | disclosed |
| EP-3208270-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-3207128-A2 | BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES | Kodiak Sciences Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-3207031-A1 | ATAXIA TELENGIECTASIA AND RAD3-RELATED (ATR) PROTEIN KINASE INHIBITORS | Atrin Pharmaceuticals LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-3206692-A1 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | Corcept Therapeutics, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-2512462-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9737075-B2 | Synergistic benzoxaborole-containing anti-fungicidal composition | THE PENN STATE RESEARCH FOUNDATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738637-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170231995-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | LUCID TRUSTEE SERVICES LIMITED (GB) | 2017-08-17 | — | — | US | disclosed |
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-08-17 | — | — | US | disclosed |
| EP-3205644-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-3204353-A1 | ALL PURPOSE RAFT AGENT | Commonwealth Scientific and Industrial Research Organisation (AU) | 2017-08-16 | — | — | EP | disclosed |
| EP-3203991-A1 | HIF-2 INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS | The Board of Regents of The University of Texas System (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2668179-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-08-16 | — | — | EP | disclosed |
| EP-3204395-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | Yale University (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730943-B2 | Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9731321-B2 | Polymerisation process and polymer product | THE UNIVERSITY OF SYDNEY (AU) | 2017-08-15 | — | — | US | disclosed |
| US-9732092-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170226093-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226130-A1 | Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase Inhibitors | Atrin Pharmaceuticals LLC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224688-A1 | Methods of Using BTK Inhibitors to Treat Dermatoses | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| US-20170224682-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017136466-A1 | HEME PROTEIN CATALYSTS FOR CARBON-SILICON BOND FORMATION IN VITRO AND IN VIVO | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-08-10 | — | — | WO | disclosed |
| EP-2240451-B1 | Isoquinolinone derivatives substituted with a purine useful as PI3K inhibitors | INTELLIKINE LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2909181-B1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-9725441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| WO-2017129796-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-08-03 | — | — | WO | disclosed |
| US-20170217946-A1 | AMINO-SUBSTITUTED ISOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| WO-2017132463-A1 | SURFACE PRIMER COMPOSITIONS AND METHODS OF USE | ACatechol, Inc. (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20170218346-A1 | Heme Protein Catalysts for Carbon-Silicon Bond Formation In Vitro and In Vivo | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-08-03 | — | — | US | disclosed |
| WO-2017132538-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20170216765-A1 | COMPOSITE GAS SEPARATION MEMBRANE | THE UNIVERSITY OF MELBOURNE (AU) | 2017-08-03 | — | — | US | disclosed |
| WO-2017132484-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | ACatechol, Inc. (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20170217997-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | ORMCO CORPORATION | 2017-08-03 | — | — | US | disclosed |
| US-20170217999-A1 | SURFACE PRIMER COMPOSITIONS AND METHODS OF USE | ORMCO CORPORATION | 2017-08-03 | — | — | US | disclosed |
| US-20170218021-A1 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | REGENERON PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170216304-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170217980-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-03 | — | — | US | disclosed |
| US-20170217850-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| EP-3197562-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | The Procter and Gamble Company (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197989-A1 | IONIC LIQUIDS | The Procter and Gamble Company (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197883-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718821-B2 | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717770-B2 | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | UNIGEN, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| CN-106999481-A | Processes and intermediates for preparing C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-107001339-A | Novel compounds | 特殊治疗有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2017127442-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-27 | — | — | WO | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20170210701-A1 | SUBSTITUTED CYANO CYCLOALKYL PENTA-2,4-DIENES, CYANO CYCLOALKYL PENT-2-EN-4-YNES, CYANO HETEROCYCLYL PENTA-2,4-DIENES AND CYANO HETEROCYCLYL PENT-2-EN-4-YNES AS ACTIVE SUBSTANCES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-3193851-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3193880-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Hydra Biosciences, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2886540-B1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | XUANZHU PHARMA CO LTD (CN) | 2017-07-26 | — | — | EP | disclosed |
| EP-3194387-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3193601-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2970211-B1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3193881-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9714230-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714246-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714244-B2 | Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors | ALMAC DISCOVERY LIMITED (GB) | 2017-07-25 | — | — | US | disclosed |
| CN-106967257-A | Form polythiophene:The method of polysulfonate complex compound | 新加坡科技研究局 | 2017-07-21 | — | — | CN | disclosed |
| US-20170202816-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204032-A1 | PROCESS FOR PREPARING BRANCHED ALLYL COMPOUNDS | SOUTH UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA (CN) | 2017-07-20 | — | — | US | disclosed |
| WO-2017122175-A1 | THERAPEUTIC COMBINATIONS OF AN ANTIFOLATE AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017121684-A1 | 5-SUBSTITUTED 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017123766-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DISEASE | SPEROVIE BIOSCIENCES, INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| EP-2887963-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2948460-B1 | LOW TEMPERATURE SYNTHESIS OF RAPAMYCIN DERIVATIVES | BIOSENSORS INT GROUP LTD (BM) | 2017-07-19 | — | — | EP | disclosed |
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| US-9709571-B2 | Method of drug design | VAST BIOSCIENCE PTY LIMITED (AU) | 2017-07-18 | — | — | US | disclosed |
| US-9708326-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170197982-A1 | THIOPHENE DERIVATIVES | GANZHOU HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2017-07-13 | — | — | US | disclosed |
| US-20170198287-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197910-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170196854-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170196903-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197979-A1 | BENZOTHIADIAZOLAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-13 | — | — | US | disclosed |
| EP-3189038-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-2134723-B1 | 2,6 DIAMINO-9H-PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2017-07-12 | — | — | EP | disclosed |
| US-9701657-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9700554-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701792-B2 | Composite compositions and methods of preparing and using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-07-11 | — | — | US | disclosed |
| US-9702870-B2 | Fluorescent dyes and related methods | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170189434-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METRO INTERNATIONAL BIOTECH, LLC | 2017-07-06 | — | — | US | disclosed |
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190766-A1 | ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170190698-A1 | ENZYME INTERACTING AGENTS | CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED (AU) | 2017-07-06 | — | — | US | disclosed |
| WO-2017117464-A1 | ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017117154-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017117528-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2017-07-06 | — | — | WO | disclosed |
| EP-2925761-B1 | TRIAZOLOPYRAZINES AS BRD4 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2017-07-05 | — | — | EP | disclosed |
| WO-2017109488-A1 | CYANOPYRROLIDINE DERVIVATIVES AS INHIBITORS FOR DUBS | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112902-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112909-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170183325-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | H. LUNDBECK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| WO-2017112904-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170183338-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-06-29 | — | — | US | disclosed |
| US-20170183356-A1 | New Imaging Agents and Methods of Identifying Same | THR TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-06-29 | — | — | US | disclosed |
| EP-3183254-A1 | NEW SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-06-28 | — | — | EP | disclosed |
| US-9689877-B2 | Water soluble fluorescent or colored dyes and methods for their use | SONY CORPORATION (JP) | 2017-06-27 | — | — | US | disclosed |
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170173072-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174695-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170173569-A1 | Fe-ppm Pd, Cu and/or Ni Nanoparticle-Catalyzed Reactions in Water | LIPSHUTZ BRUCE H (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170176475-A1 | NOVEL METHODS AND KITS FOR DETECTING A RIFAMYCIN, OR DERIVATIVE OR ANALOGUE THEREOF | UNIV DREXEL (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | Rhe Trustees of The University of Pennsylvania | 2017-06-22 | — | — | US | disclosed |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174656-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2017106426-A1 | FE NANOPARTICLES WITH PPM CONTENTS OF PD, CU AND/OR NI, REACTIONS IN WATER CATALYZED BY THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017103614-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017105439-A1 | CINCHONINE-DERIVED CATALYSTS AND METHODS OF USING SAME | BRANDEIS UNIVERSITY (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-3179992-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | Acerta Pharma B.V. (NL) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181553-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
| EP-3180337-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3180345-A1 | THIENO- AND FURO[2,3-D]PYRIMIDINE-2,4[1H,3H]-DIONE DERIVATIVES AS TRPC5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3180318-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3180342-A1 | PYRROLO[3,2-D]PYRIMIDINE-2,4(3H,5H)-DIONE DERIVATIVES | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3179991-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | Acerta Pharma B.V. (NL) | 2017-06-21 | — | — | EP | disclosed |
| EP-3180340-A1 | PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2395993-B1 | SKIN TREATMENT | LEO LABORATORIES LTD (IE) | 2017-06-21 | — | — | EP | disclosed |
| EP-2976327-B1 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| EP-3179990-A1 | FATTY ACID SYNTHASE INHIBITOR FOR USE IN THE TREATMENT OF DRUG RESISTANT CANCER | 3-V Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682097-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| US-20170166549-A1 | Substituted 5-hydroxy-2-heteroaryl-3-phenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators | BAYER CROPSCIENCE AKTIENGESELLSHAFT (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170168073-A1 | CHALCONE-UREA DERIVATIVES AS INSULIN SENSORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| WO-2017100546-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017098328-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHAMACEUTICALS, INC. (BB) | 2017-06-15 | — | — | WO | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| EP-3177619-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-9675616-B2 | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9675612-B2 | Substituted thiazolopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676762-B2 | Pyrimidine compounds containing seven-membered fused ring systems | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676766-B2 | Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9675694-B2 | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2017-06-13 | — | — | US | disclosed |
| US-9676724-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-13 | — | — | US | disclosed |
| US-9676770-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| CN-104684906-B | Nampt inhibitor | 艾伯维公司 | 2017-06-09 | — | — | CN | disclosed |
| WO-2017096315-A1 | TRIAZOLE DAGL(α) INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158681-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170158664-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| WO-2017096025-A1 | NORPREGNANE DERIVATIVES FOR THE RISK REDUCTION OF BREAST CANCER | Helix Twelve Pharmaceuticals Corporation, Inc. (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017091854-A1 | SODIUM-ION ELECTROLYTE COMPOSITION | DEAKIN UNIVERSITY (AU) | 2017-06-08 | — | — | WO | disclosed |
| US-20170157143-A1 | NORPREGNANE DERIVATIVES FOR THE RISK REDUCTION OF BREAST CANCER | Helix Twelve Pharmaceuticals Corporation, Inc. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-08 | — | — | US | disclosed |
| WO-2017093718-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30. | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA CAMBRIDGE LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158685-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2017-06-08 | — | — | US | disclosed |
| EP-3174539-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, LLC (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2581372-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-06-07 | — | — | EP | disclosed |
| EP-2638043-B1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER IP GMBH (DE) | 2017-06-07 | — | — | EP | disclosed |
| US-9670202-B2 | Substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-06 | — | — | US | disclosed |
| US-9669038-B1 | Heterocyclic compounds and uses thereof | GLOBAVIR BIOSCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2017091150-A1 | A POLYMERIC COMPOSITION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017091781-A1 | AMMONIUM BASED IONIC LIQUIDS USEFUL FOR LIGNOCELLULOSIC PROCESSING | SANDIA CORPORATION (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170152221-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| EP-2900674-B1 | COMPOUNDS AND METHODS FOR PREVENTING, TREATING AND/OR PROTECTING AGAINST SENSORY HAIR CELL DEATH | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-3172204-A1 | AMINO-SUBSTITUTED ISOXAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2758401-B1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-3172192-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-3172194-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2984090-B1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| CN-106727587-A | A kind of pharmaceutical composition for treating arrhythmia cordis | 李娜 | 2017-05-31 | — | — | CN | disclosed |
| CN-105102463-B | Low Temperature Synthesis of Rapamycin Derivatives | 生物传感器国际集团有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9663528-B2 | Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9663634-B2 | Scratch resistant polymers | TENASITECH PTY LTD (AU) | 2017-05-30 | — | — | US | disclosed |
| US-9663535-B2 | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors | Atrin Pharmaceuticals LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-9661848-B2 | Substituted 4-cyan-3-(pyridyl)-4-phenylbutanoates, method for the production thereof and uses as herbicides and plant growth regulators | BAYER CROPSCIENCE AG (DE) | 2017-05-30 | — | — | US | disclosed |
| US-20170143727-A1 | USE OF CINNABARINIC ACID AS A MODULATOR OF IMMUNE RESPONSE IN AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-25 | — | — | US | disclosed |
| US-20170143841-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170143712-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | ACERTA PHARMA BV (NL) | 2017-05-25 | — | — | US | disclosed |
| EP-3169325-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2017-05-24 | — | — | EP | disclosed |
| CN-106715456-A | Lymphatic prodrugs | 莫纳什大学 | 2017-05-24 | — | — | CN | disclosed |
| US-9656932-B2 | Preparation of pentanol with ethanol derived from fermentation | Pioneer Energy (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655921-B2 | Compositions and methods for treating hyperkalemia | ARDELYX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656988-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655892-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170137402-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20170135343-A1 | AGRICULTURAL PHEROMONE COMPOSITIONS COMPRISING POSITIONAL ISOMERS | PROVIVI, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| WO-2017081003-A1 | SUBSTITUTED PYRAZOLOPYRIDINAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-18 | — | — | WO | disclosed |
| US-20170135994-A9 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | disclosed |
| US-20170136014-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | ACERTA PHARMA BV (NL) | 2017-05-18 | — | — | US | disclosed |
| EP-2716633-B1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| EP-2350083-B1 | PYRIMIDO[5,4-D]PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-3166605-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | Intervet International B.V. (NL) | 2017-05-17 | — | — | EP | disclosed |
| US-9650450-B2 | RAFT polymers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-05-16 | — | — | US | disclosed |
| US-9650391-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650358-B2 | Pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170128443-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170131278-A1 | METHOD FOR SCREENING INHIBITORS OF RAS | ARAXES PHARMA LLC | 2017-05-11 | — | — | US | disclosed |
| WO-2017079564-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR COLORING EDIBLE MATERIALS | THE PENN STATE RESEARCH FOUNDATION (US) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017079641-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170128444-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128456-A1 | CARBON MONOXIDE-RELEASING MOLECULES FOR THERAPEUTIC APPLICATIONS AND METHODS OF MAKING AND USING THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC, (US) | 2017-05-11 | — | — | US | disclosed |
| EP-3164380-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2970303-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3164401-A1 | NEW SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-3164509-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| CN-106661032-A | 1,3-substituted 2-aminoindole derivatives and analogues useful in the treatment or prevention of diabetes mellitus, obesity and inflammatory bowel disease | 武田药品工业株式会社 | 2017-05-10 | — | — | CN | disclosed |
| CN-106661229-A | Silicone ligands for quantum dots | 纳米系统公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-106661005-A | Functionalized and substituted indoles as anticancer agents | 诺沃根公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-104105718-B | RAFT polymers | 联邦科学和工业研究组织 | 2017-05-10 | — | — | CN | disclosed |
| US-9643974-B2 | Amino-substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-05-09 | — | — | US | disclosed |
| US-9643971-B2 | Breathing control modulating compounds, and methods of using same | GALLEON PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643965-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170121363-A1 | Compounds, Compositions and Methods for Coloring Edible Materials | THE PENN STATE RESEARCH FOUNDATION | 2017-05-04 | — | — | US | disclosed |
| WO-2017070743-A1 | POLYURETHANE/UREA MATERIALS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075531-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2017-05-04 | — | — | WO | disclosed |
| US-20170121633-A1 | Fragrance Compositions Comprising Ionic Liquids | THE PROCTER & GAMBLE COMPANY | 2017-05-04 | — | — | US | disclosed |
| US-20170119923-A1 | POLYURETHANE/UREA COMPOSITIONS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION | 2017-05-04 | — | — | US | disclosed |
| WO-2017075522-A2 | GLP-2 POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075299-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | THE PROCTER & GAMBLE COMPANY (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075505-A2 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170121338-A1 | AMINO PRYAN RING DERIVATIVE AND COMPOSITION AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20170119904-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2017-05-04 | — | — | US | disclosed |
| US-20170121752-A1 | DETECTION OF ACRYLIC ACID | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-05-04 | — | — | US | disclosed |
| EP-3160965-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2017-05-03 | — | — | EP | disclosed |
| EP-3161000-A2 | DUAL PDGF/VEGF ANTAGONISTS | Kodiak Sciences Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-3160949-A1 | ENZYME INTERACTING AGENTS | Monash University (AU) | 2017-05-03 | — | — | EP | disclosed |
| EP-3160955-A1 | 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE | Takeda Pharmaceutical Company Limited (JP) | 2017-05-03 | — | — | EP | disclosed |
| EP-3160956-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9637487-B2 | Purinone compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | disclosed |
| US-20170114055-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2017-04-27 | — | — | US | disclosed |
| US-20170114024-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | QUANTIEL PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114070-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-20170114074-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2017070256-A2 | METHOD FOR SCREENING INHIBITORS OF RAS | ARAXES PHARMA LLC (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070448-A1 | 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-3157933-A2 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3157916-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3159344-A1 | AMINO PYRANOID RING DERIVATIVE AND COMPOSITION AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2017-04-26 | — | — | EP | disclosed |
| US-9630975-B2 | Thiophene derivatives | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2017-04-25 | — | — | US | disclosed |
| US-9630979-B2 | Inhibitors of monoacylglycerol lipase and methods of their use | INFINITY PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| WO-2017066454-A2 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | X-THERMA, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20170107245-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2017-04-20 | — | — | US | disclosed |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107212-A1 | NOVEL COMPOUNDS | Bayer Pharma AG (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107440-A1 | LUBRICATING COMPOSITIONS AND METHODS FOR THE USE THEREOF | JPMORGAN CHASE BANK, N.A. | 2017-04-20 | — | — | US | disclosed |
| EP-3154537-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-3036228-B1 | NEW 6-ALKYNYL PYRIDINE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-04-19 | — | — | EP | disclosed |
| EP-3036235-B1 | NEW BIS-AMIDO PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-04-19 | — | — | EP | disclosed |
| EP-2791184-B1 | PROCESS FOR REMOVING THIOCARBONYLTHIO GROUPS FROM RAFT POLYMERS | COMMW SCIENT IND RES ORG (AU) | 2017-04-19 | — | — | EP | disclosed |
| EP-3156387-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2017-04-19 | — | — | EP | disclosed |
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9622472-B2 | Molecules that induce disease resistance in plants | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624228-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624224-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-20170101388-A1 | C-GLYCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-13 | — | — | US | disclosed |
| WO-2017062823-A1 | THERAPEUTIC CANCER TREATMENTS BASED ON TP53 GENE MUTATIONS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060431-A1 | SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-13 | — | — | WO | disclosed |
| EP-3153023-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9617277-B2 | Polymeric materials | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-04-11 | — | — | US | disclosed |
| US-9617242-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170096391-A1 | NOVEL LACTAMS | BIOSIGNAL LIMITED (AU) | 2017-04-06 | — | — | US | disclosed |
| US-20170095471-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-04-06 | — | — | US | disclosed |
| US-20170095554-A1 | AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS | AUCKLAND UNISERVICES LIMITED (NZ) | 2017-04-06 | — | — | US | disclosed |
| EP-3149003-A1 | BENZOTHIADIAZOLAMINES | Bayer Pharma Aktiengesellschaft (DE) | 2017-04-05 | — | — | EP | disclosed |
| EP-3150203-A1 | COMPOUNDS WITH (1E,6E)-1,7-BIS-(3,4- DIMETHOXYPHENYL)-4,4-DISSTITUTED-HEPA-1,6-DIENE-3,5-DI-ONE STRUCTURAL SCAFFOLD,THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | Allianz Pharmascience Ltd (TW) | 2017-04-05 | — | — | EP | disclosed |
| EP-3008062-B1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-04-05 | — | — | EP | disclosed |
| EP-2766359-B9 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES | AMBIT BIOSCIENCES CORP (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3150609-A1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | Intellikine, LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2809708-B1 | HALOGENATED ORGANOSILICON ELECTROLYTES, METHODS OF USING THEM, AND ELECTROCHEMICAL DEVICES CONTAINING THEM | SILATRONIX INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3150617-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9611252-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-04-04 | — | — | US | disclosed |
| US-9611186-B2 | Synthesis of high caloric fuels and chemicals via ketene and diketene intermediates | Pioneer Energy (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611271-B2 | C20′ urea derivatives of vinca alkaloids | SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611221-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| WO-2017053886-A2 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017053192-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-03-30 | — | — | WO | disclosed |
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-2389395-B1 | RAFT POLYMERISATION | COMMW SCIENT IND RES ORG (AU) | 2017-03-29 | — | — | EP | disclosed |
| EP-2621923-B1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INT BV (NL) | 2017-03-29 | — | — | EP | disclosed |
| EP-3147285-A2 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9604989-B2 | Imidazopyridazines as Akt kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-28 | — | — | US | disclosed |
| US-9606440-B2 | Lithographically produced features | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-03-28 | — | — | US | disclosed |
| US-9604961-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605003-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| WO-2017046304-A1 | NO-DONORS FOR THE TREATMENT OF CEREBROVASCULAR VASOSPASMS AFTER BRAIN HEMORRHAGE | EHLERT ANGELIKA (DE) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046746-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR AND A GITR BINDING MOLECULE, A 4-1BB AGONIST, OR AN OX40 AGONIST | ACERTA PHARMA B.V. (NL) | 2017-03-23 | — | — | WO | disclosed |
| US-20170079960-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | NAIA Metabolic, Inc. | 2017-03-23 | — | — | US | disclosed |
| EP-3143015-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| EP-3004092-B1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| EP-2714692-B1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-03-22 | — | — | EP | disclosed |
| CN-106537124-A | Detection of acrylic acid | 新加坡科技研究局 | 2017-03-22 | — | — | CN | disclosed |
| CN-106536503-A | Tyrosine kinase inhibitor and uses thereof | 山东轩竹医药科技有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9598439-B2 | Purification of rapamycin derivatives using temperature induced phase separation | BIOSENSORS INTERNATIONAL GROUP, LTD. (BM) | 2017-03-21 | — | — | US | disclosed |
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170073340-A1 | SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| WO-2017044659-A1 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | VIEWPOINT THERAPEUTICS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017041139-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2017-03-16 | — | — | WO | disclosed |
| US-20170071962-A1 | Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-03-16 | — | — | US | disclosed |
| WO-2017044043-A1 | PROCESS FOR DIRECT AMIDATION OF AMINES VIA RH(I)-CATALYZED ADDITION OF BOROXINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-03-16 | — | — | WO | disclosed |
| EP-3140304-A1 | BENZIMIDAZOLE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| EP-2598660-B1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | BIOMATRICA INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2663309-B1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | INFINITY PHARMACEUTICALS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9593096-B2 | α7 nicotinic acetylcholine receptor modulators and uses thereof-III | MERCK SHARP & DOHME CORP. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593106-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-03-14 | — | — | US | disclosed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE PHARMACEUTICALS INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065575-A1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-03-09 | — | — | US | disclosed |
| WO-2017035570-A1 | AMPHIPHILIC RAFT AGENT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-03-09 | — | — | WO | disclosed |
| EP-3137169-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| CN-106488919-A | 3-substituted 2-aminoindole derivatives | 武田药品工业株式会社 | 2017-03-08 | — | — | CN | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586939-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-9587104-B2 | Release media | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-03-07 | — | — | US | disclosed |
| US-9586958-B2 | Prodrug derivatives of substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9586902-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586901-B2 | Lactams | UNILEVER PLC (GB) | 2017-03-07 | — | — | US | disclosed |
| WO-2017033113-A1 | THERAPEUTIC COMBINATIONS OF A MEK INHIBITOR AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057976-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-2621903-B1 | N-HETEROARYL COMPOUNDS | INTERVET INT BV (NL) | 2017-03-01 | — | — | EP | disclosed |
| EP-3134410-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Hydra Biosciences, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| CN-104168768-B | The method of preparation Cgrp receptor antagonist | 默沙东公司 | 2017-03-01 | — | — | CN | disclosed |
| US-9580416-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050970-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170051278-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| CN-106432557-A | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | 科迪亚科学企业公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-104508049-B | Silicone ligands for stabilizing quantum dot films | 纳米系统公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9573930-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170042891-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2017025493-A1 | QUINOLINE EZH2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025814-A1 | METHODS OF TREATING CANCERS, IMMUNE AND AUTOIMMUNE DISEASES, AND INFLAMMATORY DISEASES BASED ON BTK OCCUPANCY AND BTK RESYNTHESIS RATE | ACERTA PHARMA B.V. (NL) | 2017-02-16 | — | — | WO | disclosed |
| EP-3128996-A1 | Novel 7-Dehydrocholesterol Derivatives and Methods Using Same | Women and Infants Hospital of Rhode Island Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-3129380-A1 | SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE DERIVATIVES AND THEIR USE AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-15 | — | — | EP | disclosed |
| CN-106414480-A | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | 莫纳什大学 | 2017-02-15 | — | — | CN | disclosed |
| CN-104109168-B | Tetra-cyclo-kinase inhibitor | 山东轩竹医药科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-20170035881-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-02-09 | — | — | US | disclosed |
| WO-2017023912-A1 | 2,4,6-TRIALKOXYSTRYL ARYL SULFONES, SULFONAMIDES AND CARBOXAMIDES, AND METHODS OF PREPARATION AND USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170035756-A1 | METHODS OF BLOCKING THE CXCR-4/SDF-1 SIGNALING PATHWAY WITH INHIBITORS OF BRUTON'S TYROSINE KINASE | ACERTA PHARMA B.V. (NL) | 2017-02-09 | — | — | US | disclosed |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| WO-2017024255-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | disclosed |
| EP-2978758-B1 | DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-02-08 | — | — | EP | disclosed |
| EP-3126005-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | The Trustees Of The University Of Pennsylvania (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-2978757-B1 | INDOLINONE ANALOGUES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-02-08 | — | — | EP | disclosed |
| US-9562029-B2 | C-glycoside derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2017-02-07 | — | — | US | disclosed |
| US-9562025-B2 | Compounds with (1E, 6E)-1,7-Bis-(3,4-dimethoxyphenyl)-4-4-distributed-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | ALLIANZ PHARMASCIENCE LTD. (TW) | 2017-02-07 | — | — | US | disclosed |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-02-02 | — | — | US | disclosed |
| US-20170029459-A1 | Novel 7-Dehydrocholesterol Derivatives and Methods Using Same | WOMEN & INFANTS HOSPITAL OF RHODE ISLAND | 2017-02-02 | — | — | US | disclosed |
| WO-2017015720-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2017-02-02 | — | — | WO | disclosed |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170027172-A1 | USE OF SUBSTITUTE OXO TETRAHYDROQUINOLINE SULFONAMIDES OR SALTS THEREOF FOR RAISING STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029478-A1 | High Molecular Weight, Post-Translationally Modified Protein Brushes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029441-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9556181-B2 | Substituted pyrazolopyrimidinylamino-indazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-20170022189-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2017-01-26 | — | — | US | disclosed |
| WO-2017015562-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND THEIR USE AS INHIBITORS OF G12C MUTANT KRAS, HRAS AND/OR NRAS PROTEINS | ARAXES PHARMA LLC (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20170022247-A1 | WITHANOLIDES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | IMSTAR THERAPEUTICS INC. (CA) | 2017-01-26 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-20170020859-A1 | 6-ALKYNYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2017-01-26 | — | — | US | disclosed |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2017-01-26 | — | — | US | disclosed |
| EP-3119397-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-2212328-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORP (KR) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121208-A1 | POLYMERIC MATERIALS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2017-01-25 | — | — | EP | disclosed |
| EP-3119759-A1 | NOVEL COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3119787-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | Bayer Pharma Aktiengesellschaft (DE) | 2017-01-25 | — | — | EP | disclosed |
| US-9549947-B2 | Pharmaceutical compositions for treating hyperkalemia | ARDELYX, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549932-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20170015671-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-01-19 | — | — | US | disclosed |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| WO-2017009650-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-01-19 | — | — | WO | disclosed |
| WO-2017011323-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-01-19 | — | — | WO | disclosed |
| EP-2411352-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBVIE INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9545425-B2 | Pharmaceutical compositions for treating hyperkalemia | ARDELYX, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20170007710-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2017-01-12 | — | — | US | disclosed |
| EP-1689706-B1 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIV - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-11 | — | — | EP | disclosed |
| US-9540410-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2017-01-10 | — | — | US | disclosed |
| US-9540353-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2017-01-10 | — | — | US | disclosed |
| US-9540385-B2 | Pyrrolopyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| WO-2017001924-A1 | THERAPEUTIC INHIBITORY COMPOUDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017003822-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | GALLEON PHARMACEUTICALS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017001926-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC (BB) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017004543-A1 | ARYL SULFONAMIDE COMPOUNDS AS CARBONIC ANHYDRASE INHIBITORS AND THEIR THERAPEUTIC USE | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017001936-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-01-05 | — | — | WO | disclosed |
| US-20170003293-A1 | ENCODED CHROMOPHORIC POLYMER PARTICLES AND METHODS OF USE THEREOF | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-01-05 | — | — | US | disclosed |
| EP-2819996-B1 | 6-ALKYNYL PYRIDINES AS SMAC MIMETICS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-04 | — | — | EP | disclosed |
| US-9533991-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-9533999-B2 | Fused thiazin-3-ones as KCA3.1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-03 | — | — | US | disclosed |
| WO-2016207104-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016207103-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| US-20160376522-A1 | IONIC LIQUID SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2016-12-29 | — | — | US | disclosed |
| WO-2016207089-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| US-20160375026-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-29 | — | — | US | disclosed |
| WO-2016210352-A2 | SYNTHESIS OF PHEROMONES AND OTHER OXY-FUNCTIONALIZED PRODUCTS VIA ENZYMATIC HYDROXYLATION OF CARBOXYLIC ACIDS | PROVIVI, INC. (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20160376256-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| US-20160376587-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| WO-2016207094-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| US-9527847-B2 | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527829-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160367962-A1 | ZIF-CONTAINING ADSORBENT MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2016-12-22 | — | — | US | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2016202898-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016205590-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016202935-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | disclosed |
| US-20160368893-A1 | CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF | Peloton Therapeutics ,Inc. | 2016-12-22 | — | — | US | disclosed |
| EP-3105209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| EP-1976828-B1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2705181-B1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-3105210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-9522146-B2 | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522876-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2016-12-20 | — | — | US | disclosed |
| WO-2016197187-A1 | VERSATILE RAFT AGENT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016200840-A1 | MONO AND BICYCLIC RING BORONIC ACID, ESTER AND SALT COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016200956-A1 | PROCESS FOR THE PREPARATION OF POLYURETHANE SOLUTIONS BASED ON SILICON-POLYCARBONATE DIOLS | MAGUIRE FRANCIS P (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362390-A1 | TRICYCLIC INHIBITORS OF HIF-2-ALPHA AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160362405-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362404-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| EP-3102207-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | Agency For Science, Technology And Research (SG) | 2016-12-14 | — | — | EP | disclosed |
| EP-2265607-B1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160355503-A1 | NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016197027-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | KURA ONCOLOGY, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016195776-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | KURA ONCOLOGY, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016193284-A1 | PESTICIDALLY ACTIVE OXIME AND HYDRAZONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-08 | — | — | WO | disclosed |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2016-12-08 | — | — | US | disclosed |
| WO-2016193680-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | BERGENBIO AS (NO) | 2016-12-08 | — | — | WO | disclosed |
| US-20160355539-A1 | SELECTIVE SOLVENT FREE PHOSPHORYLATION | CHROMADEX, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2016196897-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS | SAREPTA THERAPEUTICS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| EP-3099682-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-07 | — | — | EP | disclosed |
| EP-2355853-B1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | POLYACTIVA PTY LTD (AU) | 2016-12-07 | — | — | EP | disclosed |
| US-9512126-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160347714-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160346318-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160347733-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2016191612-A2 | HEMOPROTEIN CATALYSTS FOR IMPROVED ENANTIOSELECTIVE ENZYMATIC SYNTHESIS OF TICAGRELOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-12-01 | — | — | WO | disclosed |
| EP-2773614-B1 | SUBSTITUTED 4.CYAN-3-(PHENYL-4-(PYRIDIN-3-YL) BUTANOATES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER IP GMBH (DE) | 2016-11-30 | — | — | EP | disclosed |
| CN-104039762-B | Nampt inhibitor | ABBVIE INC. (US) | 2016-11-30 | — | — | CN | disclosed |
| US-20160339418-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | LIPSHUTZ BRUCE H (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160341736-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES AND METHODS FOR THEIR USE | SONY CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
| US-20160338342-A1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | EXACT SCIENCES CORPORATION | 2016-11-24 | — | — | US | disclosed |
| EP-3094687-A2 | WATER SOLUBLE FLUORESCENT OR COLORED DYES | Sony Corporation (JP) | 2016-11-23 | — | — | EP | disclosed |
| CN-106164064-A | Substituted cyclopentane, oxolane and pyrrolidine as orexin receptor antagonists | 武田药品工业株式会社 | 2016-11-23 | — | — | CN | disclosed |
| CN-106164047-A | 1,2 substituted cyclopentanes as orexin receptor antagonists | 武田药品工业株式会社 | 2016-11-23 | — | — | CN | disclosed |
| US-9499521-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-22 | — | — | US | disclosed |
| US-9500640-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499693-B2 | Clean polycarbonate material for use in hard disk drive and semiconductor applications | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2016-11-22 | — | — | US | disclosed |
| US-9499547-B2 | Amino-substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| US-20160332970-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-11-17 | — | — | US | disclosed |
| WO-2016183185-A1 | ULTRA BRIGHT DIMERIC OR POLYMERIC DYES | SONY CORPORATION (JP) | 2016-11-17 | — | — | WO | disclosed |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016179645-A1 | 4H-PYRAN COMPOUNDS AS INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS | MONASH UNIVERSITY (AU) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183586-A1 | HIGH MOLECULAR WEIGHT, POST-TRANSLATIONALLY MODIFIED PROTEIN BRUSHES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160331800-A1 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | REGENERON PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160333048-A1 | Antimicrobial Peptidomimetics | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-17 | — | — | US | disclosed |
| EP-2665775-B1 | UV STABILIZATION OF ISOSORBIDE POLYCARBONATES | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2016-11-16 | — | — | EP | disclosed |
| EP-3092242-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-11-16 | — | — | EP | disclosed |
| US-9493799-B2 | In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493419-B2 | Quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-11-15 | — | — | US | disclosed |
| US-9493432-B2 | Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| US-9493482-B2 | Compounds and methods for preventing or treating sensory hair cell death | UNIVERSITY OF WASHINGTON (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2016179349-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NORTHWESTERN UNIVERSITY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160324160-A1 | SYNERGISTIC BENZOXABOROLE-CONTAINING ANTI-FUNGICIDAL COMPOSITION | THE PENN STATE RESEARCH FOUNDATION | 2016-11-10 | — | — | US | disclosed |
| US-20160326186-A1 | COMPOUNDS AND METHODS FOR PREVENTING, TREATING AND/OR PROTECTING AGAINST SENSORY HAIR CELL DEATH | FRED HUTCHINSON CANCER CENTER | 2016-11-10 | — | — | US | disclosed |
| EP-2947072-B1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | AMBIT BIOSCIENCES CORP (US) | 2016-11-09 | — | — | EP | disclosed |
| CN-106075466-A | Multi-functional amphoteric ion polymer conjugate | 科迪亚科学企业公司 | 2016-11-09 | — | — | CN | disclosed |
| US-9487523-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487471-B1 | Synthesis of pyrethroids and pyrethroid-containing compositions | PROVIVI, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487545-B2 | Fused ring-containing oxazolidinones antibiotics | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-08 | — | — | US | disclosed |
| US-9487535-B2 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-08 | — | — | US | disclosed |
| US-9486457-B2 | Use of cinnabarinic acid as a modulator of immune responses in autoimmune disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160317486-A1 | METHOD FOR WOUND HEALING | PEPLIN RESEARCH PTY LTD (AU) | 2016-11-03 | — | — | US | disclosed |
| WO-2016176330-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| WO-2016176562-A1 | NOVEL EPHA4 INHIBITORS TARGETING ITS LIGAND BINDING DOMAIN | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016176396-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | FORESIGHT BIOTHERAPEUTICS, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| EP-3087091-A1 | VAR2CSA-DRUG CONJUGATES | Zymeworks Inc. (CA) | 2016-11-02 | — | — | EP | disclosed |
| EP-2331556-B1 | BISTABLE CARBAZOLE COMPOUNDS | ST MICROELECTRONICS SRL (IT) | 2016-11-02 | — | — | EP | disclosed |
| EP-2217610-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-3086815-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | Zymeworks Inc. (CA) | 2016-11-02 | — | — | EP | disclosed |
| EP-2918589-B1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | INTELLIKINE LLC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9481673-B2 | 6-alkynyl-pyridine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-01 | — | — | US | disclosed |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160313312-A1 | Fluorescent Dyes and Related Methods | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2016-10-27 | — | — | US | disclosed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-2897957-B1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-106061980-A | Thienopyrimidines as MKNK1 and MKNK2 Inhibitors | 拜耳制药股份公司 | 2016-10-26 | — | — | CN | disclosed |
| US-9475795-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475824-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| WO-2016168349-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168510-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. | 2016-10-20 | — | — | US | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016168540-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168682-A2 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160303134-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | disclosed |
| EP-2507280-B1 | POLYMERIC MATERIALS | COMMW SCIENT IND RES ORG (AU) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080100-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9469642-B2 | Purinone compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468635-B2 | Fused ring compound for use as mineralocorticoid receptor antagonist | KBP BIOSCIENCES CO., LTD. (CN) | 2016-10-18 | — | — | US | disclosed |
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9469664-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160297775-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297820-A1 | DIMERIZER COMPOUND | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-10-13 | — | — | US | disclosed |
| US-20160297811-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-13 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164589-A1 | SYNERGISTIC BENZOXABOROLE-CONTAINING ANTI-FUNGICIDAL COMPOSITION | THE PENN STATE RESEARCH FOUNDATION (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160297833-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma AG (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-3077003-A1 | COMBINATION OF PI3K-INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-12 | — | — | EP | disclosed |
| EP-3076974-A1 | THERAPEUTIC COMBINATION OF A PI3K INHIBITOR AND A BTK INHIBITOR | Acerta Pharma B.V. (NL) | 2016-10-12 | — | — | EP | disclosed |
| EP-2488177-B1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-3077388-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, LLC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2723748-B1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-10-12 | — | — | EP | disclosed |
| CN-104797582-B | Substituted pyrrolo-pyrimidine radicals amino-benzothiazole ketone as MKNK inhibitors of kinases | 拜耳药业股份公司 | 2016-10-12 | — | — | CN | disclosed |
| US-9464033-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464060-B2 | Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464065-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| WO-2016161248-A1 | TARGETING PIM KINASES IN COMBINATION WITH BTK INHIBITION | TOLERO PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016156816-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2016-10-06 | — | — | WO | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287601-A1 | ENHANCED TREATMENT REGIMENS USING PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS INC | 2016-10-06 | — | — | US | disclosed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287597-A1 | Treatment Regimens Using Multiple Pharmaceutical Agents | INTELLIKINE LLC | 2016-10-06 | — | — | US | disclosed |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | FAETH THERAPEUTICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-2552905-B1 | B-Raf kinase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2016-10-05 | — | — | EP | disclosed |
| EP-3074390-A2 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SignalChem Lifesciences Corporation (CA) | 2016-10-05 | — | — | EP | disclosed |
| EP-3074385-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | Takeda Pharmaceutical Company Limited (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-3074414-A1 | WITHANOLIDES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Imstar Therapeutics Inc. (CA) | 2016-10-05 | — | — | EP | disclosed |
| US-9458088-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458159-B2 | Substituted pyrido[1′,2′:4,5]pyrazino[1,2-a]azepines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458178-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| US-9458129-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2016154629-A1 | THERAPY FOR MALIGNANT DISEASE | WOMAN & INFANTS' HOSPITAL OF RHODE ISLAND (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016149765-A1 | SODIUM CHANNEL MODULATORS | THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (AU) | 2016-09-29 | — | — | WO | disclosed |
| EP-2484679-B1 | N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS INC (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2590510-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-3071591-A2 | ANTIMICROBIAL PEPTIDOMIMETICS | Agency For Science, Technology And Research (SG) | 2016-09-28 | — | — | EP | disclosed |
| EP-3071204-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SignalChem Lifesciences Corp. (CA) | 2016-09-28 | — | — | EP | disclosed |
| US-9452148-B2 | Insulin sensitisers and methods of treatment | VERVA PHARMACEUTICALS LTD (AU) | 2016-09-27 | — | — | US | disclosed |
| US-9452167-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2016149404-A1 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016149401-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160272602-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| US-20160272668-A1 | NICOTINIC ACID RIBOSIDE OR NICOTINAMIDE RIBOSIDE COMPOSITIONS, REDUCED DERIVATIVES THEREOF, AND THE USE THEREOF TO ENHANCE SKIN PERMEATION IN TREATING SKIN CONDITIONS | ChromaDex Inc. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271178-A1 | NANOPARTICLE-CONTAINING HYDROGELS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-09-22 | — | — | US | disclosed |
| US-20160272649-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3070110-A1 | POLYMERS HAVING ORTHOGONAL REACTIVE GROUPS AND USES THEREOF | NVS Technologies Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| US-9447045-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447078-B2 | Substituted heterocyclic compounds for disease treatment | ACUCELA INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447114-B2 | Thieno- and furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447046-B2 | Histone demethylase inhibitors | Celegene Quanticel Research, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| WO-2016144825-A1 | AROMATIC COMPOUNDS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160263013-A1 | Skin Care Compositions and Methods of Use Thereof | UNIGEN, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160266149-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2016145045-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016145032-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | PELOTON THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160264539-A1 | COMPOUNDS WITH (1E, 6E)-1,7-BIS-(3,4-DIMETHOXYPHENYL)-4-4-DISUBSTITUTED-HEPTA-1,6-DIENE-3,5-DIONE STRUCTURAL SCAFFOLD, THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | Annji Pharmaceutical Co., Ltd. (TW) | 2016-09-15 | — | — | US | disclosed |
| WO-2016145298-A1 | METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016144826-A1 | SUBSTITUTED PYRIDINES AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-2734520-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2825540-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-3067358-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2277848-B1 | Indene derivatives as pharmaceutical agents | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-09-14 | — | — | EP | disclosed |
| EP-3066104-A1 | TRIAZOLOPYRAZINE DERIVATIVES AS BRD4 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-09-14 | — | — | EP | disclosed |
| CN-104520292-B | Sulphonylpiperidine derivant and they are for treating the purposes of disease of front dynein mediation | 武田药品工业株式会社 | 2016-09-14 | — | — | CN | disclosed |
| CN-104144929-B | Cinchona alkaloid double-quaternary salt as asymmetric phase transfer catalyst | 默沙东公司 | 2016-09-14 | — | — | CN | disclosed |
| US-9440973-B2 | Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440983-B2 | Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440898-B2 | Preparation of pentanol with ethanol derived from fermentation | Pioneer Energy (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440972-B2 | Pyrido[2,3-d]pyrimidine-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257671-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| EP-2817308-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-3062767-A1 | SKIN CARE COMPOSITIONS AND METHODS OF USE THEREOF | Unigen, Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| CN-105934498-A | Encoded chromophoric polymer particles | 华盛顿大学商业中心 | 2016-09-07 | — | — | CN | disclosed |
| CN-105934440-A | Antimicrobial Peptide Mimetics | 新加坡科技研究局 | 2016-09-07 | — | — | CN | disclosed |
| CN-103965180-B | Benzsulfamide azoles and thiazole inhibitors of kinases | 通化济达医药有限公司 | 2016-09-07 | — | — | CN | disclosed |
| US-9433604-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434720-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DIRMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434744-B2 | Low temperature synthesis of rapamycin derivatives | BIOSENSORS INTERNATIONAL GROUP, LTD. (BM) | 2016-09-06 | — | — | US | disclosed |
| US-9433640-B2 | Compositions and methods for treating hyperkalemia | ARDELYX, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2016138457-A1 | PHENYLETHYNYLNAPHTHALENE DYES AND METHODS FOR THEIR USE | SONY CORPORATION (JP) | 2016-09-01 | — | — | WO | disclosed |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251374-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | BURNS BARBIER LINDSAY (US) | 2016-09-01 | — | — | US | disclosed |
| WO-2016138461-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES COMPRISING CONJUGATING GROUPS | SONY CORPORATION (JP) | 2016-09-01 | — | — | WO | disclosed |
| EP-2639226-B1 | Anti-infective pyrimidines and uses thereof | ABBVIE BAHAMAS LTD (BS) | 2016-08-31 | — | — | EP | disclosed |
| CN-105916841-A | Functionalised and substituted indoles as anti-cancer agents | 诺沃根公司 | 2016-08-31 | — | — | CN | disclosed |
| US-9428515-B2 | Benzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-9428513-B2 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| WO-2016131794-A1 | 3-CARBAMOYLPHENYL-4-CARBOXAMIDE AND ISOPHTALAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016131810-A1 | N-PHENYL-(MORPHOLIN-4-YL OR PIPERAZINYL)ACETAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016131808-A1 | 1,3,4-THIADIAZOL-2-YL-BENZAMIDE DERIVATIVES AS INHIBITORSOF THE WNT SIGNALLING PATHWAY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | WO | disclosed |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-08-25 | — | — | US | disclosed |
| EP-3057957-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-08-24 | — | — | EP | disclosed |
| EP-2346508-B1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-3057586-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| CN-103987711-B | 8-carbamoyl-2- (2, 3-disubstituted pyridin-6-yl) -1,2,3, 4-tetrahydroisoquinoline derivatives as apoptosis inducers for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-103857664-B | The method being prepared 5 hydroxymethyl furfural by carbohydrate | 新加坡科技研究局 | 2016-08-24 | — | — | CN | disclosed |
| US-9422290-B2 | Triazolopyridazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9421210-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9421214-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9420790-B2 | Molecules that induce disease resistance and improve growth in plants | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237035-A1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237089-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237426-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-08-18 | — | — | US | disclosed |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2016-08-18 | — | — | US | disclosed |
| WO-2016130092-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128912-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR, AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-08-18 | — | — | WO | disclosed |
| EP-3054956-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9416141-B2 | Compounds and methods for preventing, treating and/or protecting against sensory hair cell death | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2016-08-16 | — | — | US | disclosed |
| WO-2016127123-A2 | COMPOUNDS AND METHODS FOR PREVENTING OR TREATING SENSORY HAIR CELL DEATH | UNIVERSITY OF WASHINGTON (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016127133-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160229869-A1 | COMPOUNDS AND METHODS FOR PREVENTING OR TREATING SENSORY HAIR CELL DEATH | FRED HUTCHINSON CANCER CENTER | 2016-08-11 | — | — | US | disclosed |
| US-20160229865-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2016-08-11 | — | — | US | disclosed |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229959-A1 | ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-08-11 | — | — | US | disclosed |
| EP-2766361-B1 | 8-CARBAMOYL-2-(2,3-DISUBSTITUTED PYRID-6-YL)-1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-3052493-A1 | ENHANCED TREATMENT REGIMENS USING PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-3052486-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2678016-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-3052485-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| CN-103936728-B | Thiazole inhibitors of kinases | 通化济达医药有限公司 | 2016-08-10 | — | — | CN | disclosed |
| US-9408919-B2 | Biodegradable polymer—bioactive moiety conjugates | POLYACTIVA PTY LTD. (AU) | 2016-08-09 | — | — | US | disclosed |
| US-9409889-B2 | Amino-substituted imidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-09 | — | — | US | disclosed |
| US-9410947-B2 | Fluorescent dyes and related methods | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408840-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | ARDELYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160222016-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| WO-2016123361-A1 | LIGAND-ENABLED META-C-H ACTIVATION USING A TRANSIENT MEDIATOR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123392-A2 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-2725031-B1 | C-GLYCOSIDE DERIVATIVES | XUANZHU PHARMA CO LTD (CN) | 2016-08-03 | — | — | EP | disclosed |
| CN-105828838-A | NANOPARTICLE-CONTAINING HYDROGELS | 新加坡科技研究局 | 2016-08-03 | — | — | CN | disclosed |
| US-20160213787-A1 | POLYMER-FLAVONOID CONJUGATES AND HYDROGELS FOR BIOMEDICAL APPLICATIONS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-07-28 | — | — | US | disclosed |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2016116777-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LEUKEMIA USING A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-07-28 | — | — | WO | disclosed |
| EP-3046572-A1 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-3046913-A1 | CONVERSION AND PURIFICATION OF BIOMASS | Agency For Science, Technology And Research (SG) | 2016-07-27 | — | — | EP | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-3048105-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2016-07-27 | — | — | EP | disclosed |
| EP-2504374-B1 | WATER CURABLE RESIN FORMULATIONS | PETROLIAM NASIONAL BERHAD PETRONAS (MY) | 2016-07-27 | — | — | EP | disclosed |
| US-20160208100-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES AND METHODS FOR THEIR USE | Sony Group Corporation (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207899-A1 | CONVERSION AND PURIFICATION OF BIOMASS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-07-21 | — | — | US | disclosed |
| US-20160207880-A1 | AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160207915-A1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160206611-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-07-21 | — | — | US | disclosed |
| CN-105793249-A | Piperidine derivatives for the treatment or prevention of psychiatric and neurological disorders | 武田药品工业株式会社 | 2016-07-20 | — | — | CN | disclosed |
| US-9394279-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394299-B2 | Rilyazine derivatives and compositions for the treatment of cancer | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394313-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394257-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199501-A1 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2016111855-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| US-20160200645-A1 | Fuels and Chemicals from Lower Alkanes | PIONEER ENERGY INC (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3042895-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2016-07-13 | — | — | EP | disclosed |
| EP-3041830-A1 | POLYMER-FLAVONOID CONJUGATES AND HYDROGELS FOR BIOMEDICAL APPLICATIONS | Agency For Science, Technology And Research (SG) | 2016-07-13 | — | — | EP | disclosed |
| EP-3041840-A1 | RILYAZINE DERIVATIVES AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Warner-Babcock Institute For Green Chemistry LLC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9388183-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388177-B2 | Method for preparing substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-12 | — | — | US | disclosed |
| US-9388140-B2 | Substituted benzimidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193209-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194439-A1 | CONJUGATED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-07-07 | — | — | US | disclosed |
| US-20160194315-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-07-07 | — | — | US | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194335-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-07-07 | — | — | US | disclosed |
| EP-3039021-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| EP-2571357-B1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS INC (US) | 2016-07-06 | — | — | EP | disclosed |
| EP-2697193-B1 | SUBSTITUTED 5-(CYCLOHEX-2-EN-1-YL)-PENTA-2,4-DIENES AND 5-(CYCLOHEX-2-EN-1-YL)-PENT-2-EN-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER IP GMBH (DE) | 2016-07-06 | — | — | EP | disclosed |
| CN-103270034-B | The 2-pyridine carboxylic acid replaced and salt and acid derivative, and the purposes as herbicide | 拜耳知识产权有限责任公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-105742702-A | Rechargeable lithium battery | 三星SDI株式会社 | 2016-07-06 | — | — | CN | disclosed |
| CN-105745196-A | Conversion and purification of biomass | 新加坡科技研究局 | 2016-07-06 | — | — | CN | disclosed |
| US-9382255-B2 | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2016102435-A2 | NOVEL ISOTHIAZOLAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016102493-A1 | IMIDAZOPYRIDINE EZH2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016103192-A1 | AMINO ACID AND PEPTIDE CONJUGATES AND USES THEREOF | BRIMBLE MARGARET ANNE (NZ) | 2016-06-30 | — | — | WO | disclosed |
| US-20160190644-A1 | RECHARGEABLE LITHIUM BATTERY | SAMSUNG SDI CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185728-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2016-06-30 | — | — | US | disclosed |
| US-20160184281-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184445-A1 | BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160184282-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184387-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | CHARMOT DOMINIQUE (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185800-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185752-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-30 | — | — | US | disclosed |
| EP-3036235-A1 | NEW BIS-AMIDO PYRIDINES | Boehringer Ingelheim International GmbH (DE) | 2016-06-29 | — | — | EP | disclosed |
| EP-3038194-A1 | RECHARGEABLE LITHIUM BATTERY | Samsung SDI Co., Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
| EP-3036228-A1 | NEW 6-ALKYNYL PYRIDINE | Boehringer Ingelheim International GmbH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-9376447-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376431-B2 | Bis-quaternary cinchona alkaloid salts as asymmetric phase transfer catalysts | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376709-B2 | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures | BIOMATRICA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| WO-2016100711-A1 | MODULATORS OF HEPATIC LIPOPROTEIN METABOLISM | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096721-A1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176894-A1 | TAXANE AND ABEO-TAXANE ANALOGS | Arbor Therapeutics, LLC (US) | 2016-06-23 | — | — | US | disclosed |
| WO-2016100123-A1 | IONIC LIQUID SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160175346-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING HYPERKALEMIA | ARDELYX, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160175345-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING HYPERKALEMIA | ARDELYX, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176885-A1 | SUBSTITUTED 1,2,3,4,6,8,12,12a-OCTAHYDRO-1,4-METHANODIPYRIDO[1,2-a:1',2'-d]PYRAZINES AND METHODS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160175344-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160177222-A1 | IONIC LIQUID SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2016-06-23 | — | — | US | disclosed |
| EP-3033335-A1 | PYRIDINONES | Boehringer Ingelheim International GmbH (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2852596-B1 | THIENOPYRIMIDINES | Bayer Pharma AG (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2575462-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2852595-B1 | SUBSTITUTED BENZOTHIENOPYRIMIDINES | Bayer Pharma AG (DE) | 2016-06-22 | — | — | EP | disclosed |
| CN-103596431-B | Pyrimidine cyclohexyl glucocorticoid receptor modulators | 科赛普特治疗公司 | 2016-06-22 | — | — | CN | disclosed |
| US-9370510-B2 | Small molecule compounds to treat hearing loss | FATE THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160168149-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160167015-A1 | ADSORBENT FOR HETEROATOM SPECIES REMOVAL AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160168173-A1 | ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094777-A1 | ORGANOSILICA MATERIALS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168171-A1 | METHODS OF PRODUCING ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094773-A1 | ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168477-A1 | Synthesis of Drop-in Liquid Fuels and Chemicals from Methanol, Ethanol or Syngas Using Mixed Catalysts | Pioneer Energy Inc. (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094784-A1 | COATING METHODS USING ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094866-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEM COMPRISING MESOPOROUS ORGANOSILICA SUPPORT | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168134-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168174-A1 | ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094830-A1 | METHODS OF SEPARATING AROMATIC COMPOUNDS FROM LUBE BASE STOCKES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094769-A1 | AROMATIC HYDROGENATION CATALYSTS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168333-A1 | ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094788-A1 | ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094489-A1 | PHOSPHORUS LIGANDS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094774-A2 | METHODS OF PRODUCING ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-16 | — | — | US | disclosed |
| WO-2016094820-A1 | ADSORBENT FOR HETEROATOM SPECIES REMOVAL AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094848-A1 | ORGANOSILICA MATERIALS FOR USE AS ADSORBENTS FOR OXYGENATE REMOVAL | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168172-A1 | ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094778-A1 | ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160167016-A1 | COATING METHODS USING ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094770-A1 | ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094803-A1 | MEMBRANE FABRICATION METHODS USING ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094843-A2 | OLEFIN POLYMERIZATION CATALYST SYSTEM COMPRISING MESOPOROUS ORGANOSILICA SUPPORT | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160167032-A1 | AROMATIC HYDROGENATION CATALYSTS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094846-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168484-A1 | METHODS OF SEPARATING AROMATIC COMPOUNDS FROM LUBE BASE STOCKS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168157-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160168485-A1 | MEMBRANE FABRICATION METHODS USING ORGANOSILICA MATERIALS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-16 | — | — | US | disclosed |
| EP-3030553-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| EP-3030252-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9365499-B2 | 9-aminomethyl substituted tetracycline compounds | KBP BIOSCIENCES CO., LTD. (CN) | 2016-06-14 | — | — | US | disclosed |
| US-20160161475-A1 | HYBRID SEMICONDUCTING POLYMER NANOPARTICLES AS POLARIZATION-SENSITIVE FLUORESCENT PROBES | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2016-06-09 | — | — | US | disclosed |
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| WO-2016087488-A1 | ADMINISTRATION REGIME FOR AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090313-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087994-A1 | BTK INHIBITORS TO TREAT SOLID TUMORS THROUGH MODULATION OF THE TUMOR MICROENVIRONMENT | ACERTA PHARMA B.V. (NL) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090240-A1 | PHARMACEUTICAL COMPOSITIONS FOR INCREASING THE BIOAVAILABILITY OF POORLY SOLUBLE DRUGS | ASTEX PHARMACEUTICALS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087490-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090317-A1 | SULFONAMIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | AQUINNAH PHARMACEUTICALS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20160159816-A1 | SUBSTITUTED THIENOPYRIMIDINES AND PHARMACEUTICAL USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160158218-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2016-06-09 | — | — | US | disclosed |
| CN-105658633-A | Polymer-flavonoid conjugates and hydrogels for biomedical applications | 新加坡科技研究局 | 2016-06-08 | — | — | CN | disclosed |
| US-9359344-B2 | Biaryl heterocycle substituted oxazolidinone antibacterial agents | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9362126-B2 | Process for making a patterned metal oxide structure | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-06-07 | — | — | US | disclosed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359359-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359352-B2 | Substituted benzimidazoles as PI3 kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359365-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152619-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | HCR COLLATERAL MANAGEMENT, LLC | 2016-06-02 | — | — | US | disclosed |
| US-20160152595-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151527-A1 | Ionic Liquids | THE PROCTER & GAMBLE COMPANY | 2016-06-02 | — | — | US | disclosed |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160150782-A1 | USE OF SELECTED PYRIDONE CARBOXAMIDES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2016-06-02 | — | — | US | disclosed |
| US-9353124-B2 | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353126-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353091-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9354223-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| EP-2670731-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AND USES THEREOF. | BIONOMICS LTD (AU) | 2016-05-25 | — | — | EP | disclosed |
| US-9345706-B2 | Benzoxazole kinase inhibitors and methods of use | INTELLIKINE, LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346813-B2 | Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346785-B2 | Process for making HCV protease inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160137649-A1 | PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ABIDE THERAPEUTICS, INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2016075457-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | TAKEDA CAMBRIDGE LIMITED (GB) | 2016-05-19 | — | — | WO | disclosed |
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-3019559-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES AND METHODS FOR THEIR USE | Sony Corporation (JP) | 2016-05-18 | — | — | EP | disclosed |
| EP-3019503-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-3019443-A1 | HYBRID SEMICONDUCTING POLYMER NANOPARTICLES AS POLARIZATION SENSITIVE FLUORESCENT PROBES | University Of Washington Through Its Center For Commercialization (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-3019499-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-3019505-A1 | SUBSTITUTED PYRAZOLO-PYRIDINAMINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-18 | — | — | EP | disclosed |
| CN-105593320-A | Coating layer, coating solution, method for forming the coating layer, and method for producing medical tool | KANEKA CORP | 2016-05-18 | — | — | CN | disclosed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340558-B2 | Filamin a binding anti-inflammatory and analgesic | PAIN THERAPEUTICS INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340498-B2 | Raft polymerisation | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESERACH ORGANISATION (AU) | 2016-05-17 | — | — | US | disclosed |
| US-9339781-B2 | Polymer particles | THE UNIVERSITY OF SYDNEY (AU) | 2016-05-17 | — | — | US | disclosed |
| US-20160130247-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | QUANTIEL PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160129001-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-12 | — | — | US | disclosed |
| EP-3016653-A1 | PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | Abide Therapeutics, Inc. (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-3016953-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, LLC (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-3017013-A1 | REFRIGERATION SYSTEM WITH DUAL REFRIGERANTS AND LIQUID WORKING FLUIDS | Xu, Yanjie (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9334264-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2016-05-10 | — | — | US | disclosed |
| WO-2016069542-A2 | LACTONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122317-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-05 | — | — | US | disclosed |
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-05-05 | — | — | US | disclosed |
| US-20160120854-A1 | PHARMACEUTICAL COMPOSITIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122514-A1 | SCRATCH RESISTANT POLYMERS | MILLER WASTE MILLS INC. DBA RTP COMPANY | 2016-05-05 | — | — | US | disclosed |
| EP-3013789-A2 | AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS | Auckland Uniservices Limited (NZ) | 2016-05-04 | — | — | EP | disclosed |
| EP-2781520-B1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | XUANZHU PHARMA CO LTD (CN) | 2016-05-04 | — | — | EP | disclosed |
| EP-2739626-B1 | NOVEL SPIROINDOLINE COMPOUNDS | INTERVET INT BV (NL) | 2016-05-04 | — | — | EP | disclosed |
| US-9326992-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328112-B2 | Tetracyclic CDK9 kinase inhibitors | ABBVIE INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328100-B2 | Process for the preparation of β-C-arylglucosides | SCINOPHARM TAIWAN, LTD. (TW) | 2016-05-03 | — | — | US | disclosed |
| US-20160115131-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-04-28 | — | — | US | disclosed |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160113277-A1 | Substituted 5-Hydroxy-2,3-Diphenylpentanonitrile Derivatives, Processes For Their Preparation And Their Use As Herbicides And/Or Plant Growth Regulators | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-04-28 | — | — | US | disclosed |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160115424-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | THE PROCTER & GAMBLE COMPANY | 2016-04-28 | — | — | US | disclosed |
| EP-3010928-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | Unigen, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-3010900-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | Takeda Pharmaceutical Company Limited (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-3010550-A2 | CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS | California Institute of Technology (US) | 2016-04-27 | — | — | EP | disclosed |
| CN-102304300-B | The solid particulate materials of polymeric encapsulate and comprise its discrete particle | UNIV. OF SYDNEY (AU) | 2016-04-27 | — | — | CN | disclosed |
| CN-105530814-A | Use of selected pyridone carboxamides or salts thereof as active substances against abiotic plant stress | BAYER CROPSCIENCE AG | 2016-04-27 | — | — | CN | disclosed |
| US-9320739-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321749-B1 | Heterocyclic compounds and uses thereof | GLOBAVIR BIOSCIENCES, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| US-9320737-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-26 | — | — | US | disclosed |
| US-9321736-B2 | Pyrimidine cyclohexyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321724-B2 | Heteroaryl compounds with A-cyclic bridging unit | INTERVET INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160106849-A1 | FORMULATIONS OF PHENYL URACIL COMPOUNDS | ABBVIE INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20160106749-A1 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160107995-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2016061195-A1 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2016061562-A2 | BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2016061097-A1 | ATAXIA TELENGIECTASIA AND RAD3-RELATED (ATR) PROTEIN KINASE INHIBITORS | Atrin Pharmaceuticals LLC (US) | 2016-04-21 | — | — | WO | disclosed |
| US-20160108436-A1 | SYNTHESIS OF OLEFINIC ALCOHOLS VIA ENZYMATIC TERMINAL HYDROXYLATION | PROVIVI, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| EP-3008061-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009436-A1 | KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2590965-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-04-20 | — | — | EP | disclosed |
| CN-105517949-A | Hybrid semiconducting polymer nanoparticles as polarization sensitive fluorescent probes | UNIV OF WASHINGTON CENTER FOR COMMERCIALIZATION | 2016-04-20 | — | — | CN | disclosed |
| CN-103228141-B | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-20 | — | — | CN | disclosed |
| US-9315505-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-9314467-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315509-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2016057242-A1 | HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057600-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055982-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS | ACERTA PHARMA B.V. (NL) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016054689-A1 | ALL PURPOSE RAFT AGENT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102307-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-04-14 | — | — | US | disclosed |
| US-20160102104-A1 | Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase Inhibitors | Atrin Pharmaceuticals LLC (US) | 2016-04-14 | — | — | US | disclosed |
| EP-3003309-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-3004093-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-3004239-A1 | SCRATCH RESISTANT POLYMERS | Tenasitech Pty Ltd. (AU) | 2016-04-13 | — | — | EP | disclosed |
| EP-2766359-B1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES | AMBIT BIOSCIENCES CORP (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-3003381-A1 | PHARMACEUTICAL COMPOSITIONS | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-3004083-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | The California Institute for Biomedical Research (US) | 2016-04-13 | — | — | EP | disclosed |
| US-9309508-B2 | Boronic and borinic acid compound as inhibitors of sulfenic acid-containing proteins | THE PENN STATE RESEARCH FOUNDATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308207-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309211-B2 | Arylalkene derivatives and use thereof as selective estrogen receptor modulators | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-9309259-B2 | Process for ixabepilone, and intermediates thereof | SCINOPHARM TAIWAN, LTD. (TW) | 2016-04-12 | — | — | US | disclosed |
| WO-2016054491-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20160096869-A1 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2016-04-07 | — | — | US | disclosed |
| EP-2807166-B1 | 5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLINES AS IGF-1R/IR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2611300-B1 | SUBSTITUTED ANNELATED DIHYDROPYRIMIDINONE COMPOUNDS | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-9303026-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2016-04-05 | — | — | US | disclosed |
| WO-2016049568-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049565-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | INTELLIKINE LLC | 2016-03-31 | — | — | US | disclosed |
| WO-2016049390-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016048982-A2 | COMBINATION TREATMENT WITH PI3Kα INHIBITORS AND TAXANES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049391-A1 | IONIC LIQUIDS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | disclosed |
| CN-105451553-A | Substituted 5-hydroxy-2,3-diphenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators | BAYER CROPSCIENCE AG | 2016-03-30 | — | — | CN | disclosed |
| US-9296748-B2 | Pyridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9296723-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296742-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296757-B2 | Substituted benzothienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9295673-B2 | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296665-B2 | Synthesis of drop-in liquid fuels and chemicals from methanol, ethanol or syngas using mixed catalysts | Pioneer Energy Inc. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044771-A1 | HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016044429-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044777-A1 | HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044138-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044342-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044772-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044792-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160083387-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-03-24 | — | — | US | disclosed |
| EP-2794568-B1 | SUBSTITUTED 4-CYANO-3-PHENYL-4-(PYRIDIN-3-YL) BUTANOATES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER IP GMBH (DE) | 2016-03-23 | — | — | EP | disclosed |
| EP-2091527-B1 | SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2367824-B1 | Anti-viral derivatives of pyrimidine | ABBVIE INC (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2373648-B1 | SUBSTITUTED 1-(THIAZOLYL)- AND 1-(ISOTHIAZOLYL)PYRAZOL-4-YL ACETIC ACIDS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER IP GMBH (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-9289429-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289430-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290507-B2 | B-RAF kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-22 | — | — | US | disclosed |
| US-9290456-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-22 | — | — | US | disclosed |
| US-9290497-B2 | Processes for preparing isoquinolinones and solid forms of isoquinolinones | INFINITY PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290482-B2 | — | — | 2016-03-22 | — | — | US | disclosed |
| WO-2016037221-A1 | LIGHT ACTIVATED ELECTROCHEMISTRY | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040330-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160075716-A1 | POLYMERIC MATERIALS | COMMONWEALTH SCIENTIFIC INDUSTRIAL AND RESEARCH ORGANISATION (AU) | 2016-03-17 | — | — | US | disclosed |
| US-20160075684-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-III | MERCK SHARP & DOHME CORP. (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2691375-B1 | SUBSTITUTED BENZIMIDAZOLES AS MPS-1 KINASE INHIBITORS | BAYER IP GMBH (DE) | 2016-03-16 | — | — | EP | disclosed |
| EP-2619232-B1 | CONTINUOUS FLOW POLYMERISATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2016-03-16 | — | — | EP | disclosed |
| US-9284319-B2 | Heterocyclyl aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-9284317-B2 | Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| WO-2016037005-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20160067296-A1 | Compositions and Methods for Joint Health | UNIGEN, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068524-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
| US-20160068534-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
| US-20160067242-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160068522-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
| US-20160068507-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-10 | — | — | US | disclosed |
| EP-2993165-A2 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USE THEREOF | Allianz Pharmascience Ltd (TW) | 2016-03-09 | — | — | EP | disclosed |
| EP-2822954-B1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| CN-101605763-B | Radioprotector compounds and methods involving | PETER MACCALLUM CANCER INSTITUTE (AU) | 2016-03-09 | — | — | CN | disclosed |
| US-9278102-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278978-B2 | 6-Alkynyl Pyridine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-08 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060247-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-03-03 | — | — | US | disclosed |
| EP-2498600-B1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS INC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160050895-A1 | TRANSGENIC NON-HUMAN ORGANISMS WITH NON-FUNCTIONAL TSPO GENES | THE UNIVERSITY OF SYDNEY (AU) | 2016-02-25 | — | — | US | disclosed |
| US-20160052938-A1 | SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-25 | — | — | US | disclosed |
| WO-2016026937-A1 | NEW SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-25 | — | — | WO | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| EP-2628481-B1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | ABBVIE BAHAMAS LTD (BS) | 2016-02-24 | — | — | EP | disclosed |
| EP-2307013-B1 | PAIN-RELIEVING COMPOSITIONS OF FUROXAN NO DONORS AND USES THEREOF | UNIV QUEENSLAND (AU) | 2016-02-24 | — | — | EP | disclosed |
| CN-105358617-A | Scratch resistant polymers | TENASITECH PTY LTD | 2016-02-24 | — | — | CN | disclosed |
| US-9266877-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266919-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266891-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-23 | — | — | US | disclosed |
| WO-2016023832-A1 | THIENO- AND FURO[2,3-D]PYRIMIDINE-2,4[1H,3H]-DIONE DERIVATIVES AS TRPC5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160045559-A1 | COMPOSITIONS AND METHODS FOR MANAGING OR IMPROVING BONE DISORDERS, CARTILAGE DISORDERS, OR BOTH | UNIGEN, INC. (KR) | 2016-02-18 | — | — | US | disclosed |
| WO-2016024232-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR AND/OR A CDK 4/6 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023826-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024231-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023830-A1 | PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160046635-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2016-02-18 | — | — | US | disclosed |
| WO-2016024227-A1 | BTK INHIBITORS TO TREAT SOLID TUMORS THROUGH MODULATION OF THE TUMOR MICROENVIRONMENT | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025816-A1 | FATTY ACID SYNTHASE INHIBITOR FOR USE IN THE TREATMENT OF DRUG RESISTANT CANCER | 3-V BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023825-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024228-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024230-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023831-A1 | PYRROLO[3,2-D]PYRIMIDINE-2,4(3H,5H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160046624-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-18 | — | — | US | disclosed |
| EP-1877481-B1 | STABILISER COMPOSITION FOR HALIDE-CONTAINING POLYMERS | SUN ACE KAKOH PTE LTD (SG) | 2016-02-17 | — | — | EP | disclosed |
| US-9260441-B2 | Heteroaryl compounds with cyclic bridging unit | INTERVET INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260655-B2 | Alkyl-acid ligands for nanocrystals | NANOSYS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9259402-B2 | Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyI)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | ALLIANZ PHARMASCIENCE LTD. (TW) | 2016-02-16 | — | — | US | disclosed |
| US-9260367-B2 | Methods of converting polyols | Univesity of Washington Through Its Center For Communication (US) | 2016-02-16 | — | — | US | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-02-11 | — | — | US | disclosed |
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD. (AU) | 2016-02-11 | — | — | US | disclosed |
| WO-2016020901-A1 | METHODS OF TREATING CANCERS, IMMUNE AND AUTOIMMUNE DISEASES, AND INFLAMMATORY DISEASES BASED ON BTK OCCUPANCY AND BTK RESYNTHESIS RATE | ACERTA PHARMA B.V. (NL) | 2016-02-11 | — | — | WO | disclosed |
| US-20160039831-A1 | PYRROLO[3,2-d]PYRIMIDINE-2,4(3H,5H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039814-A1 | 6-ALKYNYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160040199-A1 | ENZYMATIC METHODS FOR NITROGEN-ATOM TRANSFER | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160039723-A1 | STEREODYNAMIC CHEMOSENSORS | GEORGETOWN UNIVERSITY (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039841-A1 | THIENO- AND FURO[2,3-d]PYRIMIDINE-2,4[1H,3H]-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160038497-A1 | Enhanced Treatment Regimens Using mTOR Inhibitors | FAETH THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
| CN-102858437-B | For the substrate and preparation method thereof of fixed function material | TEMASEK POLYTECHNIC (SG) | 2016-02-10 | — | — | CN | disclosed |
| US-9255198-B2 | Water swellable polymer materials comprising particulate core and water swellable R.A.F.T polymer shell | THE UNIVERSITY OF SYDNEY (AU) | 2016-02-09 | — | — | US | disclosed |
| US-9255097-B2 | Inhibitors of lysine specific demethylase-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255108-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255100-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| US-20160031813-A1 | Nampt Inhibitors | ABBVIE INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2016019237-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016019233-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-02-04 | — | — | WO | disclosed |
| US-20160031891-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031776-A1 | Preparation of Butanol from Ethanol Derived from Fermentation | PIONEER ENERGY, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031899-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-02-04 | — | — | US | disclosed |
| US-20160032330-A1 | P-450-CATALYZED ENANTIOSELECTIVE CYCLOPROPANATION OF ELECTRON-DEFICIENT OLEFINS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031886-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2978758-A1 | DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2685827-B1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-2980088-A1 | Amino-substituted isothiazoles | Bayer Pharma Aktiengesellschaft (DE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2978757-A1 | INDOLINONE ANALOGUES AS BRD4 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-02-03 | — | — | EP | disclosed |
| CN-105308041-A | Preparation method for ixabepilone and intermediate thereof | SCINOPHARM TAIWAN LTD | 2016-02-03 | — | — | CN | disclosed |
| US-9249138-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9248193-B2 | Formulations of phenyl uracil compounds | ABBVIE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249151-B2 | Bis-amido pyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| WO-2016012477-A1 | AMINO-SUBSTITUTED ISOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| WO-2016012481-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | YALE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-20160022692-A1 | TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2016012474-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| EP-2977376-A1 | Amino-substituted isoxazoles | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2670749-B1 | NEW AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2316827-B1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2016-01-27 | — | — | EP | disclosed |
| EP-2977377-A1 | Amino-substituted isoxazoles | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2976327-A2 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2976343-A2 | SUBSTITUTED N-BIPHENYL-3-ACETYLAMINO-BENZAMIDES AND N-[3-(ACETYLAMINO)PHENYL]-BIPHENYL-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-9242968-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242945-B2 | Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-01-26 | — | — | US | disclosed |
| US-20160018395-A1 | POLYMER DOT COMPOSITIONS AND RELATED METHODS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2016-01-21 | — | — | US | disclosed |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2016-01-21 | — | — | US | disclosed |
| WO-2016011209-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2016-01-21 | — | — | WO | disclosed |
| US-20160018405-A1 | METHODS AND SYSTEMS FOR ANALYSIS USING POLYMER DOTS | University of Washington Through it's Center for Commercialization (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160017099-A1 | Silicone Ligands for Quantum Dots | SHOEI CHEMICAL INC. (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| EP-2972349-A1 | POLYMER DOT COMPOSITIONS AND RELATED METHODS | University Of Washington Through Its Center For Commercialization (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2668178-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2971007-A1 | TRANSGENIC NON-HUMAN ORGANISMS WITH NON-FUNCTIONAL TSPO GENES | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2016-01-20 | — | — | EP | disclosed |
| EP-2969007-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2972258-A1 | PURIFICATION OF RAPAMYCIN DERIVATIVES | Biosensors International Group, Ltd. (SG) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968329-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | Galleon Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970316-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | Hydra Biosciences, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968265-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970100-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970264-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970299-A1 | PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970122-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968440-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | Centre For Drug Research And Development (CA) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970211-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970205-A2 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | Tolero Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968264-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970309-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968340-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | Intellikine, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970099-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970200-A1 | PYRIDINE CDK9 KINASE INHIBITORS | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970121-A1 | COVALENT INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105263855-A | Western blot analysis using polymer dots | UNIV WASHINGTON CT COMMERCIALIZATION | 2016-01-20 | — | — | CN | disclosed |
| WO-2016005577-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INTERNATIONAL B.V. (NL) | 2016-01-14 | — | — | WO | disclosed |
| US-20160009734-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-14 | — | — | US | disclosed |
| EP-2964645-A1 | PROCESS FOR IXABEPILONE, AND INTERMEDIATES THEREOF | Scinopharm Taiwan Ltd. (TW) | 2016-01-13 | — | — | EP | disclosed |
| EP-2964656-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2614063-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2964565-A1 | WESTERN BLOT ANALYSIS USING POLYMER DOTS | University Of Washington Through Its Center For Commercialization (US) | 2016-01-13 | — | — | EP | disclosed |
| CN-102612514-B | Anti influenza agent | GRIFFITH UNIVERSITY (AU) | 2016-01-13 | — | — | CN | disclosed |
| CN-105247010-A | Method for solventless quantum dot exchange | NANOSYS INC | 2016-01-13 | — | — | CN | disclosed |
| WO-2016004105-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016003917-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004272-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004305-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002245-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-07 | — | — | US | disclosed |
| WO-2016001376-A1 | NEW SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002682-A1 | IN VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | UNITED STATES DEPARTMENT OF ENERGY | 2016-01-07 | — | — | US | disclosed |
| US-20160004163-A1 | LITHOGRAPHICALLY PRODUCED FEATURES | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-01-07 | — | — | US | disclosed |
| US-20160000764-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002262-A1 | PURIFICATION OF RAPAMYCIN DERIVATIVES USING TEMPERATURE INDUCED PHASE SEPARATION | BIOSENSORS INTERNATIONAL GROUP, LTD. (BM) | 2016-01-07 | — | — | US | disclosed |
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | SCHRODINGER, LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160002201-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002241-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, LLC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2802595-B1 | PROCESSES FOR MAKING HCV PROTEASE INHIBITORS | ABBVIE INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9227963-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9226505-B2 | 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives as agents against abiotic plant stress | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-9227983-B2 | Taxane and abeo-taxane analogs | Arbor Therapeutics, LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150376399-A1 | Water Curable Resin Formulations | PETROLIAM NASIONAL BERHAD (PETRONAS) (MY) | 2015-12-31 | — | — | US | disclosed |
| US-20150376189-A1 | AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20150376179-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| US-20150376141-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20150376169-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150376271-A1 | DUAL PDGF/VEGF ANTAGONISTS | OLIGASIS, LLC (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2015200905-A2 | DUAL PDGF/VEGF ANTAGONISTS | OLIGASIS, LLC (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015198045-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015198046-A1 | 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200843-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015196258-A1 | ENZYME INTERACTING AGENTS | MONASH UNIVERSITY (AU) | 2015-12-30 | — | — | WO | disclosed |
| EP-2958920-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | disclosed |
| CN-105209916-A | Polymer dot compositions and related methods | UNIV WASHINGTON CT COMMERCIALIZATION | 2015-12-30 | — | — | CN | disclosed |
| US-20150368264-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150368250-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
| EP-2483249-B1 | PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-23 | — | — | EP | disclosed |
| WO-2015195656-A2 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES ,INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015195228-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015192175-A1 | POLYMER HYDROGEL | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-23 | — | — | WO | disclosed |
| CN-105189584-A | Alkyl-acid ligands for nanocrystals | NANOSYS INC | 2015-12-23 | — | — | CN | disclosed |
| CN-103502282-B | Amine-functionalized polyolefine and preparation method thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-12-23 | — | — | CN | disclosed |
| US-9216996-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216982-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2015-12-22 | — | — | US | disclosed |
| WO-2015191799-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | WO | disclosed |
| EP-2953940-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-9212192-B2 | Bicyclic carboxamide inhibitors of kinases | ABBVIE INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212184-B2 | 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-15 | — | — | US | disclosed |
| US-9212257-B2 | Polymeric materials | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2015-12-15 | — | — | US | disclosed |
| US-20150353832-A1 | PHOSPHINATE IONIC LIQUID COMPOSITIONS AND METHODS OF USE | H & C Scientific Resources International, LLC (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2015187827-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20150353854-A1 | SYNTHESIS OF FUELS AND CHEMICALS FROM SUGARS | PIONEER ENERGY INC (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2951181-A1 | AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-09 | — | — | EP | disclosed |
| EP-2951175-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-09 | — | — | EP | disclosed |
| CN-105143235-A | Polyhedral oligomeric silsesquioxane nanocrystal stabilization ligands | NANOSYS INC | 2015-12-09 | — | — | CN | disclosed |
| US-9206185-B2 | Imidazopyridazines as Akt kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9205038-B2 | Brightener-containing hair relaxer | SHURNEY GLENN (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206182-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2015-12-08 | — | — | US | disclosed |
| WO-2015181104-A1 | BENZOTHIADIAZOLAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150344523-A1 | MUTANT AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-03 | — | — | US | disclosed |
| EP-2692346-B1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | ABBVIE BAHAMAS LTD (BS) | 2015-12-02 | — | — | EP | disclosed |
| US-9198420-B2 | Rodenticidal norbormide analogues | LANDCARE RESEARCH NEW ZEALAND LIMITED (NZ) | 2015-12-01 | — | — | US | disclosed |
| US-9199988-B2 | Dihydroquinazolinone analogues | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199999-B2 | Substituted imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| WO-2015179563-A2 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR IDENTIFICATION OF SERINE HYDROLASE TARGETS | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20150337128-A1 | RELEASE MEDIA | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-11-26 | — | — | US | disclosed |
| US-20150336892-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2015-11-26 | — | — | US | disclosed |
| EP-2947072-A1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | Ambit Biosciences Corporation (US) | 2015-11-25 | — | — | EP | disclosed |
| CN-105102463-A | Low temperature synthesis of rapamycin derivatives | BIOSENSORS INTERNANTIONAL GROUP LTD | 2015-11-25 | — | — | CN | disclosed |
| CN-105102967-A | Purification of rapamycin derivatives | BIOSENSORS INTERNANTIONAL GROUP LTD | 2015-11-25 | — | — | CN | disclosed |
| US-9193716-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2015-11-24 | — | — | US | disclosed |
| US-9193669-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193723-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| WO-2015176020-A1 | SYNTHESIS OF OLEFINIC ALCOHOLS VIA ENZYMATIC TERMINAL HYDROXYLATION | PROVIVI, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015175845-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015175632-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150327546-A1 | SUBSTITUTED 4-CYAN-3-(PYRIDYL)-4-PHENYLBUTANOATES, METHOD FOR THE PRODUCTION THEREOF AND USES AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2015-11-19 | — | — | US | disclosed |
| EP-2943470-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2015-11-18 | — | — | EP | disclosed |
| CN-105072906-A | Substituted 4-cyano-3- (pyridyl) -4-phenylbutyrates, method for the production thereof and use thereof as herbicides and plant growth regulators | BAYER CROPSCIENCE AG | 2015-11-18 | — | — | CN | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-9185914-B2 | Substituted 5-(cyclohex-2-en-1-yl)-penta-2,4-dienes and 5-(cyclohex-2-en-1-yl)-pent-2-en-4-ines as active agents against abiotic stress in plants | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187458-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-9187472-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2015169962-A1 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-12 | — | — | WO | disclosed |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | disclosed |
| WO-2015171543-A1 | MUTANT AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150320727-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC | 2015-11-12 | — | — | US | disclosed |
| US-20150322064-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322086-A1 | LOW TEMPERATURE SYNTHESIS OF RAPAMYCIN DERIVATIVES | JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC. D/B/A JOHNSON MATTHEY PHARMA SERVICES | 2015-11-12 | — | — | US | disclosed |
| US-20150322073-A1 | Benzimidazole Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-12 | — | — | US | disclosed |
| EP-2942350-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-11-11 | — | — | EP | disclosed |
| CN-105051605-A | Lithographically produced features | UNIV QUEENSLAND | 2015-11-11 | — | — | CN | disclosed |
| US-9181221-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181244-B1 | Substituted pyrido[2,3-c]pyridazin-4(1H)-ones as tumor necrosis factor alpha and phosphodiesterase 4 inhibitors | Xuanzhu Pharma Co., Ltd. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181246-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9182402-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-9181239-B2 | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9180122-B2 | 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| WO-2015168466-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168079-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS PI3K INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150315187-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315146-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYCLOALKENYLETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-05 | — | — | US | disclosed |
| EP-2313414-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2419404-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9174994-B2 | Enhanced treatment regimens using mTor inhibitors | INTELLIKINE, LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173395-B2 | Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9173882-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173397-B2 | Formulation component | SYNGENTA LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9176380-B2 | Photoinduced alkyne-azide click reactions | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174949-B2 | Hedgehog inhibitors | SELEXAGEN THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2015164419-A1 | PUPILLOMETRIC ASSESSMENT OF RETINAL PHARMACODYNAMICS AND RESPONSES THEREFROM | ACUCELA INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20150306105-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | FAETH THERAPEUTICS, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20150307426-A9 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2015-10-29 | — | — | US | disclosed |
| US-20150305334-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYCLOALKENYL ETHYNYL)-CYCLOHEXANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-10-29 | — | — | US | disclosed |
| WO-2015164643-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| EP-2934145-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2935217-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-20150299131-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2748149-B1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-9161948-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9161537-B2 | Substituted 4-cyan-3-phenyl-4-(pyridine-3-yl)butanoates, processes for preparation thereof and use thereof as herbicides and plant growth regulators | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| US-9162992-B2 | Compounds and compositions for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162939-B2 | Carbon nanohoops and methods of making | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163017-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20150291599-A1 | AMINOIMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150289511-A1 | MOLECULES THAT INDUCE DISEASE RESISTANCE AND IMPROVE GROWTH IN PLANTS | UNIV CALIFORNIA (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2015157262-A1 | Novel 7-Dehydrocholesterol Derivatives and Methods Using Same | WOMEN & INFANTS HOSPITAL OF RHODE ISLAND (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2015155332-A1 | SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE DERIVATIVES AND THEIR USE AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | WO | disclosed |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2015155739-A1 | PROCESS FOR THE PREPARATION OF BETA-C-ARYLGLUCOSIDES | SCINOPHARM TAIWAN, LTD. (TW) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291569-A1 | PROCESS FOR THE PREPARATION OF beta-C-ARYLGLUCOSIDES | SCINOPHARM TAIWAN, LTD. (TW) | 2015-10-15 | — | — | US | disclosed |
| WO-2015157512-A1 | NOVEL METHODS AND KITS FOR DETECTING A RIFAMYCIN, OR DERIVATIVE OR ANALOGUE THEREOF | DREXEL UNIVERSITY (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291611-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150293080-A1 | Fluorescent Dyes and Related Methods | NATIONAL SCIENCE FOUNDATION | 2015-10-15 | — | — | US | disclosed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | disclosed |
| US-20150291610-A1 | C20' Urea Derivatives of Vinca Alkaloids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| US-20150291529-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2928471-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2476679-B1 | Substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2694510-B1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER IP GMBH (DE) | 2015-10-14 | — | — | EP | disclosed |
| US-9156820-B2 | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156853-B2 | AKT inhibitor compounds for treatment of cancer | ALMAC DISCOVERY LIMITED (GB) | 2015-10-13 | — | — | US | disclosed |
| US-9156829-B2 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015153554-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150284420-A1 | E-SELECTIN ANTAGONIST COMPOUNDS AND METHODS OF USE | GLYCOMIMETICS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2925761-A1 | TRIAZOLOPYRAZINE | Boehringer Ingelheim International GmbH (DE) | 2015-10-07 | — | — | EP | disclosed |
| CN-104968353-A | Gemcitabine prodrugs and uses thereof | BOYEN THERAPEUTICS INC | 2015-10-07 | — | — | CN | disclosed |
| US-9150578-B2 | 5,8-dihydro-6H-pyrazolo[3,4-h]quinazolines as IGF-1R/IR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150608-B2 | Neuro-protective compounds and their use | Biotechnology Research Corp. Ltd. (CN) | 2015-10-06 | — | — | US | disclosed |
| US-20150272939-A1 | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase | YALE UNIVERSITY (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2576560-B1 | SUBSTITUTED IMIDAZOPYRAZINES | BAYER IP GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| EP-2731933-B1 | 2,3-DIPHENYL-VALERONITRILE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER IP GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| US-20150270573-A1 | HALOGENATED ORGANOSILICON ELECTROLYTES, METHODS OF USING THEM, AND ELECTROCHEMICAL DEVICES CONTAINING THEM | SILATRONIX, INC. (US) | 2015-09-24 | — | — | US | disclosed |
| WO-2015140195-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140196-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015143012-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| US-20150267232-A1 | IN VIVO AND IN VITRO CARBENE INSERTION AND NITRENE TRANSFER REACTIONS CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150267135-A1 | SYNTHESIS OF C3-C7 ALCOHOL FUEL COMPOSITIONS | PIONEER ENERGY, INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150267002-A1 | NOVEL COMPOSITE COMPOSITIONS AND METHODS OF PREPARING AND USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-24 | — | — | US | disclosed |
| EP-2920155-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | Galleon Pharmaceuticals, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-2920180-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-2920176-A1 | AMINOIMIDAZOPYRIDAZINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2651944-B1 | SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER IP GMBH (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2919790-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | Boyen Therapeutics, Inc. (TW) | 2015-09-23 | — | — | EP | disclosed |
| EP-2920175-A1 | TRIAZOLOPYRIDAZINE | Boehringer Ingelheim International GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-9139536-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139770-B2 | Silicone ligands for stabilizing quantum dot films | NANOSYS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2918587-A2 | Filamin a binding anti-inflammatory and analgesic | Pain Therapeutics, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2918589-A1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | Intellikine, LLC (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2729454-B1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-9133394-B2 | Polyhedral oligomeric silsesquioxane nanocrystal stabilization ligands | NANOSYS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133154-B2 | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133097-B2 | Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150252047-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-10 | — | — | US | disclosed |
| EP-2914295-A1 | TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING P13 KINASE INHIBITORS | Infinity Pharmaceuticals, Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2914296-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| US-9127000-B2 | Heterocyclic compounds and uses thereof | Intellikine, LLC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | disclosed |
| US-20150246029-A1 | Positive Allosteric Modulators and Uses Thereof | MERCK SHARP & DOHME CORP. | 2015-09-03 | — | — | US | disclosed |
| US-20150246919-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INT (DE) | 2015-09-03 | — | — | US | disclosed |
| US-20150246932-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-09-03 | — | — | US | disclosed |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2015131100-A1 | LIGAND-CONTROLLED C(SP3)-H ARYLATION AND OLEFINATION IN SYNTHESIS OF UNNATURAL CHIRAL ALPHA AMINO ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150246862-A1 | PREPARATION OF PENTANOL WITH ETHANOL DERIVED FROM FERMENTATION | PIONEER ENERGY, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| CN-104884432-A | Alpha7 nicotinic acetylcholine receptor modulators and uses thereof-I | MERCK SHARP & DOHME | 2015-09-02 | — | — | CN | disclosed |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239825-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239897-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| EP-2909181-A2 | PKM2 MODULATORS AND METHODS FOR THEIR USE | Tolero Pharmaceuticals, Inc. (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2663553-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORP (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115056-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150232476-A1 | COMPOUNDS AND METHODS FOR PREVENTING, TREATING AND/OR PROTECTING AGAINST SENSORY HAIR CELL DEATH | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2015-08-20 | — | — | US | disclosed |
| WO-2015121210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | disclosed |
| US-20150232484-A1 | FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-20 | — | — | US | disclosed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | disclosed |
| WO-2015121209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| US-20150232455-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-08-20 | — | — | US | disclosed |
| EP-2906607-A2 | POLYMERS HAVING ORTHOGONAL REACTIVE GROUPS AND USES THEREOF | NVS Technologies Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| US-9107916-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2015119712-A1 | TETRACYCLIC CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2015119579-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-08-13 | — | — | WO | disclosed |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| EP-2903988-A1 | COMPOUNDS USEFUL FOR MAKING HCV PROTEASE INHIBITORS | AbbVie Inc. (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2904048-A1 | SUSTAINABLE ISOSORBIDE - CONTAINING POLYCARBONATE - POLYLACTIDE BLENDS | SABIC Global Technologies B.V. (NL) | 2015-08-12 | — | — | EP | disclosed |
| EP-2408752-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-08-12 | — | — | EP | disclosed |
| US-9102636-B2 | Analgesic compounds, compositions, and uses thereof | GALLEON PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102684-B2 | Indolinone analogues | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| WO-2015113920-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015113927-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | WO | disclosed |
| US-20150216168-A1 | USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150219657-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-08-06 | — | — | US | disclosed |
| US-20150218194-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150216864-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-08-06 | — | — | US | disclosed |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218110-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218165-A1 | TETRACYCLIC CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2547680-B1 | IMIDAZOPYRAZINES | BAYER IP GMBH (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900239-A1 | DIHYDRO-6-AZAPHENALENE DERIVATIVES FOR THE TREATMENT OF CNS, ONCOLOGICAL DISEASES AND RELATED DISORDERS | The Warner-Babcock Institute For Green Chemistry LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2029516-B1 | PROCESS FOR PREPARING FLUORINATED MOLECULES | BAYER IP GMBH (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900671-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900674-A1 | COMPOUNDS AND METHODS FOR PREVENTING, TREATING AND/OR PROTECTING AGAINST SENSORY HAIR CELL DEATH | University of Washington through its Center for Commercialization (US) | 2015-08-05 | — | — | EP | disclosed |
| US-9096604-B2 | Pyrrolopyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096599-B2 | Spiroindoline compounds | INTERVET INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096590-B2 | Substituted benzoxazoles as PI3 kinase inhibitors | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-20150210683-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-30 | — | — | US | disclosed |
| WO-2015110923-A2 | METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LEUKEMIA USNG A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015112093-A2 | ANTIMICROBIAL PEPTIDOMIMETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-30 | — | — | WO | disclosed |
| EP-2791136-B1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER IP GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2104659-B1 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USES THEREOF | ANDROSCIENCE CORP (US) | 2015-07-29 | — | — | EP | disclosed |
| WO-2015109136-A2 | WATER SOLUBLE FLUORESCENT OR COLORED DYES AND METHODS FOR THEIR USE | SONY CORPORATION (JP) | 2015-07-23 | — | — | WO | disclosed |
| EP-2114896-B1 | RADIOPROTECTOR COMPOUNDS AND RELATED METHODS | PETER MACCALLUM CANCER INST (AU) | 2015-07-22 | — | — | EP | disclosed |
| CN-104797257-A | Polymer-NSAID conjugate | POLYACTIVA PTY LTD | 2015-07-22 | — | — | CN | disclosed |
| US-9085534-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085511-B2 | Atropisomeric 1,8-bisphenolnapthalenes and their use in enantioselective recognition and asymmetric synthesis | GEORGETOWN UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| US-9084425-B2 | 2,3-diphenyl-valeronitrile derivatives, method for the production thereof and use thereof as herbicides and plant growth regulators | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085560-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150196566-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-07-16 | — | — | US | disclosed |
| WO-2015104254-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-16 | — | — | WO | disclosed |
| US-9079898-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079825-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078440-B2 | 6-(2-aminophenyl)picolinates and their use as herbicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-9080119-B2 | Synthesis of high caloric fuels and chemicals including pentanol from coal, natural gas, and biomass | Pioneer Energy (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150192589-A1 | METHOD USING FLUORESCENT TURN-ON PROBES FOR CELL-SPECIFIC DETECTION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-09 | — | — | US | disclosed |
| US-20150190351-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2015-07-09 | — | — | US | disclosed |
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | ARDELYX, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-9073922-B2 | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2015095953-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015095952-A1 | VAR2CSA-DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| EP-2887963-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2887964-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| US-9066967-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091315-A1 | SPIRO[INDOLIN-3,4'-PIPERIDINE] DERIVATIVES AS GNRH RECEPTOR ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175534-A1 | Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I | MERCK SHARP & DOHME CORP. | 2015-06-25 | — | — | US | disclosed |
| EP-2886540-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-24 | — | — | EP | disclosed |
| EP-2590655-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2015-06-24 | — | — | EP | disclosed |
| CN-104736153-A | Apoptosis-inducing agents | ABBVIE INC | 2015-06-24 | — | — | CN | disclosed |
| US-9062013-B2 | Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof | BIONOMICS LIMITED (AU) | 2015-06-23 | — | — | US | disclosed |
| US-9062073-B2 | Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062058-B2 | — | — | 2015-06-23 | — | — | US | disclosed |
| US-9062026-B2 | Fused pyrimidines and substituted quinazolines as inhibitors of p97 | CLEAVE BIOSCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166494-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166495-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150164905-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2015089192-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150164904-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150164872-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2882439-A1 | APOPTOSIS-INDUCING AGENTS | AbbVie Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2882428-A2 | A METHOD OF INHIBITING TAU PHOSPHORYLATION | Pain Therapeutics, Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| CN-104718250-A | Sustainable isosorbide-containing polycarbonate-polylactide blends | SABIC INNOVATIVE PLASTICS IP | 2015-06-17 | — | — | CN | disclosed |
| US-9056849-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056843-B2 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-9056877-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| WO-2015083008-A1 | THERAPEUTIC COMBINATION OF A PI3K INHIBITOR AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015082378-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015082376-A2 | USE OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158880-A1 | TAXANE AND ABEO-TAXANE ANALOGS | Arbor Therapeutics, LLC (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150157637-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-11 | — | — | US | disclosed |
| WO-2015084998-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
| WO-2015082374-A1 | SPIROINDOLINE-THIOPYRAN-IMINE-OXIDE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158909-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158859-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2881391-A1 | Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof | Bayer Pharma Aktiengesellschaft (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-1973917-B1 | PROTEIN KINASE INHIBITORS | ABBVIE INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-9049863-B2 | Substituted (3R,4R)-4-cyan-3,4-diphenylbutanoates, method for the production thereof and use thereof as herbicides and plant growth regulators | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051327-B2 | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150152121-A1 | Substituted Benzothienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20150152022-A1 | CARBON NANOHOOPS AND METHODS OF MAKING | ENERGY, UNITED STATES DEPARTMENT OF | 2015-06-04 | — | — | US | disclosed |
| US-20150152097-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-06-04 | — | — | US | disclosed |
| WO-2015081257-A2 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015080665-A1 | CHALCONE-UREA DERIVATIVES AS INSULIN SENSORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-06-04 | — | — | WO | disclosed |
| US-20150150999-A1 | POLYMER-NSAID CONJUGATE | POLYACTIVA PTY LTD (AU) | 2015-06-04 | — | — | US | disclosed |
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2015-06-04 | — | — | US | disclosed |
| WO-2015079224-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-06-04 | — | — | WO | disclosed |
| EP-2350091-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | disclosed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | disclosed |
| CN-104684850-A | Melamine-aldehyde polymers | AGENCY SCIENCE TECH & RES | 2015-06-03 | — | — | CN | disclosed |
| US-9045429-B2 | Substituted phenoxypyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| WO-2015077780-A1 | WITHANOLIDES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | IMSTAR THERAPEUTICS INC. (CA) | 2015-05-28 | — | — | WO | disclosed |
| US-20150148542-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| WO-2015077375-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP. (CA) | 2015-05-28 | — | — | WO | disclosed |
| EP-2651946-B1 | 2-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER IP GMBH (DE) | 2015-05-27 | — | — | EP | disclosed |
| EP-2694500-B1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | Bayer Pharma AG (DE) | 2015-05-27 | — | — | EP | disclosed |
| EP-2875018-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | Cleave Biosciences, Inc. (US) | 2015-05-27 | — | — | EP | disclosed |
| US-9040757-B2 | Synthesis of high caloric fuels and chemicals | Pioneer Energy (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150140635-A1 | Boronic and Borinic Acid Compound as Inhibitors of Sulfenic Acid-Containing Proteins | THE PENN STATE RESEARCH FOUNDATION | 2015-05-21 | — | — | US | disclosed |
| US-20150141398-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2872506-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2872899-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATENT | Pain Therapeutics, Inc. (US) | 2015-05-20 | — | — | EP | disclosed |
| CN-104640972-A | Release medium | UNIV QUEENSLAND | 2015-05-20 | — | — | CN | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma AG (DE) | 2015-05-14 | — | — | US | disclosed |
| WO-2015067770-A1 | TRIAZOLOPYRAZINE DERIVATIVES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150132298-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2015-05-14 | — | — | US | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133447-A1 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150126501-A1 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist | NOVO NORDISK A/S (DK) | 2015-05-07 | — | — | US | disclosed |
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-20150126507-A1 | COMPOUNDS TO TREAT HEARING LOSS | US ARMY, SECRETARY OF THE ARMY | 2015-05-07 | — | — | US | disclosed |
| WO-2015066352-A1 | SKIN CARE COMPOSITIONS AND METHODS OF USE THEREOF | UNIGEN, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20150126747-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-05-07 | — | — | US | disclosed |
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2015-05-07 | — | — | US | disclosed |
| EP-2268623-B1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-05-06 | — | — | EP | disclosed |
| US-9023957-B2 | Compound for use in peptide synthesis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-05-05 | — | — | US | disclosed |
| US-9023759-B2 | Molecules that induce disease resistance and improve growth in plants | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150119397-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-30 | — | — | US | disclosed |
| US-20150119435-A1 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME | YALE UNIVERSITY | 2015-04-30 | — | — | US | disclosed |
| US-20150119429-A1 | Iron Chelators as HIV-1 Inhibitors | HOWARD UNIVERSITY (US) | 2015-04-30 | — | — | US | disclosed |
| EP-2864420-A1 | SILICONE LIGANDS FOR STABILIZING QUANTUM DOT FILMS | Nanosys, Inc. (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2863902-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | Infinity Pharmaceuticals, Inc. (US) | 2015-04-29 | — | — | EP | disclosed |
| CN-104583194-A | Pyridazine and pyridine derivatives as NAMPT inhibitors | ABBVIE INC | 2015-04-29 | — | — | CN | disclosed |
| WO-2015055994-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-23 | — | — | US | disclosed |
| WO-2014205317-A9 | CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2014152287-A9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150105548-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105385-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150104526-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| WO-2015054027-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| EP-2858993-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2015-04-15 | — | — | EP | disclosed |
| CN-104520279-A | Novel 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics | WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR | 2015-04-15 | — | — | CN | disclosed |
| US-9005480-B2 | Method for solventless quantum dot exchange | NANOSYS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006281-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006387-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| WO-2015051193-A1 | ENHANCED TREATMENT REGIMENS USING PI3Kα INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20150099128-A1 | LINEAR GLYCIDYL CARBAMATE (GC) RESINS FOR HIGHLY FLEXIBLE COATINGS | NDSU RESEARCH FOUNDATION | 2015-04-09 | — | — | US | disclosed |
| WO-2015051241-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20150099658-A1 | ANTI-GP41 ANTIBODY-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-04-09 | — | — | US | disclosed |
| WO-2015051244-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-2855438-A2 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | Galleon Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2212330-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORP (KR) | 2015-04-08 | — | — | EP | disclosed |
| EP-2855449-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| CN-104508049-A | Silicone ligands for stabilizing quantum dot films | NANOSYS INC | 2015-04-08 | — | — | CN | disclosed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000222-B2 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | ANDROSCIENCE CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2015048689-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-04-02 | — | — | US | disclosed |
| US-20150094319-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-04-02 | — | — | US | disclosed |
| US-20150094300-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | US | disclosed |
| EP-2570441-B1 | Bioabsorbable surgical composition | COVIDIEN LP (US) | 2015-04-01 | — | — | EP | disclosed |
| EP-2852596-A1 | THIENOPYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-01 | — | — | EP | disclosed |
| EP-2853531-A2 | Antiviral compounds | AbbVie Bahamas Ltd. (BS) | 2015-04-01 | — | — | EP | disclosed |
| EP-2852595-A1 | SUBSTITUTED BENZOTHIENOPYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-01 | — | — | EP | disclosed |
| EP-2464354-B1 | PYRIMIDO-PYRROLO-QUINOXALINEDIONE INHIBITORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR | UNIV CALIFORNIA (US) | 2015-04-01 | — | — | EP | disclosed |
| CN-104487097-A | Chromophoric polymer dots with narrow-band emission | UNIV WASHINGTON CT COMMERCIALIZATION | 2015-04-01 | — | — | CN | disclosed |
| US-8993697-B2 | Conducting and semiconducting organic materials | Commonwealth Scientific and Industrial Research Institute Organisation (AU) | 2015-03-31 | — | — | US | disclosed |
| US-8993807-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993262-B2 | In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993671-B2 | Poly(aliphatic ester)-polycarbonate copolymer/polylactic acid blend | Sabic Global Technolgies B.V. (NL) | 2015-03-31 | — | — | US | disclosed |
| US-20150087618-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2015042202-A1 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015041601-A1 | CONVERSION AND PURIFICATION OF BIOMASS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-03-26 | — | — | WO | disclosed |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087631-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| EP-2699575-B1 | TRIAZOLOPYRIDINES | BAYER IP GMBH (DE) | 2015-03-25 | — | — | EP | disclosed |
| US-8986740-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987538-B2 | Carbon nanohoops and methods of making | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987493-B2 | Process for synthesis of silane dipeptide analogs | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987461-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2015038904-A1 | ANTI-GP41 ANTIBODY-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-03-19 | — | — | WO | disclosed |
| US-20150080374-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| WO-2015038933-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-03-19 | — | — | WO | disclosed |
| US-20150080340-A1 | BORONIC ACID CONJUGATES OF OLIGONUCLEOTIDE ANALOGUES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2015-03-19 | — | — | US | disclosed |
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | DOMAIN PARTNERS VIII, L.P. | 2015-03-19 | — | — | US | disclosed |
| US-20150080365-A1 | HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT | INTERVET INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150078999-A1 | CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-19 | — | — | US | disclosed |
| EP-2847163-A1 | IRON CHELATORS AS HIV-1 INHIBITORS | Howard University (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2456444-B1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | INTELLIKINE LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2846784-A1 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME | Yale University (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2655355-B1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-8980544-B2 | Boronic and borinic acid compounds as inhibitors of sulfenic acid-containing proteins | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981153-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150072953-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | UNIGEN, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| WO-2015034440-A2 | A Dimerizer Compound | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015034436-A1 | POLYMER-FLAVONOID CONJUGATES AND HYDROGELS FOR BIOMEDICAL APPLICATIONS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-03-12 | — | — | WO | disclosed |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-03-12 | — | — | US | disclosed |
| US-20150072978-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-03-12 | — | — | US | disclosed |
| WO-2015034785-A1 | RILYAZINE DERIVATIVES AND COMPOSITIONS FOR THE TREATMENT OF CANCER | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-2844636-A2 | METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES | Acucela, Inc. (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8975412-B2 | Substituted 4-cyano-3-phenyl-4-(pyridin-3-yl)butanoates, processes for preparation thereof and use thereof as herbicides and plant growth regulators | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-10 | — | — | US | disclosed |
| US-8975278-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-03-10 | — | — | US | disclosed |
| US-8975288-B2 | F2 derivatives as antibacterial agents | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975398-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20150065510-A1 | Rilyazine Derivatives and Compositions for The Treatment of Cancer | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065542-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-03-05 | — | — | US | disclosed |
| WO-2015031613-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20150065532-A1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. | 2015-03-05 | — | — | US | disclosed |
| US-8969377-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969587-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969343-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969363-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969375-B2 | CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2015025019-A1 | NEW 6-ALKYNYL PYRIDINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015027176-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES AND METHODS FOR THEIR USE | SONY CORPORATION (JP) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057298-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2015-02-26 | — | — | US | disclosed |
| US-20150057286-A1 | NEW BIS-AMIDO PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-26 | — | — | US | disclosed |
| US-20150057295-A1 | New 6-Alkynyl Pyridine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-26 | — | — | US | disclosed |
| WO-2015025018-A1 | NEW BIS-AMIDO PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057279-A1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | ABBVIE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2838902-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-02-25 | — | — | EP | disclosed |
| CN-103221435-B | Continuous flow polymerisation process | COMMW SCIENT IND RES ORG | 2015-02-25 | — | — | CN | disclosed |
| US-8962606-B2 | Substituted benzosulphonamides | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962529-B2 | Substituted picolinic acids, salts and acid derivatives thereof, and use thereof as herbicides | BAYER CROPSCIENCE AG (DE) | 2015-02-24 | — | — | US | disclosed |
| US-20150051404-A1 | PAIN-RELIEVING COMPOSITIONS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-02-19 | — | — | US | disclosed |
| US-20150051208-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051207-A1 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| WO-2015022332-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
| EP-2836487-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2044938-B1 | Radioprotectors | PETER MACCALLUM CANCER INST (AU) | 2015-02-18 | — | — | EP | disclosed |
| CN-102361556-B | Pyrimindine-4-ylpropane dinitrile derivatives, method for the production thereof, and use thereof as herbicide and plant growth regulators | BAYER CROPSCIENCE AG | 2015-02-18 | — | — | CN | disclosed |
| US-8956613-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2015-02-17 | — | — | US | disclosed |
| WO-2015021358-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | CHARMOT DOMINIQUE (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015019103-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-02-12 | — | — | WO | disclosed |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2015-02-12 | — | — | US | disclosed |
| US-20150045377-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2015-02-12 | — | — | US | disclosed |
| US-20150045444-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-02-12 | — | — | US | disclosed |
| EP-2106213-B1 | SUBSTITUTED 1-(3-PYRIDINYL)PYRAZOL-4-YL-ACETIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDE AND PLANT GROWTH REGULATORS | BAYER IP GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| EP-2834245-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-02-11 | — | — | EP | disclosed |
| US-8952151-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952058-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952178-B2 | Thiophene derivatives | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-02-10 | — | — | US | disclosed |
| US-20150037686-A1 | HALOGENATED ORGANOSILICON ELECTROLYTES, METHODS OF USING THEM, AND ELECTROCHEMICAL DEVICES CONTAINING THEM | ORBIA FLUOR & ENERGY MATERIALS USA, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038485-A1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-05 | — | — | US | disclosed |
| US-8946360-B2 | Continuous flow polymerisation process | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2015-02-03 | — | — | US | disclosed |
| US-8946279-B2 | Fused ring compound for use as mineralocorticoid receptor antagonist | KBP BIOSCIENCES CO., LTD. (CN) | 2015-02-03 | — | — | US | disclosed |
| US-20150031891-A1 | BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS | MERCK SHARP & DOHME CORP. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031884-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8940742-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940737-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20150025266-A1 | SYNTHESIS OF HIGH CALORIC FUELS AND CHEMICALS | PIONEER ENERGY, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025113-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | ANIMAL CONTROL PRODUCTS LIMITED (NZ) | 2015-01-22 | — | — | US | disclosed |
| US-20150025096-A1 | SMALL MOLECULE COMPOUNDS TO TREAT HEARING LOSS | FATE THERAPEUTICS, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20150025108-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-20150024488-A1 | NUCLEIC ACID COMPLEX | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2015-01-22 | — | — | US | disclosed |
| EP-2825540-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825536-A1 | BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS | Merck Sharp & Dohme Corp. (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825044-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8937150-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-01-20 | — | — | US | disclosed |
| WO-2015006733-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015004024-A1 | SUBSTITUTED PYRAZOLO-PYRIDINAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015006731-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-2822938-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | Landcare Research New Zealand Limited (NZ) | 2015-01-14 | — | — | EP | disclosed |
| CN-102884054-B | Fluoroalkyl-substituted 2-amidobenzimidazoles and the use thereof for boosting stress tolerance in plants | BAYER IP GMBH | 2015-01-14 | — | — | CN | disclosed |
| CN-102099408-B | Polymer microgel beads and method for producing same | UNIV SYDNEY | 2015-01-14 | — | — | CN | disclosed |
| WO-2015002894-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015003002-A1 | PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ABIDE THERAPEUTICS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| EP-2819996-A1 | 6 - ALKYNYL PYRIDINES AS SMAC MIMETICS | Boehringer Ingelheim International GmbH (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-8927789-B1 | Synthesis of high caloric fuels and chemicals | Pioneer Energy (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927711-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20150004128-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS, LLC (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014151871-A9 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207708-A2 | AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-12-31 | — | — | WO | disclosed |
| US-8921514-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921546-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378510-A1 | SMALL MOLECULE ACTIVATORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140377285-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2014-12-25 | — | — | US | disclosed |
| US-20140378490-A1 | Formulations of Phenyl Uracil Compounds | ABBVIE INC. (US) | 2014-12-25 | — | — | US | disclosed |
| WO-2014204866-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | UNIGEN, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014205317-A2 | CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014202999-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2014-12-24 | — | — | WO | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916270-B2 | Glass filled copolymer products for thin wall and high surface gloss articles | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2014-12-23 | — | — | US | disclosed |
| US-8916580-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2014-12-23 | — | — | US | disclosed |
| US-20140371493-A1 | METHODS OF CONVERTING POLYOLS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2014-12-18 | — | — | US | disclosed |
| WO-2014198594-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371252-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-12-18 | — | — | US | disclosed |
| US-20140371450-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | HCR COLLATERAL MANAGEMENT, LLC | 2014-12-18 | — | — | US | disclosed |
| US-20140371205-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| EP-2507236-B1 | Triazolopyridine derivates | BAYER IP GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-8912124-B2 | Use of derivatives of (1-cyanocyclopropyl)phenylphosphinic acid, esters thereof and/or salts thereof for enhancing tolerance in plants to abiotic stress | BAYER CROPSCIENCE AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912229-B2 | Taxane and abeo-taxane analogs | Arbor Therapeutics, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140364616-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (IL) | 2014-12-11 | — | — | US | disclosed |
| WO-2014194380-A1 | SCRATCH RESISTANT POLYMERS | TENASITECH PTY LTD (AU) | 2014-12-11 | — | — | WO | disclosed |
| US-20140364435-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-11 | — | — | US | disclosed |
| WO-2014195408-A1 | PHARMACEUTICAL COMPOSITIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014195276-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
| US-20140364617-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2014-12-11 | — | — | US | disclosed |
| US-20140364315-A1 | SUBSTITUTED 4-CYAN-3-PHENYL-4-(PRYRIDINE-3-YL)BUTANOATES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-11 | — | — | US | disclosed |
| EP-1827438-B2 | PIPERAZIN DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC (CA) | 2014-12-10 | — | — | EP | disclosed |
| EP-2651947-B1 | 6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER IP GMBH (DE) | 2014-12-10 | — | — | EP | disclosed |
| EP-2809672-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2809708-A1 | HALOGENATED ORGANOSILICON ELECTROLYTES, METHODS OF USING THEM, AND ELECTROCHEMICAL DEVICES CONTAINING THEM | Silatronix, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8906922-B2 | Substituted triazoles useful as AXl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906917-B2 | Pyrimidine cyclohexyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| WO-2014190398-A1 | INHIBITION OF AMYLOID FIBRIL FORMATION | THE UNIVERSITY OF MELBOURNE (AU) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014194254-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20140357878-A1 | METHOD OF PRODUCING 5-HYDROXYMETHYLFURFURAL FROM CARBOHYDRATES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-12-04 | — | — | US | disclosed |
| US-20140357655-A1 | SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140352351-A1 | REFRIGERATION SYSTEM WITH DUAL REFRIGERANTS AND LIQUID WORKING FLUIDS | H & C Scientific Resources International, LLC (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357616-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357651-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CALITHERA BIOSCIENCES, INC. | 2014-12-04 | — | — | US | disclosed |
| WO-2014193857-A1 | REFRIGERATION SYSTEM WITH DUAL REFRIGERANTS AND LIQUID WORKING FLUIDS | XU YANJIE (US) | 2014-12-04 | — | — | WO | disclosed |
| EP-2807166-A1 | 5, 8 -DIHYDRO- 6H- PYRAZOLO [3, 4 -H]QUINAZOLINES AS IGF-LR/LR INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2014-12-03 | — | — | EP | disclosed |
| CN-101606069-B | Tagged petroleum products and methods of detecting the same | AUTHENTIX INC | 2014-12-03 | — | — | CN | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140350183-A1 | CHROMOPHORIC POLYMER DOTS WITH NARROW-BAND EMISSION | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2014-11-27 | — | — | US | disclosed |
| US-20140350182-A1 | RAFT POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2014-11-27 | — | — | US | disclosed |
| US-20140349918-A1 | DERIVATIVES OF XANTHONE COMPOUNDS | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2014-11-27 | — | — | US | disclosed |
| WO-2014190199-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-27 | — | — | WO | disclosed |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2014-11-27 | — | — | US | disclosed |
| EP-2804605-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2455376-B1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | ABBVIE BAHAMAS LTD (BS) | 2014-11-26 | — | — | EP | disclosed |
| EP-2804864-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2804867-A1 | SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS | Bayer Intellectual Property GmbH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-8895549-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895782-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140343057-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140341894-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140343286-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2014-11-20 | — | — | US | disclosed |
| EP-2802595-A1 | PROCESSES FOR MAKING HCV PROTEASE INHIBITORS | AbbVie Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2655358-B1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| EP-2032583-B1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8889675-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889696-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889665-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889684-B2 | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20140336168-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2014-11-13 | — | — | US | disclosed |
| US-20140336167-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-8883791-B2 | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases | INTERVET INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883784-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140329684-A1 | USE OF 4-SUBSTITUTED 1-PHENYLPYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-06 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329932-A1 | POLYMER PARTICLES | THE UNIVERSITY OF SYDNEY (AU) | 2014-11-06 | — | — | US | disclosed |
| US-20140326672-A1 | MELAMINE ALDEHYDE POLYMERS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-11-06 | — | — | US | disclosed |
| EP-2797889-A1 | NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Centaurus Biopharma Co., Ltd. (CN) | 2014-11-05 | — | — | EP | disclosed |
| US-8877720-B2 | Epirubicin derivatives | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2014-11-04 | — | — | US | disclosed |
| US-8877934-B2 | N-heteroaryl compounds | INTERVET INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140323527-A1 | ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS | HOWARD FLOREY INSTITUTE (AU) | 2014-10-30 | — | — | US | disclosed |
| US-20140323490-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323721-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC | 2014-10-30 | — | — | US | disclosed |
| EP-2435411-B1 | 2,4-DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2793893-A2 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | Intellikine, LLC (US) | 2014-10-29 | — | — | EP | disclosed |
| CN-104125945-A | Substituted 4-cyano-3-phenyl-4- (pyridin-3-yl) butanoic acid esters, process for their preparation and their use as herbicides and plant growth regulators | BAYER IP GMBH | 2014-10-29 | — | — | CN | disclosed |
| CN-102245214-B | Biodegradable polymer-bioactive moiety conjugates | POLYACTIVA PTY LTD. (AU) | 2014-10-29 | — | — | CN | disclosed |
| US-8871718-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| EP-2791136-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2507235-B1 | TRIAZOLOPYRIMIDINES | BAYER IP GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2552907-B1 | PYRIDYLTRIAZOLES | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| CN-104114547-A | Derivatives of xanthone compounds | AGENCY SCIENCE TECH & RES | 2014-10-22 | — | — | CN | disclosed |
| US-8865703-B2 | Pyridyltriazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| EP-2788488-A2 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | Sarepta Therapeutics, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2387395-B1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2788487-A2 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | Sarepta Therapeutics, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| CN-104105718-A | RAFT polymers | COMMW SCIENT IND RES ORG | 2014-10-15 | — | — | CN | disclosed |
| US-8859541-B2 | 6-alkynylpyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859765-B2 | Process for the manufacture of chiral catalysts and their salts | SCINOPHARM TAIWAN, LTD. (TW) | 2014-10-14 | — | — | US | disclosed |
| US-20140302010-A1 | SUBSTITUTED BENZIMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140302987-A1 | USE OF SUBSTITUTED ISOQUINOLINONES, ISOQUINOLINDIONES, ISOQUINOLINTRIONES AND DIHYDROISOQUINOLINONES OR IN EACH CASE SALTS THEREOF AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| WO-2014164905-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-2785650-A1 | Melamine Aldehyde Polymers | Agency For Science, Technology And Research (SG) | 2014-10-08 | — | — | EP | disclosed |
| US-8853420-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8853330-B2 | Hybrid polymers | AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) | 2014-10-07 | — | — | US | disclosed |
| US-8852641-B2 | Polymer microgel beads and preparative method thereof | THE UNIVERSITY OF SYDNEY (AU) | 2014-10-07 | — | — | US | disclosed |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296073-A1 | SUBSTITUTED 4-CYANO-3-PHENYL-4-(PYRIDIN-3-YL)BUTANOATES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20140296230-A1 | DIHYDROQUINAZOLINONE ANALOGUES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20140296321-A1 | METHODS AND COMPOSITIONS FOR MANIPULATING TRANSLATION OF PROTEIN ISOFORMS FROM ALTERNATIVE INITIATION OF START SITES | SAREPTA THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014154762-A1 | DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014154760-A1 | INDOLINONE ANALOGUES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296220-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014158654-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296231-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| WO-2014160017-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160028-A1 | PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140296229-A1 | INDOLINONE ANALOGUES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| EP-2782571-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, LLC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2782962-A1 | POLY(ALIPHATIC ESTER)-POLYCARBONATE COPOLYMER/POLYLACTIC ACID BLEND | SABIC Innovative Plastics IP B.V. (NL) | 2014-10-01 | — | — | EP | disclosed |
| US-8846689-B2 | Substituted pyrimidines for the treatment of diseases such as cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140287031-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE, LLC (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014152287-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140283438-A1 | Synthesis of High Caloric Fuels and Chemicals | Pioneer Energy (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014151871-A2 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152229-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151444-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140287945-A1 | SURFACE OXIDATION FOR SEQUESTERING BIOMOLECULES AND RELATED METHODS | NVS Technologies, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014151106-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014149837-A1 | COMPOUNDS AND METHODS TO ENHANCE THE ORAL AVAILABILITY OF GLYCOMIMETICS | GLYCOMIMETICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152536-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152518-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152588-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151462-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151945-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014147182-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151147-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153051-A1 | POLYMER DOT COMPOSITIONS AND RELATED METHODS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2780299-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | Sarepta Therapeutics, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2781520-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| CN-101563331-B | Substituted 2, 4-diamino-1, 3, 5-triazines, method for the production thereof and use thereof as herbicides and plant growth regulators | BAYER CROPSCIENCE AG | 2014-09-24 | — | — | CN | disclosed |
| US-8840339-B2 | Soil remediation process | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-09-23 | — | — | US | disclosed |
| US-20140275431-A1 | ALKYL-ACID LIGANDS FOR NANOCRYSTALS | NANOSYS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014138791-A1 | TRANSGENIC NON-HUMAN ORGANISMS WITH NON-FUNCTIONAL TSPO GENES | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275598-A1 | POLYHEDRAL OLIGOMERIC SILSESQUIOXANE NANOCRYSTAL STABILIZATION LIGANDS | NANOSYS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014144871-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2014-09-18 | — | — | WO | disclosed |
| US-20140274700-A1 | MOLECULES THAT INDUCE DISEASE RESISTANCE AND IMPROVE GROWTH IN PLANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275004-A1 | PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014143561-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| US-20140274699-A1 | MOLECULES THAT INDUCE DISEASE RESISTANCE IN PLANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275153-A1 | CDK9 KINASE INHIBITORS | ABBIVE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140264189-A1 | METHOD FOR SOLVENTLESS QUANTUM DOT EXCHANGE | NANOSYS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275192-A1 | F2 DERIVATIVES AS ANTIBACTERIAL AGENTS | THE PENN STATE RESEARCH FOUNDATION | 2014-09-18 | — | — | US | disclosed |
| WO-2014144197-A1 | STEREODYNAMIC CHEMOSENSORS | GEORGETOWN UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145780-A1 | PURIFICATION OF RAPAMYCIN DERIVATIVES | BIOSENSORS INTERNATIONAL GROUP, LTD. (SG) | 2014-09-18 | — | — | WO | disclosed |
| EP-2776434-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776475-A1 | CLEAN POLYCARBONATE MATERIAL FOR USE IN HARD DISK DRIVE AND SEMICONDUCTOR APPLICATIONS | SABIC Innovative Plastics IP B.V. (NL) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776837-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | Intellikine, LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2428515-B9 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776393-A1 | NAMPT INHIBITORS | Abbvie Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776441-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | Intellikine, LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| CN-104053729-A | Polymer particles | UNIV SYDNEY | 2014-09-17 | — | — | CN | disclosed |
| CN-102361889-B | Raft polymerisation | COMMW SCIENT IND RES ORG | 2014-09-17 | — | — | CN | disclosed |
| US-8836218-B2 | Methods of treatment using combination therapy | AMBIT BIOSCIENCES CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| WO-2014135480-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138312-A1 | WESTERN BLOT ANALYSIS USING POLYMER DOTS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014136099-A1 | PROCESS FOR IXABEPILONE, AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (CN) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256992-A1 | SYNTHESIS OF HIGH CALORIC FUELS AND CHEMICALS | Pioneer Energy (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140255392-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256952-A1 | PROCESS FOR IXABEPILONE, AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2014-09-11 | — | — | US | disclosed |
| US-20140255342-A1 | THIOPHENE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2014-09-11 | — | — | US | disclosed |
| EP-2542533-B1 | FLUORALKYL-SUBSTITUTED 2-AMIDOBENZIMIDAZOLES AND THEIR USE FOR INCREASING STRESS TOLERANCE IN PLANTS | BAYER IP GMBH (DE) | 2014-09-10 | — | — | EP | disclosed |
| US-8828998-B2 | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829244-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140245658-A1 | SYNTHESIS OF ETHANOL AND HIGHER ALCOHOLS BY HYDROGENATION OF KETENE | PIONEER ENERGY INC (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2326641-B1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-1910308-B1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| US-8822509-B2 | Pain-relieving compositions and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-09-02 | — | — | US | disclosed |
| US-8822424-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822446-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140243353-A1 | 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243288-A1 | FUSED RING-CONTAINING OXAZOLIDINONES ANTIBIOTICS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-28 | — | — | US | disclosed |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242647-A1 | IN VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014130693-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014128093-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014127430-A1 | LITHOGRAPHICALLY PRODUCED FEATURES | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-08-28 | — | — | WO | disclosed |
| CN-102099407-B | Polymer microgel beads | UNIV SYDNEY | 2014-08-27 | — | — | CN | disclosed |
| US-8815908-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815910-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. | 2014-08-21 | — | — | US | disclosed |
| US-20140235446-A1 | 2,3-DIPHENYL-VALERONITRILE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-21 | — | — | US | disclosed |
| EP-2766359-A2 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES | Ambit Biosciences Corporation (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2498599-B1 | ANALGESIC THAT BINDS FILAMIN A | PAIN THERAPEUTICS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2766361-A1 | 8 - CARBAMOYL - 2 - (2,3- DI SUBSTITUTED PYRID - 6 - YL) -1,2,3,4 -TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS - INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8809364-B2 | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809349-B2 | Processes for preparing isoquinolinones and solid forms of isoquinolinones | INFINITY PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8808702-B2 | Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809339-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809347-B2 | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2014122474-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | WO | disclosed |
| US-20140228370-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-14 | — | — | US | disclosed |
| EP-2350052-B1 | ANTIPROLIFERATIVE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | disclosed |
| EP-2368882-B1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBVIE BAHAMAS LTD (BS) | 2014-08-13 | — | — | EP | disclosed |
| EP-2558469-B1 | PYRROLOPYRAZINONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20140221355-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| WO-2014118135-A1 | AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120488-A1 | PHOSPHINATE IONIC LIQUID COMPOSITIONS AND METHODS OF USE | XU YANJIE (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014118226-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-07 | — | — | WO | disclosed |
| EP-2762480-A1 | OXAZOLIDINONE ANTIBIOTICS CONTAINING FUSED RING | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-06 | — | — | EP | disclosed |
| EP-2762479-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINON ANTIBACTERIAL DRUG | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-06 | — | — | EP | disclosed |
| CN-103974932-A | Preparation method of chiral catalyst and salt thereof | SCINOPHARM TAIWAN LTD | 2014-08-06 | — | — | CN | disclosed |
| US-8796277-B2 | Radioprotector compounds and related methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2014-08-05 | — | — | US | disclosed |
| US-8796359-B2 | Polymer product and interfacial polymerisation process using raft agent | THE UNIVERSITY OF SYDNEY (AU) | 2014-08-05 | — | — | US | disclosed |
| US-8796289-B2 | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796259-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140213617-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213601-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213595-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2758400-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2014-07-30 | — | — | EP | disclosed |
| EP-2758401-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2014-07-30 | — | — | EP | disclosed |
| EP-2212329-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORP (KR) | 2014-07-30 | — | — | EP | disclosed |
| US-20140206684-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2337781-B1 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | ABBVIE BAHAMAS LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2291175-B1 | ADMINISTRABLE COMPOSITIONS | UNIV SYDNEY (AU) | 2014-07-23 | — | — | EP | disclosed |
| US-8785454-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785464-B2 | Pyrimidine derivatives that inhibit FAK/PTK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8785456-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2014110036-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-07-17 | — | — | WO | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779029-B2 | Polymer product and interfacial polymerisation process using raft agent | THE UNIVERSITY OF SYDNEY (AU) | 2014-07-15 | — | — | US | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194291-A1 | SUBSTITUTED (3R,4R)-4-CYAN-3,4-DIPHENYLBUTANOATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194469-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| EP-2751093-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2752415-A1 | Fluorinated ligands for targeting peripheral benzodiazepine receptors | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2014-07-09 | — | — | EP | disclosed |
| EP-2752417-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2014-07-09 | — | — | EP | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187548-A1 | 6 SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| EP-2035421-B1 | 2-Arylpyrazolo[l,5-alpha]pyrimidin-3-yl acetamide derivatives as ligands for translocator protein (18 kDa) | UNIV SYDNEY (AU) | 2014-07-02 | — | — | EP | disclosed |
| CN-103906747-A | Preparation method of cabazitaxel and intermediate thereof | SCINOPHARM TAIWAN LTD | 2014-07-02 | — | — | CN | disclosed |
| US-8765183-B2 | Polymer microgel beads | THE UNIVERSITY OF SYDNEY (AU) | 2014-07-01 | — | — | US | disclosed |
| US-8766006-B2 | Use of nitroaniline derivatives for the production of nitric oxide | STMICROELECTRONICS S.R.L. (IT) | 2014-07-01 | — | — | US | disclosed |
| US-8765432-B2 | Targeted drug phosphorylcholine polymer conjugates | OLIGASIS, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765939-B2 | Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers | ASTRAZENECA AB (SE) | 2014-07-01 | — | — | US | disclosed |
| US-8766007-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140178322-A1 | BRIGHTENER-CONTAINING HAIR RELAXER | SHURNEY GLENN (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014100463-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100818-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100450-A1 | BRIGHTENER-CONTAINING HAIR RELAXER | SHURNEY GLENN (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179638-A1 | 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-06-26 | — | — | US | disclosed |
| US-20140179709-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-06-26 | — | — | US | disclosed |
| EP-1998809-B1 | CAMPTOTHECIN-CELL PENETRATING PEPTIDE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DRAIS PHARMACEUTICALS INC (US) | 2014-06-25 | — | — | EP | disclosed |
| CN-103889954-A | Substituted 4-cyano-3-phenyl-4-(pyridin-3-yl)butanoates, processes for preparation thereof and use thereof as herbicides and plant growth regulators | BAYER IP GMBH | 2014-06-25 | — | — | CN | disclosed |
| US-20140171691-A1 | Synthesis of Drop-in Liquid Fuels and Chemicals from Methanol, Ethanol or Syngas Using Mixed Catalysts | Pioneer Energy Inc. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171432-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| CN-102762625-B | Polymeric materials | COMMW SCIENT IND RES ORG | 2014-06-18 | — | — | CN | disclosed |
| US-8754233-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140162361-A1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. | 2014-06-12 | — | — | US | disclosed |
| US-20140163056-A1 | NOVEL SPIROINDOLINE COMPOUNDS | INTERVET INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2014089364-A1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS, INC (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| EP-2739678-A1 | GLASS FILLED COPOLYMER PRODUCTS FOR THIN WALL AND HIGH SURFACE GLOSS ARTICLES | SABIC Innovative Plastics IP B.V. (NL) | 2014-06-11 | — | — | EP | disclosed |
| EP-2740720-A1 | Substituted bicyclic and tricyclic pent-2-en-4-inic acid derivatives and their use for enhancing the stress tolerance in plants | Bayer CropScience AG (DE) | 2014-06-11 | — | — | EP | disclosed |
| EP-2740356-A1 | Substituted (2Z)-5(1-Hydroxycyclohexyl)pent-2-en-4-inic acid derivatives | Bayer CropScience AG (DE) | 2014-06-11 | — | — | EP | disclosed |
| CN-103857664-A | Method of producing 5-hydroxymethylfurfural from carbohydrates | AGENCY SCIENCE TECH & RES | 2014-06-11 | — | — | CN | disclosed |
| US-8748443-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| WO-2014084944-A1 | BORONIC AND BORINIC ACID COMPOUNDS AS INHIBITORS OF SULFENIC ACID-CONTAINING PROTEINS | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155386-A1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2738156-A1 | 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND | KBP Biosciences Co., Ltd. (CN) | 2014-06-04 | — | — | EP | disclosed |
| US-8741967-B2 | Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741898-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741914-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140147905-A1 | Boronic and Borinic Acid Compounds as Inhibitors of Sulfenic Acid-Containing Proteins | THE PENN STATE RESEARCH FOUNDATION | 2014-05-29 | — | — | US | disclosed |
| US-20140148342-A1 | FORMULATION COMPONENT | SYNGENTA LIMITED (GB) | 2014-05-29 | — | — | US | disclosed |
| EP-2734520-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2734530-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8735418-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735386-B2 | Aminopyrazoloquinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20140142098-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| WO-2014078575-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142126-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2014078295-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014076146-A1 | TRIAZOLOPYRIDAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014076237-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014076162-A1 | AMINOIMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-22 | — | — | WO | disclosed |
| EP-2732035-A2 | METHODS AND COMPOSITIONS FOR MANIPULATING TRANSLATION OF PROTEIN ISOFORMS FROM ALTERNATIVE INITIATION START SITES | Sarepta Therapeutics, Inc. (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2731953-A1 | TRICYCLIC INHIBITORS OF KINASES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Abbvie Inc. (US) | 2014-05-21 | — | — | EP | disclosed |
| CN-103813809-A | Polymer conjugated prostaglandin analogues | POLYACTIVA PTY LTD | 2014-05-21 | — | — | CN | disclosed |
| CN-103814009-A | Substituted 4-cyan-3-(2,6-difluorophenyl)-4-phenylbutanoates, method for the production thereof and use thereof as herbicides and plant growth regulators | BAYER CROPSCIENCE AG | 2014-05-21 | — | — | CN | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-20140135319-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-20140135336-A1 | TRIAZOLOPYRIDAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-20140134160-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2014-05-15 | — | — | US | disclosed |
| EP-2729454-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| EP-2729182-A1 | NUCLEIC ACID COMPLEX | Commonwealth Scientific and Industrial Research Organisation (AU) | 2014-05-14 | — | — | EP | disclosed |
| EP-2454262-B1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LAB (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8722851-B2 | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A | PAIN THERAPEUTICS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722900-B2 | Process for cabazitaxel, and intermediates thereof | SCINOPHARM TAIWAN, LTD. (TW) | 2014-05-13 | — | — | US | disclosed |
| US-20140124709-A1 | CLEAN POLYCARBONATE MATERIAL FOR USE IN HARD DISK DRIVE AND SEMICONDUCTOR APPLICATIONS | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2014-05-08 | — | — | US | disclosed |
| US-20140128331-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-20140128599-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140127127-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128637-A1 | ATROPISOMERIC 1,8-BISPHENOLNAPTHALENES AND THEIR USE IN ENANTIOSELECTIVE RECOGNITION AND ASYMMETRIC SYNTHESIS | NATIONAL SCIENCE FOUNDATION | 2014-05-08 | — | — | US | disclosed |
| WO-2014071105-A1 | TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING P13 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014071109-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-2428515-B1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-05-07 | — | — | EP | disclosed |
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8716297-B2 | Chemical entities to be used for Wee1 inhibition for the treatment of cancer | ABBVIE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716528-B2 | Aryloxy amine compounds and their use as sodium channel modulators | HOWARD FLOREY INSTITUTE (AU) | 2014-05-06 | — | — | US | disclosed |
| US-8716529-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140120060-A1 | TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| WO-2014066506-A2 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140120083-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140120087-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-01 | — | — | US | disclosed |
| US-20140120058-A1 | POLYMER CONJUGATED PROSTAGLANDIN ANALOGUES | POLYACTIVA PTY LTD | 2014-05-01 | — | — | US | disclosed |
| EP-2725031-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-04-30 | — | — | EP | disclosed |
| EP-2723748-A1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2014-04-30 | — | — | EP | disclosed |
| EP-2725015-A1 | Uracil or thymine derivative for treating hepatitis c | AbbVie Bahamas Ltd. (BS) | 2014-04-30 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710272-B2 | Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | ANDROSCIENCE CORPORATION (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8709486-B2 | Administrable compositions | THE UNIVERSITY OF SYDNEY (AU) | 2014-04-29 | — | — | US | disclosed |
| US-20140113896-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| WO-2014062838-A2 | PKM2 MODULATORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| US-20140113895-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-20140113901-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| US-20140113012-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-24 | — | — | US | disclosed |
| EP-2569316-B1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8703822-B2 | Method for removing undifferentiated and dedifferentiated stem cell | NANYANG POLYTECHNIC (SG) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703778-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703777-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140107074-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2014058794-A1 | COMPOUNDS USEFUL FOR MAKING HCV PROTEASE INHIBITORS | ABBVIE INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| EP-2719698-A1 | Methods for preparing aurora kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140100364-A1 | Compounds Useful For Making HCV Protease Inhibitors | ABBVIE INC. | 2014-04-10 | — | — | US | disclosed |
| WO-2014055634-A1 | IDENTIFICATION OF SMALL MOLECULE INHIBITORS OF JUMONJI AT-RICH INTERACTIVE DOMAIN 1A (JARID1A) AND 1B (JARID1B) HISTONE DEMETHYLASE | YALE UNIVERSITY (US) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014053878-A1 | SUSTAINABLE ISOSORBIDE - CONTAINING POLYCARBONATE - POLYLACTIDE BLENDS | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2014-04-10 | — | — | WO | disclosed |
| US-20140100214-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140087949-A1 | SUBSTITUTED 5-(CYCLOHEX-2-EN-1-YL)-PENTA-2,4-DIENES AND 5-(CYCLOHEX-2-EN-1-YL)-PENT-2-EN-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-03-27 | — | — | US | disclosed |
| US-20140086941-A1 | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140087945-A1 | SUBSTITUTED 4-CYAN-3-(2,6-DIFLUOROPHENYL)-4-PHENYLBUTANOATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| EP-2710004-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-03-26 | — | — | EP | disclosed |
| EP-2710119-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | Cleave Biosciences, Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| CN-102424703-B | Surface polymerisation process and polymer product using RAFT agent | UNIV SYDNEY | 2014-03-26 | — | — | CN | disclosed |
| US-20140080704-A1 | SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-20 | — | — | US | disclosed |
| US-20140080821-A1 | PYRIMIDO-PYRROLO-OXAZINE-DIONE COMPOUND INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-20 | — | — | US | disclosed |
| US-8673975-B2 | Indene derivatives as pharmaceutical agents | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8674137-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140073640-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2014-03-13 | — | — | US | disclosed |
| EP-1807118-B1 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HARBOR BIOSCIENCES INC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2705181-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Intellikine, LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD. (AU) | 2014-03-06 | — | — | US | disclosed |
| US-20140066462-A1 | TREATMENT OF POLYCYSTIC DISEASE | INTELLIKINE LLC (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2701505-A1 | FORMULATION COMPONENT | Syngenta Limited (GB) | 2014-03-05 | — | — | EP | disclosed |
| US-8664266-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2014029983-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029984-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| EP-2699575-A1 | TRIAZOLOPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-2086970-B1 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8658606-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20140051674-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| US-20140051689-A1 | Polycyclic Agents for the Treatment of Respiratory Syncytial Virus Infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140051577-A1 | SUBSTITUTED 5-(BICYCLO[4.1.0]HEPT-3-EN-2-YL)PENTA-2,4-DIENES AND 5-(BICYCLO[4.1.0]HEPT-3-EN-2-YL)PENT-2-ENE-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESSES IN PLANTS | FRACKENPOHL JENS (DE) | 2014-02-20 | — | — | US | disclosed |
| WO-2014028381-A1 | APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| CN-103596431-A | Pyrimidine cyclohexyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS INC | 2014-02-19 | — | — | CN | disclosed |
| CN-103596923-A | Substituted 5-(cyclohex-2-en-1-yl)-penta-2,4-dienes and 5-(cyclohex-2-en-1-yl)-pent-2-en-4-ines as active agents against abiotic stress in plants | BAYER CROPSCIENCE AG | 2014-02-19 | — | — | CN | disclosed |
| US-8653041-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653087-B2 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653142-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653068-B2 | Filamin A binding anti-inflammatory and analgesic | PAIN THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653042-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20140046018-A1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | POLYACTIVA PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20140046005-A1 | HYBRID POLYMERS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-02-13 | — | — | US | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2226632-B1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694500-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694055-A1 | TAXANE AND ABEO-TAXANE ANALOGS | Arbor Therapeutics, LLC (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-1799739-B1 | GELS | AORTECH INTERNAT PLC (GB) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694510-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-02-12 | — | — | EP | disclosed |
| US-20140038822-A1 | USE OF SUBSTITUTED SPIROCYCLIC SULFONAMIDOCARBOXYLIC ACIDS, CARBOXYLIC ESTERS THEREOF, CARBOXAMIDES THEREOF AND CARBONITRILES THEREOF OR SALTS THEREOF FOR ENHANCEMENT OF STRESS TOLERANCE IN PLANTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| WO-2014020041-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-06 | — | — | WO | disclosed |
| US-20140038993-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140039048-A1 | METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES | ACUCELA INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2014020043-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-06 | — | — | WO | disclosed |
| EP-2692726-A1 | Anti-viral compounds | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2691375-A1 | SUBSTITUTED BENZIMIDAZOLES | Bayer Intellectual Property GmbH (DE) | 2014-02-05 | — | — | EP | disclosed |
| EP-2692346-A1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-20140030256-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031395-A1 | Positive Allosteric Modulators of the Alpha 7 Nicotinic Acetylcholine Receptor and uses Thereof | BIONOMICS LIMITED (AU) | 2014-01-30 | — | — | US | disclosed |
| EP-2078010-B1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2014-01-29 | — | — | EP | disclosed |
| CN-103547577-A | Fused ring compound for use as mineralocorticoid receptor antagonist | KBP BIOSCIENCES CO LTD | 2014-01-29 | — | — | CN | disclosed |
| US-8637549-B2 | Pyridons as PDK1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20140024583-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-23 | — | — | US | disclosed |
| WO-2014015291-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | ZHOU HAN-JIE (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20140024776-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | OLIGASIS (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | CLEAVE BIOSCIENCES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140024821-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2222646-B1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBVIE BAHAMAS LTD (BS) | 2014-01-22 | — | — | EP | disclosed |
| EP-2285881-B1 | POLYMER MICROGEL BEADS AND PREPARATIVE METHOD THEREOF | UNIV SYDNEY (AU) | 2014-01-22 | — | — | EP | disclosed |
| EP-2685964-A1 | FORMULATIONS OF PHENYL URACIL COMPOUNDS | AbbVie Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2558459-B1 | PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-01-22 | — | — | EP | disclosed |
| CN-101583614-B | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENT MANAGEMENT | 2014-01-22 | — | — | CN | disclosed |
| US-8633265-B2 | UV stabilization of isosorbide polycarbonates | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| WO-2014012054-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATENT | PAIN THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017165-A1 | DNA REPAIR ENZYME INHIBITOR NANOPARTICLES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-01-16 | — | — | US | disclosed |
| WO-2014009219-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-16 | — | — | WO | disclosed |
| US-20140017761-A1 | SUBSTRATE FOR IMMOBILIZING FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME | TEMASEK POLYTECHNIC (SG) | 2014-01-16 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| WO-2014011917-A2 | A METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| EP-2401267-B1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND THEIR USE IN METHODS | AMBIT BIOSCIENCES CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8624025-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-01-07 | — | — | US | disclosed |
| WO-2014004470-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-20140004111-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2014-01-02 | — | — | US | disclosed |
| US-20140004215-A1 | COMPOSITIONS AND METHODS FOR MANAGING WEIGHT | UNIGEN, INC. (KR) | 2014-01-02 | — | — | US | disclosed |
| EP-2678334-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-1723139-B1 | CELL TARGETING CONJUGATES | PETER MACCALLUM CANCER INST (AU) | 2014-01-01 | — | — | EP | disclosed |
| EP-2678016-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, LLC (US) | 2014-01-01 | — | — | EP | disclosed |
| CN-103492489-A | High molecular weight zwitterionic polymers | OLIGASIS | 2014-01-01 | — | — | CN | disclosed |
| CN-101801375-B | Insulin sensitisers and methods of treatment | VERVA PHARMACEUTICALS LTD | 2014-01-01 | — | — | CN | disclosed |
| CN-103492371-A | Spiro-containing dihydropyrazole compounds | KBP BIOSCIENCES CO LTD | 2014-01-01 | — | — | CN | disclosed |
| US-8618331-B2 | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| WO-2013191964-A1 | SILICONE LIGANDS FOR STABILIZING QUANTUM DOT FILMS | NANOSYS, INC. (US) | 2013-12-27 | — | — | WO | disclosed |
| WO-2013191984-A1 | FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-27 | — | — | WO | disclosed |
| US-20130345216-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130344061-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130345458-A1 | SILICONE LIGANDS FOR STABILIZING QUANTUM DOT FILMS | NANOSYS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8614324-B2 | Filamin A binding anti-inflammatory and analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-8614318-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| US-20130336920-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130336921-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130336919-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130336918-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130338161-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS INC (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130338160-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2013-12-19 | — | — | US | disclosed |
| US-8610111-B2 | Bistable carbazole compounds | STMICROELECTRONICS S.R.L. (IT) | 2013-12-17 | — | — | US | disclosed |
| US-8609661-B2 | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-17 | — | — | US | disclosed |
| US-8609650-B2 | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130330327-A1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-12 | — | — | US | disclosed |
| EP-2670749-A1 | NEW AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-12-11 | — | — | EP | disclosed |
| US-8604032-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| WO-2013181217-A2 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| WO-2013179024-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | WO | disclosed |
| US-20130324576-A1 | THERAPEUTIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| US-20130323642-A1 | Photoinduced Alkyne-Azide Click Reactions | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2013181296-A2 | COMPOSITIONS AND METHODS FOR MANAGING WEIGHT | UNIGEN, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20130326735-A1 | 6-(2-Aminophenyl)picolinates and their use as herbicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-05 | — | — | US | disclosed |
| EP-2668178-A1 | NEW 5-ALKYNYL-PYRIDINES | Boehringer Ingelheim International GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| EP-2668179-A1 | NEW 5-ALKYNYL-PYRIDINES | Boehringer Ingelheim International GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| EP-2668189-A1 | NEW PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| US-8598194-B2 | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2013-12-03 | — | — | US | disclosed |
| US-8598193-B2 | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2013-12-03 | — | — | US | disclosed |
| US-8598157-B2 | 5-alkynyl-pyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-03 | — | — | US | disclosed |
| US-20130317045-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130317004-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-28 | — | — | US | disclosed |
| WO-2013174744-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013174735-A1 | SUBSTITUTED BENZOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | disclosed |
| EP-1755373-B2 | METHOD OF ALTERING THE ALKALOID COMPOSITION IN POPPY PLANTS | GLAXOSMITHKLINE AUSTRALIA PTY LTD (AU) | 2013-11-27 | — | — | EP | disclosed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| EP-2491025-B1 | AZAAZULENE COMPOUNDS | IND TECH RES INST (TW) | 2013-11-27 | — | — | EP | disclosed |
| EP-2665724-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| EP-2665727-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| EP-2665775-A1 | UV STABILIZATION OF ISOSORBIDE POLYCARBONATES | SABIC Innovative Plastics IP B.V. (NL) | 2013-11-27 | — | — | EP | disclosed |
| US-8592399-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2013-11-26 | — | — | US | disclosed |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-8586770-B2 | Unsaturated steroid compounds | Harbor Therapeutics, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586618-B2 | Furanone compounds and lactam analogues thereof | BIOSIGNAL LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| US-20130303509-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303511-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2013169361-A1 | IRON CHELATORS AS HIV-1 INHIBITORS | HOWARD UNIVERSITY (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130303508-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303510-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303547-A1 | HCV Protease Inhibitors and Uses Thereof | ABBVIE INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2013170147-A1 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME | YALE UNIVERSITY (US) | 2013-11-14 | — | — | WO | disclosed |
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580809-B2 | Filamin A-binding anti-inflammatory analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130291430-A1 | Synthesis of High Caloric Fuels and Chemicals | Pioneer Energy (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2013166449-A2 | METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES | ACUCELA INC. (US) | 2013-11-07 | — | — | WO | disclosed |
| EP-2398797-B1 | PYRIMIDO[5,4-D]PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | BOEHRINGER INGELHEIM INT (DE) | 2013-11-06 | — | — | EP | disclosed |
| EP-2507233-B1 | Substituted triazolopyridines | BAYER IP GMBH (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20130288369-A1 | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289105-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER CENTER | 2013-10-31 | — | — | US | disclosed |
| US-20130289029-A1 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist | NOVO NORDISK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-20130289217-A1 | CONDUCTING AND SEMICONDUCTING ORGANIC MATERIALS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-10-31 | — | — | US | disclosed |
| EP-2368890-B9 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-10-30 | — | — | EP | disclosed |
| EP-2655355-A1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-10-30 | — | — | EP | disclosed |
| EP-2655358-A1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-10-30 | — | — | EP | disclosed |
| CN-103380116-A | 6-(2-aminophenyl)picolinates and their use as herbicides | BAYER IP GMBH | 2013-10-30 | — | — | CN | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-8569316-B2 | Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8568920-B2 | Electrolytic solution and lithium battery employing the same | SAMSUNG SDI CO., LTD. (KR) | 2013-10-29 | — | — | US | disclosed |
| US-8569323-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569303-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130281468-A1 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2013-10-24 | — | — | US | disclosed |
| WO-2013158845-A1 | LINEAR GLYCIDYL CARBAMATE (GC) RESINS FOR HIGHLY FLEXIBLE COATINGS | NDSU RESEARCH FOUNDATION (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281460-A1 | 6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| EP-2651924-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651920-A2 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651946-A1 | 2-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651945-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651948-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651950-A1 | 6 SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651925-A2 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651944-A1 | SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651947-A1 | 6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651885-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| CN-101723949-B | Polycyclic agents for treatment of respiratory syncytial virus infections | BIOTA SCIENT MAN | 2013-10-23 | — | — | CN | disclosed |
| US-8561811-B2 | Substrate for immobilizing functional substances and method for preparing the same | TEMASEK POLYTECHNIC (SG) | 2013-10-22 | — | — | US | disclosed |
| US-8563559-B2 | Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| WO-2013154712-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-10-17 | — | — | WO | disclosed |
| US-20130274483-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | PACIRA PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2013154793-A1 | F2 DERIVATIVES AS ANTIBACTERIAL AGENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 2013-10-17 | — | — | WO | disclosed |
| WO-2013154878-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130274285-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC | 2013-10-17 | — | — | US | disclosed |
| EP-2648754-A2 | METHODS OF INHIBITING METASTASIS FROM CANCER | Philadelphia Health and Education Corporation D/B/A (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2121639-B1 | SUBSTITUTED 2,4-DIAMINO-1,3,5-TRIAZINES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8557842-B2 | Cocaine analogs and methods of preparation and uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557810-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557737-B2 | Methods of altering poppy characteristics | GlaxoSmithKline Australia, Pty, Ltd (AU) | 2013-10-15 | — | — | US | disclosed |
| US-8557783-B2 | Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders | Pharmaxis Pty Limited (AU) | 2013-10-15 | — | — | US | disclosed |
| US-20130267527-A1 | SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-10 | — | — | US | disclosed |
| WO-2013149909-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-10 | — | — | WO | disclosed |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2431371-B1 | THIOPHENE DERIVATIVES | TIANJIN HEMAY BIO TECH CO LTD (CN) | 2013-10-09 | — | — | EP | disclosed |
| EP-2646423-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | Galleon Pharmaceuticals, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| CN-103347866-A | Novel compound as respiratory stimulants for treatment of breathing control disorder or disease | GALLEON PHARMACEUTICALS INC | 2013-10-09 | — | — | CN | disclosed |
| CN-103342682-A | Intermediate for preparing pyrimidine derivatives | ASTRAZENECA AB | 2013-10-09 | — | — | CN | disclosed |
| US-8551980-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| WO-2013144189-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261121-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-03 | — | — | US | disclosed |
| EP-2642997-A1 | NITRIC OXIDE DONORS IN THERAPY OF NITRIC OXIDE DEFICIENCY-INDUCED DISTURBANCES OF CEREBRAL MICROCIRCULATION | Westfälische Wilhelms-Universität Münster (DE) | 2013-10-02 | — | — | EP | disclosed |
| US-8546443-B2 | Benzylic oxindole pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546433-B2 | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546405-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20130252959-A1 | NITRIC OXIDE DONORS IN THERAPY OF NITRIC OXIDE DEFICIENCY-INDUCED DISTURBANCES OF CEREBRAL MICROCIRCULATION | West-Falische Wilhelms-Universitat Munster (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252922-A1 | SUBSTITUTED PHENOXYPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130253064-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2013-09-26 | — | — | US | disclosed |
| EP-2640704-A1 | NAMPT INHIBITORS | Abbvie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2640735-A1 | ANTIBACTERIAL AMIINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-1558585-B1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2013-09-25 | — | — | EP | disclosed |
| US-8541457-B2 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2013-09-24 | — | — | US | disclosed |
| US-8541424-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541448-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013138418-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013135612-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-19 | — | — | WO | disclosed |
| US-20130244956-A1 | CAMPTOTHEAN-PEPTIDE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DRAIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245327-A1 | CARBON NANOHOOPS AND METHODS OF MAKING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013138413-A1 | BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | WO | disclosed |
| EP-2639226-A1 | Anti-infective pyrimidines and uses thereof | ABBOTT LABORATORIES (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638044-A1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638045-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2177226-B1 | Hydroxamate compositions | COVIDIEN LP (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638043-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2637669-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8535655-B2 | Biodegradable polymer—bioactive moiety conjugates | POLYACTIVA PTY LTD. (AU) | 2013-09-17 | — | — | US | disclosed |
| WO-2013133726-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | LANDCARE RESEARCH NEW ZEALAND LIMITED (NZ) | 2013-09-12 | — | — | WO | disclosed |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237507-A1 | Novel Amide Compounds | ASTRAZENECA AB INTELLECTUAL PROPERTY (GB) | 2013-09-12 | — | — | US | disclosed |
| WO-2013130013-A1 | NOVEL COMPOUNDS AND USES THEREOF | NANYANG POLYTECHNIC (SG) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013127729-A1 | 6 - ALKYNYL PYRIDINES AS SMAC MIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-06 | — | — | WO | disclosed |
| EP-2632899-A1 | SUBSTITUTED PHENOXYPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-1830837-B1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY STEAROYL-COA DESATURASE ENZYMES | XENON PHARMACEUTICALS INC (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-8524689-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524675-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130225562-A1 | PYRIDYLTRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130224114-A1 | Translocator Protein Ligands | THE UNIVERSITY OF SYDNEY (AU) | 2013-08-29 | — | — | US | disclosed |
| US-20130225615-A1 | 2-CYCLOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130224083-A1 | USE OF NITROANILINE DERIVATIVES FOR THE PRODUCTION OF NITRIC OXIDE | STMICROELECTRONICS S.R.I. (IT) | 2013-08-29 | — | — | US | disclosed |
| WO-2013126805-A2 | SMALL MOLECULE COMPOUNDS TO TREAT HEARING LOSS | FATE THERAPEUTICS, INC. (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225567-A1 | 5-Alkynyl Pyridine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225614-A1 | 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225578-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225589-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2013-08-29 | — | — | US | disclosed |
| CN-103270034-A | NOVEL SUBSTITUTED PICOLINIC ACIDS, SALTS AND ACID DERIVATIVES THEREOF, AND USE THEREOF AS HERBICIDES | BAYER IP GMBH | 2013-08-28 | — | — | CN | disclosed |
| US-20130217642-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217726-A1 | INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS AND USES THEREOF | ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-08-22 | — | — | US | disclosed |
| US-20130217841-A1 | CONTINUOUS FLOW POLYMERISATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-08-22 | — | — | US | disclosed |
| WO-2013123071-A1 | METHODS AND COMPOSITIONS FOR JAMM PROTEASE INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2628481-A1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | AbbVie Bahamas Ltd. (BS) | 2013-08-21 | — | — | EP | disclosed |
| EP-2627651-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-1869022-B1 | NAPHTHALAMIDE DERIVATIVES HAVING ANTIPROLIFERATIVE ACTIVITY | AGENCY SCIENCE TECH & RES (SG) | 2013-08-21 | — | — | EP | disclosed |
| EP-1804799-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | disclosed |
| EP-1807085-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | disclosed |
| CN-101742996-B | Application of ingenol in preparation of medicine for treating non-cancerous skin injury | LEO LAB LTD | 2013-08-21 | — | — | CN | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130209997-A1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | BIOMATRICA, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210143-A1 | NOVEL METHODS FOR PREVENTING OR TREATING DIABETES | FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD (ES) | 2013-08-15 | — | — | US | disclosed |
| US-20130210111-A1 | SUBSTRATE FOR IMMOBILIZING FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME | TEMASEK POLYTECHNIC (SG) | 2013-08-15 | — | — | US | disclosed |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210815-A1 | SUBSTITUTED IMIDAZOPYRAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-8507539-B2 | Potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2013-08-13 | — | — | US | disclosed |
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| WO-2013116382-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013116836-A1 | HALOGENATED ORGANOSILICON ELECTROLYTES, METHODS OF USING THEM, AND ELECTROCHEMICAL DEVICES CONTAINING THEM | SILATRONIX, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130203768-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INC. | 2013-08-08 | — | — | US | disclosed |
| US-8501238-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501724-B1 | Purinone compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501746-B2 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2013-08-06 | — | — | US | disclosed |
| US-8501889-B2 | Conducting and semiconducting organic materials | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-08-06 | — | — | US | disclosed |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | INTERVET INC. | 2013-08-01 | — | — | US | disclosed |
| US-20130196131-A1 | GLASS FILLED COPOLYMER PRODUCTS FOR THIN WALL AND HIGH SURFACE GLOSS ARTICLES | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2013-08-01 | — | — | US | disclosed |
| US-20130197014-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013110585-A1 | 5, 8 -DIHYDRO- 6H- PYRAZOLO [3, 4 -H] QUINAZOLINES AS IGF-LR/LR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | WO | disclosed |
| US-20130195848-A1 | IMIDAZOPYRAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-8497275-B2 | HCV protease inhibitors and uses thereof | ABBVIE INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130190377-A1 | Novel Lactams | BIOSIGNAL LIMITED (AU) | 2013-07-25 | — | — | US | disclosed |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013109991-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013107743-A1 | SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | WO | disclosed |
| US-20130190286-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190305-A1 | NEW 5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLINES AS IGF-1R/IR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| CN-103221435-A | Continuous flow polymerisation process | COMMW SCIENT IND RES ORG | 2013-07-24 | — | — | CN | disclosed |
| US-8492379-B2 | Translocator protein ligands | THE UNIVERSITY OF SYDNEY (AU) | 2013-07-23 | — | — | US | disclosed |
| US-8492349-B2 | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A | PAIN THERAPEUTICS, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492373-B2 | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492354-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492589-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492374-B2 | Azaazulene compounds | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2013-07-23 | — | — | US | disclosed |
| WO-2013106029-A1 | TAXANE AND ABEO-TAXANE ANALOGS | Arbor Therapeutics, LLC (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013106631-A1 | PROCESSES FOR MAKING HCV PROTEASE INHIBITORS | ABBVIE INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130178438-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178630-A1 | PROCESS FOR MAKING HCV PROTEASE INHIBITORS | ABBVIE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| EP-2611502-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611789-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611793-A1 | 2-CYCLOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611812-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611448-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8481502-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2013097773-A1 | NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-07-04 | — | — | WO | disclosed |
| US-20130172210-A1 | METHOD OF DRUG DESIGN | ALCHEMIA LIMITED (AU) | 2013-07-04 | — | — | US | disclosed |
| US-8476282-B2 | Benzoxazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476431-B2 | Benzoxazole kinase inhibitors and methods of use | Itellikine LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130165439-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
| EP-2607363-A1 | FUSED RING COMPOUND FOR USE AS MINERALOCORTICOID RECEPTOR ANTAGONIST | KBP Biosciences Co., Ltd. (CN) | 2013-06-26 | — | — | EP | disclosed |
| CN-102076436-B | Soil remediation process | UNIV QUEENSLAND | 2013-06-26 | — | — | CN | disclosed |
| US-8470782-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130156756-A1 | Substituted Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013087579-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013087581-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-8466162-B2 | 5-alkynyl-pyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466188-B2 | Use of spiro-oxindole compounds as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-8466155-B2 | Pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20130150574-A1 | PROCESS FOR THE MANUFACTURE OF CHIRAL CATALYSTS AND THEIR SALTS | SCINOPHARM TAIWAN, LTD. (TW) | 2013-06-13 | — | — | US | disclosed |
| WO-2013086441-A2 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086444-A2 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-8461147-B2 | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8461403-B2 | Carbon nanohoops and methods of making | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013081552-A1 | Melamine Aldehyde Polymers | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-06-06 | — | — | WO | disclosed |
| EP-2598661-A2 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | Biomatrica, INC. (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2598660-A2 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | Biomatrica, INC. (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2598125-A2 | NOVEL METHODS FOR PREVENTING OR TREATING DIABETES | Fundación Pública Andaluza Progreso Y Salud (ES) | 2013-06-05 | — | — | EP | disclosed |
| US-8455432-B2 | Insulin sensitisers and methods of treatment | VERVA PHARMACEUTICALS LTD. (AU) | 2013-06-04 | — | — | US | disclosed |
| US-20130137804-A1 | POLY(ALIPHATIC ESTER)- POLYCARBONATE COPOLYMER/POLYLACTIC ACID BLEND | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2013-05-30 | — | — | US | disclosed |
| US-20130136848-A1 | POLYMERISATION PROCESS AND POLYMER PRODUCT | THE UNIVERSITY OF SYDNEY (AU) | 2013-05-30 | — | — | US | disclosed |
| US-20130137644-A1 | CELL PENETRATING PEPTIDE CONJUGATES FOR DELIVERING OF NUCLEIC ACIDS INTO A CELL | CELLECTIS (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137650-A1 | METHODS OF TREATMENT USING COMBINATION THERAPY | AMBIT BIOSCIENCES CORP. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013078441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013076626-A1 | POLY(ALIPHATIC ESTER)-POLYCARBONATE COPOLYMER/POLYLACTIC ACID BLEND | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078440-A2 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| EP-2595987-A1 | NEW AMINOPYRAZOLOQUINAZOLINES | Boehringer Ingelheim International GmbH (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-8450070-B2 | Method for screening of cell-protecting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-8450329-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-8450320-B2 | Pyrrolopyrazinone inhibitors of kinases | ABBVIE INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450334-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450527-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450480-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| WO-2013074834-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20130131286-A1 | COMPOUND FOR USE IN PEPTIDE SYNTHESIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2013-05-23 | — | — | US | disclosed |
| US-20130131001-A1 | Epirubicin Derivatives | Tianjin Michele Sci-Tech Development Co., (CN) | 2013-05-23 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445476-B2 | Carbacephem β-lactam antibiotics | ACHAOGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445142-B2 | Organic electrolytic solution and lithium battery employing the same | SAMSUNG SDI CO., LTD. (KR) | 2013-05-21 | — | — | US | disclosed |
| WO-2013071264-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013067710-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123243-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130118063-A1 | Synthesis of High Caloric Fuels and Chemicals | Pioneer Energy (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013070966-A1 | SYNTHESIS OF HIGH CALORIC FUELS AND CHEMICALS | Pioneer Energy (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013067579-A1 | ADIPOSITY-MODULATING MOLECULES AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013070976-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013068929-A1 | CLEAN POLYCARBONATE MATERIAL FOR USE IN HARD DISK DRIVE AND SEMICONDUCTOR APPLICATIONS | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2013-05-16 | — | — | WO | disclosed |
| EP-2590939-A1 | COMPOUND FOR USE IN PEPTIDE SYNTHESIS | Nanyang Technological University (SG) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590510-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590655-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590656-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590965-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8440849-B2 | Use of nitroaniline derivatives for the production of nitric oxide | STMICROELECTRONICS S.R.L. (IT) | 2013-05-14 | — | — | US | disclosed |
| US-8440441-B2 | Method of preparing a substrate for immobilization of functional substances thereon and the substrate obtained therefrom | TEMASEK POLYTECHNIC (SG) | 2013-05-14 | — | — | US | disclosed |
| US-20130116444-A1 | PROCESS FOR CABAZITAXEL, AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2013-05-09 | — | — | US | disclosed |
| EP-2205592-B1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20130109695-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130102590-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102633-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013059485-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| EP-2001892-B1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AMBIT BIOSCIENCES CORP (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2582699-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2013-04-24 | — | — | EP | disclosed |
| US-8425972-B2 | Antimicrobial materials and coatings | COVIDIEN LP (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426345-B2 | Method of drug design | ALCHEMIA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| US-20130096335-A1 | PROCESS FOR SYNTHESIS OF SILANE DIPEPTIDE ANALOGS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| WO-2013055897-A1 | 8 - CARBAMOYL - 2 - (2,3- DI SUBSTITUTED PYRID - 6 - YL) -1,2,3,4 -TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS - INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130095054-A1 | COPOLYMERS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-04-18 | — | — | US | disclosed |
| WO-2013056070-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096120-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2421845-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LAB (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2581372-A1 | CYANOQUINOLINE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-04-17 | — | — | EP | disclosed |
| EP-2368890-B1 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-04-17 | — | — | EP | disclosed |
| US-8420863-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130090330-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130087736-A1 | WATER SWELLABLE POLYMER MATERIALS | THE UNIVERSITY OF SYDNEY (AU) | 2013-04-11 | — | — | US | disclosed |
| EP-2576560-A1 | SUBSTITUTED IMIDAZOPYRAZINES | Bayer Intellectual Property GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| EP-2575462-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, LLC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8415351-B2 | Anti-infective agents and uses thereof | ABBOTT LABORATORIES (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415370-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-04-09 | — | — | US | disclosed |
| EP-2443091-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2013-04-03 | — | — | EP | disclosed |
| US-8410045-B2 | Camptothecin-peptide conjugates and pharmaceutical compositions containing the same | DRAIS PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410272-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410126-B2 | Pyrimidine inhibitors of PKTK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| WO-2013041634-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-28 | — | — | WO | disclosed |
| US-20130078796-A1 | PROCESS FOR MAKING A PATTERNED METAL OXIDE STRUCTURE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-03-28 | — | — | US | disclosed |
| US-20130079354-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-03-28 | — | — | US | disclosed |
| US-20130079293-A1 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2013-03-28 | — | — | US | disclosed |
| EP-2571357-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | Intellikine, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2571877-A1 | 1H - IMIDAZO [4, 5 - C]QUINOLINES | Boehringer Ingelheim International GmbH (DE) | 2013-03-27 | — | — | EP | disclosed |
| EP-2177552-B1 | Bioabsorbable surgical composition | COVIDIEN LP (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8404674-B2 | Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20130072486-A1 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130068294-A1 | DYE-SENSITISED SOLAR CELL WITH NICKEL CATHODE | Commwealth Scientific and Industrial Reseach Organisation | 2013-03-21 | — | — | US | disclosed |
| EP-2285882-B1 | POLYMER MICROGEL BEADS | UNIV SYDNEY (AU) | 2013-03-20 | — | — | EP | disclosed |
| EP-2570441-A2 | Bioabsorbable surgical composition | Covidien LP (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-1799667-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2013-03-20 | — | — | EP | disclosed |
| US-8399419-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| WO-2013034570-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036207-A1 | DERIVATIVES OF XANTHONE COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-03-14 | — | — | WO | disclosed |
| EP-2300458-B1 | SUBSTITUTED 1-(DIAZINYL) PYRAZOLE-4-YL-ACETIC ACIDS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2013032591-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-2564859-A1 | Hydroxamate compositions | Covidien LP (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8389557-B2 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389771-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130048559-A1 | Method of Preparing a Substrate for Immobilization of Functional Substances Thereon and the Substrate Obtained Therefrom | TEMASEK POLYTECHNIC (SG) | 2013-02-28 | — | — | US | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| EP-2561759-A1 | Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth | Bayer Cropscience AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560971-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560967-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
| CN-102946877-A | Neuroprotective effect of mastoid fruits (Adelostemma gracilimum) and isolated compounds thereof | BIOTECHNOLOGY RES CORP LTD | 2013-02-27 | — | — | CN | disclosed |
| US-8383623-B2 | Phthalazin-(2H)-one inhibitors of kinases | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383624-B2 | Pyrrolopyrazine inhibitors of kinases | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383596-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383873-B2 | Terminal 1,1-disubstituted alkenes, method of making and using thereof | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2013-02-26 | — | — | US | disclosed |
| US-8383628-B2 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-02-26 | — | — | US | disclosed |
| US-20130045522-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045955-A1 | NOVEL COMPOUNDS | BENNETT NICHOLAS J (GB) | 2013-02-21 | — | — | US | disclosed |
| EP-2558459-A1 | PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-2558469-A1 | PYRROLOPYRAZINONE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8377943-B2 | 2,4-diaminopyrimidine derivates as PTK2-inhibitors for the treatment of abnormal cell growth | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-19 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| WO-2013022793-A1 | SMALL MOLECULE ACTIVATORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-2114954-B1 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2556058-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | Peter MacCallum Cancer Institute (AU) | 2013-02-13 | — | — | EP | disclosed |
| EP-2114955-B1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2013-02-13 | — | — | EP | disclosed |
| CN-102933578-A | Cyanoquinoline derivatives | TIANJIN HEMAY BIO TECH CO LTD | 2013-02-13 | — | — | CN | disclosed |
| US-8372813-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130035333-A1 | USE OF CINNABARINIC ACID AS A MODULATOR OF IMMUNE RESPONSES IN AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20130034517-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2013020004-A1 | GLASS FILLED COPOLYMER PRODUCTS FOR THIN WALL AND HIGH SURFACE GLOSS ARTICLES | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2013-02-07 | — | — | WO | disclosed |
| EP-2552907-A1 | PYRIDYLTRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2013-02-06 | — | — | EP | disclosed |
| EP-2552905-A1 | B-RAF KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-02-06 | — | — | EP | disclosed |
| US-8367625-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2013014579-A1 | PROCESS FOR THE BORYLATION OF ORGANOHALIDES | BASF SE (DE) | 2013-01-31 | — | — | WO | disclosed |
| US-20130029920-A1 | Metal Nanoparticles | BRIMBLE MARGARET A (NZ) | 2013-01-31 | — | — | US | disclosed |
| US-20130030026-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029993-A1 | AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130023689-A1 | PROCESS FOR THE BORYLATION OF ORGANOHALIDES | BASF SE (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023523-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2013012681-A1 | TRICYCLIC INHIBITORS OF KINASES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013013031-A1 | PYRIDAZINO [4, 5 -D] PYRIMIDIN- (6H) -ONE INHIBITORS OF WEE - 1 KINASE | ABBVIE INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012918-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012915-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012752-A2 | METHODS AND COMPOSITIONS FOR MANIPULATING TRANSLATION OF PROTEIN ISOFORMS FROM ALTERNATIVE INITIATION START SITES | SAREPTA THERAPEUTICS, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130023533-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023531-A1 | PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023519-A1 | 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| EP-2548873-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | Abbott Laboratories (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-1802662-B1 | SURFACE POLYMERISATION PROCESS AND POLYMER PRODUCT USING RAFT AGENT | UNIV SYDNEY (AU) | 2013-01-23 | — | — | EP | disclosed |
| EP-2547680-A1 | IMIDAZOPYRAZINES | Bayer Intellectual Property GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-8357690-B2 | Methods of treatment using combination therapy | AMBIT BIOSCIENCES CORPORATION (US) | 2013-01-22 | — | — | US | disclosed |
| US-20130018045-A1 | New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer | ABBOTT LABORATORIES (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018077-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| EP-2545923-A1 | Antibacterial agents | Alchemia Limited (AU) | 2013-01-16 | — | — | EP | disclosed |
| EP-2544542-A1 | ANALGESIC COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Galleon Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546249-A1 | 5-Alkynyl-pyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354554-B2 | Process for preparing organometalloids | THE CHINESE UNIVERSITY OF HONGKONG (CN) | 2013-01-15 | — | — | US | disclosed |
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| WO-2013003887-A1 | NUCLEIC ACID COMPLEX | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-01-10 | — | — | WO | disclosed |
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2013-01-10 | — | — | US | disclosed |
| EP-2222648-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2013-01-09 | — | — | EP | disclosed |
| US-8349838-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349851-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20130005736-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-03 | — | — | US | disclosed |
| EP-2540296-A1 | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2013-01-02 | — | — | EP | disclosed |
| EP-1904047-B1 | APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012175591-A1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| WO-2012175514-A1 | PYRIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329828-A1 | Cocaine Analogs and Methods of Preparation and Uses Thereof | NEW YORK UNIVERSITY (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120328611-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120328610-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| EP-2536686-A1 | CYCLIC KETO-ENOLS FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| EP-2536485-A1 | A SUBSTRATE FOR IMMOBILIZING FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME | Temasek Polytechnic (SG) | 2012-12-26 | — | — | EP | disclosed |
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012162742-A1 | POLYMER PARTICLES | THE UNIVERSITY OF SYDNEY (AU) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166645-A1 | PRODRUGS OF AZACITIDINE 5' -DIPHOSPHATE | SYNDAX PHARMACEUTICALS, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166658-A1 | PYRIMIDO-PYRROLO-OXAZINE-DIONE COMPOUND INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012163942-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| EP-1934388-B1 | METHOD OF DRUG DESIGN | ALCHEMIA LTD (AU) | 2012-12-05 | — | — | EP | disclosed |
| CN-102811713-A | Multifunctional Zwitterionic Polymer Conjugates | OLIGASIS | 2012-12-05 | — | — | CN | disclosed |
| US-8324190-B2 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | Temple University—Of the Commonwealth System of Higher Education (US) | 2012-12-04 | — | — | US | disclosed |
| WO-2012162578-A2 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162580-A2 | ANTI-VIRAL COMPOUNDS | ABBVIE INC (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012160029-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| CN-102796147-A | Compounds library | ALCHEMIA LTD | 2012-11-28 | — | — | CN | disclosed |
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-8318685-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120295856-A1 | FREDERICAMYCIN DERIVATIVES | ZENTOPHARM GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2012156367-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158435-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | ZHOU HAN-JIE (US) | 2012-11-22 | — | — | WO | disclosed |
| US-8314138-B2 | Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8314103-B2 | Pyridyl derivatives, their preparation and use | Piramal Enterprises Limited (IN) | 2012-11-20 | — | — | US | disclosed |
| WO-2012154610-A1 | REACTIVE PI3K KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154608-A1 | REACTIVE MTOR AND PI3 KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| EP-2121608-B1 | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | BAYER IP GMBH (DE) | 2012-11-14 | — | — | EP | disclosed |
| EP-2521451-A1 | HEDGEHOG INHIBITORS | Selexagen Therapeutics, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| US-8309557-B2 | Pyrimidin-4-ylpropanedinitrile derivatives, processes for their preparation and their use as herbicides and plant growth regulators | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309545-B2 | Benzofuran potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-11-13 | — | — | US | disclosed |
| US-20120283209-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283207-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283208-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012151562-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-1789079-B1 | Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof | FLOREY HOWARD INST (AU) | 2012-11-07 | — | — | EP | disclosed |
| WO-2012146888-A1 | FORMULATION COMPONENT | SYNGENTA LIMITED (GB) | 2012-11-01 | — | — | WO | disclosed |
| CN-101945851-B | peptidyl nitriles and their use as dipeptidyl peptidase I inhibitors | ASTRAZENECA AB | 2012-10-31 | — | — | CN | disclosed |
| CN-102762625-A | Polymeric materials | COMMW SCIENT IND RES ORG | 2012-10-31 | — | — | CN | disclosed |
| US-8299307-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8298994-B2 | Substituted 1-(diazinyl)pyrazol-4-ylacetic acids, processes for their preparation and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE AG (DE) | 2012-10-30 | — | — | US | disclosed |
| WO-2012142670-A1 | NUCLEAR MAGNETIC RESONANCE AGENT | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143329-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-20120269804-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120269831-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120269803-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270901-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| EP-2514423-A2 | Method of treatment of age-related macular degeneration (AMD) | Prana Biotechnology Ltd (AU) | 2012-10-24 | — | — | EP | disclosed |
| EP-1651606-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-10-24 | — | — | EP | disclosed |
| CN-102746239-A | Uracil or thymine derivatives for the treatment of hepatitis C | ABBOTT LAB | 2012-10-24 | — | — | CN | disclosed |
| CN-102746240-A | Anti-infective pyrimidines and uses thereof | ABBOTT LAB | 2012-10-24 | — | — | CN | disclosed |
| US-8293812-B2 | Containing thermoplastic resin having solid particles dispersed throughout; controlling particle size; modulus; high tensile strength | The University of Queensland St. Lucia (AU) | 2012-10-23 | — | — | US | disclosed |
| US-8293738-B2 | Indazole inhibitors of kinase | ABBOTT LABORATORIES (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120264740-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120263670-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120263714-A1 | SUBSTITUTED HALOPHENOXYBENZAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-18 | — | — | US | disclosed |
| EP-2511255-A1 | Substituted prop-2-in-1-ol and prop-2-en-1-ol derivatives | Bayer CropScience AG (DE) | 2012-10-17 | — | — | EP | disclosed |
| EP-2510786-A1 | Substituted Prop-2-in-1-ol and Prop-2-en-1-ol derivatives | Bayer CropScience AG (DE) | 2012-10-17 | — | — | EP | disclosed |
| CN-102741363-A | Water swellable polymer materials | UNIV SYDNEY | 2012-10-17 | — | — | CN | disclosed |
| US-8288382-B2 | Diaminothiazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2012136776-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012136531-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | WO | disclosed |
| US-20120258925-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-2507235-A1 | TRIAZOLOPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-2507233-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-2507236-A1 | TRIAZOLOPYRIDINE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-2507280-A1 | POLYMERIC MATERIALS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2012-10-10 | — | — | EP | disclosed |
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2507322-A1 | WATER SWELLABLE POLYMER MATERIALS | The University Of Sydney (AU) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012130905-A1 | SUBSTITUTED BENZIMIDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | WO | disclosed |
| EP-2504374-A1 | WATER CURABLE RESIN FORMULATIONS | Petroliam Nasional Berhad (PETRONAS) (MY) | 2012-10-03 | — | — | EP | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120245284-A1 | WATER CURABLE RESIN FORMULATIONS | PETROLIAM NASIONAL BERHAD (PETRONAS) (MY) | 2012-09-27 | — | — | US | disclosed |
| US-20120244119-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012129099-A1 | FORMULATIONS OF PHENYL URACIL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
| US-8273403-B2 | Generation of surface coating diversity | BIO-LAYER PTY LTD. (AU) | 2012-09-25 | — | — | US | disclosed |
| US-20120237951-A1 | ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A | PAIN THERAPEUTICS | 2012-09-20 | — | — | US | disclosed |
| US-20120238706-A1 | POLYMERIC MATERIALS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2012-09-20 | — | — | US | disclosed |
| US-20120238542-A1 | AMINOPYRAZOLOQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-20 | — | — | US | disclosed |
| EP-2498600-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | Pain Therapeutics, Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2498599-A1 | ANALGESIC THAT BINDS FILAMIN A | Pain Therapeutics, Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| CN-102675290-A | Bicyclic dihydropyrazole compounds | SHANDONG HENGLI MEDICAL TECHNOLOGY CO LTD | 2012-09-19 | — | — | CN | disclosed |
| CN-101278079-B | Drug design method | ALCHEMIA LTD | 2012-09-19 | — | — | CN | disclosed |
| US-8268990-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-8263775-B2 | Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof | HOWARD FLOREY INSTITUTE (AU) | 2012-09-11 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220562-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012116237-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116257-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| EP-2491016-A1 | SUBSTITUTED BENZOSULPHONAMIDES | Bayer Pharma Aktiengesellschaft (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2491014-A1 | SUBSTITUTED HALOPHENOXYBENZAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2491015-A1 | SUBSTITUTED BENZOSULPHONAMIDES | Bayer Pharma Aktiengesellschaft (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2491025-A1 | AZAAZULENE COMPOUNDS | Industrial Technology Research Institute (TW) | 2012-08-29 | — | — | EP | disclosed |
| US-8252723-B2 | Substituted 1-(3-pyridinyl)pyrazol-4-ylacetic acids, processes for their preparation and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE AG (DE) | 2012-08-28 | — | — | US | disclosed |
| US-20120214759-A1 | TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214760-A1 | TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213733-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-08-23 | — | — | US | disclosed |
| EP-2488177-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | Pain Therapeutics, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8247424-B2 | Water soluble groups on ring A; antitumor antibiotics; 1-Desoxy-5-C-[(8R)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3-yl]pentitol; topoisomerase inhibitors; cyclodextrin inclusions; stereoisomers | ZENTOPHARM GMBH (DE) | 2012-08-21 | — | — | US | disclosed |
| US-20120208781-A1 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208822-A1 | PYRIMIDO-PYRROLO-QUINOXALINEDIONE INHIBITORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2486044-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202877-A1 | ANTI-INFLUENZA AGENTS | GRIFFITH UNIVERSITY (AU) | 2012-08-09 | — | — | US | disclosed |
| WO-2012104388-A1 | NEW AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-09 | — | — | WO | disclosed |
| US-20120202860-A2 | Analgesic Compounds, Compositions and Uses Thereof | GALLEON PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-2483264-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | Novartis AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| EP-2483249-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-08-08 | — | — | EP | disclosed |
| EP-2484679-A2 | N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors | Rigel Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8236852-B2 | Drugs/cosmetics having at least one (substituted phenyl)-propenal moiety; bioavailability' water solubility; antiandrogens; antiinflammatory and wound healing agents; antiarthritic agents; acne; alopecia, hirsutism; anticarcinogenic agents; cancer of the bladder, liver, breast; Kennedy's disease | ANDROSCIENCE CORPORATION (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236835-B2 | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20120196791-A1 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2012101184-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101238-A1 | NEW PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101186-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| EP-1888543-B1 | APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8232246-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120189546-A1 | Radiolabelling Method Using Cycloalkyl Groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120189580-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120189548-A1 | 2-ARYLPYRAZOLO[L,5-ALPHA]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA) | THE UNIVERSITY OF SYDNEY (AU) | 2012-07-26 | — | — | US | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012097684-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098513-A1 | UV STABILIZATION OF ISOSORBIDE POLYCARBONATES | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097682-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| CN-102612514-A | Anti -influenza agents | UNIV GRIFFITH | 2012-07-25 | — | — | CN | disclosed |
| US-20120184501-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184651-A1 | UV Stabilization of Isosorbide Polycarbonates | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2012-07-19 | — | — | US | disclosed |
| US-20120184568-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | HCR COLLATERAL MANAGEMENT, LLC | 2012-07-19 | — | — | US | disclosed |
| WO-2012097049-A2 | DNA REPAIR ENZYME INHIBITOR NANOPARTICLES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-2476679-A2 | Substituted triazoles useful as AXL inhibitors | Rigel Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-1905773-B1 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | MILLENNIUM PHARM INC (US) | 2012-07-18 | — | — | EP | disclosed |
| CN-101460525-B | Polymer products and interfacial polymerization process using RAFT agents | UNIV SYDNEY | 2012-07-18 | — | — | CN | disclosed |
| US-20120178726-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-07-12 | — | — | US | disclosed |
| EP-2473478-A2 | NOVEL USES | Nanyang Polytechnic (SG) | 2012-07-11 | — | — | EP | disclosed |
| EP-2473498-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-8217171-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2012-07-10 | — | — | US | disclosed |
| US-8217189-B2 | Chromenone potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| EP-2471363-A1 | Use of aryl-, heteroaryl- and benzylsulfonamide carboxylic acids, -carboxylic acid esters, -carboxylic acid amides and -carbonitriles and/or its salts for increasing stress tolerance in plants | Bayer CropScience AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471536-A1 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Harbor BioSciences, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471776-A1 | Pyridin-2-ylpropandinitriles and their use as herbicides | Bayer CropScience AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471787-A1 | New compounds | Boehringer Ingelheim International GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012085126-A1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012083866-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085127-A1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| US-20120165370-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | US | disclosed |
| EP-2468269-A1 | Nitric oxide donors in therapy of nitric oxide deficiency-induced disturbances of cerebral microcirculation | Universitätsklinikum Münster (DE) | 2012-06-27 | — | — | EP | disclosed |
| EP-2467141-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8207245-B2 | Gels | AORTECH INTERNATIONAL PLC (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| WO-2012083058-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080232-A1 | 2-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083164-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080229-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083048-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083170-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080236-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| US-20120157314-A1 | NOVEL SUBSTITUTED PICOLINIC ACIDS, SALTS AND ACID DERIVATIVES THEREOF, AND USE THEREOF AS HERBICIDES | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2012080234-A1 | SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2012080230-A1 | 6 SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080228-A1 | 6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| EP-2464354-A1 | PYRIMIDO-PYRROLO-QUINOXALINEDIONE INHIBITORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR | The Regents of the University of California (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8202997-B2 | Compositions and methods for treating or preventing hypoxic or ischemic injury | IKARIA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202905-B2 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | ANDROSCIENCE CORPORATION (US) | 2012-06-19 | — | — | US | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| WO-2012078633-A2 | METHODS OF INHIBITING METASTASIS FROM CANCER | PHILADELPHIA HEALTH AND EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICENE (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198308-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| WO-2012074999-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012074931-A2 | PHOTOLINDUCED ALKYNE-AZIDE CLICK REACTIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012069620-A1 | NITRIC OXIDE DONORS IN THERAPY OF NITRIC OXIDE DEFICIENCY-INDUCED DISTURBANCES OF CEREBRAL MICROCIRCULATION | Westfälische Wilhelms-Universität Münster (DE) | 2012-05-31 | — | — | WO | disclosed |
| EP-2456444-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Intellikine, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2456842-A1 | IONIC LIQUID FLAME RETARDANTS | H & C Scientific Resources International, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-8188104-B2 | Anti-infective agents and uses thereof | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188112-B2 | Naphthalamide derivatives having antiproliferative activity | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-05-29 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129860-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2012-05-24 | — | — | US | disclosed |
| WO-2012067978-A1 | ANTIBACTERIAL AMIINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120128743-A1 | POLYMER PARTICLES | THE UNIVERSITY OF SYDNEY (AU) | 2012-05-24 | — | — | US | disclosed |
| WO-2012067963-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2455376-A1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2454230-A1 | RADIOLABELLING METHOD USING CYCLOALKYL GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| EP-2454248-A1 | ANTI -INFLUENZA AGENTS | Griffith University (AU) | 2012-05-23 | — | — | EP | disclosed |
| WO-2012062745-A1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062748-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064973-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062743-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122924-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122809-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122909-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| CN-102459186-A | Anthelmintic agents and uses thereof | ANTHELMINTIC AGENTS AND THEIR USE | 2012-05-16 | — | — | CN | disclosed |
| CN-102459306-A | Novel amide derivatives of steroidal [3,2-C ] pyrazole compounds having glucocorticoid activity | ASTRAZENECA AB | 2012-05-16 | — | — | CN | disclosed |
| US-8178548-B2 | Anti-infective agents and uses thereof | ABBOTT LABORATORIES (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2448569-A2 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | Acucela, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| CN-102448920-A | Antiviral compounds and uses thereof | ABBOTT LAB | 2012-05-09 | — | — | CN | disclosed |
| CN-102448952-A | Antiviral compounds and uses thereof | ABBOTT LAB | 2012-05-09 | — | — | CN | disclosed |
| US-8173811-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2012055953-A1 | SUBSTITUTED PHENOXYPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-03 | — | — | WO | disclosed |
| US-20120107269-A1 | THIOPHENE DERIVATIVES | Tianjin Hemay Biotech Co., Ltd (CN) | 2012-05-03 | — | — | US | disclosed |
| EP-1651616-B1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | disclosed |
| EP-1651605-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | disclosed |
| CN-102439049-A | Polymer particles | UNIV SYDNEY | 2012-05-02 | — | — | CN | disclosed |
| US-8168636-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120100104-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-26 | — | — | US | disclosed |
| CN-102424703-A | Surface polymerisation process and polymer product using RAFT agent | UNIV SYDNEY | 2012-04-25 | — | — | CN | disclosed |
| US-8163724-B2 | Glucocorticosteroids, processes for their preparation, pharmaceutical compositions containing them and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| WO-2012051361-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094963-A1 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | of Queen Elizabeth near Dublin | 2012-04-19 | — | — | US | disclosed |
| EP-2440548-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | Abbott Laboratories (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120088768-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2012045196-A1 | PHOSPHOGLYCERATE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-1851205-B1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-04-11 | — | — | EP | disclosed |
| US-8153741-B2 | Furanone copolymers | TYCO HEALTHCARE GROUP LP (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153636-B2 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| US-8153593-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153788-B2 | Substituted 2,4-diamino-1,3,5-triazines, processes for their use as herbicides and crop growth regulators | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20120083532-A1 | NOVEL USES | NANYANG POLYTECHNIC (SG) | 2012-04-05 | — | — | US | disclosed |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2435411-A1 | 2, 4 -DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | Boehringer Ingelheim International GmbH (DE) | 2012-04-04 | — | — | EP | disclosed |
| US-8148378-B2 | Pyridazine derivatives and their use as inhibitors of stearoyl-CoA desaturase-1 activity in a mammal | XENON PHARMACEUTICALS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8143284-B2 | 2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide; allergic encephalitis, arthritis, cardiac and kidney toxicities from doxorubicin-based and platinum-based antineoplastic agents, carcinoma of the breast, central nervous system inflammation, cervical carcinoma, | ABBOTT LABORATORIES (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2012037217-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071681-A1 | PROCESS FOR PREPARING ORGANOMETALLOIDS | THE CHINESE UNIVERSITY OF HONGKONG (CN) | 2012-03-22 | — | — | US | disclosed |
| EP-2431371-A1 | THIOPHENE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2012-03-21 | — | — | EP | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2428515-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427195-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| CN-102372710-A | Fused cyclic compound being taken as mineral corticoid recept antagonist | KBP BIOSCIENCES CO LTD | 2012-03-14 | — | — | CN | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2012031243-A2 | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030918-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030910-A1 | 2-CYCLOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030912-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030894-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-2424537-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | Bayer Pharma Aktiengesellschaft (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-8129190-B2 | Via violanthrone compounds | APPLIED NANOTECH HOLDINGS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129374-B2 | Method of using imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
| US-20120052572-A1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | EXACT SCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
| US-20120053176-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-1542997-B1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA CANADA INC (CA) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011044502-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046270-A1 | PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120045455-A1 | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC DISORDERS | Pharmaxis Pty Limited (AU) | 2012-02-23 | — | — | US | disclosed |
| WO-2012024583-A2 | OXYSTEROL COMPOUNDS | FATE THERAPEUTICS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022776-A1 | SUBSTITUTED THIOPENES OR FURANS AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-02-23 | — | — | WO | disclosed |
| EP-2419404-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| CN-102361889-A | Raft polymerisation | COMMW SCIENT IND RES ORG | 2012-02-22 | — | — | CN | disclosed |
| WO-2012021146-A1 | IONIC LIQUID FLAME RETARDANTS | H & C Scientific Resources International, LLC (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041064-A1 | SKIN TREATMENT | PEPLIN RESEARCH PTY LTD (AU) | 2012-02-16 | — | — | US | disclosed |
| EP-2073806-B1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-15 | — | — | EP | disclosed |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | CORRIDOR PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| WO-2012018638-A2 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | BIOMATRICA, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011044503-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012018639-A2 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | BIOMATRICA, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011044498-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| US-20120035199-A9 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2410987-A1 | METHODS OF TREATMENT USING COMBINATION THERAPY | Ambit Biosciences Corporation (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-1888595-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-8106087-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| WO-2012010704-A1 | NEW AMINOPYRAZOLOQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-26 | — | — | WO | disclosed |
| EP-2408752-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-8101647-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009263-A1 | COCAINE ANALOGS AND METHODS OF PREPARATION AND USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-8097630-B2 | Pinane-substituted pyrimidinediamine derivatives derivatives and pharmaceutical compositions containing the dthe activity of the receptor protein tyrosine kinase Axl. Methods of using erivatives are disclosed as being useful in inhibiting activity of enzyme | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| WO-2012006477-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006474-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012005691-A1 | COMPOUND FOR USE IN PEPTIDE SYNTHESIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010124-A9 | Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell | DIATOS (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| WO-2012006473-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| CN-102316866-A | Skin treatment | PEPLIN RESEARCH PTY LTD | 2012-01-11 | — | — | CN | disclosed |
| US-8093227-B2 | Monosaccharide compounds and methods therefor | ALCHEMIA PTY LTD (AU) | 2012-01-10 | — | — | US | disclosed |
| US-8093396-B2 | Benzthiazole inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2012-01-10 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-20120004381-A1 | RAFT POLYMERISATION | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2012-01-05 | — | — | US | disclosed |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2401304-A1 | POLYMER PARTICLES | The University Of Sydney (AU) | 2012-01-04 | — | — | EP | disclosed |
| EP-2401267-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402334-A1 | Inhibitors of E1 Activating Enzymes | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| CN-102304300-A | Polymer product and interfacial polymerisation process using raft agent | UNIV SYDNEY | 2012-01-04 | — | — | CN | disclosed |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | BUCKMAN BRAD (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD (AU) | 2011-12-29 | — | — | US | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| EP-2398797-A1 | PYRIMIDO [5,4-D]PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | Boehringer Ingelheim International GmbH (DE) | 2011-12-28 | — | — | EP | disclosed |
| US-8084607-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084503-B2 | Indene derivatives as pharmaceutical agents | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-12-27 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | disclosed |
| EP-2395996-A1 | COMPOUNDS AND METHODS FOR INHIBITING MMP2 AND MMP9 | Indiana University Research and Technology Corporation (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8080657-B2 | Compounds of reverse turn mimetics and the use thereof | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-20 | — | — | US | disclosed |
| CN-102281875-A | Combination therapy using AXL inhibitors for the prevention, treatment or management of metastatic cancer | — | 2011-12-14 | — | — | CN | disclosed |
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| WO-2011151259-A1 | SUBSTITUTED IMIDAZOPYRAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | WO | disclosed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-8071603-B2 | Contacting a source of hSCD with N-(2-Cyclopropyl-ethyl)-4-[4-(5-fluoro-2-trifluoromethyl-benzoyl)-piperazin-1-yl]-benzamide; elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2011-12-06 | — | — | US | disclosed |
| US-8071764-B2 | Compounds of reverse turn mimetics and the use thereof (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| US-20110293744-A1 | BENZOXAZOLE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110293643-A1 | COMPOUNDS AND METHODS FOR INHIBITING MMP2 AND MMP9 | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2011-12-01 | — | — | US | disclosed |
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20110294766-A1 | 16 Alpha, 17 Alpha-Acetal Glucocorticosteroidal Derivatives and their Use | ASTRAZENECA AB (SE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294664-A1 | USE OF DERIVATIVES OF (1-CYANOCYCLOPROPYL)PHENYLPHOSPHINIC ACID, ESTERS THEREOF AND/OR SALTS THEREOF FOR ENHANCING TOLERANCE IN PLANTS TO ABIOTIC STRESS | BAYER CROPSCIENCE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| WO-2011150198-A1 | AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011150201-A2 | AZOLYL AMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| CN-102264737-A | Anti-viral compounds | — | 2011-11-30 | — | — | CN | disclosed |
| US-8067611-B2 | Substituted 1-(thiazolyl)-and 1-(isothiazolyl)pyrazol-4-ylacetic acids, processes for their preparation and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE AG (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8067409-B2 | Protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| WO-2011144725-A2 | NOVEL METHODS FOR PREVENTING OR TREATING DIABETES | FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD (ES) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288109-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288041-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110286995-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2011-11-24 | — | — | US | disclosed |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| WO-2011144622-A1 | 1H - IMIDAZO [4, 5 - C] QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146842-A1 | PROCESS FOR SYNTHESIS OF SILANE DIPEPTIDE ANALOGS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146882-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INTELLIKINE, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8063093-B2 | Derivatives of 5-(halo)alkanoyl-6-hydroxy- benozofuran, benzothiophene, or indole; autoimmune diseases; systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis and psoriasis, transplant rejection; antiproliferative, anticarcinogenic, antidiabetic, antiinflammatory and antiulcer agents | HARVEY ANDREW J (AU) | 2011-11-22 | — | — | US | disclosed |
| US-8063051-B2 | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-8063053-B2 | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110280824-A1 | Furanone Copolymers | TYCO HEALTHCARE GROUP LP (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281846-A1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281868-A1 | INDAZOLE INHIBITORS OF KINASE | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281842-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| CN-102245604-A | Antiviral compounds | ABBOTT LAB | 2011-11-16 | — | — | CN | disclosed |
| US-20110275633-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110274713-A1 | ANTIGEN-PRESENTING SCAFFOLDS | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-11-10 | — | — | US | disclosed |
| US-20110275586-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-1651620-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-11-09 | — | — | EP | disclosed |
| EP-2069353-B1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENT MANAGEMENT (AU) | 2011-11-09 | — | — | EP | disclosed |
| CN-102239166-A | Substituted 1- (thiazolyl) -and 1- (isothiazolyl) pyrazol-4-ylacetic acids, method for the production thereof and use thereof as herbicides and plant growth regulators | BAYER CROPSCIENCE AG | 2011-11-09 | — | — | CN | disclosed |
| US-20110269779-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS | INTELLIKINE, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2010132760-A9 | ANTIBACTERIAL DERIVATIVES OF TOBRAMYCIN | ACHAOGEN, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-20110263565-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011133388-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131741-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| EP-2181985-B1 | Antiviral Agent | SHIONOGI & CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2139894-B1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-8044067-B2 | Isoquinolines as IGF-1R inhibitors | ANALYTECON S.A. (CH) | 2011-10-25 | — | — | US | disclosed |
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20110257152-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257187-A1 | PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257189-A1 | PYRROLOPYRAZINONE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257014-A1 | 1-(Heteroaryl)pyrazol-4-ylacetic acids, processes for their preparation and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE AG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2011-10-20 | — | — | US | disclosed |
| WO-2011130478-A1 | PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130481-A1 | PYRROLOPYRAZINONE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-20 | — | — | WO | disclosed |
| EP-2377854-A1 | N-phenyl-dioxo-hydropyrimidines useful as hepatitis C virus (HCV) inhibitors | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377869-A1 | Synthesis of Bortezomib | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20110251224-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| WO-2011123890-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-10-13 | — | — | WO | disclosed |
| WO-2010132765-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| EP-1534755-B1 | GENERATION OF SURFACE COATING DIVERSITY | BIO LAYER PTY LTD (AU) | 2011-10-12 | — | — | EP | disclosed |
| US-20110243884-A1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | THE BIONICS INSTITUTE OF AUSTRALIA (AU) | 2011-10-06 | — | — | US | disclosed |
| EP-2370416-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Boehringer Ingelheim International GmbH (DE) | 2011-10-05 | — | — | EP | disclosed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | disclosed |
| US-8030488-B2 | Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-10-04 | — | — | US | disclosed |
| US-20110237598-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| WO-2011117382-A1 | PYRIDYLTRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011117381-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237567-A9 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-09-29 | — | — | US | disclosed |
| EP-2367799-A1 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2367800-A2 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368882-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-09-28 | — | — | EP | disclosed |
| CN-102203058-A | Sulfur-linked compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2011-09-28 | — | — | CN | disclosed |
| US-8026237-B2 | For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide | EXELIXIS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026360-B2 | Substituted pyridazines as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| WO-2011114220-A1 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011113862-A1 | IMIDAZOPYRAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-22 | — | — | WO | disclosed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | disclosed |
| EP-1487428-B1 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010147836-A9 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010132839-A9 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2010132768-A9 | ANTIBACTERIAL DERIVATIVES OF SISOMICIN | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112602-A1 | ANALGESIC COMPOUNDS, COMPOSITIONS, AND USES THEREOF | GALLEON PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224269-A1 | Analgesic Compounds, Compositions, and Uses Thereof | GALLEON PHARMACEUTICALS, INC. | 2011-09-15 | — | — | US | disclosed |
| US-8017599-B2 | Sequence selective pyrrole and imidazole polyamide metallocomplexes | UNIVERSITY OF WESTERN SYDNEY (AU) | 2011-09-13 | — | — | US | disclosed |
| WO-2010132759-A9 | ANTIBACTERIAL DERIVATIVES OF DIBEKACIN | ACHAOGEN, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20110218103-A1 | Fluoroalkyl-substituted 2-amidobenzimidazoles | BAYER CROPSCIENCE AG (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2363419-A1 | Polymer product formed using raft agent | The University of Sydney (AU) | 2011-09-07 | — | — | EP | disclosed |
| US-8012965-B2 | e.g. 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N3-(5,7-ethano-5,7,8-trihydro-6-methyl-1,6-naphthyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine; angiogenesis inhibitor, antiproliferative agent | RIGEL PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110212966-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| CN-101193921-B | Carbon-bridged cyclopentadienyl-fluorenyl ligands | TOTAL PETROCHEMICALS RES FELUY | 2011-08-31 | — | — | CN | disclosed |
| US-8008325-B2 | Plasma carboxypeptidase B inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-30 | — | — | US | disclosed |
| WO-2011102807-A1 | A SUBSTRATE FOR IMMOBILIZING FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME | TEMASEK POLYTECHNIC (SG) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010132757-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201840-A1 | TERMINAL 1,1-DISUBSTITUTED ALKENES, METHOD OF MAKING AND USING THEREOF | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2011-08-18 | — | — | US | disclosed |
| EP-2355814-A2 | PYRONES FOR THE TREATMENT OF METABOLIC DISORDERS | Limerick BioPharma, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7999010-B2 | Indene derivatives as pharmaceutical agents | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-08-16 | — | — | US | disclosed |
| US-7999051-B2 | Furanone copolymers | TYCO HEALTHCARE GROUP LP (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110196088-A1 | POLYMER PRODUCT AND INTERFACIAL POLYMERISATION PROCESS USING RAFT AGENT | THE UNIVERSITY OF SYDNEY (AU) | 2011-08-11 | — | — | US | disclosed |
| US-20110195305-A1 | Organic electrolyte and lithium battery including the same | SAMSUNG SDI CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| EP-2203431-B1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LAB (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7994346-B2 | such as methyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate, useful in treating inflammatory and autoimmune disorders in humans | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-09 | — | — | US | disclosed |
| US-20110190566-A1 | POLYMER MICROGEL BEADS | UNIVERSITY OF SYDNEY (AU) | 2011-08-04 | — | — | US | disclosed |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2349236-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | Ikaria, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2350083-A1 | PYRIDO [5, 4-D]PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | disclosed |
| EP-2350052-A2 | ANTIPROLIFERATIVE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2350091-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | disclosed |
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-7989656-B2 | Biaryl carboxylic acid apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183986-A1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182670-A1 | SOIL REMEDIATION PROCESS | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-07-28 | — | — | US | disclosed |
| WO-2011091131-A2 | ESLICARBAZEPINE ACETATE AND ITS POLYMORPHS | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-07-28 | — | — | WO | disclosed |
| EP-2346508-A1 | HETEROCYCLIC KINASE INHIBITORS | Intellikine, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1534284-B1 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Valocor Therapeutics, Inc. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110177002-A1 | CYLIC POLYAMINES FOR BINDING PHOSPHATIDYLSERINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-21 | — | — | US | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| WO-2011085261-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085128-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110172126-A1 | LIBRARIES OF PEPTIDE CONJUGATES AND METHODS FOR MAKING THEM | XENOME LTD (AU) | 2011-07-14 | — | — | US | disclosed |
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-20110172258-A9 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| EP-2343294-A1 | Substituted triazolopyridines | Bayer Schering Pharma AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343297-A1 | Triazolopyridines | Bayer Schering Pharma AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343295-A1 | Triazolopyridine derivates | Bayer Schering Pharma AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-7977489-B2 | Benzylthiazolone inhibitors of estrogen-related receptors (ERR) | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110166298-A1 | CONDUCTING AND SEMICONDUCTING ORGANIC MATERIALS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL ORGANISATION (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166390-A1 | CARBON NANOHOOPS AND METHODS OF MAKING | LAWRENCE BERKELEY NATIONAL LABORATORY (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| EP-2340242-A2 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-2340271-A1 | POLYMER-BIOACTIVE AGENT CONJUGATES | The Bionic Ear Institute (AU) | 2011-07-06 | — | — | EP | disclosed |
| US-7973161-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973171-B2 | Process for synthesis of dialkoxyorganoboranes | BURKHARDT ELIZABETH | 2011-07-05 | — | — | US | disclosed |
| US-20110155996-A1 | BISTABLE CARBAZOLE COMPOUNDS | STMICROELECTRONICS S.R.L. (IT) | 2011-06-30 | — | — | US | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011076687-A1 | PYRIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-30 | — | — | WO | disclosed |
| EP-2337781-A2 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | Abbott Laboratories (US) | 2011-06-29 | — | — | EP | disclosed |
| CN-102112453-A | Novel potassium channel blockers and uses thereof | BIONOMICS LTD | 2011-06-29 | — | — | CN | disclosed |
| WO-2011075185-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS (US) | 2011-06-23 | — | — | WO | disclosed |
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-20110142757-A1 | NOVEL COMPOUNDS AND THEIR USES IN DIAGNOSIS | THE UNIVERSITY OF SYDNEY | 2011-06-16 | — | — | US | disclosed |
| US-20110144112-A9 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | EXELIXIS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144139-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2011-06-16 | — | — | US | disclosed |
| EP-2331556-A1 | BISTABLE CARBAZOLE COMPOUNDS | STMicroelectronics S.r.l. (IT) | 2011-06-15 | — | — | EP | disclosed |
| EP-2331514-A2 | CYCLIC POLYAMINES FOR BINDING PHOSPHATIDYLSERINE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-15 | — | — | EP | disclosed |
| EP-2203430-B1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LAB (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110137633-A1 | ANTI-VIRAL COMPOUNDS AND METHODS OF IDENTIFYING THE SAME | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2011066616-A1 | POLYMERIC MATERIALS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011066608-A1 | WATER SWELLABLE POLYMER MATERIALS | THE UNIVERSITY OF SYDNEY (AU) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136988-A1 | CONDENSATION POLYMERS WITH MODIFIED PROPERTIES | Commonwealth Scientific an dIndustrial Research Organisation (AU) | 2011-06-09 | — | — | US | disclosed |
| US-20110137057-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-06-09 | — | — | US | disclosed |
| US-7956185-B2 | Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases | ABBOTT LABORATORIES (US) | 2011-06-07 | — | — | US | disclosed |
| WO-2011065813-A1 | WATER CURABLE RESIN FORMULATIONS | PETROLIAM NASIONAL BERHAD (PETRONAS) (MY) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011064328-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011063907-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011063908-A1 | TRIAZOLOPYRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110129417-A1 | ADMINISTRABLE COMPOSITIONS | UNIVERSITY OF SYDNEY (AU) | 2011-06-02 | — | — | US | disclosed |
| EP-2326641-A2 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7951805-B2 | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase | XENON PHARMACEUTICALS INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| EP-2324012-A1 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2323986-A2 | HETOEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| CN-102076436-A | Soil remediation process | UNIV QUEENSLAND | 2011-05-25 | — | — | CN | disclosed |
| US-7947854-B2 | Phospholipase inhibitor; prevention or therapy of microbial infection; bactericides; fungicides; viricides; parasiticides; using quaternary or phosphonium group containing compounds | THE UNIVERSITY OF SYDNEY (AU) | 2011-05-24 | — | — | US | disclosed |
| US-7947733-B2 | Phosphorylated pyrone analogs and methods | LIMERICK BIOPHARMA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110118533-A1 | POLYMER MICROGEL BEADS AND PREPARATIVE METHOD THEREOF | UNIVERSITY OF SYDNEY (AU) | 2011-05-19 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| EP-2321299-A2 | PYRIDONS AS PDK1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20110112162-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-12 | — | — | US | disclosed |
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105481-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105511-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110105496-A1 | Methods For The Treatment Of Myosin Heavy Chain-Mediated Conditions Using 4,7-Dihydrothieno[2,3-B]Pyridine Compounds | GILEAD COLORADO, INC. | 2011-05-05 | — | — | US | disclosed |
| EP-2316458-A1 | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316457-A1 | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316827-A1 | Piperazine derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316825-A1 | Pyridyl derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316828-A1 | Piperazine derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316826-A1 | Pyridazine derivatives and their use as therapeutics agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| US-7935693-B2 | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935721-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-05-03 | — | — | US | disclosed |
| US-20110098274-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011047788-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011047795-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011047796-A1 | SUBSTITUTED HALOPHENOXYBENZAMIDE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | WO | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| US-20110098317-A1 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2314582-A1 | Heterocyclic compounds as antiviral agents | Biota Scientific Management Pty Ltd (AU) | 2011-04-27 | — | — | EP | disclosed |
| EP-2313414-A2 | KINASE INHIBITORS AND METHODS OF USE | Intellikine, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110092502-A1 | DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| US-7928255-B2 | Intermediates for the preparation of lipoxin A4 analogs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-19 | — | — | US | disclosed |
| WO-2011044501-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044498-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044502-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044503-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-2308812-A2 | N-acylsulfonamide apoptosis promoters | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2307379-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2307013-A1 | PAIN-RELIEVING COMPOSITIONS OF FUROXAN NO DONORS AND USES THEREOF | The University Of Queensland (AU) | 2011-04-13 | — | — | EP | disclosed |
| CN-102015750-A | 16 alpha, 17 beta-acetal glucocorticoid derivative and application thereof | ASTRAZENECA AB | 2011-04-13 | — | — | CN | disclosed |
| US-7923439-B2 | Hydroxamate compositions | TYCO HEALTHCARE GROUP LP (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| WO-2011039344-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039358-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| EP-1888592-B1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-04-06 | — | — | EP | disclosed |
| CN-101198615-B | Method for synthesizing dialkoxyorganoborane | BASF AG | 2011-04-06 | — | — | CN | disclosed |
| CN-102007124-A | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases | RIGEL PHARMACEUTICALS INC | 2011-04-06 | — | — | CN | disclosed |
| US-7919484-B2 | Combination therapy | XENON PHARMACEUTICALS INC. (CA) | 2011-04-05 | — | — | US | disclosed |
| US-7919496-B2 | 5-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]-[1,3,4]thiadiazole-2-carboxylic acid ethyl ester; metabolic disorders type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia and metabolic syndrome; cardiovascular disorders | XENON PHARMACEUTICALS INC. (CA) | 2011-04-05 | — | — | US | disclosed |
| US-20110073331-A1 | Ionic Liquid Flame Retardants | H & C Scientific Resources International, LLC | 2011-03-31 | — | — | US | disclosed |
| US-20110077252-A1 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE | Piramal Enterprises Limited (IN) | 2011-03-31 | — | — | US | disclosed |
| CN-101993451-A | Process for synthesis of dialkoxyorganoboranes | BASF SE | 2011-03-30 | — | — | CN | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2011-03-24 | — | — | US | disclosed |
| US-20110071158-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071133-A1 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7910742-B2 | Survivin inhibitors | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910755-B2 | Stem cell expansion and uses | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| WO-2011031745-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031743-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | PIRAMAL IMAGING SA (CH) | 2011-03-17 | — | — | US | disclosed |
| WO-2011031740-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031744-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| WO-2011026579-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-10 | — | — | WO | disclosed |
| US-20110060163-A1 | Process for Synthesis of Dialkoxyorganoboranes | BASF SE (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2291175-A1 | ADMINISTRABLE COMPOSITIONS | THE UNIVERSITY OF SYDNEY (AU) | 2011-03-09 | — | — | EP | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| EP-2289510-A1 | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes | Xenon Pharmaceuticals Inc. (CA) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20110044898-A1 | TRANSLOCATOR PROTEIN LIGANDS | UNIVERSITY OF SYDNEY (AU) | 2011-02-24 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| WO-2011022439-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| EP-2285882-A1 | POLYMER MICROGEL BEADS | THE UNIVERSITY OF SYDNEY (AU) | 2011-02-23 | — | — | EP | disclosed |
| EP-2287167-A1 | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2011-02-23 | — | — | EP | disclosed |
| EP-2285784-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth LLC (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2285881-A1 | POLYMER MICROGEL BEADS AND PREPARATIVE METHOD THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2011-02-23 | — | — | EP | disclosed |
| WO-2011019737-A1 | PYRIMIDO-PYRROLO-QUINOXALINEDIONE INHIBITORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20110039467-A1 | Ionic liquid flame retardants | H&C Chemical (US) | 2011-02-17 | — | — | US | disclosed |
| EP-1615866-B1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC (CA) | 2011-02-16 | — | — | EP | disclosed |
| EP-2282981-A1 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-16 | — | — | EP | disclosed |
| US-20110034500-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-02-10 | — | — | US | disclosed |
| EP-1379508-B9 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-02-09 | — | — | EP | disclosed |
| US-7884119-B2 | protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20110028437-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2011014888-A1 | NOVEL HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS (US) | 2011-02-03 | — | — | WO | disclosed |
| EP-2279174-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-7879856-B2 | 5-(quinoxalin-2-yl)-N2-(3,4,5-trimethoxyphenyl)thiazole-2,4-diamine; useful in inhibiting the activity of the receptor protein tyrosine kinase Axl; rheumatoid arthritis, vascular disease, vascular injury, psoriasis, visual impairment due to macular degeneration, diabetic retinopathy, retinopathy | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20110021577-A1 | ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS | HOWARD FLOREY INSTITUTE (AU) | 2011-01-27 | — | — | US | disclosed |
| US-20110020731-A1 | POLYMER ELECTROLYTE COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20110021563-A1 | INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS AND USES THEREOF | HOWARD FLOREY INSTITUTE (AU) | 2011-01-27 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| EP-2277848-A1 | Indene derivatives as pharmaceutical agents | Aquinox Pharmaceuticals Inc. (CA) | 2011-01-26 | — | — | EP | disclosed |
| EP-1697377-B1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENT MANAGEMENT (AU) | 2011-01-26 | — | — | EP | disclosed |
| EP-2094663-B1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-01-26 | — | — | EP | disclosed |
| EP-1572660-B1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| WO-2011008302-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011006208-A1 | ANTI -INFLUENZA AGENTS | GRIFFITH UNIVERSITY (AU) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011006621-A1 | RADIOLABELLING METHOD USING CYCLOALKYL GROUPS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | disclosed |
| US-7872000-B2 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20110009439-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-01-13 | — | — | US | disclosed |
| US-20110009414-A9 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-13 | — | — | US | disclosed |
| EP-1827438-B1 | PYRIDINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC (CA) | 2011-01-12 | — | — | EP | disclosed |
| CN-101945851-A | Peptidyl nitriles and their use as dipeptidyl peptidase I inhibitors | ASTRAZENECA AB | 2011-01-12 | — | — | CN | disclosed |
| US-20110003895-A1 | Pharmacology of Visual Cycle Modulators | ACUCELA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003740-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | VERVA PHARMACEUTICALS LTD. (AU) | 2011-01-06 | — | — | US | disclosed |
| WO-2011003103-A2 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| EP-2269610-A2 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270104-A1 | POLYMER ELECTROLYTE COMPOSITION | Sumitomo Chemical Company, Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7863298-B2 | Bridged ring structures as pharmaceutical agents | EXELIXIS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330155-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | FLAGSHIP VENTURES (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2266566-A2 | Nicotinamide derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265607-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | Rigel Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266569-A2 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265654-A1 | POLYURETHANES | Commonwealth Scientific and Industrial Research Organisation (AU) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265661-A1 | CONDENSATION POLYMERS WITH MODIFIED PROPERTIES | Commonwealth Scientific and Industrial Research Organisation (AU) | 2010-12-29 | — | — | EP | disclosed |
| US-7858827-B2 | Process for synthesis of dialkoxyorganoboranes | BASF SE (DE) | 2010-12-28 | — | — | US | disclosed |
| WO-2010147836-A1 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100323981-A1 | TREATMENT OF STATIN SIDE EFFECTS | MAGRAL LIMITED (AU) | 2010-12-23 | — | — | US | disclosed |
| EP-2078723-B1 | Process for synthesis of organo-oxazaborolidines | BASF SE (DE) | 2010-12-22 | — | — | EP | disclosed |
| EP-2262797-A1 | INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS AND USES THEREOF | Howard Florey Institute (AU) | 2010-12-22 | — | — | EP | disclosed |
| CN-101925584-A | Pyrimidine Derivatives for the Treatment of Asthma, COPD, Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis, Cancer, Hepatitis B, Hepatitis C, HIV, HPV, Bacterial Infections and Skin Diseases | ASTRAZENECA AB | 2010-12-22 | — | — | CN | disclosed |
| WO-2010144059-A2 | NOVEL USES | NANYANG POLYTECHNIC (SG) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144055-A1 | NOVEL COMPOUNDS AND USES THEREOF | NANYANG POLYTECHNIC (SG) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144646-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144468-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2010-12-16 | — | — | US | disclosed |
| CN-101917980-A | Amine derivative compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2010-12-15 | — | — | CN | disclosed |
| CN-101918369-A | Uracil or thymine derivatives for the treatment of hepatitis C | ABBOTT LAB | 2010-12-15 | — | — | CN | disclosed |
| US-20100311763-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | NOVARTIS PHARMA AG (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311721-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| EP-2257291-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | Xenon Pharmaceuticals Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| US-7847101-B2 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | Valocor Therapeutics, Inc. (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20100305099-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305138-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-12-02 | — | — | US | disclosed |
| WO-2010136559-A1 | 2, 4 -DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-7842661-B2 | Glycopegylated erythropoietin formulations | NOVO NORDISK A/S (DK) | 2010-11-30 | — | — | US | disclosed |
| US-7842743-B2 | Stabiliser composition for halide-containing polymers | SUN ACE KAKOH (PTE.) LTD. (SG) | 2010-11-30 | — | — | US | disclosed |
| US-7842681-B2 | Treatment of myeoproliferative diseases | ABBOTT LABORATORIES (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100297508-A1 | Organic electrolytic solution and lithium battery employing the same | SAMSUNG SDI CO., LTD. (KR) | 2010-11-25 | — | — | US | disclosed |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | DYNAMIS THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132765-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132770-A1 | TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132777-A2 | TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132839-A2 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132760-A1 | ANTIBACTERIAL DERIVATIVES OF TOBRAMYCIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132759-A1 | ANTIBACTERIAL DERIVATIVES OF DIBEKACIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132757-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292177-A1 | Methods of treatment using combination therapy | AMBIT BIOSCIENCES CORP. | 2010-11-18 | — | — | US | disclosed |
| US-20100292342-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2010-11-18 | — | — | US | disclosed |
| WO-2010132352-A2 | SPIRO COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132768-A1 | ANTIBACTERIAL DERIVATIVES OF SISOMICIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2250171-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | Achaogen, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| CN-101888989-A | Novel aryl potassium channel blockers and uses thereof | BIONOMICS LTD | 2010-11-17 | — | — | CN | disclosed |
| CN-101889017-A | Alkoxy compounds for the treatment of diseases | ACUCELA INC | 2010-11-17 | — | — | CN | disclosed |
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-11-11 | — | — | US | disclosed |
| WO-2007143597-A9 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285374-A1 | Electrolytic solution and lithium battery employing the same | SAMSUNG SDI CO., LTD. (KR) | 2010-11-11 | — | — | US | disclosed |
| WO-2010129816-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-1996217-B1 | NOVEL ANTIBIOTIC COMPOSITIONS | CAMBRIDGE ENTPR LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| CN-101883778-A | Steroidal [3, 2-C] pyrazole compounds, with glucocorticoid activity | ASTRAZENECA AB | 2010-11-10 | — | — | CN | disclosed |
| US-7829712-B2 | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase | XENON PHARMACEUTICALS INC. (CA) | 2010-11-09 | — | — | US | disclosed |
| US-20100279311-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100280012-A1 | AZAAZULENE COMPOUNDS | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2010-11-04 | — | — | US | disclosed |
| US-20100280061-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BARBIER LINDSAY BURNS | 2010-11-04 | — | — | US | disclosed |
| US-20100279996-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BARBIER LINDSAY BURNS | 2010-11-04 | — | — | US | disclosed |
| US-20100280057-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BURNS BARBIER LINDSAY | 2010-11-04 | — | — | US | disclosed |
| US-20100279997-A1 | ANALGESIC THAT BINDS FILAMIN A | PAIN THERAPEUTICS | 2010-11-04 | — | — | US | disclosed |
| WO-2010124648-A1 | AZAAZULENE COMPOUNDS | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (CN) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | disclosed |
| EP-1916889-B1 | METHODS OF ALTERING POPPY CHARACTERISTICS | GLAXOSMITHKLINE AUSTRALIA PTY (AU) | 2010-11-03 | — | — | EP | disclosed |
| EP-2029572-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010123997-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-7820657-B2 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2010118471-A1 | REACTOR AND METHOD FOR PERFORMING A CHEMICAL REACTION | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010118575-A1 | RACEMIC ENANTIOMERS RESOLUTING | CHENGDU ORGANIC CHEMICALS CO., LTD, CHINESE ACADEMY OF SCIENCE (CN) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-2240451-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Intellikine, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-2240452-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Intellikine, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256105-A1 | NOVEL COMPOUNDS | ASTRAZENECA R&D | 2010-10-07 | — | — | US | disclosed |
| US-20100256104-A1 | NOVEL AMIDE COMPOUNDS | ASTRAZENECA R&D (SE) | 2010-10-07 | — | — | US | disclosed |
| WO-2010111172-A1 | METHODS OF TREATMENT USING COMBINATION THERAPY | AMBIT BIOSCIENCES CORPORATION (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-2231620-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | Boehringer Ingelheim International GmbH (DE) | 2010-09-29 | — | — | EP | disclosed |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-23 | — | — | US | disclosed |
| WO-2010106097-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-20100240715-A1 | Apoptosis promoters | ABBOTT LABORATORIES | 2010-09-23 | — | — | US | disclosed |
| US-20100240536-A1 | PYRIMIDIN-4-YLPROPANEDINITRILE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240657-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240713-A1 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-23 | — | — | US | disclosed |
| EP-2229813-A1 | Pyrimidine-4-ylpropandinitrile derivatives, method for their manufacture and their use as herbicides and plant growth regulators | Bayer CropScience AG (DE) | 2010-09-22 | — | — | EP | disclosed |
| CN-101842360-A | Anti-infective pyrimidines and uses thereof | ABBOTT LAB | 2010-09-22 | — | — | CN | disclosed |
| US-7799798-B2 | Spiroheterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-09-21 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| US-20100234456-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-09 | — | — | US | disclosed |
| EP-2226632-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010096867-A1 | POLYMER PARTICLES | THE UNIVERSITY OF SYDNEY (AU) | 2010-09-02 | — | — | WO | disclosed |
| US-20100222303-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-02 | — | — | US | disclosed |
| WO-2010099379-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-2222682-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1379508-B1 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010094695-A1 | PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010096619-A1 | PROCESS, PURIFICATION AND CRYSTALLIZATION OF 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | WYETH LLC (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210644-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100209345-A1 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION | 2010-08-19 | — | — | US | disclosed |
| WO-2010093607-A1 | COMPOUNDS AND METHODS FOR INHIBITING MMP2 AND MMP9 | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010091472-A1 | SKIN TREATMENT | PEPLIN RESEARCH PTY LTD (AU) | 2010-08-19 | — | — | WO | disclosed |
| US-20100210630-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | ESTRELLITA PHARMACEUTICALS, LLC | 2010-08-19 | — | — | US | disclosed |
| EP-2217265-A2 | MODIFIED INSULIN POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2217610-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7777036-B2 | Heterocyclic derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-08-17 | — | — | US | disclosed |
| US-7777076-B2 | Macrocyclic inhibitors of BCL proteins | ABBOTT LABORATORIES (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100204318-A1 | TREATMENT OF VIRALLY INDUCED LESIONS | PEPLIN RESEARCH PTY LTD (AU) | 2010-08-12 | — | — | US | disclosed |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-08-12 | — | — | US | disclosed |
| CN-101801935-A | Uracil or thymine derivatives for the treatment of hepatitis C | ABBOTT LAB | 2010-08-11 | — | — | CN | disclosed |
| CN-101801375-A | Insulin sensitisers and methods of treatment | VERVA PHARMACEUTICALS LTD | 2010-08-11 | — | — | CN | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197501-A1 | SUBSTITUTED 1-(THIAZOLYL)-AND 1-(ISOTHIAZOLYL)PYRAZOL-4-YLACETIC ACIDS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2010-08-05 | — | — | US | disclosed |
| EP-2212330-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | disclosed |
| EP-2212329-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | disclosed |
| EP-2212328-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | disclosed |
| US-7767684-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767677-B2 | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2010-08-03 | — | — | US | disclosed |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| EP-2210892-A2 | Neurologically-active compounds | Prana Biotechnology Limited (AU) | 2010-07-28 | — | — | EP | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763618-B2 | 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; inhibitors of stearoyl-CoA desaturase; cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2010-07-27 | — | — | US | disclosed |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100183743-A1 | BENZTHIAZOLE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010083465-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100184607-A1 | MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR | ALCHEMIA PTY LTD. (AU) | 2010-07-22 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| CN-101784188-A | Alkynyl phenyl derivative compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2010-07-21 | — | — | CN | disclosed |
| US-7759348-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-07-20 | — | — | US | disclosed |
| EP-2205600-A1 | CARBACEPHEM ß -LACTAM ANTIBIOTICS | Achaogen, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2205592-A1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7754711-B2 | Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders | XENON PHARMACEUTICALS INC. (CA) | 2010-07-13 | — | — | US | disclosed |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
| EP-2204373-A1 | Phosphonic acid as Plasma Carboxypeptidase B Inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-07-07 | — | — | EP | disclosed |
| EP-2203431-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7750004-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010072734-A2 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2010-07-01 | — | — | WO | disclosed |
| US-20100168416-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168170-A1 | Piperidinones Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168384-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168138-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168167-A1 | Piperidinones Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-7744889-B2 | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745553-B2 | Aqueous dispersions of polymer particles | UNIVERSITY OF SYDNEY (AU) | 2010-06-29 | — | — | US | disclosed |
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| WO-2010040345-A9 | ECDYSONE DERIVATIVES AND THE USE THEREOF | VERDEVITAL BERATUNGS-, IMPORT- UND VERTRIEBSGESELLSCHAFT MBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| US-20100160355-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160164-A1 | SUBSTITUTED 1-(DIAZINYL)PYRAZOL-4-YLACETIC ACIDS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100152220-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | disclosed |
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | disclosed |
| CN-101742996-A | Treatment of viral-induced lesions | PEPLIN RESEARCH PTY LTD | 2010-06-16 | — | — | CN | disclosed |
| US-7737159-B2 | Antibacterial compounds | ABBOTT LABORATORIES (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737145-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | ESTRELLITA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| US-20100144665-A1 | TREATMENT OF STATIN SIDE EFFECTS | MAGRAL LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| EP-2194052-A1 | Substituted 1.(1-thiazolyl)- and 1-(isothiazolyl)pyrazol-4-yl acetic acids, method for their production and their use as herbicides and plant growth regulators | Bayer CropScience AG (DE) | 2010-06-09 | — | — | EP | disclosed |
| CN-101723949-A | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENT MAN | 2010-06-09 | — | — | CN | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| WO-2010058030-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010058032-A2 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059593-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS | INTELLIKINE, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130487-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-27 | — | — | US | disclosed |
| US-20100130713-A1 | FURANONE COPOLYMERS | COVIDIEN LP | 2010-05-27 | — | — | US | disclosed |
| US-20100130555-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | IKARIA, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010056644-A1 | 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS | WYETH LLC (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055117-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056979-A1 | PHENOTHIAZINE DERIVATIVES FOR TREATMENT OF ASTHMA | IMMUNE CONTROL, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010053998-A1 | SPIRO-CONDENSED INDOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS, INC. (CA) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120779-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119695-A1 | ANTIMICROBIAL MATERIALS AND COATINGS | COVIDIEN LP | 2010-05-13 | — | — | US | disclosed |
| EP-2182957-A2 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | Limerick BioPharma, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-2182801-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | Limerick BioPharma, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010051497-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051374-A1 | ANALGESIC THAT BINDS FILAMIN A | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010051476-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-2181108-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | Boehringer Ingelheim International GmbH (DE) | 2010-05-05 | — | — | EP | disclosed |
| US-7709482-B2 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20100105685-A1 | S-Nitrosothiol Compounds and Related Derivatives | GALLEON PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
| WO-2010048332-A2 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
| US-20100099728-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-04-22 | — | — | US | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2010045197-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045582-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | IKARIA, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177226-A1 | Hydroxamate compositions | Tyco Healthcare Group LP (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-2177554-A2 | Hydroxamate-initiated polymers | Tyco Healthcare Group LP (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-2176249-A2 | NEW CHEMICAL COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-04-21 | — | — | EP | disclosed |
| EP-2177552-A1 | Bioabsorbable surgical composition | Tyco Healthcare Group LP (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-2177235-A2 | Coating compositions | Tyco Healthcare Group LP (US) | 2010-04-21 | — | — | EP | disclosed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010040187-A1 | POLYMER-BIOACTIVE AGENT CONJUGATES | THE BIONIC EAR INSTITUTE (AU) | 2010-04-15 | — | — | WO | disclosed |
| US-20100093846-A1 | HYDROXAMATE COMPOSITIONS | TYCO HEALTHCARE GROUP LP | 2010-04-15 | — | — | US | disclosed |
| WO-2010040345-A2 | ECDYSONE DERIVATIVES AND THE USE THEREOF | VERDEVITAL BERATUNGS-, IMPORT- UND VERTRIEBSGESELLSCHAFT MBH (DE) | 2010-04-15 | — | — | WO | disclosed |
| US-20100094338-A1 | HYDROXAMATE-INITIATED POLYMERS | TYCO HEALTHCARE GROUP LP | 2010-04-15 | — | — | US | disclosed |
| US-20100092533-A1 | Bioabsorbable Surgical Composition | COVIDIEN LP | 2010-04-15 | — | — | US | disclosed |
| US-20100094340-A1 | COATING COMPOSITIONS | TYCO HEALTHCARE GROUP LP | 2010-04-15 | — | — | US | disclosed |
| WO-2010042851-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042886-A2 | PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042850-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-2173734-A2 | CHEMICAL COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-04-14 | — | — | EP | disclosed |
| US-20100087443-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | US | disclosed |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-04-08 | — | — | US | disclosed |
| WO-2010037169-A1 | PROCESS FOR EXTRACTION OF MINED MATERIAL | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-04-08 | — | — | WO | disclosed |
| EP-2172457-A2 | Fredericamycin derivatives | Biofrontera Discovery Gmbh (DE) | 2010-04-07 | — | — | EP | disclosed |
| EP-2170884-A2 | CHEMICAL COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172491-A1 | Polymer obtained by the use of RAFT-agents and process of encapsulating of particulate material by said polymer. | The University of Sydney (AU) | 2010-04-07 | — | — | EP | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| WO-2010036380-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034838-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| EP-2167465-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Boehringer Ingelheim International GmbH (DE) | 2010-03-31 | — | — | EP | disclosed |
| CN-101686665-A | styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC | 2010-03-31 | — | — | CN | disclosed |
| WO-2009141090-A9 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-25 | — | — | WO | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-1755373-B1 | METHOD OF ALTERING THE ALKALOID COMPOSITION IN POPPY PLANTS | GLAXOSMITHKLINE AUSTRALIA PTY (AU) | 2010-03-24 | — | — | EP | disclosed |
| WO-2010030811-A2 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010028836-A1 | BISTABLE CARBAZOLE COMPOUNDS | STMICROELECTRONICS S.R.L. (IT) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030810-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030727-A1 | 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030704-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030967-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100059363-A1 | SURFACE TREATMENT OF ALUMINA FILMS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2010-03-11 | — | — | US | disclosed |
| US-20100061982-A1 | 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2010026262-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| EP-2160192-A1 | ANTIMICROBIAL MATERIALS AND COATINGS | Tyco Healthcare Group LP (US) | 2010-03-10 | — | — | EP | disclosed |
| EP-2160193-A1 | FURANONE COPOLYMERS | Tyco Healthcare Group LP (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7674569-B2 | Optical recording material and optical recording medium | ADEKA CORPORATION (JP) | 2010-03-09 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7671054-B1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-02 | — | — | US | disclosed |
| WO-2010020008-A1 | POLYMER COATINGS | POLYMERS CRC LIMITED (AU) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048750-A1 | VESICULATED POLYMER PARTICLES | THE UNIVERSITY OF SYDNEY (AU) | 2010-02-25 | — | — | US | disclosed |
| US-20100048584-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| US-20100041613-A1 | NOVEL ANTIBIOTIC COMPOSITIONS | CAMBRIDGE ENTERPRISE LTD. (GB) | 2010-02-18 | — | — | US | disclosed |
| EP-2152261-A1 | TREATMENT OF VIRALLY INDUCED LESIONS | Peplin Research Pty Ltd. (AU) | 2010-02-17 | — | — | EP | disclosed |
| US-20100036123-A1 | PROCESS FOR THE PREPARATION OF 2,4-DICHLORO-7H-PYRROLO[2,3H]QUINAZOLINE | WYETH (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| WO-2010015037-A1 | THERAPEUTIC METHODS AND COMPOSITIONS | HOWARD FLOREY INSTITUTE (AU) | 2010-02-11 | — | — | WO | disclosed |
| US-20100028368-A1 | SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029686-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029718-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2010-02-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2010012747-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
| US-20100021458-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022557-A1 | RADIOPROTECTOR COMPOUNDS AND RELATED METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2010-01-28 | — | — | US | disclosed |
| WO-2010011620-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-2147919-A1 | Heterocyclic substituted amides, method for their manufacture and their use as herbicides | Bayer CropScience Aktiengesellschaft (DE) | 2010-01-27 | — | — | EP | disclosed |
| WO-2010007116-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
| US-20100015136-A1 | CAMPTOTHECIN-PEPTIDE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DIATOS, S.A. (FR) | 2010-01-21 | — | — | US | disclosed |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2010007114-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010006755-A2 | A COMPOUND FOR IMAGING CELL DEATH | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-21 | — | — | WO | disclosed |
| EP-1675812-B1 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2010-01-20 | — | — | EP | disclosed |
| CN-101631788-A | 8-alkynyl xanthine and derivative | SANOL ARZNEI SCHWARZ GMBH | 2010-01-20 | — | — | CN | disclosed |
| CN-100582109-C | Polycyclic agents for the treatment of respiratory syncytial virus infection | BIOTA SCIENT MAN | 2010-01-20 | — | — | CN | disclosed |
| US-7648966-B2 | Mannose-6-phosphonate compounds for the treatment of inflammatory diseases | Pharmaxis Pty Limited (AU) | 2010-01-19 | — | — | US | disclosed |
| WO-2010005876-A2 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005851-A1 | COMBINATION THERAPY FOR TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010006086-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-7645760-B2 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG. (CH) | 2010-01-12 | — | — | US | disclosed |
| WO-2010000019-A1 | PAIN-RELIEVING COMPOSITIONS OF FUROXAN NO DONORS AND USES THEREOF | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010000008-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2010-01-07 | — | — | WO | disclosed |
| US-20100004333-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS | STOCKER ROLAND O | 2010-01-07 | — | — | US | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2139894-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | AstraZeneca AB (SE) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141163-A1 | Substituted thiazolidinones, their production and utilisation as medicine | Bayer Schering Pharma AG (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326017-A1 | PAIN-RELIEVING COMPOSITIONS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-12-31 | — | — | US | disclosed |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009156484-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| EP-2137150-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2009-12-30 | — | — | EP | disclosed |
| EP-2135865-A1 | Substituted 1-(diazinyl)pyrazol-4-yl acetic acids, method for their production and their use as herbicides and plant growth regulators | Bayer CropScience AG (DE) | 2009-12-23 | — | — | EP | disclosed |
| EP-2134723-A1 | 9H- PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | Boehringer Ingelheim International GmbH (DE) | 2009-12-23 | — | — | EP | disclosed |
| EP-2134686-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2009-12-23 | — | — | EP | disclosed |
| US-20090312260-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| WO-2009151920-A2 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090312272-A1 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; AND THE WASHINGTON UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
| US-20090311176-A1 | 2-Arylpyrazolo[L,5-Alpha] Pyrimidin-3-YL Acetamide Derivatives as Ligands for Translocator Protein (18 Kda) | THE UNIVERSITY OF SYDNEY (AU) | 2009-12-17 | — | — | US | disclosed |
| US-7632946-B2 | Naphthyridine-based antibacterial compositions | ABBOTT LABORATORIES (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306373-A1 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | GILEAD COLORADO, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306090-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-12-10 | — | — | US | disclosed |
| CN-100567271-C | 4,4 ' (5 ')-di-t-butyl hexamethylene also-the improvement purification process of hexaoxacyclooctadecane-6-6 | PG RES FOUNDATION (US) | 2009-12-09 | — | — | CN | disclosed |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-03 | — | — | US | disclosed |
| US-7625579-B2 | Antimicrobial coatings | UNISEARCH LIMITED (AU) | 2009-12-01 | — | — | US | disclosed |
| WO-2009141090-A1 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090291957-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| EP-2121671-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121621-A1 | LXR AND FXR MODULATORS | Exelixis, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121608-A1 | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma AG (DE) | 2009-11-25 | — | — | EP | disclosed |
| EP-2123620-A1 | {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009137888-A1 | POLYMER MICROGEL BEADS AND PREPARATIVE METHOD THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009137890-A1 | ADMINISTRABLE COMPOSITIONS | THE UNIVERSITY OF SYDNEY (AU) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009137889-A1 | POLYMER MICROGEL BEADS | THE UNIVERSITY OF SYDNEY (AU) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286835-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| CN-101583614-A | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENT MAN (AU) | 2009-11-18 | — | — | CN | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| WO-2009137130-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2114896-A1 | RADIOPROTECTOR COMPOUNDS AND RELATED METHODS | Peter MacCallum Cancer Institute (AU) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114954-A1 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009133045-A1 | NEW BORANE-AMINE COMPLEXES AND THEIR APPLICATION IN SUZUKI-TYPE CROSS -COUPLING REACTIONS | BASF SE (DE) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275557-A1 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes | IMMUNE CONTROL, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| EP-2111223-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009127011-A1 | MODIFIED CONDENSATION POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127009-A1 | CONDENSATION POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127012-A1 | POLYURETHANES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127010-A1 | CONDENSATION POLYMERS WITH MODIFIED PROPERTIES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2009-10-22 | — | — | WO | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-7605161-B2 | 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; inhibitors of stearoyl-CoA desaturase; cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2009-10-20 | — | — | US | disclosed |
| US-7605150-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258979-A1 | POLYMER PRODUCT AND INTERFACIAL POLYMERISATION PROCESS USING RAFT AGENT | THE UNIVERSITY OF SYDNEY (AU) | 2009-10-15 | — | — | US | disclosed |
| US-20090256111-A1 | DIALKYLBORANE AMINE COMPLEXES | BASF SE PATENTS, TRADEMARKS AND LICENSES (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| CN-101558065-A | Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2009-10-14 | — | — | CN | disclosed |
| US-7601874-B2 | Antiinflammatory agents; antiarthritic agents; brain disorders; multiple sclerosis; gout; inflammatory bowel disorders; gastrointestinal disorders; psoriasis; antiallergens; autoimmune disease | AQUINOX PHARMACEUTICALS INC. (CA) | 2009-10-13 | — | — | US | disclosed |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| EP-2106260-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | Verva Pharmaceuticals Ltd (AU) | 2009-10-07 | — | — | EP | disclosed |
| US-7598401-B2 | Multifunctional cationic photoinitiators, their preparation and use | SUN CHEMICAL CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598232-B2 | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2104659-A1 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USES THEREOF | AndroScience Corporation (US) | 2009-09-30 | — | — | EP | disclosed |
| CN-101547703-A | S-nitrosothiol compounds and related derivatives | GALLEON PHARMACEUTICALS INC (US) | 2009-09-30 | — | — | CN | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009114981-A1 | PROCESS FOR PREPARING SULFOXIDE COMPOUNDS | CHENGDU LIKAI CHIRAL TECH CO., LTD (CN) | 2009-09-24 | — | — | WO | disclosed |
| EP-2101765-A1 | USE OF EPOTHILONES IN THE TREATMENT OF OSTEOPOROSIS AND RELATED DISEASES | Bayer Schering Pharma AG (DE) | 2009-09-23 | — | — | EP | disclosed |
| US-7592343-B2 | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2009-09-22 | — | — | US | disclosed |
| WO-2009111830-A1 | CONJUGATED UNSATURATED COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2009-09-17 | — | — | WO | disclosed |
| CN-101535317-A | Dialkylborane amine complexes | BASF SE (DE) | 2009-09-16 | — | — | CN | disclosed |
| EP-1519724-B1 | FREDERICAMYCIN DERIVATIVES AS MEDICAMENTS FOR TREATING TUMOURS | ZENTOPHARM GMBH (DE) | 2009-09-09 | — | — | EP | disclosed |
| CN-101528226-A | Fluorinated ligands targeting peripheral benzodiazepine receptors | AUSTRALIAN NUCLEAR SCIENCE TEC (AU) | 2009-09-09 | — | — | CN | disclosed |
| US-20090221624-A1 | 4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | OLIVO PAUL D | 2009-09-03 | — | — | US | disclosed |
| WO-2009106991-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-09-03 | — | — | WO | disclosed |
| US-20090220554-A1 | Transglutaminase Inhibitors and Methods of Use Thereof | PHARMIX CORPORATION | 2009-09-03 | — | — | US | disclosed |
| EP-1838714-A4 | METHODS OF TREATING PAIN | UNIV QUEENSLAND (AU) | 2009-09-02 | — | — | EP | disclosed |
| EP-1893622-B1 | PROCESS FOR SYNTHESIS OF DIALKOXYORGANOBORANES | BASF SE (DE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009103360-A1 | POLYISOPRENOID EPOXIDES USEFUL FOR DECREASING CHOLESTEROL AND/OR INCREASING COENZYME Q BIOSYNTHESIS | NEWBIOTECHNIC, S.A. (ES) | 2009-08-27 | — | — | WO | disclosed |
| US-20090215884-A1 | METHOD FOR WOUND HEALING | PEPLIN RESEARCH PTY LTD. (AU) | 2009-08-27 | — | — | US | disclosed |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1802662-A4 | SURFACE POLYMERISATION PROCESS AND POLYMER PRODUCT USING RAFT AGENT | UNIV SYDNEY (AU) | 2009-08-26 | — | — | EP | disclosed |
| EP-2093222-A1 | Polyisoprenoid epoxides useful for decreasing cholesterol and/or increasing coenzyme Q biosynthesis | NEWBIOTECHNIC, S.A. (ES) | 2009-08-26 | — | — | EP | disclosed |
| EP-1539700-B1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LTD (AU) | 2009-08-26 | — | — | EP | disclosed |
| US-7579313-B2 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579465-B2 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGMENT PTY. LTD. (AU) | 2009-08-25 | — | — | US | disclosed |
| WO-2009103032-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090209577-A1 | Novel Triazolopyridine Compounds | PFIZER INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| EP-1628987-B1 | MANNOSE-6-PHOSPHONATE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | PHARMAXIS PTY LTD (AU) | 2009-08-19 | — | — | EP | disclosed |
| CN-101511853-A | Preparation of diphenyl-bridged substituted cyclopentadienyl-fluorenyl ligands | TOTAL PETROCHEMICALS RES FELUY (BE) | 2009-08-19 | — | — | CN | disclosed |
| US-20090203728-A1 | Naphthalamide derivatives having antiproliferative activity | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-08-13 | — | — | US | disclosed |
| EP-2086970-A2 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | Novartis AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| EP-1996217-A4 | NOVEL ANTIBIOTIC COMPOSITIONS | INFLAZYME PHARM LTD (CA) | 2009-08-12 | — | — | EP | disclosed |
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | disclosed |
| US-20090197890-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | disclosed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | disclosed |
| US-20090197870-A1 | Pharmaceutical Compositions | EXELIXIS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090191284-A1 | USE OF NITROANILINE DERIVATIVES FOR THE PRODUCTION OF NITRIC OXIDE | STMICROELECTRONICS S.R.I. (IT) | 2009-07-30 | — | — | US | disclosed |
| US-20090191579-A1 | ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A | PAIN THERAPEUTICS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186901-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186802-A1 | Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell | DIATOS (FR) | 2009-07-23 | — | — | US | disclosed |
| EP-2079736-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-2079737-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-22 | — | — | EP | disclosed |
| EP-1503988-B1 | FREDERICAMYCIN DERIVATIVES | BIOFRONTERA DISCOVERY GMBH (DE) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009088990-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009088986-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090182337-A1 | Antimicrobial Coatings | TYCO HEALTHCARE GROUP LP | 2009-07-16 | — | — | US | disclosed |
| US-20090182133-A1 | BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL AGENTS | SINGAPORE POLYTECHNIC | 2009-07-16 | — | — | US | disclosed |
| EP-1794172-B1 | ANTIVIRAL 4'-AZIDO-NUCLEOSIDES | HOFFMANN LA ROCHE (CH) | 2009-07-15 | — | — | EP | disclosed |
| EP-2078010-A2 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-2078723-A1 | Process for synthesis of organo-oxazaborolidines | BASF SE (DE) | 2009-07-15 | — | — | EP | disclosed |
| EP-1740587-A4 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| EP-2076124-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2076514-A1 | SPIRO (FURO Ý3, 2-C¨PYRIDINE-3-3 ' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2009-07-08 | — | — | EP | disclosed |
| EP-2076122-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2076518-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-08 | — | — | EP | disclosed |
| US-7557118-B2 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2009-07-07 | — | — | US | disclosed |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1507549-A4 | DRUG THERAPY FOR CELIAC SPRUE | UNIV LELAND STANFORD JUNIOR (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-2074115-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-2073806-A2 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163373-A1 | Method of Drug Design | ALCHEMIA LIMITED (AU) | 2009-06-25 | — | — | US | disclosed |
| WO-2009076598-A1 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156615-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-2069353-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2009-06-17 | — | — | EP | disclosed |
| EP-2068855-A2 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-06-17 | — | — | EP | disclosed |
| US-7547698-B2 | Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD) | XENON PHARMACEUTICALS INC. (CA) | 2009-06-16 | — | — | US | disclosed |
| WO-2009071535-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2066664-A1 | HETEROCYCLIC ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| EP-1869022-A4 | NAPHTHALAMIDE DERIVATIVES HAVING ANTIPROLIFERATIVE ACTIVITY | AGENCY SCIENCE TECH & RES (SG) | 2009-06-10 | — | — | EP | disclosed |
| US-20090143417-A1 | METHODS OF TREATING PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-06-04 | — | — | US | disclosed |
| WO-2009070516-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090138041-A1 | Halogenated Cyclic Lactones and Polymers Made Therefrom | TYCO HEALTHCARE GROUP LP | 2009-05-28 | — | — | US | disclosed |
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAYZME PHARMACEUTICALS LTD. (CA) | 2009-05-28 | — | — | US | disclosed |
| WO-2009067636-A2 | MODIFIED INSULIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009065169-A1 | INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS AND USES THEREOF | HOWARD FLOREY INSTITUTE (AU) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067692-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-2061560-A2 | BCL INHIBITORS FOR TREATING PLATELET EXCESS | Abbott Laboratories (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| EP-2061755-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| CN-101443334-A | Anti-viral compounds | ABBOTT LAB (US) | 2009-05-27 | — | — | CN | disclosed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | disclosed |
| EP-2059496-A1 | ACETYLENIC COMPOUNDS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2009-05-20 | — | — | EP | disclosed |
| EP-2056816-A2 | LIPOXIN A4 ANALOGS FOR THE TREATMENT AND PREVENTION OF INTESTINAL FIBROSIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009059225-A2 | ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A | PAIN THERAPEUTICS, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090118455-A1 | SILOXANE-CONTAINING POLYURETHANE-UREA COMPOSITIONS | AORTECH BIOMATERIAL PTY LTD. | 2009-05-07 | — | — | US | disclosed |
| WO-2009055869-A1 | ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS | HOWARD FLOREY INSTITUTE (AU) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-7528173-B2 | Plasma carboxypeptidase B inhibitors | SCHERING AKTIENGESELLSHAFT (DE) | 2009-05-05 | — | — | US | disclosed |
| WO-2009054864-A1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090111816-A1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2009055696-A1 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090110842-A1 | Boron-based wood preservatives and treatment of wood with boron-based preservatives | THE UNIVERSITY OF MELBOUME (AU) | 2009-04-30 | — | — | US | disclosed |
| WO-2009051399-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051397-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051398-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099133-A1 | Isoquinolines Derivatives as Igf-1R Inhibitors | ANALYTECON S.A. (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | ANALYTECON S.A (CH) | 2009-04-16 | — | — | US | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | BUCKMAN BRAD | 2009-04-09 | — | — | US | disclosed |
| EP-2044938-A2 | Radioprotectors | Peter MacCallum Cancer Institute (AU) | 2009-04-08 | — | — | EP | disclosed |
| US-7514436-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2009-04-07 | — | — | US | disclosed |
| EP-2041116-A1 | PHENYL SUBSTITUTED HETEROARYL-DERIVATIVES AND USE THEREOF AS ANTI-TUMOR AGENTS | Boehringer Ingelheim International GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090082400-A1 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS | LIMERICK BIOPHARMA, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090075822-A1 | Method of Altering the Alkaloid Composition in Poppy Plants | GLAXOSMITHKLINE AUSTRALIA PTY LTD (AU) | 2009-03-19 | — | — | US | disclosed |
| EP-2035421-A1 | 2-ARYLPYRAZOLO[L,5-alpha]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA) | THE UNIVERSITY OF SYDNEY (AU) | 2009-03-18 | — | — | EP | disclosed |
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
| EP-2032583-A1 | NEW CHEMICAL COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-03-11 | — | — | EP | disclosed |
| EP-1916889-A4 | METHODS OF ALTERING POPPY CHARACTERISTICS | GLAXOSMITHKLINE AUSTRALIA PTY (AU) | 2009-03-11 | — | — | EP | disclosed |
| CN-101384592-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| CN-101384591-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1472209-B1 | LIPOXIN A4 ANALOGS | BAYER SCHERING PHARMA AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| EP-2029572-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| EP-2029138-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-04 | — | — | EP | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| EP-2026825-A2 | FURANONE-INITIATED POLYMERS | Tyco Healthcare Group, LP (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20090048461-A1 | Regulators of Bacterial Signalling Pathways | BIOSIGNAL LIMITED (AU) | 2009-02-19 | — | — | US | disclosed |
| EP-2024370-A1 | SPIRO- (THO) BENZOPYRAN-2, 4' -PIPERIDINE-AND CYCLOHEXANE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE ENZYMES | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| EP-2024113-A1 | ANTIMICROBIAL COATINGS | Tyco Healthcare Group LP (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090042848-A1 | COPPER COMPLEXES | LAY PETER | 2009-02-12 | — | — | US | disclosed |
| US-20090042806-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2009-02-12 | — | — | US | disclosed |
| WO-2009018320-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018326-A2 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018350-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036310-A1 | Substituted 1-(3-pyridinyl)pyrazol-4-ylacetic Acids, Processes for Their Preparation and Their Use as Herbicides and Plant Growth Regulators | BAYER CORPSCIENCE GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| WO-2009018338-A2 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| CN-101360506-A | Methods for wound healing | PEPLIN RESEARCH PTY LTD (AU) | 2009-02-04 | — | — | CN | disclosed |
| US-7485667-B2 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-20090030008-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-01-29 | — | — | US | disclosed |
| US-20090030000-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2009-01-29 | — | — | US | disclosed |
| US-20090030123-A1 | STABILISER COMPOSITION FOR HALIDE-CONTAINING POLYMERS | SUN ACE KAKOH (PTE.) LTD. (SG) | 2009-01-29 | — | — | US | disclosed |
| EP-2018373-A1 | FURANONE ENDCAPPED POLYMERS | Tyco Healthcare Group, LP (US) | 2009-01-28 | — | — | EP | disclosed |
| EP-2018361-A1 | HALOGENATED CYCLIC LACTONES AND POLYMERS MADE THEREFROM | Tyco Healthcare Group, LP (US) | 2009-01-28 | — | — | EP | disclosed |
| US-7482366-B2 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482488-B2 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090022824-A1 | Pesticidal formulations | AKHIL TECHNOLOGIES PTY LTD (AU) | 2009-01-22 | — | — | US | disclosed |
| US-20090023669-A1 | Antibacterial Agents | ALCHEMIA LIMITED (AU) | 2009-01-22 | — | — | US | disclosed |
| EP-2017264-A1 | Substituted phenyl propargyl compounds, method for their manufacture and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-7479471-B2 | 2-Amino-4-bicyclylamino-6H-1,3,5-triazines, processes for their preparation and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE GMBH (DE) | 2009-01-20 | — | — | US | disclosed |
| EP-2012789-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION(AMD) | Prana Biotechnology Limited (AU) | 2009-01-14 | — | — | EP | disclosed |
| WO-2009003998-A2 | ANTIPROLIFERATIVE COMPOUNDS BASED ON 5-MEMBERED HETEROCYCLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003999-A2 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005794-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005250-A1 | Substituted 2,4-diamino-1,3,5-triazines, processes for their use as herbicides and crop growth regulators | BAYER CROPSCIENCE AG (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-2007790-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-12-31 | — | — | EP | disclosed |
| EP-1149075-B1 | SYNTHESIS OF DITHIOESTER CHAIN TRANSFER AGENTS | COMMW SCIENT IND RES ORG (AU) | 2008-12-31 | — | — | EP | disclosed |
| WO-2009000832-A2 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-31 | — | — | WO | disclosed |
| US-20080318942-A1 | Fredericamycin Derivatives | BIOAGENCY AG (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318417-A1 | METHOD OF FORMING RUTHENIUM FILM FOR METAL WIRING STRUCTURE | ASM JAPAN K.K. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080311040-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | FLAGSHIP VENTURES (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2008152013-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152014-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| EP-2001911-A1 | POLYMER PRODUCT AND INTERFACIAL POLYMERISATION PROCESS USING RAFT AGENT | The University of Sydney (AU) | 2008-12-17 | — | — | EP | disclosed |
| EP-2001892-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | Ambit Biosciences Corporation (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1968569-A4 | BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-CORONAVIRAL AGENTS | SINGAPORE POLYTECHNIC (SG) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008151288-A2 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-12-11 | — | — | WO | disclosed |
| EP-1998809-A2 | CAMPTOTHECIN-CELL PENETRATING PEPTIDE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Diatos S.A. (FR) | 2008-12-10 | — | — | EP | disclosed |
| WO-2008147864-A2 | METHODS OF USING PIPERAZINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-12-04 | — | — | WO | disclosed |
| US-20080299170-A1 | Medical Devices and Coatings Therefor | ASTON UNIVERSITY (GB) | 2008-12-04 | — | — | US | disclosed |
| EP-1996217-A2 | NOVEL ANTIBIOTIC COMPOSITIONS | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-12-03 | — | — | EP | disclosed |
| US-7459462-B2 | Fredericamycin derivatives | BIOFRONTERA DISCOVERY GMBH (DE) | 2008-12-02 | — | — | US | disclosed |
| WO-2008144248-A1 | FURANONE COPOLYMERS | TYCO HEALTHCARE GROUP LP (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293844-A1 | Gels | AORTECH BIOMATERIALS PTY LTD (AU) | 2008-11-27 | — | — | US | disclosed |
| WO-2008144247-A1 | ANTIMICROBIAL MATERIALS AND COATINGS | TYCO HEALTHCARE GROUP LP (US) | 2008-11-27 | — | — | WO | disclosed |
| US-7456180-B2 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-11-25 | — | — | US | disclosed |
| US-20080280916-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080281016-A1 | Polymer Composite | MILLER WASTE MILLS INC. DBA RTP COMPANY | 2008-11-13 | — | — | US | disclosed |
| US-20080280985-A1 | Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes | STOCKER, ROLAND (AU) | 2008-11-13 | — | — | US | disclosed |
| WO-2008134547-A1 | METHODS OF USING HYDROXYCYCLOHEXANE AND HYDROXYPIPERIDINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008131491-A1 | TREATMENT OF VIRALLY INDUCED LESIONS | PEPLIN RESEARCH PTY LTD (AU) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008134553-A1 | METHODS OF USING BICYCLIC COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES | XENON PHARMACEUTICALS INC. (CA) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | THE UNIVERSITY OF SYDNEY (AU) | 2008-11-06 | — | — | US | disclosed |
| WO-2008131368-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080269058-A1 | Methods of Altering Poppy Characteristics | SUN PHARMACEUTICAL INDUSTRIES (AUSTRALIA) PTY LTD (AU) | 2008-10-30 | — | — | US | disclosed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080268250-A1 | Polymerisation Process and Polymer Product | THE UNIVERSITY OF SYDNEY (AU) | 2008-10-30 | — | — | US | disclosed |
| WO-2008127381-A2 | ARTEMISININ DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1981844-A1 | NOVEL LACTAMS | Biosignal Limited (AU) | 2008-10-22 | — | — | EP | disclosed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7435484-B2 | a ruthenium(Ru) thin film on a substrate in a reaction chamber, includes: (i) supplying a gas of a ruthenium precursor into the reaction chamber so that the gas of the ruthenium precursor is adsorbed onto the substrate, wherein the ruthenium precursor a ruthenium complex contains a non-cyclic diene | ASM JAPAN K.K. (JP) | 2008-10-14 | — | — | US | disclosed |
| WO-2008121861-A2 | PYRAZOLE AND PYRROLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121859-A1 | METHODS OF USING TRICYCLIC COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
| EP-1976828-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Schering Aktiengesellschaft (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1363880-A4 | SYNTHESIS FOR THE PREPARATION OF COMPOUNDS FOR SCREENING AS POTENTIAL TUBULIN BINDING AGENTS | UNIV AUSTRALIAN (AU) | 2008-10-08 | — | — | EP | disclosed |
| EP-1478628-B1 | 2-AMINO-4-BICYCLYL AMINO-6H-1.3.5-TRIAZINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2008-10-08 | — | — | EP | disclosed |
| CN-101282935-A | Isoquinoline derivatives as insulin-like growth factor-1 receptor inhibitors | ANALYTECON SA (CH) | 2008-10-08 | — | — | CN | disclosed |
| WO-2008118946-A1 | METHODS AND COMPOSITIONS USING CERTAIN PHENOLIC DERIVATIVES FOR THE TREATMENT OF DIABETES | ATHEROGENICS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118790-A1 | DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| EP-1973917-A2 | PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008114006-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234327-A1 | DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080233102-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008113006-A1 | METHODS OF USING QUINOLINONE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227789-A1 | DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2008110794-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110793-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| EP-1968643-A2 | CELL PENETRATING PEPTIDE CONJUGATES FOR DELIVERING OF NUCLEIC ACIDS INTO A CELL | Diatos (FR) | 2008-09-17 | — | — | EP | disclosed |
| EP-1968979-A2 | 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1495003-B1 | FREDERICAMYCIN DERIVATIVES | BIOFRONTERA DISCOVERY GMBH (DE) | 2008-09-17 | — | — | EP | disclosed |
| EP-1968569-A1 | BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-CORONAVIRAL AGENTS | Singapore Polytechnic (SG) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008109105-A2 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH SIRNA | FLAGSHIP VENTURES (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107444-A1 | 9H- PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109840-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109856-A2 | METHODS OF USING DIAZEPINONE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221194-A1 | Novel Potassium channel Blockers and Uses Thereof | HARVEY ANDREW J | 2008-09-11 | — | — | US | disclosed |
| EP-1294705-B1 | SYNTHESIS OF CYCLIC COMPOUNDS | BIOSIGNAL LTD (AU) | 2008-09-10 | — | — | EP | disclosed |
| EP-1965796-A2 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | Gilead Colorado, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1965818-A1 | METHODS FOR WOUND HEALING | Peplin Research Pty Ltd. (AU) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008106633-A1 | METHODS OF USING BENZODIOXINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-04 | — | — | WO | disclosed |
| EP-1962840-A1 | USE OF 4, 7-DIHYDROTHIENO [2, 3-B]PYRIDINE COMPOUNDS IN THE TREATMENT OF CARDIOVASCULAR DISEASES | Gilead Colorado, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1962864-A1 | ANTIBACTERIAL AGENTS | Alchemia Limited (AU) | 2008-09-03 | — | — | EP | disclosed |
| CN-101258130-A | Isoquinolines as insulin-like growth factor-1 receptor inhibitors | ANALYTECON SA (CH) | 2008-09-03 | — | — | CN | disclosed |
| US-20080207587-A1 | Pyridazine Derivatives for Inhibiting Human Stearoyl-Coa-Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-7417129-B2 | Combinatorial libraries of monosaccharides | ALCHEMIA PTY LTD (AU) | 2008-08-26 | — | — | US | disclosed |
| WO-2008101029-A2 | USE OF THIAZOLE, OXAZOLE AND IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-21 | — | — | WO | disclosed |
| US-20080200728-A1 | Process for Synthesis of Dialkoxyorganoboranes | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080194636-A1 | Enzyme Inhibitors and Uses Thereof | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2008-08-14 | — | — | US | disclosed |
| WO-2008097991-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | WO | disclosed |
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | disclosed |
| US-20080194691-A1 | Apoptosis Promoters | ABBOTT LABORATORIES (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1954285-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | Alvine Pharmaceuticals, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008094909-A2 | QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-07 | — | — | WO | disclosed |
| US-20080188488-A1 | Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-08-07 | — | — | US | disclosed |
| US-20080188454-A1 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188557-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2008-08-07 | — | — | US | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1476149-B1 | SUBSTITUTED HYDRAZONES AS INHIBITORS OF CYCLOOXYGENASE-2 | UNIV TEMPLE (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182834-A1 | Multi-Nuclear Metal Complexes Partially Encapsulated by Cucurbit[7-12]Urils | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2008-07-31 | — | — | US | disclosed |
| WO-2008089521-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | VERVA PHARMACEUTICALS LTD (AU) | 2008-07-31 | — | — | WO | disclosed |
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| EP-1725558-A4 | METHOD FOR PREPARING COMPOUNDS COMPRISING CUCURBITURIL GROUPS | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008089439-A2 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080176858-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176847-A1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| EP-1296673-B1 | ANTIMICROBIAL COATINGS | BIOSIGNAL AUSTRALIA PTY LTD (AU) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008085984-A1 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USES THEREOF | ANDROSCIENCE CORPORATION (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-1054004-B1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20080167321-A1 | Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2008-07-10 | — | — | US | disclosed |
| WO-2008083356-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008083353-A1 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008083354-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008083367-A2 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1940796-A1 | ISOQUINOLINES DERIVATIVES AS IGF-1R INHIBITORS | Analytecon S.A. (CH) | 2008-07-09 | — | — | EP | disclosed |
| CN-100400531-C | 2-oxabicyclo 3.3.0 octane compounds, process for producing the same, optical resolver, method of separating diastereomer mixture, and method of optically resolving alcohol | ZEON CORP (JP) | 2008-07-09 | — | — | CN | disclosed |
| WO-2008080134-A2 | 4-AMIN0-2- (HETERO) ARYLAMINO-5- (HETERO) ARYLTHIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| EP-1939197-A1 | 8-ethinylxanthine derivatives as selective A2A receptor antagonists | SCHWARZ PHARMA AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1937719-A2 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | Neose Technologies, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1938686-A1 | Substituted 1-(3-pyridinyl)pyrazol-4-yl-acetic acids, process for their preparation and their use as herbicide and plant growth regulator. | Bayer CropScience AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1558585-A4 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2008-07-02 | — | — | EP | disclosed |
| US-7393869-B2 | Methods of using thiazolidine derivatives to treat cancer or inflammation | QLT INC. (CA) | 2008-07-01 | — | — | US | disclosed |
| WO-2008074078-A1 | SELECTIVELY DELIVERABLE ISATIN-BASED CYTOTOXIC AGENTS | UNIVERSITY OF WOLLONGONG (AU) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074835-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074091-A1 | RADIOPROTECTOR COMPOUNDS AND RELATED METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| EP-1934388-A1 | METHOD OF DRUG DESIGN | Alchemia Ltd (AU) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008071451-A1 | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080146626-A1 | USE OF EPOTHILONES IN THE TREATMENT OF OSTEOPOROSIS AND RELATED DISEASES | BAYER SCHERING PHARMA AG (DE) | 2008-06-19 | — | — | US | disclosed |
| EP-1678133-A4 | SEQUENCE SELECTIVE PYRROLE AND IMIDAZOLE POLYAMIDE METALLOCOMPLEXES | UNIV WESTERN SYDNEY (AU) | 2008-06-18 | — | — | EP | disclosed |
| EP-1931205-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-06-18 | — | — | EP | disclosed |
| CN-101203230-A | Modulation of angiogenesis with NOD factors such as glucosamine oligosaccharides | RICHARD PARISH CHRISTOPHER (AU) | 2008-06-18 | — | — | CN | disclosed |
| WO-2008070741-A1 | COMPOSITIONS AND METHODS FOR ENHANCING SURVIVAL AND REDUCING INJURY UNDER ISCHEMIC OR HYPOXIC CONDITIONS | IKARIA, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068043-A1 | USE OF EPOTHILONES IN THE TREATMENT OF OSTEOPOROSIS AND RELATED DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
| EP-1930004-A1 | Use of epothilones in the treatment of osteoporosis and related diseases | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | disclosed |
| CN-101198615-A | Method for synthesizing dialkoxyorganoborane | BASF AG (DE) | 2008-06-11 | — | — | CN | disclosed |
| WO-2008064432-A1 | POLYCYCLIC MOLECULAR COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2008-06-05 | — | — | WO | disclosed |
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| CN-101193921-A | Carbon-bridged cyclopentadienyl-fluorenyl ligands | TOTAL PETROCHEMICALS RES FELUY (BE) | 2008-06-04 | — | — | CN | disclosed |
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | US | disclosed |
| US-20080124484-A1 | METHOD OF FORMING RU FILM AND METAL WIRING STRUCTURE | ASM JAPAN K.K. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| EP-1274420-A4 | MICROBIAL INHIBITORY COMPOSITIONS | BIOSIGNAL AUSTRALIA PTY LTD (AU) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008060789-A2 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
| US-20080118982-A1 | Tagged Petroleum Products and Methods of Detecting Same | AUTHENTIX, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119439-A1 | Treatment and prevention of intestinal fibrosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2008-05-22 | — | — | US | disclosed |
| EP-1922310-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1765755-A4 | REGULATORS OF BACTERIAL SIGNALLING PATHWAYS | BIOSIGNAL LTD (AU) | 2008-05-21 | — | — | EP | disclosed |
| US-7371755-B1 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2008-05-13 | — | — | US | disclosed |
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ABBVIE INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080108629-A1 | Heterocyclic Derivatives for the Treatment of Diseases Mediated by Stearoyl-Coa Desaturase Enzymes | XENON PHARMACEUTICALS INC. (CA) | 2008-05-08 | — | — | US | disclosed |
| EP-1916889-A1 | METHODS OF ALTERING POPPY CHARACTERISTICS | Glaxosmithkline Australia PTY Ltd. (AU) | 2008-05-07 | — | — | EP | disclosed |
| EP-1755373-A4 | METHOD OF ALTERING THE ALKALOID COMPOSITION IN POPPY PLANTS | GLAXOSMITHKLINE AUSTRALIA PTY (AU) | 2008-05-07 | — | — | EP | disclosed |
| US-20080103191-A1 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103151-A9 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-05-01 | — | — | US | disclosed |
| WO-2008046156-A1 | VESICULATED POLYMER PARTICLES | THE UNIVERSITY OF SYDNEY (AU) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008046155-A1 | METHODS FOR REGULATING GLUCOSE HOMEOSTASIS AND AGENTS THEREFOR | DIA-B TECH LIMITED (AU) | 2008-04-24 | — | — | WO | disclosed |
| US-20080096895-A1 | Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| WO-2008046049-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3 ' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008046087-A2 | SPIRO COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008046046-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008046084-A2 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008046082-A2 | USE OF HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045978-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008046065-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1910307-A1 | PYRAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910308-A1 | IMIDAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1907027-A2 | MEDICAL DEVICES AND COATINGS THEREFOR | Aston University (GB) | 2008-04-09 | — | — | EP | disclosed |
| US-20080081917-A1 | MULTIFUNCTIONAL CATIONIC PHOTOINITIATORS, THEIR PREPARATION AND USE | SUN CHEMICAL CORPORATION (US) | 2008-04-03 | — | — | US | disclosed |
| WO-2008037011-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-04-03 | — | — | WO | disclosed |
| EP-1904047-A2 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080076779-A1 | Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008034895-A2 | ANSAMYCIN DERIVATIVES | DISCOVERY PARTNERS INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036715-A1 | HETEROCYCLIC ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
| EP-1366015-A4 | BENZENE-1 2-DIOL MANNICH BASES LIGANDS POLYMERS AND METHOD OF SELECTIVE METAL IONS REMOVAL | TECH RESOURCES PTY LTD (AU) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008031157-A1 | ACETYLENIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2008-03-20 | — | — | WO | disclosed |
| EP-1697377-A4 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENT MANAGEMENT (AU) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008030836-A2 | BCL INHIBITORS TREATING PLATELET EXCESS | ABBOTT LABORATORIES (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080054472-A1 | a ruthenium(Ru) thin film on a substrate in a reaction chamber, includes: (i) supplying a gas of a ruthenium precursor into the reaction chamber so that the gas of the ruthenium precursor is adsorbed onto the substrate, wherein the ruthenium precursor a ruthenium complex contains a non-cyclic diene | ASM JAPAN K.K. (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1893622-A2 | PROCESS FOR SYNTHESIS OF DIALKOXYORGANOBORANES | BASF SE (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008022807-A2 | LIPOXIN A4 ANALOGS FOR THE TREATMENT AND PREVENTION OF INTESTINAL FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024390-A2 | 2- (PYRAZIN-2-YL) -THIAZOLE AND 2- (1H-PYRAZ0L-3-YL) -THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | disclosed |
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-02-21 | — | — | US | disclosed |
| EP-1888098-A2 | GLYCOPEGYLATED ERYTHROPOIETIN FORMULATIONS | Neose Technologies, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1888543-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| EP-1888592-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| US-20080039522-A1 | Composition Containing a Complex Comprising a Metal Ion and a Carboxylate Ligand Having Anti-Inflammatory Activity | MEDICAL THERAPIES LIMITED (AU) | 2008-02-14 | — | — | US | disclosed |
| US-20080033179-A1 | Optical Recording Material and Optical Recording Medium | ADEKA CORPORATION (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1879892-A2 | 2-PYRROLIDONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND PAIN | XENON PHARMACEUTICALS INC. (CA) | 2008-01-23 | — | — | EP | disclosed |
| EP-1732898-B1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20080015230-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-17 | — | — | US | disclosed |
| US-20080015192-A1 | INHIBITORS OF POLO-LIKE KINASES | ABBVIE INC. | 2008-01-17 | — | — | US | disclosed |
| EP-1877481-A2 | STABILISER COMPOSITION FOR HALIDE-CONTAINING POLYMERS | Sun Ace Kakoh (Pte.) Ltd. (SG) | 2008-01-16 | — | — | EP | disclosed |
| EP-1877378-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-16 | — | — | EP | disclosed |
| WO-2008003770-A1 | PHENYL SUBSTITUTED HETEROARYL-DERIVATIVES AND USE THEREOF AS ANTI-TUMOR AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004986-A1 | CATALYST SYSTEM FOR OLIGOMERIZATION OF OLEFINS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009418-A1 | Selective Inhibitors | ALCHEMIA LTD. (AU) | 2008-01-10 | — | — | US | disclosed |
| EP-1874322-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1871357-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871392-A1 | MODULATING ANGIOGENESIS WITH NOD FACTORS SUCH AS GLUCOSAMINE OLIGOSACCHARIDES | Parish, Christopher Richard (AU) | 2008-01-02 | — | — | EP | disclosed |
| US-20070297980-A1 | Geldanamycin and Derivatives Inhibit Cancer Invasion and Identify Novel Targets | MICHIGAN STATE UNIVERSITY | 2007-12-27 | — | — | US | disclosed |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | disclosed |
| EP-1869022-A1 | NAPHTHALAMIDE DERIVATIVES HAVING ANTIPROLIFERATIVE ACTIVITY | Agency for Science, Technology and Research (SG) | 2007-12-26 | — | — | EP | disclosed |
| EP-1868995-A1 | COPPER COMPLEXES | MEDICAL THERAPIES LIMITED (AU) | 2007-12-26 | — | — | EP | disclosed |
| US-7312194-B2 | Delivery systems | ALCHEMIA PTY. LTD. (AU) | 2007-12-25 | — | — | US | disclosed |
| WO-2007144370-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070292477-A1 | Association of Antimicrobial Compounds with Surfaces and Polymers | BIOSIGNAL LIMITED (AT) | 2007-12-20 | — | — | US | disclosed |
| US-20070293399-A1 | SUBSTITUTED DIAMINO-1,3,5-TRIAZINES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND CROP GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| US-20070287836-A1 | Method for Preparing Compounds Comprising Cucurbituril Groups | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2007-12-13 | — | — | US | disclosed |
| US-20070287700-A1 | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENTFIC MANAGEMENMT PTY LTD. (AU) | 2007-12-13 | — | — | US | disclosed |
| US-20070287855-A1 | Process for Preparing Fluorinated Molecules | BAYER CROPSCIENCE AG (DE) | 2007-12-13 | — | — | US | disclosed |
| WO-2007143597-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007136746-A2 | MACROCYCLIC COMPOUNDS AND THEIR USES AS STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007134362-A1 | 2-ARYLPYRAZOLO[L,5-α]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA) | THE UNIVERSITY OF SYDNEY (AU) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007133777-A1 | FURANONE ENDCAPPED POLYMERS | TYCO HEALTHCARE GROUP LP (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133783-A1 | HALOGENATED CYCLIC LACTONES AND POLYMERS MADE THEREFROM | TYCO HEALTHCARE GROUP LP (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133782-A1 | ANTIMICROBIAL COATINGS | TYCO HEALTHCARE GROUP LP (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133781-A2 | FURANONE-INITIATED POLYMERS | TYCO HEALTHCARE GROUP LP (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | UNIVERSITY OF WESTERN SYDNEY (AU) | 2007-11-15 | — | — | US | disclosed |
| WO-2007128782-A1 | SPIRO- (THO) BENZOPYRAN-2, 4' -PIPERIDINE-AND CYCLOHEXANE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE ENZYMES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130075-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-15 | — | — | WO | disclosed |
| EP-1689706-A4 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1851205-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007118276-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION(AMD) | PRANA BIOTECHNOLOGY LTD (AU) | 2007-10-25 | — | — | WO | disclosed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | disclosed |
| US-20070244134-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2007-10-18 | — | — | US | disclosed |
| WO-2007117394-A2 | COMPOSITIONS AND METHODS RELATED TO FRUCTOSAMINE-3-KINASE INHIBITORS | DYNAMIS THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1844009-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS | Stocker, Roland O. (AU) | 2007-10-17 | — | — | EP | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007112492-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113687-A2 | CAMPTOTHECIN-CELL PENETRATING PEPTIDE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DIATOS S.A. (FR) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007112503-A1 | POLYMER PRODUCT AND INTERFACIAL POLYMERISATION PROCESS USING RAFT AGENT | THE UNIVERSITY OF SYDNEY (AU) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007110745-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | MEDICAL THERAPIES LIMITED (AU) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007109845-A1 | PROPHYLAXIS OR TREATMENT OF DIABETES | MEDICAL THERAPIES LIMITED (AU) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007109843-A1 | METAL COMPLEXES HAVING ANTI-INFLAMMATORY ACTIVITY | MEDICAL THERAPIES LIMITED (AU) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007109844-A1 | ANTI-INFLAMMATORY METAL COMPLEXES | MEDICAL THERAPIES LIMITED (AU) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| EP-1838772-A2 | METHOD FOR TRANSFORMATION OF CONVENTIONAL AND COMMERCIALLY IMPORTANT POLYMERS INTO DURABLE AND RECHARGEABLE ANTIMICROBIAL POLYMERIC MATERIALS | Board of Regents, The University of Texas System (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1838714-A1 | METHODS OF TREATING PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-10-03 | — | — | EP | disclosed |
| EP-1734945-A4 | A COMPOSITION CONTAINING A COMPLEX COMPRISING A METAL ION AND A CARBOXYLATE LIGAND HAVING ANTI-INFLAMMATORY ACTIVITY | MEDICAL THERAPIES LTD (AU) | 2007-10-03 | — | — | EP | disclosed |
| US-20070225377-A1 | Bridged Ring Structures as Pharmaceutical Agents | X-CEPTOR THERAPEUTICS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007109120-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109324-A2 | POTENT AND SELECTIVE NAV 1.7 SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS, INC. (CA) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219211-A1 | Bicyclic Heterocyclic Derivatives and Their Use as Inhibitors of Stearoyl-Coadesaturase (Scd) | XENON PHARMACEUTICALS INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| WO-2007103548-A2 | NOVEL ANTIBIOTIC COMPOSITIONS | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| EP-1827438-A2 | PYRIDINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-09-05 | — | — | EP | disclosed |
| EP-1689698-A4 | BIS-CATIONIC COMPOUNDS AND USE THEREOF | UNIV SYDNEY (AU) | 2007-09-05 | — | — | EP | disclosed |
| US-7265093-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265131-B2 | Isoquinolinone derivatives and their use as therapeutic agents | EXELIXIS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007095696-A1 | POLYKETIDE XANTHONES AND USES THEREOF | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-30 | — | — | WO | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1343488-B1 | TREATMENT OF STATIN SIDE EFFECTS | MAGRAL LTD (AU) | 2007-08-15 | — | — | EP | disclosed |
| EP-1817041-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1814551-A2 | PYRIDAZINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-08-08 | — | — | EP | disclosed |
| EP-0980867-B1 | KETONE DERIVATIVES AND MEDICINAL USE THEREOF | TORAY INDUSTRIES (JP) | 2007-08-08 | — | — | EP | disclosed |
| WO-2007085042-A1 | NOVEL LACTAMS | BIOSIGNAL LIMITED (AU) | 2007-08-02 | — | — | WO | disclosed |
| EP-1809281-A2 | USE OF EPOTHILONES IN THE TREATMENT OF BONE METASTASES AND BONE TUMORS OR CANCERS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-1807085-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-07-18 | — | — | EP | disclosed |
| EP-1608623-A4 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2007-07-18 | — | — | EP | disclosed |
| US-7244741-B2 | Fredericamycin derivatives as medicaments for treating tumours | BIOFRONTERA DISCOVERY GMBH (DE) | 2007-07-17 | — | — | US | disclosed |
| WO-2007079164-A2 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079003-A2 | AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079078-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| EP-1804792-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF STEAROYL-COA-DESATURASE (SCD) | XENON PHARMACEUTICALS INC. (CA) | 2007-07-11 | — | — | EP | disclosed |
| EP-1539675-A4 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1805154-A2 | PHARMACEUTICAL COMPOSITIONS | Exelixis, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1558617-A4 | AMIDINE COMPOUNDS | UNIV MONASH (AU) | 2007-07-11 | — | — | EP | disclosed |
| EP-1804799-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-07-11 | — | — | EP | disclosed |
| CN-1325476-C | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, noval compounds thereof and their use as chemotherapeutic agents | UNIV AUSTRALIAN (AU) | 2007-07-11 | — | — | CN | disclosed |
| US-20070155726-A1 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
| WO-2007075145-A1 | BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-CORONAVIRAL AGENTS | SINGAPORE POLYTECHNIC (SG) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155834-A1 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007076379-A2 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | GILEAD COLORADO, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1802662-A1 | SURFACE POLYMERISATION PROCESS AND POLYMER PRODUCT USING RAFT AGENT | The University of Sydney (AU) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802590-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | Pharmacia & Upjohn Company LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007070947-A1 | ANTIBACTERIAL AGENTS | ALCHEMIA LTD (AU) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| WO-2007073555-A1 | USE OF 4, 7-DIHYDROTHIENO [2, 3-B] PYRIDINE COMPOUNDS IN THE TREATMENT OF CARDIOVASCULAR DISEASES | GILEAD COLORADO, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070148124-A1 | Cellulose and acrylic based polymers and the use thereof for the treatment of infectious diseases | NOVAFLUX INC. | 2007-06-28 | — | — | US | disclosed |
| EP-1799739-A1 | GELS | AorTech Biomaterials Pty Ltd (AU) | 2007-06-27 | — | — | EP | disclosed |
| EP-1799664-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| EP-1799668-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| EP-1799667-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| US-20070142353-A1 | ANTIBACTERIAL COMPOUNDS | ABBVIE INC. | 2007-06-21 | — | — | US | disclosed |
| WO-2007069068-A2 | CELL PENETRATING PEPTIDE CONJUGATES FOR DELIVERING NUCLEIC ACIDS INTO CELLS | DIATOS (FR) | 2007-06-21 | — | — | WO | disclosed |
| US-20070140970-A1 | Cell targeting conjugates | PETER MACCALLUM CANCER INSTITUTE | 2007-06-21 | — | — | US | disclosed |
| EP-1797428-A1 | SELECTIVE INHIBITORS | Alchemia Pty Ltd (AU) | 2007-06-20 | — | — | EP | disclosed |
| EP-1797901-A1 | Cell penetrating peptide conjugates for delivering nucleic acids into cells | Diatos (FR) | 2007-06-20 | — | — | EP | disclosed |
| CN-1321644-C | Process for preparing substituted pyrazoles | PHARMACIA CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| WO-2007067781-A2 | 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135387-A1 | Inhibitors of protein kinases | ABBOTT LABORATORIES | 2007-06-14 | — | — | US | disclosed |
| US-20070135392-A1 | Apoptosis promoters | ABBVIE INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | disclosed |
| WO-2007059584-A1 | METHODS FOR WOUND HEALING | PEPLIN RESEARCH PTY LTD (AU) | 2007-05-31 | — | — | WO | disclosed |
| EP-1789079-A1 | ENZYME INHIBITORS AND USES THEREOF | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2007-05-30 | — | — | EP | disclosed |
| US-7223798-B2 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7220881-B2 | Process for production of acid anhydride | TOKUYAMA CORPORATION (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7217702-B2 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2007-05-15 | — | — | US | disclosed |
| WO-2007051255-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS CONTAINING AN AZACYCLIC RING SYSTEM | THE UNIVERSITY OF SYDNEY (AU) | 2007-05-10 | — | — | WO | disclosed |
| US-20070105862-A1 | Heat-shock protein binders | ABBOTT LABORATORIES | 2007-05-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-10 | — | — | US | disclosed |
| EP-1334092-B1 | PROCESS FOR PREPARATION OF BICYCLIC AND POLYCYCLIC MOLECULES | UNIV MONASH (AU) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007050124-A1 | FUSED PIPERIDINE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050795-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | ALVINE PHARMACEUTICALS, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007046868-A2 | THIAZOLIDINE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007046867-A2 | PIPERIDINE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007044085-A2 | HETEROARYL COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088040-A1 | Antibacterial compounds | ABBVIE INC. | 2007-04-19 | — | — | US | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070082850-A1 | Mannose-6-phosphonate compounds for the treatment of inflammatory diseases | PHARMAXIX PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
| WO-2007038829-A1 | METHOD OF DRUG DESIGN | ALCHEMIA LTD (AU) | 2007-04-12 | — | — | WO | disclosed |
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| US-7199155-B2 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199129-B2 | Derivatives of morphine-like opioid compounds | MONASH UNIVERSITY (AU) | 2007-04-03 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070072833-A1 | Survivin inhibitors | ABBVIE INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1765755-A1 | REGULATORS OF BACTERIAL SIGNALLING PATHWAYS | Biosignal Limited (AU) | 2007-03-28 | — | — | EP | disclosed |
| US-7196200-B2 | Antibacterial compounds | ABBOTT LABORATORIES (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1483253-A4 | AN ANTIMICROBIAL AGENT | UNIV GRIFFITH (AU) | 2007-03-21 | — | — | EP | disclosed |
| EP-1763350-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-03-21 | — | — | EP | disclosed |
| WO-2007030680-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007029107-A1 | ISOQUINOLINES DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20070060551-A1 | Methods of using isothiazole derivatives to treat cancer or inflammation | QLT, INC. (CA) | 2007-03-15 | — | — | US | disclosed |
| WO-2007026240-A1 | SUNSCREEN AND COSMETIC COMPOSITIONS FOR PROPHYLAXIS OR TREATMENT OF SKIN CANCERS | MEDICAL THERAPIES LIMITED (AU) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007024744-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007025247-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007022561-A1 | METHODS OF ALTERING POPPY CHARACTERISTICS | GLAXOSMITHKLINE AUSTRALIA PTY LTD (AU) | 2007-03-01 | — | — | WO | disclosed |
| EP-1755373-A1 | METHOD OF ALTERING THE ALKALOID COMPOSITION IN POPPY PLANTS | Glaxosmithkline Australia PTY Ltd. (AU) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007022512-A2 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1754703-A2 | N-Heterocyclic derivatives as nos inhibitors | Berlex, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-7176207-B2 | Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-13 | — | — | US | disclosed |
| EP-1749041-A2 | CELLULOSE AND ACRYLIC BASED POLYMERS AND THE USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES | Nova Flux Biosciences, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20070027285-A1 | Polyurethanes | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2007-02-01 | — | — | US | disclosed |
| CN-1297537-C | Sulfonium salt compound | WAKO PURE CHEM IND LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| WO-2007010201-A2 | MEDICAL DEVICES AND COATINGS THEREFOR | ASTON UNIVERSITY (GB) | 2007-01-25 | — | — | WO | disclosed |
| EP-0968206-B8 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX INC (US) | 2007-01-24 | — | — | EP | disclosed |
| US-7166604-B2 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-01-23 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2007008627-A2 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | BIOVIE INC. | 2007-01-18 | — | — | US | disclosed |
| CN-1898247-A | Polycyclic agents for the treatment of respiratory syncytial virus infection | BIOTA SCIENT MAN (AU) | 2007-01-17 | — | — | CN | disclosed |
| EP-1740587-A2 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | Adenosine Therapeutics, LLC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-7161031-B2 | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-01-09 | — | — | US | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007001240-A1 | SURFACE TREATMENT OF ALUMINA FILMS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002563-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1737825-A1 | GELDANAMYCIN AND DERIVATIVES INHIBIT CANCER INVASION AND IDENTIFY NOVEL TARGETS | Van Andel Research Institute (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-12-28 | — | — | US | disclosed |
| EP-1734945-A1 | A COMPOSITION CONTAINING A COMPLEX COMPRISING A METAL ION AND A CARBOXYLATE LIGAND HAVING ANTI-INFLAMMATORY ACTIVITY | THE UNIVERSITY OF SYDNEY (AU) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006134074-A2 | PROCESS FOR SYNTHESIS OF DIALKOXYORGANOBORANES | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060287224-A1 | Conjugates between erythropoietin and polyoxyethylene glycol groups, linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group; enhancing red blood cell production; treating a tissue injury | NEOSE TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060287307-A1 | Antibacterial compounds | HINMAN MIRA M | 2006-12-21 | — | — | US | disclosed |
| US-20060280746-A1 | (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents | ONCONOVA THERAPEUTICS INC. | 2006-12-14 | — | — | US | disclosed |
| US-20060281798-A1 | Methods of using thiazolidinedithione derivatives | QLT INC. (CA) | 2006-12-14 | — | — | US | disclosed |
| EP-1727526-A2 | PIPERAZINE UREA DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | Schering Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2006127910-A2 | GLYCOPEGYLATED ERYTHROPOIETIN FORMULATIONS | NEOSE TECHNOLOGIES, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127364-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1725558-A1 | METHOD FOR PREPARING COMPOUNDS COMPRISING CUCURBITURIL GROUPS | Newsouth Innovations Pty Limited (AU) | 2006-11-29 | — | — | EP | disclosed |
| CN-1871247-A | Novel sulfenamides | UNIV GRIFFITH (AU) | 2006-11-29 | — | — | CN | disclosed |
| CN-1871248-A | Novel sulfenamide oxides | UNIV GRIFFITH (AU) | 2006-11-29 | — | — | CN | disclosed |
| WO-2006125180-A1 | PIPERAZINE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006125194-A2 | PIPERAZINE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006125181-A2 | PIPERIDINE DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006122344-A1 | POLYMERISATION AGENT | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006125178-A2 | TRICYCLIC PYRIDAZINE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006125179-A1 | TRICYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-11-23 | — | — | WO | disclosed |
| US-7138418-B2 | For therapy of atherosclerosis and hypercholesterolemia; 5-Pentafluorophenylsulfonamidoindazole for example; increasing LDL receptor gene expression in a cell | AMGEN, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060258659-A1 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| EP-0968206-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LAB (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7135468-B2 | Antibacterial compounds | ABBOTT LABORATORIES (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| US-20060252798-A1 | Metal ion chelators and therapeutic use thereof | RICHARDSON, DESI (AU) | 2006-11-09 | — | — | US | disclosed |
| WO-2006116817-A1 | PESTICIDAL FORMULATIONS | AKHIL TECHNOLOGIES PTY LTD (AU) | 2006-11-09 | — | — | WO | disclosed |
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| US-20060252758-A1 | Spiroheterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | QLT INC. (CA) | 2006-11-02 | — | — | US | disclosed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | disclosed |
| WO-2006113875-A2 | 2 - PYRROLIDONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND PAIN | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006113247-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006113864-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
| EP-1713483-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | Schering Aktiengesellschaft (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | US | disclosed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110918-A1 | PYRROLE COMPOUNDS AND USES THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110112-A2 | STABILISER COMPOSITION FOR HALIDE-CONTAINING POLYMERS | SUN ACE KAKOH (PTE.) LTD. (SG) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110654-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235061-A1 | Methods of using benzothiophenone derivatives to treat cancer or inflammation | QLT,INC. (CA) | 2006-10-19 | — | — | US | disclosed |
| EP-1078010-B1 | NON-ELASTOMERIC POLYURETHANE COMPOSITIONS | AORTECH BIOMATERIALS PTY LTD (AU) | 2006-10-18 | — | — | EP | disclosed |
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | disclosed |
| US-7122571-B2 | Substituted hydrazones as inhibitors of cyclooxygenase-2 | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-10-17 | — | — | US | disclosed |
| US-7122694-B2 | Hydroboronation process | BORON MOLECULAR PTY LIMITED (AU) | 2006-10-17 | — | — | US | disclosed |
| US-7122699-B2 | Process for preparing organic boronic acid derivatives using diboronic acid | BORON MOLECULAR LIMITED (AU) | 2006-10-17 | — | — | US | disclosed |
| WO-2006108149-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
| US-20060229310-A1 | Antibacterial compounds | ABBOTT LABORATORIES | 2006-10-12 | — | — | US | disclosed |
| US-7119203-B2 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| WO-2006104461-A1 | NAPHTHALAMIDE DERIVATIVES HAVING ANTIPROLIFERATIVE ACTIVITY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102717-A1 | MODULATING ANGIOGENESIS WITH NOD FACTORS SUCH AS GLUCOSAMINE OLIGOSACCHARIDES | PARISH CHRISTOPHER RICHARD (AU) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223936-A1 | Polymerization of a dispersion having a continuous aqueous phase and a dispersed organic phase of an unsaturated monomer(s), and an amphiphilic RAFT agent, which is an addition polymer residue capped with a compound containing a dithio ester or a trithiocarbonate group; paint, filler, adhesive, seals | UNIVERSITY OF SYDNEY (AU) | 2006-10-05 | — | — | US | disclosed |
| EP-1423392-B1 | DERIVATIVES OF MORPHINE-LIKE OPIOID COMPOUNDS | NEURO THERAPEUTICS LTD (AU) | 2006-10-04 | — | — | EP | disclosed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | disclosed |
| CN-1277855-C | Novel fluoroalkyl polymers containing cationic segment | 3M INNOVATIVE PROPERTIES CO (US) | 2006-10-04 | — | — | CN | disclosed |
| US-7115632-B1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2006101521-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006099685-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CARCINOMAS | MEDICAL THERAPIES LIMITED (AU) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006099677-A1 | METAL COMPLEXES | MEDICAL THERAPIES LIMITED (AU) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006099684-A1 | COPPER COMPLEXES | MEDICAL THERAPIES LIMITED (AU) | 2006-09-28 | — | — | WO | disclosed |
| EP-1701988-A1 | POLYURETHANES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2006-09-20 | — | — | EP | disclosed |
| US-20060205713-A1 | Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders; [4-(6-Phenethyloxy-pyridazin-3-yl)piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; stearoyl-CoA desaturase modulators | XENON PHARMACEUTICALS INC. (CA) | 2006-09-14 | — | — | US | disclosed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| WO-2006093518-A2 | THIENYL COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | APATH, LLC (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1697377-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2006-09-06 | — | — | EP | disclosed |
| EP-1515943-B1 | USE OF ALKYLAMIDOMANDELATES AS FLAVOURINGS | SYMRISE GMBH & CO KG (DE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006086447-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| US-20060183782-A1 | Methods of using thiazolidine derivatives to treat cancer or inflammation | QLT INC. (CA) | 2006-08-17 | — | — | US | disclosed |
| EP-1689698-A1 | BIS-CATIONIC COMPOUNDS AND USE THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2006-08-16 | — | — | EP | disclosed |
| EP-1534284-A4 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689388-A1 | ASSOCIATION OF ANTIMICROBIAL COMPOUNDS WITH SURFACES AND POLYMERS | Biosignal Limited (AU) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689706-A2 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689743-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7091338-B2 | Purification of 4,4′(5′)- di-t-butylcyclohexano-18-crown-6 | PG RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060173004-A1 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG (CH) | 2006-08-03 | — | — | US | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060167271-A1 | Purified compounds that inhibit intracellular alphax4/paxillin binding | GINSBERG MARK | 2006-07-27 | — | — | US | disclosed |
| US-20060167317-A1 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-07-27 | — | — | US | disclosed |
| US-20060167000-A1 | Neurologically-active compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2006-07-27 | — | — | US | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | disclosed |
| US-7078403-B1 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2006-07-18 | — | — | US | disclosed |
| WO-2006074455-A2 | METHOD FOR TRANSFORMATION OF CONVENTIONAL AND COMMERCIALLY IMPORTANT POLYMERS INTO DURABLE AND RECHARGEABLE ANTIMICROBIAL POLYMERIC MATERIALS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1678133-A1 | SEQUENCE SELECTIVE PYRROLE AND IMIDAZOLE POLYAMIDE METALLOCOMPLEXES | University of Western Sydney (AU) | 2006-07-12 | — | — | EP | disclosed |
| US-20060148848-A1 | Compounds and methods for treating cancer and inflammation | QLT, INC. | 2006-07-06 | — | — | US | disclosed |
| EP-1675812-A2 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006066362-A1 | METHODS OF TREATING PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-06-29 | — | — | WO | disclosed |
| EP-1539700-A4 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LTD (AU) | 2006-06-28 | — | — | EP | disclosed |
| CN-1795185-A | Process for preparing substituted pyrazoles | PHARMACIA CORP (US) | 2006-06-28 | — | — | CN | disclosed |
| US-7067670-B2 | Sulfamato hydroxamic acid metalloprotease inhibitor | WARNER LAMBERT COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | BAUMAN JOHN G | 2006-06-22 | — | — | US | disclosed |
| WO-2006063408-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS | STOCKER RONALD O (AU) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20060128608-A1 | Novel chemical compounds and their use | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2006-06-15 | — | — | US | disclosed |
| EP-1664071-A1 | NOVEL SULFENAMIDE OXIDES | GRIFFITH UNIVERSITY (AU) | 2006-06-07 | — | — | EP | disclosed |
| EP-1664072-A1 | NOVEL SULFENAMIDES | GRIFFITH UNIVERSITY (AU) | 2006-06-07 | — | — | EP | disclosed |
| EP-1296673-A4 | ANTIMICROBIAL COATINGS | UNISEARCH LTD (AU) | 2006-06-07 | — | — | EP | disclosed |
| US-7057049-B2 | Process for making substituted pyrazoles | PHARMACIA CORPORATION (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1660089-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MYOCARDITIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-31 | — | — | EP | disclosed |
| US-20060111309-A1 | Chalcomycin derivatives | BIOFRONTERA DISCOVERY GMBH (DE) | 2006-05-25 | — | — | US | disclosed |
| US-20060111381-A1 | Amidine compounds | MONASH UNIVERSITY (AU) | 2006-05-25 | — | — | US | disclosed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | disclosed |
| EP-1463765-A4 | AQUEOUS DISPERSIONS OF POLYMER PARTICLES | UNIV SYDNEY (AU) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006047269-A2 | PHARMACEUTICAL COMPOSITIONS | EXELIXIS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| EP-1651605-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651606-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651616-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651620-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | disclosed |
| US-20060089380-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LTD. (AU) | 2006-04-27 | — | — | US | disclosed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | disclosed |
| US-20060083678-A1 | Radio-labeled compounds, compositions, and methods of making the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-04-20 | — | — | US | disclosed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060083858-A1 | Generation of surface coating diversity | ANTEO TECHNOLOGIES PTY LTD (AU) | 2006-04-20 | — | — | US | disclosed |
| WO-2006040666-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | BARTA THOMAS E | 2006-04-20 | — | — | US | disclosed |
| WO-2006041808-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | disclosed |
| EP-1487428-A4 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2006037159-A1 | SELECTIVE INHIBITORS | ALCHEMIA LIMITED (AU) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006037161-A1 | SURFACE POLYMERISATION PROCESS AND POLYMER PRODUCT USING RAFT AGENT | THE UNIVERSITY OF SYDNEY (AU) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006037185-A1 | NOVEL SULFENAMIDES AND SULFENAMIDE OXIDES | GRIFFITH UNIVERSITY (AU) | 2006-04-13 | — | — | WO | disclosed |
| US-7026323-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | disclosed |
| US-7026423-B2 | Silicon-based polycarbonates | AORTECH BIOMATERIALS PTY LTD. (AU) | 2006-04-11 | — | — | US | disclosed |
| US-20060074243-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | PHARMACIA CORPORATION | 2006-04-06 | — | — | US | disclosed |
| WO-2006034547-A1 | GELS | AORTECH BIOMATERIALS PTY LTD (AU) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006032537-A2 | USE OF EPOTHILONES IN THE TREATMENT OF BONE METASTASES AND BONE TUMORS OR CANCERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034441-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034312-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF STEAROYL-COA-DESATURASE (SCD) | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034446-A2 | PYRIDINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034279-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| US-20060069136-A1 | Use of Epothilones in the treatment of bone metastasis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | US | disclosed |
| WO-2006034338-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034440-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034341-A2 | PYRIDAZINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| EP-1640004-A1 | Use of epothilones in the treatment of bone metastases and bone tumors or cancers | Schering Aktiengesellschaft (DE) | 2006-03-29 | — | — | EP | disclosed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
| US-7019000-B1 | Method of treating a disease condition caused or exacerbated by an HPV | INSTITUTE OF MOLECULAR & CELL BIOLOGY (SG) | 2006-03-28 | — | — | US | disclosed |
| WO-2006026832-A1 | ENZYME INHIBITORS AND USES THEREOF | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2006-03-16 | — | — | WO | disclosed |
| US-7012142-B2 | Process for preparation of bicyclic and polycyclic molecules | MONASH UNIVERSITY (AU) | 2006-03-14 | — | — | US | disclosed |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-03-09 | — | — | US | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024068-A1 | POLYMER COMPOSITE | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-03-09 | — | — | WO | disclosed |
| EP-1628987-A2 | MANNOSE-6-PHOSPHONATE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Pharmaxis Pty Ltd. (AU) | 2006-03-01 | — | — | EP | disclosed |
| US-20060035838-A1 | Drug therapy for celiac sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-02-16 | — | — | US | disclosed |
| WO-2006014168-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-02-09 | — | — | WO | disclosed |
| US-6995156-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-02-07 | — | — | US | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1621533-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2006-02-01 | — | — | EP | disclosed |
| EP-1615866-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | Inflazyme Pharmaceuticals, Ltd. (CA) | 2006-01-18 | — | — | EP | disclosed |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| EP-1613616-A2 | PROCESS FOR MAKING SUBSTITUTED PYRAZOLES | Pharmacia Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005123645-A1 | REGULATORS OF BACTERIAL SIGNALLING PATHWAYS | BIOSIGNAL LIMITED (AU) | 2005-12-29 | — | — | WO | disclosed |
| EP-1478760-A4 | ESTERASES WITH LIPASE ACTIVITY | COMMW SCIENT IND RES ORG (AU) | 2005-12-28 | — | — | EP | disclosed |
| EP-1379508-A4 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1332138-B1 | RADIOPHARMACEUTICALS FOR DIAGNOSING ALZHEIMER'S DISEASE | SCHERING AG (DE) | 2005-12-28 | — | — | EP | disclosed |
| EP-1608623-A1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | UNISEARCH LIMITED (AU) | 2005-12-28 | — | — | EP | disclosed |
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2005-12-22 | — | — | US | disclosed |
| US-6977258-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-20 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| US-6972290-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-06 | — | — | US | disclosed |
| WO-2005111112-A2 | CELLULOSE AND ACRYLIC BASED POLYMERS AND THE USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES | NOVA FLUX BIOSCIENCES, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005107436-A1 | METHOD OF ALTERING THE ALKALOID COMPOSITION IN POPPY PLANTS | GLAXOSMITHKLINE AUSTRALIA PTY LTD (AU) | 2005-11-17 | — | — | WO | disclosed |
| US-20050256066-A1 | Water soluble groups on ring A; antitumor antibiotics; 1-Desoxy-5-C-[(8R)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3-yl]pentitol; topoisomerase inhibitors; cyclodextrin inclusions; stereoisomers | BIOFRONTERA DISCOVERY GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| US-20050256150-A1 | Enantioselective acyl transfer catalysts and their use in kinetic resolution of alcohols and desymmetrization of meso-diols | WASHINGTON UNIVERSITY | 2005-11-17 | — | — | US | disclosed |
| EP-0981517-B1 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES | UNIV AUSTRALIAN (AU) | 2005-11-16 | — | — | EP | disclosed |
| CN-1227229-C | Ethylene derivatives and pesticides containing the same | NISSAN CHEMICAL IND LTD (JP) | 2005-11-16 | — | — | CN | disclosed |
| US-20050250674-A1 | Nutritional and food supplement preparation comprising creatine and orotic acid complexes, derivatives and analogs | AMATO DANIEL | 2005-11-10 | — | — | US | disclosed |
| US-6962929-B2 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. (US) | 2005-11-08 | — | — | US | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-6958145-B2 | Synthesis of cyclic compounds | UNISEARCH LIMITED (AU) | 2005-10-25 | — | — | US | disclosed |
| US-20050234053-A1 | 9-oxo-3,4,6,9-tetrahydro-2H-[1,4]-(oxazino, thiazino, or pyrazino)[3,2-b][1,8]naphthyridine-8-carboxylic acids; fish or mammals; bacterial protein biosynthesis inhibitors | ABBVIE INC. | 2005-10-20 | — | — | US | disclosed |
| WO-2005097140-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005094809-A1 | A COMPOSITION CONTAINING A COMPLEX COMPRISING A METAL ION AND A CARBOXYLATE LIGAND HAVING ANTI-INFLAMMATORY ACTIVITY | MEDICAL THERAPIES LIMITED (AU) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095347-A1 | GELDANAMYCIN AND DERIVATIVES INHIBIT CANCER INVASION AND IDENTIFY NOVEL TARGETS | VAN ANDEL RESEARCH INSTITUTE (US) | 2005-10-13 | — | — | WO | disclosed |
| CN-1678602-A | 2-oxabicyclo [3.3.0] octane compounds, process for producing the same, optical resolution agent, process for separating diastereomer mixture, and process for optically resolving alcohol | ZEON CORP (JP) | 2005-10-05 | — | — | CN | disclosed |
| US-20050215772-A1 | Furanone derivatives and methods of making same | BIOSIGNAL LIMITED (AT) | 2005-09-29 | — | — | US | disclosed |
| US-20050215579-A1 | Fredericamycin derivatives as medicaments for treating tumours | BIOFRONTERA DISCOVERY GMBH (DE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005090351-A1 | METHOD FOR PREPARING COMPOUNDS COMPRISING CUCURBITURIL GROUPS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2005-09-29 | — | — | WO | disclosed |
| CN-1220676-C | Method for producing acid anhydride | TOKUYAMA CORP (JP) | 2005-09-28 | — | — | CN | disclosed |
| US-20050208084-A1 | Use of alkylamidomandelates as flavourings | SYMRISE GMBH & CO. KG (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20050209278-A1 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-09-22 | — | — | US | disclosed |
| EP-1572660-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1476149-A4 | SUBSTITUTED HYDRAZONES AS INHIBITORS OF CYCLOOXYGENASE-2 | UNIV TEMPLE (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1112250-A4 | THERAPEUTIC COMPOUNDS AND METHODS | INST OF MOLECUL & CELL BIOLOGY (SG) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005082873-A2 | 1,4-BENZOTHIAZEPANS AND DERIVATIVES THEREOF | BIOAGENCY AG (DE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005079769-A2 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-01 | — | — | WO | disclosed |
| US-20050192282-A1 | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-01 | — | — | US | disclosed |
| US-20050191385-A1 | Natural product derivatives as food supplements and pharmaceuticals | AMATO DANIEL K (US) | 2005-09-01 | — | — | US | disclosed |
| WO-2005080549-A2 | TRIOXACARCINS AND THEIR USE AGAINST INFECTIONS | BIOFRONTERA DISCOVERY GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005077372-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-25 | — | — | WO | disclosed |
| EP-1565459-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-08-24 | — | — | EP | disclosed |
| CN-1215835-C | Ketone derivatives and medical use thereof | TORAY INDUSTRIES (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1216056-C | Sulfamidohydroxamic acid metalloprotease inhibitor | SEARLE & CO (US) | 2005-08-24 | — | — | CN | disclosed |
| WO-2005075527-A1 | HYPERBRANCHED POLYMERS | THE GENERAL HOSPITAL CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005075477-A1 | ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | disclosed |
| EP-1534755-A4 | GENERATION OF SURFACE COATING DIVERSITY | BIO LAYER PTY LTD (AU) | 2005-08-17 | — | — | EP | disclosed |
| EP-1562928-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050176118-A1 | Esterases with lipase activity | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2005-08-11 | — | — | US | disclosed |
| WO-2005072731-A1 | 3-PHENYL-N- ((1, 3, 4) THIADIAZOL-2-YL) -ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ESTROGEN-RELATED RECEPTORS FOR THE TREATMENT OF E.G. CANCER, RHEUMATOID ARTHRITIS OR NEUROLOGICAL DISORDERS | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| EP-1558585-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | Prana Biotechnology Ltd (AU) | 2005-08-03 | — | — | EP | disclosed |
| EP-1558594-A2 | 1-(4-BENZYL-PIPERAZIN-1-YL)-3-PHENYL-PROPENONE DERIVATIVES | Novartis AG (CH) | 2005-08-03 | — | — | EP | disclosed |
| EP-1558617-A1 | AMIDINE COMPOUNDS | Monash University (AU) | 2005-08-03 | — | — | EP | disclosed |
| US-20050164999-A1 | Benzamides and compositions benzamides for use as fungicizide | E. I. DU PONT DE NEMOURS AND COMPANY | 2005-07-28 | — | — | US | disclosed |
| US-20050159423-A1 | Antibacterial compounds | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| US-20050154004-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | AUSTRALIAN NATIONAL UNIVERSITY, THE (AU) | 2005-07-14 | — | — | US | disclosed |
| US-20050153997-A1 | Fredericamycin derivatives | BIOFRONTERA DISCOVERY GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| US-6916805-B2 | Quinoxalinones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-07-12 | — | — | US | disclosed |
| WO-2005061485-A1 | PROCESS FOR MAKING SUBSTITUTED PYRAZOLES | PHARMACIA CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061513-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2005-07-07 | — | — | WO | disclosed |
| US-20050148669-A1 | Amino acid esters as nutrient supplements and methods of use | AMATO DANIEL (US) | 2005-07-07 | — | — | US | disclosed |
| EP-1542997-A2 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | QLT, Inc. (CA) | 2005-06-22 | — | — | EP | disclosed |
| US-20050130942-A1 | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-06-16 | — | — | US | disclosed |
| US-20050130221-A1 | Synthesis for the preparation of compounds for screening as potential tubulin binding agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2005-06-16 | — | — | US | disclosed |
| WO-2005053684-A1 | ASSOCIATION OF ANTIMICROBIAL COMPOUNDS WITH SURFACES AND POLYMERS | BIOSIGNAL LIMITED (AU) | 2005-06-16 | — | — | WO | disclosed |
| EP-1539700-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | Prana Biotechnology Ltd (AU) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539675-A2 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005052019-A1 | POLYURETHANES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2005-06-09 | — | — | WO | disclosed |
| US-20050124559-A1 | Antimicrobial agent | UNIVERSITY, MONASH (AU) | 2005-06-09 | — | — | US | disclosed |
| WO-2005051960-A2 | HYDROCARBYL AMINOHYDROCARBONOATES AND AMINOHYDROCARBONOL HYDROCARBONOATES AS ANTIMICROBIAL AND ANTIVIRAL AGENTS | MIDWEST RESEARCH LABORATORIES, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-1121365-B1 | ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS | COMMW SCIENT IND RES ORG (AU) | 2005-06-08 | — | — | EP | disclosed |
| EP-1019414-B1 | PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID | COMMW SCIENT IND RES ORG (AU) | 2005-06-08 | — | — | EP | disclosed |
| CN-1205198-C | Cyclic ketone derivative and pharmaceutical use thereof | TORAY INDUSTRIES (JP) | 2005-06-08 | — | — | CN | disclosed |
| US-20050119461-A1 | Novel receptor, and compounds which bind thereto | THE UNIVERSITY OF MELBOURNE | 2005-06-02 | — | — | US | disclosed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1534284-A2 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534755-A1 | GENERATION OF SURFACE COATING DIVERSITY | Bio-Layer Pty Limited (AU) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005046599-A2 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050113274-A1 | Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents | MIDWEST RESEARCH LABORATORIES, LLC | 2005-05-26 | — | — | US | disclosed |
| WO-2005047230-A1 | BIS-CATIONIC COMPOUNDS AND USE THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2005-05-26 | — | — | WO | disclosed |
| EP-1254899-B1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-05-25 | — | — | EP | disclosed |
| US-6897318-B2 | Process for making substituted pyrazoles | PHARMACIA CORPORATION (US) | 2005-05-24 | — | — | US | disclosed |
| WO-2005042521-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050101641-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-05-12 | — | — | US | disclosed |
| CN-1615303-A | Improved purification process for 4,4 '(5') -di-tert-butylcyclohexa-18-crown-6 | PG RES FOUNDATION (US) | 2005-05-11 | — | — | CN | disclosed |
| US-6890937-B2 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-6890928-B2 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050096484-A1 | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | ONCONOVA THERAPEUTICS, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6887865-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| WO-2005037755-A2 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | disclosed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| WO-2005033077-A1 | SEQUENCE SELECTIVE PYRROLE AND IMIDAZOLE POLYAMIDE METALLOCOMPLEXES | UNIVERSITY OF WESTERN SYDNEY (AU) | 2005-04-14 | — | — | WO | disclosed |
| EP-1521577-A1 | METHODS OF USING ISOTHIAZOLE DERIVATIVES TO TREAT CANCER OR INFLAMMATION | QLT, Inc. (CA) | 2005-04-13 | — | — | EP | disclosed |
| US-6878690-B2 | Compounds and methods | PHARMAXIS PTY LTD. (AU) | 2005-04-12 | — | — | US | disclosed |
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | PHARMACIA CORPORATION | 2005-04-07 | — | — | US | disclosed |
| EP-1519724-A1 | FREDERICAMYCIN DERIVATIVES AS MEDICAMENTS FOR TREATING TUMOURS | Biofrontera Pharmaceuticals Holding AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| US-6872381-B1 | Radiopharmaceuticals for diagnosing Alzheimer's disease | SCHERING AG (DE) | 2005-03-29 | — | — | US | disclosed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| EP-1515951-A1 | ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1187859-A4 | POLYMER GELS, METHODS FOR THEIR PREPARATION AND THEIR USE IN ELECTROPHORETIC APPLICATIONS | UNIV MELBOURNE (AU) | 2005-03-23 | — | — | EP | disclosed |
| EP-1515943-A1 | USE OF ALKYLAMIDOMANDELATES AS FLAVOURINGS | Symrise GmbH & Co. KG (DE) | 2005-03-23 | — | — | EP | disclosed |
| US-20050054722-A1 | Inhibition of two-component signal transduction systems | UNISEARCH LIMITED, (AU) | 2005-03-10 | — | — | US | disclosed |
| WO-2005021547-A2 | HETEROCYCLIC CANNABINOID CB2 RECEPTOR ANTAGONISTS | PHARMAXIS PTY LTD. (AU) | 2005-03-10 | — | — | WO | disclosed |
| EP-1511743-A1 | PYRAZOLE-DERIVATIVES AS P38 KINASE INHIBITORS | Pharmacia Corporation (US) | 2005-03-09 | — | — | EP | disclosed |
| US-6864263-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-6864368-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLAX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| WO-2005018642-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MYOCARDITIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019237-A1 | NOVEL SULFENAMIDES | GRIFFITH UNIVERSITY (AU) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019236-A1 | NOVEL SULFENAMIDE OXIDES | GRIFFITH UNIVERSITY (AU) | 2005-03-03 | — | — | WO | disclosed |
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-6861424-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050043318-A1 | Chemokine inhibiting piperazine derivatives and their use to treat myocarditis | SCHERING AKTIEGESELLSCHAFT (DE) | 2005-02-24 | — | — | US | disclosed |
| US-20050043533-A1 | Process for making alpha-substituted hydroxamic acids | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| EP-1507772-A1 | METHODS OF USING THIAZOLIDINEDITHIONE DERIVATIVES | QLT, Inc. (CA) | 2005-02-23 | — | — | EP | disclosed |
| EP-1507549-A2 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2005-02-23 | — | — | EP | disclosed |
| US-6858680-B2 | Shape memory polyurethane or polyurethane-urea polymers | AORTECH BIOMATERIALS PTY LTD (AU) | 2005-02-22 | — | — | US | disclosed |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-17 | — | — | US | disclosed |
| EP-1506213-A1 | AN ANTIMICROBIAL AGENT | GRIFFITH UNIVERSITY (AU) | 2005-02-16 | — | — | EP | disclosed |
| EP-1505970-A1 | METHODS OF USING THIAZOLIDINE DERIVATIVES TO TREAT CANCER OR INFLAMMATION | QLT Inc. (CA) | 2005-02-16 | — | — | EP | disclosed |
| US-6855726-B1 | Quinolones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-15 | — | — | US | disclosed |
| WO-2005011656-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005011657-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005011654-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005011653-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
| EP-1453813-A4 | IMPROVED PURIFICATION OF 4, 4'(5')-DI- i t /i -BUTYLCYCLOHEXANO-18-CROWN-6 | PG RES FOUNDATION (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-0934310-B1 | THIO ACID DERIVED MONOCYCLIC N-HETEROCYCLICS AS ANTICOAGULANTS | SCHERING AG (DE) | 2005-02-09 | — | — | EP | disclosed |
| EP-1294705-A4 | SYNTHESIS OF CYCLIC COMPOUNDS | UNISEARCH LTD (AU) | 2005-02-09 | — | — | EP | disclosed |
| US-6852795-B2 | Prepolymeric (meth)acrylates with polycyclic or aromatic segments | 3M ESPE AG (DE) | 2005-02-08 | — | — | US | disclosed |
| EP-1501827-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACID AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| CN-1575176-A | Process for preparing substituted pyrazoles | PHARMACIA CORP (US) | 2005-02-02 | — | — | CN | disclosed |
| US-6849739-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-0983267-B1 | AMIDOAROMATIC RING SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6846829-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20050013939-A1 | Boron-based wood preservatives and treatment of wood with boron-based preservatives | THE UNIVERSITY OF MELBOURNE (AU) | 2005-01-20 | — | — | US | disclosed |
| EP-1497300-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-01-19 | — | — | EP | disclosed |
| EP-0857067-A4 | RADIOPROTECTORS | PETER MACCALLUM CANCER INST (AU) | 2005-01-19 | — | — | EP | disclosed |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-1495003-A1 | FREDERICAMYCIN DERIVATIVES | Biofrontera Discovery Gmbh (DE) | 2005-01-12 | — | — | EP | disclosed |
| US-6841674-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-6841673-B2 | N-heterocyclic derivatives as nos inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-20050000889-A1 | Substrate with interstitial gaps having a polymeric membrane that is thinner than cross-sectional thickness of substrate | SOLOMON DAVID HENRY (AU) | 2005-01-06 | — | — | US | disclosed |
| US-20050004086-A1 | Antiinflammatory agents; antiarthritic agents; brain disorders; multiple sclerosis; gout; inflammatory bowel disorders; gastrointestinal disorders; psoriasis; antiallergens; autoimmune disease | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2005-01-06 | — | — | US | disclosed |
| EP-1353911-A4 | ANTIVIRAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2005-01-05 | — | — | EP | disclosed |
| EP-1000108-B1 | AQUEOUS POLYIMIDE PROCESS | COMMW SCIENT IND RES ORG (AU) | 2005-01-05 | — | — | EP | disclosed |
| EP-1284979-B1 | PREPOLYMERIC (METH)ACRYLATES WITH POLYCYCLIC OR AROMATIC SEGMENTS | 3M ESPE AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| EP-1487428-A2 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6831186-B2 | Antiinflammatory agents; autoimmune disease | SCHERING AKTIENGESELLSCHFT (DE) | 2004-12-14 | — | — | US | disclosed |
| EP-1483253-A1 | AN ANTIMICROBIAL AGENT | GRIFFITH UNIVERSITY (AU) | 2004-12-08 | — | — | EP | disclosed |
| US-20040242929-A1 | Process for production of acid anhydride | TOKUYAMA CORPORATION (JP) | 2004-12-02 | — | — | US | disclosed |
| WO-2004104015-A2 | MANNOSE-6-PHOSPHONATE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | PHARMAXIS PTY LTD. (AU) | 2004-12-02 | — | — | WO | disclosed |
| US-20040242616-A1 | Derivatives of morphine-like opioid compounds | NEURO THERAPEUTICS LIMITED (AU) | 2004-12-02 | — | — | US | disclosed |
| EP-0977745-B1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040235818-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1478760-A1 | ESTERASES WITH LIPASE ACTIVITY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-11-24 | — | — | EP | disclosed |
| EP-1476149-A2 | SUBSTITUTED HYDRAZONES AS INHIBITORS OF CYCLOOXYGENASE-2 | Temple University of the Commonwealth System of Higher Education (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1423392-A4 | DERIVATIVES OF MORPHINE-LIKE OPIOID COMPOUNDS | POLYCHIP PHARMACEUTICALS PTY (AU) | 2004-11-17 | — | — | EP | disclosed |
| US-6818718-B2 | IMPROVED SEPARATION OF PROTEINS, ENZYMES, PEPTIDES, OLIGONUCLEOTIDES, POLYNUCLEOTIDES, AND CARBOHYDRATES | THE UNIVERSITY OF MELBOURNE (AU) | 2004-11-16 | — | — | US | disclosed |
| WO-2004096766-A1 | A METHOD OF INDOLE SYNTHESIS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2004-11-11 | — | — | WO | disclosed |
| EP-1472209-A2 | LIPOXIN A4 ANALOGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-03 | — | — | EP | disclosed |
| EP-1472244-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004091549-A2 | PROCESS FOR MAKING ALPHA-SUBSTITUTED HYDROXAMIC ACIDS | PHARMACIA CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092100-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2004-10-28 | — | — | WO | disclosed |
| EP-1005453-B1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS | TULARIK INC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040209914-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | X-CEPTOR THERAPEUTICS INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004087074-A2 | PROCESS FOR MAKING SUBSTITUTED PYRAZOLES | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| CN-1537097-A | Method for producing acid anhydride | ��ʽ�����ɽ | 2004-10-13 | — | — | CN | disclosed |
| WO-2004085551-A1 | CORROSION INHIBITING COATING | MONASH UNIVERSITY (AU) | 2004-10-07 | — | — | WO | disclosed |
| EP-1463765-A1 | AQUEOUS DISPERSIONS OF POLYMER PARTICLES | University of Sydney (AU) | 2004-10-06 | — | — | EP | disclosed |
| US-6800646-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6794511-B2 | AN ENZYME INHIBITORS OF METALLOPROTEASE; TREATING CONNECTIVE TISSUE DEGRADATION CAUSED BY INFLAMMATION OR TUMOR | G. D. SEARLE | 2004-09-21 | — | — | US | disclosed |
| US-20040176281-A1 | Delivery systems | ALCHEMIA LIMITED (AU) | 2004-09-09 | — | — | US | disclosed |
| EP-1453803-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | Zentaris GmbH (DE) | 2004-09-08 | — | — | EP | disclosed |
| EP-1453813-A2 | IMPROVED PURIFICATION OF 4, 4'(5')-DI- i t /i -BUTYLCYCLOHEXANO-18-CROWN-6 | PG Research Foundation (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040171516-A1 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2004-09-02 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| US-6783809-B2 | LOW VISCOSITY PHOTOCURABLE COMPOSITIONS WHICH, WHEN FULLY CURED, GIVE MOULDED ARTICLES OF EXCELLENT FLEXIBILITY | HUNTSMAN ADVANCED MATERIALS AMERICAS INC. | 2004-08-31 | — | — | US | disclosed |
| US-20040167182-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-08-26 | — | — | US | disclosed |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | disclosed |
| CN-1524095-A | Novel fluoroalkyl polymers containing cationic segment | 3M | 2004-08-25 | — | — | CN | disclosed |
| WO-2004069801-A1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | UNISEARCH LIMITED (AU) | 2004-08-19 | — | — | WO | disclosed |
| US-20040162433-A1 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | US | disclosed |
| EP-1334092-A4 | PROCESS FOR PREPARATION OF BICYCLIC AND POLYCYCLIC MOLECULES | UNIV MONASH (AU) | 2004-08-11 | — | — | EP | disclosed |
| WO-2004065334-A1 | METHOD OF REMOVING ORGANOTIN RESIDUE | CHIROGEN PTY LIMITED (AU) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004065335-A1 | ENANTIOSELECTIVE REDUCTION METHOD | CHIROGEN PTY LIMITED (AU) | 2004-08-05 | — | — | WO | disclosed |
| US-20040147595-A1 | Biofilm degrading or sloughing compositions and methods | UNISEARCH LIMITED (AU) | 2004-07-29 | — | — | US | disclosed |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
| US-20040142877-A1 | Ligands of the $g(a)v$g(b)6 integrin | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | US | disclosed |
| US-20040138488-A1 | Benzene-1 2-diol mannich bases ligands polymers and method of selective metal ions removal | TECHNOLOGICAL RESOURCES PTY LTD. (AU) | 2004-07-15 | — | — | US | disclosed |
| WO-2004058717-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040133028-A1 | Hydroboronation process | COMMONWEALTH SCIENTIFIC | 2004-07-08 | — | — | US | disclosed |
| US-20040127524-A1 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| WO-2004054988-A1 | ARYLTHIOETHERPYRIMIDINE AND ARYLOXYETHERPYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USES | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2004-07-01 | — | — | WO | disclosed |
| EP-1429773-A1 | PROCESS FOR MAKING SUBSTITUTED PYRAZOLES | Pharmacia Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004050677-A1 | NOVEL CHEMICAL COMPUNDS AND THEIR USE | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-06-17 | — | — | WO | disclosed |
| US-6750233-B2 | SELECTIVITY | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20040110727-A1 | Aldehyde-releasing compounds | LA TROBE UNIVERSITY (AU) | 2004-06-10 | — | — | US | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040110805-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-06-10 | — | — | US | disclosed |
| US-20040110966-A1 | Synthesis of cyclic compounds | UNISEARCH LIMITED (AU) | 2004-06-10 | — | — | US | disclosed |
| US-6747031-B2 | MUSCLE RELAXANTS, CONTROLLING IMMUNOLOGY, STROKES, ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2004-06-08 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
| EP-1423392-A1 | DERIVATIVES OF MORPHINE-LIKE OPIOID COMPOUNDS | Polychip Pharmaceuticals Pty. Ltd. (AU) | 2004-06-02 | — | — | EP | disclosed |
| CN-1501827-A | Ligands of the alpha-v-beta 6 integrin | Ĭ��ר������˾ | 2004-06-02 | — | — | CN | disclosed |
| WO-2004043350-A2 | PURIFIED COMPOUNDS THAT INHIBIT INTRACELLULAR α4/PAXILLIN BINDING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043943-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040097487-A1 | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds | G.D. SEARLE & CO. | 2004-05-20 | — | — | US | disclosed |
| US-6737111-B2 | POLYMERIC MEMBRANE COMPONENTS RESIDE WITHIN THE INTERSTITIAL GAPS OF THE SUBSTRATE; ULTRA-THIN; POLYMERIZATION AND CROSSLINKING OF POLYACRYLAMIDE GEL | GRADIPORE LIMITED (AU) | 2004-05-18 | — | — | US | disclosed |
| WO-2004037796-A2 | 1-(4-BENZYL-PIPERAZIN-1-YL)-3-PHENYL-PROPENONE DERIVATIVES | NOVARTIS AG (CH) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037751-A2 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040082551-A1 | Novel pyrazoles and their use as p38 kinase inhibitors | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
| WO-2004035598-A2 | CHALCOMYCIN DERIVATIVES | BIOFRONTERA DISCOVERY GMBH (DE) | 2004-04-29 | — | — | WO | disclosed |
| EP-1413572-A1 | PROCESS FOR PRODUCING ACID ANHYDRIDE | Tokuyama Corporation (JP) | 2004-04-28 | — | — | EP | disclosed |
| EP-0888271-B1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY AMINO ACID AND HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2004-04-28 | — | — | EP | disclosed |
| CN-1147294-C | Pentafluorobenzenesulfonamides and analogs | �㽭�пؼ����ɷ�����˾ | 2004-04-28 | — | — | CN | disclosed |
| WO-2004033458-A1 | AMIDINE COMPOUNDS | MONASH UNIVERSITY (AU) | 2004-04-22 | — | — | WO | disclosed |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2004-04-22 | — | — | US | disclosed |
| WO-2004031198-A1 | ENANTIOSELECTIVE REDUCTIVE METHODS USING CHIRAL ORGANOSTANNANES | CHIROGEN PTY LIMITED (AU) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031161-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-04-15 | — | — | WO | disclosed |
| EP-1301522-A4 | NOVEL COMPOUNDS AND METHODS | PHARMAXIS PTY LTD (AU) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406602-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406626-A2 | SULPHONYL ARYL HYDROXAMATES AND THEIR USE AS MMP INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1127060-B1 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2004-04-07 | — | — | EP | disclosed |
| CN-1144793-C | Polar-substituted hydrocarbons | ˮ�ɺ� | 2004-04-07 | — | — | CN | disclosed |
| US-6716844-B2 | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | PHARMACIA CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040063661-A1 | Treatment of statin side effects | MAGRAL LIMITED (AU) | 2004-04-01 | — | — | US | disclosed |
| US-6713566-B1 | CATALYTIC HYDROBORATION OF OLEFINIC OR ACETYLENIC FUNCTIONA-LIZED MATERIAL UNDER MILD CONDITIONS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-03-30 | — | — | US | disclosed |
| EP-1071684-B1 | IMIDAZO 1,2-a]PYRIDINES AS PERIPHERAL BENZODIAZEPINE RECEPTOR BINDING AGENTS | AUSTRALIAN NUCLEAR SCIENCE TEC (AU) | 2004-03-17 | — | — | EP | disclosed |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-03-11 | — | — | US | disclosed |
| WO-2003097657-A9 | AN ANTIMICROBIAL AGENT | UNIV GRIFFITH (AU) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004019986-A1 | METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004018487-A1 | CHIRAL ORGANOSILICON HYDRIDES | CHIROGEN PTY LIMITED (AU) | 2004-03-04 | — | — | WO | disclosed |
| EP-1390337-A1 | PRECURSORS FOR KETONES AND ALDEHYDES | Givaudan SA (CH) | 2004-02-25 | — | — | EP | disclosed |
| US-6696611-B2 | Chemical methods | CHIROGEN PTY. LIMITED (AU) | 2004-02-24 | — | — | US | disclosed |
| US-6696449-B2 | CONTROL DEGRADATION OF CONENCTING TISSUE; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | PHARMACIA CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-6689794-B2 | SUPPRESSING MATRIX METALLOPROTEINASE AND/OR AGGRECANASE ACTIVITY | PHARMACIA CORPORATION | 2004-02-10 | — | — | US | disclosed |
| US-20040024024-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-02-05 | — | — | US | disclosed |
| WO-2004011460-A2 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | QLT, INC. (CA) | 2004-02-05 | — | — | WO | disclosed |
| WO-2004011473-A1 | ORGANOGERMANIUM COMPOUNDS AND METHODS FOR THEIR USE | CHIROGEN PTY LIMITED (AU) | 2004-02-05 | — | — | WO | disclosed |
| EP-1385836-A2 | AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-0813525-B9 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6686364-B2 | 4-HYDROXY-3-((3,5-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6683093-B2 | ENZYME INHIBITORS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6683078-B2 | REDUCING DEGRADATION OF CONNECTIVE TISSUE DUE TO CANCER OR INFLAMMATION | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| WO-2004007461-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-01-22 | — | — | WO | disclosed |
| US-6680401-B1 | BORON COMPOUNDS SUCH AS 4-(METHOXYMETHYL)-1,3,2-DIOXABOROLANE, USED AS COUPLERS OR CHEMICAL INTERMEDIATES FOR DRUGS, PESTICIDES OR IN COMBINATORIAL CHEMISTRY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-01-20 | — | — | US | disclosed |
| WO-2004004834-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND INFLAMMATION | QLT INC. (CA) | 2004-01-15 | — | — | WO | disclosed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | disclosed |
| US-20040010140-A1 | Process for preparation of bicyclic and polycyclic molecules | MONASH UNIVERSITY (AU) | 2004-01-15 | — | — | US | disclosed |
| US-20040010019-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-01-15 | — | — | US | disclosed |
| WO-2004004713-A1 | FREDERICAMYCIN DERIVATIVES AS MEDICAMENTS FOR TREATING TUMOURS | BIOFRONTERA DISCOVERY GMBH (DE) | 2004-01-15 | — | — | WO | disclosed |
| EP-1379508-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6676926-B2 | FOR ADMINISTERING TO A HUMAN IN NEED OF SUCH DIAGNOSIS AND MEASURING THE RADIOACTIVITY ARISING FROM THE ADMINISTRATION OF THE COMPOUND TO THE HUMAN EITHER BY USING A GAMMA CAMERA OR BY POSITRON EMISSION TOMOGRAPHY | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20040002424-A1 | 2-Amino-4-bicyclylamino-6H-1,3,5-triazines, processes for their preparation and their use as herbicides and plant growth regulators | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-01-01 | — | — | US | disclosed |
| WO-2004000314-A1 | METHODS OF USING BENZOTHIOPHENONE DERIVATIVES TO TREAT CANCER OR INFLAMMATION | QLT INC. (CA) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000811-A1 | ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
| CN-1132836-C | Synthesis of various lamellarin compounds and analogs and intermediates | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2003-12-31 | — | — | CN | disclosed |
| US-6670473-B2 | Inhibitors of nitric oxide synthase (nos) | BERLEX LABORATORIES, INC. | 2003-12-30 | — | — | US | disclosed |
| WO-2003106404-A1 | USE OF ALKYLAMIDOMANDELATES AS FLAVOURINGS | SYMRISE GMBH & CO. KG (DE) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003105843-A1 | METHODS OF USING ISOTHIAZOLE DERIVATIVES TO TREAT CANCER OR INFLAMMATION | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003103675-A2 | COMBINATION TREATMENTS FOR PURINOCEPTOR-RELATED DISORDERS | ENDACEA, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003104223-A1 | PYRAZOLE-DERIVATIVES AS P38 KINASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030232766-A1 | Combinatorial libraries of monosaccharides | VAST BIOSCIENCE PTY LIMITED (AU) | 2003-12-18 | — | — | US | disclosed |
| EP-1206467-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LAB (US) | 2003-12-17 | — | — | EP | disclosed |
| WO-2003101373-A2 | THIAZOLIDINEDIONE DERIVATIVES IN THERAPEUTIC AND PROPHYLACTIC METHODS | QLT INC. (CA) | 2003-12-11 | — | — | WO | disclosed |
| US-20030224942-A1 | Alkylamino-1,3,5-triazines, processes for their preparation and their use as herbicides and plant growth regulators | AHRENS HARTMUT (DE) | 2003-12-04 | — | — | US | disclosed |
| US-20030225108-A1 | Process for making substituted pyrazoles | PHARMACIA CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-20030224032-A1 | Antimicrobial coatings | UNISEARCH LIMITED (AU) | 2003-12-04 | — | — | US | disclosed |
| EP-1366015-A1 | BENZENE-1 2-DIOL MANNICH BASES LIGANDS POLYMERS AND METHOD OF SELECTIVE METAL IONS REMOVAL | TECHNOLOGICAL RESOURCES PTY. LTD. (AU) | 2003-12-03 | — | — | EP | disclosed |
| US-6656954-B2 | Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity | PHARMACIA CORPORATION | 2003-12-02 | — | — | US | disclosed |
| WO-2003097657-A1 | AN ANTIMICROBIAL AGENT | GRIFFITH UNIVERSITY (AU) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097621-A1 | METHODS OF USING THIAZOLIDINEDITHIONE DERIVATIVES | QLT INC. (CA) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003096979-A2 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030220520-A1 | Process for preparing organic boronic acid derivatives using diboronic acid | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-11-27 | — | — | US | disclosed |
| EP-1363880-A1 | SYNTHESIS FOR THE PREPARATION OF COMPOUNDS FOR SCREENING AS POTENTIAL TUBULIN BINDING AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003095494-A1 | GENERATION OF SURFACE COATING DIVERSITY | BIO-LAYER PTY LIMITED (AU) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003094916-A1 | METHODS OF USING THIAZOLIDINE DERIVATIVES TO TREAT CANCER OR INFLAMMATION | QLT INC. (CA) | 2003-11-20 | — | — | WO | disclosed |
| EP-0973392-B1 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | MONSANTO CO (US) | 2003-11-19 | — | — | EP | disclosed |
| US-6646009-B2 | Use against proliferative disorders including cancer, and as a radioprotective compound for normal cells from ionizing radiation | Temple University — Of Commonwealth System of Higher Education | 2003-11-11 | — | — | US | disclosed |
| WO-2003091247-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-1358155-A1 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMATES AND THEIR USE AS MMP INHIBITORS | Pharmacia Corporation (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003087060-A1 | FREDERICAMYCIN DERIVATIVES | BIOFRONTERA DISCOVERY GMBH (DE) | 2003-10-23 | — | — | WO | disclosed |
| US-20030198692-A1 | Microbial inhibitory compositions | UNISEARCH LIMITED (AU) | 2003-10-23 | — | — | US | disclosed |
| EP-1353911-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2003-10-22 | — | — | EP | disclosed |
| EP-1149075-A4 | SYNTHESIS OF DITHIOESTER CHAIN TRANSFER AGENTS AND USE OF BIS(THIOACYL) DISULFIDES OR DITHIOESTERS AS CHAIN TRANSFER AGENTS | DU PONT (US) | 2003-10-22 | — | — | EP | disclosed |
| CN-1449379-A | Sulfonium salt compound | WAKO PURE CHEM IND LTD (JP) | 2003-10-15 | — | — | CN | disclosed |
| US-20030191144-A1 | Compounds, compositions and methods for modulating beta-amyloid production | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-10-09 | — | — | US | disclosed |
| US-20030191317-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO., (US) | 2003-10-09 | — | — | US | disclosed |
| WO-2003080631-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | disclosed |
| US-20030187035-A1 | Substituted hydrazones as inhibitors of cyclooxygenase-2 | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-10-02 | — | — | US | disclosed |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | disclosed |
| EP-0813525-B1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2003-10-01 | — | — | EP | disclosed |
| EP-0920430-B1 | PURINE DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | SCHERING AG (DE) | 2003-09-24 | — | — | EP | disclosed |
| EP-0984959-B1 | AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030176363-A1 | Novel compounds and methods | PHARMAXIS PTY LTD. (AU) | 2003-09-18 | — | — | US | disclosed |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | PHARMACIA CORPORATION | 2003-09-11 | — | — | US | disclosed |
| EP-0896533-B1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1000070-B1 | SILICON-CONTAINING CHAIN EXTENDERS | AORTECH BIOMATERIALS PTY LTD (AU) | 2003-09-10 | — | — | EP | disclosed |
| EP-0939627-B1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030166816-A1 | Prepolymeric (meth) acrylates with polycyclic or aromatic segments | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-04 | — | — | US | disclosed |
| WO-2003072063-A2 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072062-A2 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20030166979-A1 | Catalytic reduction using hydrogen | DAKTERNIEKS DAINIS (AU) | 2003-09-04 | — | — | US | disclosed |
| WO-2003070715-A1 | AN ANTIMICROBIAL AGENT | GRIFFITH UNIVERSITY (AU) | 2003-08-28 | — | — | WO | disclosed |
| US-20030162817-A1 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. | 2003-08-28 | — | — | US | disclosed |
| US-20030158205-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | US | disclosed |
| WO-2003066873-A1 | ESTERASES WITH LIPASE ACTIVITY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-08-14 | — | — | WO | disclosed |
| EP-1334092-A1 | PROCESS FOR PREPARATION OF BICYCLIC AND POLYCYCLIC MOLECULES | Monash University (AU) | 2003-08-13 | — | — | EP | disclosed |
| EP-1334719-A2 | Pentafluorobenzenesulfonamides and analogs | TULARIK, INC. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030148062-A1 | POLYMERIC MEMBRANE COMPONENTS RESIDE WITHIN THE INTERSTITIAL GAPS OF THE SUBSTRATE; ULTRA-THIN; POLYMERIZATION AND CROSSLINKING OF POLYACRYLAMIDE GEL | SOLOMON DAVID HENRY (AU) | 2003-08-07 | — | — | US | disclosed |
| EP-1332138-A1 | RADIOPHARMACEUTICALS FOR DIAGNOSING ALZHEIMER'S DISEASE | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-06 | — | — | EP | disclosed |
| US-6603004-B2 | Reacting diboron tetrahydroxide with boronic acid derivatives in presence of group 8-11 metal catalyst; one pot; no need for hydrolysis or hydrogenolysis | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-08-05 | — | — | US | disclosed |
| US-20030144302-A1 | Process for making substituted pyrazoles | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20030139376-A1 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| US-20030139425-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| US-20030139470-A1 | 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants | HAARMANN & REIMER GMBH (DE) | 2003-07-24 | — | — | US | disclosed |
| WO-2003055919-A1 | AQUEOUS DISPERSIONS OF POLYMER PARTICLES | UNIVERSITY OF SYDNEY (AU) | 2003-07-10 | — | — | WO | disclosed |
| US-20030125381-A1 | Inhibition of two-component signal transduction systems | UNISEARCH LIMITED (AU) | 2003-07-03 | — | — | US | disclosed |
| US-6585873-B1 | Polymer gels and methods for their preparation | UNIVERSITY OF MELBOURNE (AU) | 2003-07-01 | — | — | US | disclosed |
| WO-2003051837-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | ZENTARIS GMBH (DE) | 2003-06-26 | — | — | WO | disclosed |
| US-6583299-B1 | Matrix metalloprotease inhibitors; nonsuppression of tumor necrosis factor production | G.D. SEARLE & CO. | 2003-06-24 | — | — | US | disclosed |
| WO-2003049698-A2 | SUBSTITUTED HYDRAZONES AS INHIBITORS OF CYCLOOXYGENASE-2 | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030114638-A1 | Alkene borates and a process for covalently coupling organic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-06-19 | — | — | US | disclosed |
| US-20030104945-A1 | 2,4-Diamino-1,3,5-triazines, their preparation, and their use as herbicides and plant growth regulators | AVENTIS CROPSCIENCE GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2003045944-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-20030105375-A1 | Purification of 4,4'(5')- di-t-butylcyclohexano-18-crown-6 | PG RESEARCH FOUNDATION | 2003-06-05 | — | — | US | disclosed |
| US-6573266-B1 | Compounds used for treating multitiple sclerosis and encephalomyelitis | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| WO-2003043960-A2 | IMPROVED PURIFICATION OF 4, 4'(5')-DI-t-BUTYLCYCLOHEXANO-18-CROWN-6 | PG RESEARCH FOUNDATION (US) | 2003-05-30 | — | — | WO | disclosed |
| US-6566413-B1 | For dental and dental engineering applications | 3M ESPE AG (DE) | 2003-05-20 | — | — | US | disclosed |
| US-20030092678-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-05-15 | — | — | US | disclosed |
| WO-2003040080-A2 | LIPOXIN A4 ANALOGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-15 | — | — | WO | disclosed |
| US-20030092864-A1 | Silicon-based polycarbonates | AORTECH BIOMATERIALS PTY LTD. | 2003-05-15 | — | — | US | disclosed |
| US-20030087761-A1 | Synergistic active compound combinations for controlling harmful plants | AVENTIS CROPSCIENCE GMBH (DE) | 2003-05-08 | — | — | US | disclosed |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | WASHINGTON UNIVERSITY | 2003-05-08 | — | — | US | disclosed |
| US-6559310-B2 | Reacting a halogen aromatic derivative at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a suitable base for covalently coupling organic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-05-06 | — | — | US | disclosed |
| US-20030083332-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-05-01 | — | — | US | disclosed |
| US-6555537-B2 | Inhibit activity of chemokines, macrophage inflammatory protein-1 (MIP-1 alpha) and RANTES; 1-((4-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine for example | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| US-20030078265-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-24 | — | — | US | disclosed |
| EP-1139973-B1 | POLYMERISABLE MATERIALS WHICH ARE BASED ON HARDENABLE SILOXANE COMPOUNDS | 3M ESPE AG (DE) | 2003-04-23 | — | — | EP | disclosed |
| US-6551684-B1 | Substrate with interstitial gaps having polymeric membrane within the gaps that are thinner than the cross-sectional thickness of the substrate | GRADIPORE LIMITED (AU) | 2003-04-22 | — | — | US | disclosed |
| US-20030073718-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-17 | — | — | US | disclosed |
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| EP-0922045-B1 | BICYCLIC PYRIMIDINE DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | SCHERING AG (DE) | 2003-04-16 | — | — | EP | disclosed |
| EP-1301522-A1 | NOVEL COMPOUNDS AND METHODS | Pharmaxis Pty Ltd (AU) | 2003-04-16 | — | — | EP | disclosed |
| US-6548505-B1 | Protecting biological materials from damage caused by radiation; side effect reduction during radiotherapy or chemotherapy; indole, benzimidazole, benzoxazole or benzothiazole compounds substituted with 4-alkylpiperazino | PETER MACCALLUM CANCER INSTITUTE (AU) | 2003-04-15 | — | — | US | disclosed |
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-10 | — | — | US | disclosed |
| US-20030069307-A1 | 2-(3,4-Dihydroxyphenyl)ethyl-substituted carbonic acid derivatives and their use | HAARMANN & REIMER GMBH (DE) | 2003-04-10 | — | — | US | disclosed |
| CN-1105114-C | Sulfonyl divalent aryl alpha-hydroxamic acid compounds | MANSANTO CO (US) | 2003-04-09 | — | — | CN | disclosed |
| WO-2003026663-A1 | PROCESS FOR MAKING SUBSTITUTED PYRAZOLES | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1296941-A2 | 3,4-DIHYDROXYBENZYL-SUBSTITUTED CARBONIC ACID DERIVATIVES AND THE USE THEREOF AS ANTIOXIDANTS | HAARMANN & REIMER GMBH (DE) | 2003-04-02 | — | — | EP | disclosed |
| EP-1296673-A1 | ANTIMICROBIAL COATINGS | UNISEARCH LIMITED (AU) | 2003-04-02 | — | — | EP | disclosed |
| US-6541489-B1 | Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1 | G. D. SEARLE & COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-6541476-B1 | Treating multiple sclerosis or encephalomyelitis in a human | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | disclosed |
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-03-27 | — | — | US | disclosed |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
| EP-1294705-A1 | SYNTHESIS OF CYCLIC COMPOUNDS | UNISEARCH LIMITED (AU) | 2003-03-26 | — | — | EP | disclosed |
| US-6534509-B1 | Derivatives are useful as anti-inflammatory agents. This invention is also directed to pharmacetutical compostions for inflammation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-18 | — | — | US | disclosed |
| WO-2003020268-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF CACHEXIA | WASHINGTON UNIVERSITY (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-0939628-B1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1284979-A1 | PREPOLYMERIC (METH)ACRYLATES WITH POLYCYCLIC OR AROMATIC SEGMENTS | 3M Espe AG (DE) | 2003-02-26 | — | — | EP | disclosed |
| EP-1285912-A2 | Process for the selective reduction of alkynic compounds | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-26 | — | — | EP | disclosed |
| WO-2003014122-A1 | DERIVATIVES OF MORPHINE-LIKE OPIOID COMPOUNDS | POLYCHIP PHARMACEUTICALS PTY LTD (AU) | 2003-02-20 | — | — | WO | disclosed |
| EP-1284145-A1 | 2-(3,4-Dihydroxyphenyl)ethyl substituted carbonic acid derivatives and their use | HAARMANN & REIMER GMBH (DE) | 2003-02-19 | — | — | EP | disclosed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-02-06 | — | — | US | disclosed |
| US-6515160-B2 | Boronic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-02-04 | — | — | US | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003007930-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| US-6512081-B1 | Synthesis of dithioester chain transfer agents and use of bis(thioacyl) disulfides or dithioesters as chain transfer agents | E.I. DUPONT NEMOURS AND COMPANY | 2003-01-28 | — | — | US | disclosed |
| EP-1056751-A4 | BORONIC COMPOUNDS | COMMW SCIENT IND RES ORG (AU) | 2003-01-22 | — | — | EP | disclosed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | disclosed |
| EP-1274420-A1 | MICROBIAL INHIBITORY COMPOSITIONS | Unisearch Limited (AU) | 2003-01-15 | — | — | EP | disclosed |
| US-6506925-B2 | Synthesis from haloalkenes or pseudo-haloalkenes | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-01-14 | — | — | US | disclosed |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-01-02 | — | — | US | disclosed |
| US-20030004064-A1 | Synergistic active compound combinations for controlling harmful plants | AVENTIS CROPSCIENCE GMBH (DE) | 2003-01-02 | — | — | US | disclosed |
| EP-1090008-A4 | SYNTHESES OF A VARIETY OF LAMELLARIN COMPOUNDS AND ANALOGUES | UNIV AUSTRALIAN (AU) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002102370-A1 | BIOFILM DEGRADING OR SLOUGHING COMPOSITIONS AND METHODS | UNISEARCH LIMITED (AU) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002102560-A1 | BORON-BASED WOOD PRESERVATIVES AND TREATMENT OF WOOD WITH BORON-BASED PRESERVATIVES | THE UNIVERSITY OF MELBOURNE (AU) | 2002-12-27 | — | — | WO | disclosed |
| CN-1387514-A | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | SEARLE & CO (US) | 2002-12-25 | — | — | CN | disclosed |
| US-20020193604-A1 | Aryl borates | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-12-19 | — | — | US | disclosed |
| US-6492367-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | G. D. SEARLE & COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002096850-A1 | PRECURSORS FOR KETONES AND ALDEHYDES | GIVAUDAN SA (CH) | 2002-12-05 | — | — | WO | disclosed |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGSCHELLSCHAFT | 2002-11-28 | — | — | US | disclosed |
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2002-11-28 | — | — | US | disclosed |
| WO-2002092588-A2 | AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020173508-A1 | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds | PHARMACIA CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-6482860-B1 | such as batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene), use as antiproliferative agents to treat cancer | TULARIK INC. | 2002-11-19 | — | — | US | disclosed |
| US-6479485-B2 | 4-HYDROXY-3-((3,4-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; INHIBITION OF BLOOD COAGGULATION FACTOR XA | BERLEX LABORATORIES, INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-11-07 | — | — | US | disclosed |
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | ONCONOVA THERAPEUTICS, INC. | 2002-11-07 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-6476027-B1 | N-hydroxy 4-sulfonyl butanamide compounds | MONSANTO COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020161114-A1 | Shape memory polyurethane or polyurethane-urea polymers | AORTECH BIOMATERIALS PTY LTD. (AU) | 2002-10-31 | — | — | US | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-1203038-A4 | SHAPE MEMORY POLYURETHANE OR POLYURETHANE-UREA POLYMERS | AORTECH BIOMATERIALS PTY LTD (AU) | 2002-10-30 | — | — | EP | disclosed |
| EP-1187827-A4 | ANTIVIRAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2002-10-24 | — | — | EP | disclosed |
| US-6469171-B1 | NON-TOXIC MODULATORS OF THE MULTIDRUG RESISTANT PHENOTYPE | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20020151743-A1 | Process for preparing organic boronic avid derivatives using diboronic acid | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-10-17 | — | — | US | disclosed |
| US-6465459-B2 | INHIBIT THE ENZYME, FACTOR XA | BERLEX LABORATORIES, INC. | 2002-10-15 | — | — | US | disclosed |
| CN-1373751-A | 'Alpha'-amino-'beta'-sulfonyl hydroxamic acid compounds | SEARLE & CO (US) | 2002-10-09 | — | — | CN | disclosed |
| US-20020143036-A1 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. | 2002-10-03 | — | — | US | disclosed |
| EP-0877730-B1 | ARYL ACRYLICS FOR USE AS FUNGICIDE | MONSANTO TECHNOLOGY LLC (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020131932-A1 | Radiopharmaceuticals for diagnosing alzheimer's disease | SCHERING AG (DE) | 2002-09-19 | — | — | US | disclosed |
| US-20020133039-A1 | Chemical methods | DEAKIN UNIVERSITY (AU) | 2002-09-19 | — | — | US | disclosed |
| EP-0984997-B1 | SILICON-BASED POLYCARBONATES | AORTECH BIOMATERIALS PTY LTD (AU) | 2002-09-18 | — | — | EP | disclosed |
| CN-1370144-A | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | SEARLE & CO (US) | 2002-09-18 | — | — | CN | disclosed |
| CN-1370048-A | Azabicyclo and azacyclo oxime and amine compounds as pesticides | AVENTIS CROPSCIONCE GMBH (DE) | 2002-09-18 | — | — | CN | disclosed |
| US-6451791-B1 | Amidoaromatic ring sulfonamide hydroxamic acid compounds | MONSANTO COMPANY | 2002-09-17 | — | — | US | disclosed |
| WO-2002070456-A1 | BENZENE-1 2-DIOL MANNICH BASES LIGANDS POLYMERS AND METHOD OF SELECTIVE METAL IONS REMOVAL | TECHNOLOGICAL RESOURCES PTY LIMITED (AU) | 2002-09-12 | — | — | WO | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| WO-2002067865-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1236727-A1 | Azabicyclo compounds as pesticides | Bayer CropScience GmbH (DE) | 2002-09-04 | — | — | EP | disclosed |
| US-6437073-B1 | Non-elastomeric polyurethane compositions | AORTECH BIOMATERIALS PTY LTD. (AU) | 2002-08-20 | — | — | US | disclosed |
| WO-2002062756-A1 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMATES AND THEIR USE AS MMP INHIBITORS | PHARMACIA CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0986541-A4 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMW SCIENT IND RES ORG (AU) | 2002-08-14 | — | — | EP | disclosed |
| US-6432947-B1 | NERVOUS SYSTEM DISORDERS; MUSCLE RELAXANTS; ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2002-08-13 | — | — | US | disclosed |
| US-6432963-B1 | ANTIINFLAMMATORY AGENTS; TYROSINE KINASE INHIBITOR | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| WO-2002060872-A1 | SYNTHESIS FOR THE PREPARATION OF COMPOUNDS FOR SCREENING AS POTENTIAL TUBULIN BINDING AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2002-08-08 | — | — | WO | disclosed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-20020103239-A1 | Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds | BEDELL LOUIS J (US) | 2002-08-01 | — | — | US | disclosed |
| EP-1224190-A1 | SUBSTITUTED DIBORON COMPOUNDS | Commonwealth Scientific and Research Organisation (AU) | 2002-07-24 | — | — | EP | disclosed |
| CN-1360577-A | Hydroxamic acid derivs. as matrix metalloprotease inhibitors | SEARLE & CO (US) | 2002-07-24 | — | — | CN | disclosed |
| US-6420452-B1 | POLYURETHANES WITH EXTENDERS | AORTECH BIOMATERIALS PTY LTD (AU) | 2002-07-16 | — | — | US | disclosed |
| WO-2002053572-A1 | DELIVERY SYSTEMS | ALCHEMIA PTY LTD (AU) | 2002-07-11 | — | — | WO | disclosed |
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | DUDLEY DANETTE ANDREA (US) | 2002-07-04 | — | — | US | disclosed |
| WO-2002050045-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2002-06-27 | — | — | WO | disclosed |
| US-6410536-B1 | ANTICOAGULANTS | WARNER-LAMBERT COMPANY | 2002-06-25 | — | — | US | disclosed |
| WO-2002047681-A1 | REGULATION OF BACTERIAL VIRULENCE | UNISEARCH LIMITED (AU) | 2002-06-20 | — | — | WO | disclosed |
| EP-1214317-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2002-06-19 | — | — | EP | disclosed |
| EP-1019414-A4 | PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID | COMMW SCIENT IND RES ORG (AU) | 2002-05-29 | — | — | EP | disclosed |
| US-6388131-B2 | Benzenesulfonamide compounds, which encompasses the compound batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene) | TULARIK, INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2002036581-A1 | RADIOPHARMACEUTICALS FOR DIAGNOSING ALZHEIMER'S DISEASE | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1203038-A1 | SHAPE MEMORY POLYURETHANE OR POLYURETHANE-UREA POLYMERS | AorTech Biomaterials Pty Ltd (AU) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002034736-A1 | PROCESS FOR PREPARATION OF BICYCLIC AND POLYCYCLIC MOLECULES | MONASH UNIVERSITY (AU) | 2002-05-02 | — | — | WO | disclosed |
| US-6380258-B2 | METALLOPROTEASE INHIBITOR | G. D. SEARLE, L.L.C. | 2002-04-30 | — | — | US | disclosed |
| US-6379649-B1 | USEFUL FOR DIAGNOSIS AND TREATMENT, INCLUDING RADIOTHERAPY, OF DISORDERS THAT ARE CHARACTERIZED BY AN ABNORMAL DENSITY OF PERIPHERAL BENZODIAZEPINE RECEPTORS; NERVE SYSTEM DISPORDERS | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2002-04-30 | — | — | US | disclosed |
| WO-2002032963-A1 | IMMUNOADJUVANT SYSTEMS | ALCHEMIA PTY LTD (AU) | 2002-04-25 | — | — | WO | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| WO-2002028345-A2 | ALDEHYDE-RELEASING COMPOUNDS | LA TROBE UNIVERSITY (AU) | 2002-04-11 | — | — | WO | disclosed |
| US-6362183-B1 | PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS | G. D. SEARLE & COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-20020035109-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-21 | — | — | US | disclosed |
| EP-1187859-A1 | POLYMER GELS, METHODS FOR THEIR PREPARATION AND THEIR USE IN ELECTROPHORETIC APPLICATIONS | THE UNIVERSITY OF MELBOURNE (AU) | 2002-03-20 | — | — | EP | disclosed |
| EP-1187827-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2002-03-20 | — | — | EP | disclosed |
| US-20020032339-A1 | ARYL BORATES | BORON MOLECULAR LIMITED (AU) | 2002-03-14 | — | — | US | disclosed |
| US-20020032223-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-14 | — | — | US | disclosed |
| US-20020028820-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-07 | — | — | US | disclosed |
| US-20020028901-A1 | Siloxane-containing polyurethane-urea compositions | ELASTOMEDIC PTY LIMITED | 2002-03-07 | — | — | US | disclosed |
| EP-1121365-A4 | ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS | COMMW SCIENT IND RES ORG (AU) | 2002-03-06 | — | — | EP | disclosed |
| EP-1183239-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6350746-B1 | FACTOR XA ENZYME INHIBITORS | BERLEX LABORATORIES, INC. | 2002-02-26 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| US-6346639-B1 | Boronic compounds | THE COMMONWEALTH OF AUSTRALIA COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 2002-02-12 | — | — | US | disclosed |
| US-20020016489-A1 | Alkene borates and a process for covalently coupling organic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION | 2002-02-07 | — | — | US | disclosed |
| EP-1177173-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | disclosed |
| CN-1333777-A | Organoboron derivatives and methods of coupling organic compounds | COMMW SCIENT IND RES ORG (AU) | 2002-01-30 | — | — | CN | disclosed |
| WO-2002004472-A1 | NOVEL COMPOUNDS AND METHODS | PHARMAXIS PTY LTD (AU) | 2002-01-17 | — | — | WO | disclosed |
| EP-1044194-A4 | RECEPTOR WITH AN AFFINITY FOR COMPOUNDS OF THE OXAZOLINE CLASS | UNIV MELBOURNE (AU) | 2002-01-09 | — | — | EP | disclosed |
| WO-2002000639-A1 | SYNTHESIS OF CYCLIC COMPOUNDS | UNISEARCH LIMITED (AU) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001098235-A2 | 3,4-DIHYDROXYBENZYL-SUBSTITUTED CARBONIC ACID DERIVATIVES AND THE USE THEREOF AS ANTIOXIDANTS | HAARMANN & REIMER GMBH (DE) | 2001-12-27 | — | — | WO | disclosed |
| US-6333391-B1 | FROM AMINES AND CARBOXYLIC ACIDS OR ANHYDRIDES, IN WATER; | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-12-25 | — | — | US | disclosed |
| WO-2001094348-A1 | ANTIVIRAL AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001092271-A1 | PREPOLYMERIC (METH)ACRYLATES WITH POLYCYCLIC OR AROMATIC SEGMENTS | 3M ESPE AG (DE) | 2001-12-06 | — | — | WO | disclosed |
| US-20010049449-A1 | Aromatic sulfonyl alpha-cycloamino hydroxamates and their use as MMP inhibitors | PHARMACIA CORPORATION | 2001-12-06 | — | — | US | disclosed |
| WO-2001085680-A2 | SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORPORATION (US) | 2001-11-15 | — | — | WO | disclosed |
| US-6316484-B1 | FOR THERAPY OR PROPHYLAXIS OF ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA | TULARIK INC. | 2001-11-13 | — | — | US | disclosed |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | PHARMACIA CORPORATION | 2001-11-08 | — | — | US | disclosed |
| EP-0764165-B1 | PREPARATION OF STEREOCHEMICALLY PURE OXIMES WITH MUSCARINIC ACTIVITY | WARNER LAMBERT CO (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-1149075-A1 | SYNTHESIS OF DITHIOESTER CHAIN TRANSFER AGENTS AND USE OF BIS(THIOACYL) DISULFIDES OR DITHIOESTERS AS CHAIN TRANSFER AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-10-31 | — | — | EP | disclosed |
| US-6306884-B1 | ANTICOAGULANTS AND BLOOD COAGULATION FACTOR | BERLEX LABORATORIES, INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2001076594-A1 | ANTIMICROBIAL COATINGS | UNISEARCH LIMITED (AU) | 2001-10-18 | — | — | WO | disclosed |
| EP-1071684-A4 | IMIDAZO 1,2-a]PYRIDINES AS PERIPHERAL BENZODIAZEPINE RECEPTOR BINDING AGENTS | AUSTRALIAN NUCLEAR SCIENCE TEC (AU) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001068090-A1 | MICROBIAL INHIBITORY COMPOSITIONS | UNISEARCH LIMITED (AU) | 2001-09-20 | — | — | WO | disclosed |
| US-20010020021-A1 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | G.D. SEARLE & CO. | 2001-09-06 | — | — | US | disclosed |
| US-20010020079-A1 | Electrophoresis gels and cross-linking agents for their preparation | THE UNIVERSITY OF MELBOURNE | 2001-09-06 | — | — | US | disclosed |
| US-6284923-B1 | BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS | TULARIK INC | 2001-09-04 | — | — | US | disclosed |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | BARTA THOMAS E (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1121365-A1 | ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-08-08 | — | — | EP | disclosed |
| CN-1307580-A | Synthesis of various lamellarin compounds and analogs | UNIV AUSTRALIAN (AU) | 2001-08-08 | — | — | CN | disclosed |
| EP-0920405-B1 | FLUOROVINYL DERIVATIVE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORP (JP) | 2001-07-11 | — | — | EP | disclosed |
| US-6258806-B1 | PEPTIDES WITH CYCLIC DIAZAALKANES FOR PREVENTION OF PREMATURE METABOLISM METHOD FOR INHIBITING AN HIV PROTEASE IN A MAMMAL IN NEED OF SUCH PROTEASE INHIBITION, COMPRISING ADMINISTERING TO SAID MAMMAL AN EFFECTIVE DOSAGE | NARHEX LIMITED (HK) | 2001-07-10 | — | — | US | disclosed |
| EP-1078010-A4 | NON-ELASTOMERIC POLYURETHANE COMPOSITIONS | ELASTOMEDIC PTY LTD (AU) | 2001-07-04 | — | — | EP | disclosed |
| EP-1112250-A1 | THERAPEUTIC COMPOUNDS AND METHODS | Institute of Molecular and Cell Biology (SG) | 2001-07-04 | — | — | EP | disclosed |
| US-6242454-B1 | Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants | BERLEX LABORATORIES INC. | 2001-06-05 | — | — | US | disclosed |
| EP-0983257-A4 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS | MONSANTO CO (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-0984959-A4 | AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS | MONSANTO CO (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-0973392-A4 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | MONSANTO CO (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2001029051-A1 | SUBSTITUTED DIBORON COMPOUNDS | COMMONWEALTH SCIENTIFIC AND RESEARCH ORGANISATION (AU) | 2001-04-26 | — | — | WO | disclosed |
| US-6221886-B1 | Thio acid derived monocyclic N-heterocyclics as anticoagulants | BERLEX LABORATORIES, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-1091955-A1 | QUINOLONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-1090008-A1 | SYNTHESES OF A VARIETY OF LAMELLARIN COMPOUNDS AND ANALOGUES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2001-04-11 | — | — | EP | disclosed |
| US-6215016-B1 | HEMATOPOIETIC AGENTS; PREVENTING CYTOPENIA | TORAY INDUSTRIES, INC. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6207076-B1 | HIGH ELASTIC CONSTANT RATIO, LOW VISCOSITY, WIDE NEMATIC PHASE TEMPERATURE RANGE, CHEMICAL STABILITY | CHISSO CORPORATION (JP) | 2001-03-27 | — | — | US | disclosed |
| WO-2001019822-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2001-03-22 | — | — | WO | disclosed |
| US-6197906-B1 | ASSYMETRIC AGENTS SUCH AS (2-METHACRYLOYLOXYETHYL)ACRYLAMIDE, (2-ACRYLOYLOXYETHYL)METHACRYLAMIDE, AND (N-METHYL-N-ACRYLOYLAMINO)ETHYL METHACRYLATE | THE UNIVERSITY OF MELBOURNE (AU) | 2001-03-06 | — | — | US | disclosed |
| EP-1078010-A1 | NON-ELASTOMERIC POLYURETHANE COMPOSITIONS | Elastomedic Pty Limited (AU) | 2001-02-28 | — | — | EP | disclosed |
| US-6194414-B1 | CANCER THERAPY; PREVENT RADIATION DAMAGE | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 2001-02-27 | — | — | US | disclosed |
| US-6184245-B1 | Cyclic ketone derivatives and their medical applications | TORAY INDUSTRIES INC. (JP) | 2001-02-06 | — | — | US | disclosed |
| WO-2001007499-A1 | SHAPE MEMORY POLYURETHANE OR POLYURETHANE-UREA POLYMERS | AORTECH BIOMATERIALS PTY LTD. (AU) | 2001-02-01 | — | — | WO | disclosed |
| EP-1071684-A1 | IMIDAZO 1,2-a]PYRIDINES AS PERIPHERAL BENZODIAZEPINE RECEPTOR BINDING AGENTS | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2001-01-31 | — | — | EP | disclosed |
| EP-0981517-A4 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | UNIV AUSTRALIAN (AU) | 2001-01-24 | — | — | EP | disclosed |
| EP-1068190-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| CN-1279669-A | Aromatic sulfone hydroxamic acid metalloprotease inhibitors | SEARLE & CO (US) | 2001-01-10 | — | — | CN | disclosed |
| WO-2000078746-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2000-12-28 | — | — | WO | disclosed |
| US-6166014-A | Thio acid derived monocyclic N-heterocyclics as anticoagulants | BERLEX LABORATORIES, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6166088-A | CONTROLLING THROMBOSIS | BERLEX LABORATORIES, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6162807-A | Thio acid derived monocyclic N-heterocyclics as anticoagulants | BERLEX LABORATORIES, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1056751-A1 | BORONIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-12-06 | — | — | EP | disclosed |
| CN-1275984-A | Process for preparing organic boronic acid derivatives using diboronic acid | COMMW SCIENT IND RES ORG (AU) | 2000-12-06 | — | — | CN | disclosed |
| WO-2000069821-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069819-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
| EP-1054004-A1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-11-22 | — | — | EP | disclosed |
| US-6150382-A | ENZYME INHIBITORS OF BLOOD COAGULATION FACTOR XA, A SERINE PROTEASE CLASS OF ENZYMES; E.G., 4-HYDROXY-3-((4-(2-CARBOXY-METHYL)THIO-6-(3-(1-METHYL)-6-(3-(1 -METHYL)IMIDAZOLIN-2-YL)-PHENOXY-3,5-DIFLUOROPYRIDINE AND DERIVATIVES | BERLEX LABORATORIES, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1044194-A1 | RECEPTOR WITH AN AFFINITY FOR COMPOUNDS OF THE OXAZOLINE CLASS | THE UNIVERSITY OF MELBOURNE (AU) | 2000-10-18 | — | — | EP | disclosed |
| EP-1042290-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | disclosed |
| CN-1268940-A | Preparation of thiochloroformates | BASF AG (DE) | 2000-10-04 | — | — | CN | disclosed |
| WO-2000056792-A1 | POLYMER GELS, METHODS FOR THEIR PREPARATION AND THEIR USE IN ELECTROPHORETIC APPLICATIONS | THE UNIVERSITY OF MELBOURNE (AU) | 2000-09-28 | — | — | WO | disclosed |
| US-6121304-A | SUCH AS 1-(PENTAFLUOROPHENYLSULFONYL)INDOLE; USEFUL IN TREATING ATHEROSCLEROSIS AND HYPERCHOLESTEROLERNIA | TULARIK INC (US) | 2000-09-19 | — | — | US | disclosed |
| CN-1264386-A | Alkene borates and process for covalently coupling organic compounds | COMMW SCIENT IND RES ORG (AU) | 2000-08-23 | — | — | CN | disclosed |
| CN-1262677-A | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | UNIV AUSTRALIAN (AU) | 2000-08-09 | — | — | CN | disclosed |
| US-6100292-A | Ketone derivatives and their medical applications | TORAY INDUSTRIES, INC. (JP) | 2000-08-08 | — | — | US | disclosed |
| EP-0920412-A4 | ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION | UNIV MELBOURNE (AU) | 2000-08-02 | — | — | EP | disclosed |
| EP-1019414-A1 | PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-07-19 | — | — | EP | disclosed |
| US-6087359-A | A MATRIX METALLOPROTEASE ENZYME INHIBITOR | PHARMACIA CORPORATION | 2000-07-11 | — | — | US | disclosed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| US-6071895-A | RETROVIRAL PROTEASES INHIBITOR; USEFUL FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS VIRAL INFECTIONS SUCH AS ACQUIRED IMMUNODEFICIENCY SYNDROME(AIDS); COMPOUND CONTAINING A CYCLIC DIAZAALKANE GROUP | NARHEX LIMITED (HK) | 2000-06-06 | — | — | US | disclosed |
| US-6071912-A | INHIBIT HUMAN FACTOR XA AND ARE THEREFORE USEFUL AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY; AMINO-, OXY- AND THIA-SUBSTITUTED TRIAZINES | BERLEX LABORATORIES, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| CN-1255123-A | Method for Covalently Coupling Organic Compounds Using Diboron Derivatives | COMMW SCIENT IND RES ORG (AU) | 2000-05-31 | — | — | CN | disclosed |
| CN-1254337-A | N-hydroxy 4-sulfonylbutyramide compounds | MONSANTO CO (US) | 2000-05-24 | — | — | CN | disclosed |
| CN-1253559-A | Sulfonyl divalent aryl alpha-hydroxamic acid compounds | MONSANTO CO (US) | 2000-05-17 | — | — | CN | disclosed |
| CN-1253474-A | Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds | MONSANTO CO (US) | 2000-05-17 | — | — | CN | disclosed |
| WO-2000021966-A1 | ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-04-20 | — | — | WO | disclosed |
| EP-0986541-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000014063-A1 | THERAPEUTIC COMPOUNDS AND METHODS | INSTITUTE OF MOLECULAR & CELL BIOLOGY (SG) | 2000-03-16 | — | — | WO | disclosed |
| EP-0888271-A4 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY AMINO ACID AND HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0984959-A1 | AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0983257-A1 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS | Monsanto Company (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0983267-A1 | AMIDOAROMATIC RING SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 2000-03-08 | — | — | EP | disclosed |
| US-6034084-A | CARDIOVASCULAR DISORDERS | BERLEX LABORATORIES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-6034103-A | THROMBOSIS THERAPY | BERLEX LABORATORIES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0981517-A1 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2000-03-01 | — | — | EP | disclosed |
| EP-0980867-A1 | KETONE DERIVATIVES AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2000-02-23 | — | — | EP | disclosed |
| EP-0977745-A1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998050365-A9 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | UNIV AUSTRALIAN (AU) | 2000-02-03 | — | — | WO | disclosed |
| EP-0973392-A1 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| CN-1242770-A | Cyclic ketone derivative and pharmaceutical use thereof | TORAY INDUSTRIES (JP) | 2000-01-26 | — | — | CN | disclosed |
| US-6013649-A | BOND DISORDERS; AUTOIMMUNE DISEASES; ANTITUMOR AGENTS | MONSANTO COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| US-6013836-A | PARTICULARLY ACTIVE AGAINST MOTHS AND BEETLES AND THEIR INSECT GROWTH REGULATING ACTIVITY WITHOUT ADVERSE IMPACT ON BENEFICIAL INSECTS; CROPS; FORESTRY | ROHM AND HAAS COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0968206-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999067250-A1 | SYNTHESES OF A VARIETY OF LAMELLARIN COMPOUNDS AND ANALOGUES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1999-12-29 | — | — | WO | disclosed |
| US-6004981-A | HUMAN FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 1999-12-21 | — | — | US | disclosed |
| US-6004985-A | BLOOD-COAGULATION FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| CN-1238688-A | Thiol sulfonamide metalloprotease inhibitors | MONSANTO CO (US) | 1999-12-15 | — | — | CN | disclosed |
| EP-0962456-A1 | CYCLIC KETONE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1999-12-08 | — | — | EP | disclosed |
| US-5994375-A | ANTICOAGULANTS | BERLEX LABORATORIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| CN-1235172-A | Process for producing cycloolefin copolymer, cycloolefin copolymer produced by the process, and use of the copolymer | HOECHST AG (DE) | 1999-11-17 | — | — | CN | disclosed |
| WO-1999051594-A1 | IMIDAZO[1,2-a]PYRIDINES AS PERIPHERAL BENZODIAZEPINE RECEPTOR BINDING AGENTS | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999050263-A1 | QUINOLONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999050254-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999050327-A1 | NON-ELASTOMERIC POLYURETHANE COMPOSITIONS | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 1999-10-07 | — | — | WO | disclosed |
| CN-1230884-A | Thiol sulfone metalloprotease inhibitors | MONSANTO CO (US) | 1999-10-06 | — | — | CN | disclosed |
| US-5942504-A | INHIBITORS OF RETROVIRAL PROTEASES; TREATMENT OF AIDS AND HIV | NARHEX LIMITED (HK) | 1999-08-24 | — | — | US | disclosed |
| EP-0934310-A1 | THIO ACID DERIVED MONOCYCLIC $i(N)-HETEROCYCLICS AS ANTICOAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-08-11 | — | — | EP | disclosed |
| CN-1225009-A | Pentafluorobenzenesulfonamides and analogs thereof | TULARIK INC (US) | 1999-08-04 | — | — | CN | disclosed |
| WO-1999033845-A1 | BORONIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-07-08 | — | — | WO | disclosed |
| EP-0920412-A1 | ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION | THE UNIVERSITY OF MELBOURNE (AU) | 1999-06-09 | — | — | EP | disclosed |
| WO-1999025687-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999024411-A1 | RECEPTOR WITH AN AFFINITY FOR COMPOUNDS OF THE OXAZOLINE CLASS | THE UNIVERSITY OF MELBOURNE (AU) | 1999-05-20 | — | — | WO | disclosed |
| EP-0896533-A4 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5889005-A | Benzamidine derivatives and their use for treating thrombotic diseases | BERLEX LABORATORIES, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5888992-A | PROTEASE INHIBITOR; VIRICIDE | NARHEX LIMITED (HK) | 1999-03-30 | — | — | US | disclosed |
| WO-1999012940-A1 | PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-03-18 | — | — | WO | disclosed |
| US-5883100-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5880151-A | TREATING OR PREVENTING DISEASE CHARACTERIZED BY HIGH LEVELS OF LOW DENSITY LIPOPROTEIN PARTICLES OR CHOLESTEROL IN BLOOD | TULARIK INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5879585-A | EXHIBIT GOOD MISCIBILITY WITH OTHER LIQUID CRYSTALLINE COMPOUNDS; USEFUL FOR DISPLAY OF WATCHES, COMPUTER TERMINALS, AND TELEVISIONS | CHISSO CORPORATION (JP) | 1999-03-09 | — | — | US | disclosed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5877181-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5877119-A | HERBICIDE | ROHM AND HAAS COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0896533-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1999-02-17 | — | — | EP | disclosed |
| US-5872111-A | TOILET BAR SOAP, FACIAL BODY CLEANSER, SHAMPOO, CONDITIONER, COSMETIC,SHAVING CREAM OR LOTION, SHOWER GEL, FABRIC SOFTENING CONDITIONER, AND UNDERARM DEODORANT/ANTI-PERSPIRANT | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1999005099-A1 | SYNTHESIS OF DITHIOESTER CHAIN TRANSFER AGENTS AND USE OF BIS(THIOACYL) DISULFIDES OR DITHIOESTERS AS CHAIN TRANSFER AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-02-04 | — | — | WO | disclosed |
| EP-0888271-A1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY AMINO ACID AND HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5846972-A | Bicyclic pyrimidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5846970-A | Bicyclic pyrimidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5843867-A | Substituted pyridine compounds | ROHM AND HAAS COMPANY (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0813556-B1 | LIQUID PHASE POWDER BED SYNDIOTACTIC VINYLAROMATIC POLYMERIZATION | DOW CHEMICAL CO (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998050365-A1 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1998-11-12 | — | — | WO | disclosed |
| US-5824625-A | HERBICIDES, HETEROCYCLIC GROUP(S) ATTACHED TO PYRIDINE RING | ROHM AND HAAS COMPANY | 1998-10-20 | — | — | US | disclosed |
| WO-1998045265-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1998-10-15 | — | — | WO | disclosed |
| CN-1194580-A | Ketone derivatives and medical use thereof | TORAY INDUSTRIES (JP) | 1998-09-30 | — | — | CN | disclosed |
| WO-1998039313-A1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039315-A1 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039326-A1 | AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998038859-A1 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039329-A1 | AMIDOAROMATIC RING SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998037079-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 1998-08-27 | — | — | WO | disclosed |
| EP-0857067-A1 | RADIOPROTECTORS | The Inner and Eastern Health Care Network (AU) | 1998-08-12 | — | — | EP | disclosed |
| US-5753635-A | Purine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0841063-A1 | KETONE DERIVATIVES AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1998-05-13 | — | — | EP | disclosed |
| EP-0837045-A1 | Liquid crystalline compound having alkynyl group, and liquid crystal composition and liquid crystal display device therefrom | Chisso Corporation (JP) | 1998-04-22 | — | — | EP | disclosed |
| WO-1998015547-A1 | THIO ACID DERIVED MONOCYCLIC N-HETEROCYCLICS AS ANTICOAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-04-16 | — | — | WO | disclosed |
| US-5739140-A | AGRICULTURAL FUNGICIDES | MONSANTO COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1998001419-A1 | ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION | THE UNIVERSITY OF MELBOURNE (AU) | 1998-01-15 | — | — | WO | disclosed |
| EP-0813525-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5693641-A | ENZYME INHIBITOR TREATING BLOOD DISORDER | BERLEX LABORATORIES INC. (US) | 1997-12-02 | — | — | US | disclosed |
| US-5691364-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| US-5679688-A | RETROVIRAL PROTEASE INHIBITORS; AIDS THERAPY | NARHEX LIMITED (HK) | 1997-10-21 | — | — | US | disclosed |
| WO-1997030677-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997029067-A1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY AMINO ACID AND HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (DE) | 1997-08-14 | — | — | WO | disclosed |
| US-5648349-A | PHOSPHOLIPASE INHIBITORS | MONSANTO COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5643854-A | HERBICIDES | ROHM AND HAAS COMPANY (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0586556-B1 | SUBSTITUTED 2,6-SUBSTITUTED PYRIDINE HERBICIDES | ROHM & HAAS (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1997004776-A1 | RADIOPROTECTORS | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 1997-02-13 | — | — | WO | disclosed |
| CN-1135212-A | polar substituted hydrocarbons | NARHEX AUSTRALIA PTY LTD (AU) | 1996-11-06 | — | — | CN | disclosed |
| WO-1996028427-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| EP-0717736-A4 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LTD (HK) | 1996-08-28 | — | — | EP | disclosed |
| EP-0717736-A1 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LIMITED (HK) | 1996-06-26 | — | — | EP | disclosed |
| WO-1996016094-A1 | PREPARATION OF SYNDIOTACTIC POLYOLEFINS FROM PROCHIRAL OLEFINS | THE DOW CHEMICAL COMPANY (US) | 1996-05-30 | — | — | WO | disclosed |
| US-5514812-A | Preparation of stereochemically pure oximes with muscarinic activity | WARNER-LAMBERT COMPANY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5512536-A | HERBICIDE | ROHN AND HAAS COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| US-5504255-A | Optically active compounds and a method for producing them | CHISSO CORPORATION (JP) | 1996-04-02 | — | — | US | disclosed |
| US-5504237-A | PLA2 inhibitors | MONSANTO COMPANY (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0445731-B1 | Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof | WARNER LAMBERT CO (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5482938-A | Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
| CN-1112564-A | Metallocenes and their use as catalysts | HOECHST AG (DE) | 1995-11-29 | — | — | CN | disclosed |
| WO-1995031202-A1 | CAGE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1995-11-23 | — | — | WO | disclosed |
| US-5464842-A | Azabicyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| CN-1108666-A | Process for preparing polyolefins | HOECHST AG (DE) | 1995-09-20 | — | — | CN | disclosed |
| US-5446175-A | Optically active compounds and a method for producing them | CHISSO CORPORATION (JP) | 1995-08-29 | — | — | US | disclosed |
| US-5434288-A | Phospholipase A2 inhibitor | MONSANTO COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5424333-A | Anthelmintic N'-substituted-N,N'-disubstitutedhydrazines | ROHM AND HAAS COMPANY (US) | 1995-06-13 | — | — | US | disclosed |
| EP-0382463-B1 | Maleimide compounds and fungicides containing them | SUNTORY LTD (JP) | 1995-04-26 | — | — | EP | disclosed |
| WO-1995007269-A1 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LIMITED (HK) | 1995-03-16 | — | — | WO | disclosed |
| EP-0641337-A1 | CYCLIC ALKYLIDENE SUBSTITUTED PYRIDINE HERBICIDES | ROHM AND HAAS COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5391540-A | Herbicides | ROHM AND HAAS COMPANY (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0292990-B1 | 4-Halopyridine-3-carboxamide compounds and herbicidal composition thereof | DAICEL CHEM (JP) | 1995-02-01 | — | — | EP | disclosed |
| US-5380812-A | Storage stability | DOW CORNING CORPORATION (US) | 1995-01-10 | — | — | US | disclosed |
| US-5364922-A | Storage stable polymers | DOW CORNING CORPORATION (US) | 1994-11-15 | — | — | US | disclosed |
| US-5354762-A | Insecticides | ROHM AND HAAS COMPANY (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0371264-B1 | Phosphonate reagent compositions and methods of making same | UNIV LOYOLA CHICAGO (US) | 1994-09-14 | — | — | EP | disclosed |
| US-5346911-A | Analgesics, cognition activators, treatment of alzheimer*s s disease | WARNER-LAMBERT COMPANY (US) | 1994-09-13 | — | — | US | disclosed |
| US-5318978-A | Azabicyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1994-06-07 | — | — | US | disclosed |
| US-5306718-A | Analgesics, cognition activators | WARNER-LAMBERT COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
| US-5306638-A | Stereoselective | EASTMAN KODAK COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
| EP-0586556-A1 | SUBSTITUTED 2,6-SUBSTITUTED PYRIDINE HERBICIDES. | MONSANTO CO (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0581095-A2 | Substituted acrylic acid esters and plant-protecting agents containing them | BASF Aktiengesellschaft (DE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0573575-A1 | SUBSTITUTED PYRIDINE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 1993-12-15 | — | — | EP | disclosed |
| EP-0361645-B1 | ORGANIC HYDRAZINE DERIVATIVES FOR PHARMACEUTICAL USE | ROHM AND HAAS COMPANY (US) | 1993-09-29 | — | — | EP | disclosed |
| EP-0347216-B1 | INSECTICIDAL N'-SUBSTITUTED-N-ALKYLCARBONYL-N'-ACYLHYDRAZINES AND N'-SUBSTITUTED -N-ACYL-N'-ALKYLCARBONYL HYDRAZINES | ROHM AND HAAS COMPANY (US) | 1993-09-01 | — | — | EP | disclosed |
| EP-0312019-B1 | CONDENSED HETEROCYCLIC COMPOUNDS, A PROCESS FOR PREPARING THE SAME AND A HERBICIDAL COMPOSITION THEREOF | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5228897-A | Herbicides | MONSANTO COMPANY (US) | 1993-07-20 | — | — | US | disclosed |
| US-5225443-A | Lepidotera and Coleoptera insecticides to protect plants | ROHM AND HAAS COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0339854-B1 | SYNTHESIS OF N-T-ALKYL-1,2-DIACYLHYDRAZINES | ROHM AND HAAS COMPANY (US) | 1993-05-26 | — | — | EP | disclosed |
| WO-1993008191-A1 | AZABICYCLO OXIME AND AMINE CHOLINERGIC AGENTS AND METHODS OF TREATMENT | WARNER-LAMBERT COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0173848-B1 | BENZOPYRAN COMPOUNDS FOR USE IN THE CARDIOVASCULAR SYSTEM | BEECHAM GROUP PLC (GB) | 1992-12-23 | — | — | EP | disclosed |
| EP-0261755-B1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVES OF N'-SUBSTITUTED-N,N'-DIACYLHYDRAZINES | ROHM AND HAAS COMPANY (US) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992021674-A1 | CYCLIC ALKYLIDENE SUBSTITUTED PYRIDINE HERBICIDES | MONSANTO COMPANY (US) | 1992-12-10 | — | — | WO | disclosed |
| US-5169432-A | 2-and/or 6-fluoroalkyl substituted and a carbonyl oxy(thio) ester or a heterocyclo-carbonyl at the 3 or 5 position | MONSANTO COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| WO-1992020659-A1 | SUBSTITUTED 2,6-SUBSTITUTED PYRIDINE HERBICIDES | MONSANTO COMPANY (US) | 1992-11-26 | — | — | WO | disclosed |
| CN-1066060-A | Medicinal compound | LILLY CO ELI (US) | 1992-11-11 | — | — | CN | disclosed |
| EP-0510947-A1 | N-Hydroxy (thio)ureas as 5-lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
| US-5156670-A | Low soil mobility | MONSANTO COMPANY (US) | 1992-10-20 | — | — | US | disclosed |
| WO-1992014711-A1 | SUBSTITUTED PYRIDINE COMPOUNDS | MONSANTO COMPANY (US) | 1992-09-03 | — | — | WO | disclosed |
| US-5130485-A | For treatment of asthma, arthritis, allergy, inflammatory bowel disease, psoriasis, respiratory system disorders and antiischemic agents | ELI LILLY AND COMPANY (US) | 1992-07-14 | — | — | US | disclosed |
| US-5125956-A | Preemergence herbicides | MONSANTO COMPANY (US) | 1992-06-30 | — | — | US | disclosed |
| EP-0245950-B1 | INSECTICIDAL N-SUBSTITUTED-N' - SUBSTITUTED-N, N'-DIACYLHYDRAZINES | ROHM AND HAAS COMPANY (US) | 1992-06-17 | — | — | EP | disclosed |
| US-5117057-A | Insecticidal N' substituted-N-N'-disubstituted-hydrazines | ROHM AND HAAS COMPANY (US) | 1992-05-26 | — | — | US | disclosed |
| US-5110986-A | Reaction of a 1,3,4-oxadiazole with a tert-alkyl cation precursor in presence of strong acid catalyst | ROHM AND HAAS COMPANY (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0176689-B1 | BENZOPYRAN COMPOUNDS FOR THE TREATMENT OF SMOOTH MUSCLES CONTRACTION | BEECHAM GROUP PLC (GB) | 1992-04-01 | — | — | EP | disclosed |
| EP-0204285-B1 | IMIDAZOHETEROCYCLIC COMPOUNDS PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| EP-0253468-B1 | SIX-MEMBERED HETEROCYCLIC DERIVATIVES OF N'SUBSTITUTED-N,N'-DIACYLHYDRAZINES | ROHM AND HAAS COMPANY (US) | 1991-11-06 | — | — | EP | disclosed |
| EP-0207614-B1 | BENZOPYRAN COMPOUNDS IN THE TREATMENT OF INCONTINENCE | BEECHAM GROUP PLC (GB) | 1991-09-25 | — | — | EP | disclosed |
| CN-1054601-A | Azabicyclo and azepine cyclic oximes and amine cholinergic agents thing and methods of treatment thereof | WARNER LAMBERT CO (US) | 1991-09-18 | — | — | CN | disclosed |
| EP-0445731-A1 | Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof | WARNER-LAMBERT COMPANY (US) | 1991-09-11 | — | — | EP | disclosed |
| US-5039696-A | Maleimide derivatives and fungicides for agriculture and horticulture containing the same | SUNTORY LIMITED (JP) | 1991-08-13 | — | — | US | disclosed |
| US-5032596-A | Hypotensive | BEECHAM GROUP P.L.C. (GB) | 1991-07-16 | — | — | US | disclosed |
| EP-0234944-B1 | INSECTICIDAL N'-SUBSTITUTED-N-ACYL-N'-ALKYLCARBONYLHYDRAZINES | ROHM AND HAAS COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
| EP-0232075-B1 | INSECTICIDAL N'-SUBSTITUTED-N-ALKYLCARBONYL-N'-ACYL HYDRAZINES | ROHM AND HAAS COMPANY (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0286746-B1 | INSECTICIDAL N-(OPTIONALLY SUBSTITUTED) - N'-SUBSTITUTED-N,N'-DISUBSTITUTED- HYDRAZINES | ROHM AND HAAS COMPANY (US) | 1991-02-27 | — | — | EP | disclosed |
| US-4985461-A | Insecticidal N'-substituted-N,N'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4978385-A | 4-halopyridine-3-carboxamide compounds and herbicidal compositions thereof | DAICEL CHEMICAL INDUSTRIES LTD. (JP) | 1990-12-18 | — | — | US | disclosed |
| EP-0193853-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| EP-0382463-A1 | Maleimide compounds and fungicides containing them | SUNTORY LIMITED (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4943314-A | Pyridine-3-carboxamide derivatives having plant growth inhibiting activity | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-07-24 | — | — | US | disclosed |
| US-4936121-A | Condensed heterocyclic compounds, a process for preparing the same and a herbicidal composition thereof | DAICEL CHEMICAL INDUSTRIES LTD. (JP) | 1990-06-26 | — | — | US | disclosed |
| EP-0361645-A2 | Organic hydrazine derivatives for pharmaceutical use | ROHM AND HAAS COMPANY (US) | 1990-04-04 | — | — | EP | disclosed |
| EP-0347216-A2 | Insecticidal N'-substituted-N-alkylcarbonyl-N'-acylhydrazines and N'-substituted -N-acyl-N'-alkylcarbonyl hydrazines | ROHM AND HAAS COMPANY (US) | 1989-12-20 | — | — | EP | disclosed |
| US-4886546-A | Pyrone-3-carboxamide compounds and herbicidal composition thereof | DAICEL CHEMICAL INDUSTRIES LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0339071-A1 | IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS | Aktiebolaget Hässle (SE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0339854-A2 | Synthesis of N-t-alkyl-1,2-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1989-11-02 | — | — | EP | disclosed |
| EP-0149760-B1 | SUBSTITUTED O-ACYL GLYCOSYLAMIDES, METHODS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1989-08-23 | — | — | EP | disclosed |
| EP-0193887-B1 | SUBSTITUTED O-SULFONYL-GLYCOSYL AMIDES, METHOD FOR THEIR PREPARATION AND THEIR USE AS MEDIACMENTS | BAYER AG (DE) | 1989-07-26 | — | — | EP | disclosed |
| US-4844732-A | PLANT GROWTH REGULATORS | DAICEL CHEMICAL INDUSTRIES LTD. (JP) | 1989-07-04 | — | — | US | disclosed |
| EP-0149093-B1 | N-GLYCOSYLATED UREAS, CARBAMATES AND THIOCARBAMATES, THEIR PREPARATION METHOD AND THEIR USE | BAYER AG (DE) | 1989-05-31 | — | — | EP | disclosed |
| WO-1989003833-A1 | IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS | Aktiebolaget Hässle (SE) | 1989-05-05 | — | — | WO | disclosed |
| EP-0312019-A2 | Condensed heterocyclic compounds, a process for preparing the same and a herbicidal composition thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-19 | — | — | EP | disclosed |
| EP-0140321-B1 | USE OF DERIVATIVES OF AMIDES OF CARBOXYLIC ACIDS IN WHICH THE N ATOM IS SUBSTITUTED BY A GLYCOSYL RADICAL AS GROWTH PROMOTOR IN ANIMAL NUTRITION | BAYER AG (DE) | 1989-04-12 | — | — | EP | disclosed |
| EP-0143385-B1 | PHOSPHORYLISED GLYCOSIL AMIDES, UREAS, CARBAMATES AND THIOCARBAMATES, METHOD FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1989-03-15 | — | — | EP | disclosed |
| EP-0301713-A2 | Chroman derivatives for treatment of pulmonary hypertension | BEECHAM GROUP PLC (GB) | 1989-02-01 | — | — | EP | disclosed |
| EP-0292990-A1 | 4-Halopyridine-3-carboxamide compounds and herbicidal composition thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1988-11-30 | — | — | EP | disclosed |
| US-4786639-A | ADMINISTERING BENZOPYRAN DERIVATIVES | BEECHAM GROUP P.L.C. (GB) | 1988-11-22 | — | — | US | disclosed |
| EP-0286746-A1 | Insecticidal N-(optionally substituted) - N'-substituted-N,N'-disubstituted- hydrazines | ROHM AND HAAS COMPANY (US) | 1988-10-19 | — | — | EP | disclosed |
| US-4777256-A | PLANT GROWTH REGULATORS, ANTIINFLAMMATORY AGENTS | DAICEL CHEMICAL INDUSTRIES LTD. (JP) | 1988-10-11 | — | — | US | disclosed |
| US-4772603-A | CHROMENE COMPOUNDS | BEECHAM GROUP P.L.C. (GB) | 1988-09-20 | — | — | US | disclosed |
| US-4755598-A | 1'-(substituted)ethyl-7β-[2-(2-aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylate derivatives having antibacterial utility | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-07-05 | — | — | US | disclosed |
| US-4744819-A | 4-oxo pyridinecarboxamide derivatives as plant growth regulators | DAICEL CHEMICAL INDUSTRIES LTD. (JP) | 1988-05-17 | — | — | US | disclosed |
| US-4739083-A | REACTING 1,3-DIOXAN-4-ONE WITH (AMINE OR IMINE) SUBSTITUTED AMIDE | DAICEL CHEMICAL INDUSTRIES LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| US-4738963-A | NITROGEN SUBSTITUTED BENZO(B)PYRAN | BEECHAM GROUP P.L.C. (GB) | 1988-04-19 | — | — | US | disclosed |
| US-4737488-A | Immune system-stimulating N-glycosylated ureas and carbamates | BAYER AKTIENGESELLSCHAFT (DE) | 1988-04-12 | — | — | US | disclosed |
| EP-0261755-A2 | Five-membered heterocyclic derivatives of N'-substituted-N,N'-Diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1988-03-30 | — | — | EP | disclosed |
| US-4725306-A | Pyridinecarboxamide plant growth inhibitors | DAICEL CHEMICAL INDUSTRIES LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| US-4725601-A | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| EP-0253468-A2 | Six-membered heterocyclic derivatives of N'substituted-N,N'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
| US-4716152-A | IMMUNOSTIMULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1987-12-29 | — | — | US | disclosed |
| US-4710491-A | N-glycosylated carboxylic acid derivatives as agents for combating rheumatic diseases | TROPONWERKE GMBH & CO., KG (DE) | 1987-12-01 | — | — | US | disclosed |
| EP-0245950-A2 | Insecticidal n-substituted-n' - substituted-n, n'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1987-11-19 | — | — | EP | disclosed |
| US-4699899-A | IMMUNE STIMULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1987-10-13 | — | — | US | disclosed |
| EP-0234944-A1 | Insecticidal N'-substituted-N-acyl-N'-alkylcarbonylhydrazines | ROHM AND HAAS COMPANY (US) | 1987-09-02 | — | — | EP | disclosed |
| EP-0232075-A1 | Insecticidal N'-substituted-N-alkylcarbonyl-N'-acyl hydrazines | ROHM AND HAAS COMPANY (US) | 1987-08-12 | — | — | EP | disclosed |
| US-4686208-A | Phosphorylated glycosyl-amides, -ureas, -carbamates and -thiocarbamates and method of use | BAYER AKTIENGESELLSCHAFT (DE) | 1987-08-11 | — | — | US | disclosed |
| US-4683222-A | STIMULANTS FOR IMMUNE SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1987-07-28 | — | — | US | disclosed |
| US-4680287-A | N-glycosylated carboxamide derivatives as growth-promoters in livestock feeding | BAYER AKTIENGESELLSCHAFT (DE) | 1987-07-14 | — | — | US | disclosed |
| CN-86104313-A | The preparation method of Imidazoheterocyclic compounds | — | 1987-03-04 | — | — | CN | disclosed |
| EP-0091645-B1 | DERIVATIVES OF AMIDES OF CARBOXYLIC ACIDS IN WHICH THE N ATOM IS SUBSTITUTED BY A GLYCOSYL RADICAL, METHOD FOR THEIR PREPARATION AND THEIR USE TO INFLUENCE THE IMMUNOGENIC SYSTEM | BAYER AG (DE) | 1987-02-25 | — | — | EP | disclosed |
| EP-0207614-A2 | Benzopyran compounds in the treatment of incontinence | BEECHAM GROUP PLC (GB) | 1987-01-07 | — | — | EP | disclosed |
| US-4631272-A | N-acylated 1-alkylamino-1-deoxy-ketose derivatives, a process for their preparation and their use | BAYER AKTIENGESELLSCHAFT (DE) | 1986-12-23 | — | — | US | disclosed |
| US-4629734-A | HYPOTENSIVE AGENTS | BEECHAM GROUP P.L.C. (GB) | 1986-12-16 | — | — | US | disclosed |
| EP-0204285-A1 | Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-12-10 | — | — | EP | disclosed |
| EP-0193887-A2 | Substituted O-sulfonyl-glycosyl amides, method for their preparation and their use as mediacments | BAYER AG (DE) | 1986-09-10 | — | — | EP | disclosed |
| EP-0189596-A1 | Benzofuran and benzothiophene derivatives | SHIONOGI & CO., LTD. (JP) | 1986-08-06 | — | — | EP | disclosed |
| EP-0176689-A2 | Benzopyran compounds for the treatment of smooth muscles contraction | BEECHAM GROUP PLC (GB) | 1986-04-09 | — | — | EP | disclosed |
| EP-0173848-A2 | Benzopyran compounds for use in the cardiovascular system | BEECHAM GROUP PLC (GB) | 1986-03-12 | — | — | EP | disclosed |
| US-4574122-A | ANTIBODIES, IMMUNOLOGY | BAYER AKTIENGESELLSCHAFT (DE) | 1986-03-04 | — | — | US | disclosed |
| US-4556415-A | POST-EMERGENCE | MONSANTO COMPANY (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0155625-A2 | Glycolipid-like substances in liposome form | BAYER AG (DE) | 1985-09-25 | — | — | EP | disclosed |
| EP-0152856-A2 | N-acylated 1-alkylamimo-1-desoxy ketose derivatives, method for their preparation and use | BAYER AG (DE) | 1985-08-28 | — | — | EP | disclosed |
| EP-0152630-A2 | Organosiloxane polymers and compositions containing same curable upon exposure to gaseous oxygen | UNION CARBIDE CORPORATION (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0149760-A2 | Substituted O-acyl glycosylamides, methods for their preparation and their use | BAYER AG (DE) | 1985-07-31 | — | — | EP | disclosed |
| EP-0149093-A2 | N-glycosylated ureas, carbamates and thiocarbamates, their preparation method and their use | BAYER AG (DE) | 1985-07-24 | — | — | EP | disclosed |
| EP-0147777-A2 | Derivatives of M-glycosylated amides of carboxylic acids as a product for combating diseases of the rheumatism type | Troponwerke GmbH & Co. KG (DE) | 1985-07-10 | — | — | EP | disclosed |
| US-4526954-A | Contains olefinically polyunsaturated radical containing 1,3- or 1,4-pentadienylene group bonded to silicon | UNION CARBIDE CORPORATION (US) | 1985-07-02 | — | — | US | disclosed |
| EP-0144894-A2 | Therapeutic application of substituted O-acyl-glycosides | BAYER AG (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0143385-A2 | Phosphorylised glycosil amides, ureas, carbamates and thiocarbamates, method for their preparation and their use | BAYER AG (DE) | 1985-06-05 | — | — | EP | disclosed |
| EP-0140321-A2 | Use of derivatives of amides of carboxylic acids in which the N atom is substituted by a glycosyl radical as growth promotor in animal nutrition | BAYER AG (DE) | 1985-05-08 | — | — | EP | disclosed |
| EP-0128028-A2 | Cephalosporin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1984-12-12 | — | — | EP | disclosed |
| EP-0091645-A1 | Derivatives of amides of carboxylic acids in which the N atom is substituted by a glycosyl radical, method for their preparation and their use to influence the immunogenic system | BAYER AG (DE) | 1983-10-19 | — | — | EP | disclosed |
| US-4349552-A | TREATMENT OF CANCER | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1982-09-14 | — | — | US | disclosed |
| EP-0002938-B1 | NOVEL HETEROCYCLIC CARBOTHIOAMIDES, COMPOSITIONS CONTAINING THEM, THEIR PREPARATION AND USE | ELI LILLY AND COMPANY (US) | 1982-05-12 | — | — | EP | disclosed |
| EP-0002939-B1 | NOVEL CARBOTHIOAMIDES, COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION | ELI LILLY AND COMPANY (US) | 1982-04-21 | — | — | EP | disclosed |
| EP-0003081-B1 | THIAZOLIDINECARBOTHIOAMIDES, THEIR PREPARATION, COMPOSITIONS AND USE AS INSECTICIDES | ELI LILLY AND COMPANY (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4289766-A | Heterocyclic carbothioamides | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| US-4289778-A | SYSTEMIC INSECTICIDES | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0010941-A1 | 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-14 | — | — | EP | disclosed |
| US-4195092-A | INSECTICIDES FOR TREATING MEXICAN BEAN BEETLE | ELI LILLY AND COMPANY (US) | 1980-03-25 | — | — | US | disclosed |
| US-4166908-A | SELECTIVE PREEMERGENT ACTIVITY | AMERICAN CYANAMID COMPANY (US) | 1979-09-04 | — | — | US | disclosed |
| EP-0003081-A2 | Thiazolidinecarbothioamides, their preparation, compositions and use as insecticides | ELI LILLY AND COMPANY (US) | 1979-07-25 | — | — | EP | disclosed |
| EP-0002939-A2 | Novel carbothioamides, compositions containing them and their preparation | ELI LILLY AND COMPANY (US) | 1979-07-11 | — | — | EP | disclosed |
| EP-0002938-A2 | Novel heterocyclic carbothioamides, compositions containing them, their preparation and use | ELI LILLY AND COMPANY (US) | 1979-07-11 | — | — | EP | disclosed |
| US-3971825-A | (5,6) (10,11) BIS-METHYLENE, BRONCHODILATORS | SANKYO COMPANY LIMITED (JA) | 1976-07-27 | — | — | US | disclosed |
| US-3943153-A | BACTERICIDES | MERCK & CO., INC. (US) | 1976-03-09 | — | — | US | disclosed |
| US-3943153-A | BACTERICIDES | MERCK & CO., INC. (US) | 1976-03-09 | — | — | US | disclosed |